Index	Sentence	Entity	Entity_Startindex	Entity_Stopindex	Entity_Info
PMC4940519_OgerInput.txtOger_out.csv:65	The XTT-test was carried according to the protocol of Scudiero et al.. The activity of cytochrome P450 1A2 was determined by means of O-demethylation of 7-ethoxyresorufine to resorufin. 	cytochrome P450	9944	9959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC4940519_OgerInput.txtOger_out.csv:65	The XTT-test was carried according to the protocol of Scudiero et al.. The activity of cytochrome P450 1A2 was determined by means of O-demethylation of 7-ethoxyresorufine to resorufin. 	cytochrome P450	9944	9959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:24	Moreover, liver cells show a high level of cytochrome P450 activity and often are the main site of metabolic transformation. 	cytochrome P450	3857	3872	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:24	Moreover, liver cells show a high level of cytochrome P450 activity and often are the main site of metabolic transformation. 	cytochrome P450	3857	3872	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:33	The results obtained will allow predicting metabolic pathways of target compounds in patients differing in the level of cytochrome P450 isoenzymes and, in turn, can probably be helpful in designing personalized antibacterial treatments including these drugs. 	cytochrome P450	5410	5425	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:33	The results obtained will allow predicting metabolic pathways of target compounds in patients differing in the level of cytochrome P450 isoenzymes and, in turn, can probably be helpful in designing personalized antibacterial treatments including these drugs. 	cytochrome P450	5410	5425	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:80	This is in agreement with the general knowledge that this group of cytochrome P450 isoenzymes participates in metabolism of numerous drugs. 	cytochrome P450	12319	12334	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:80	This is in agreement with the general knowledge that this group of cytochrome P450 isoenzymes participates in metabolism of numerous drugs. 	cytochrome P450	12319	12334	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:146	Besides cytochrome P450, other important elements of microsomal fraction of liver cells include flavin monooxigenase (FMO) and glucuronosyltransferase (UDP). 	cytochrome P450	22332	22347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:146	Besides cytochrome P450, other important elements of microsomal fraction of liver cells include flavin monooxigenase (FMO) and glucuronosyltransferase (UDP). 	cytochrome P450	22332	22347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:151	One can assume that LIN and CEF, owing to their chemical structure and pharmacological properties, do not constitute a substrate for any of the tested isoenzymes of cytochrome P450. 	cytochrome P450	23440	23455	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:151	One can assume that LIN and CEF, owing to their chemical structure and pharmacological properties, do not constitute a substrate for any of the tested isoenzymes of cytochrome P450. 	cytochrome P450	23440	23455	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:152	It is thus possible that other isoenzymes belonging to cytochrome P450 play a part in the metabolism of the studied drugs. 	cytochrome P450	23512	23527	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:152	It is thus possible that other isoenzymes belonging to cytochrome P450 play a part in the metabolism of the studied drugs. 	cytochrome P450	23512	23527	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:158	Among the multiple microsomal fraction enzymes of liver cells, the ones most involved in biotransformations of foreign substances are isoenzymes of cytochrome P450; ca. 	cytochrome P450	24610	24625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:158	Among the multiple microsomal fraction enzymes of liver cells, the ones most involved in biotransformations of foreign substances are isoenzymes of cytochrome P450; ca. 	cytochrome P450	24610	24625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:170	Besides, the presence and the appropriate level of NADPH-dependent cytochrome P450 reductase in liver cells is a necessary condition for proper physiological actions of its isoenzymes. 	cytochrome P450	26160	26175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:170	Besides, the presence and the appropriate level of NADPH-dependent cytochrome P450 reductase in liver cells is a necessary condition for proper physiological actions of its isoenzymes. 	cytochrome P450	26160	26175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:195	All the postulated phase I metabolic reactions are typical for processes catalyzed by isoenzymes of the cytochrome P450 group. 	cytochrome P450	30827	30842	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5116318_OgerInput.txtOger_out.csv:195	All the postulated phase I metabolic reactions are typical for processes catalyzed by isoenzymes of the cytochrome P450 group. 	cytochrome P450	30827	30842	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:50	We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were detected in human cardiovascular tissue. 	cytochrome P450	7283	7298	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:50	We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were detected in human cardiovascular tissue. 	cytochrome P450	7283	7298	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	cytochrome P450	3426	3441	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	cytochrome P450	3426	3441	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:1	 Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. 	cytochrome P450	37	52	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:1	 Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. 	cytochrome P450	37	52	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:5	We have previously demonstrated that Doxorubicin alters the expression of several cytochrome P450 enzymes in the hearts of male rats. 	cytochrome P450	481	496	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:5	We have previously demonstrated that Doxorubicin alters the expression of several cytochrome P450 enzymes in the hearts of male rats. 	cytochrome P450	481	496	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:32	We have demonstrated that acute DOX-induced cardiotoxicity alters the expression of several cytochrome P450 enzymes in the H9c2 cardiomyoblasts in vitro and in the hearts of male Sprague Dawley rats in vivo. 	cytochrome P450	4910	4925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:32	We have demonstrated that acute DOX-induced cardiotoxicity alters the expression of several cytochrome P450 enzymes in the H9c2 cardiomyoblasts in vitro and in the hearts of male Sprague Dawley rats in vivo. 	cytochrome P450	4910	4925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:21	A revelation from the first genome sequence of M. tuberculosis (that for the virulent H37Rv strain) was that 20 different cytochrome P450 (CYP or P450) enzymes were encoded. 	cytochrome P450	3406	3421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:21	A revelation from the first genome sequence of M. tuberculosis (that for the virulent H37Rv strain) was that 20 different cytochrome P450 (CYP or P450) enzymes were encoded. 	cytochrome P450	3406	3421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5270706_OgerInput.txtOger_out.csv:23	TF6 cytochrome P450 alkane hydroxylase, were predicted. 	cytochrome P450	2974	2989	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5270706_OgerInput.txtOger_out.csv:23	TF6 cytochrome P450 alkane hydroxylase, were predicted. 	cytochrome P450	2974	2989	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:2	N-benzyl-N-cyclopropylamine (BCA) has been attracting great interests for decades for its partial suicide inactivation role to cytochrome P450 (P450) via a ring-opening mechanism besides acting as a role of normal substrates. 	cytochrome P450	278	293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:2	N-benzyl-N-cyclopropylamine (BCA) has been attracting great interests for decades for its partial suicide inactivation role to cytochrome P450 (P450) via a ring-opening mechanism besides acting as a role of normal substrates. 	cytochrome P450	278	293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:9	Besides, discovery of such inhibitors for an enzyme, eg, cytochrome P450, whose mechanisms are not well-characterized should provide an equally specific and effective probe. 	cytochrome P450	1966	1981	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:9	Besides, discovery of such inhibitors for an enzyme, eg, cytochrome P450, whose mechanisms are not well-characterized should provide an equally specific and effective probe. 	cytochrome P450	1966	1981	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:11	Cyclopropylamines are one kind of such prototypical inhibitors for cytochrome P450 enzymes (P450s), which are widely found in biologically active natural products, synthetic drugs and also widely used as mechanistic probes to reveal elusive reaction mechanisms, such as that involved in P450-catalyzed amine oxidations (Bhakta and Wimalasena, ; Ortiz de Montellano and De Voss, ; Totah and Hanzlik, ; Bhakta et al.,. 	cytochrome P450	2340	2355	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:11	Cyclopropylamines are one kind of such prototypical inhibitors for cytochrome P450 enzymes (P450s), which are widely found in biologically active natural products, synthetic drugs and also widely used as mechanistic probes to reveal elusive reaction mechanisms, such as that involved in P450-catalyzed amine oxidations (Bhakta and Wimalasena, ; Ortiz de Montellano and De Voss, ; Totah and Hanzlik, ; Bhakta et al.,. 	cytochrome P450	2340	2355	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:29	Furthermore, according to Hanzlik, the incubation of 1 with microsomes indeed caused a time-, concentration- and cofactor-dependent loss of cytochrome P450 activity, which was, however, not vanished completely but instead remained 25-30% of it (Cerny and Hanzlik,. 	cytochrome P450	6894	6909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:29	Furthermore, according to Hanzlik, the incubation of 1 with microsomes indeed caused a time-, concentration- and cofactor-dependent loss of cytochrome P450 activity, which was, however, not vanished completely but instead remained 25-30% of it (Cerny and Hanzlik,. 	cytochrome P450	6894	6909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:46	recently investigated the mechanism-based inactivation of cytochrome P450 by 1,1-dimethylhydrazine (UMDH) (Hirao et al., ), they examined four possible reaction pathways including H-abstractions from the primary amine moiety and the methyl moiety, as well as the direct oxidations on two nitrogen atoms. 	cytochrome P450	10156	10171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:46	recently investigated the mechanism-based inactivation of cytochrome P450 by 1,1-dimethylhydrazine (UMDH) (Hirao et al., ), they examined four possible reaction pathways including H-abstractions from the primary amine moiety and the methyl moiety, as well as the direct oxidations on two nitrogen atoms. 	cytochrome P450	10156	10171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:104	In other words, the present N-H bond activation should be achieved via a PCET(ET) mechanism as the findings of Usharani et al.. As mentioned by Cerny and Hanzlik, cytochrome P450 activity was not vanished completely but instead remained 25-30% during the incubation with BCA. 	cytochrome P450	21584	21599	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:104	In other words, the present N-H bond activation should be achieved via a PCET(ET) mechanism as the findings of Usharani et al.. As mentioned by Cerny and Hanzlik, cytochrome P450 activity was not vanished completely but instead remained 25-30% during the incubation with BCA. 	cytochrome P450	21584	21599	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:126	For decades, the mechanism-based inactivation role of N-benzyl-N-cyclopropylamine to cytochrome P450 has been attracting great interests. 	cytochrome P450	26012	26027	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:126	For decades, the mechanism-based inactivation role of N-benzyl-N-cyclopropylamine to cytochrome P450 has been attracting great interests. 	cytochrome P450	26012	26027	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5294638_OgerInput.txtOger_out.csv:199	A foliar application of methyl jasmonate caused a higher expression level of HMGR and the farnesyl diphosphate synthase gene in leaves and stems of treated S. album seedlings compared to untreated plants at 4 h, but expression of cytochrome P450 showed no change in both leaves and stems. 	cytochrome P450	32636	32651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5294638_OgerInput.txtOger_out.csv:199	A foliar application of methyl jasmonate caused a higher expression level of HMGR and the farnesyl diphosphate synthase gene in leaves and stems of treated S. album seedlings compared to untreated plants at 4 h, but expression of cytochrome P450 showed no change in both leaves and stems. 	cytochrome P450	32636	32651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5306091_OgerInput.txtOger_out.csv:93	Docetaxel is mainly metabolized by hepatic cytochrome P450 isoenzymes, whereas Monoclonal Antibodies are primarily eliminated through large-capacity, non-specific, Fc receptor-mediated IgG clearance mechanisms and through specific, target-mediated drug disposition pathways. 	cytochrome P450	19759	19774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5306091_OgerInput.txtOger_out.csv:93	Docetaxel is mainly metabolized by hepatic cytochrome P450 isoenzymes, whereas Monoclonal Antibodies are primarily eliminated through large-capacity, non-specific, Fc receptor-mediated IgG clearance mechanisms and through specific, target-mediated drug disposition pathways. 	cytochrome P450	19759	19774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5307856_OgerInput.txtOger_out.csv:145	In this section, we highlight the diversity of SM production in the aspergilli and the role of cytochrome P450 (CYP) genes in secondary metabolism. 	cytochrome P450	25717	25732	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5307856_OgerInput.txtOger_out.csv:145	In this section, we highlight the diversity of SM production in the aspergilli and the role of cytochrome P450 (CYP) genes in secondary metabolism. 	cytochrome P450	25717	25732	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5307856_OgerInput.txtOger_out.csv:335	A cytochrome P450 nor (nitric oxide reductase) that reduces NO to N_2O was found in Fusarium oxysporum. 	cytochrome P450	57336	57351	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5307856_OgerInput.txtOger_out.csv:335	A cytochrome P450 nor (nitric oxide reductase) that reduces NO to N_2O was found in Fusarium oxysporum. 	cytochrome P450	57336	57351	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5314637_OgerInput.txtOger_out.csv:125	This analysis revealed that P-Coumaroyl Ester 3-Hydroxylase is a member of the cytochrome P450 family, an oxireductase acting as monooxygenase (InterPro). 	cytochrome P450	21638	21653	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5314637_OgerInput.txtOger_out.csv:125	This analysis revealed that P-Coumaroyl Ester 3-Hydroxylase is a member of the cytochrome P450 family, an oxireductase acting as monooxygenase (InterPro). 	cytochrome P450	21638	21653	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:8	With respect to environmental stress, we note a proliferation of various detoxification genes, including glutatione-S-transferases and those in the cytochrome P450 families. 	cytochrome P450	1282	1297	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:8	With respect to environmental stress, we note a proliferation of various detoxification genes, including glutatione-S-transferases and those in the cytochrome P450 families. 	cytochrome P450	1282	1297	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:125	Most CYP450 genes in ant genomes are members of cytochrome P450 9th, 6th and 4th families (Fig. 	cytochrome P450	17542	17557	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:125	Most CYP450 genes in ant genomes are members of cytochrome P450 9th, 6th and 4th families (Fig. 	cytochrome P450	17542	17557	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:224	We studied the cytochrome P450 superfamily in detail, as it is known for its crucial role in resistance to xenobiotics [,. 	cytochrome P450	30020	30035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:224	We studied the cytochrome P450 superfamily in detail, as it is known for its crucial role in resistance to xenobiotics [,. 	cytochrome P450	30020	30035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:237	L. niger and C. floridanus, which belong to the subfamily Formicinae, contain approximately the same number of cytochrome P450 genes, and this number is higher than that in other species of ants. 	cytochrome P450	31670	31685	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:237	L. niger and C. floridanus, which belong to the subfamily Formicinae, contain approximately the same number of cytochrome P450 genes, and this number is higher than that in other species of ants. 	cytochrome P450	31670	31685	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:241	It is possible that the large set of cytochrome P450 genes provide for polyphagia by enabling specific and nonspecific neutralization of various phyto and mycotoxins (phytotoxin resistance would enable L. niger to feed on nectar and resistance to mycotoxins would enable it to feed on dead insects). 	cytochrome P450	32101	32116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:241	It is possible that the large set of cytochrome P450 genes provide for polyphagia by enabling specific and nonspecific neutralization of various phyto and mycotoxins (phytotoxin resistance would enable L. niger to feed on nectar and resistance to mycotoxins would enable it to feed on dead insects). 	cytochrome P450	32101	32116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:243	Some cytochrome P450 genes can oxidize some of these chemicals, eg, benzo(a)pyren. 	cytochrome P450	32538	32553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:243	Some cytochrome P450 genes can oxidize some of these chemicals, eg, benzo(a)pyren. 	cytochrome P450	32538	32553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:95	^ CYP2J2 comes from a superfamily of monooxygenases of cytochrome P450 (CYP450) enzymes, and we choose its gene as candidate to investigate the relationship between CYP2J2 and IS in Chinese Han population. 	cytochrome P450	14059	14074	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:95	^ CYP2J2 comes from a superfamily of monooxygenases of cytochrome P450 (CYP450) enzymes, and we choose its gene as candidate to investigate the relationship between CYP2J2 and IS in Chinese Han population. 	cytochrome P450	14059	14074	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	cytochrome P450	23809	23824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	cytochrome P450	23809	23824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:160	DNA oxidation damage in rodents exposed to DLCs is probably induced through upregulation of cytochrome P450 superfamily of enzymes, mediated by AhR-dependent pathways. 	cytochrome P450	28551	28566	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:160	DNA oxidation damage in rodents exposed to DLCs is probably induced through upregulation of cytochrome P450 superfamily of enzymes, mediated by AhR-dependent pathways. 	cytochrome P450	28551	28566	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:24	^ However, MMF is of possible concern and its combination with drugs, environmental pollutants, or food constituents, which activate cytochrome P450 transcriptional factor, may represent a significant toxicological risk. 	cytochrome P450	4464	4479	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:24	^ However, MMF is of possible concern and its combination with drugs, environmental pollutants, or food constituents, which activate cytochrome P450 transcriptional factor, may represent a significant toxicological risk. 	cytochrome P450	4464	4479	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:28	P-glycoprotein (Pgp) and cytochrome P450 3A4 have been recognized as determinants of the bioavailability of widely used immunosuppressants such as CsA, tacrolimus, and sirolimus. 	cytochrome P450	5327	5342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:28	P-glycoprotein (Pgp) and cytochrome P450 3A4 have been recognized as determinants of the bioavailability of widely used immunosuppressants such as CsA, tacrolimus, and sirolimus. 	cytochrome P450	5327	5342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:120	Proliferation signal inhibitors such as sirolimus and EVR are substrates of cytochrome P450 3A4 and Pgp and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with proliferation signal inhibitors are comparable to those with CNIs. 	cytochrome P450	20455	20470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:120	Proliferation signal inhibitors such as sirolimus and EVR are substrates of cytochrome P450 3A4 and Pgp and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with proliferation signal inhibitors are comparable to those with CNIs. 	cytochrome P450	20455	20470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5393875_OgerInput.txtOger_out.csv:28	suggested that DIO induces anticancer activity in MCF7 breast cancer cells by causing cytochrome P450 bioactivation. 	cytochrome P450	3354	3369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5393875_OgerInput.txtOger_out.csv:28	suggested that DIO induces anticancer activity in MCF7 breast cancer cells by causing cytochrome P450 bioactivation. 	cytochrome P450	3354	3369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:163	While the contribution of some dietary polyphenols in the management of Benign Prostatic Hyperplasia has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 enzymes. 	cytochrome P450	32644	32659	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:163	While the contribution of some dietary polyphenols in the management of Benign Prostatic Hyperplasia has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 enzymes. 	cytochrome P450	32644	32659	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5437572_OgerInput.txtOger_out.csv:179	Acetaminophen is metabolically activated to form a reactive metabolite by several types of cytochrome P450 such as cytochromes 2E1, 1A2, 3A4, and 2A6 via a direct two-electron oxidation. 	cytochrome P450	26790	26805	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5437572_OgerInput.txtOger_out.csv:179	Acetaminophen is metabolically activated to form a reactive metabolite by several types of cytochrome P450 such as cytochromes 2E1, 1A2, 3A4, and 2A6 via a direct two-electron oxidation. 	cytochrome P450	26790	26805	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5437572_OgerInput.txtOger_out.csv:196	Of These, Acetaminophen is metabolized by cytochrome P450 to form a reactive metabolites, NAPQI, which then reacts with hepatic glutathione (GSH) causing the latter depletion by approximately 90%. 	cytochrome P450	28874	28889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5437572_OgerInput.txtOger_out.csv:196	Of These, Acetaminophen is metabolized by cytochrome P450 to form a reactive metabolites, NAPQI, which then reacts with hepatic glutathione (GSH) causing the latter depletion by approximately 90%. 	cytochrome P450	28874	28889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:109	Although lipids can be oxidized by lipoxygenases, cyclooxygenases, and cytochrome P450 to generate signaling molecules, Reactive Oxygen Species (eg, hydroxyl radical-HO^ and hydroperoxyl-HO2.) 	cytochrome P450	22991	23006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:109	Although lipids can be oxidized by lipoxygenases, cyclooxygenases, and cytochrome P450 to generate signaling molecules, Reactive Oxygen Species (eg, hydroxyl radical-HO^ and hydroperoxyl-HO2.) 	cytochrome P450	22991	23006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:3	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency. 	cytochrome P450	432	447	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:3	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency. 	cytochrome P450	432	447	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:11	Herbal drugs (eg, Hypericum perforatum, Ginkgo biloba, Camellia sinensis, Glycyrrhiza glabra, Allium sativum, Rhizoma Coptidis, and Fructus Silybi) and their constituents cause herb-drug interactions via the induction or inhibition of major drug-metabolizing enzymes, cytochrome P450 and result in the toxicity and therapeutic failure of various concomitant drugs. 	cytochrome P450	3206	3221	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:11	Herbal drugs (eg, Hypericum perforatum, Ginkgo biloba, Camellia sinensis, Glycyrrhiza glabra, Allium sativum, Rhizoma Coptidis, and Fructus Silybi) and their constituents cause herb-drug interactions via the induction or inhibition of major drug-metabolizing enzymes, cytochrome P450 and result in the toxicity and therapeutic failure of various concomitant drugs. 	cytochrome P450	3206	3221	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:158	For example, the cytochrome P450 enzymes are a class of phase I enzymes. 	cytochrome P450	20202	20217	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:158	For example, the cytochrome P450 enzymes are a class of phase I enzymes. 	cytochrome P450	20202	20217	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome P450	1280	1295	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome P450	1280	1295	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome P450	3731	3746	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome P450	3731	3746	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome P450	3768	3783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome P450	3768	3783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:17	For a complete understanding of their active interactions, it is crucial to obtain the structural information of the biologically active full-length forms with both transmembrane and extramembranous domains, especially in the case of membrane-bound cytochrome P450 complexes^, -, -,. 	cytochrome P450	4227	4242	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:17	For a complete understanding of their active interactions, it is crucial to obtain the structural information of the biologically active full-length forms with both transmembrane and extramembranous domains, especially in the case of membrane-bound cytochrome P450 complexes^, -, -,. 	cytochrome P450	4227	4242	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:27	In this study, we demonstrate the feasibility of ssNMR spectroscopy^- for probing transmembrane interactions of membrane-bound bitopic proteins, namely the intact mammalian cytochrome P450-cytochrome b_5 complex, in lipid bilayers. 	cytochrome P450	6785	6800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:27	In this study, we demonstrate the feasibility of ssNMR spectroscopy^- for probing transmembrane interactions of membrane-bound bitopic proteins, namely the intact mammalian cytochrome P450-cytochrome b_5 complex, in lipid bilayers. 	cytochrome P450	6785	6800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:30	As a key step in their catalytic cycles, their oxidation of substrates requires two electrons to be transferred to the heme-containing reaction center of cytochromes P450 from their redox partners, such as cytochromes b_5, and cytochrome P450 reductases^,. 	cytochrome P450	7492	7507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:30	As a key step in their catalytic cycles, their oxidation of substrates requires two electrons to be transferred to the heme-containing reaction center of cytochromes P450 from their redox partners, such as cytochromes b_5, and cytochrome P450 reductases^,. 	cytochrome P450	7492	7507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:32	This crucial transmembrane-transmembrane interaction of the full-length liver microsomal cytochrome P450 2B4 with its full-length redox partner, cytochrome b_5, is investigated in this study. 	cytochrome P450	7747	7762	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:32	This crucial transmembrane-transmembrane interaction of the full-length liver microsomal cytochrome P450 2B4 with its full-length redox partner, cytochrome b_5, is investigated in this study. 	cytochrome P450	7747	7762	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome P450	8424	8439	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome P450	8424	8439	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome P450	8552	8567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome P450	8552	8567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome P450	8727	8742	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome P450	8727	8742	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome P450	8893	8908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome P450	8893	8908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome P450	9146	9161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome P450	9146	9161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9379	9394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9379	9394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9807	9822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9807	9822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9878	9893	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome P450	9878	9893	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:39	These high-resolution full-length structures are significant breakthroughs towards the complete understanding of the functional aspects of membrane-bound mammalian cytochromes, as it is known that the lack of transmembrane anchors reduces to only 40% of all enzymatic activities in the case of cytochrome P450 2B4, and results in a total loss of electron transfer capability to cytochromes P450 in the case of cytochrome b_5 ^, --. 	cytochrome P450	10195	10210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:39	These high-resolution full-length structures are significant breakthroughs towards the complete understanding of the functional aspects of membrane-bound mammalian cytochromes, as it is known that the lack of transmembrane anchors reduces to only 40% of all enzymatic activities in the case of cytochrome P450 2B4, and results in a total loss of electron transfer capability to cytochromes P450 in the case of cytochrome b_5 ^, --. 	cytochrome P450	10195	10210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:40	A recent solution NMR study from our group revealed the first full-length dynamic interactions of the membrane-bound complex between rabbit cytochrome P450 2B4 and cytochrome b_5 reconstituted in isotropic bicelles and the electron transfer pathway between catalytic domains of the complex. 	cytochrome P450	10473	10488	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:40	A recent solution NMR study from our group revealed the first full-length dynamic interactions of the membrane-bound complex between rabbit cytochrome P450 2B4 and cytochrome b_5 reconstituted in isotropic bicelles and the electron transfer pathway between catalytic domains of the complex. 	cytochrome P450	10473	10488	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:41	However, these traditional solution NMR techniques could not have explained the importance of the transmembrane domains for the catalytic activities of the cytochrome P450 complex due to the experimental limitations of solution NMR spectroscopy, which are attributed to the intermediate time scale of dynamics of transmembrane helices^. 	cytochrome P450	10780	10795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:41	However, these traditional solution NMR techniques could not have explained the importance of the transmembrane domains for the catalytic activities of the cytochrome P450 complex due to the experimental limitations of solution NMR spectroscopy, which are attributed to the intermediate time scale of dynamics of transmembrane helices^. 	cytochrome P450	10780	10795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:43	The combination of these developments have enabled us to report the DNP solid-state NMR spectroscopy probing transmembrane-transmembrane interactions of the cytochrome P450-cytochrome b_5 complex embedded in lipid bilayers at an atomic-level for the first time. 	cytochrome P450	11433	11448	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:43	The combination of these developments have enabled us to report the DNP solid-state NMR spectroscopy probing transmembrane-transmembrane interactions of the cytochrome P450-cytochrome b_5 complex embedded in lipid bilayers at an atomic-level for the first time. 	cytochrome P450	11433	11448	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:54	The overexpression and purification of selectively ^13C-labeled cytochrome b_5 and uniformly ^15N-labeled cytochrome P450 were reported previously^,. 	cytochrome P450	12609	12624	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:54	The overexpression and purification of selectively ^13C-labeled cytochrome b_5 and uniformly ^15N-labeled cytochrome P450 were reported previously^,. 	cytochrome P450	12609	12624	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome P450	13034	13049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome P450	13034	13049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome P450	13366	13381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome P450	13366	13381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:68	Rabbit cytochrome b_5 and cytochrome P450 were overexpressed and purified from E. Coli ^, and then reconstituted^,  into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid bilayers hydrated with biradical solutions of [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) containing DNP polarizing agents, AMUPol^ or TOTAPOL (1-(TEMPO-4-oxy)-3-(TEMPO-4-amino)propan-2-ol)^, as described in the previous section. 	cytochrome P450	14991	15006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:68	Rabbit cytochrome b_5 and cytochrome P450 were overexpressed and purified from E. Coli ^, and then reconstituted^,  into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid bilayers hydrated with biradical solutions of [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) containing DNP polarizing agents, AMUPol^ or TOTAPOL (1-(TEMPO-4-oxy)-3-(TEMPO-4-amino)propan-2-ol)^, as described in the previous section. 	cytochrome P450	14991	15006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:70	In fact, the yield of isotopically labeled full-length cytochrome P450 is extremely low, which is unfavorable for traditional ssNMR-based structural studies which generally require large sample quantities. 	cytochrome P450	15572	15587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:70	In fact, the yield of isotopically labeled full-length cytochrome P450 is extremely low, which is unfavorable for traditional ssNMR-based structural studies which generally require large sample quantities. 	cytochrome P450	15572	15587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:91	In the previous studies, high-resolution structural interactions between the soluble domains of the cytochrome P450-cytochrome b_5 complex have been investigated, and structure of the complex was reported^,. 	cytochrome P450	20195	20210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:91	In the previous studies, high-resolution structural interactions between the soluble domains of the cytochrome P450-cytochrome b_5 complex have been investigated, and structure of the complex was reported^,. 	cytochrome P450	20195	20210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome P450	27478	27493	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome P450	27478	27493	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:123	Particularly, it is known that the soluble domain (particularly, the F-G loop region) of cytochrome P450 is tightly bound to the lipid membrane due to its hydrophobicity; therefore, its redox binding partners, like cytochrome b_5, have to be suitably oriented to form a productive complex^,. 	cytochrome P450	27586	27601	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:123	Particularly, it is known that the soluble domain (particularly, the F-G loop region) of cytochrome P450 is tightly bound to the lipid membrane due to its hydrophobicity; therefore, its redox binding partners, like cytochrome b_5, have to be suitably oriented to form a productive complex^,. 	cytochrome P450	27586	27601	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome P450	27840	27855	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome P450	27840	27855	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome P450	27886	27901	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome P450	27886	27901	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome P450	29495	29510	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome P450	29495	29510	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome P450	30037	30052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome P450	30037	30052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome P450	30114	30129	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome P450	30114	30129	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome P450	30439	30454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome P450	30439	30454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome P450	31075	31090	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome P450	31075	31090	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:139	It is also known that cytochrome P450 is relatively unstable at ambient temperatures; however, the use of DNP spectroscopy under frozen conditions can circumvent this shortcoming^,. 	cytochrome P450	31360	31375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:139	It is also known that cytochrome P450 is relatively unstable at ambient temperatures; however, the use of DNP spectroscopy under frozen conditions can circumvent this shortcoming^,. 	cytochrome P450	31360	31375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome P450	32382	32397	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome P450	32382	32397	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome P450	32621	32636	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome P450	32621	32636	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome P450	33337	33352	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome P450	33337	33352	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:153	Furthermore, the helical wheel diagram of Supplementary Figure  suggests that cytochrome P450 2B4 contains many leucine residues in the N-terminal transmembrane ALPHA-helix region. 	cytochrome P450	34534	34549	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:153	Furthermore, the helical wheel diagram of Supplementary Figure  suggests that cytochrome P450 2B4 contains many leucine residues in the N-terminal transmembrane ALPHA-helix region. 	cytochrome P450	34534	34549	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome P450	34734	34749	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome P450	34734	34749	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome P450	34837	34852	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome P450	34837	34852	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:160	Herein, possible driving forces for the transmembrane complex formation in cytochrome P450-cytochrome b_5 would be a combination of: (i) van der Waals-London interactions^, (ii) electrostatic attraction, estimated by 1-3 kcal, between oppositely charged electric dipolar moments in the association of C- and N-terminal ALPHA-helices^, and (iii) hydrophobic interactions of ALPHA-helices near the surface of the lipid bilayer based on the leucine zipper-like motifs ^, -,. 	cytochrome P450	35868	35883	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:160	Herein, possible driving forces for the transmembrane complex formation in cytochrome P450-cytochrome b_5 would be a combination of: (i) van der Waals-London interactions^, (ii) electrostatic attraction, estimated by 1-3 kcal, between oppositely charged electric dipolar moments in the association of C- and N-terminal ALPHA-helices^, and (iii) hydrophobic interactions of ALPHA-helices near the surface of the lipid bilayer based on the leucine zipper-like motifs ^, -,. 	cytochrome P450	35868	35883	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome P450	36391	36406	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome P450	36391	36406	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome P450	36445	36460	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome P450	36445	36460	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:162	This observation suggests that the roles of transmembrane interaction in the complex formation of cytochrome P450-cytochrome P450 reductase could be different. 	cytochrome P450	36621	36636	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:162	This observation suggests that the roles of transmembrane interaction in the complex formation of cytochrome P450-cytochrome P450 reductase could be different. 	cytochrome P450	36621	36636	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:162	This observation suggests that the roles of transmembrane interaction in the complex formation of cytochrome P450-cytochrome P450 reductase could be different. 	cytochrome P450	36637	36652	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:162	This observation suggests that the roles of transmembrane interaction in the complex formation of cytochrome P450-cytochrome P450 reductase could be different. 	cytochrome P450	36637	36652	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:163	Such NMR studies of cytochrome P450-cytochrome P450 reductase are currently under investigation in our laboratory. 	cytochrome P450	36703	36718	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:163	Such NMR studies of cytochrome P450-cytochrome P450 reductase are currently under investigation in our laboratory. 	cytochrome P450	36703	36718	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:163	Such NMR studies of cytochrome P450-cytochrome P450 reductase are currently under investigation in our laboratory. 	cytochrome P450	36719	36734	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:163	Such NMR studies of cytochrome P450-cytochrome P450 reductase are currently under investigation in our laboratory. 	cytochrome P450	36719	36734	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:164	This study represents the first experimental report revealing the topology and structure of the transmembrane domains of membrane-bound cytochrome P450-cytochrome b_5 complex in the functional full-length form. 	cytochrome P450	36934	36949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:164	This study represents the first experimental report revealing the topology and structure of the transmembrane domains of membrane-bound cytochrome P450-cytochrome b_5 complex in the functional full-length form. 	cytochrome P450	36934	36949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	cytochrome P450	2008	2023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	cytochrome P450	2008	2023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	cytochrome P450	4883	4898	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	cytochrome P450	4883	4898	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:14	The cytochrome P450 superfamily is involved in the metabolism of a diverse range of xenobiotics and endogenous compounds. 	cytochrome P450	1764	1779	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:14	The cytochrome P450 superfamily is involved in the metabolism of a diverse range of xenobiotics and endogenous compounds. 	cytochrome P450	1764	1779	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	cytochrome P450	2094	2109	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	cytochrome P450	2094	2109	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:51	This is a two-step oxidation reaction catalyzed by cytochrome P450 enzymes. 	cytochrome P450	8495	8510	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:51	This is a two-step oxidation reaction catalyzed by cytochrome P450 enzymes. 	cytochrome P450	8495	8510	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:1	 Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. 	cytochrome P450	12	27	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:1	 Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. 	cytochrome P450	12	27	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:2	Most drugs are metabolized by hepatic cytochrome P450 3A4, resulting in their reduced bioavailability. 	cytochrome P450	123	138	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:2	Most drugs are metabolized by hepatic cytochrome P450 3A4, resulting in their reduced bioavailability. 	cytochrome P450	123	138	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	cytochrome P450	1772	1787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	cytochrome P450	1772	1787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:2	The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. 	cytochrome P450	177	192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:2	The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. 	cytochrome P450	177	192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:16	The complex tamoxifen metabolism is primarily catalyzed by cytochrome P450 (CYP) enzymes, which are subject to substantial differences in inter-individual expression and activity^-. 	cytochrome P450	2232	2247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:16	The complex tamoxifen metabolism is primarily catalyzed by cytochrome P450 (CYP) enzymes, which are subject to substantial differences in inter-individual expression and activity^-. 	cytochrome P450	2232	2247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	cytochrome P450	2138	2153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	cytochrome P450	2138	2153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:43	We found that this sequence has an extra long (~29 amino acids) N terminus with no functional annotations when compared with most other CYP152 members including those cytochrome P450 family proteins from other Staphylococcus species (Additional file : Figure S1). 	cytochrome P450	8296	8311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:43	We found that this sequence has an extra long (~29 amino acids) N terminus with no functional annotations when compared with most other CYP152 members including those cytochrome P450 family proteins from other Staphylococcus species (Additional file : Figure S1). 	cytochrome P450	8296	8311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:51	A widely accepted criterion for the identification of cytochrome P450 is a Soret peak at around 450 nm in the reduced CO difference spectrum. 	cytochrome P450	9895	9910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:51	A widely accepted criterion for the identification of cytochrome P450 is a Soret peak at around 450 nm in the reduced CO difference spectrum. 	cytochrome P450	9895	9910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:135	Furthermore, analysis of mRNA  sequences of cytochrome P450 family proteins from other Staphylococcus species such as S. agnetis (GenBank: JPRT01000001.1) and S. pseudintermedius (GenBank: CP002439.1) also revealed a similar pattern of the strong 5-6 G-C pairs of Shine-Dalgarno complementarity preceding a GUG start codon. 	cytochrome P450	26075	26090	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:135	Furthermore, analysis of mRNA  sequences of cytochrome P450 family proteins from other Staphylococcus species such as S. agnetis (GenBank: JPRT01000001.1) and S. pseudintermedius (GenBank: CP002439.1) also revealed a similar pattern of the strong 5-6 G-C pairs of Shine-Dalgarno complementarity preceding a GUG start codon. 	cytochrome P450	26075	26090	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:137	P420 species was generally thought to be an inactive form of cytochrome P450 enzymes. 	cytochrome P450	26522	26537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:137	P420 species was generally thought to be an inactive form of cytochrome P450 enzymes. 	cytochrome P450	26522	26537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:310	Duplications of members of enzyme families (eg cytochromes P450, glycosyltransferases, methyltransferases, BAHD acyltransferases) also play major roles in generating chemical novelty, with biosynthesis of >40,000 structurally diverse terpenoids - produced partly due to genomic clustering of terpene synthases and cytochrome P450 enzymes - as an extreme example. 	cytochrome P450	45243	45258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:310	Duplications of members of enzyme families (eg cytochromes P450, glycosyltransferases, methyltransferases, BAHD acyltransferases) also play major roles in generating chemical novelty, with biosynthesis of >40,000 structurally diverse terpenoids - produced partly due to genomic clustering of terpene synthases and cytochrome P450 enzymes - as an extreme example. 	cytochrome P450	45243	45258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:535	Indeed, the structural diversity in a single individual could be a reflection of promiscuous enzyme activities, given large enzyme families such as BAHDs, cytochrome P450s, glycosyltransferases play a role in the biosynthesis of several specialized metabolite classes. 	cytochrome P450	85580	85595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:535	Indeed, the structural diversity in a single individual could be a reflection of promiscuous enzyme activities, given large enzyme families such as BAHDs, cytochrome P450s, glycosyltransferases play a role in the biosynthesis of several specialized metabolite classes. 	cytochrome P450	85580	85595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5599026_OgerInput.txtOger_out.csv:25	In fact, mitochondria appear uniquely susceptible to toxicants as a result of: 1) accumulation of toxicants due to the high lipid content of the mitochondrial membranes, slight negative charge of the mitochondrial matrix, and presence of metal cation transporters; 2) ability to activate organic compounds via mitochondrial cytochrome P450s; 3) the presence of the reactive oxygen species generating electron transport chain; 4) reduced repair mechanisms for mitochondrial DNA in comparison to the nuclear genome, and 5) the potential for toxicant exposure to increase the endogenous level of production of reactive oxygen species. 	cytochrome P450	3950	3965	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5599026_OgerInput.txtOger_out.csv:25	In fact, mitochondria appear uniquely susceptible to toxicants as a result of: 1) accumulation of toxicants due to the high lipid content of the mitochondrial membranes, slight negative charge of the mitochondrial matrix, and presence of metal cation transporters; 2) ability to activate organic compounds via mitochondrial cytochrome P450s; 3) the presence of the reactive oxygen species generating electron transport chain; 4) reduced repair mechanisms for mitochondrial DNA in comparison to the nuclear genome, and 5) the potential for toxicant exposure to increase the endogenous level of production of reactive oxygen species. 	cytochrome P450	3950	3965	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:44	The receptor panel profiling and cytochrome P450 inhibition assays on S2218 were conducted at Eurofins PanlabsTaiwan Ltd., Taipei, Taiwan. 	cytochrome P450	10144	10159	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:44	The receptor panel profiling and cytochrome P450 inhibition assays on S2218 were conducted at Eurofins PanlabsTaiwan Ltd., Taipei, Taiwan. 	cytochrome P450	10144	10159	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	cytochrome P450	35814	35829	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	cytochrome P450	35814	35829	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:214	For the two compounds active against TbPTR1 (4m and 4o), IC_50 against hERG, cytochrome P450, and mitochondrial toxicity were determined (reported in Supporting Information). 	cytochrome P450	37109	37124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:214	For the two compounds active against TbPTR1 (4m and 4o), IC_50 against hERG, cytochrome P450, and mitochondrial toxicity were determined (reported in Supporting Information). 	cytochrome P450	37109	37124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:449	Obes Rev 17: 42941 [PMID:26997580] The cytochrome P450 enzyme family (CYP450), E.C. 	cytochrome P450	52762	52777	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:449	Obes Rev 17: 42941 [PMID:26997580] The cytochrome P450 enzyme family (CYP450), E.C. 	cytochrome P450	52762	52777	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:468	(2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. 	cytochrome P450	54349	54364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:468	(2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. 	cytochrome P450	54349	54364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:472	(2017) Spectroscopic studies of the cytochrome P450 reaction mechanisms. 	cytochrome P450	54636	54651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:472	(2017) Spectroscopic studies of the cytochrome P450 reaction mechanisms. 	cytochrome P450	54636	54651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:476	(2017) Keeping the spotlight on cytochrome P450. 	cytochrome P450	54902	54917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:476	(2017) Keeping the spotlight on cytochrome P450. 	cytochrome P450	54902	54917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:482	In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [11, 154, 488]. 	cytochrome P450	55944	55959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:482	In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [11, 154, 488]. 	cytochrome P450	55944	55959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:508	Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450like epoxygenases, particularly CYP2J2. 	cytochrome P450	57984	57999	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:508	Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450like epoxygenases, particularly CYP2J2. 	cytochrome P450	57984	57999	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:515	Subsequent to the formation of PGH_2, the cytochrome P450 activities thromboxane synthase (CYP5A1, TBXAS1, P24557, EC 5.3.99.5) and prostacyclin synthase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A_2 and prostacyclin (PGI_2), respectively (see Cytochrome P450s). 	cytochrome P450	59010	59025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:515	Subsequent to the formation of PGH_2, the cytochrome P450 activities thromboxane synthase (CYP5A1, TBXAS1, P24557, EC 5.3.99.5) and prostacyclin synthase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A_2 and prostacyclin (PGI_2), respectively (see Cytochrome P450s). 	cytochrome P450	59010	59025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:1	 Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. 	cytochrome P450	58	73	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:1	 Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. 	cytochrome P450	58	73	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:2	Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. 	cytochrome P450	228	243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:2	Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. 	cytochrome P450	228	243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome P450	3618	3633	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome P450	3618	3633	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:1	 Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies. 	cytochrome P450	63	78	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:1	 Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies. 	cytochrome P450	63	78	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:2	The utility of HepG2 cells to assess drug metabolism and toxicity induced by chemical compounds is hampered by their low cytochrome P450 activities. 	cytochrome P450	300	315	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:2	The utility of HepG2 cells to assess drug metabolism and toxicity induced by chemical compounds is hampered by their low cytochrome P450 activities. 	cytochrome P450	300	315	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:27	; Chiangsom et al.. Several studies have evaluated the inhibitory potential of R. rosea toward cytochrome P450 enzymes. 	cytochrome P450	3267	3282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:27	; Chiangsom et al.. Several studies have evaluated the inhibitory potential of R. rosea toward cytochrome P450 enzymes. 	cytochrome P450	3267	3282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:142	), and metyrapone on Ndemethylation of aminopyrine by mixed function oxidase cytochrome P450 in rat (Roots and Hildebrandt. 	cytochrome P450	20223	20238	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:142	), and metyrapone on Ndemethylation of aminopyrine by mixed function oxidase cytochrome P450 in rat (Roots and Hildebrandt. 	cytochrome P450	20223	20238	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:1	 Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs. 	cytochrome P450	15	30	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:1	 Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs. 	cytochrome P450	15	30	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:2	Determining drug-metabolizing enzyme activities on an individual basis is an important component of personalized medicine, and cytochrome P450 enzymes play a principal role in hepatic drug metabolism. 	cytochrome P450	243	258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:2	Determining drug-metabolizing enzyme activities on an individual basis is an important component of personalized medicine, and cytochrome P450 enzymes play a principal role in hepatic drug metabolism. 	cytochrome P450	243	258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:62	Microsomal protein per gram of liver contents were determined using cytochrome P450 oxidoreductase activity as measured in homogenates and microsomes obtained from the same liver tissue sample; The liver weight was calculated by multiplying the liver volume by the liver density, where liver volume (ml) = 12.5  Body Weight + 536.4 and the liver density was 1.001 g/ml. 	cytochrome P450	12253	12268	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:62	Microsomal protein per gram of liver contents were determined using cytochrome P450 oxidoreductase activity as measured in homogenates and microsomes obtained from the same liver tissue sample; The liver weight was calculated by multiplying the liver volume by the liver density, where liver volume (ml) = 12.5  Body Weight + 536.4 and the liver density was 1.001 g/ml. 	cytochrome P450	12253	12268	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:5	This study aims to observe TSG-provided the aggravation on acetaminophen (APAP)-induced hepatotoxicity in mice by inducing hepatic expression of cytochrome P450 enzymes. 	cytochrome P450	531	546	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:5	This study aims to observe TSG-provided the aggravation on acetaminophen (APAP)-induced hepatotoxicity in mice by inducing hepatic expression of cytochrome P450 enzymes. 	cytochrome P450	531	546	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	cytochrome P450	25939	25954	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	cytochrome P450	25939	25954	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5713417_OgerInput.txtOger_out.csv:250	Although insects have detoxification mechanisms (eg, cytochrome P450 monooxygenases, glutathione S-transferases, and esterases), some symbionts within the host-associated bacterial community are responsible for the detoxification of plant secondary metabolites. 	cytochrome P450	45299	45314	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5713417_OgerInput.txtOger_out.csv:250	Although insects have detoxification mechanisms (eg, cytochrome P450 monooxygenases, glutathione S-transferases, and esterases), some symbionts within the host-associated bacterial community are responsible for the detoxification of plant secondary metabolites. 	cytochrome P450	45299	45314	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	cytochrome P450	90	105	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	cytochrome P450	90	105	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450	2490	2505	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450	2490	2505	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:225	One of the most important mechanisms through which interactions occur is via the interference of herbal products with human hepatic drug metabolizing enzyme activities particularly the cytochrome P450 enzymes. 	cytochrome P450	40564	40579	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:225	One of the most important mechanisms through which interactions occur is via the interference of herbal products with human hepatic drug metabolizing enzyme activities particularly the cytochrome P450 enzymes. 	cytochrome P450	40564	40579	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:12	Human thromboxane synthase belongs to the cytochrome P450 superfamily (CYP5A1). 	cytochrome P450	1915	1930	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:12	Human thromboxane synthase belongs to the cytochrome P450 superfamily (CYP5A1). 	cytochrome P450	1915	1930	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:23	Sort=Bait also performs other functions: catalyze monooxygenase reactions characteristic of cytochrome P450 and involving redox partners. 	cytochrome P450	3454	3469	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:23	Sort=Bait also performs other functions: catalyze monooxygenase reactions characteristic of cytochrome P450 and involving redox partners. 	cytochrome P450	3454	3469	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:45	Sort=Bait and cytochrome P450 reductase (http://hdl.handle. 	cytochrome P450	6406	6421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:45	Sort=Bait and cytochrome P450 reductase (http://hdl.handle. 	cytochrome P450	6406	6421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:52	Sort=Bait using a LC-MS/MS-analysis, one of which was cytochrome P450 (CYP2E1). 	cytochrome P450	7511	7526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:52	Sort=Bait using a LC-MS/MS-analysis, one of which was cytochrome P450 (CYP2E1). 	cytochrome P450	7511	7526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	cytochrome P450	20682	20697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	cytochrome P450	20682	20697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	cytochrome P450	20822	20837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	cytochrome P450	20822	20837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	cytochrome P450	25429	25444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	cytochrome P450	25429	25444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:3	Methicillin-Resistant Staphylococcus Aureus infection can modulate the effects of drugs, which may occur through an influence on cytochrome P450, the drug-metabolizing enzyme in the liver. 	cytochrome P450	459	474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:3	Methicillin-Resistant Staphylococcus Aureus infection can modulate the effects of drugs, which may occur through an influence on cytochrome P450, the drug-metabolizing enzyme in the liver. 	cytochrome P450	459	474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:19	There are many causes for change in the expression of liver drug metabolic enzymes; the most important is the inflammation and oxidative stress caused by pathogenic microbial infection.- Studies have shown that a component of the gut microbiome, Citrobacter rodentium, the hepatitis C virus, and other infectious agents modulate the expression of hepatic cytochrome P450.- Matsumoto et al reported that Methicillin-Resistant Staphylococcus Aureus infections influenced the pharmacokinetics and pharmacodynamics of teicoplanin in patients. 	cytochrome P450	4687	4702	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:19	There are many causes for change in the expression of liver drug metabolic enzymes; the most important is the inflammation and oxidative stress caused by pathogenic microbial infection.- Studies have shown that a component of the gut microbiome, Citrobacter rodentium, the hepatitis C virus, and other infectious agents modulate the expression of hepatic cytochrome P450.- Matsumoto et al reported that Methicillin-Resistant Staphylococcus Aureus infections influenced the pharmacokinetics and pharmacodynamics of teicoplanin in patients. 	cytochrome P450	4687	4702	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:20	We speculated that this effect was a result of changes in the expression of the cytochrome P450 enzyme caused by Methicillin-Resistant Staphylococcus Aureus infection. 	cytochrome P450	4951	4966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:20	We speculated that this effect was a result of changes in the expression of the cytochrome P450 enzyme caused by Methicillin-Resistant Staphylococcus Aureus infection. 	cytochrome P450	4951	4966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:109	Importantly, however, the results with the various strains indicate that the genetic cytochrome P450 manipulations in these mice did not compromise overall long-term survival of these mice relative to their WT founder strain or to CD-1 mice. 	cytochrome P450	14542	14557	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:109	Importantly, however, the results with the various strains indicate that the genetic cytochrome P450 manipulations in these mice did not compromise overall long-term survival of these mice relative to their WT founder strain or to CD-1 mice. 	cytochrome P450	14542	14557	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:3	A cytochrome P450, CYP73, with cinnamate 4-hydroxylase (C4H) activity, catalyzes the first plant-specific and rate-limiting step in this pathway. 	cytochrome P450	198	213	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:3	A cytochrome P450, CYP73, with cinnamate 4-hydroxylase (C4H) activity, catalyzes the first plant-specific and rate-limiting step in this pathway. 	cytochrome P450	198	213	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:150	Our extensive mining of the most recent sequencing data is in line with the hypothesis that the CYP73 family of cytochrome P450 enzymes evolved upon plant colonization of land. 	cytochrome P450	24979	24994	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:150	Our extensive mining of the most recent sequencing data is in line with the hypothesis that the CYP73 family of cytochrome P450 enzymes evolved upon plant colonization of land. 	cytochrome P450	24979	24994	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:291	As a control, experimental N-terminal helical segments of ScErg11p (CYP51), the first crystal structure for any full-length cytochrome P450 enzyme showing resolution of the membrane spanning helix available in PDB, were also submitted to PPM server. 	cytochrome P450	46985	47000	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:291	As a control, experimental N-terminal helical segments of ScErg11p (CYP51), the first crystal structure for any full-length cytochrome P450 enzyme showing resolution of the membrane spanning helix available in PDB, were also submitted to PPM server. 	cytochrome P450	46985	47000	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:151	Fg02458 and Fg00012 are members of the CYP63 family, which is predicted to take part in the degradation of fatty acids, and members of the subfamily CYP537A2 (Fg12737) are known to be related to benzoate 4-monooxygenase cytochrome P450. 	cytochrome P450	22563	22578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:151	Fg02458 and Fg00012 are members of the CYP63 family, which is predicted to take part in the degradation of fatty acids, and members of the subfamily CYP537A2 (Fg12737) are known to be related to benzoate 4-monooxygenase cytochrome P450. 	cytochrome P450	22563	22578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:4	The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy. 	cytochrome P450	768	783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:4	The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy. 	cytochrome P450	768	783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:20	While much work has been conducted investigating the clinical importance of the cytochrome P450 (P450) gene variants, there is relatively little data specifically addressing P450 variation and its consequences in Indigenous populations. 	cytochrome P450	3839	3854	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:20	While much work has been conducted investigating the clinical importance of the cytochrome P450 (P450) gene variants, there is relatively little data specifically addressing P450 variation and its consequences in Indigenous populations. 	cytochrome P450	3839	3854	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:35	A search of PubMed was performed using the keywords Alaska Native, American Indian, Native American, Canadian Native Indian, First Nations, Canadian Inuit, Mexico Amerindian, Mexico Indigenous, cytochrome P450 polymorphisms, Pharmacogenetics, and CYP450 allele frequencies, drug disposition, and drug metabolism. 	cytochrome P450	7440	7455	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:35	A search of PubMed was performed using the keywords Alaska Native, American Indian, Native American, Canadian Native Indian, First Nations, Canadian Inuit, Mexico Amerindian, Mexico Indigenous, cytochrome P450 polymorphisms, Pharmacogenetics, and CYP450 allele frequencies, drug disposition, and drug metabolism. 	cytochrome P450	7440	7455	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:88	Additional analysis of the gene using InterproScan found it to be a cytochrome P450 domain containing gene. 	cytochrome P450	11772	11787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:88	Additional analysis of the gene using InterproScan found it to be a cytochrome P450 domain containing gene. 	cytochrome P450	11772	11787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:172	For example, the g5566t.1 gene that was identified to represent the highest degree of connectivity was initially identified as uncharacterized and containing cytochrome P450 domain information. 	cytochrome P450	24141	24156	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:172	For example, the g5566t.1 gene that was identified to represent the highest degree of connectivity was initially identified as uncharacterized and containing cytochrome P450 domain information. 	cytochrome P450	24141	24156	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:173	While multiple genes have been identified to be involved with cytochrome P450 and pathogenicity for other pathogens, the protein sequence would have been initially missed because it was returned as uncharacterized during the initial BLAST analysis against F. graminearum. 	cytochrome P450	24239	24254	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5891612_OgerInput.txtOger_out.csv:173	While multiple genes have been identified to be involved with cytochrome P450 and pathogenicity for other pathogens, the protein sequence would have been initially missed because it was returned as uncharacterized during the initial BLAST analysis against F. graminearum. 	cytochrome P450	24239	24254	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:41	Through this tool, metabolism using certain cytochrome P450 enzymes was evaluated comparing whether the compounds were substrates for cytochromes CYP450 2D6, CYP450 3A4, and CYP450 2C9; whether they were inhibitors of cytochrome CYP450 1A2, CYP450 2C9, CYP450 2D6, CYP450 2C19, and CYP450 3A4; and whether there was cytochrome inhibition promiscuity. 	cytochrome P450	6725	6740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:41	Through this tool, metabolism using certain cytochrome P450 enzymes was evaluated comparing whether the compounds were substrates for cytochromes CYP450 2D6, CYP450 3A4, and CYP450 2C9; whether they were inhibitors of cytochrome CYP450 1A2, CYP450 2C9, CYP450 2D6, CYP450 2C19, and CYP450 3A4; and whether there was cytochrome inhibition promiscuity. 	cytochrome P450	6725	6740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:169	An elevated production of Nitric Oxide decreases regulation of cytochrome P450; it triggers suppression of hepatic proteins and the synthesis of DNA and thus induces apoptosis and necrosis [,. 	cytochrome P450	26530	26545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:169	An elevated production of Nitric Oxide decreases regulation of cytochrome P450; it triggers suppression of hepatic proteins and the synthesis of DNA and thus induces apoptosis and necrosis [,. 	cytochrome P450	26530	26545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:107	^ While MCF-7 cells used to develop the ER-Luc cells express metabolic enzymes from the cytochrome P450 superfamily (and thus possess the ability for endogenous biotransformation of chemicals), formation of MBP was dependent on the presence of S9 enzymes. 	cytochrome P450	23273	23288	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:107	^ While MCF-7 cells used to develop the ER-Luc cells express metabolic enzymes from the cytochrome P450 superfamily (and thus possess the ability for endogenous biotransformation of chemicals), formation of MBP was dependent on the presence of S9 enzymes. 	cytochrome P450	23273	23288	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:4	We undertook an in-depth assessment of extracts of Hyptis verticillata Jacq., via its impact on activities of key cytochrome P450 (CYP) enzymes (CYPs 1A1, 1A2, 1B1, 3A4 and 2D6), its antioxidant properties (determined by DPPH assays) and chemical characterisation (using LC-MS). 	cytochrome P450	486	501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:4	We undertook an in-depth assessment of extracts of Hyptis verticillata Jacq., via its impact on activities of key cytochrome P450 (CYP) enzymes (CYPs 1A1, 1A2, 1B1, 3A4 and 2D6), its antioxidant properties (determined by DPPH assays) and chemical characterisation (using LC-MS). 	cytochrome P450	486	501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:179	to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6. 	cytochrome P450	28759	28774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:179	to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6. 	cytochrome P450	28759	28774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	cytochrome P450	28995	29010	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	cytochrome P450	28995	29010	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:3	In this report, we show that the multiplication of cytochrome P450 variants within the CYP71AZ subfamily has contributed to the diversification of these molecules. 	cytochrome P450	330	345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:3	In this report, we show that the multiplication of cytochrome P450 variants within the CYP71AZ subfamily has contributed to the diversification of these molecules. 	cytochrome P450	330	345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:11	This approach may explain the evolution of this cytochrome P450 family regarding the appearance of FCs in parsnip and possibly in the Apiaceae. 	cytochrome P450	1318	1333	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:11	This approach may explain the evolution of this cytochrome P450 family regarding the appearance of FCs in parsnip and possibly in the Apiaceae. 	cytochrome P450	1318	1333	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:14	Beside dioxygenases, the cytochrome P450s (P450s) are the most diversified enzyme family in plants and are estimated to represent up to 1% of the annotated genes in plant genomes. 	cytochrome P450	1810	1825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:14	Beside dioxygenases, the cytochrome P450s (P450s) are the most diversified enzyme family in plants and are estimated to represent up to 1% of the annotated genes in plant genomes. 	cytochrome P450	1810	1825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:153	In summary, the data provided unequivocal evidence that the SRS regions of CYP71AZs are intimately involved in the specificities of these enzymes and confirm the relevance commonly assigned to SRSs in cytochrome P450s. 	cytochrome P450	24253	24268	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:153	In summary, the data provided unequivocal evidence that the SRS regions of CYP71AZs are intimately involved in the specificities of these enzymes and confirm the relevance commonly assigned to SRSs in cytochrome P450s. 	cytochrome P450	24253	24268	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:185	Here, we provide a new example of the importance of cytochrome P450s, which have already been identified to be deeply involved in this diversification, and suggest how they can be involved in the appearance of new molecules to meet further challenges for an ecological function (;. 	cytochrome P450	28902	28917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:185	Here, we provide a new example of the importance of cytochrome P450s, which have already been identified to be deeply involved in this diversification, and suggest how they can be involved in the appearance of new molecules to meet further challenges for an ecological function (;. 	cytochrome P450	28902	28917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:3	Buried active sites in cytochrome P450 enzymes are connected to the solvent by a network of channels exiting at the distal surface of the protein. 	cytochrome P450	264	279	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:3	Buried active sites in cytochrome P450 enzymes are connected to the solvent by a network of channels exiting at the distal surface of the protein. 	cytochrome P450	264	279	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:43	For a rather long period, besides the ribosomal tunnel of the nascently synthesized polypeptide, cytochrome P450s and haloalkane dehalogenases were the only known enzymes with a deeply buried active site with no easily visible pathway leading from the protein surface to the catalytic cavity. 	cytochrome P450	6905	6920	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:43	For a rather long period, besides the ribosomal tunnel of the nascently synthesized polypeptide, cytochrome P450s and haloalkane dehalogenases were the only known enzymes with a deeply buried active site with no easily visible pathway leading from the protein surface to the catalytic cavity. 	cytochrome P450	6905	6920	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:44	Historically, the first attempt to identify access channels in cytochrome P450 was made twenty years ago by Rebecca Wade and her coworkers on cytochrome P450cam (CYP101A1). 	cytochrome P450	7164	7179	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:44	Historically, the first attempt to identify access channels in cytochrome P450 was made twenty years ago by Rebecca Wade and her coworkers on cytochrome P450cam (CYP101A1). 	cytochrome P450	7164	7179	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:44	Historically, the first attempt to identify access channels in cytochrome P450 was made twenty years ago by Rebecca Wade and her coworkers on cytochrome P450cam (CYP101A1). 	cytochrome P450	7243	7258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:44	Historically, the first attempt to identify access channels in cytochrome P450 was made twenty years ago by Rebecca Wade and her coworkers on cytochrome P450cam (CYP101A1). 	cytochrome P450	7243	7258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:118	Detailed stopped-flow kinetics of binding of camphor to cytochrome P450cam have been studied for site-directed mutants of P450cam. 	cytochrome P450	20522	20537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:118	Detailed stopped-flow kinetics of binding of camphor to cytochrome P450cam have been studied for site-directed mutants of P450cam. 	cytochrome P450	20522	20537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:277	The authors have identified all of the channels in the network that this enzyme, which is not a cytochrome P450, exhibits. 	cytochrome P450	49178	49193	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:277	The authors have identified all of the channels in the network that this enzyme, which is not a cytochrome P450, exhibits. 	cytochrome P450	49178	49193	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6033001_OgerInput.txtOger_out.csv:22	Secnidazole is rapidly and completely absorbed following oral administration and demonstrates a longer terminal elimination halflife of approximately 17 to 29 hours vs other drugs in its class.,  It is metabolized by oxidation in the liver to a hydroxyethyl metabolite without any effects, neither induction nor inhibition, on cytochrome P450 enzymes, ; elimination is mainly through the urinary route, with approximately 50% excreted by 96 hours. 	cytochrome P450	6033	6048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6033001_OgerInput.txtOger_out.csv:22	Secnidazole is rapidly and completely absorbed following oral administration and demonstrates a longer terminal elimination halflife of approximately 17 to 29 hours vs other drugs in its class.,  It is metabolized by oxidation in the liver to a hydroxyethyl metabolite without any effects, neither induction nor inhibition, on cytochrome P450 enzymes, ; elimination is mainly through the urinary route, with approximately 50% excreted by 96 hours. 	cytochrome P450	6033	6048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:5	This review collects available information of which-taken with great caution because of the still very limited data-the most salient points are: in the skin of all animal species and skin-derived in vitro systems considered in this review cytochrome P450 (CYP)-dependent monooxygenase activities (largely responsible for initiating xenobiotica metabolism in the organ which provides most of the xenobiotica metabolism of the mammalian organism, the liver) are very low to undetectable. 	cytochrome P450	893	908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:5	This review collects available information of which-taken with great caution because of the still very limited data-the most salient points are: in the skin of all animal species and skin-derived in vitro systems considered in this review cytochrome P450 (CYP)-dependent monooxygenase activities (largely responsible for initiating xenobiotica metabolism in the organ which provides most of the xenobiotica metabolism of the mammalian organism, the liver) are very low to undetectable. 	cytochrome P450	893	908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:45	A notable example of this is many cytochrome P450 (CYP)-dependent activities.In many (actually in most) cases in the original literature crucial details are not given. 	cytochrome P450	7594	7609	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:45	A notable example of this is many cytochrome P450 (CYP)-dependent activities.In many (actually in most) cases in the original literature crucial details are not given. 	cytochrome P450	7594	7609	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:2	The effect of non-synonymous single nucleotide polymorphisms on cytochrome P450 drug metabolism is currently poorly understood due to the large number of polymorphisms, the diversity of potential substrates and the complexity of Cytochrome P450 function. 	cytochrome P450	191	206	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:2	The effect of non-synonymous single nucleotide polymorphisms on cytochrome P450 drug metabolism is currently poorly understood due to the large number of polymorphisms, the diversity of potential substrates and the complexity of Cytochrome P450 function. 	cytochrome P450	191	206	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:25	Single amino acid substitutions can affect haem binding, substrate access and binding, interactions with redox partner cytochrome P450 reductase, oligomerisation and/or the conformation and structural stability of the enzyme. 	cytochrome P450	5154	5169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:25	Single amino acid substitutions can affect haem binding, substrate access and binding, interactions with redox partner cytochrome P450 reductase, oligomerisation and/or the conformation and structural stability of the enzyme. 	cytochrome P450	5154	5169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:33	To account for direct effects of mutations on protein function, a cytochrome P450 SNP map was created which combined information from previous functional studies to delineate regions important for substrate recognition^,, haem binding, interactions with CPR^- and residues implicated in the gating of substrate and product access/egress tunnels^-. 	cytochrome P450	6724	6739	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:33	To account for direct effects of mutations on protein function, a cytochrome P450 SNP map was created which combined information from previous functional studies to delineate regions important for substrate recognition^,, haem binding, interactions with CPR^- and residues implicated in the gating of substrate and product access/egress tunnels^-. 	cytochrome P450	6724	6739	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6128993_OgerInput.txtOger_out.csv:8	In addition, a real-time reverse transcription PCR (qRT-PCR) study was performed to study the regulatory role of the biosynthetic genes HMG-CoA reductase, farnesyl diphosphate synthase, epikunzeaol synthase (TgTPS2) and the cytochrome P450 (TgCYP76AE2) of stem, leaf and callus tissues. 	cytochrome P450	1398	1413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6128993_OgerInput.txtOger_out.csv:8	In addition, a real-time reverse transcription PCR (qRT-PCR) study was performed to study the regulatory role of the biosynthetic genes HMG-CoA reductase, farnesyl diphosphate synthase, epikunzeaol synthase (TgTPS2) and the cytochrome P450 (TgCYP76AE2) of stem, leaf and callus tissues. 	cytochrome P450	1398	1413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:3	This study aimed to illustrate the effects of protoberberines on aryl hydrocarbon receptor (AhR) activation and cytochrome P450 (CYP) 1 in the estrogen receptor (ER)ALPHA(+) MCF-7 breast cancer cells. 	cytochrome P450	408	423	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:3	This study aimed to illustrate the effects of protoberberines on aryl hydrocarbon receptor (AhR) activation and cytochrome P450 (CYP) 1 in the estrogen receptor (ER)ALPHA(+) MCF-7 breast cancer cells. 	cytochrome P450	408	423	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:9	The aryl hydrocarbon receptor (AhR) downstream targets, cytochrome P450 (CYP) 1 isoforms, play very important roles in the detoxification and bioactivation of environmental pollutants, carcinogens and physiological compounds, such as benzo(a)pyrene (B(a)P) and estradiol (E2). 	cytochrome P450	1271	1286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:9	The aryl hydrocarbon receptor (AhR) downstream targets, cytochrome P450 (CYP) 1 isoforms, play very important roles in the detoxification and bioactivation of environmental pollutants, carcinogens and physiological compounds, such as benzo(a)pyrene (B(a)P) and estradiol (E2). 	cytochrome P450	1271	1286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:31	By using univariate analysis, human hepatic cytochrome P450 (P450, CYP) 1A1 protein levels were negatively correlated with miR-21-5p (mature miR-21), miR-132 and miR-142-3p levels. 	cytochrome P450	4828	4843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:31	By using univariate analysis, human hepatic cytochrome P450 (P450, CYP) 1A1 protein levels were negatively correlated with miR-21-5p (mature miR-21), miR-132 and miR-142-3p levels. 	cytochrome P450	4828	4843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:7	Although there have been studies on the biological activities of selaginellins, their modulatory potential of cytochrome P450 (P450) and uridine 5-diphosphoglucuronosyltransferase activities have not been previously evaluated. 	cytochrome P450	741	756	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:7	Although there have been studies on the biological activities of selaginellins, their modulatory potential of cytochrome P450 (P450) and uridine 5-diphosphoglucuronosyltransferase activities have not been previously evaluated. 	cytochrome P450	741	756	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:24	Among the numerous drug-metabolizing enzymes, cytochrome P450s (P450s) and uridine 5-diphosphoglucuronosyltransferases, which are responsible for the metabolic clearance of 90% of commercial drugs, have been shown to a play key roles in drug metabolism and drug interactions. 	cytochrome P450	3160	3175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:24	Among the numerous drug-metabolizing enzymes, cytochrome P450s (P450s) and uridine 5-diphosphoglucuronosyltransferases, which are responsible for the metabolic clearance of 90% of commercial drugs, have been shown to a play key roles in drug metabolism and drug interactions. 	cytochrome P450	3160	3175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:31	In the present study, we investigated the inhibitory effect of two selaginellins against ten cytochrome P450 isoforms and six Uridine 5-Diphosphoglucuronosyltransferase isoforms using human liver microsomes. 	cytochrome P450	4620	4635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:31	In the present study, we investigated the inhibitory effect of two selaginellins against ten cytochrome P450 isoforms and six Uridine 5-Diphosphoglucuronosyltransferase isoforms using human liver microsomes. 	cytochrome P450	4620	4635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6151793_OgerInput.txtOger_out.csv:84	Thus, interconversion of 7OH-DHEA via 7-oxo-DHEA is probably specific only to these animals cytochrome P450s. 	cytochrome P450	12369	12384	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6151793_OgerInput.txtOger_out.csv:84	Thus, interconversion of 7OH-DHEA via 7-oxo-DHEA is probably specific only to these animals cytochrome P450s. 	cytochrome P450	12369	12384	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:179	Firstly, the behavior as substrate or inhibitor of the target molecules in the most important isoforms of the cytochrome P450 participants in the metabolism of therapeutic drugs was evaluated. 	cytochrome P450	30117	30132	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:179	Firstly, the behavior as substrate or inhibitor of the target molecules in the most important isoforms of the cytochrome P450 participants in the metabolism of therapeutic drugs was evaluated. 	cytochrome P450	30117	30132	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:181	Evaluation of the target molecules as substrates of Cytochrome P450 shows that 1-4 act as non-substrates of the 2C9 and 2D6 isoforms of cytochrome P450. 	cytochrome P450	30547	30562	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:181	Evaluation of the target molecules as substrates of Cytochrome P450 shows that 1-4 act as non-substrates of the 2C9 and 2D6 isoforms of cytochrome P450. 	cytochrome P450	30547	30562	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:23	Levels of other xenobiotics, including caffeine, are also reported to increase in older subjects, possibly reflecting decreased activity of hepatic cytochrome P450 (CYP) enzymes. 	cytochrome P450	3363	3378	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:23	Levels of other xenobiotics, including caffeine, are also reported to increase in older subjects, possibly reflecting decreased activity of hepatic cytochrome P450 (CYP) enzymes. 	cytochrome P450	3363	3378	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:109	A number of PhM studies have focused on the prediction of individual drug metabolism by measuring the cytochrome P450 activity of drug-metabolizing enzymes. 	cytochrome P450	16978	16993	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:109	A number of PhM studies have focused on the prediction of individual drug metabolism by measuring the cytochrome P450 activity of drug-metabolizing enzymes. 	cytochrome P450	16978	16993	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:44	Pyrethroid/permethrin resistant mosquitoes exhibit insecticide resistance through elevated levels of multiple detoxification enzymes, including Glutathion S-Transferases, ATP-binding cassette transporters, carboxylesterase, and cytochrome P450. 	cytochrome P450	4631	4646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:44	Pyrethroid/permethrin resistant mosquitoes exhibit insecticide resistance through elevated levels of multiple detoxification enzymes, including Glutathion S-Transferases, ATP-binding cassette transporters, carboxylesterase, and cytochrome P450. 	cytochrome P450	4631	4646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:202	These transcripts encoded one alcohol dehydrogenase, two aldehyde oxidases, one aldo-keto reductase, two Carboxy/choline esterases, one core 1 UDP-galactose galactosyltransferase, 33 cytochrome P450, one d-amino acid oxidase, one epoxide hydrolase, seven glucosyl/glucuronosyl transferases, one glutamate semialdehyde dehydrogenase, three n-acetylgalactosaminyltransferases, one prophenoloxidase, four short-chain dehydrogenases, one sterol desaturase, and one thioredoxin peroxidase. 	cytochrome P450	26898	26913	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:202	These transcripts encoded one alcohol dehydrogenase, two aldehyde oxidases, one aldo-keto reductase, two Carboxy/choline esterases, one core 1 UDP-galactose galactosyltransferase, 33 cytochrome P450, one d-amino acid oxidase, one epoxide hydrolase, seven glucosyl/glucuronosyl transferases, one glutamate semialdehyde dehydrogenase, three n-acetylgalactosaminyltransferases, one prophenoloxidase, four short-chain dehydrogenases, one sterol desaturase, and one thioredoxin peroxidase. 	cytochrome P450	26898	26913	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:203	Four cytochrome P450 (AAEL009018, AAEL014609, AAEL014617, and AAEL014893) were reported as associated with insecticide resistance in several populations of Ae. 	cytochrome P450	27205	27220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:203	Four cytochrome P450 (AAEL009018, AAEL014609, AAEL014617, and AAEL014893) were reported as associated with insecticide resistance in several populations of Ae. 	cytochrome P450	27205	27220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:4	In vitro studies have suggested that UVB enhances B[a]P genotoxicity by activating the AhR pathway and overexpressing the cytochrome P450 enzymes responsible for the conversion of B[a]P into DNA damaging metabolites. 	cytochrome P450	514	529	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:4	In vitro studies have suggested that UVB enhances B[a]P genotoxicity by activating the AhR pathway and overexpressing the cytochrome P450 enzymes responsible for the conversion of B[a]P into DNA damaging metabolites. 	cytochrome P450	514	529	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:6	We found that topically applied B[a]P strongly induced expression of cutaneous cytochrome P450 genes and formation of DNA adducts. 	cytochrome P450	824	839	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:6	We found that topically applied B[a]P strongly induced expression of cutaneous cytochrome P450 genes and formation of DNA adducts. 	cytochrome P450	824	839	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:19	However, metabolization via phase I enzymes, mainly cytochrome P450 oxygenases, convert Polycyclic Aromatic Hydrocarbons into reactive metabolite intermediaries^. 	cytochrome P450	2400	2415	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:19	However, metabolization via phase I enzymes, mainly cytochrome P450 oxygenases, convert Polycyclic Aromatic Hydrocarbons into reactive metabolite intermediaries^. 	cytochrome P450	2400	2415	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:5	The purpose of this research was to study the microbial structural complexes of the pesticide-contaminated soils in these dumping zones, and to search for and select microorganisms destructors with cytochrome P450 genes for pesticide degradation. 	cytochrome P450	630	645	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:5	The purpose of this research was to study the microbial structural complexes of the pesticide-contaminated soils in these dumping zones, and to search for and select microorganisms destructors with cytochrome P450 genes for pesticide degradation. 	cytochrome P450	630	645	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:7	The universal primer set for the 16S ribosomal RNA (rRNA) gene and the specific primer set P450R were used to amplify the cytochrome P450 hydroxylase gene. 	cytochrome P450	935	950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:7	The universal primer set for the 16S ribosomal RNA (rRNA) gene and the specific primer set P450R were used to amplify the cytochrome P450 hydroxylase gene. 	cytochrome P450	935	950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:66	; Qureshi et al.. Among oxidoreductases, the most frequent are monooxygenases like cytochrome P450, dioxygenases, peroxidases, and oxidases; hydrolases like A-esterase are involved in biodegradation pathways. 	cytochrome P450	9408	9423	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:66	; Qureshi et al.. Among oxidoreductases, the most frequent are monooxygenases like cytochrome P450, dioxygenases, peroxidases, and oxidases; hydrolases like A-esterase are involved in biodegradation pathways. 	cytochrome P450	9408	9423	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:71	The main purpose of this research is to study the microbial structural complexes of pesticide-contaminated soils in these dumping zones, and to search for and select microorganism destructors with cytochrome P450 genes for pesticide degradation. 	cytochrome P450	9961	9976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:71	The main purpose of this research is to study the microbial structural complexes of pesticide-contaminated soils in these dumping zones, and to search for and select microorganism destructors with cytochrome P450 genes for pesticide degradation. 	cytochrome P450	9961	9976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:128	The primer set alkB-F and alkB-R was used to amplify the alkane hydroxylase, and P450R was used to amplify the cytochrome P450 alkane hydroxylase. 	cytochrome P450	18056	18071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:128	The primer set alkB-F and alkB-R was used to amplify the alkane hydroxylase, and P450R was used to amplify the cytochrome P450 alkane hydroxylase. 	cytochrome P450	18056	18071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:186	; Matsumoto et al.. Most of the DNA samples extracted from the soil in the enrichment culture were amplified with P450 fw1 and P450 rv3 primers, demonstrating the presence of cytochrome P450 genes (Fig. 	cytochrome P450	27650	27665	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:186	; Matsumoto et al.. Most of the DNA samples extracted from the soil in the enrichment culture were amplified with P450 fw1 and P450 rv3 primers, demonstrating the presence of cytochrome P450 genes (Fig. 	cytochrome P450	27650	27665	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:238	The presence of such microorganisms involved in the biodegradation process was proved by amplification of the cytochrome P450 genes that encode this process. 	cytochrome P450	35068	35083	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:238	The presence of such microorganisms involved in the biodegradation process was proved by amplification of the cytochrome P450 genes that encode this process. 	cytochrome P450	35068	35083	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:190	Steroidogenesis in ovarian follicular cells is mediated by a number of well-known enzymes such as, for example, steroidogenic acute regulatory protein STAR, cytochrome P450 side chain cleavage CYP450scc, 3-beta-hydroxysteroid dehydrogenase HSD3BETA, and CYP450 aromatase in theca and granulosa cells. 	cytochrome P450	36738	36753	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:190	Steroidogenesis in ovarian follicular cells is mediated by a number of well-known enzymes such as, for example, steroidogenic acute regulatory protein STAR, cytochrome P450 side chain cleavage CYP450scc, 3-beta-hydroxysteroid dehydrogenase HSD3BETA, and CYP450 aromatase in theca and granulosa cells. 	cytochrome P450	36738	36753	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:23	75% of the enzymes that metabolize drugs in the human body are cytochrome P450s. 	cytochrome P450	3224	3239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:23	75% of the enzymes that metabolize drugs in the human body are cytochrome P450s. 	cytochrome P450	3224	3239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:24	Five cytochrome P450s account for 90% of the drug metabolism. 	cytochrome P450	3247	3262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:24	Five cytochrome P450s account for 90% of the drug metabolism. 	cytochrome P450	3247	3262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:29	Thus, they reach systemic circulation as aglycones, and as such are exposed to the cytochrome P450 enzymes. 	cytochrome P450	4006	4021	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:29	Thus, they reach systemic circulation as aglycones, and as such are exposed to the cytochrome P450 enzymes. 	cytochrome P450	4006	4021	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	cytochrome P450	17338	17353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	cytochrome P450	17338	17353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	cytochrome P450	18428	18443	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	cytochrome P450	18428	18443	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:7	Besides serving as a simple model for the first step of the cytochrome P450 catalytic cycle, the spin switch can be used to switch the spin-lattice relaxation time T1 of the water protons by a factor of 15. 	cytochrome P450	809	824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:7	Besides serving as a simple model for the first step of the cytochrome P450 catalytic cycle, the spin switch can be used to switch the spin-lattice relaxation time T1 of the water protons by a factor of 15. 	cytochrome P450	809	824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:13	Substrate binding to cytochrome P450 triggers a change in the spin state of the heme-bound Fe(III) from the resting state, low spin (S = ^1/_2), to high spin (S = ^5/_2). 	cytochrome P450	1723	1738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:13	Substrate binding to cytochrome P450 triggers a change in the spin state of the heme-bound Fe(III) from the resting state, low spin (S = ^1/_2), to high spin (S = ^5/_2). 	cytochrome P450	1723	1738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:158	The active center of cytochrome P450 contains a low spin Fe(III) porphyrin in its resting state. 	cytochrome P450	26906	26921	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:158	The active center of cytochrome P450 contains a low spin Fe(III) porphyrin in its resting state. 	cytochrome P450	26906	26921	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:5	Here, using a microarray-based genome-wide transcription and qRT-PCR analysis, we showed that metabolic resistance mechanisms through over-expression of cytochrome P450 and glutathione S-transferase genes (GSTs) are a major contributor to DDT and permethrin resistance in Anopheles funestus from Kpome. 	cytochrome P450	666	681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:5	Here, using a microarray-based genome-wide transcription and qRT-PCR analysis, we showed that metabolic resistance mechanisms through over-expression of cytochrome P450 and glutathione S-transferase genes (GSTs) are a major contributor to DDT and permethrin resistance in Anopheles funestus from Kpome. 	cytochrome P450	666	681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:29	Metabolic resistance is the main resistance mechanism recorded, and cytochrome P450 genes are playing a major role while target-site resistance like the knockdown resistance (kdr) is absent. 	cytochrome P450	3785	3800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:29	Metabolic resistance is the main resistance mechanism recorded, and cytochrome P450 genes are playing a major role while target-site resistance like the knockdown resistance (kdr) is absent. 	cytochrome P450	3785	3800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:41	In this study, using a genome-wide microarray-based transcription analysis, the underlying molecular mechanisms conferring DDT and permethrin resistance in Kpome were characterised revealing that both glutathione S-transferases, notably the GSTe2, and cytochrome P450 genes are the main drivers of resistance. 	cytochrome P450	5751	5766	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:41	In this study, using a genome-wide microarray-based transcription analysis, the underlying molecular mechanisms conferring DDT and permethrin resistance in Kpome were characterised revealing that both glutathione S-transferases, notably the GSTe2, and cytochrome P450 genes are the main drivers of resistance. 	cytochrome P450	5751	5766	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:108	Among these genes, the transcripts for glycogenin (Afun000500) and CYP6M7, belonging to the cytochrome P450 gene family, were the most commonly overexpressed detoxification gene in R_perm-S (FC of 36.2 for Afun000500 and 34.6 for CYP6M7) and C-S (FC of 38.1 for Afun000500 and 28.9 for CYP6M7). 	cytochrome P450	14019	14034	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:108	Among these genes, the transcripts for glycogenin (Afun000500) and CYP6M7, belonging to the cytochrome P450 gene family, were the most commonly overexpressed detoxification gene in R_perm-S (FC of 36.2 for Afun000500 and 34.6 for CYP6M7) and C-S (FC of 38.1 for Afun000500 and 28.9 for CYP6M7). 	cytochrome P450	14019	14034	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:126	The cytochrome P450 gene CYP307A1 was also upregulated with FC 3.3 in R_DDT-S and FC 2.2 in C-S. 	cytochrome P450	17355	17370	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:126	The cytochrome P450 gene CYP307A1 was also upregulated with FC 3.3 in R_DDT-S and FC 2.2 in C-S. 	cytochrome P450	17355	17370	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:133	These genes include alcohol dehydrogenase Afun013475 (FC 3.2), the most upregulated gene (FC 3.2) as well as CYP302A1 (FC 2.6), CYP4D15 (FC 2.4), CYP4J5 (FC 2.2), gb-CYP12F3 (FC 2.1) and the cytochrome P450 (Afun010630) (FC 2.1). 	cytochrome P450	18423	18438	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:133	These genes include alcohol dehydrogenase Afun013475 (FC 3.2), the most upregulated gene (FC 3.2) as well as CYP302A1 (FC 2.6), CYP4D15 (FC 2.4), CYP4J5 (FC 2.2), gb-CYP12F3 (FC 2.1) and the cytochrome P450 (Afun010630) (FC 2.1). 	cytochrome P450	18423	18438	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:150	funestus from Kpome notably through overexpression of genes involved in insecticide detoxification such as cytochrome P450 genes, GSTs, aldehyde oxidases, and other gene families previously associated with resistance of An. 	cytochrome P450	20895	20910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:150	funestus from Kpome notably through overexpression of genes involved in insecticide detoxification such as cytochrome P450 genes, GSTs, aldehyde oxidases, and other gene families previously associated with resistance of An. 	cytochrome P450	20895	20910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:152	The cytochrome P450, CYP6M7 was the most overexpressed detoxification gene in permethrin exposed mosquitoes compared to the FANG susceptible strain as well as to the unexposed mosquitoes from microarrays analysis. 	cytochrome P450	21042	21057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:152	The cytochrome P450, CYP6M7 was the most overexpressed detoxification gene in permethrin exposed mosquitoes compared to the FANG susceptible strain as well as to the unexposed mosquitoes from microarrays analysis. 	cytochrome P450	21042	21057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:197	The two duplicated cytochrome P450 genes, CYP6P9a (FC = 3.7) and CYP6P9b (FC = 3.9), which confer pyrethroid resistance in southern African populations of An. 	cytochrome P450	27321	27336	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6247751_OgerInput.txtOger_out.csv:197	The two duplicated cytochrome P450 genes, CYP6P9a (FC = 3.7) and CYP6P9b (FC = 3.9), which confer pyrethroid resistance in southern African populations of An. 	cytochrome P450	27321	27336	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	cytochrome P450	650	665	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	cytochrome P450	650	665	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:20	The major enzymes responsible for the metabolism of xenobiotics are members of the cytochrome P450 (CYP) family. 	cytochrome P450	3251	3266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:20	The major enzymes responsible for the metabolism of xenobiotics are members of the cytochrome P450 (CYP) family. 	cytochrome P450	3251	3266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:229	However, no cytochrome P450 involved in downstream in the alkaloid biosynthetic pathway has been cloned or identified in Dendrobium plants. 	cytochrome P450	34947	34962	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:229	However, no cytochrome P450 involved in downstream in the alkaloid biosynthetic pathway has been cloned or identified in Dendrobium plants. 	cytochrome P450	34947	34962	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:1	 Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3Acatalysed hydroxylation by sulfaphenazole. 	cytochrome P450	39	54	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:1	 Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3Acatalysed hydroxylation by sulfaphenazole. 	cytochrome P450	39	54	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:2	The aim of this study was to characterize the human cytochrome P450s (CYPs) involved in oxidative bioactivation of flucloxacillin to 5hydroxymethyl flucloxacillin, a metabolite with high cytotoxicity towards biliary epithelial cells. 	cytochrome P450	215	230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:2	The aim of this study was to characterize the human cytochrome P450s (CYPs) involved in oxidative bioactivation of flucloxacillin to 5hydroxymethyl flucloxacillin, a metabolite with high cytotoxicity towards biliary epithelial cells. 	cytochrome P450	215	230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:29	Nonrenal clearance of flucloxacillin occurs predominantly by cytochrome P450mediated hydroxylation of flucloxacillin to 5HMFLX and partly by hydrolysis to the corresponding penicilloic acid, showed that CYP3A4 was able to catalyse the 5hydroxylation of flucloxacillin. 	cytochrome P450	6004	6019	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:29	Nonrenal clearance of flucloxacillin occurs predominantly by cytochrome P450mediated hydroxylation of flucloxacillin to 5HMFLX and partly by hydrolysis to the corresponding penicilloic acid, showed that CYP3A4 was able to catalyse the 5hydroxylation of flucloxacillin. 	cytochrome P450	6004	6019	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	cytochrome P450	647	662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	cytochrome P450	647	662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	cytochrome P450	3610	3625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	cytochrome P450	3610	3625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:13	Progesterone Receptor Membrane Component1 is also involved in diverse biological functions, such as regulation of cytochrome P450, progesterone signaling, vesicle trafficking, steroidogenesis, cell cycle regulation, anchorage-independent growth, invasive growth, angiogenesis, hypoxic biology, and autophagy promotion^,. 	cytochrome P450	2457	2472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:13	Progesterone Receptor Membrane Component1 is also involved in diverse biological functions, such as regulation of cytochrome P450, progesterone signaling, vesicle trafficking, steroidogenesis, cell cycle regulation, anchorage-independent growth, invasive growth, angiogenesis, hypoxic biology, and autophagy promotion^,. 	cytochrome P450	2457	2472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:2	Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6 enzyme, is associated with substratespecific altered clearance of multiple drugs. 	cytochrome P450	131	146	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:2	Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6 enzyme, is associated with substratespecific altered clearance of multiple drugs. 	cytochrome P450	131	146	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:18	We further attempted to measure cytochrome P450mediated nicotine metabolism in human brain microsomes, where FMO activity was previously demonstrated,,  using nicotine and other CYP2B6 probe substrates. 	cytochrome P450	3153	3168	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:18	We further attempted to measure cytochrome P450mediated nicotine metabolism in human brain microsomes, where FMO activity was previously demonstrated,,  using nicotine and other CYP2B6 probe substrates. 	cytochrome P450	3153	3168	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:80	Extensive evidence demonstrates that functional variation in cytochrome P450 genes can significantly affect the metabolism of many small molecules including pharmaceuticals and toxins. 	cytochrome P450	14792	14807	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:80	Extensive evidence demonstrates that functional variation in cytochrome P450 genes can significantly affect the metabolism of many small molecules including pharmaceuticals and toxins. 	cytochrome P450	14792	14807	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:95	This provided an opportunity to further investigate possible cytochrome P450related nicotine metabolism in postmortem samples known to retain detectable microsomal enzyme activity. 	cytochrome P450	18032	18047	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:95	This provided an opportunity to further investigate possible cytochrome P450related nicotine metabolism in postmortem samples known to retain detectable microsomal enzyme activity. 	cytochrome P450	18032	18047	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:101	We therefore conclude that the iminium ion detected was not due to cytochrome P450s or any typical enzymatic activity. 	cytochrome P450	19039	19054	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:101	We therefore conclude that the iminium ion detected was not due to cytochrome P450s or any typical enzymatic activity. 	cytochrome P450	19039	19054	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	cytochrome P450	670	685	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	cytochrome P450	670	685	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	cytochrome P450	704	719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	cytochrome P450	704	719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	cytochrome P450	37871	37886	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	cytochrome P450	37871	37886	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	820	835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	820	835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	855	870	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	855	870	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:36	Consequently, search terms used included names of individual drugs AND overdose, toxicokinetics, pharmacokinetics, cytochrome P450 (CYP) enzyme, metabolism, or active metabolites. 	cytochrome P450	5193	5208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:36	Consequently, search terms used included names of individual drugs AND overdose, toxicokinetics, pharmacokinetics, cytochrome P450 (CYP) enzyme, metabolism, or active metabolites. 	cytochrome P450	5193	5208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	cytochrome P450	43	58	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	cytochrome P450	43	58	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	cytochrome P450	203	218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	cytochrome P450	203	218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450	3232	3247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450	3232	3247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:9	Moreover, seventy-eight cytochrome P450s and multiple transcription factors (five MYB, two bHLH, and three WD40 family genes) may be associated with the regulation of the flavonoid biosynthesis process. 	cytochrome P450	1417	1432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:9	Moreover, seventy-eight cytochrome P450s and multiple transcription factors (five MYB, two bHLH, and three WD40 family genes) may be associated with the regulation of the flavonoid biosynthesis process. 	cytochrome P450	1417	1432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:24	In addition, glycosyltransferases and cytochrome P450s also contribute to flavonoid regulation in plants. 	cytochrome P450	4192	4207	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:24	In addition, glycosyltransferases and cytochrome P450s also contribute to flavonoid regulation in plants. 	cytochrome P450	4192	4207	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:59	These enzymes belong to three pathways, namely (a) the COX pathway (COX1, COX2) resulting in production of prostaglandins, (b) the Lipoxygenases pathway (5-LOX, 1LOX, 15LOX) resulting in production of leukotrienes and lipoxins, and (c) the cytochrome P450 pathway which forms the hydroxyeicosotetranoic acids and the epoxyeicosotrienoic acids (Hanna and Hafez,. 	cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:59	These enzymes belong to three pathways, namely (a) the COX pathway (COX1, COX2) resulting in production of prostaglandins, (b) the Lipoxygenases pathway (5-LOX, 1LOX, 15LOX) resulting in production of leukotrienes and lipoxins, and (c) the cytochrome P450 pathway which forms the hydroxyeicosotetranoic acids and the epoxyeicosotrienoic acids (Hanna and Hafez,. 	cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:18	The MPB genome contains 86 different cytochrome P450 genes, and three of these P450s have previously been shown to function in terpenoid metabolism or terpenoid pheromone biosynthesis in the MPB. 	cytochrome P450	2648	2663	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:18	The MPB genome contains 86 different cytochrome P450 genes, and three of these P450s have previously been shown to function in terpenoid metabolism or terpenoid pheromone biosynthesis in the MPB. 	cytochrome P450	2648	2663	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:17	Second, an oxidative cyclisation cascade consisting typically of three to four cytochrome P450 (Oxy) enzymes (one enzyme per ring formed, see Fig ) is then recruited to the NRPS-bound heptapeptide in order to perform the stepwise cyclisation of the peptide into a rigid, active antibiotic^,. 	cytochrome P450	2981	2996	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:17	Second, an oxidative cyclisation cascade consisting typically of three to four cytochrome P450 (Oxy) enzymes (one enzyme per ring formed, see Fig ) is then recruited to the NRPS-bound heptapeptide in order to perform the stepwise cyclisation of the peptide into a rigid, active antibiotic^,. 	cytochrome P450	2981	2996	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450	8216	8231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450	8216	8231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450	31143	31158	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450	31143	31158	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450	17863	17878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450	17863	17878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:18	Insects have employed cytochrome P450 monooxygenases (P450s) that promote more a rapid metabolism to defer the cost of a counter-defence against toxic plant compounds. 	cytochrome P450	2700	2715	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:18	Insects have employed cytochrome P450 monooxygenases (P450s) that promote more a rapid metabolism to defer the cost of a counter-defence against toxic plant compounds. 	cytochrome P450	2700	2715	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	cytochrome P450	17929	17944	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	cytochrome P450	17929	17944	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:3	The expression of cytochrome P450, sodA (encoding Fe/Mn superoxide dismutase), recA, and superoxide anion radical generation rate increased after the addition of all studied hydrocarbons. 	cytochrome P450	366	381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:3	The expression of cytochrome P450, sodA (encoding Fe/Mn superoxide dismutase), recA, and superoxide anion radical generation rate increased after the addition of all studied hydrocarbons. 	cytochrome P450	366	381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:27	The aim of this study was to evaluate the expression of genes, cytochrome P450, superoxide dismutases A and C, recA, as well as generation of superoxide anion radical and hydrogen peroxide under the influence of hydrocarbons on Rhodococcus. 	cytochrome P450	3411	3426	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:27	The aim of this study was to evaluate the expression of genes, cytochrome P450, superoxide dismutases A and C, recA, as well as generation of superoxide anion radical and hydrogen peroxide under the influence of hydrocarbons on Rhodococcus. 	cytochrome P450	3411	3426	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:134	It is well known that in the course of enzymatic reactions of cytochrome P450 the socalled disjunction of the cycle may occur when the flow of electrons derived from NAD(P)H to P450 molecules leads to the generation of superoxide anion radical and/or hydrogen peroxide instead of the products of monooxygenase reaction (Guengerich, ; Goeptar, Scheerens, & Vermeulen,. 	cytochrome P450	18072	18087	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:134	It is well known that in the course of enzymatic reactions of cytochrome P450 the socalled disjunction of the cycle may occur when the flow of electrons derived from NAD(P)H to P450 molecules leads to the generation of superoxide anion radical and/or hydrogen peroxide instead of the products of monooxygenase reaction (Guengerich, ; Goeptar, Scheerens, & Vermeulen,. 	cytochrome P450	18072	18087	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:162	The ROS produced by cytochrome P450 are likely to cause DNA damage. 	cytochrome P450	22635	22650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:162	The ROS produced by cytochrome P450 are likely to cause DNA damage. 	cytochrome P450	22635	22650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:3	A growing amount of data have demonstrated the biosynthesis of flavonoids through multienzyme complexes of which the membrane-bounded cytochrome P450 supergene family shares a crucial part. 	cytochrome P450	377	392	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:3	A growing amount of data have demonstrated the biosynthesis of flavonoids through multienzyme complexes of which the membrane-bounded cytochrome P450 supergene family shares a crucial part. 	cytochrome P450	377	392	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450	2279	2294	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450	2279	2294	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:16	In most of the plant species, cytochrome P450 is found abundantly and produces multiple groups of secondary metabolites through hydroxylation and monooxygenation reactions. 	cytochrome P450	2338	2353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:16	In most of the plant species, cytochrome P450 is found abundantly and produces multiple groups of secondary metabolites through hydroxylation and monooxygenation reactions. 	cytochrome P450	2338	2353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:17	CYP701, a member of cytochrome P450 encoding ent-kaurene oxidase, is essential for the biosynthesis of gibberellins. 	cytochrome P450	2501	2516	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:17	CYP701, a member of cytochrome P450 encoding ent-kaurene oxidase, is essential for the biosynthesis of gibberellins. 	cytochrome P450	2501	2516	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:19	Furthermore, several other studies have discovered the pharmacological importance of the cytochrome P450 supergene family by stimulating plant immunity against various pathogens. 	cytochrome P450	3035	3050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:19	Furthermore, several other studies have discovered the pharmacological importance of the cytochrome P450 supergene family by stimulating plant immunity against various pathogens. 	cytochrome P450	3035	3050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:26	Though the diversity of flavonoid biosynthesis has been reported in Arabidopsis thaliana seeds, the mechanism of stress-responsive cytochrome P450 genes encoding a single or group of enzymes promoting the flavonoid biosynthesis pathway in Arabidopsis remains unexplained. 	cytochrome P450	4247	4262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:26	Though the diversity of flavonoid biosynthesis has been reported in Arabidopsis thaliana seeds, the mechanism of stress-responsive cytochrome P450 genes encoding a single or group of enzymes promoting the flavonoid biosynthesis pathway in Arabidopsis remains unexplained. 	cytochrome P450	4247	4262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:27	As a point of paramount significance, it is important to focus on studies related to identification and characterization of putative cytochrome P450 genes promoting the flavonoid biosynthetic pathway in plants. 	cytochrome P450	4521	4536	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:27	As a point of paramount significance, it is important to focus on studies related to identification and characterization of putative cytochrome P450 genes promoting the flavonoid biosynthetic pathway in plants. 	cytochrome P450	4521	4536	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:134	Based on predicted open-reading frames, the unigenes were further subjected to cytochrome P450 database (http://drnelson.uthsc.edu/CytochromeP450.html). 	cytochrome P450	22343	22358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:134	Based on predicted open-reading frames, the unigenes were further subjected to cytochrome P450 database (http://drnelson.uthsc.edu/CytochromeP450.html). 	cytochrome P450	22343	22358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:244	In the present study, we also predicted the computational structure of rutin against a comprehensive metabolite prediction tool (GLORY) that contained the cytochrome P450 prediction module according to the instructions of. 	cytochrome P450	40431	40446	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:244	In the present study, we also predicted the computational structure of rutin against a comprehensive metabolite prediction tool (GLORY) that contained the cytochrome P450 prediction module according to the instructions of. 	cytochrome P450	40431	40446	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:265	These findings provide a theoretical and practical basis for identifying the intrinsic relation of a stress-responsive cytochrome P450 gene during flavonoid biosynthesis in plants.	cytochrome P450	44748	44763	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:265	These findings provide a theoretical and practical basis for identifying the intrinsic relation of a stress-responsive cytochrome P450 gene during flavonoid biosynthesis in plants.	cytochrome P450	44748	44763	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6830213_OgerInput.txtOger_out.csv:18	Heme enzymes, such as the cytochrome P450s, are involved in the metabolism/breakdown of approximately 90% of small-molecule drugs, and are more generally themselves drug targets in yeast, fungi and tuberculosis infections (McLean & Munro, 2017; Guengerich et al., 2016; Rendic & Guengerich, 2015). 	cytochrome P450	3031	3046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6830213_OgerInput.txtOger_out.csv:18	Heme enzymes, such as the cytochrome P450s, are involved in the metabolism/breakdown of approximately 90% of small-molecule drugs, and are more generally themselves drug targets in yeast, fungi and tuberculosis infections (McLean & Munro, 2017; Guengerich et al., 2016; Rendic & Guengerich, 2015). 	cytochrome P450	3031	3046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:30	Two major functional classes of enzymes are involved in the biosynthesis of all steroid hormones, namely the cytochrome P450 and hydroxysteroid dehydrogenase enzymes. 	cytochrome P450	5069	5084	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:30	Two major functional classes of enzymes are involved in the biosynthesis of all steroid hormones, namely the cytochrome P450 and hydroxysteroid dehydrogenase enzymes. 	cytochrome P450	5069	5084	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	cytochrome P450	6332	6347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	cytochrome P450	6332	6347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:12	Phenobarbital metabolism is highly dependent upon the cytochrome P450 and genetic polymorphisms can lead to variability in active drug levels. 	cytochrome P450	1572	1587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:12	Phenobarbital metabolism is highly dependent upon the cytochrome P450 and genetic polymorphisms can lead to variability in active drug levels. 	cytochrome P450	1572	1587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	cytochrome P450	29282	29297	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:50	We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were detected in human cardiovascular tissue. 	cytochrome P450 enzymes	7283	7306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:5	We have previously demonstrated that Doxorubicin alters the expression of several cytochrome P450 enzymes in the hearts of male rats. 	cytochrome P450 enzymes	481	504	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:32	We have demonstrated that acute DOX-induced cardiotoxicity alters the expression of several cytochrome P450 enzymes in the H9c2 cardiomyoblasts in vitro and in the hearts of male Sprague Dawley rats in vivo. 	cytochrome P450 enzymes	4910	4933	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:11	Cyclopropylamines are one kind of such prototypical inhibitors for cytochrome P450 enzymes (P450s), which are widely found in biologically active natural products, synthetic drugs and also widely used as mechanistic probes to reveal elusive reaction mechanisms, such as that involved in P450-catalyzed amine oxidations (Bhakta and Wimalasena, ; Ortiz de Montellano and De Voss, ; Totah and Hanzlik, ; Bhakta et al.,. 	cytochrome P450 enzymes	2340	2363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:163	While the contribution of some dietary polyphenols in the management of Benign Prostatic Hyperplasia has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 enzymes. 	cytochrome P450 enzymes	32644	32667	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:158	For example, the cytochrome P450 enzymes are a class of phase I enzymes. 	cytochrome P450 enzymes	20202	20225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	cytochrome P450 enzymes	2008	2031	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:51	This is a two-step oxidation reaction catalyzed by cytochrome P450 enzymes. 	cytochrome P450 enzymes	8495	8518	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:137	P420 species was generally thought to be an inactive form of cytochrome P450 enzymes. 	cytochrome P450 enzymes	26522	26545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:310	Duplications of members of enzyme families (eg cytochromes P450, glycosyltransferases, methyltransferases, BAHD acyltransferases) also play major roles in generating chemical novelty, with biosynthesis of >40,000 structurally diverse terpenoids - produced partly due to genomic clustering of terpene synthases and cytochrome P450 enzymes - as an extreme example. 	cytochrome P450 enzymes	45243	45266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:27	; Chiangsom et al.. Several studies have evaluated the inhibitory potential of R. rosea toward cytochrome P450 enzymes. 	cytochrome P450 enzymes	3267	3290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:2	Determining drug-metabolizing enzyme activities on an individual basis is an important component of personalized medicine, and cytochrome P450 enzymes play a principal role in hepatic drug metabolism. 	cytochrome P450 enzymes	243	266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:5	This study aims to observe TSG-provided the aggravation on acetaminophen (APAP)-induced hepatotoxicity in mice by inducing hepatic expression of cytochrome P450 enzymes. 	cytochrome P450 enzymes	531	554	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:225	One of the most important mechanisms through which interactions occur is via the interference of herbal products with human hepatic drug metabolizing enzyme activities particularly the cytochrome P450 enzymes. 	cytochrome P450 enzymes	40564	40587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:150	Our extensive mining of the most recent sequencing data is in line with the hypothesis that the CYP73 family of cytochrome P450 enzymes evolved upon plant colonization of land. 	cytochrome P450 enzymes	24979	25002	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:41	Through this tool, metabolism using certain cytochrome P450 enzymes was evaluated comparing whether the compounds were substrates for cytochromes CYP450 2D6, CYP450 3A4, and CYP450 2C9; whether they were inhibitors of cytochrome CYP450 1A2, CYP450 2C9, CYP450 2D6, CYP450 2C19, and CYP450 3A4; and whether there was cytochrome inhibition promiscuity. 	cytochrome P450 enzymes	6725	6748	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	cytochrome P450 enzymes	28995	29018	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:3	Buried active sites in cytochrome P450 enzymes are connected to the solvent by a network of channels exiting at the distal surface of the protein. 	cytochrome P450 enzymes	264	287	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6033001_OgerInput.txtOger_out.csv:22	Secnidazole is rapidly and completely absorbed following oral administration and demonstrates a longer terminal elimination halflife of approximately 17 to 29 hours vs other drugs in its class.,  It is metabolized by oxidation in the liver to a hydroxyethyl metabolite without any effects, neither induction nor inhibition, on cytochrome P450 enzymes, ; elimination is mainly through the urinary route, with approximately 50% excreted by 96 hours. 	cytochrome P450 enzymes	6033	6056	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:4	In vitro studies have suggested that UVB enhances B[a]P genotoxicity by activating the AhR pathway and overexpressing the cytochrome P450 enzymes responsible for the conversion of B[a]P into DNA damaging metabolites. 	cytochrome P450 enzymes	514	537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:29	Thus, they reach systemic circulation as aglycones, and as such are exposed to the cytochrome P450 enzymes. 	cytochrome P450 enzymes	4006	4029	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	cytochrome P450 enzymes	647	670	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	cytochrome P450 enzymes	37871	37894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450 enzymes	820	843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	cytochrome P450 enzymes	43	66	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	cytochrome P450 enzymes	203	226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450 enzymes	3232	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450 enzymes	8216	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450 enzymes	31143	31166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	cytochrome P450 enzymes	5969	5992	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:50	We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were detected in human cardiovascular tissue. 	P450 enzymes	7294	7306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:50	We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were detected in human cardiovascular tissue. 	P450 enzymes	7294	7306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:5	We have previously demonstrated that Doxorubicin alters the expression of several cytochrome P450 enzymes in the hearts of male rats. 	P450 enzymes	492	504	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:5	We have previously demonstrated that Doxorubicin alters the expression of several cytochrome P450 enzymes in the hearts of male rats. 	P450 enzymes	492	504	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:6	Nevertheless, the sex-dependent effect of Doxorubicin on the expression of Cytochrome P450 enzymes is still not known. 	P450 enzymes	619	631	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:6	Nevertheless, the sex-dependent effect of Doxorubicin on the expression of Cytochrome P450 enzymes is still not known. 	P450 enzymes	619	631	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	P450 enzymes	2065	2077	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	P450 enzymes	2065	2077	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:32	We have demonstrated that acute DOX-induced cardiotoxicity alters the expression of several cytochrome P450 enzymes in the H9c2 cardiomyoblasts in vitro and in the hearts of male Sprague Dawley rats in vivo. 	P450 enzymes	4921	4933	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:32	We have demonstrated that acute DOX-induced cardiotoxicity alters the expression of several cytochrome P450 enzymes in the H9c2 cardiomyoblasts in vitro and in the hearts of male Sprague Dawley rats in vivo. 	P450 enzymes	4921	4933	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	P450 enzymes	5063	5075	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	P450 enzymes	5063	5075	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	P450 enzymes	5153	5165	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	P450 enzymes	5153	5165	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	P450 enzymes	5831	5843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	P450 enzymes	5831	5843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:138	A growing body of evidence suggests an important role of Cytochrome P450 enzymes in the pathogenesis of DOX-induced cardiotoxicity [,. 	P450 enzymes	25141	25153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:138	A growing body of evidence suggests an important role of Cytochrome P450 enzymes in the pathogenesis of DOX-induced cardiotoxicity [,. 	P450 enzymes	25141	25153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:139	Cytochrome P450 enzymes play important roles in metabolizing sex steroids and other endogenous compounds, such as arachidonic acid that have significant biological effects on the cardiovascular system. 	P450 enzymes	25219	25231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:139	Cytochrome P450 enzymes play important roles in metabolizing sex steroids and other endogenous compounds, such as arachidonic acid that have significant biological effects on the cardiovascular system. 	P450 enzymes	25219	25231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:140	Interestingly, there is a significant sex-divergent expression of several Cytochrome P450 enzymes in both humans and experimental animals. 	P450 enzymes	25495	25507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:140	Interestingly, there is a significant sex-divergent expression of several Cytochrome P450 enzymes in both humans and experimental animals. 	P450 enzymes	25495	25507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:141	Therefore, we hypothesized that Doxorubicin alters Cytochrome P450 enzymes in a sex-dependent manner to mediate sexual dimorphism of DOX-induced cardiotoxicity. 	P450 enzymes	25611	25623	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:141	Therefore, we hypothesized that Doxorubicin alters Cytochrome P450 enzymes in a sex-dependent manner to mediate sexual dimorphism of DOX-induced cardiotoxicity. 	P450 enzymes	25611	25623	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:113	This position is consistent with those seen in other P450 enzymes (eg the fatty acid/fatty acyl-ACP oxidizing P450 BioI (CYP107H1) at 1090 nm and CYP121A1 at 1125 nm) (,. 	P450 enzymes	20707	20719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:113	This position is consistent with those seen in other P450 enzymes (eg the fatty acid/fatty acyl-ACP oxidizing P450 BioI (CYP107H1) at 1090 nm and CYP121A1 at 1125 nm) (,. 	P450 enzymes	20707	20719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:157	The dimer interface is made by the BC- and FG-loop regions, both of which are associated with substrate entry into P450 enzymes. 	P450 enzymes	29188	29200	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:157	The dimer interface is made by the BC- and FG-loop regions, both of which are associated with substrate entry into P450 enzymes. 	P450 enzymes	29188	29200	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:11	Cyclopropylamines are one kind of such prototypical inhibitors for cytochrome P450 enzymes (P450s), which are widely found in biologically active natural products, synthetic drugs and also widely used as mechanistic probes to reveal elusive reaction mechanisms, such as that involved in P450-catalyzed amine oxidations (Bhakta and Wimalasena, ; Ortiz de Montellano and De Voss, ; Totah and Hanzlik, ; Bhakta et al.,. 	P450 enzymes	2351	2363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:11	Cyclopropylamines are one kind of such prototypical inhibitors for cytochrome P450 enzymes (P450s), which are widely found in biologically active natural products, synthetic drugs and also widely used as mechanistic probes to reveal elusive reaction mechanisms, such as that involved in P450-catalyzed amine oxidations (Bhakta and Wimalasena, ; Ortiz de Montellano and De Voss, ; Totah and Hanzlik, ; Bhakta et al.,. 	P450 enzymes	2351	2363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:163	While the contribution of some dietary polyphenols in the management of Benign Prostatic Hyperplasia has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 enzymes. 	P450 enzymes	32655	32667	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:163	While the contribution of some dietary polyphenols in the management of Benign Prostatic Hyperplasia has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 enzymes. 	P450 enzymes	32655	32667	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	P450 enzymes	32692	32704	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	P450 enzymes	32692	32704	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:172	One thing most of these studies reporting on the interaction of polyphenols with Cytochrome P450 enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes. 	P450 enzymes	34458	34470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:172	One thing most of these studies reporting on the interaction of polyphenols with Cytochrome P450 enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes. 	P450 enzymes	34458	34470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	P450 enzymes	12509	12521	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	P450 enzymes	12509	12521	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	P450 enzymes	12596	12608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	P450 enzymes	12596	12608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:13	In vitro inhibitory effects of the pharmacologically active lignans such as aschantin, honokiol, machilin A, phyllantin, hypophyllantin, and podophyllotoxin on Cytochrome P450 enzymes have been reported. 	P450 enzymes	3667	3679	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:13	In vitro inhibitory effects of the pharmacologically active lignans such as aschantin, honokiol, machilin A, phyllantin, hypophyllantin, and podophyllotoxin on Cytochrome P450 enzymes have been reported. 	P450 enzymes	3667	3679	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:14	However, there are no reports on the in vitro and in vivo inhibitory effects of the bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on human Cytochrome P450 enzymes. 	P450 enzymes	3923	3935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:14	However, there are no reports on the in vitro and in vivo inhibitory effects of the bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on human Cytochrome P450 enzymes. 	P450 enzymes	3923	3935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:16	The reversible and time-dependent inhibitory potencials (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 enzymes were investigated in human liver microsomes. 	P450 enzymes	4541	4553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:16	The reversible and time-dependent inhibitory potencials (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 enzymes were investigated in human liver microsomes. 	P450 enzymes	4541	4553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	P450 enzymes	5350	5362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	P450 enzymes	5350	5362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:24	In this study, the in vitro inhibitory effects of bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major Cytochrome P450 enzymes were, for the first time, evaluated in pooled human liver microsomes. 	P450 enzymes	7165	7177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:24	In this study, the in vitro inhibitory effects of bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major Cytochrome P450 enzymes were, for the first time, evaluated in pooled human liver microsomes. 	P450 enzymes	7165	7177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:158	For example, the cytochrome P450 enzymes are a class of phase I enzymes. 	P450 enzymes	20213	20225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:158	For example, the cytochrome P450 enzymes are a class of phase I enzymes. 	P450 enzymes	20213	20225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:172	Gene expression profiles of P450 enzymes change in the developing liver and the normal adult P450 expression is not established in mice until a specific postnatal age. 	P450 enzymes	22087	22099	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:172	Gene expression profiles of P450 enzymes change in the developing liver and the normal adult P450 expression is not established in mice until a specific postnatal age. 	P450 enzymes	22087	22099	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	P450 enzymes	2019	2031	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	P450 enzymes	2019	2031	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:51	This is a two-step oxidation reaction catalyzed by cytochrome P450 enzymes. 	P450 enzymes	8506	8518	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:51	This is a two-step oxidation reaction catalyzed by cytochrome P450 enzymes. 	P450 enzymes	8506	8518	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:97	The formation of active tamoxifen metabolites in patients carrying reduced or increased CYP2C19 function alleles may be sufficiently compensated through parallel and serial metabolic pathways catalyzed by other P450 enzymes. 	P450 enzymes	16083	16095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:97	The formation of active tamoxifen metabolites in patients carrying reduced or increased CYP2C19 function alleles may be sufficiently compensated through parallel and serial metabolic pathways catalyzed by other P450 enzymes. 	P450 enzymes	16083	16095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:2	P450 fatty acid decarboxylases represented by the unusual CYP152 peroxygenase family member OleTJE have been receiving great attention recently since these P450 enzymes are able to catalyze the simple and direct production of 1-alkenes for potential applications in biofuels and biomaterials. 	P450 enzymes	263	275	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:2	P450 fatty acid decarboxylases represented by the unusual CYP152 peroxygenase family member OleTJE have been receiving great attention recently since these P450 enzymes are able to catalyze the simple and direct production of 1-alkenes for potential applications in biofuels and biomaterials. 	P450 enzymes	263	275	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:66	As a result, while the control P450 monooxygenase P450_BM3 was successfully reduced by the addition of NADPH and exhibited an almost complete transition to P450 spectrum in the presence of lauric acid (LA) substrate (Additional file : Figure S4), neither CYP-Aa162 nor CYP-Sm4629 showed a P450 chromophore after incubation with the redox partner proteins CamAB (ie, putidaredoxin reductase and putidaredoxin that are able to support the in vitro activity of both P450 enzymes, see below) and their optimal cofactor NADH in the presence of LA. 	P450 enzymes	12968	12980	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:66	As a result, while the control P450 monooxygenase P450_BM3 was successfully reduced by the addition of NADPH and exhibited an almost complete transition to P450 spectrum in the presence of lauric acid (LA) substrate (Additional file : Figure S4), neither CYP-Aa162 nor CYP-Sm4629 showed a P450 chromophore after incubation with the redox partner proteins CamAB (ie, putidaredoxin reductase and putidaredoxin that are able to support the in vitro activity of both P450 enzymes, see below) and their optimal cofactor NADH in the presence of LA. 	P450 enzymes	12968	12980	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:113	This may suggest that the substrate binding pocket of the two P450 enzymes could accommodate more than one C_12 molecules and that the binding of one C_12 molecule could facilitate the binding of the other to the same P450 enzyme, particularly at low to medium substrate concentrations (10-80 M). 	P450 enzymes	22246	22258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:113	This may suggest that the substrate binding pocket of the two P450 enzymes could accommodate more than one C_12 molecules and that the binding of one C_12 molecule could facilitate the binding of the other to the same P450 enzyme, particularly at low to medium substrate concentrations (10-80 M). 	P450 enzymes	22246	22258	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:137	P420 species was generally thought to be an inactive form of cytochrome P450 enzymes. 	P450 enzymes	26533	26545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:137	P420 species was generally thought to be an inactive form of cytochrome P450 enzymes. 	P450 enzymes	26533	26545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:143	Whether the failure of observing a P450 species in CYP-Sm4629 is due to the instability of the thiolate-ligated P450 species that quickly reverts to a P420 form as with EpoK, or an alternative proximal ligand-coordinated species as in P420_cam, P450 enzymes that undergo peroxide shunt pathway are insensitive to the nature of the proximal ligand as they do not require electron transfer to the heme iron. 	P450 enzymes	27935	27947	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:143	Whether the failure of observing a P450 species in CYP-Sm4629 is due to the instability of the thiolate-ligated P450 species that quickly reverts to a P420 form as with EpoK, or an alternative proximal ligand-coordinated species as in P420_cam, P450 enzymes that undergo peroxide shunt pathway are insensitive to the nature of the proximal ligand as they do not require electron transfer to the heme iron. 	P450 enzymes	27935	27947	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:217	Spectra of the CO-bound NAD(P)H-reduced forms of the P450 enzymes were subsequently recorded. 	P450 enzymes	41424	41436	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:217	Spectra of the CO-bound NAD(P)H-reduced forms of the P450 enzymes were subsequently recorded. 	P450 enzymes	41424	41436	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:310	Duplications of members of enzyme families (eg cytochromes P450, glycosyltransferases, methyltransferases, BAHD acyltransferases) also play major roles in generating chemical novelty, with biosynthesis of >40,000 structurally diverse terpenoids - produced partly due to genomic clustering of terpene synthases and cytochrome P450 enzymes - as an extreme example. 	P450 enzymes	45254	45266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5595436_OgerInput.txtOger_out.csv:310	Duplications of members of enzyme families (eg cytochromes P450, glycosyltransferases, methyltransferases, BAHD acyltransferases) also play major roles in generating chemical novelty, with biosynthesis of >40,000 structurally diverse terpenoids - produced partly due to genomic clustering of terpene synthases and cytochrome P450 enzymes - as an extreme example. 	P450 enzymes	45254	45266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:395	In addition, none of the aforementioned benzothiadiazine analogs significantly inhibit the major Cytochrome P450 enzymes indicating that these compounds should not affect the metabolism of drug substances. 	P450 enzymes	66969	66981	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:395	In addition, none of the aforementioned benzothiadiazine analogs significantly inhibit the major Cytochrome P450 enzymes indicating that these compounds should not affect the metabolism of drug substances. 	P450 enzymes	66969	66981	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:396	In vitro studies using both rat and human liver microsomes have shown that these benzothiadiazine derivatives themselves are resistant to oxidative metabolism by Cytochrome P450 enzymes with >97% of the parent compounds remaining after a 60 min incubation with microsomes of either species. 	P450 enzymes	67240	67252	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:396	In vitro studies using both rat and human liver microsomes have shown that these benzothiadiazine derivatives themselves are resistant to oxidative metabolism by Cytochrome P450 enzymes with >97% of the parent compounds remaining after a 60 min incubation with microsomes of either species. 	P450 enzymes	67240	67252	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	P450 enzymes	417	429	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	P450 enzymes	417	429	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:21	The commercial R. rosea industry is large, with over 46 registered international companies, giving the herb a global distribution (Galambosi ; Edwards et al.. CYP2C9 is a part of the CYP2C family of enzymes, which accounts for about 20% of all P450 enzymes in the human liver (Niwa and Yamazaki. 	P450 enzymes	2313	2325	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:21	The commercial R. rosea industry is large, with over 46 registered international companies, giving the herb a global distribution (Galambosi ; Edwards et al.. CYP2C9 is a part of the CYP2C family of enzymes, which accounts for about 20% of all P450 enzymes in the human liver (Niwa and Yamazaki. 	P450 enzymes	2313	2325	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:27	; Chiangsom et al.. Several studies have evaluated the inhibitory potential of R. rosea toward cytochrome P450 enzymes. 	P450 enzymes	3278	3290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:27	; Chiangsom et al.. Several studies have evaluated the inhibitory potential of R. rosea toward cytochrome P450 enzymes. 	P450 enzymes	3278	3290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:39	The inhibition of Cytochrome P450 enzymes can broadly be divided into two types; reversible and irreversible. 	P450 enzymes	5945	5957	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:39	The inhibition of Cytochrome P450 enzymes can broadly be divided into two types; reversible and irreversible. 	P450 enzymes	5945	5957	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	P450 enzymes	16847	16859	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	P450 enzymes	16847	16859	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:2	Determining drug-metabolizing enzyme activities on an individual basis is an important component of personalized medicine, and cytochrome P450 enzymes play a principal role in hepatic drug metabolism. 	P450 enzymes	254	266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:2	Determining drug-metabolizing enzyme activities on an individual basis is an important component of personalized medicine, and cytochrome P450 enzymes play a principal role in hepatic drug metabolism. 	P450 enzymes	254	266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:5	This study aims to observe TSG-provided the aggravation on acetaminophen (APAP)-induced hepatotoxicity in mice by inducing hepatic expression of cytochrome P450 enzymes. 	P450 enzymes	542	554	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:5	This study aims to observe TSG-provided the aggravation on acetaminophen (APAP)-induced hepatotoxicity in mice by inducing hepatic expression of cytochrome P450 enzymes. 	P450 enzymes	542	554	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:17	Liver Cytochrome P450 enzymes is the most important drug metabolizing enzymes and responsible for more than 80% of drug metabolism^,. 	P450 enzymes	2475	2487	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:17	Liver Cytochrome P450 enzymes is the most important drug metabolizing enzymes and responsible for more than 80% of drug metabolism^,. 	P450 enzymes	2475	2487	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	P450 enzymes	4584	4596	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	P450 enzymes	4584	4596	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	P450 enzymes	16606	16618	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	P450 enzymes	16606	16618	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	P450 enzymes	16779	16791	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	P450 enzymes	16779	16791	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:90	Previous studies showed that some chemical agents were reported to exacerbate APAP-induced liver injury by enhancing its liver metabolism via inducing the expression of Cytochrome P450 enzymes^-. 	P450 enzymes	17023	17035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:90	Previous studies showed that some chemical agents were reported to exacerbate APAP-induced liver injury by enhancing its liver metabolism via inducing the expression of Cytochrome P450 enzymes^-. 	P450 enzymes	17023	17035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:129	Cytochrome P450 enzymes constitute a superfamily of proteins that play an important role in the metabolism and detoxification of xenobiotics (Brown et al.,. 	P450 enzymes	20471	20483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:129	Cytochrome P450 enzymes constitute a superfamily of proteins that play an important role in the metabolism and detoxification of xenobiotics (Brown et al.,. 	P450 enzymes	20471	20483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:225	One of the most important mechanisms through which interactions occur is via the interference of herbal products with human hepatic drug metabolizing enzyme activities particularly the cytochrome P450 enzymes. 	P450 enzymes	40575	40587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:225	One of the most important mechanisms through which interactions occur is via the interference of herbal products with human hepatic drug metabolizing enzyme activities particularly the cytochrome P450 enzymes. 	P450 enzymes	40575	40587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:43	Cytochrome P450 enzymes were isolated and prepared by differential centrifugation and analyzed for their activity by the use of liver microsomes.. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), weighed, and homogenized in 0.05 mM Tris/KCl buffer (pH 7.4). 	P450 enzymes	8052	8064	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:43	Cytochrome P450 enzymes were isolated and prepared by differential centrifugation and analyzed for their activity by the use of liver microsomes.. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), weighed, and homogenized in 0.05 mM Tris/KCl buffer (pH 7.4). 	P450 enzymes	8052	8064	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:113	NF-B has been implicated in the regulation of P450s through interaction with their induction mechanisms.- Our results demonstrated that Methicillin-Resistant Staphylococcus Aureus has a strong inhibitory effect on the mRNA levels and enzyme activities of Cytochrome P450 enzymes. 	P450 enzymes	20905	20917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:113	NF-B has been implicated in the regulation of P450s through interaction with their induction mechanisms.- Our results demonstrated that Methicillin-Resistant Staphylococcus Aureus has a strong inhibitory effect on the mRNA levels and enzyme activities of Cytochrome P450 enzymes. 	P450 enzymes	20905	20917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:116	This inhibition of Cytochrome P450 enzymes was also accompanied by an increase in oxidative stress in the livers of mice infected with Methicillin-Resistant Staphylococcus Aureus. 	P450 enzymes	21452	21464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:116	This inhibition of Cytochrome P450 enzymes was also accompanied by an increase in oxidative stress in the livers of mice infected with Methicillin-Resistant Staphylococcus Aureus. 	P450 enzymes	21452	21464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:83	All three enzymes showed high and very similar dissociation constants (in the M range) for the binding of cinnamate, and high catalytic efficiencies, around 100 min^1 M^1, for the conversion of cinnamate into p-coumarate, which are among the best reported for membrane-bound P450 enzymes. 	P450 enzymes	13249	13261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:83	All three enzymes showed high and very similar dissociation constants (in the M range) for the binding of cinnamate, and high catalytic efficiencies, around 100 min^1 M^1, for the conversion of cinnamate into p-coumarate, which are among the best reported for membrane-bound P450 enzymes. 	P450 enzymes	13249	13261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:150	Our extensive mining of the most recent sequencing data is in line with the hypothesis that the CYP73 family of cytochrome P450 enzymes evolved upon plant colonization of land. 	P450 enzymes	24990	25002	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:150	Our extensive mining of the most recent sequencing data is in line with the hypothesis that the CYP73 family of cytochrome P450 enzymes evolved upon plant colonization of land. 	P450 enzymes	24990	25002	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:185	Some mammalian P450 enzymes with a single TMH have been reported to enter the secretory pathway and to be targeted to the plasma membrane, some of them facing the extracellular space. 	P450 enzymes	30495	30507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:185	Some mammalian P450 enzymes with a single TMH have been reported to enter the secretory pathway and to be targeted to the plasma membrane, some of them facing the extracellular space. 	P450 enzymes	30495	30507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:37	The following data were abstracted from selected studies: number of individuals in the study, the study population, P450 enzymes, method for genotyping and phenotyping, allele frequencies and conclusions from the study. 	P450 enzymes	7896	7908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:37	The following data were abstracted from selected studies: number of individuals in the study, the study population, P450 enzymes, method for genotyping and phenotyping, allele frequencies and conclusions from the study. 	P450 enzymes	7896	7908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:41	Through this tool, metabolism using certain cytochrome P450 enzymes was evaluated comparing whether the compounds were substrates for cytochromes CYP450 2D6, CYP450 3A4, and CYP450 2C9; whether they were inhibitors of cytochrome CYP450 1A2, CYP450 2C9, CYP450 2D6, CYP450 2C19, and CYP450 3A4; and whether there was cytochrome inhibition promiscuity. 	P450 enzymes	6736	6748	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5932986_OgerInput.txtOger_out.csv:41	Through this tool, metabolism using certain cytochrome P450 enzymes was evaluated comparing whether the compounds were substrates for cytochromes CYP450 2D6, CYP450 3A4, and CYP450 2C9; whether they were inhibitors of cytochrome CYP450 1A2, CYP450 2C9, CYP450 2D6, CYP450 2C19, and CYP450 3A4; and whether there was cytochrome inhibition promiscuity. 	P450 enzymes	6736	6748	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:102	CHO-K1 cells do not metabolize steroid hormones,^ and no expression of CYP P450 enzymes was detected in CHO cells;^ this indicates that metabolites were exclusively formed by enzymes provided by the S9-mix. 	P450 enzymes	22240	22252	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:102	CHO-K1 cells do not metabolize steroid hormones,^ and no expression of CYP P450 enzymes was detected in CHO cells;^ this indicates that metabolites were exclusively formed by enzymes provided by the S9-mix. 	P450 enzymes	22240	22252	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:179	to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6. 	P450 enzymes	28830	28842	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:179	to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6. 	P450 enzymes	28830	28842	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	P450 enzymes	29006	29018	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	P450 enzymes	29006	29018	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:97	Various studies have reported the pivotal role of P450 enzymes in the synthesis of FCs (,; ,. 	P450 enzymes	14462	14474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6018538_OgerInput.txtOger_out.csv:97	Various studies have reported the pivotal role of P450 enzymes in the synthesis of FCs (,; ,. 	P450 enzymes	14462	14474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:3	Buried active sites in cytochrome P450 enzymes are connected to the solvent by a network of channels exiting at the distal surface of the protein. 	P450 enzymes	275	287	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:3	Buried active sites in cytochrome P450 enzymes are connected to the solvent by a network of channels exiting at the distal surface of the protein. 	P450 enzymes	275	287	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:6	Amino acid residues at the entrance of the channels may participate to a first global ligand recognition of ligands by P450 enzymes before they reach the buried active site. 	P450 enzymes	791	803	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:6	Amino acid residues at the entrance of the channels may participate to a first global ligand recognition of ligands by P450 enzymes before they reach the buried active site. 	P450 enzymes	791	803	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:7	Moreover, different P450 enzymes show different networks of predicted channels. 	P450 enzymes	866	878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:7	Moreover, different P450 enzymes show different networks of predicted channels. 	P450 enzymes	866	878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:10	The mechanism of action of all P450 enzymes, except a few ones, is to catalyze molecular dioxygen reduction by splitting the dioxygen molecule in two, one oxygen atom is inserted in the substrate to yield the oxidized product, and the second is reduced to water, a typical monooxygenase activity. 	P450 enzymes	1220	1232	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:10	The mechanism of action of all P450 enzymes, except a few ones, is to catalyze molecular dioxygen reduction by splitting the dioxygen molecule in two, one oxygen atom is inserted in the substrate to yield the oxidized product, and the second is reduced to water, a typical monooxygenase activity. 	P450 enzymes	1220	1232	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:11	Two biochemical properties characterize P450 enzymes among other hemoproteins. 	P450 enzymes	1526	1538	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:11	Two biochemical properties characterize P450 enzymes among other hemoproteins. 	P450 enzymes	1526	1538	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:15	The P450 enzymes, which are divided into gene families and subfamilies on the basis of the amount of identity between amino acid sequences, can be broadly classified in two main classes depending on their global substrate specificity. 	P450 enzymes	1836	1848	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:15	The P450 enzymes, which are divided into gene families and subfamilies on the basis of the amount of identity between amino acid sequences, can be broadly classified in two main classes depending on their global substrate specificity. 	P450 enzymes	1836	1848	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:16	A first class includes P450 enzymes that have a strong preference for a single substrate. 	P450 enzymes	2090	2102	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:16	A first class includes P450 enzymes that have a strong preference for a single substrate. 	P450 enzymes	2090	2102	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:18	The second class comprises P450 enzymes featuring a broad specificity for substrates, often very different in size and chemical nature, mostly comprising the P450s that are involved in the drug and pollutant metabolism in vertebrates. 	P450 enzymes	2327	2339	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:18	The second class comprises P450 enzymes featuring a broad specificity for substrates, often very different in size and chemical nature, mostly comprising the P450s that are involved in the drug and pollutant metabolism in vertebrates. 	P450 enzymes	2327	2339	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:19	Consequently, P450 enzymes are frequently designated as unspecific monooxygenases (EC1.14.14.1). 	P450 enzymes	2549	2561	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:19	Consequently, P450 enzymes are frequently designated as unspecific monooxygenases (EC1.14.14.1). 	P450 enzymes	2549	2561	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:20	P450 enzymes of either classes share the same similar catalytic cycle and a similar folding. 	P450 enzymes	2632	2644	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:20	P450 enzymes of either classes share the same similar catalytic cycle and a similar folding. 	P450 enzymes	2632	2644	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:24	This plant P450 exhibits a crystal structure that is highly similar to any other P450 enzymes, such as that of human CYP2B6, which reduces molecular dioxygen and reacts with hundreds of different substrates. 	P450 enzymes	3346	3358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:24	This plant P450 exhibits a crystal structure that is highly similar to any other P450 enzymes, such as that of human CYP2B6, which reduces molecular dioxygen and reacts with hundreds of different substrates. 	P450 enzymes	3346	3358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:25	The extraordinary chemical ability of P450 enzymes is mainly based on three features that all of these enzymes share. 	P450 enzymes	3511	3523	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:25	The extraordinary chemical ability of P450 enzymes is mainly based on three features that all of these enzymes share. 	P450 enzymes	3511	3523	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:28	This iron-cysteinate bond is at the heart of the different redox states that the iron ion may access during P450 catalysis, leading to the sophisticated catalytic cycle of P450 enzymes. 	P450 enzymes	4053	4065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:28	This iron-cysteinate bond is at the heart of the different redox states that the iron ion may access during P450 catalysis, leading to the sophisticated catalytic cycle of P450 enzymes. 	P450 enzymes	4053	4065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:30	Besides these common features, all of the P450 enzymes also present a typical structural feature, the absence of a clear visible access between the protein surface and the active site that is always buried deep in the protein core. 	P450 enzymes	4265	4277	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:30	Besides these common features, all of the P450 enzymes also present a typical structural feature, the absence of a clear visible access between the protein surface and the active site that is always buried deep in the protein core. 	P450 enzymes	4265	4277	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:35	Differences in the networks of channels among P450 enzymes may account for the differences in ligand selectivity, and hence, for the ways that P450 enzymes control at several levels their substrate selectivity. 	P450 enzymes	5074	5086	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:35	Differences in the networks of channels among P450 enzymes may account for the differences in ligand selectivity, and hence, for the ways that P450 enzymes control at several levels their substrate selectivity. 	P450 enzymes	5074	5086	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:35	Differences in the networks of channels among P450 enzymes may account for the differences in ligand selectivity, and hence, for the ways that P450 enzymes control at several levels their substrate selectivity. 	P450 enzymes	5171	5183	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:35	Differences in the networks of channels among P450 enzymes may account for the differences in ligand selectivity, and hence, for the ways that P450 enzymes control at several levels their substrate selectivity. 	P450 enzymes	5171	5183	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:59	have classified and named the different access channels that were found by CAVER on structurally characterized P450 enzymes in a systematic manner. 	P450 enzymes	10292	10304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:59	have classified and named the different access channels that were found by CAVER on structurally characterized P450 enzymes in a systematic manner. 	P450 enzymes	10292	10304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:60	The different ligand access channels that were identified in P450 enzymes were each named by a different number (channels 1, 2, 3, 4, W, and S). 	P450 enzymes	10390	10402	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:60	The different ligand access channels that were identified in P450 enzymes were each named by a different number (channels 1, 2, 3, 4, W, and S). 	P450 enzymes	10390	10402	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:76	P450cam (CYP101), which is one of the best characterized of all P450 enzymes, is considered as a model for P450s with narrow substrate specificity. 	P450 enzymes	13191	13203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:76	P450cam (CYP101), which is one of the best characterized of all P450 enzymes, is considered as a model for P450s with narrow substrate specificity. 	P450 enzymes	13191	13203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:90	It appears that the inhibitor metyrapone binds the heme iron ion by one of its pyridine nitrogen, and that the progesterone is bound on the CYP3A4 surface to a pocket made by the F/G region, and which colocalized with the mouth of either CAVER channel 3 or 4 in P450 enzymes. 	P450 enzymes	15587	15599	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:90	It appears that the inhibitor metyrapone binds the heme iron ion by one of its pyridine nitrogen, and that the progesterone is bound on the CYP3A4 surface to a pocket made by the F/G region, and which colocalized with the mouth of either CAVER channel 3 or 4 in P450 enzymes. 	P450 enzymes	15587	15599	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:114	For all mammalian P450 enzymes that were considered, a network of several access channels linking the catalytic cavity to the distal face of the protein is consistently predicted. 	P450 enzymes	19822	19834	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:114	For all mammalian P450 enzymes that were considered, a network of several access channels linking the catalytic cavity to the distal face of the protein is consistently predicted. 	P450 enzymes	19822	19834	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:117	However, in P450 enzymes, discrete side chains reorganizations and some secondary elements are also prone to conformational change, both types of protein dynamics seem to take place. 	P450 enzymes	20295	20307	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:117	However, in P450 enzymes, discrete side chains reorganizations and some secondary elements are also prone to conformational change, both types of protein dynamics seem to take place. 	P450 enzymes	20295	20307	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:121	This result suggests that in P450 enzymes preliminary ligand recognition takes place at the surface of the enzyme before channeling it to the catalytic cavity. 	P450 enzymes	20941	20953	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:121	This result suggests that in P450 enzymes preliminary ligand recognition takes place at the surface of the enzyme before channeling it to the catalytic cavity. 	P450 enzymes	20941	20953	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:124	This was the first study to demonstrate that phospholipids were not just playing a structural role bymaking the membrane, but also could play a role in the function of the P450 enzymes. 	P450 enzymes	21671	21683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:124	This was the first study to demonstrate that phospholipids were not just playing a structural role bymaking the membrane, but also could play a role in the function of the P450 enzymes. 	P450 enzymes	21671	21683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:125	It is known, though surprisingly enough not much worked, that phospholipids indeed play a role in modulating the activity of membrane-bound P450 enzymes. 	P450 enzymes	21825	21837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:125	It is known, though surprisingly enough not much worked, that phospholipids indeed play a role in modulating the activity of membrane-bound P450 enzymes. 	P450 enzymes	21825	21837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:129	This work thus shows that the dynamic of channels in P450 enzymes may also be influenced by the nature of phospholipids present in their vicinity. 	P450 enzymes	22465	22477	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:129	This work thus shows that the dynamic of channels in P450 enzymes may also be influenced by the nature of phospholipids present in their vicinity. 	P450 enzymes	22465	22477	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:137	All of these results indicate that at least two notions have to be kept in mind when looking at channels and ligand selectivity in P450 enzymes. 	P450 enzymes	23978	23990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:137	All of these results indicate that at least two notions have to be kept in mind when looking at channels and ligand selectivity in P450 enzymes. 	P450 enzymes	23978	23990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:141	The association to the membrane and the F/G cassette are key elements in the relationships between channels and ligand selectivity in P450 enzymes. 	P450 enzymes	24460	24472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:141	The association to the membrane and the F/G cassette are key elements in the relationships between channels and ligand selectivity in P450 enzymes. 	P450 enzymes	24460	24472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:142	The F/G region of P450 enzymes have not only been highlighted by molecular dynamics simulations, but also by biochemical and biophysical experiments, and this, both for bacterial and eukaryotic P450s. 	P450 enzymes	24492	24504	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:142	The F/G region of P450 enzymes have not only been highlighted by molecular dynamics simulations, but also by biochemical and biophysical experiments, and this, both for bacterial and eukaryotic P450s. 	P450 enzymes	24492	24504	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:147	Whether a given channel opens up depends on the physicochemical properties of the interface between the F/G structural block and the rest of the P450 molecule, and also on structural features, such as the extent of the F/G loop and the arrangement of F and G helices within the F/G region in mammalian P450 enzymes. 	P450 enzymes	25462	25474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:147	Whether a given channel opens up depends on the physicochemical properties of the interface between the F/G structural block and the rest of the P450 molecule, and also on structural features, such as the extent of the F/G loop and the arrangement of F and G helices within the F/G region in mammalian P450 enzymes. 	P450 enzymes	25462	25474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:155	This result points out how Nature may use a few specific sequence motifs to modulate the channel opening of the different P450 enzymes, and thus their associated ligand specificity, by using local flexibility of some definite secondary structure elements. 	P450 enzymes	26936	26948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:155	This result points out how Nature may use a few specific sequence motifs to modulate the channel opening of the different P450 enzymes, and thus their associated ligand specificity, by using local flexibility of some definite secondary structure elements. 	P450 enzymes	26936	26948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:156	This motion was observed both when comparing the crystal structures of the same P450 complexed with different ligands and in silicoby revealing the malleability of this region in P450 enzymes. 	P450 enzymes	27249	27261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:156	This motion was observed both when comparing the crystal structures of the same P450 complexed with different ligands and in silicoby revealing the malleability of this region in P450 enzymes. 	P450 enzymes	27249	27261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:158	In this respect, it is interesting to note that two of the less-studied channels that were seen with CAVER in P450 enzymes, namely channels 3 and 4, have their opening right in-between the F and the G helices, one being very close to the F/G helices(channel 4) and the other close to the F/F loop. 	P450 enzymes	27661	27673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:158	In this respect, it is interesting to note that two of the less-studied channels that were seen with CAVER in P450 enzymes, namely channels 3 and 4, have their opening right in-between the F and the G helices, one being very close to the F/G helices(channel 4) and the other close to the F/F loop. 	P450 enzymes	27661	27673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:182	It thus appears that P450 enzymes show structural regions with major differences in flexibility. 	P450 enzymes	32578	32590	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:182	It thus appears that P450 enzymes show structural regions with major differences in flexibility. 	P450 enzymes	32578	32590	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:196	The atomic models of six human P450 enzymes including CYP3A4 anchored to a lipid bilayer were constructed and investigated by molecular dynamics simulations for the position and orientation of the P450 protein on the model membrane. 	P450 enzymes	35550	35562	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:196	The atomic models of six human P450 enzymes including CYP3A4 anchored to a lipid bilayer were constructed and investigated by molecular dynamics simulations for the position and orientation of the P450 protein on the model membrane. 	P450 enzymes	35550	35562	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:206	The P450 enzymes seem to not have the same affinity for these cholesterol-rich microdomains. 	P450 enzymes	37591	37603	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:206	The P450 enzymes seem to not have the same affinity for these cholesterol-rich microdomains. 	P450 enzymes	37591	37603	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	P450 enzymes	37870	37882	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	P450 enzymes	37870	37882	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:213	The accessibility of the occluded catalytic cavity of P450 enzymes originates from the analyses of crystal structures, which offer only a static view, and it is known that shortcomings, such as crystal packing causing non-native contacts and constraints, may affect conclusions that are deduced from the comparison of crystal structures. 	P450 enzymes	38924	38936	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:213	The accessibility of the occluded catalytic cavity of P450 enzymes originates from the analyses of crystal structures, which offer only a static view, and it is known that shortcomings, such as crystal packing causing non-native contacts and constraints, may affect conclusions that are deduced from the comparison of crystal structures. 	P450 enzymes	38924	38936	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:228	This important work was also showing that different substrates may use different channels to access the active site in P450 enzymes. 	P450 enzymes	41334	41346	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:228	This important work was also showing that different substrates may use different channels to access the active site in P450 enzymes. 	P450 enzymes	41334	41346	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:230	This opens the way to a study of the relationships between the functions and the composition of the channel networks, as they are systematically observed in P450 enzymes. 	P450 enzymes	41813	41825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:230	This opens the way to a study of the relationships between the functions and the composition of the channel networks, as they are systematically observed in P450 enzymes. 	P450 enzymes	41813	41825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:247	A combination between the substrate access channel and the F-helix break could act as a structural determinant of substrate specificity in this family of P450 enzymes. 	P450 enzymes	44505	44517	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:247	A combination between the substrate access channel and the F-helix break could act as a structural determinant of substrate specificity in this family of P450 enzymes. 	P450 enzymes	44505	44517	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:271	The network of channels observed in all P450 enzymes is thus likely involved in the control of their substrate specificity. 	P450 enzymes	48404	48416	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:271	The network of channels observed in all P450 enzymes is thus likely involved in the control of their substrate specificity. 	P450 enzymes	48404	48416	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:274	Channels are an element of the structural determinants of the substrate specificity in P450 enzymes. 	P450 enzymes	48804	48816	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:274	Channels are an element of the structural determinants of the substrate specificity in P450 enzymes. 	P450 enzymes	48804	48816	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:296	Future prospects on channels in P450 enzymes could include the possibility to transfer a specific channel from a P450 to another, in which this specific channel is missing. 	P450 enzymes	51950	51962	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:296	Future prospects on channels in P450 enzymes could include the possibility to transfer a specific channel from a P450 to another, in which this specific channel is missing. 	P450 enzymes	51950	51962	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:301	All of these future studies will rely on extensive and specific multiple mutations in P450 enzymes, and, for the moment, their feasibility and outcome are hardly predictable.	P450 enzymes	53048	53060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:301	All of these future studies will rely on extensive and specific multiple mutations in P450 enzymes, and, for the moment, their feasibility and outcome are hardly predictable.	P450 enzymes	53048	53060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6033001_OgerInput.txtOger_out.csv:22	Secnidazole is rapidly and completely absorbed following oral administration and demonstrates a longer terminal elimination halflife of approximately 17 to 29 hours vs other drugs in its class.,  It is metabolized by oxidation in the liver to a hydroxyethyl metabolite without any effects, neither induction nor inhibition, on cytochrome P450 enzymes, ; elimination is mainly through the urinary route, with approximately 50% excreted by 96 hours. 	P450 enzymes	6044	6056	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6033001_OgerInput.txtOger_out.csv:22	Secnidazole is rapidly and completely absorbed following oral administration and demonstrates a longer terminal elimination halflife of approximately 17 to 29 hours vs other drugs in its class.,  It is metabolized by oxidation in the liver to a hydroxyethyl metabolite without any effects, neither induction nor inhibition, on cytochrome P450 enzymes, ; elimination is mainly through the urinary route, with approximately 50% excreted by 96 hours. 	P450 enzymes	6044	6056	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	P450 enzymes	15749	15761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	P450 enzymes	15749	15761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:9	Cytochrome P450 enzymes, arguably natures most versatile catalysts, are a superfamily of haem-thiolate proteins found across all lineages of life^. 	P450 enzymes	1613	1625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:9	Cytochrome P450 enzymes, arguably natures most versatile catalysts, are a superfamily of haem-thiolate proteins found across all lineages of life^. 	P450 enzymes	1613	1625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:11	While there are more than 57 different Cytochrome P450 enzymes in humans, only a small number of highly polymorphic isoforms are responsible for the majority of drug metabolism^. 	P450 enzymes	1920	1932	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:11	While there are more than 57 different Cytochrome P450 enzymes in humans, only a small number of highly polymorphic isoforms are responsible for the majority of drug metabolism^. 	P450 enzymes	1920	1932	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:4	In vitro studies have suggested that UVB enhances B[a]P genotoxicity by activating the AhR pathway and overexpressing the cytochrome P450 enzymes responsible for the conversion of B[a]P into DNA damaging metabolites. 	P450 enzymes	525	537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:4	In vitro studies have suggested that UVB enhances B[a]P genotoxicity by activating the AhR pathway and overexpressing the cytochrome P450 enzymes responsible for the conversion of B[a]P into DNA damaging metabolites. 	P450 enzymes	525	537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:171	In conclusion, our study provides for the first time an extensive picture of the impact of Simulated Sunlight, namely a combination of both UVB and UVA components, on the metabolism and genotoxicity of B[a]P. In contrast to previous data obtained in vitro with pure UVB, solar Ultraviolet radiation appears to have a strong repressive effect on B[a]P-induced gene induction of Cytochrome P450 enzymes and delays formation of BPDE-DNA adducts in skin. 	P450 enzymes	25578	25590	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:171	In conclusion, our study provides for the first time an extensive picture of the impact of Simulated Sunlight, namely a combination of both UVB and UVA components, on the metabolism and genotoxicity of B[a]P. In contrast to previous data obtained in vitro with pure UVB, solar Ultraviolet radiation appears to have a strong repressive effect on B[a]P-induced gene induction of Cytochrome P450 enzymes and delays formation of BPDE-DNA adducts in skin. 	P450 enzymes	25578	25590	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:21	Cytochrome P450 enzymes are the major heme-containing enzyme family and the most important drug-metabolizing enzymes. 	P450 enzymes	2896	2908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:21	Cytochrome P450 enzymes are the major heme-containing enzyme family and the most important drug-metabolizing enzymes. 	P450 enzymes	2896	2908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:29	Thus, they reach systemic circulation as aglycones, and as such are exposed to the cytochrome P450 enzymes. 	P450 enzymes	4017	4029	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:29	Thus, they reach systemic circulation as aglycones, and as such are exposed to the cytochrome P450 enzymes. 	P450 enzymes	4017	4029	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	P450 enzymes	471	483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	P450 enzymes	471	483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:99	Molecules more soluble in water do not make good substrates for P450 enzymes. 	P450 enzymes	14619	14631	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:99	Molecules more soluble in water do not make good substrates for P450 enzymes. 	P450 enzymes	14619	14631	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:107	These results indicate that rooibos extracts may potentially cause herb-drug interactions when co-administered with substrates or drugs metabolized by these P450 enzymes. 	P450 enzymes	15677	15689	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:107	These results indicate that rooibos extracts may potentially cause herb-drug interactions when co-administered with substrates or drugs metabolized by these P450 enzymes. 	P450 enzymes	15677	15689	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	P450 enzymes	658	670	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	P450 enzymes	658	670	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:116	This study includes the quantitative measurement of drug-like properties such as, lipophilicity, solubility, pKa (negative logarithmic measure of acid dissociation constant), permeability, absorption, bioavailability, blood-brain barrier penetration, transporters, dermal and ocular penetration, plasma-protein binding, metabolism and drug-drug interaction, volume of distribution (V_d), clearance, half-life, p-glycoprotein efflux and inhibition as well as inhibition of the hepatic organic anion transporting polypeptide (OATP-1B1) transporter, cytochromes P450 enzymes, and UDP-glucuronosyltransferases. 	P450 enzymes	17749	17761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:116	This study includes the quantitative measurement of drug-like properties such as, lipophilicity, solubility, pKa (negative logarithmic measure of acid dissociation constant), permeability, absorption, bioavailability, blood-brain barrier penetration, transporters, dermal and ocular penetration, plasma-protein binding, metabolism and drug-drug interaction, volume of distribution (V_d), clearance, half-life, p-glycoprotein efflux and inhibition as well as inhibition of the hepatic organic anion transporting polypeptide (OATP-1B1) transporter, cytochromes P450 enzymes, and UDP-glucuronosyltransferases. 	P450 enzymes	17749	17761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	P450 enzymes	37882	37894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	P450 enzymes	37882	37894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:240	In identifying the affinity of studies compound with CYP-P450 enzymes in quantitative terms, the Michaelis-Menten constant (K_m), maximum metabolic rate (V_max) and intrinsic clearance (C_Lint) calculated, which provide the knowledge of the rate of metabolism. 	P450 enzymes	38682	38694	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:240	In identifying the affinity of studies compound with CYP-P450 enzymes in quantitative terms, the Michaelis-Menten constant (K_m), maximum metabolic rate (V_max) and intrinsic clearance (C_Lint) calculated, which provide the knowledge of the rate of metabolism. 	P450 enzymes	38682	38694	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	P450 enzymes	831	843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	P450 enzymes	831	843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	P450 enzymes	54	66	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	P450 enzymes	54	66	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	P450 enzymes	214	226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	P450 enzymes	214	226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	P450 enzymes	3243	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	P450 enzymes	3243	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	P450 enzymes	22650	22662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	P450 enzymes	22650	22662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	P450 enzymes	34777	34789	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	P450 enzymes	34777	34789	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	P450 enzymes	34972	34984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	P450 enzymes	34972	34984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	P450 enzymes	35384	35396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	P450 enzymes	35384	35396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	P450 enzymes	35634	35646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	P450 enzymes	35634	35646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	P450 enzymes	35864	35876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	P450 enzymes	35864	35876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	P450 enzymes	556	568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	P450 enzymes	556	568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	P450 enzymes	8227	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	P450 enzymes	8227	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:86	The active site heme iron is coordinated by the thiolate of the conserved, proximal Cys332 residue, whilst the I-helix that runs across the top of the heme contains the Glu/Gln pair of residues (Glu228, Gln229) that are required in P450 enzymes to maintain an effective protonation cascade during oxygen activation. 	P450 enzymes	17338	17350	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:86	The active site heme iron is coordinated by the thiolate of the conserved, proximal Cys332 residue, whilst the I-helix that runs across the top of the heme contains the Glu/Gln pair of residues (Glu228, Gln229) that are required in P450 enzymes to maintain an effective protonation cascade during oxygen activation. 	P450 enzymes	17338	17350	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	P450 enzymes	2814	2826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	P450 enzymes	2814	2826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:51	The values of mean microsomal fractions of the human heart for CYP enzymes (CYP2C8, CYP2C9, and CYP2J2) were used in computing total cardiac clearance in Equations and. 	CYP2C8	7429	7435	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:51	The values of mean microsomal fractions of the human heart for CYP enzymes (CYP2C8, CYP2C9, and CYP2J2) were used in computing total cardiac clearance in Equations and. 	CYP2C8	7429	7435	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7725	7731	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7725	7731	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7756	7762	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7756	7762	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7770	7776	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7770	7776	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7863	7869	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7863	7869	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7969	7975	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	7969	7975	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	8145	8151	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:53	where: CL_int2C8_per_mgC8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg], CL_int2C8_per_pmolC8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol], CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg], CL_int 2C8C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h], W_he - average heart weight [g], CLu_int 2C8C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h], fu_mic - fraction of drug unbound in an in vitro microsomal preparation, ISEF_2C8C8 - Inter System Extrapolation Factor for CYP2C8. 	CYP2C8	8145	8151	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP2C8	843	849	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP2C8	843	849	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2C8	1320	1326	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2C8	1320	1326	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP2C8	1767	1773	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP2C8	1767	1773	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2C8	4691	4697	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2C8	4691	4697	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2C8	5204	5210	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2C8	5204	5210	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5587	5593	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5587	5593	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5854	5860	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5854	5860	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5998	6004	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C8	5998	6004	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:22	Fargesin decreased CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pre-incubation time- and concentration-dependent manners in human liver microsomes. 	CYP2C8	6398	6404	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:22	Fargesin decreased CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pre-incubation time- and concentration-dependent manners in human liver microsomes. 	CYP2C8	6398	6404	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:23	The apparent K_i and maximal inactivation rate (k_inact) values of fargesin were 10.7 M and 0.082 min^1 for CYP2C8-catalyzed amodiaquine N-deethylation, 3.7 M and 0.102 min^1 for CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and 23.0 M and 0.050 min^1 for CYP3A4-catalyzed midazolam 1-hydroxylation, respectively, in human liver microsomes. 	CYP2C8	6736	6742	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:23	The apparent K_i and maximal inactivation rate (k_inact) values of fargesin were 10.7 M and 0.082 min^1 for CYP2C8-catalyzed amodiaquine N-deethylation, 3.7 M and 0.102 min^1 for CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and 23.0 M and 0.050 min^1 for CYP3A4-catalyzed midazolam 1-hydroxylation, respectively, in human liver microsomes. 	CYP2C8	6736	6742	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2C8	7298	7304	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2C8	7298	7304	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C8	7548	7554	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C8	7548	7554	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C8	7691	7697	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C8	7691	7697	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP2C8	7945	7951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP2C8	7945	7951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:32	Fargesin showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pooled human liver microsomes. 	CYP2C8	8786	8792	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:32	Fargesin showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pooled human liver microsomes. 	CYP2C8	8786	8792	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9028	9034	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9028	9034	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9167	9173	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9167	9173	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9384	9390	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:33	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C8 (7.66 min^1 nM^1) was comparable to that of aschantin (k_inact/K_i = 5.49 min^1 nM^1), but was higher than those of mechanism-based CYP2C8 inhibitors such as amiodarone (0.57 min^1 nM^1), phenelzine (3.17 min^1 nM^1), and gemfibrozil (1.24 min^1 nM^1) in human liver microsomes, indicating that fargesin may be a potent mechanism-based inhibitor of CYP2C8. 	CYP2C8	9384	9390	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2C8	11754	11760	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2C8	11754	11760	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:64	The mechanism-based inhibition potency of fargesin against human liver microsomal CYP2C8, CYP2C19, and CYP3A4 activities was evaluated. 	CYP2C8	17075	17081	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:64	The mechanism-based inhibition potency of fargesin against human liver microsomal CYP2C8, CYP2C19, and CYP3A4 activities was evaluated. 	CYP2C8	17075	17081	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	CYP2C8	17477	17483	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	CYP2C8	17477	17483	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP2C8	18362	18368	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP2C8	18362	18368	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2C8	18673	18679	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2C8	18673	18679	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP2C8	19153	19159	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP2C8	19153	19159	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	CYP2C8	38495	38501	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	CYP2C8	38495	38501	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2C8	17000	17006	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2C8	17000	17006	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2C8	16270	16276	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2C8	16270	16276	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C8	16495	16501	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C8	16495	16501	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C8	17004	17010	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C8	17004	17010	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2C8	17544	17550	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2C8	17544	17550	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:9	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation with IC50 values of 0.5 and 0.9 M, respectively. 	CYP2C8	1263	1269	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:9	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation with IC50 values of 0.5 and 0.9 M, respectively. 	CYP2C8	1263	1269	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:34	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation, respectively, indicating that herbal drugs containing selaginellins may be used carefully with drugs metabolized by CYP2C8, such as anti-cancer drugs (paclitaxel and sorafenib), antidiabetics (repaglinide), and diuretics (torsemide) in order to avoid drug interactions. 	CYP2C8	5140	5146	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:34	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation, respectively, indicating that herbal drugs containing selaginellins may be used carefully with drugs metabolized by CYP2C8, such as anti-cancer drugs (paclitaxel and sorafenib), antidiabetics (repaglinide), and diuretics (torsemide) in order to avoid drug interactions. 	CYP2C8	5140	5146	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:34	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation, respectively, indicating that herbal drugs containing selaginellins may be used carefully with drugs metabolized by CYP2C8, such as anti-cancer drugs (paclitaxel and sorafenib), antidiabetics (repaglinide), and diuretics (torsemide) in order to avoid drug interactions. 	CYP2C8	5301	5307	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:34	Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine O-demethylation, respectively, indicating that herbal drugs containing selaginellins may be used carefully with drugs metabolized by CYP2C8, such as anti-cancer drugs (paclitaxel and sorafenib), antidiabetics (repaglinide), and diuretics (torsemide) in order to avoid drug interactions. 	CYP2C8	5301	5307	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:35	The inhibitory potential of these two selaginellins on CYP2C8 (IC_50 < 1 M) were lower than that of troglitazone (IC_50 = 2.3 M) and quercetin (IC_50 = 7.2 M). 	CYP2C8	5510	5516	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:35	The inhibitory potential of these two selaginellins on CYP2C8 (IC_50 < 1 M) were lower than that of troglitazone (IC_50 = 2.3 M) and quercetin (IC_50 = 7.2 M). 	CYP2C8	5510	5516	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:36	Their inhibitory potentials, however, were less potent than montelukast, an strong CYP2C8 inhibitor (IC_50 = 0.019 M). 	CYP2C8	5698	5704	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:36	Their inhibitory potentials, however, were less potent than montelukast, an strong CYP2C8 inhibitor (IC_50 = 0.019 M). 	CYP2C8	5698	5704	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:38	CYP2C8, CYP2C9, and CYP2J2 metabolize approximately 4.7, 12.8, and 3% of clinically used drugs (n = 248), respectively. 	CYP2C8	6009	6015	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:38	CYP2C8, CYP2C9, and CYP2J2 metabolize approximately 4.7, 12.8, and 3% of clinically used drugs (n = 248), respectively. 	CYP2C8	6009	6015	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:45	Therefore, it might be used with anticancer or antidiabetic drugs which are metabolized by CYP2C8 (paclitaxel), CYP2C9 (tolbutamide), or UGT1A1 (irinotecan). 	CYP2C8	7060	7066	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:45	Therefore, it might be used with anticancer or antidiabetic drugs which are metabolized by CYP2C8 (paclitaxel), CYP2C9 (tolbutamide), or UGT1A1 (irinotecan). 	CYP2C8	7060	7066	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2C8	9341	9347	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2C8	9341	9347	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP2C8	485	491	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP2C8	485	491	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:6	Unfermented (GRT) and fermented (FRE) rooibos extracts inhibited the activity of CYP2C8 (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) and CYP3A4 (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) based on their respective IC50 concentrations. 	CYP2C8	1037	1043	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:6	Unfermented (GRT) and fermented (FRE) rooibos extracts inhibited the activity of CYP2C8 (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) and CYP3A4 (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) based on their respective IC50 concentrations. 	CYP2C8	1037	1043	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:7	Both extracts dose- and time-dependently inhibited CYP2C8 activity, but only time-dependently inhibited CYP2C9. 	CYP2C8	1259	1265	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:7	Both extracts dose- and time-dependently inhibited CYP2C8 activity, but only time-dependently inhibited CYP2C9. 	CYP2C8	1259	1265	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP2C8	4899	4905	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP2C8	4899	4905	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP2C8	5781	5787	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP2C8	5781	5787	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP2C8	6299	6305	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP2C8	6299	6305	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP2C8	7216	7222	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP2C8	7216	7222	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP2C8	7446	7452	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP2C8	7446	7452	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP2C8	7531	7537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP2C8	7531	7537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:55	GRT and FRE showed strong inhibition of CYP2C8 activity (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) (a). 	CYP2C8	7778	7784	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:55	GRT and FRE showed strong inhibition of CYP2C8 activity (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) (a). 	CYP2C8	7778	7784	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:57	GRT and FRE reduced the remaining CYP2C8 activity in a moderate to strong concentration-dependent manner from 25 g/mL (70.1% and 82.1%, respectively; p < 0.001), 50 g/mL (31% and 39.7%, respectively; p < 0.001), and 100 g/mL (15.9% and 18.1%, respectively; p < 0.001) (a). 	CYP2C8	8074	8080	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:57	GRT and FRE reduced the remaining CYP2C8 activity in a moderate to strong concentration-dependent manner from 25 g/mL (70.1% and 82.1%, respectively; p < 0.001), 50 g/mL (31% and 39.7%, respectively; p < 0.001), and 100 g/mL (15.9% and 18.1%, respectively; p < 0.001) (a). 	CYP2C8	8074	8080	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:58	ASP significantly inhibited CYP2C8 activity, albeit that the percentage remaining activity at 50 and 100 g/mL was still at 84.4% and 85.5%, respectively. 	CYP2C8	8341	8347	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:58	ASP significantly inhibited CYP2C8 activity, albeit that the percentage remaining activity at 50 and 100 g/mL was still at 84.4% and 85.5%, respectively. 	CYP2C8	8341	8347	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:62	Both GRT and FRE showed time-dependent inhibition of CYP2C8 activity (a). 	CYP2C8	8958	8964	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:62	Both GRT and FRE showed time-dependent inhibition of CYP2C8 activity (a). 	CYP2C8	8958	8964	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP2C8	10820	10826	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP2C8	10820	10826	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2C8	11151	11157	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2C8	11151	11157	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:95	A strong concentration- and time-dependent inhibition of CYP2C8 activity was observed for both GRT and FRE. 	CYP2C8	14195	14201	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:95	A strong concentration- and time-dependent inhibition of CYP2C8 activity was observed for both GRT and FRE. 	CYP2C8	14195	14201	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:96	However, ASP and PPAG had no effect on CYP2C8. 	CYP2C8	14285	14291	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:96	However, ASP and PPAG had no effect on CYP2C8. 	CYP2C8	14285	14291	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP2C8	15289	15295	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP2C8	15289	15295	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP2C8	17079	17085	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP2C8	17079	17085	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP2C8	17537	17543	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP2C8	17537	17543	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP2C8	17929	17935	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP2C8	17929	17935	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP2C8	18698	18704	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP2C8	18698	18704	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP2C8	18937	18943	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP2C8	18937	18943	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP2C8	19231	19237	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP2C8	19231	19237	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP2C8	19431	19437	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP2C8	19431	19437	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP2C8	19860	19866	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP2C8	19860	19866	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP2C8	19987	19993	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP2C8	19987	19993	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C8	20140	20146	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C8	20140	20146	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C8	20467	20473	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C8	20467	20473	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP2C8	20837	20843	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP2C8	20837	20843	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP2C8	20967	20973	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP2C8	20967	20973	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C8	21579	21585	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C8	21579	21585	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C8	22061	22067	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C8	22061	22067	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP2C8	22946	22952	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP2C8	22946	22952	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:45	456255), CYP2C8 (Lot No. 	CYP2C8	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:45	456255), CYP2C8 (Lot No. 	CYP2C8	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C8	12868	12874	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C8	12868	12874	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C8	14147	14153	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C8	14147	14153	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C8	19945	19951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C8	19945	19951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2C8	24531	24537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2C8	24531	24537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	CYP2C8	1970	1976	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	CYP2C8	1970	1976	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:119	Combination of ellagic acid with warfarin significantly inhibited activities of CYP2C8, 2C9 and 3A4 (p < 0.05), however treatment of cells with ellagic acid alone presented significant inhibition on CYP2C9 activity despite other CYPs (p < 0.05). 	CYP2C8	18753	18759	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:119	Combination of ellagic acid with warfarin significantly inhibited activities of CYP2C8, 2C9 and 3A4 (p < 0.05), however treatment of cells with ellagic acid alone presented significant inhibition on CYP2C9 activity despite other CYPs (p < 0.05). 	CYP2C8	18753	18759	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:120	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01) and however, inhibited the activities of CYP2C9 and 3A4 when used alone and concomitantly with warfarin (p-values are marked in Figs. 	CYP2C8	18983	18989	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:120	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01) and however, inhibited the activities of CYP2C9 and 3A4 when used alone and concomitantly with warfarin (p-values are marked in Figs. 	CYP2C8	18983	18989	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC5209692_OgerInput.txtOger_out.csv:51	The values of mean microsomal fractions of the human heart for CYP enzymes (CYP2C8, CYP2C9, and CYP2J2) were used in computing total cardiac clearance in Equations and. 	CYP2C9	7437	7443	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2C9	926	932	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2C9	3547	3553	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2C9	3912	3918	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2C9	4763	4769	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:100	In addition, LD was observed between rs2153628 and rs9332168 (r^2 = 0.88) in the CYP2C9 gene, and between rs11597626 and rs12268020 (r^2 = 0.84) in CYP2C19 in the remaining SNP set. 	CYP2C9	17353	17359	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP2C9	19901	19907	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:158	However, SNPs in CYP2C9 and CYP2D6 present an average MAF = 0.06, significantly limiting their use in clinical practice, since they can only be detected in a small fraction of the population. 	CYP2C9	27237	27243	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:169	in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity in vitro which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. 	CYP2C9	33794	33800	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP2C9	642	648	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2C9	1424	1430	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP2C9	1775	1781	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2C9	4938	4944	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2C9	5212	5218	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:21	Fargesin exhibited competitive inhibition of CYP2C9-catalyzed diclofenac 4-hydroxylation with a K_i value of 16.3 M (,. 	CYP2C9	6304	6310	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2C9	7374	7380	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C9	7556	7562	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP2C9	7953	7959	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:30	Fargesin exhibited competitive inhibition of CYP2C9-catalyzed diclofenac 4-hydroxylation (K_i, 16.3 M), but aschantin showed mechanism-based inhibition of CYP2C9 (K_i, 3.7 M; k_inact, 0.044 min^1). 	CYP2C9	8398	8404	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:30	Fargesin exhibited competitive inhibition of CYP2C9-catalyzed diclofenac 4-hydroxylation (K_i, 16.3 M), but aschantin showed mechanism-based inhibition of CYP2C9 (K_i, 3.7 M; k_inact, 0.044 min^1). 	CYP2C9	8508	8514	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:31	Other pharmacologically active lignans such as honokiol, deoxypodophyllotoxin, and podophyllotoxin potently inhibited CYP2C9 activity with K_i values of 0.54, 3.5, and 2.0 M, respectively. 	CYP2C9	8669	8675	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2C9	11762	11768	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:62	To determine the K_i values and inhibition mode of fargesin for CYP2C9, various concentrations of fargesin (0-16 M) and diclofenac (2-20 M) were incubated with human liver microsomes (0.1 mg/mL), 10 mM MgCl_2, 1 mM NADPH, 50 mM potassium phosphate buffer (pH 7.4) in a total volume of 100 L for 10 min at 37 C. The reaction was stopped by adding 100 L of ice-cold d_9-1-hydroxybufuralol in methanol (10 ng/mL), and the mixtures were centrifuged at 13,000 g for 4 min. 	CYP2C9	16487	16493	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP2C9	18194	18200	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2C9	18778	18784	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP2C9	19161	19167	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP2C9	2171	2177	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2C9	38326	38332	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2C9	15810	15816	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP2C9	2174	2180	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2C9	35850	35856	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2C9	459	465	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2C9	5824	5830	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:42	Next, the HS4-CAG-CYP2C9 plasmid was digested with NheI/AscI site and ligated with the HS4-CAG-CYP2C19, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 plasmid. 	CYP2C9	6516	6522	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:42	Next, the HS4-CAG-CYP2C9 plasmid was digested with NheI/AscI site and ligated with the HS4-CAG-CYP2C19, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 plasmid. 	CYP2C9	6686	6692	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2C9	6938	6944	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2C9	13131	13137	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2C9	14109	14115	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2C9	18308	18314	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:50	Between the WGS and targeted genotyping data sets, there were six discordant genotypes in three genes (one in CYP2C9, one in HLA-A and four in IFNL3) limited a complete comparison of these platforms. 	CYP2C9	7946	7952	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:83	Overall, six discordant genotype calls (both false positive and false negative) were observed between WGS (Complete Genomics) and our targeted genotyping panel in three different genes (CYP2C9, HLA-A, and IFNL3), which are currently being investigated, we were able to manually inspect the ratios of reference and alternate allele reads at informative positions in the whole-genome data to deduce the duplicated allele. 	CYP2C9	14242	14248	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2C9	24870	24876	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:1	 Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product. 	CYP2C9	36	42	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:2	A commercial Rhodiola rosea (R. rosea) product has previously demonstrated CYP2C9 inhibition in humans. 	CYP2C9	167	173	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:4	Another aim was to examine the in vitro influence of ethanol on the CYP2C9 activity. 	CYP2C9	412	418	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:5	Human CYP2C9 (wild type) isolated from a baculovirusinfected cell system was incubated with 0.8 mol/L losartan for 20 min. 	CYP2C9	435	441	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:8	Formation of the CYP2C9produced losartan metabolite EXP3174 was determined by validated LCMS/MS methodology. 	CYP2C9	688	694	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:12	CYP2C9 was inhibited by Arctic Root with an IC 50 (extract concentration yielding 50% reduction in enzyme activity) of 19.2  2.7 g/mL. 	CYP2C9	1012	1018	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:16	The presence of ethanol inhibited CYP2C9 activity in a concentrationdependent manner. 	CYP2C9	1404	1410	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:17	In conclusion, the commercial R. rosea product Arctic Root demonstrated noncompetitive inhibition of CYP2C9 in vitro. 	CYP2C9	1557	1563	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:21	The commercial R. rosea industry is large, with over 46 registered international companies, giving the herb a global distribution (Galambosi ; Edwards et al.. CYP2C9 is a part of the CYP2C family of enzymes, which accounts for about 20% of all P450 enzymes in the human liver (Niwa and Yamazaki. 	CYP2C9	2228	2234	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:22	CYP2C9 metabolizes more than 20% of all therapeutic drugs, including drugs with a narrow therapeutic index, such as phenytoin and warfarin (Miners and Birkett ; Danielson ; Niwa and Yamazaki. 	CYP2C9	2365	2371	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:23	Inhibition of CYP2C9 activity has been shown clinically relevant for numerous drug inhibitors like amiodarone, trimethoprim, and sulfaphenazole (Miners and Birkett. 	CYP2C9	2571	2577	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:24	Inhibition studies by these drugs, and also by herbal supplement extracts, have shown that CYP2C9 can be subject to different types of inhibition, including competitive inhibition (St. 	CYP2C9	2813	2819	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:30	evaluated the influence of 50 mg/kg R. rosea extracts on CYP2C9 metabolism of warfarin in rats. 	CYP2C9	3923	3929	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:32	This result was opposed by Spanakis et al., who found an almost twofold increase in Area Under The Curve of the CYP2C9 substrate losartan after a 50 mg/kg concurrent administration of a commercial R. rosea extract to six rabbits in a twoway crossover study, concluding that R. rosea could be categorized as a moderate in vivo inhibitor and that a study in humans was needed. 	CYP2C9	4214	4220	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2C9	4534	4540	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:34	In this study, using a twophase, randomized crossover cocktail study in 13 males, we found a 21% reduction in the EXP3174/losartan ratio, indicating a significant inhibition of CYP2C9 enzyme activity (Thu et al.. For herbal products with identified bioactive constituents, in vitro studies are usually performed with isolated constituents only, yielding specific data, which can be extrapolated to herbal products with similar constituent concentration. 	CYP2C9	4851	4857	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:42	Given the previous studies, where Arctic Root was found to be the most potent in vitro inhibitor among a selection of commercially available R. rosea products and also was displaying CYP2C9 inhibition in humans, this study was undertaken with the aim to provide CYP2C9 in vitro inhibition data, including the classification of the type of inhibition, using this particular R. rosea product. 	CYP2C9	6801	6807	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:42	Given the previous studies, where Arctic Root was found to be the most potent in vitro inhibitor among a selection of commercially available R. rosea products and also was displaying CYP2C9 inhibition in humans, this study was undertaken with the aim to provide CYP2C9 in vitro inhibition data, including the classification of the type of inhibition, using this particular R. rosea product. 	CYP2C9	6880	6886	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:50	Baculovirus expressed human wildtype CYP2C9*1 (cat. 	CYP2C9	7324	7330	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:71	The CYP2C9*1 enzyme preparation used was a recombinant cDNAexpressed wildtype CYP2C9*1 prepared from a baculovirusinfected insect cell system. 	CYP2C9	9104	9110	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:71	The CYP2C9*1 enzyme preparation used was a recombinant cDNAexpressed wildtype CYP2C9*1 prepared from a baculovirusinfected insect cell system. 	CYP2C9	9178	9184	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:72	CYP2C9*1 content was 278 pmol/mg protein. 	CYP2C9	9243	9249	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:73	CYP2C9 (12.5 nmol/L) was incubated in conical glass tubes in a shaking water bath for 15 min at 37C in a 0.1 mmol/L potassiumphosphate buffer (pH 7.4) containing losartan (0.8 mol/L) and a NADPH regenerating system (1.25 mmol/L NADP^+, 3.3 mmol/L Glucose6phosphate, 3.3 mmol/L MgCl_2, and 0.4 U/mL glucose6phosphate dehydrogenase). 	CYP2C9	9285	9291	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:77	The formation of EXP3174 was linear from 5 to 20 min with CYP2C9 concentrations up to at least 30 nmol/L and a losartan concentration ranging from 0.05 to 40 mol/L. 	CYP2C9	10199	10205	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:79	In the timedependent assay, CYP2C9 was preincubated at 37C with R. rosea in the presence of the NADPH regenerating system, but without substrate. 	CYP2C9	10435	10441	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:82	The NADPHdependent assay was performed by preincubating CYP2C9 with R. rosea as described above, but in the presence and absence of the NADPH regenerating system for 0 and 45 min. 	CYP2C9	10881	10887	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:90	The CYP2C9 activity was determined from the formation rate of EXP3174 from losartan when based on a total CYP2C9 amount of 5 pmol in the incubation solution and an incubation time of 15 min. 	CYP2C9	11627	11633	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:90	The CYP2C9 activity was determined from the formation rate of EXP3174 from losartan when based on a total CYP2C9 amount of 5 pmol in the incubation solution and an incubation time of 15 min. 	CYP2C9	11729	11735	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:91	Enzyme activity was expressed as pmol EXP3174 formed per pmol CYP2C9 and min. 	CYP2C9	11876	11882	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:92	The IC_50 value of Arctic Root was estimated from nonlinear regression of the inhibition plot where CYP2C9 activity was plotted against increasing herbal concentrations using Sigmaplot (Sigmaplot, Ver. 	CYP2C9	11992	11998	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:95	K_m and V _max values for CYP2C9mediated metabolism of losartan were estimated by incubating CYP2C9 with increasing substrate concentrations (0.4-8.0 mol/L), K _m (app) and V _max (app) were obtained in the presence of control inhibitor and R. rosea. 	CYP2C9	12163	12169	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:95	K_m and V _max values for CYP2C9mediated metabolism of losartan were estimated by incubating CYP2C9 with increasing substrate concentrations (0.4-8.0 mol/L), K _m (app) and V _max (app) were obtained in the presence of control inhibitor and R. rosea. 	CYP2C9	12230	12236	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:99	A twosample ttest was used to evaluate the effect of the herbal preparation and inhibitor control on CYP2C9 enzyme activity and linear regression analyses were performed on standard curves and inhibition plots. 	CYP2C9	12805	12811	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:107	CYP2C9 mean enzyme reference (control) activity without inhibitor was 0.378  0.061 pmol metabolite/(pmol enzyme min). 	CYP2C9	13367	13373	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:109	Results were CYP2C9 activities of 49.5  0.0, 53.8  0.1, 54.5  0.1, and 51.2  0.1% compared to reference without inhibitor, respectively. 	CYP2C9	13632	13638	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:110	NADPH dependency was evaluated by preincubating CYP2C9 with Arctic Root extract (20 g/mL) with and without NADPH for 45 min. 	CYP2C9	13804	13810	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:111	Results were CYP2C9 activities of 51.2  0.1 and 52.2  0.2%, respectively. 	CYP2C9	13894	13900	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:114	The plot indicates that the commercial R. rosea Arctic Root is a noncompetitive inhibitor of the CYP2C9mediated metabolism of losartan. 	CYP2C9	14200	14206	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:119	In this study, the in vitro inhibitory potential and inhibition characteristics of the commercial R. rosea product Arctic Root was investigated using cDNA baculovirusexpressed human CYP2C9 Supersomes. 	CYP2C9	14870	14876	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:122	In addition, we have previously verified the product quality by quantification of the established R. rosea markers salidroside, tyrosol, rosavin, rosarin, and rosin (Thu et al.. The IC_50 value of the positive control sulfaphenazole on CYP2C9 activity was 0.25  0.1 mol/L, and falls within the range found in studies using similar methodology (Dinger et al.. The influence of ethanol at relevant methodological concentrations presented in Figure  demonstrates a strong decrease in activity with increasing ethanol concentration. 	CYP2C9	15764	15770	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:124	where only a small inhibition of 7  6% at 3% ethanol concentration was found when quantifying the CYP2C9mediated formation of 4hydroxydiclofenac from diclofenac. 	CYP2C9	16201	16207	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2C9	16302	16308	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2C9	16526	16532	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2C9	16793	16799	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2C9	16941	16947	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:127	These findings show that care must be taken when conducting experiments with CYP2C9 where ethanol is used as a solvent, to ensure an identical ethanol concentration throughout the experimental setup. 	CYP2C9	17154	17160	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:128	In this study, we found an in vitro CYP2C9 IC_50 value of 19.2  2.7 g/mL. 	CYP2C9	17313	17319	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP2C9	17605	17611	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2C9	17675	17681	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2C9	17776	17782	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2C9	17915	17921	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:136	Similar studies have also found a noncompetitive inhibition of CYP2C9 by other herbal products like Bacopa monnieri (IC_50/K _i = 36.49/12.5 g/mL) (Ramasamy et al. 	CYP2C9	19257	19263	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:155	In conclusion, this study found a noncompetitive inhibition of CYP2C9 by the commercial R. rosea product Arctic Root and adds to the increasing evidence of both in vitro and in vivo Cytochrome P450 inhibitory potential of R. rosea. 	CYP2C9	22239	22245	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2C9	16186	16192	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2C9	16325	16331	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C9	16530	16536	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2C9	18751	18757	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2C9	8814	8820	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:83	The CYP2C9 enzyme metabolizes medications across many therapeutic classes including nonsteroidal anti-inflammatories (eg, naproxen), angiotensin II blockers (eg, losartan), as well as narrow therapeutic index drugs such as (S)-warfarin, tolbutamide and phenytoin. 	CYP2C9	14923	14929	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:86	This observed difference in warfarin dosing is clinically meaningful and thought to be due, in part, to genetic polymorphisms in the CYP2C9, VKORC1 and CYP4F2 genes. 	CYP2C9	15731	15737	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:87	For example, individuals with CYP2C9*2 or CYP2C9*3 variant alleles require a lower warfarin dose to achieve therapeutic anticoagulation. 	CYP2C9	15794	15800	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:87	For example, individuals with CYP2C9*2 or CYP2C9*3 variant alleles require a lower warfarin dose to achieve therapeutic anticoagulation. 	CYP2C9	15806	15812	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:88	In the Indigenous population of Canada, the previously studied CYP2C9 variant allele frequencies were found to be distinct from the European and Asian reference groups, particularly for the Inuit population, where CYP2C9*2, *3 and *4 were absent. 	CYP2C9	15964	15970	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:88	In the Indigenous population of Canada, the previously studied CYP2C9 variant allele frequencies were found to be distinct from the European and Asian reference groups, particularly for the Inuit population, where CYP2C9*2, *3 and *4 were absent. 	CYP2C9	16115	16121	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:89	The MAF of CYP2C9*2, *3 and *4 were 3.0%, 6.0% and 0.0%, respectively in the FN population. 	CYP2C9	16159	16165	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:90	Through deep resequencing to identify novel variants and subsequent genotyping to establish population frequencies, the prevalence of novel and previously known CYP2C9 variants was determined in the Yupik AN, AIAN at Southcentral Foundation (SCF) (with multiple AN sub-cultures and an aggregate of AI tribes) and the Confederated Salish and Kootenai Tribes (CSKT) AI populations. 	CYP2C9	16401	16407	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:91	The MAFs of CYP2C9*2 and *3 were lower in AIAN populations with CYP2C9*2 at 0.3%, 5.2% and 5.2% in the Yupik, SCF and CSKT populations, respectively, compared to European populations at 15.2%. 	CYP2C9	16632	16638	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:91	The MAFs of CYP2C9*2 and *3 were lower in AIAN populations with CYP2C9*2 at 0.3%, 5.2% and 5.2% in the Yupik, SCF and CSKT populations, respectively, compared to European populations at 15.2%. 	CYP2C9	16684	16690	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:92	The prevalence of CYP2C9*3 was found to be 2.1%, 3.4% and 2.7% in the Yupik, SCF and CSKT populations, respectively, compared to European populations at 6.6%. 	CYP2C9	16831	16837	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:93	CYP2C9*29, a rare coding-region variant, was found at 2.1% in the Yupik population. 	CYP2C9	16972	16978	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:94	In another study of AI youth in the Northwestern United States, the MAFs of CYP2C9*2, *3 and *5 were 5.8%, 2.7% and 0.4%, respectively. 	CYP2C9	17132	17138	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:95	With respect to novel variation, one new novel coding variant, CYP2C9 K119T, was identified in the CSKT population at a frequency of 0.57%. 	CYP2C9	17255	17261	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:96	In addition, two novel coding-region CYP2C9 were identified in the Yupik and SCF populations: CYP2C9 M1L (M1L) and CYP2C9 N218I (N218I). 	CYP2C9	17369	17375	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:96	In addition, two novel coding-region CYP2C9 were identified in the Yupik and SCF populations: CYP2C9 M1L (M1L) and CYP2C9 N218I (N218I). 	CYP2C9	17426	17432	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:96	In addition, two novel coding-region CYP2C9 were identified in the Yupik and SCF populations: CYP2C9 M1L (M1L) and CYP2C9 N218I (N218I). 	CYP2C9	17447	17453	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:101	However, there is increased confidence that individuals who are heterozygous or homozygous for the M1L variant would have a lower warfarin dose requirement, among phenotypic changes for other CYP2C9 substrates. 	CYP2C9	18462	18468	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:103	determined the CYP2C9*2, *3 and *6 allele frequencies in eight Amerindian populations from Northwest Mexico: Tepehuano, Mexicanera and Huichol from Durango, Cora from Nayarit, Seri, Guarijo and Mayo from Sonora and Tarahumara from Chihuahua. 	CYP2C9	18514	18520	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:104	The MAF of CYP2C9*2 in Seris and Mayos was 2.6% and 5.7%, respectively; this variant was not found in the other six Amerindian populations. 	CYP2C9	18752	18758	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:105	With regard to CYP2C9*3, the MAF was 10.4%, 9.1%, 7.5%, 6.7%, 3.7% and 3.3% in Tarahumaras, Mayos, Tepehuanos, Guarijos, Coras and Huicholes, respectively, while it was not detected in Mexicanera or Seri Amerindians. 	CYP2C9	18896	18902	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:106	CYP2C9*6 was not detected in any of the eight Amerindian groups studied. 	CYP2C9	19098	19104	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:108	found that the MAF of CYP2C9*2 and *3 in the Tepehuano population was 1.0% and 1.5%, respectively, while CYP2C9*4, *5 and *6 were not detected. 	CYP2C9	19207	19213	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:108	found that the MAF of CYP2C9*2 and *3 in the Tepehuano population was 1.0% and 1.5%, respectively, while CYP2C9*4, *5 and *6 were not detected. 	CYP2C9	19290	19296	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:110	tested for CYP2C9*2 and CYP2C9*3 in five Amerindian groups: Nahua from Central Mexico, Teenek from the Huasteca Potosina region, Tarahumara from Chihuahua, Purepecha from Michoacan and Huichol from Nayarit. 	CYP2C9	19363	19369	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:110	tested for CYP2C9*2 and CYP2C9*3 in five Amerindian groups: Nahua from Central Mexico, Teenek from the Huasteca Potosina region, Tarahumara from Chihuahua, Purepecha from Michoacan and Huichol from Nayarit. 	CYP2C9	19376	19382	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:111	In the Nahua and Teenek groups, the CYP2C9*2 MAF was 0.7% and 0.5%, respectively and the CYP2C9*3 MAF was 0.4% and 0.5%, respectively. 	CYP2C9	19595	19601	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:111	In the Nahua and Teenek groups, the CYP2C9*2 MAF was 0.7% and 0.5%, respectively and the CYP2C9*3 MAF was 0.4% and 0.5%, respectively. 	CYP2C9	19648	19654	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:112	The CYP2C9*2 and *3 alleles were absent from the Tarahumara, Purepecha and Huichol Amerindian groups. 	CYP2C9	19698	19704	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:113	With regard to CYP2C9*2 in the Tepehuano and Tarahumara populations, the results reported by Dorado et al. 	CYP2C9	19811	19817	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:117	However, there is a notable difference in CYP2C9*3 allele frequencies reported by these authors for the Tepehuano and Tarahumara populations. 	CYP2C9	20101	20107	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:125	The ratio of losartan to losartan carboxylic acid was significantly greater in CYP2C9*2 or *3 homozygotes or carriers, compared to those with the reference genotype. 	CYP2C9	20751	20757	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:233	CYP4F2 enzyme catabolizes vitamin K and, along with CYP2C9 and vitamin K oxidoreductase (VKOR), can affect the pharmacological response of warfarin, a VKOR antagonist. 	CYP2C9	35516	35522	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:248	With regards to CYP2C9, there was a lack of CYP2C9*2 in the Canadian Inuit population as well as many Amerindian groups including the Mexicanera, Huichol, Guarijo, Cora, Tarahumara and Purepecha. 	CYP2C9	38031	38037	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:248	With regards to CYP2C9, there was a lack of CYP2C9*2 in the Canadian Inuit population as well as many Amerindian groups including the Mexicanera, Huichol, Guarijo, Cora, Tarahumara and Purepecha. 	CYP2C9	38059	38065	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:249	CYP2C9*3 was also absent from the Canadian Inuit, Mexicanera, Seri, Purepecha and Huichol populations. 	CYP2C9	38211	38217	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:256	The allele frequencies of known and recently reported CYP2C9 variants in the AN Yupik population illustrate this scenario. 	CYP2C9	39293	39299	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:257	The CYP2C9*2 and *3 alleles that define the CYP2C9 PM phenotype in the European population are found at very low frequencies in the Yupik population. 	CYP2C9	39366	39372	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:257	The CYP2C9*2 and *3 alleles that define the CYP2C9 PM phenotype in the European population are found at very low frequencies in the Yupik population. 	CYP2C9	39406	39412	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:258	The novel and relatively common M1L and N218I variants found in the Yupik population, in addition to CYP2C9*2 and *3 alleles, that are predicted to confer a CYP2C9 PM phenotype. 	CYP2C9	39613	39619	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:258	The novel and relatively common M1L and N218I variants found in the Yupik population, in addition to CYP2C9*2 and *3 alleles, that are predicted to confer a CYP2C9 PM phenotype. 	CYP2C9	39669	39675	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:259	Importantly, if only the allele frequencies known to be clinically relevant in the European population are applied to the Yupik population, an individual homozygous or heterozygous for the M1L or N218I variants would be classified as a CYP2C9 EM and improper warfarin dosing could result in adverse events for these individuals. 	CYP2C9	39926	39932	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:260	This potential for misclassification and inappropriate drug dosing has also been described of African populations, where the CYP2C9*8 allele contributes to the PM phenotype. 	CYP2C9	40144	40150	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2C9	40258	40264	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:127	CYP1A1, 1A2 and CYP2C9 are not expressed in human kidney, whereas the CYP3A4 expression in kidney is highly variable and remains to be elucidated^. 	CYP2C9	22069	22075	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:150	Moreover, the shift of the F-helix and of the F/F loop in CYP2C9 in high-temperature molecular dynamics simulations are shown to close the solvent channel and to open the channel 2b.. A large conformational shift of the F/F loop is also seen in CYP3A4 crystal structures complexed with ketoconazole (a P450 inhibitor) or erythromycin (a CYP3A4 substrate). 	CYP2C9	25837	25843	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:201	The structure of human CYP2C9 is known from X-ray experiments, but its mode of insertion into the membrane remains unsolved. 	CYP2C9	36586	36592	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:202	Atomistic models of complete CYP2C9 embedded in a bilayer membrane were constructed and evolved by molecular dynamics simulations. 	CYP2C9	36717	36723	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:203	The entry of the substrate access channel was found to be facing the membrane interior, while the exit of the product egress channel is found to be located above the interface between phospholipid heads and the water solvent.Moreover, the positions of the mouths of the substrate access and the product egress channels roughly correspond to the positions of energy minima for the location of CYP2C9 substrate and its metabolite in the membrane. 	CYP2C9	37211	37217	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2C9	12082	12088	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP2C9	33535	33541	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2C9	58808	58814	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:394	observed in total human skin, in human epidermis, in EpiSkin^ and in EpiskinTMF^ mRNAs for the following CYPs: Low levels (below 200,000 copies/g total RNA): CYP2B6, 2D6, 2E1, 1A1, 1B1, 2C8, 2C18, 2F1 and 3A5; very low levels (below 10,000 copies/g total RNA): CYP2C9, 1A2 and 3A7. 	CYP2C9	63088	63094	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP2C9	64181	64187	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP2C9	70197	70203	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:518	; Oesch and Arand ] and in part by CYP2C9, and CYP3A48; (Gautier et al. 	CYP2C9	80093	80099	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:617	CYP2C subfamily In contrast to other CYPs, as pointed out above, the mRNAs coding for the major human CYP2C proteins, CYP2C9, CYP2C18 and CYP2C19 were found in the skin of all individuals investigated by Yengi et al.. On the other hand, in proliferating human keratinocytes in culture CYP2C19 mRNA was found only after induction by clofibrate Gonzalez et al.. In line with the failure of finding constitutive expression in proliferating keratinocytes, the localization of CYP2C mRNAs as well as CYP2C proteins is in most cases in the outer suprabasal cell layers of the epidermis, where differentiated keratinocytes are located (Du et al.. As found in skin or other systems CYP2Cs metabolize: many physiological compounds (CYP2C9: retinoic, arachidonic and linoleic acids, 5-alpha-androstane-3-alpha,17-beta-diol; 2C18: retinoic acid, progesterone; 2C19: progesterone, testosterone, retinal, arachidonic and linoleic acids);natural compounds (2C9: limonene, capsaicin, nicotine, galangin, genistein 4-methyl ether, ochrotoxine A; 2C18: limonene; 2C19: limonene, capsaicin, nicotine, genistein 4-methyl ether, ochratoxin A, tetrahydrocannabinol);pharmaceutical drugs [2C9: (S)-warfarin, tolbutamide, diclofenac, ibuprofen, indomethacin, phenytoin; 2C19: (R)-warfarin, omeprazole, pantoprazole, lansoprazole, (S)-mephenytoin, diazepam, amitryptiline] (Du et al. 	CYP2C9	94444	94450	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:617	CYP2C subfamily In contrast to other CYPs, as pointed out above, the mRNAs coding for the major human CYP2C proteins, CYP2C9, CYP2C18 and CYP2C19 were found in the skin of all individuals investigated by Yengi et al.. On the other hand, in proliferating human keratinocytes in culture CYP2C19 mRNA was found only after induction by clofibrate Gonzalez et al.. In line with the failure of finding constitutive expression in proliferating keratinocytes, the localization of CYP2C mRNAs as well as CYP2C proteins is in most cases in the outer suprabasal cell layers of the epidermis, where differentiated keratinocytes are located (Du et al.. As found in skin or other systems CYP2Cs metabolize: many physiological compounds (CYP2C9: retinoic, arachidonic and linoleic acids, 5-alpha-androstane-3-alpha,17-beta-diol; 2C18: retinoic acid, progesterone; 2C19: progesterone, testosterone, retinal, arachidonic and linoleic acids);natural compounds (2C9: limonene, capsaicin, nicotine, galangin, genistein 4-methyl ether, ochrotoxine A; 2C18: limonene; 2C19: limonene, capsaicin, nicotine, genistein 4-methyl ether, ochratoxin A, tetrahydrocannabinol);pharmaceutical drugs [2C9: (S)-warfarin, tolbutamide, diclofenac, ibuprofen, indomethacin, phenytoin; 2C19: (R)-warfarin, omeprazole, pantoprazole, lansoprazole, (S)-mephenytoin, diazepam, amitryptiline] (Du et al. 	CYP2C9	95049	95055	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:1	 Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. 	CYP2C9	99	105	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:4	Here we have determined the effect of eight CYP3A4 and seven CYP2C9 Single Nucleotide Polymorphisms on the thermostability of proteins in solution to test these predictions. 	CYP2C9	659	665	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:5	Thermostability assays revealed distinct Cytochrome P450 sub-populations with only 65-70% of wild-type CYP3A4 and CYP2C9 susceptible to rapid heat-induced P450 to P420 conversion. 	CYP2C9	886	892	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:6	CYP3A4 mutations G56D, P218R, S222P, I223R, L373F and M445T and CYP2C9 mutations V76M, I359L and I359T were destabilising, increasing the proportion of protein sensitive to the rapid heat-induced P450 to P420 conversion and/or reducing the half-life of this conversion. 	CYP2C9	1016	1022	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:7	CYP2C9 Q214L was the only stabilising mutation. 	CYP2C9	1222	1228	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:14	Over 100 non-synonymous single amino acid substitutions have been reported for isoforms CYP3A4 and CYP2C9 alone^,; these two isoforms are jointly responsible for nearly half of Cytochrome P450 mediated drug metabolism^. 	CYP2C9	2517	2523	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:38	The aim of this study was to test our previous in silico stability prediction in vitro, using a selection of recombinantly expressed CYP3A4 and CYP2C9 mutants. 	CYP2C9	8291	8297	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:39	The 8 CYP3A4 and 7 CYP2C9 variants tested included mutations previously predicted to be neutral, stabilising and destabilising, falling within both functional and undefined regions of the protein structure^. 	CYP2C9	8326	8332	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:40	The positions of the CYP3A4 and CYP2C9 variants selected for in vitro testing are shown in Fig. 	CYP2C9	8547	8553	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:41	Recombinant wild-type and variant His-tagged CYP3A4 and CYP2C9 proteins were expressed in E. coli and purified using immobilized metal affinity chromatography. 	CYP2C9	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:42	The specific holoprotein content of each CYP3A4 and CYP2C9 variant protein sample was determined using carbon monoxide P450 spectral assays^,. 	CYP2C9	8823	8829	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:45	To test the thermostability of the CYP3A4 and CYP2C9, Wild-Type and variant proteins, Carbon Monoxide P450 difference spectra were used to measure the decrease in P450 content at an elevated temperature as a function of time. 	CYP2C9	9369	9375	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:47	Different temperatures were tested to ensure the decrease in P450 could be monitored at a constant temperature over a 30-minute period: 34 C was chosen for CYP3A4 proteins and 48 C for the more stable CYP2C9 proteins. 	CYP2C9	9945	9951	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:48	CYP3A4 and CYP2C9 Wild-Type protein samples both showed an exponential decrease in P450 content, although the graphs did not tend to zero, suggesting either the presence of a stable P450 sub-population or background signal. 	CYP2C9	9973	9979	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:60	Figure  shows the thermostability results for the CYP2C9 Wild-Type and variant proteins. 	CYP2C9	12114	12120	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:61	The one phase exponential decay model was the preferred model for all the CYP2C9 proteins. 	CYP2C9	12227	12233	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:63	P279T had a half-life of 15.3 minutes (33% higher than WT) and I359L had a half-life of 7.5 minutes (35% lower than WT); however, differences in the half-lives were not significantly different for any of the CYP2C9 variants compared to Wild-Type. 	CYP2C9	12571	12577	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:67	Size exclusion chromatography was carried out on CYP3A4 and CYP2C9 Wild-Type protein samples to determine whether protein oligomerisation could provide an explanation for the presence of P450 sub-populations with different stabilities in solution. 	CYP2C9	13047	13053	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:69	Figure  shows the elution profiles for CYP3A4 and CYP2C9 Wild-Type proteins monitored at 410 nm, the maximum absorbance wavelength of the haem-bound protein. 	CYP2C9	13385	13391	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:71	The data provides evidence that both isoforms do indeed oligomerise in solution; the major peak for both CYP3A4 (66 kDa in monomeric form) and CYP2C9 (63 kDa in monomeric form) correspond roughly to oligomeric structures made up of 9 and 8 subunits respectively. 	CYP2C9	13754	13760	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:73	CYP2C9 shows two secondary peaks (~ 83 and 32 kDa), which do not correspond well to the expected size of a CYP2C9 dimer and monomer, however the columns capability of accurately predicting protein sizes in the lower molecular weight range may be limiting. 	CYP2C9	13970	13976	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:73	CYP2C9 shows two secondary peaks (~ 83 and 32 kDa), which do not correspond well to the expected size of a CYP2C9 dimer and monomer, however the columns capability of accurately predicting protein sizes in the lower molecular weight range may be limiting. 	CYP2C9	14077	14083	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:74	In order to test previous in silico predictions on the effects of Single Nucleotide Polymorphisms on Cytochrome P450 stability, recombinant soluble CYP2C9 and CYP3A4 Wild-Type and variant proteins, lacking their N-terminal membrane binding region, were expressed in E. coli and purified from the cell lysate. 	CYP2C9	14374	14380	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP2C9	14602	14608	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP2C9	14706	14712	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:77	Notably, the P420 form of the protein was not detected in any of the CYP2C9 samples, while the P420 form was present in all CYP3A4 samples. 	CYP2C9	14913	14919	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:78	Exponential decay curves for both CYP3A4 and CYP2C9 indicated energetically distinct P450 sub-populations that did not interconvert between each other during the course of the assay. 	CYP2C9	15029	15035	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:98	In this study we observed similar conformational heterogeneity for both CYP3A4 and CYP2C9 in solution; only 65-70% of the P450 was susceptible to rapid heat-induced P450 to P420 conversion at a constant elevated temperature while the remaining fraction was much more stable, consistent with the literature. 	CYP2C9	18462	18468	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:99	Size exclusion chromatography experiments confirmed that both CYP3A4 and CYP2C9 were predominantly in the oligomeric form in solution. 	CYP2C9	18759	18765	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:104	Our Size Exclusion Chromatography results suggest that CYP2C9 is predominantly in the octomeric form; this does not readily explain the 1:2 conformer distribution observed here. 	CYP2C9	19519	19525	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:105	Little is known about the quaternary structure of CYP2C9 in solution or in the membrane. 	CYP2C9	19692	19698	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:123	In some Cytochrome P450 structures this region is comprised of two short F and G helixes (eg CYP2C9 PDB 1OG2^) while in other structures it is a disordered loop region (eg CYP2C9 PDB 1R9O^). 	CYP2C9	23739	23745	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:123	In some Cytochrome P450 structures this region is comprised of two short F and G helixes (eg CYP2C9 PDB 1OG2^) while in other structures it is a disordered loop region (eg CYP2C9 PDB 1R9O^). 	CYP2C9	23818	23824	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:137	CYP2C9 variant Q214L, another mutation to a buried residue within the F-G loop and substrate recognition site (2,3), was the only variant predicted to be stabilising by Site Directed Mutator and the only variant that showed a significant increase in thermostability, showing a significant increase in the proportion of stable conformer in solution, but no significant difference in the half-life of the fast phase. 	CYP2C9	26439	26445	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:140	I359L and I359T mutations in CYP2C9 decrease the proportion of protein making up the stable P450 sub-population. 	CYP2C9	27391	27397	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:142	Site Directed Mutator correctly predicts that a mutation to threonine at this position will destabilise the protein fold but incorrectly predicts the effect of the conserved mutation to leucine; while isoleucine and leucine are both hydrophobic residues with the same volume and similar properties, the subtle difference between these residues at this position significantly affects the conformation of the CYP2C9 fold. 	CYP2C9	28027	28033	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:144	I359L and I359T are the non-synonymous amino acid substitutions associated with CYP2C9*3 and CYP2C9*4 alleles, respectively. 	CYP2C9	28413	28419	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:144	I359L and I359T are the non-synonymous amino acid substitutions associated with CYP2C9*3 and CYP2C9*4 alleles, respectively. 	CYP2C9	28426	28432	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:147	CYP2C9 variant V76M also showed significantly less P450 in the stable sub-population than observed for the Wild-Type protein but was not predicted to be a destabilising mutation by Site Directed Mutator. 	CYP2C9	28880	28886	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:149	While Val 76 is position roughly 13  from the bound haem, the model of the CYP2C9 V76M variant used to generate the Site Directed Mutator data suggests that the substitution of valine for the bulkier methionine residue at this position has a subtle long-range effect on the side chain position of His 368, which interacts with the haem propionate via a salt bridge. 	CYP2C9	29283	29289	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:151	While CYP2C9 R132Q and R150H showed no significant effect on the Cytochrome P450 stability in agreement with the in silico predictions, these Single Nucleotide Polymorphisms have both been reported to affect catalytic activity. 	CYP2C9	29868	29874	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:152	CYP2C9 R132Q, despite showing similar holo P450 levels in a baculovirus-insect cell system, showed ~90% reduction in catalytic activity towards diclofenac, losartan and glimepiride^,. 	CYP2C9	30090	30096	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:155	CYP2C9 R150H does not fall within any of the known functional regions. 	CYP2C9	30616	30622	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:156	Despite this, it has been reported to affect CYP2C9 function in vivo and in vitro. 	CYP2C9	30732	30738	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:157	The CYP2C9*8 R150H allele commonly occurs in African Americans and has been associated with decreased warfarin and phenytoin metabolism^,. 	CYP2C9	30774	30780	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	CYP2C9	32870	32876	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:168	pBJW102.2 vectors containing the N-terminal truncated CYP3A4 and CYP2C9 cDNA sequences were a gift from Procognia Ltd, Maidenhead, UK. 	CYP2C9	33549	33555	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:170	The translated CYP3A4 and CYP2C9 proteins had a 24 amino acid and 28 amino acid deletion at the N-terminus respectively. 	CYP2C9	33914	33920	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP2C9	34048	34054	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP2C9	34139	34145	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:185	CYP3A4 and CYP2C9 holo P450 protein content in the enriched protein samples was determined using carbon monoxide spectral assays^. 	CYP2C9	36562	36568	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:195	The cuvettes were then placed back into the spectrophotometer maintained at a constant temperature of 34 C (for CYP3A4 samples) or 48 C (for CYP2C9 samples) by circulating water from a heated water bath through the cell holder. 	CYP2C9	38178	38184	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:206	CYP3A4 and CYP2C9 Wild-Type protein samples were separated using the BioSep-SEC-S3000 column with exclusion range of 5 kDa to 700 kDa. 	CYP2C9	39633	39639	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:10	Selaginellin and selaginellin M also showed medium inhibitory potential against CYP2C9, CYP2J2, UGT1A1, and UGT1A3 (1 M < IC50 < 5 M). 	CYP2C9	1436	1442	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:37	Two selaginellins also showed medium inhibitory potential on CYP2C9-catalyzed tolbutamide hydroxylation, CYP2J2-catalyzed astemizole O-demethylation, UGT1A1-catalyzed SN-38 glucuronidation, and UGT1A3-catalyzed chenodeoxycholic acid glucuronidation activities (IC_50 < 5 M). 	CYP2C9	5795	5801	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:38	CYP2C8, CYP2C9, and CYP2J2 metabolize approximately 4.7, 12.8, and 3% of clinically used drugs (n = 248), respectively. 	CYP2C9	6017	6023	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:40	Therefore, the inhibitory effect of selaginellins might be important for producing potential herb-drug interaction with drugs which undergo CPY2C8, CYP2C9, CYP2J2, and UGT1A1-mediated biotransformation; such drugs include glipizide, irinotecan, losartan, paclitaxel, tolbutamide, and warfarin. 	CYP2C9	6393	6399	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:45	Therefore, it might be used with anticancer or antidiabetic drugs which are metabolized by CYP2C8 (paclitaxel), CYP2C9 (tolbutamide), or UGT1A1 (irinotecan). 	CYP2C9	7081	7087	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2C9	9349	9355	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:182	The obtained results for these cytochromes can be explained by considering the usual structure of their substrates; CYP2C9 substrates possess weakly acidic properties and multiple aromatic rings. 	CYP2C9	30680	30686	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:190	Another Cytochrome P450 isoform inhibited by the studied molecules is the -CYP2C9, in agreement with result obtained in the substrate behavior studies. 	CYP2C9	32322	32328	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP2C9	20402	20408	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:135	The presence in the patients genome of the alleles R144C (CYP2C9*2) and I359L (CYP2C9*3) leads to a steady decrease in cytochrome activity (up to 90% for homozygous variants) and alters the drugs half-life. 	CYP2C9	20535	20541	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:135	The presence in the patients genome of the alleles R144C (CYP2C9*2) and I359L (CYP2C9*3) leads to a steady decrease in cytochrome activity (up to 90% for homozygous variants) and alters the drugs half-life. 	CYP2C9	20556	20562	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP2C9	3412	3418	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP2C9	493	499	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:7	Both extracts dose- and time-dependently inhibited CYP2C8 activity, but only time-dependently inhibited CYP2C9. 	CYP2C9	1312	1318	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2C9	4608	4614	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP2C9	4879	4885	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP2C9	5789	5795	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP2C9	6307	6313	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP2C9	7224	7230	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP2C9	7454	7460	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP2C9	7539	7545	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:54	ASP showed 24% inhibition of CYP2C9 at 100 g/mL and 23% inhibition of CYP3A4 at 200 g/mL activity, while PPAG had no effect on any of these enzymes. 	CYP2C9	7618	7624	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:59	PPAG, ASP, GRT, and FRE did not significantly affect CYP2C9 enzyme activity (b). 	CYP2C9	8520	8526	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:63	GRT showed a slight increase (p < 0.01) in inhibition of CYP2C9 activity after approximately 15 min, however, this inhibitory effect was more noticeable than for the positive inhibitor, sulfaphenazole (b). 	CYP2C9	9036	9042	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP2C9	10828	10834	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2C9	11159	11165	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:87	CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%-20% of drugs undergoing phase I metabolism. 	CYP2C9	12732	12738	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:88	CYP2C9 is also involved in the metabolic clearance of therapeutic drugs such as oral hypoglycemics (pioglitazone, glyburide, and tolbutamide), cyclooxygenase-2 anti-inflammatories (celecoxib, ibuprofen, and naproxen), and oral anti-coagulants (warfarin). 	CYP2C9	12897	12903	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:89	Changes in metabolic activity caused by genetic variants in CYP2C9 play a major role in the pathogenesis caused by adverse drug reactions. 	CYP2C9	13212	13218	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:90	Patients with low enzyme activity are at risk of adverse drug reactions from these CYP2C9 substrates. 	CYP2C9	13374	13380	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:92	However, a partial time-dependent decrease in CYP2C9 activity was shown for GRT and FRE with GRT demonstrating stronger inhibitory potential than the competitive CYP2C9 inhibitor, sulfaphenazole. 	CYP2C9	13539	13545	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:92	However, a partial time-dependent decrease in CYP2C9 activity was shown for GRT and FRE with GRT demonstrating stronger inhibitory potential than the competitive CYP2C9 inhibitor, sulfaphenazole. 	CYP2C9	13655	13661	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP2C9	15372	15378	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP2C9	17192	17198	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP2C9	17545	17551	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP2C9	17937	17943	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP2C9	18706	18712	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP2C9	18947	18953	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP2C9	19239	19245	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP2C9	19449	19455	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP2C9	19884	19890	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP2C9	19998	20004	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C9	20148	20154	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C9	20485	20491	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP2C9	20848	20854	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP2C9	20975	20981	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C9	21587	21593	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C9	22105	22111	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6316878_OgerInput.txtOger_out.csv:265	Queried databases included, eg, PharmGKB, PharmVar (available only for CYP2C9, 2C19, 2D6 genes), ADReCS-Target an Adverse Drug Reaction Classification System-Target Profile (http://bioinf.xmu.edu.cn/ADReCS-Target), which provides comprehensive information about ADRs caused by drug interaction with protein, gene and genetic variation, PheWas Resources (phenome-wide association studies with antineoplastic drugs), Clinvar and dbSNP. 	CYP2C9	41810	41816	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP2C9	738	744	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP2C9	872	878	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP2C9	1131	1137	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP2C9	2173	2179	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP2C9	2283	2289	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP2C9	2452	2458	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:46	456252), CYP2C9*1(Arg144) (Lot No. 	CYP2C9	8333	8339	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP2C9	12242	12248	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	12898	12904	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	12925	12931	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	13088	13094	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP2C9	13558	13564	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C9	14183	14189	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP2C9	19689	19695	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C9	19929	19935	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP2C9	20018	20024	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP2C9	20468	20474	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP2C9	21097	21103	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP2C9	21287	21293	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:129	However, fluvoxamine, the other CYP2C9 inhibitor used, did not show significant inhibition of 5HMFLX formation. 	CYP2C9	21337	21343	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:138	At both concentrations of flucloxacillin, the highest correlation coefficients were found with CYP2C9catalysed diclofenac 4hydroxylation, with Pearson correlation coefficients of 0.78 and 0.58, respectively, and CYP3Acatalysed 6BETAhydroxylation, with correlation coefficients of 0.69 and 0.58 respectively. 	CYP2C9	22900	22906	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP1A1	902	908	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP1A1	902	908	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:26	In addition, studies have showed association between rs2606345 in CYP1A1 gene and North Indian women with epilepsy, and between rs762551 in CYP1A2 and CBZ pharmacokinetics in children diagnosed with partial or generalized tonic-clonic seizures. 	CYP1A1	4315	4321	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:26	In addition, studies have showed association between rs2606345 in CYP1A1 gene and North Indian women with epilepsy, and between rs762551 in CYP1A2 and CBZ pharmacokinetics in children diagnosed with partial or generalized tonic-clonic seizures. 	CYP1A1	4315	4321	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP1A1	4739	4745	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP1A1	4739	4745	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:143	In contrast to this finding, we have previously reported that acute DOX-induced cardiotoxicity caused significant induction of CYP1A1 in the hearts of male Sprague Dawley rats. 	CYP1A1	26012	26018	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:143	In contrast to this finding, we have previously reported that acute DOX-induced cardiotoxicity caused significant induction of CYP1A1 in the hearts of male Sprague Dawley rats. 	CYP1A1	26012	26018	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	CYP1A1	23860	23866	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	CYP1A1	23860	23866	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:161	^, The dose-response and different time course induction of CYP1A1 is well characterized in the liver of female Sprague-Dawley rats following exposure to TCDD and the tertiary mixture^,,, CYP1A1 induction occurs in virtually every tissue of the body following exposure to either TCDD or the tertiary mixture. 	CYP1A1	28687	28693	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:161	^, The dose-response and different time course induction of CYP1A1 is well characterized in the liver of female Sprague-Dawley rats following exposure to TCDD and the tertiary mixture^,,, CYP1A1 induction occurs in virtually every tissue of the body following exposure to either TCDD or the tertiary mixture. 	CYP1A1	28687	28693	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:161	^, The dose-response and different time course induction of CYP1A1 is well characterized in the liver of female Sprague-Dawley rats following exposure to TCDD and the tertiary mixture^,,, CYP1A1 induction occurs in virtually every tissue of the body following exposure to either TCDD or the tertiary mixture. 	CYP1A1	28815	28821	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:161	^, The dose-response and different time course induction of CYP1A1 is well characterized in the liver of female Sprague-Dawley rats following exposure to TCDD and the tertiary mixture^,,, CYP1A1 induction occurs in virtually every tissue of the body following exposure to either TCDD or the tertiary mixture. 	CYP1A1	28815	28821	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:162	^, By using the continuous nonlinear Hill model, the induction of hepatic CYP1A1 was compared in female rats following exposure to TCDD, PCB 126, and PeCDF alone or their tertiary mixture with doses or TEQ doses ranging from 0-100 ng/kg/day for 14, 31, or 53 weeks. 	CYP1A1	29010	29016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:162	^, By using the continuous nonlinear Hill model, the induction of hepatic CYP1A1 was compared in female rats following exposure to TCDD, PCB 126, and PeCDF alone or their tertiary mixture with doses or TEQ doses ranging from 0-100 ng/kg/day for 14, 31, or 53 weeks. 	CYP1A1	29010	29016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:169	^ In summary, although the importance of CYP1A1 in the induction of oxidative DNA damage was implied previously, the complicated association between DNA oxidation damage and induction of CYP1A1 by DLCs or their mixtures cannot be completely described in our study and still requires further detailed exploration. 	CYP1A1	29969	29975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:169	^ In summary, although the importance of CYP1A1 in the induction of oxidative DNA damage was implied previously, the complicated association between DNA oxidation damage and induction of CYP1A1 by DLCs or their mixtures cannot be completely described in our study and still requires further detailed exploration. 	CYP1A1	29969	29975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:169	^ In summary, although the importance of CYP1A1 in the induction of oxidative DNA damage was implied previously, the complicated association between DNA oxidation damage and induction of CYP1A1 by DLCs or their mixtures cannot be completely described in our study and still requires further detailed exploration. 	CYP1A1	30115	30121	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:169	^ In summary, although the importance of CYP1A1 in the induction of oxidative DNA damage was implied previously, the complicated association between DNA oxidation damage and induction of CYP1A1 by DLCs or their mixtures cannot be completely described in our study and still requires further detailed exploration. 	CYP1A1	30115	30121	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:170	DNA oxidation products, oxidative stress biomarkers, CYP1A1 induction, and genomic studies consistently suggest that the simple TEF methodology cannot be applied to evaluate the diverse patterns of toxic effects induced by DLCs. 	CYP1A1	30294	30300	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:170	DNA oxidation products, oxidative stress biomarkers, CYP1A1 induction, and genomic studies consistently suggest that the simple TEF methodology cannot be applied to evaluate the diverse patterns of toxic effects induced by DLCs. 	CYP1A1	30294	30300	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:191	Dose- and time-dependent induction of CYP1A1 and CYP1A2 was detected in the livers of female rats exposed to TCDD or the tertiary mixture, which is also in accordance with our results of DNA oxidation products. 	CYP1A1	34050	34056	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:191	Dose- and time-dependent induction of CYP1A1 and CYP1A2 was detected in the livers of female rats exposed to TCDD or the tertiary mixture, which is also in accordance with our results of DNA oxidation products. 	CYP1A1	34050	34056	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:197	Although the 2-year tumor incidence data support the application of the TEF approach in the risk assessment of DLCs based on the generation of similar dose-response curves in response to TCDD and the tertiary mixture exposed female rats,^ the TEF approach cannot be applied to evaluate the DNA oxidation products in this study, CYP1A1 or CYP1A2 induction, or oxidative biomarkers. 	CYP1A1	35386	35392	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:197	Although the 2-year tumor incidence data support the application of the TEF approach in the risk assessment of DLCs based on the generation of similar dose-response curves in response to TCDD and the tertiary mixture exposed female rats,^ the TEF approach cannot be applied to evaluate the DNA oxidation products in this study, CYP1A1 or CYP1A2 induction, or oxidative biomarkers. 	CYP1A1	35386	35392	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5620569_OgerInput.txtOger_out.csv:96	These data suggest the potential involvement of CYP1A1/2 in the ribosylation of theophylline, since theonosine production appears to be greater in microsomal tissue from smokers. 	CYP1A1	14771	14777	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5620569_OgerInput.txtOger_out.csv:96	These data suggest the potential involvement of CYP1A1/2 in the ribosylation of theophylline, since theonosine production appears to be greater in microsomal tissue from smokers. 	CYP1A1	14771	14777	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	CYP1A1	6033	6039	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	CYP1A1	6033	6039	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:33	This NADH-dependent system can, therefore, function as a sole electron donor for both reduction steps in the reaction cycles of CYP1A1 and CYP3A4 [,. 	CYP1A1	6212	6218	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:33	This NADH-dependent system can, therefore, function as a sole electron donor for both reduction steps in the reaction cycles of CYP1A1 and CYP3A4 [,. 	CYP1A1	6212	6218	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	CYP1A1	9896	9902	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	CYP1A1	9896	9902	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	CYP1A1	14797	14803	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	CYP1A1	14797	14803	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP1A1	17040	17046	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP1A1	17040	17046	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:163	Various studies highlighted the interactions between tetramethoxystilbene and the AhR-CYP1A signaling pathway and define as substrates and inhibitors of CYP1A1, CYP1A2 and CYP1B1 enzymes. 	CYP1A1	25802	25808	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:163	Various studies highlighted the interactions between tetramethoxystilbene and the AhR-CYP1A signaling pathway and define as substrates and inhibitors of CYP1A1, CYP1A2 and CYP1B1 enzymes. 	CYP1A1	25802	25808	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	CYP1A1	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	CYP1A1	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:165	Among all the studies, compound tetramethoxystilbene was found to be more potent and selective in inhibiting CYP1A1, CYP1A2 and CYP1B1 activities. 	CYP1A1	26096	26102	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:165	Among all the studies, compound tetramethoxystilbene was found to be more potent and selective in inhibiting CYP1A1, CYP1A2 and CYP1B1 activities. 	CYP1A1	26096	26102	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:263	It down regulated the expression of Cyclin D1, cyclin B1 and CDK 4 as well as p27Kip1, and enhanced the level of cyclin E. Furthermore, as 3,3,4,5-THS was produced by resveratrol during metabolism, so it could also suppress the TCDD-dependent induction of CYP1A1 and CYP1B1 in HepG2 cells. 	CYP1A1	40004	40010	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:263	It down regulated the expression of Cyclin D1, cyclin B1 and CDK 4 as well as p27Kip1, and enhanced the level of cyclin E. Furthermore, as 3,3,4,5-THS was produced by resveratrol during metabolism, so it could also suppress the TCDD-dependent induction of CYP1A1 and CYP1B1 in HepG2 cells. 	CYP1A1	40004	40010	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP1A1	8782	8788	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP1A1	8782	8788	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:46	The CYP1A1 enzyme plays a role in the metabolism of caffeine as well as the bioactivation of polycyclic aromatic hydrocarbons. 	CYP1A1	9118	9124	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:46	The CYP1A1 enzyme plays a role in the metabolism of caffeine as well as the bioactivation of polycyclic aromatic hydrocarbons. 	CYP1A1	9118	9124	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:47	The CYP1A1*2A variant located in the 3 non-coding region confers a restriction endonuclease site for cleavage by Msp1. 	CYP1A1	9245	9251	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:47	The CYP1A1*2A variant located in the 3 non-coding region confers a restriction endonuclease site for cleavage by Msp1. 	CYP1A1	9245	9251	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:48	CYP1A1*2C is characterized by a nonsynonymous base change that results in an amino acid substitution associated with an increase in CYP1A1 gene inducibility. 	CYP1A1	9360	9366	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:48	CYP1A1*2C is characterized by a nonsynonymous base change that results in an amino acid substitution associated with an increase in CYP1A1 gene inducibility. 	CYP1A1	9360	9366	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:48	CYP1A1*2C is characterized by a nonsynonymous base change that results in an amino acid substitution associated with an increase in CYP1A1 gene inducibility. 	CYP1A1	9492	9498	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:48	CYP1A1*2C is characterized by a nonsynonymous base change that results in an amino acid substitution associated with an increase in CYP1A1 gene inducibility. 	CYP1A1	9492	9498	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:49	The frequencies of CYP1A1*2A and *2C were determined in two Amerindian peoples, the Teenek and Mayos and compared to the Mestizo Mexican population. 	CYP1A1	9537	9543	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:49	The frequencies of CYP1A1*2A and *2C were determined in two Amerindian peoples, the Teenek and Mayos and compared to the Mestizo Mexican population. 	CYP1A1	9537	9543	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:50	In the Teenek population, the minor allele frequencies (MAFs) of CYP1A1*2A and *2C were 71.4 and 65.4%, respectively and in the Mayos the MAFs were 46.9 and 54.6%, respectively. 	CYP1A1	9732	9738	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:50	In the Teenek population, the minor allele frequencies (MAFs) of CYP1A1*2A and *2C were 71.4 and 65.4%, respectively and in the Mayos the MAFs were 46.9 and 54.6%, respectively. 	CYP1A1	9732	9738	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:51	Both Amerindian populations had a significantly higher frequency of CYP1A1*2C compared to the Mexican Mestizo population (34.4%), while only the Teenek had a significantly higher frequency of CYP1A1*2A compared to the Mestizo population (40.1%). 	CYP1A1	9913	9919	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:51	Both Amerindian populations had a significantly higher frequency of CYP1A1*2C compared to the Mexican Mestizo population (34.4%), while only the Teenek had a significantly higher frequency of CYP1A1*2A compared to the Mestizo population (40.1%). 	CYP1A1	9913	9919	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:51	Both Amerindian populations had a significantly higher frequency of CYP1A1*2C compared to the Mexican Mestizo population (34.4%), while only the Teenek had a significantly higher frequency of CYP1A1*2A compared to the Mestizo population (40.1%). 	CYP1A1	10037	10043	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:51	Both Amerindian populations had a significantly higher frequency of CYP1A1*2C compared to the Mexican Mestizo population (34.4%), while only the Teenek had a significantly higher frequency of CYP1A1*2A compared to the Mestizo population (40.1%). 	CYP1A1	10037	10043	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:54	CYP1A1 is a well-known AhR target gene, and both compounds BaP and PCB118 are potent AhR agonists. 	CYP1A1	8080	8086	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:54	CYP1A1 is a well-known AhR target gene, and both compounds BaP and PCB118 are potent AhR agonists. 	CYP1A1	8080	8086	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:55	Addition of organic pollutants at the early stage of the induction process, ie, Time 1 led to a lower induction of CYP1A1 expression than expected: a low induction following treatment of the cells with BaP and PCB118, and no induction with PCB153. 	CYP1A1	8294	8300	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:55	Addition of organic pollutants at the early stage of the induction process, ie, Time 1 led to a lower induction of CYP1A1 expression than expected: a low induction following treatment of the cells with BaP and PCB118, and no induction with PCB153. 	CYP1A1	8294	8300	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:56	However, when the cells were co-treated with BaP and PCB118, we observed a potentiation of the CYP1A1 induction and surprisingly, such a potentiation was also observed in response to the combination of BaP with PCB153. 	CYP1A1	8522	8528	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:56	However, when the cells were co-treated with BaP and PCB118, we observed a potentiation of the CYP1A1 induction and surprisingly, such a potentiation was also observed in response to the combination of BaP with PCB153. 	CYP1A1	8522	8528	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:57	When pollutants were tested at Time 2, only BaP induced significantly the CYP1A1 expression. 	CYP1A1	8720	8726	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:57	When pollutants were tested at Time 2, only BaP induced significantly the CYP1A1 expression. 	CYP1A1	8720	8726	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:58	Surprisingly, this induction of CYP1A1 was partly repressed by a co-addition of PCB118 or PCB153. 	CYP1A1	8771	8777	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:58	Surprisingly, this induction of CYP1A1 was partly repressed by a co-addition of PCB118 or PCB153. 	CYP1A1	8771	8777	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:136	On the other hand, cytochromes P450, notably those belonging to the CYP1 family, can induce endoplasmic reticulum stress, and interestingly, our results show that combination of BaP and PCB118 induces CYP1A1 expression in adipocytes. 	CYP1A1	21466	21472	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:136	On the other hand, cytochromes P450, notably those belonging to the CYP1 family, can induce endoplasmic reticulum stress, and interestingly, our results show that combination of BaP and PCB118 induces CYP1A1 expression in adipocytes. 	CYP1A1	21466	21472	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:203	Previously, we have demonstrated that retinoids decrease the CYP1A1 induction. 	CYP1A1	30781	30787	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:203	Previously, we have demonstrated that retinoids decrease the CYP1A1 induction. 	CYP1A1	30781	30787	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:207	Inversely, concerning the expression of CYP1A1, TNFALPHA, and IL6, we observed that PCB153 enhances the effect of BaP in pre-adipocytes (Time 1 treatment). 	CYP1A1	31322	31328	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:207	Inversely, concerning the expression of CYP1A1, TNFALPHA, and IL6, we observed that PCB153 enhances the effect of BaP in pre-adipocytes (Time 1 treatment). 	CYP1A1	31322	31328	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:53	CYP1A2, CYP1A1 and NQO1 have been reported to be the major enzymes involved in AAI metabolism^,,,. 	CYP1A1	8574	8580	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:53	CYP1A2, CYP1A1 and NQO1 have been reported to be the major enzymes involved in AAI metabolism^,,,. 	CYP1A1	8574	8580	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:54	To examine whether Glycine N-Methyltransferase participates in AAI-induced nephropathy, the levels of mRNA expression for Glycine N-Methyltransferase, CYP1A1, CYP1A2, and NQO1 in mouse livers and kidneys were determined using real-time quantitative PCR analysis. 	CYP1A1	8816	8822	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:54	To examine whether Glycine N-Methyltransferase participates in AAI-induced nephropathy, the levels of mRNA expression for Glycine N-Methyltransferase, CYP1A1, CYP1A2, and NQO1 in mouse livers and kidneys were determined using real-time quantitative PCR analysis. 	CYP1A1	8816	8822	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:127	CYP1A1, 1A2 and CYP2C9 are not expressed in human kidney, whereas the CYP3A4 expression in kidney is highly variable and remains to be elucidated^. 	CYP1A1	22053	22059	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:127	CYP1A1, 1A2 and CYP2C9 are not expressed in human kidney, whereas the CYP3A4 expression in kidney is highly variable and remains to be elucidated^. 	CYP1A1	22053	22059	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:128	In mice, CYP1A1, CYP1A2 and CYP3A44/3A41 are almost not expressed in kidney^. 	CYP1A1	22210	22216	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:128	In mice, CYP1A1, CYP1A2 and CYP3A44/3A41 are almost not expressed in kidney^. 	CYP1A1	22210	22216	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:80	CYP1A1 is particularly implicated in lung, colorectal, breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and endometrium, and CYP1A2 in colorectal, lung, and breast cancers. 	CYP1A1	14043	14049	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:80	CYP1A1 is particularly implicated in lung, colorectal, breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and endometrium, and CYP1A2 in colorectal, lung, and breast cancers. 	CYP1A1	14043	14049	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP1A1	23033	23039	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP1A1	23033	23039	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	CYP1A1	37734	37740	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	CYP1A1	37734	37740	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:232	From benzo[a]pyrene, CYP1A1 produces 4,5-, 7,8-, and 9,10-epoxides in significant amounts. 	CYP1A1	41990	41996	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:232	From benzo[a]pyrene, CYP1A1 produces 4,5-, 7,8-, and 9,10-epoxides in significant amounts. 	CYP1A1	41990	41996	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:242	The three-residue disruption of helix F in CYP1A2 is extended to five residues in CYP1A1. 	CYP1A1	43777	43783	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:242	The three-residue disruption of helix F in CYP1A2 is extended to five residues in CYP1A1. 	CYP1A1	43777	43783	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:243	This suggests that this longer break in helix F and a slightly longer helix B are the only secondary structural differences that are observed between CYP1A1 and CYP1A2. 	CYP1A1	43935	43941	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:243	This suggests that this longer break in helix F and a slightly longer helix B are the only secondary structural differences that are observed between CYP1A1 and CYP1A2. 	CYP1A1	43935	43941	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:244	Moreover, the tilt that was observed in X-ray structures between the N- and C-terminal moieties of helix Fis more pronounced in CYP1A2 than in CYP1A1. 	CYP1A1	44097	44103	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:244	Moreover, the tilt that was observed in X-ray structures between the N- and C-terminal moieties of helix Fis more pronounced in CYP1A2 than in CYP1A1. 	CYP1A1	44097	44103	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:245	This causes the mouth of one of the four channels, namely channel 3, to be smaller in CYP1A2 than in CYP1A1. 	CYP1A1	44206	44212	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:245	This causes the mouth of one of the four channels, namely channel 3, to be smaller in CYP1A2 than in CYP1A1. 	CYP1A1	44206	44212	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:248	Similarly, mutation Phe240Ala in rat CYP1A1 has changed the selectivity of hydroxylation towards 2,3,7,8-tetrachloro-dibenzo-p-dioxin and 3,3,4,4-tetrachlorobiphenyl (PCB77). 	CYP1A1	44556	44562	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:248	Similarly, mutation Phe240Ala in rat CYP1A1 has changed the selectivity of hydroxylation towards 2,3,7,8-tetrachloro-dibenzo-p-dioxin and 3,3,4,4-tetrachlorobiphenyl (PCB77). 	CYP1A1	44556	44562	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:249	The F240A mutant presents an activity towards 2,3,7,8-Tetrachloro-Dibenzo-P-Dioxin, whereas the wild-type rat CYP1A1 has no activity detectable for 2,3,7,8-Tetrachloro-Dibenzo-P-Dioxin. 	CYP1A1	44804	44810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:249	The F240A mutant presents an activity towards 2,3,7,8-Tetrachloro-Dibenzo-P-Dioxin, whereas the wild-type rat CYP1A1 has no activity detectable for 2,3,7,8-Tetrachloro-Dibenzo-P-Dioxin. 	CYP1A1	44804	44810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:251	The molecular dynamics simulation performed on the wild-type and F240A mutant of rat CYP1A1, showed that the preferred channels (those that are open most of the time and are wider at bottleneck during the duration of the simulations) are not the same between the mutant and the wild-type P450 enzyme. 	CYP1A1	45087	45093	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:251	The molecular dynamics simulation performed on the wild-type and F240A mutant of rat CYP1A1, showed that the preferred channels (those that are open most of the time and are wider at bottleneck during the duration of the simulations) are not the same between the mutant and the wild-type P450 enzyme. 	CYP1A1	45087	45093	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6039966_OgerInput.txtOger_out.csv:51	We have shown that resveratrol does not strongly activate the expression of CYP1A1 in a human hepatocellular cell line. 	CYP1A1	6800	6806	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6039966_OgerInput.txtOger_out.csv:51	We have shown that resveratrol does not strongly activate the expression of CYP1A1 in a human hepatocellular cell line. 	CYP1A1	6800	6806	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP1A1	9635	9641	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP1A1	9635	9641	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP1A1	9733	9739	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP1A1	9733	9739	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:67	CYP1A1, 1A2, 2C12 were not observed in the skin (method: immunoblotting with mono-specific antibodies). 	CYP1A1	10160	10166	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:67	CYP1A1, 1A2, 2C12 were not observed in the skin (method: immunoblotting with mono-specific antibodies). 	CYP1A1	10160	10166	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	CYP1A1	11666	11672	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	CYP1A1	11666	11672	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP1A1	31984	31990	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP1A1	31984	31990	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:232	concluded that CYP1A1 converts eugenol to a sensitizing metabolite based on their observation that in contrast to wild-type mice 1A1-knockout mice are not sensitized by eugenol. 	CYP1A1	37197	37203	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:232	concluded that CYP1A1 converts eugenol to a sensitizing metabolite based on their observation that in contrast to wild-type mice 1A1-knockout mice are not sensitized by eugenol. 	CYP1A1	37197	37203	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP1A1	58800	58806	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP1A1	58800	58806	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A1	59218	59224	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A1	59218	59224	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A1	59326	59332	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A1	59326	59332	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60631	60637	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60631	60637	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60704	60710	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60704	60710	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60756	60762	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60756	60762	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60834	60840	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP1A1	60834	60840	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:387	mRNA coding for CYP1A1, CYP1A2 and CYP1B1 were increased after treatment with dioxin. 	CYP1A1	62038	62044	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:387	mRNA coding for CYP1A1, CYP1A2 and CYP1B1 were increased after treatment with dioxin. 	CYP1A1	62038	62044	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:389	mRNAs coding for CYP1A1, 1B1, 2E1, 2J2, 3A5, 4B1, low levels of RNAs coding for CYP2C18 and 3A4, but no RNA coding for CYP2B6 were recognized by Neis et al. 	CYP1A1	62171	62177	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:389	mRNAs coding for CYP1A1, 1B1, 2E1, 2J2, 3A5, 4B1, low levels of RNAs coding for CYP2C18 and 3A4, but no RNA coding for CYP2B6 were recognized by Neis et al. 	CYP1A1	62171	62177	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:392	The CYPs mRNA levels were strongly increased by liquor carbonis detergens (except of only a weak increase of CYP1A1 mRNA in Phenion^). 	CYP1A1	62786	62792	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:392	The CYPs mRNA levels were strongly increased by liquor carbonis detergens (except of only a weak increase of CYP1A1 mRNA in Phenion^). 	CYP1A1	62786	62792	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:396	found a high concordance (83-86%) of xenobiotic-metabolizing enzymes mRNA levels between Full-Thickness Human Bottom Skin (full-thickness human bottom skin) and EpiDerm^ with the exception of mRNAs for CYP1A1, 2A6, 2E1, 4  1 and 8B1 which were observed in Full-Thickness Human Bottom Skin, but not in EpiDerm^. 	CYP1A1	63321	63327	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:396	found a high concordance (83-86%) of xenobiotic-metabolizing enzymes mRNA levels between Full-Thickness Human Bottom Skin (full-thickness human bottom skin) and EpiDerm^ with the exception of mRNAs for CYP1A1, 2A6, 2E1, 4  1 and 8B1 which were observed in Full-Thickness Human Bottom Skin, but not in EpiDerm^. 	CYP1A1	63321	63327	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:404	CYP1A1 which was expressed at very low levels, was dramatically induced by BETANF (133-fold) and 3-MC (250-fold), while CYP1B1 was more moderately induced (14-fold by BETA-naphthoflavone and 12-fold by 3-MC). 	CYP1A1	64533	64539	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:404	CYP1A1 which was expressed at very low levels, was dramatically induced by BETANF (133-fold) and 3-MC (250-fold), while CYP1B1 was more moderately induced (14-fold by BETA-naphthoflavone and 12-fold by 3-MC). 	CYP1A1	64533	64539	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP1A1	64786	64792	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP1A1	64786	64792	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:408	in that CYP1A1 protein was found predominantly in the basal cells of the (buttock) epidermis, but CYP1B1 protein in the epidermal cells other than the basal cells. 	CYP1A1	64991	64997	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:408	in that CYP1A1 protein was found predominantly in the basal cells of the (buttock) epidermis, but CYP1B1 protein in the epidermal cells other than the basal cells. 	CYP1A1	64991	64997	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:409	Exposure to UVB led to an increase of epidermal CYP1A1 and 1B1 mRNA. 	CYP1A1	65195	65201	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:409	Exposure to UVB led to an increase of epidermal CYP1A1 and 1B1 mRNA. 	CYP1A1	65195	65201	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:411	observed CYP1A1, 2B6, 2E1 and 3A protein (in foreskin) predominantly localized in the suprabasal layer of the epidermis. 	CYP1A1	65300	65306	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:411	observed CYP1A1, 2B6, 2E1 and 3A protein (in foreskin) predominantly localized in the suprabasal layer of the epidermis. 	CYP1A1	65300	65306	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:413	showed in human whole skin increases of CYP1A1 protein after pretreatment with benzo[a]pyrene. 	CYP1A1	65465	65471	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:413	showed in human whole skin increases of CYP1A1 protein after pretreatment with benzo[a]pyrene. 	CYP1A1	65465	65471	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:415	demonstrated the presence of CYP1A1, 2B6, 2E1 and 3A proteins, CYP1A1 protein at least in some individual cells. 	CYP1A1	65629	65635	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:415	demonstrated the presence of CYP1A1, 2B6, 2E1 and 3A proteins, CYP1A1 protein at least in some individual cells. 	CYP1A1	65629	65635	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:415	demonstrated the presence of CYP1A1, 2B6, 2E1 and 3A proteins, CYP1A1 protein at least in some individual cells. 	CYP1A1	65663	65669	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:415	demonstrated the presence of CYP1A1, 2B6, 2E1 and 3A proteins, CYP1A1 protein at least in some individual cells. 	CYP1A1	65663	65669	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:416	Treatment with benz[a]anthracene led to a large increase in the number of cells containing CYP1A1 protein and to a large increase of the level of this protein. 	CYP1A1	65804	65810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:416	Treatment with benz[a]anthracene led to a large increase in the number of cells containing CYP1A1 protein and to a large increase of the level of this protein. 	CYP1A1	65804	65810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:514	)], 6BETA-hydroxytestosterone [produced by CYP1A1/2, CYP3A4/5/7 and CYP3A43 (Soucek et al. 	CYP1A1	79564	79570	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:514	)], 6BETA-hydroxytestosterone [produced by CYP1A1/2, CYP3A4/5/7 and CYP3A43 (Soucek et al. 	CYP1A1	79564	79570	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:517	BP was metabolized by ORS-RHE to hydroxy-, diol, catechol and dione metabolites (known to be mainly produced by CYP1B1, CYP1A1 and microsomal epoxide hydrolases (Hvastkovs et al. 	CYP1A1	79999	80005	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:517	BP was metabolized by ORS-RHE to hydroxy-, diol, catechol and dione metabolites (known to be mainly produced by CYP1B1, CYP1A1 and microsomal epoxide hydrolases (Hvastkovs et al. 	CYP1A1	79999	80005	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:529	observed that extremely low concentrations (low picomolar) of the And References Therein ligand 6-formylindolo[3,2-b]carbazole are sufficient to cause significant increases of the CYP1A1 transcript. 	CYP1A1	81591	81597	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:529	observed that extremely low concentrations (low picomolar) of the And References Therein ligand 6-formylindolo[3,2-b]carbazole are sufficient to cause significant increases of the CYP1A1 transcript. 	CYP1A1	81591	81597	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:537	reported that induction of CYP1A1 transcript by 2,3,7,8-tetrachlorodibenzofuran occurred in human keratinocytes in culture at an EC50 of 2 nM, but only in presence of either serum or high calcium (2 mM) concentration. 	CYP1A1	83015	83021	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:537	reported that induction of CYP1A1 transcript by 2,3,7,8-tetrachlorodibenzofuran occurred in human keratinocytes in culture at an EC50 of 2 nM, but only in presence of either serum or high calcium (2 mM) concentration. 	CYP1A1	83015	83021	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:538	Since these conditions were similar to those required for induction of the transcript coding for the differentiation-specific epidermal transglutaminase it appears that terminal differentiation is a prerequisite for CYP1A1 induction by And References Therein ligands to happen in human skin. 	CYP1A1	83422	83428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:538	Since these conditions were similar to those required for induction of the transcript coding for the differentiation-specific epidermal transglutaminase it appears that terminal differentiation is a prerequisite for CYP1A1 induction by And References Therein ligands to happen in human skin. 	CYP1A1	83422	83428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:543	reported that the occurrence of the CYP1 inducer PCB 126 (3,3,4,4,5-pentachlorobiphenyl)-evoqued increase in CYP1A1 mRNA and protein expression was inhibited by hypoxia. 	CYP1A1	84298	84304	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:543	reported that the occurrence of the CYP1 inducer PCB 126 (3,3,4,4,5-pentachlorobiphenyl)-evoqued increase in CYP1A1 mRNA and protein expression was inhibited by hypoxia. 	CYP1A1	84298	84304	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:545	reported that mechanisms other than ligand-binding to AhR-dependent events must exist which also lead to CYP1 induction, since carbaryl induced CYP1A1 expression in HaCaT without being an And References Therein ligand. 	CYP1A1	84518	84524	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:545	reported that mechanisms other than ligand-binding to AhR-dependent events must exist which also lead to CYP1 induction, since carbaryl induced CYP1A1 expression in HaCaT without being an And References Therein ligand. 	CYP1A1	84518	84524	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:551	In monolayer epidermal cells (NHEK) and in monolayer fibroblasts CYP1A1 mRNA was weakly, but significantly expressed in cultures derived from all three above-mentioned donors. 	CYP1A1	85307	85313	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:551	In monolayer epidermal cells (NHEK) and in monolayer fibroblasts CYP1A1 mRNA was weakly, but significantly expressed in cultures derived from all three above-mentioned donors. 	CYP1A1	85307	85313	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:552	CYP1A1 mRNA was moderately expressed in the three-dimensional epidermal reconstructed model OS-REp from all three above-mentioned donors, but in none of the three-dimensional full skin model Phenion FT Skin (Wiegand et al.. The latter discrepancy between mRNA expression in Phenion FT Skin versus native human skin is in contrast to the expression of mRNAs coding for most other xenobiotica-metabolizing enzymes which are quite well-mirrored in this three-dimensional full skin model, while the mRNA expression in the epidermal three-dimensional model OS-REp also compared quite well with that of the epidermal compartment of the native skin (see in the following chapters). 	CYP1A1	85418	85424	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:552	CYP1A1 mRNA was moderately expressed in the three-dimensional epidermal reconstructed model OS-REp from all three above-mentioned donors, but in none of the three-dimensional full skin model Phenion FT Skin (Wiegand et al.. The latter discrepancy between mRNA expression in Phenion FT Skin versus native human skin is in contrast to the expression of mRNAs coding for most other xenobiotica-metabolizing enzymes which are quite well-mirrored in this three-dimensional full skin model, while the mRNA expression in the epidermal three-dimensional model OS-REp also compared quite well with that of the epidermal compartment of the native skin (see in the following chapters). 	CYP1A1	85418	85424	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:553	CYP1A1 protein Polycyclic aromatic hydrocarbons, such as BP, dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene, and other Polycyclic Aromatic Hydrocarbon are substrates of CYP1A1 generating electrophilically reactive genotoxins including epoxides, but also phenols which are then conjugated yielding glucuronides and sulfates allowing for facilitated excretion. 	CYP1A1	86093	86099	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:553	CYP1A1 protein Polycyclic aromatic hydrocarbons, such as BP, dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene, and other Polycyclic Aromatic Hydrocarbon are substrates of CYP1A1 generating electrophilically reactive genotoxins including epoxides, but also phenols which are then conjugated yielding glucuronides and sulfates allowing for facilitated excretion. 	CYP1A1	86093	86099	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:553	CYP1A1 protein Polycyclic aromatic hydrocarbons, such as BP, dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene, and other Polycyclic Aromatic Hydrocarbon are substrates of CYP1A1 generating electrophilically reactive genotoxins including epoxides, but also phenols which are then conjugated yielding glucuronides and sulfates allowing for facilitated excretion. 	CYP1A1	86266	86272	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:553	CYP1A1 protein Polycyclic aromatic hydrocarbons, such as BP, dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene, and other Polycyclic Aromatic Hydrocarbon are substrates of CYP1A1 generating electrophilically reactive genotoxins including epoxides, but also phenols which are then conjugated yielding glucuronides and sulfates allowing for facilitated excretion. 	CYP1A1	86266	86272	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:554	As a consequence of this dual role modulations of CYP1A1 activities, eg, by induction may lead to opposite effects after different routes of administration depending whether these lead first-pass effects or to direct exposure of target tissues (Nebert et al.. Schober et al. 	CYP1A1	86506	86512	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:554	As a consequence of this dual role modulations of CYP1A1 activities, eg, by induction may lead to opposite effects after different routes of administration depending whether these lead first-pass effects or to direct exposure of target tissues (Nebert et al.. Schober et al. 	CYP1A1	86506	86512	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:555	reported that metabolic activation of dibenzo[a,l]pyrene (as far as hitherto known the most carcinogenic PAH) by heterologously expressed CYPs is most efficient with human CYP1A1 as compared to other human CYPs and as compared to any rat CYP. 	CYP1A1	86903	86909	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:555	reported that metabolic activation of dibenzo[a,l]pyrene (as far as hitherto known the most carcinogenic PAH) by heterologously expressed CYPs is most efficient with human CYP1A1 as compared to other human CYPs and as compared to any rat CYP. 	CYP1A1	86903	86909	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:557	reported that metabolic activation of dibenzo[a,l]pyrene is catalyzed by heterologously expressed CYP1A2, albeit not as well as by human CYP1A1 or by CYP1B1, but better than by other human CYPs. 	CYP1A1	87398	87404	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:557	reported that metabolic activation of dibenzo[a,l]pyrene is catalyzed by heterologously expressed CYP1A2, albeit not as well as by human CYP1A1 or by CYP1B1, but better than by other human CYPs. 	CYP1A1	87398	87404	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:563	showed that metabolic activation of the most carcinogenic member of the Polycyclic Aromatic Hydrocarbon, dibenzo[a,l]pyrene, is efficiently catalyzed by heterologously expressed human CYP1B1, much better than by other human CYPs and by rat CYPs, but less efficiently than by human CYP1A1. 	CYP1A1	88220	88226	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:563	showed that metabolic activation of the most carcinogenic member of the Polycyclic Aromatic Hydrocarbon, dibenzo[a,l]pyrene, is efficiently catalyzed by heterologously expressed human CYP1B1, much better than by other human CYPs and by rat CYPs, but less efficiently than by human CYP1A1. 	CYP1A1	88220	88226	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:673	In monolayer epidermal cells (NHEK) and in monolayer fibroblasts CYP1A1 mRNA was not expressed in cultures derived from any of the three above-mentioned donors. 	CYP1A1	103028	103034	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:673	In monolayer epidermal cells (NHEK) and in monolayer fibroblasts CYP1A1 mRNA was not expressed in cultures derived from any of the three above-mentioned donors. 	CYP1A1	103028	103034	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:674	CYP1A1 mRNA was weakly to moderately expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors, but in the three-dimensional full skin model Phenion FT Skin only weakly and only in one of the three donors (Wiegand et al.. Baron et al. 	CYP1A1	103124	103130	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:674	CYP1A1 mRNA was weakly to moderately expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors, but in the three-dimensional full skin model Phenion FT Skin only weakly and only in one of the three donors (Wiegand et al.. Baron et al. 	CYP1A1	103124	103130	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:1	 Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells. 	CYP1A1	62	68	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:1	 Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells. 	CYP1A1	62	68	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:4	Among protoberberines at non-cytotoxic concentrations (10 M), berberine had the most potent and statistically significant effects on AhR activation and CYP1A1/1A2/1B1 mRNA induction. 	CYP1A1	649	655	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:4	Among protoberberines at non-cytotoxic concentrations (10 M), berberine had the most potent and statistically significant effects on AhR activation and CYP1A1/1A2/1B1 mRNA induction. 	CYP1A1	649	655	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:5	The 24-h exposure to 10 M berberine did not change CYP1A1 mRNA stability, protein level and function. 	CYP1A1	731	737	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:5	The 24-h exposure to 10 M berberine did not change CYP1A1 mRNA stability, protein level and function. 	CYP1A1	731	737	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:6	Berberine significantly increased micro RNA (miR)-21-3p by 36% and the transfection of an inhibitor of miR-21-3p restored the induction of CYP1A1 protein with a 50% increase. 	CYP1A1	921	927	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:6	Berberine significantly increased micro RNA (miR)-21-3p by 36% and the transfection of an inhibitor of miR-21-3p restored the induction of CYP1A1 protein with a 50% increase. 	CYP1A1	921	927	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:8	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression. 	CYP1A1	1096	1102	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:8	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression. 	CYP1A1	1096	1102	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:8	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression. 	CYP1A1	1188	1194	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:8	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression. 	CYP1A1	1188	1194	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:10	In the determination of CYP1 function, 7-ethoxyresorufin is generally used as a common substrate of CYP1s, and CYP1A1 has the highest turnover rate in 7-ethoxyresorufin O-deethylation (EROD). 	CYP1A1	1603	1609	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:10	In the determination of CYP1 function, 7-ethoxyresorufin is generally used as a common substrate of CYP1s, and CYP1A1 has the highest turnover rate in 7-ethoxyresorufin O-deethylation (EROD). 	CYP1A1	1603	1609	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:11	CYP1A1 and CYP1B1 are predominantly expressed in extrahepatic tissues including the breasts (mammaries). 	CYP1A1	1684	1690	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:11	CYP1A1 and CYP1B1 are predominantly expressed in extrahepatic tissues including the breasts (mammaries). 	CYP1A1	1684	1690	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:14	The AhR nuclear translocator (ARNT) carries the AhR-ligand complex to interact with the dioxin-responsive element (DRE) of the CYP1A1, CYP1A2 and CYP1B1 genes, resulting in transcriptional induction. 	CYP1A1	2127	2133	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:14	The AhR nuclear translocator (ARNT) carries the AhR-ligand complex to interact with the dioxin-responsive element (DRE) of the CYP1A1, CYP1A2 and CYP1B1 genes, resulting in transcriptional induction. 	CYP1A1	2127	2133	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:15	Compared to the dramatic increase in CYP1A1 mRNA by TCDD in estrogen receptor (ER)ALPHA(+) MCF-7 (human breast adenocarcinoma) cells, ERALPHAMDA-MB-231 (MB-231) (human breast adenocarcinoma) cells carry an ARNT variant with an incomplete glutamine-rich region and transactivation domain, resulting in an inefficient CYP1A1 induction. 	CYP1A1	2237	2243	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:15	Compared to the dramatic increase in CYP1A1 mRNA by TCDD in estrogen receptor (ER)ALPHA(+) MCF-7 (human breast adenocarcinoma) cells, ERALPHAMDA-MB-231 (MB-231) (human breast adenocarcinoma) cells carry an ARNT variant with an incomplete glutamine-rich region and transactivation domain, resulting in an inefficient CYP1A1 induction. 	CYP1A1	2237	2243	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:15	Compared to the dramatic increase in CYP1A1 mRNA by TCDD in estrogen receptor (ER)ALPHA(+) MCF-7 (human breast adenocarcinoma) cells, ERALPHAMDA-MB-231 (MB-231) (human breast adenocarcinoma) cells carry an ARNT variant with an incomplete glutamine-rich region and transactivation domain, resulting in an inefficient CYP1A1 induction. 	CYP1A1	2516	2522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:15	Compared to the dramatic increase in CYP1A1 mRNA by TCDD in estrogen receptor (ER)ALPHA(+) MCF-7 (human breast adenocarcinoma) cells, ERALPHAMDA-MB-231 (MB-231) (human breast adenocarcinoma) cells carry an ARNT variant with an incomplete glutamine-rich region and transactivation domain, resulting in an inefficient CYP1A1 induction. 	CYP1A1	2516	2522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:17	The TCDD- and BETA-naphthoflavone-induced levels of CYP1A1 mRNA were reduced in the ERALPHA knockdown mouse mammary epithelial cell line HC11 (nontumorigenic) and the liver of ovariectomized ER knockout mice, respectively. 	CYP1A1	2667	2673	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:17	The TCDD- and BETA-naphthoflavone-induced levels of CYP1A1 mRNA were reduced in the ERALPHA knockdown mouse mammary epithelial cell line HC11 (nontumorigenic) and the liver of ovariectomized ER knockout mice, respectively. 	CYP1A1	2667	2673	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:18	However, in the MCF-7 cell line, TCDD-induced CYP1A1 mRNA levels were not affected by ERALPHA knockdown. 	CYP1A1	2884	2890	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:18	However, in the MCF-7 cell line, TCDD-induced CYP1A1 mRNA levels were not affected by ERALPHA knockdown. 	CYP1A1	2884	2890	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:19	In MCF-7 cells, concurrent exposure to E2 reduced the TCDD-mediated induction of CYP1A1 mRNA through the ERALPHA-dependent increase of DNA methylation of DRE. 	CYP1A1	3024	3030	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:19	In MCF-7 cells, concurrent exposure to E2 reduced the TCDD-mediated induction of CYP1A1 mRNA through the ERALPHA-dependent increase of DNA methylation of DRE. 	CYP1A1	3024	3030	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:22	Our previous report demonstrated that these three protoberberines could inhibit recombinant human CYP1A1 activity. 	CYP1A1	3547	3553	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:22	Our previous report demonstrated that these three protoberberines could inhibit recombinant human CYP1A1 activity. 	CYP1A1	3547	3553	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:23	A CYP1A1 inhibitor can activate AhR indirectly through inhibiting the oxidation of a photoproduct of tryptophan, 6-formylindolo(3,2-b)carbazole, in cultured cells. 	CYP1A1	3566	3572	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:23	A CYP1A1 inhibitor can activate AhR indirectly through inhibiting the oxidation of a photoproduct of tryptophan, 6-formylindolo(3,2-b)carbazole, in cultured cells. 	CYP1A1	3566	3572	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:26	Palmatine (10 M) activated DRE and increased CYP1A1 mRNA and EROD activity in HepG2 cells, whereas EROD activity remained the same in the primary culture of human hepatocytes. 	CYP1A1	4128	4134	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:26	Palmatine (10 M) activated DRE and increased CYP1A1 mRNA and EROD activity in HepG2 cells, whereas EROD activity remained the same in the primary culture of human hepatocytes. 	CYP1A1	4128	4134	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:29	In HepG2 cells, berberine elevated CYP1A1 mRNA until it approached TCDD-induced levels. 	CYP1A1	4550	4556	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:29	In HepG2 cells, berberine elevated CYP1A1 mRNA until it approached TCDD-induced levels. 	CYP1A1	4550	4556	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:30	However, the increase of CYP1A1 protein by berberine was only ~16% of that by TCDD, suggesting that berberine might cause post-transcriptional down-regulation of CYP1A1 expression. 	CYP1A1	4628	4634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:30	However, the increase of CYP1A1 protein by berberine was only ~16% of that by TCDD, suggesting that berberine might cause post-transcriptional down-regulation of CYP1A1 expression. 	CYP1A1	4628	4634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:30	However, the increase of CYP1A1 protein by berberine was only ~16% of that by TCDD, suggesting that berberine might cause post-transcriptional down-regulation of CYP1A1 expression. 	CYP1A1	4765	4771	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:30	However, the increase of CYP1A1 protein by berberine was only ~16% of that by TCDD, suggesting that berberine might cause post-transcriptional down-regulation of CYP1A1 expression. 	CYP1A1	4765	4771	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:33	The influence of miR-21-3p on CYP1A1 expression remained unclear. 	CYP1A1	5148	5154	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:33	The influence of miR-21-3p on CYP1A1 expression remained unclear. 	CYP1A1	5148	5154	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:35	The effects of E2, ERALPHA knockdown and miRs on the berberine-mediated CYP1A1 regulation is reported for the first time. 	CYP1A1	5441	5447	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:35	The effects of E2, ERALPHA knockdown and miRs on the berberine-mediated CYP1A1 regulation is reported for the first time. 	CYP1A1	5441	5447	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:48	In MCF-7 cells, 24-h exposure to 2 M B(a)P potently increased CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 8-, 3- and 6-fold, respectively (A). 	CYP1A1	7053	7059	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:48	In MCF-7 cells, 24-h exposure to 2 M B(a)P potently increased CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 8-, 3- and 6-fold, respectively (A). 	CYP1A1	7053	7059	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:49	The 24-h exposure to berberine at 1 M increased CYP1A1 and CYP1B1 mRNA levels by 3- and 2-fold, respectively. 	CYP1A1	7179	7185	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:49	The 24-h exposure to berberine at 1 M increased CYP1A1 and CYP1B1 mRNA levels by 3- and 2-fold, respectively. 	CYP1A1	7179	7185	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:50	By increasing the exposure concentration to 10 M, berberine significantly elevated the CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 4-fold, 28% and 3-fold, respectively. 	CYP1A1	7328	7334	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:50	By increasing the exposure concentration to 10 M, berberine significantly elevated the CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 4-fold, 28% and 3-fold, respectively. 	CYP1A1	7328	7334	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:51	Palmatine at 10 M elevated CYP1A1 and CYP1A2 mRNA levels by 2-fold, whereas CYP1B1 mRNA level remained unchanged. 	CYP1A1	7434	7440	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:51	Palmatine at 10 M elevated CYP1A1 and CYP1A2 mRNA levels by 2-fold, whereas CYP1B1 mRNA level remained unchanged. 	CYP1A1	7434	7440	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:52	Exposure to 10 M jatrorrhizine decreased CYP1A1 mRNA levels by 32% without affecting CYP1A2 or CYP1B1. 	CYP1A1	7562	7568	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:52	Exposure to 10 M jatrorrhizine decreased CYP1A1 mRNA levels by 32% without affecting CYP1A2 or CYP1B1. 	CYP1A1	7562	7568	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:53	Among protoberberines, berberine caused the highest induction of CYP1A1 mRNA in MCF-7 cells. 	CYP1A1	7689	7695	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:53	Among protoberberines, berberine caused the highest induction of CYP1A1 mRNA in MCF-7 cells. 	CYP1A1	7689	7695	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:55	The 24-h exposure to B(a)P (2 M) caused 4- and 2-fold increases in the CYP1A1 and CYP1B1 mRNA levels, respectively. 	CYP1A1	7858	7864	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:55	The 24-h exposure to B(a)P (2 M) caused 4- and 2-fold increases in the CYP1A1 and CYP1B1 mRNA levels, respectively. 	CYP1A1	7858	7864	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:56	Berberine, palmatine and jatrorrhizine at a concentration up to 10 M had no effects on CYP1A1 and CYP1B1 mRNA in MB-231 cells (B). 	CYP1A1	7990	7996	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:56	Berberine, palmatine and jatrorrhizine at a concentration up to 10 M had no effects on CYP1A1 and CYP1B1 mRNA in MB-231 cells (B). 	CYP1A1	7990	7996	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:57	The differential induction of CYP1A1 mRNA by protoberberines in MCF-7 cells was further examined using real-time PCR analysis. 	CYP1A1	8064	8070	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:57	The differential induction of CYP1A1 mRNA by protoberberines in MCF-7 cells was further examined using real-time PCR analysis. 	CYP1A1	8064	8070	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:58	By using two different primer sets, jatrorrhizine did not cause a significant change of CYP1A1 mRNA level. 	CYP1A1	8249	8255	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:58	By using two different primer sets, jatrorrhizine did not cause a significant change of CYP1A1 mRNA level. 	CYP1A1	8249	8255	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:59	Berberine and palmatine at 10 M induced CYP1A1 mRNA by 6-30 fold and 50%-227%, respectively (C). 	CYP1A1	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:59	Berberine and palmatine at 10 M induced CYP1A1 mRNA by 6-30 fold and 50%-227%, respectively (C). 	CYP1A1	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:60	Results of PCR analysis consistently demonstrated that berberine caused the most-potent induction of CYP1A1 mRNA. 	CYP1A1	8466	8472	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:60	Results of PCR analysis consistently demonstrated that berberine caused the most-potent induction of CYP1A1 mRNA. 	CYP1A1	8466	8472	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:64	Thus, the protein expression levels of CYP1A1 and CYP1B1 were further examined using immunoblot analysis. 	CYP1A1	8881	8887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:64	Thus, the protein expression levels of CYP1A1 and CYP1B1 were further examined using immunoblot analysis. 	CYP1A1	8881	8887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:66	The apparent molecular weights of CYP1A1, CYP1B1 and CPR were estimated to be 53, 54 and 78 kDa, respectively. 	CYP1A1	9163	9169	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:66	The apparent molecular weights of CYP1A1, CYP1B1 and CPR were estimated to be 53, 54 and 78 kDa, respectively. 	CYP1A1	9163	9169	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:67	In MCF-7 cells, exposure to 2 M B(a)P for 24 and 48 h increased CYP1A1 protein level by 2-fold and 36%, respectively (A). 	CYP1A1	9304	9310	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:67	In MCF-7 cells, exposure to 2 M B(a)P for 24 and 48 h increased CYP1A1 protein level by 2-fold and 36%, respectively (A). 	CYP1A1	9304	9310	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:69	Neither CYP1A1 nor CYP1B1 protein level was increased after 24 h and 48 h exposure to 10 M berberine in MCF-7 cells. 	CYP1A1	9449	9455	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:69	Neither CYP1A1 nor CYP1B1 protein level was increased after 24 h and 48 h exposure to 10 M berberine in MCF-7 cells. 	CYP1A1	9449	9455	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:72	In cells cultured in DCC-stripped FBS (DCCFBS)-supplemented medium, E2 alone did not change CYP1A1 mRNA level. 	CYP1A1	9871	9877	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:72	In cells cultured in DCC-stripped FBS (DCCFBS)-supplemented medium, E2 alone did not change CYP1A1 mRNA level. 	CYP1A1	9871	9877	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:73	The berberine-mediated increase in CYP1A1 mRNA was not affected by concurrent exposure to E2 at a concentration up to 10 nM (A). 	CYP1A1	9925	9931	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:73	The berberine-mediated increase in CYP1A1 mRNA was not affected by concurrent exposure to E2 at a concentration up to 10 nM (A). 	CYP1A1	9925	9931	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:74	In cells cultured in FBS-supplemented medium, the ER antagonist fulvestrant had no influence on the berberine-mediated CYP1A1 mRNA induction (B). 	CYP1A1	10138	10144	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:74	In cells cultured in FBS-supplemented medium, the ER antagonist fulvestrant had no influence on the berberine-mediated CYP1A1 mRNA induction (B). 	CYP1A1	10138	10144	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:75	The transfection of siERALPHA resulted in a 70% decrease of basal ERALPHA expression, but did not diminish the berberine-mediated CYP1A1 mRNA induction (C). 	CYP1A1	10295	10301	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:75	The transfection of siERALPHA resulted in a 70% decrease of basal ERALPHA expression, but did not diminish the berberine-mediated CYP1A1 mRNA induction (C). 	CYP1A1	10295	10301	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:76	Results revealed that berberine-mediated CYP1A1 mRNA induction could not be affected by the ERALPHA signaling. 	CYP1A1	10363	10369	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:76	Results revealed that berberine-mediated CYP1A1 mRNA induction could not be affected by the ERALPHA signaling. 	CYP1A1	10363	10369	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:77	To illustrate post-transcriptional regulation, the stability of CYP1A1 mRNA was first determined. 	CYP1A1	10497	10503	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:77	To illustrate post-transcriptional regulation, the stability of CYP1A1 mRNA was first determined. 	CYP1A1	10497	10503	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:78	The berberine (10 M, 24 h)-mediated change to the half-life of CYP1A1 mRNA was minimal (control cells: 9.3  3.4 h; berberine-exposed cells: 11.7  2.4 h) (A). 	CYP1A1	10594	10600	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:78	The berberine (10 M, 24 h)-mediated change to the half-life of CYP1A1 mRNA was minimal (control cells: 9.3  3.4 h; berberine-exposed cells: 11.7  2.4 h) (A). 	CYP1A1	10594	10600	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:81	Transfection of a miR-21-3p hairpin inhibitor restored the berberine-mediated induction of CYP1A1 protein with a 50  19% increase (C). 	CYP1A1	10996	11002	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:81	Transfection of a miR-21-3p hairpin inhibitor restored the berberine-mediated induction of CYP1A1 protein with a 50  19% increase (C). 	CYP1A1	10996	11002	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:82	In miR-21-5p hairpin inhibitor-transfected cells, CYP1A1 protein level remained unchanged after berberine exposure. 	CYP1A1	11090	11096	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:82	In miR-21-5p hairpin inhibitor-transfected cells, CYP1A1 protein level remained unchanged after berberine exposure. 	CYP1A1	11090	11096	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:84	These results revealed that berberine stimulated miR-21-3p, suppressing the elevation of CYP1A1 protein. 	CYP1A1	11359	11365	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:84	These results revealed that berberine stimulated miR-21-3p, suppressing the elevation of CYP1A1 protein. 	CYP1A1	11359	11365	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:86	Among protoberberines, berberine caused the most-potent AhR activation and CYP1A1 mRNA stimulation in MCF-7 cells, but not in MB-231 cells. 	CYP1A1	11705	11711	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:86	Among protoberberines, berberine caused the most-potent AhR activation and CYP1A1 mRNA stimulation in MCF-7 cells, but not in MB-231 cells. 	CYP1A1	11705	11711	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:87	Consistent with the report of the effect of TCDD, the increases in CYP1B1 mRNA by berberine and palmatine were less than the elevation of CYP1A1 mRNA. 	CYP1A1	11908	11914	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:87	Consistent with the report of the effect of TCDD, the increases in CYP1B1 mRNA by berberine and palmatine were less than the elevation of CYP1A1 mRNA. 	CYP1A1	11908	11914	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:89	The IC_50 values for the inhibition of recombinant human CYP1A1 were in the following order: berberine (1.38 M) < jatrorrhizine (2.17 M) < palmatine (8.71 M). 	CYP1A1	12091	12097	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:89	The IC_50 values for the inhibition of recombinant human CYP1A1 were in the following order: berberine (1.38 M) < jatrorrhizine (2.17 M) < palmatine (8.71 M). 	CYP1A1	12091	12097	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:90	Although berberine was predicted to potentially activate AhR through inhibition of CYP1A1 in cells, the CYP1A1 inhibitory effects of these protoberberines did not correlate with their respective effects on AhR activation in this report. 	CYP1A1	12276	12282	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:90	Although berberine was predicted to potentially activate AhR through inhibition of CYP1A1 in cells, the CYP1A1 inhibitory effects of these protoberberines did not correlate with their respective effects on AhR activation in this report. 	CYP1A1	12276	12282	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:90	Although berberine was predicted to potentially activate AhR through inhibition of CYP1A1 in cells, the CYP1A1 inhibitory effects of these protoberberines did not correlate with their respective effects on AhR activation in this report. 	CYP1A1	12297	12303	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:90	Although berberine was predicted to potentially activate AhR through inhibition of CYP1A1 in cells, the CYP1A1 inhibitory effects of these protoberberines did not correlate with their respective effects on AhR activation in this report. 	CYP1A1	12297	12303	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:94	In rats, B(a)P elevated the CYP1A1 mRNA level in the ovaries by an amount comparable to that in the liver. 	CYP1A1	12882	12888	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:94	In rats, B(a)P elevated the CYP1A1 mRNA level in the ovaries by an amount comparable to that in the liver. 	CYP1A1	12882	12888	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:95	However, the CYP1A1 protein level and microsomal EROD activity were induced by B(a)P in the liver, but not the ovaries. 	CYP1A1	12974	12980	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:95	However, the CYP1A1 protein level and microsomal EROD activity were induced by B(a)P in the liver, but not the ovaries. 	CYP1A1	12974	12980	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:97	Elevated levels of miRs, including miR-21, can contribute to the post-transcriptional downregulation of ovary CYP1A1 protein expression. 	CYP1A1	13248	13254	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:97	Elevated levels of miRs, including miR-21, can contribute to the post-transcriptional downregulation of ovary CYP1A1 protein expression. 	CYP1A1	13248	13254	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:98	Although one immunoblot showed a weak to mild elevation in CYP1A1 protein in MCF-7 cells exposed to 10-40 M berberine for 48 h, the statistical significance has not been proven. 	CYP1A1	13334	13340	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:98	Although one immunoblot showed a weak to mild elevation in CYP1A1 protein in MCF-7 cells exposed to 10-40 M berberine for 48 h, the statistical significance has not been proven. 	CYP1A1	13334	13340	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:99	Our findings revealed that neither CYP1A1/1B1 protein levels nor EROD activity in MCF-7 cells were significantly affected by protoberberines at a non-cytotoxic concentration (10 M). 	CYP1A1	13488	13494	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:99	Our findings revealed that neither CYP1A1/1B1 protein levels nor EROD activity in MCF-7 cells were significantly affected by protoberberines at a non-cytotoxic concentration (10 M). 	CYP1A1	13488	13494	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1	13968	13974	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1	13968	13974	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1	14140	14146	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1	14140	14146	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:103	While berberine increased CYP1A1 mRNA to a level approaching that of TCDD-exposed HepG2 cells, our findings suggested that an increase in miR-21-3p might be the reason for the mild increase in CYP1A1 protein level by berberine as compared to that induced by TCDD. 	CYP1A1	14192	14198	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:103	While berberine increased CYP1A1 mRNA to a level approaching that of TCDD-exposed HepG2 cells, our findings suggested that an increase in miR-21-3p might be the reason for the mild increase in CYP1A1 protein level by berberine as compared to that induced by TCDD. 	CYP1A1	14192	14198	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:103	While berberine increased CYP1A1 mRNA to a level approaching that of TCDD-exposed HepG2 cells, our findings suggested that an increase in miR-21-3p might be the reason for the mild increase in CYP1A1 protein level by berberine as compared to that induced by TCDD. 	CYP1A1	14359	14365	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:103	While berberine increased CYP1A1 mRNA to a level approaching that of TCDD-exposed HepG2 cells, our findings suggested that an increase in miR-21-3p might be the reason for the mild increase in CYP1A1 protein level by berberine as compared to that induced by TCDD. 	CYP1A1	14359	14365	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:107	While the CYP1A1 mRNA was increased, berberine-induced miR-21-3p suppressed the increase in CYP1A1 protein and function. 	CYP1A1	14921	14927	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:107	While the CYP1A1 mRNA was increased, berberine-induced miR-21-3p suppressed the increase in CYP1A1 protein and function. 	CYP1A1	14921	14927	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:107	While the CYP1A1 mRNA was increased, berberine-induced miR-21-3p suppressed the increase in CYP1A1 protein and function. 	CYP1A1	15003	15009	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:107	While the CYP1A1 mRNA was increased, berberine-induced miR-21-3p suppressed the increase in CYP1A1 protein and function. 	CYP1A1	15003	15009	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:122	Rabbit polyclonal antibody against human CYP1A1 (AB10328), which immunoreacted with CYP1A1 in a human thyroid cancer cell line, was purchased from Merck Millipore (Billerica, MA, USA). 	CYP1A1	16342	16348	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:122	Rabbit polyclonal antibody against human CYP1A1 (AB10328), which immunoreacted with CYP1A1 in a human thyroid cancer cell line, was purchased from Merck Millipore (Billerica, MA, USA). 	CYP1A1	16342	16348	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:122	Rabbit polyclonal antibody against human CYP1A1 (AB10328), which immunoreacted with CYP1A1 in a human thyroid cancer cell line, was purchased from Merck Millipore (Billerica, MA, USA). 	CYP1A1	16385	16391	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:122	Rabbit polyclonal antibody against human CYP1A1 (AB10328), which immunoreacted with CYP1A1 in a human thyroid cancer cell line, was purchased from Merck Millipore (Billerica, MA, USA). 	CYP1A1	16385	16391	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:143	After incubation with 5% non-fat milk in phosphate-buffered saline (PBS) at 37 C for 1 h, the membranes were incubated with anti-CYP1A1 (1:2500), anti-CYP1B1 (1:200) and anti-CPR (1:2000) in PBS containing 1% non-fat milk overnight at 4 C. In the immunoblot analysis of ERALPHA and caveolin-1, cell lysate was prepared as described previously and subjected to electrophoresis as described above. 	CYP1A1	19119	19125	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:143	After incubation with 5% non-fat milk in phosphate-buffered saline (PBS) at 37 C for 1 h, the membranes were incubated with anti-CYP1A1 (1:2500), anti-CYP1B1 (1:200) and anti-CPR (1:2000) in PBS containing 1% non-fat milk overnight at 4 C. In the immunoblot analysis of ERALPHA and caveolin-1, cell lysate was prepared as described previously and subjected to electrophoresis as described above. 	CYP1A1	19119	19125	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:156	For CYP1A1*1 (NM_000499.4), primer set 1: forward primer 5-TAGACACTGATCTGGCTGCAG-3 and the reverse primer 5-GGGAAGGCTCCATCAGCATC-3 was used. 	CYP1A1	20918	20924	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:156	For CYP1A1*1 (NM_000499.4), primer set 1: forward primer 5-TAGACACTGATCTGGCTGCAG-3 and the reverse primer 5-GGGAAGGCTCCATCAGCATC-3 was used. 	CYP1A1	20918	20924	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:157	The amplification of CYP1A1, CYP1A2, CYP1B1 and BETA-actin was carried out for 35, 40, 35 and 25 cycles, respectively. 	CYP1A1	21076	21082	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:157	The amplification of CYP1A1, CYP1A2, CYP1B1 and BETA-actin was carried out for 35, 40, 35 and 25 cycles, respectively. 	CYP1A1	21076	21082	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:160	In the real-time PCR analysis of CYP1A1 mRNA level, both primer set 1 and a reported primer set 2 were used to further examine the differential effects of protoberberines. 	CYP1A1	21427	21433	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:160	In the real-time PCR analysis of CYP1A1 mRNA level, both primer set 1 and a reported primer set 2 were used to further examine the differential effects of protoberberines. 	CYP1A1	21427	21433	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:163	The relative mRNA expression level was normalized to the GAPDH transcript level, which allowed the target cDNA calculation by 2^(Ct CYP1A1Ct GAPDH)CYP1A1Ct GAPDH). 	CYP1A1	22291	22297	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:163	The relative mRNA expression level was normalized to the GAPDH transcript level, which allowed the target cDNA calculation by 2^(Ct CYP1A1Ct GAPDH)CYP1A1Ct GAPDH). 	CYP1A1	22291	22297	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:163	The relative mRNA expression level was normalized to the GAPDH transcript level, which allowed the target cDNA calculation by 2^(Ct CYP1A1Ct GAPDH)CYP1A1Ct GAPDH). 	CYP1A1	22306	22312	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:163	The relative mRNA expression level was normalized to the GAPDH transcript level, which allowed the target cDNA calculation by 2^(Ct CYP1A1Ct GAPDH)CYP1A1Ct GAPDH). 	CYP1A1	22306	22312	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:41	The effects on CYP1A1, CYP2A6, CYP2E1, and UGT1A6 activities were assumed to be a negligible (IC_50 > 25 M). 	CYP1A1	6554	6560	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:41	The effects on CYP1A1, CYP2A6, CYP2E1, and UGT1A6 activities were assumed to be a negligible (IC_50 > 25 M). 	CYP1A1	6554	6560	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:42	These findings suggest that clinical interactions between these compounds and CYP1A1, CYP2A6, CYP2E1, or UGT1A6 would not occur. 	CYP1A1	6726	6732	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:42	These findings suggest that clinical interactions between these compounds and CYP1A1, CYP2A6, CYP2E1, or UGT1A6 would not occur. 	CYP1A1	6726	6732	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:33	More recently, in vitro experiments have shown that UVB induced the expression of CYP1A1 and favored the formation of DNA adducts upon subsequent exposure to B[a]P^. 	CYP1A1	4454	4460	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:33	More recently, in vitro experiments have shown that UVB induced the expression of CYP1A1 and favored the formation of DNA adducts upon subsequent exposure to B[a]P^. 	CYP1A1	4454	4460	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:47	Expression of the phase I genes CYP1A1, CYP1A2, and CYP1B1 was then quantified, using untreated samples as references. 	CYP1A1	6379	6385	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:47	Expression of the phase I genes CYP1A1, CYP1A2, and CYP1B1 was then quantified, using untreated samples as references. 	CYP1A1	6379	6385	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:59	Like in skin, CYP1A1 was the most over-expressed gene in HNK. 	CYP1A1	7870	7876	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:59	Like in skin, CYP1A1 was the most over-expressed gene in HNK. 	CYP1A1	7870	7876	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	CYP1A1	8112	8118	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	CYP1A1	8112	8118	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:64	Interestingly, the maximal level of adducts was not observed for the largest concentration investigated (5 M), but rather at 1 M. Exposure to Simulated Sunlight resulted in a very low overexpression of CYP1A1 and 1B1 by a factor of 2, but not of CYP1A2 (Supplementary Fig. 	CYP1A1	8657	8663	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:64	Interestingly, the maximal level of adducts was not observed for the largest concentration investigated (5 M), but rather at 1 M. Exposure to Simulated Sunlight resulted in a very low overexpression of CYP1A1 and 1B1 by a factor of 2, but not of CYP1A2 (Supplementary Fig. 	CYP1A1	8657	8663	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:70	Over the time period investigated, it was observed that Simulated Sunlight reduced the stimulation of gene expression induced by B[a]P of CYP1A1 and CYP1A2, particularly at 48 hours and to a lesser extent at 72 hours, regardless of the treatment protocol used (Figs  and. 	CYP1A1	9705	9711	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:70	Over the time period investigated, it was observed that Simulated Sunlight reduced the stimulation of gene expression induced by B[a]P of CYP1A1 and CYP1A2, particularly at 48 hours and to a lesser extent at 72 hours, regardless of the treatment protocol used (Figs  and. 	CYP1A1	9705	9711	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:97	Costa et al.^ used punch biopsies of abdominal skin to test the effect of B[a]P on expression of CYP1A1. 	CYP1A1	13932	13938	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:97	Costa et al.^ used punch biopsies of abdominal skin to test the effect of B[a]P on expression of CYP1A1. 	CYP1A1	13932	13938	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:100	Emphasis was placed on classical metabolic enzymes CYP1A1, CYP1B1, and CYP1A2 found in the skin and other organs^,. 	CYP1A1	14314	14320	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:100	Emphasis was placed on classical metabolic enzymes CYP1A1, CYP1B1, and CYP1A2 found in the skin and other organs^,. 	CYP1A1	14314	14320	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:103	In agreement with Costa et al.^, our RT-qPCR analyses unambiguously showed that exposure of human skin and NHK^, to B[a]P results in a time-dependent increase of CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	14752	14758	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:103	In agreement with Costa et al.^, our RT-qPCR analyses unambiguously showed that exposure of human skin and NHK^, to B[a]P results in a time-dependent increase of CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	14752	14758	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:119	Katiyar et al.^ reported that CYP1A1 and CYP1B1 were induced following Ultraviolet exposure at both the gene and protein level in human epidermis. 	CYP1A1	17035	17041	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:119	Katiyar et al.^ reported that CYP1A1 and CYP1B1 were induced following Ultraviolet exposure at both the gene and protein level in human epidermis. 	CYP1A1	17035	17041	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:121	Accordingly, we report that Ultraviolet alone increases expression of CYP1A1 by a factor approximately 5 in skin and 2 in Normal Human Keratinocytes, in the same range of low values observed by others^,,,,,. 	CYP1A1	17351	17357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:121	Accordingly, we report that Ultraviolet alone increases expression of CYP1A1 by a factor approximately 5 in skin and 2 in Normal Human Keratinocytes, in the same range of low values observed by others^,,,,,. 	CYP1A1	17351	17357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:124	Our experiments involving irradiation followed by B[a]P treatment rather showed that preliminary irradiation of skin explants strongly inhibited the induction of Phase I CYP1A1, CYP1A2, or CYP1B1 metabolism genes. 	CYP1A1	18030	18036	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:124	Our experiments involving irradiation followed by B[a]P treatment rather showed that preliminary irradiation of skin explants strongly inhibited the induction of Phase I CYP1A1, CYP1A2, or CYP1B1 metabolism genes. 	CYP1A1	18030	18036	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	CYP1A1	31620	31626	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	CYP1A1	31620	31626	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:29	CYP1A1 is an inducible isoform that can be regulated by aryl hydrocarbon receptors. 	CYP1A1	3846	3852	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:29	CYP1A1 is an inducible isoform that can be regulated by aryl hydrocarbon receptors. 	CYP1A1	3846	3852	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:63	None of the treatments statistically increased the mRNA levels of CYP1A1, although BETA-NF and EtOH showed a 1.6- and 1.9-fold increase, respectively (c). 	CYP1A1	8992	8998	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:63	None of the treatments statistically increased the mRNA levels of CYP1A1, although BETA-NF and EtOH showed a 1.6- and 1.9-fold increase, respectively (c). 	CYP1A1	8992	8998	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP1A1	9880	9886	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP1A1	9880	9886	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP1A1	10317	10323	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP1A1	10317	10323	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:89	Fluorescent images of CYP1A1 revealed no preferential localization of this isoform at mitochondria or Endoplasmic Reticulum, yet the R values showed to be slightly higher in Endoplasmic Reticulum. 	CYP1A1	12995	13001	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:89	Fluorescent images of CYP1A1 revealed no preferential localization of this isoform at mitochondria or Endoplasmic Reticulum, yet the R values showed to be slightly higher in Endoplasmic Reticulum. 	CYP1A1	12995	13001	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP1A1	13418	13424	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP1A1	13418	13424	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:112	On the other hand, CYP1A1 was unexpectedly not induced by BETA-NF. 	CYP1A1	16367	16373	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:112	On the other hand, CYP1A1 was unexpectedly not induced by BETA-NF. 	CYP1A1	16367	16373	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:115	On the contrary, in differentiated SH-SY5Y cells, this compound was able to increase the expression of CYP1A1 at 2.5 and 5 nM. 	CYP1A1	17020	17026	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:115	On the contrary, in differentiated SH-SY5Y cells, this compound was able to increase the expression of CYP1A1 at 2.5 and 5 nM. 	CYP1A1	17020	17026	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP1A1	19001	19007	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP1A1	19001	19007	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:139	Several studies indicated that, in human liver microsomes, CYP1A1, 1A2, 2E1, 2A6, and 2B6 are the major isoforms involved in ethoxycumarin O-dealkylation reaction, although other isoforms such as 1B1, 2C, and 2D6 can play a minor role. 	CYP1A1	20754	20760	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:139	Several studies indicated that, in human liver microsomes, CYP1A1, 1A2, 2E1, 2A6, and 2B6 are the major isoforms involved in ethoxycumarin O-dealkylation reaction, although other isoforms such as 1B1, 2C, and 2D6 can play a minor role. 	CYP1A1	20754	20760	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:161	The localization images of CYP1A1 and 3A4 showed no preferential localization of these isoforms for either mitochondria or Endoplasmic Reticulum, as also shown by other groups in several models. 	CYP1A1	24397	24403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:161	The localization images of CYP1A1 and 3A4 showed no preferential localization of these isoforms for either mitochondria or Endoplasmic Reticulum, as also shown by other groups in several models. 	CYP1A1	24397	24403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:184	The quantification of relative mRNA levels for the isoforms CYP1A1, 2D6 and 2E1 was carried out after incubation of SH-SY5Y cells for 48 h with BETA-NF (4 M), dissolved in dimethyl sulfoxide (DMSO; 0.1% maximum final concentration used, v/v), and EtOH (100 mM), dissolved in water. 	CYP1A1	27774	27780	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:184	The quantification of relative mRNA levels for the isoforms CYP1A1, 2D6 and 2E1 was carried out after incubation of SH-SY5Y cells for 48 h with BETA-NF (4 M), dissolved in dimethyl sulfoxide (DMSO; 0.1% maximum final concentration used, v/v), and EtOH (100 mM), dissolved in water. 	CYP1A1	27774	27780	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP1A1	28716	28722	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP1A1	28716	28722	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:196	The analysis of protein levels was performed for isoforms CYP1A1, 2D6, 2E1, and 3A4 in both undifferentiated and differentiated SH-SY5Y cells. 	CYP1A1	29795	29801	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:196	The analysis of protein levels was performed for isoforms CYP1A1, 2D6, 2E1, and 3A4 in both undifferentiated and differentiated SH-SY5Y cells. 	CYP1A1	29795	29801	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP1A1	30711	30717	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP1A1	30711	30717	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:26	To determine the effect of B[ALPHA]P on the gene signature in human T lymphocytes, primary cultures of T lymphocytes purified from healthy blood donors and activated with anti-CD3 and anti-CD28 antibodies for 72 h, were used and co-exposed to 2 M B[ALPHA]P for the last 48 h. We previously reported an early and functional up-regulation of the Aryl Hydrocarbon by such human T lymphocyte activation during 24 h, followed by a maximal response of target genes such as CYP1A1 and CYP1B1 after exposure to 2 M B[ALPHA]P. Such a 2 M concentration is in the range of B[ALPHA]P concentrations known to lead to maximal response of target genes in cultured human cells. 	CYP1A1	5440	5446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:26	To determine the effect of B[ALPHA]P on the gene signature in human T lymphocytes, primary cultures of T lymphocytes purified from healthy blood donors and activated with anti-CD3 and anti-CD28 antibodies for 72 h, were used and co-exposed to 2 M B[ALPHA]P for the last 48 h. We previously reported an early and functional up-regulation of the Aryl Hydrocarbon by such human T lymphocyte activation during 24 h, followed by a maximal response of target genes such as CYP1A1 and CYP1B1 after exposure to 2 M B[ALPHA]P. Such a 2 M concentration is in the range of B[ALPHA]P concentrations known to lead to maximal response of target genes in cultured human cells. 	CYP1A1	5440	5446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:31	Among these genes, as expected, CYP1A1 and CYP1B1, well-known targets of Aryl Hydrocarbon, appear as the top genes over-expressed after exposure to B[ALPHA]P, thus validating our experimental conditions. 	CYP1A1	6372	6378	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:31	Among these genes, as expected, CYP1A1 and CYP1B1, well-known targets of Aryl Hydrocarbon, appear as the top genes over-expressed after exposure to B[ALPHA]P, thus validating our experimental conditions. 	CYP1A1	6372	6378	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:33	We thus selected the most significantly affected genes: CYP1A1 and 1B1, gap junction beta-2 and beta-6 (GJB6) proteins, TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), transmembrane protein 167A, oligodendrocyte transcription factor 3, cyclin-dependent kinase-binding protein (CABLES1), proto-oncogene c-KIT and E3 ubiquitin ligase specificity subunit (ASB2) for the 10 most up-regulated genes; IFN-induced proteins 44L, 44 (IFI44), p78 (MX1) with tetratricopeptide repeats 2 (IFIT2), collagen (COL6A3), microcephalin MCPH1, lysosomal trafficking regulator, enzyme oligoadenylate synthetase like, proteoglycan (PRG4), and cell surface antigen (THY1) for the 10 most down-regulated ones. 	CYP1A1	6823	6829	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:33	We thus selected the most significantly affected genes: CYP1A1 and 1B1, gap junction beta-2 and beta-6 (GJB6) proteins, TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), transmembrane protein 167A, oligodendrocyte transcription factor 3, cyclin-dependent kinase-binding protein (CABLES1), proto-oncogene c-KIT and E3 ubiquitin ligase specificity subunit (ASB2) for the 10 most up-regulated genes; IFN-induced proteins 44L, 44 (IFI44), p78 (MX1) with tetratricopeptide repeats 2 (IFIT2), collagen (COL6A3), microcephalin MCPH1, lysosomal trafficking regulator, enzyme oligoadenylate synthetase like, proteoglycan (PRG4), and cell surface antigen (THY1) for the 10 most down-regulated ones. 	CYP1A1	6823	6829	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:35	Thus, CYP1A1, CYP1B1, Gap Junction Beta-2, GJB6, TIPARP, Oligodendrocyte Transcription Factor 3, CABLES1, KIT and ASB2 transcriptional levels were confirmed to be up-regulated after B[ALPHA]P exposure; with inductions reaching a significant level for all these genes except for Oligodendrocyte Transcription Factor 3 and TIPARP (A). 	CYP1A1	7680	7686	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:35	Thus, CYP1A1, CYP1B1, Gap Junction Beta-2, GJB6, TIPARP, Oligodendrocyte Transcription Factor 3, CABLES1, KIT and ASB2 transcriptional levels were confirmed to be up-regulated after B[ALPHA]P exposure; with inductions reaching a significant level for all these genes except for Oligodendrocyte Transcription Factor 3 and TIPARP (A). 	CYP1A1	7680	7686	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:40	Among genes belonging to Aryl Hydrocarbon signaling, we recently reported the regulation of CYP1A1, CYP1B1 and the cyclin-dependent kinase inhibitor 1A in human T lymphocytes upon exposure to B[ALPHA]P. The Aryl Hydrocarbon repressor, the cyclin E2 and the NAD(P)H dehydrogenase (NQO1) have already been reported to be robust targets of B[ALPHA]P but, in different cell types, but not in primary T lymphocytes. 	CYP1A1	9162	9168	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:40	Among genes belonging to Aryl Hydrocarbon signaling, we recently reported the regulation of CYP1A1, CYP1B1 and the cyclin-dependent kinase inhibitor 1A in human T lymphocytes upon exposure to B[ALPHA]P. The Aryl Hydrocarbon repressor, the cyclin E2 and the NAD(P)H dehydrogenase (NQO1) have already been reported to be robust targets of B[ALPHA]P but, in different cell types, but not in primary T lymphocytes. 	CYP1A1	9162	9168	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:41	We then validated by RT-qPCR assays these changes in Ahr Repressor, Cyclin E2, Cyclin-Dependent Kinase Inhibitor 1a, CYP1A1, CYP1B1, and NQO1 gene expression changes using the 16 individual RNA samples isolated from Concentration Of Dmso and B[ALPHA]P-treated T lymphocyte cultures (A). 	CYP1A1	9598	9604	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:41	We then validated by RT-qPCR assays these changes in Ahr Repressor, Cyclin E2, Cyclin-Dependent Kinase Inhibitor 1a, CYP1A1, CYP1B1, and NQO1 gene expression changes using the 16 individual RNA samples isolated from Concentration Of Dmso and B[ALPHA]P-treated T lymphocyte cultures (A). 	CYP1A1	9598	9604	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:67	Additionally, except for the Aryl Hydrocarbon target genes, CYP1A1 and CYP1B1, few of the 158 differentially expressed transcripts displayed strong amplitude in the changes observed. 	CYP1A1	16998	17004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:67	Additionally, except for the Aryl Hydrocarbon target genes, CYP1A1 and CYP1B1, few of the 158 differentially expressed transcripts displayed strong amplitude in the changes observed. 	CYP1A1	16998	17004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:70	Among genes identified by our study, some have already been described to be targeted by B[ALPHA]P. This is notably true for CYP1A1, CYP1B1, the ferredoxin reductase, NQO1, Cyclin-Dependent Kinase Inhibitor 1a, Ahr Repressor, ASB2 or TIPARP up-regulated genes and MX1 or the solute carrier SLC25A37, regarding the down-regulated ones. 	CYP1A1	17692	17698	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:70	Among genes identified by our study, some have already been described to be targeted by B[ALPHA]P. This is notably true for CYP1A1, CYP1B1, the ferredoxin reductase, NQO1, Cyclin-Dependent Kinase Inhibitor 1a, Ahr Repressor, ASB2 or TIPARP up-regulated genes and MX1 or the solute carrier SLC25A37, regarding the down-regulated ones. 	CYP1A1	17692	17698	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:76	Nevertheless, AhR- and p53-target genes such as CYP1A1, CYP1B1, Ahr Repressor, ASB2 or Cyclin-Dependent Kinase Inhibitor 1a and the ribonucleotide reductase RRM2B were shown to be modulated in both type of cells, all encoding enzymes important in the detoxication and the DNA damage response induced after B[ALPHA]P exposure. 	CYP1A1	18881	18887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:76	Nevertheless, AhR- and p53-target genes such as CYP1A1, CYP1B1, Ahr Repressor, ASB2 or Cyclin-Dependent Kinase Inhibitor 1a and the ribonucleotide reductase RRM2B were shown to be modulated in both type of cells, all encoding enzymes important in the detoxication and the DNA damage response induced after B[ALPHA]P exposure. 	CYP1A1	18881	18887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:38	Hitoshi et al reported that SWCNT also downregulated genes coding other CYP isoenzymes, namely, CYP1A1 and CYP1B1. 	CYP1A1	5793	5799	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:38	Hitoshi et al reported that SWCNT also downregulated genes coding other CYP isoenzymes, namely, CYP1A1 and CYP1B1. 	CYP1A1	5793	5799	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:191	In other studies by Hitoshi et al, multi-walled carbon nanotubes downregulated CYP1A1 and in HepG2 cells by repression of AhR binding to the enhancer region. 	CYP1A1	31770	31776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:191	In other studies by Hitoshi et al, multi-walled carbon nanotubes downregulated CYP1A1 and in HepG2 cells by repression of AhR binding to the enhancer region. 	CYP1A1	31770	31776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:41	The enzymes used were CYP1A1 (Lot No. 	CYP1A1	8208	8214	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:41	The enzymes used were CYP1A1 (Lot No. 	CYP1A1	8208	8214	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A1	19969	19975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A1	19969	19975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A1	24515	24521	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A1	24515	24521	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	17977	17983	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	17977	17983	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP1A1	70351	70357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP1A1	70351	70357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A1	70523	70529	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A1	70523	70529	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A1	70856	70862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A1	70856	70862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A1	2010	2016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A1	2010	2016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2244	2250	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2244	2250	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2358	2364	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2358	2364	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:17	Although the transcriptional regulation of CYP1A1 and 1A2 may be simultaneously controlled by bidirectional gene elements, their expression patterns are different. 	CYP1A1	2422	2428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:17	Although the transcriptional regulation of CYP1A1 and 1A2 may be simultaneously controlled by bidirectional gene elements, their expression patterns are different. 	CYP1A1	2422	2428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A1	2628	2634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A1	2628	2634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP1A2	910	916	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP1A2	910	916	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:26	In addition, studies have showed association between rs2606345 in CYP1A1 gene and North Indian women with epilepsy, and between rs762551 in CYP1A2 and CBZ pharmacokinetics in children diagnosed with partial or generalized tonic-clonic seizures. 	CYP1A2	4389	4395	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:26	In addition, studies have showed association between rs2606345 in CYP1A1 gene and North Indian women with epilepsy, and between rs762551 in CYP1A2 and CBZ pharmacokinetics in children diagnosed with partial or generalized tonic-clonic seizures. 	CYP1A2	4389	4395	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP1A2	4747	4753	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP1A2	4747	4753	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:110	As illustrated in, SNP rs2472306 in CYP1A2 was the most important variable in the prediction model (MDA = 25.3), followed by the presence of HS on MRI (MDA = 25.2). 	CYP1A2	18927	18933	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:110	As illustrated in, SNP rs2472306 in CYP1A2 was the most important variable in the prediction model (MDA = 25.3), followed by the presence of HS on MRI (MDA = 25.2). 	CYP1A2	18927	18933	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP1A2	19846	19852	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP1A2	19846	19852	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:191	Dose- and time-dependent induction of CYP1A1 and CYP1A2 was detected in the livers of female rats exposed to TCDD or the tertiary mixture, which is also in accordance with our results of DNA oxidation products. 	CYP1A2	34061	34067	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:191	Dose- and time-dependent induction of CYP1A1 and CYP1A2 was detected in the livers of female rats exposed to TCDD or the tertiary mixture, which is also in accordance with our results of DNA oxidation products. 	CYP1A2	34061	34067	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:197	Although the 2-year tumor incidence data support the application of the TEF approach in the risk assessment of DLCs based on the generation of similar dose-response curves in response to TCDD and the tertiary mixture exposed female rats,^ the TEF approach cannot be applied to evaluate the DNA oxidation products in this study, CYP1A1 or CYP1A2 induction, or oxidative biomarkers. 	CYP1A2	35396	35402	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:197	Although the 2-year tumor incidence data support the application of the TEF approach in the risk assessment of DLCs based on the generation of similar dose-response curves in response to TCDD and the tertiary mixture exposed female rats,^ the TEF approach cannot be applied to evaluate the DNA oxidation products in this study, CYP1A1 or CYP1A2 induction, or oxidative biomarkers. 	CYP1A2	35396	35402	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP1A2	1058	1064	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP1A2	1058	1064	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP1A2	1400	1406	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP1A2	1400	1406	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP1A2	4809	4815	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP1A2	4809	4815	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP1A2	5180	5186	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP1A2	5180	5186	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP1A2	7350	7356	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP1A2	7350	7356	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP1A2	7524	7530	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP1A2	7524	7530	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:29	Other methylenedioxyphenyl compounds such as myristicin and podophyllotoxin exhibited mechanism-based inactivation of CYP1A2 and CYP3A4, respectively, in human liver microsomes. 	CYP1A2	8293	8299	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:29	Other methylenedioxyphenyl compounds such as myristicin and podophyllotoxin exhibited mechanism-based inactivation of CYP1A2 and CYP3A4, respectively, in human liver microsomes. 	CYP1A2	8293	8299	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP1A2	11738	11744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP1A2	11738	11744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP1A2	18567	18573	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP1A2	18567	18573	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP1A2	18754	18760	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP1A2	18754	18760	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP1A2	487	493	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP1A2	487	493	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	721	727	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	721	727	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	1044	1050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	1044	1050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP1A2	2033	2039	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP1A2	2033	2039	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP1A2	2289	2295	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP1A2	2289	2295	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP1A2	4914	4920	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP1A2	4914	4920	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:27	CYP1A2 and CYP3A4 were assumed to be the major enzymes responsible for the N-demethylation pathway, and several clinical reports provided indirect evidence for their participation in clozapine metabolism. 	CYP1A2	5197	5203	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:27	CYP1A2 and CYP3A4 were assumed to be the major enzymes responsible for the N-demethylation pathway, and several clinical reports provided indirect evidence for their participation in clozapine metabolism. 	CYP1A2	5197	5203	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:28	Concomitant treatment with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, CYP2C19, CYP3A4), significantly decreased the plasma norclozapine/clozapine ratios and patients clozapine dose requirement (;. 	CYP1A2	5480	5486	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:28	Concomitant treatment with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, CYP2C19, CYP3A4), significantly decreased the plasma norclozapine/clozapine ratios and patients clozapine dose requirement (;. 	CYP1A2	5480	5486	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:29	Cigarette smoking, inducing CYP1A2 expression, seems to increase clozapine clearance; however, CYP1A2 genetic polymorphisms do not have significant clinical effect. 	CYP1A2	5643	5649	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:29	Cigarette smoking, inducing CYP1A2 expression, seems to increase clozapine clearance; however, CYP1A2 genetic polymorphisms do not have significant clinical effect. 	CYP1A2	5643	5649	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:29	Cigarette smoking, inducing CYP1A2 expression, seems to increase clozapine clearance; however, CYP1A2 genetic polymorphisms do not have significant clinical effect. 	CYP1A2	5710	5716	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:29	Cigarette smoking, inducing CYP1A2 expression, seems to increase clozapine clearance; however, CYP1A2 genetic polymorphisms do not have significant clinical effect. 	CYP1A2	5710	5716	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP1A2	6607	6613	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP1A2	6607	6613	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP1A2	6691	6697	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP1A2	6691	6697	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP1A2	8389	8395	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP1A2	8389	8395	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	8931	8937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	8931	8937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9004	9010	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9004	9010	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9030	9036	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9030	9036	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9063	9069	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9063	9069	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9108	9114	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:50	Since CYP1A2 expression was found to be poorly associated with the presence of CYP1A2 SNPs, the patients CYP1A2 activity was estimated by CYP1A2 mRNA levels in leukocytes, and not by CYP1A2-genotype. 	CYP1A2	9108	9114	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:52	The quantities of CYP1A2 and CYP3A4 mRNAs relative to that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined. 	CYP1A2	9461	9467	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:52	The quantities of CYP1A2 and CYP3A4 mRNAs relative to that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined. 	CYP1A2	9461	9467	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:55	The cut-off values for CYP mRNA levels in leukocytes have been previously established on the basis of the cut-off values for the hepatic CYP enzyme activities (CYP1A2: phenacetin O-dealkylation; CYP3A4: nifedipine oxidation or midazolam 1- and 4-hydroxylation). 	CYP1A2	10030	10036	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:55	The cut-off values for CYP mRNA levels in leukocytes have been previously established on the basis of the cut-off values for the hepatic CYP enzyme activities (CYP1A2: phenacetin O-dealkylation; CYP3A4: nifedipine oxidation or midazolam 1- and 4-hydroxylation). 	CYP1A2	10030	10036	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:56	The cut-off values for CYP1A2 (10^-5 and 5*10^-4) and CYP3A4 (10^-6 and 10^-4) allowed a distinction between low, normal, and high expressers. 	CYP1A2	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:56	The cut-off values for CYP1A2 (10^-5 and 5*10^-4) and CYP3A4 (10^-6 and 10^-4) allowed a distinction between low, normal, and high expressers. 	CYP1A2	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP1A2	11147	11153	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP1A2	11147	11153	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13798	13804	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13798	13804	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13891	13897	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13891	13897	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13959	13965	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13959	13965	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13999	14005	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:77	CYP1A2 expression assays revealed that a substantial portion of the patients (70.7%) was low CYP1A2 expressers and less than one-third of the patients expressed CYP1A2 at normal level, whereas no high CYP1A2 expresser was found. 	CYP1A2	13999	14005	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14058	14064	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14058	14064	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14077	14083	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14077	14083	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14209	14215	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:78	Smoking is a potent inducer of CYP1A2, increasing CYP1A2 expression and enzyme activity; however, in the present study, the smoker/nonsmoker ratio was the same in the low and normal CYP1A2 expresser groups (10:17 vs 25:40, P=1.00). 	CYP1A2	14209	14215	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:79	Furthermore, the normalized clozapine concentrations were comparable in the patients expressing CYP1A2 at low and normal level (P=.6639). 	CYP1A2	14355	14361	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:79	Furthermore, the normalized clozapine concentrations were comparable in the patients expressing CYP1A2 at low and normal level (P=.6639). 	CYP1A2	14355	14361	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP1A2	16168	16174	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP1A2	16168	16174	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:110	The formation of both principal metabolites widely varied in individuals; however, the serum concentrations of clozapine metabolites appeared to be associated merely with the patients CYP3A4 expression and not with CYP1A2 mRNA levels. 	CYP1A2	20332	20338	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:110	The formation of both principal metabolites widely varied in individuals; however, the serum concentrations of clozapine metabolites appeared to be associated merely with the patients CYP3A4 expression and not with CYP1A2 mRNA levels. 	CYP1A2	20332	20338	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:115	Nevertheless, the norclozapine/clozapine concentration ratios were comparable in patients expressing CYP1A2 at a low or normal level (0.69880.2341 vs 0.70700.1824; P=0.3966). 	CYP1A2	21180	21186	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:115	Nevertheless, the norclozapine/clozapine concentration ratios were comparable in patients expressing CYP1A2 at a low or normal level (0.69880.2341 vs 0.70700.1824; P=0.3966). 	CYP1A2	21180	21186	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP1A2	22340	22346	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP1A2	22340	22346	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:125	CYP1A2 is considered to be one of the major enzymes responsible for clozapine biotransformation, which was confirmed by several clinical data. 	CYP1A2	23273	23279	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:125	CYP1A2 is considered to be one of the major enzymes responsible for clozapine biotransformation, which was confirmed by several clinical data. 	CYP1A2	23273	23279	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23429	23435	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23429	23435	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23589	23595	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23589	23595	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23635	23641	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:126	Induction of CYP1A2 by the components of cigarette smoke seems to increase clozapine dose requirement, primarily of male smokers; however, the patients with the polymorphic CYP1A2*1F allele, resulting in an increase in CYP1A2 inducibility, did not require dose adjustment. 	CYP1A2	23635	23641	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:127	On the other hand,  demonstrated an association between the frequency of clozapine-induced adverse reactions and the occurrence of the low activity CYP1A2*1C allele in patients. 	CYP1A2	23837	23843	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:127	On the other hand,  demonstrated an association between the frequency of clozapine-induced adverse reactions and the occurrence of the low activity CYP1A2*1C allele in patients. 	CYP1A2	23837	23843	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:128	The CYP1A2 substrate caffeine has been reported to inhibit clozapine metabolism, and caffeine consumption in a daily dose of 400 to 1000 mg significantly decreased clozapine clearance (;. 	CYP1A2	23871	23877	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:128	The CYP1A2 substrate caffeine has been reported to inhibit clozapine metabolism, and caffeine consumption in a daily dose of 400 to 1000 mg significantly decreased clozapine clearance (;. 	CYP1A2	23871	23877	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:129	The adjunctive fluvoxamine to ongoing clozapine therapy was found to increase clozapine plasma concentration, moreover resulting in toxic serum concentration, which was attributed to CYP1A2 inhibition by fluvoxamine (;. 	CYP1A2	24238	24244	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:129	The adjunctive fluvoxamine to ongoing clozapine therapy was found to increase clozapine plasma concentration, moreover resulting in toxic serum concentration, which was attributed to CYP1A2 inhibition by fluvoxamine (;. 	CYP1A2	24238	24244	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:130	It should be noted that fluvoxamine is not a CYP1A2-selective inhibitor, but significantly blocks the activities of other CYPs, notably it irreversibly inhibits CYP3A4 by forming a metabolic intermediate complex. 	CYP1A2	24320	24326	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:130	It should be noted that fluvoxamine is not a CYP1A2-selective inhibitor, but significantly blocks the activities of other CYPs, notably it irreversibly inhibits CYP3A4 by forming a metabolic intermediate complex. 	CYP1A2	24320	24326	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:131	The clinical observations on the dominant role of CYP1A2 were not confirmed by our findings that the patients CYP3A status rather than their CYP1A2 expression was associated with normalized clozapine concentrations. 	CYP1A2	24538	24544	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:131	The clinical observations on the dominant role of CYP1A2 were not confirmed by our findings that the patients CYP3A status rather than their CYP1A2 expression was associated with normalized clozapine concentrations. 	CYP1A2	24538	24544	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:131	The clinical observations on the dominant role of CYP1A2 were not confirmed by our findings that the patients CYP3A status rather than their CYP1A2 expression was associated with normalized clozapine concentrations. 	CYP1A2	24629	24635	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:131	The clinical observations on the dominant role of CYP1A2 were not confirmed by our findings that the patients CYP3A status rather than their CYP1A2 expression was associated with normalized clozapine concentrations. 	CYP1A2	24629	24635	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:132	The relative importance of CYP3A4 in clozapine clearance, particularly in patients with low CYP1A2 activity, may be higher than it has been previously considered (;.  	CYP1A2	24796	24802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:132	The relative importance of CYP3A4 in clozapine clearance, particularly in patients with low CYP1A2 activity, may be higher than it has been previously considered (;.  	CYP1A2	24796	24802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:133	suggested further research with the potential to demonstrate the critical roles of CYPs other than CYP1A2 for the elucidation of individual differences in clozapine metabolism. 	CYP1A2	24970	24976	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:133	suggested further research with the potential to demonstrate the critical roles of CYPs other than CYP1A2 for the elucidation of individual differences in clozapine metabolism. 	CYP1A2	24970	24976	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP1A2	25590	25596	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP1A2	25590	25596	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP1A2	25678	25684	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP1A2	25678	25684	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:136	Although the majority of the patients with schizophrenia were smokers evoking high CYP1A2 activity, in the present study, only 38% of the patients were current smokers and 4 subjects (4.3%) were heavy smokers (>20 cigarettes/d). 	CYP1A2	25820	25826	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:136	Although the majority of the patients with schizophrenia were smokers evoking high CYP1A2 activity, in the present study, only 38% of the patients were current smokers and 4 subjects (4.3%) were heavy smokers (>20 cigarettes/d). 	CYP1A2	25820	25826	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP1A2	25991	25997	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP1A2	25991	25997	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:144	The patients caffeine consumption data were not available, and the CYP1A2 inhibitory effect on clozapine clearance therefore could not be taken into account. 	CYP1A2	27447	27453	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:144	The patients caffeine consumption data were not available, and the CYP1A2 inhibitory effect on clozapine clearance therefore could not be taken into account. 	CYP1A2	27447	27453	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:154	Although the present work involved a limited number of patients and further investigation enrolling larger cohort is required, it clearly demonstrated that CYP3A status could be the major determinant of normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	29494	29500	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:154	Although the present work involved a limited number of patients and further investigation enrolling larger cohort is required, it clearly demonstrated that CYP3A status could be the major determinant of normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP1A2	29494	29500	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP1A2	2159	2165	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP1A2	2159	2165	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP1A2	38310	38316	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP1A2	38310	38316	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP1A2	15773	15779	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP1A2	15773	15779	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP1A2	35842	35848	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP1A2	35842	35848	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:216	Therefore, considering the toxicity of the compounds at 10 M, we can extrapolate that only CYP1A2 shows around 50% of inhibition at 4 M in the combination studies. 	CYP1A2	37392	37398	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:216	Therefore, considering the toxicity of the compounds at 10 M, we can extrapolate that only CYP1A2 shows around 50% of inhibition at 4 M in the combination studies. 	CYP1A2	37392	37398	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP1A2	3656	3662	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP1A2	3656	3662	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP1A2	4526	4532	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP1A2	4526	4532	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP1A2	5653	5659	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP1A2	5653	5659	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP1A2	16984	16990	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP1A2	16984	16990	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP1A2	17458	17464	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP1A2	17458	17464	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP1A2	17768	17774	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP1A2	17768	17774	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP1A2	21671	21677	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP1A2	21671	21677	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	CYP1A2	1114	1120	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	CYP1A2	1114	1120	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:10	These findings suggest that measuring the activity of CYP1A2, 2B6, 2C9, and 2C19 allowed us to accurately predict CYP2A6-, 2C8-, 2D6-, 2E1-, and 3A4/5-mediated activities in vitro and in vivo and may possibly be helpful for the assessment of an individuals drug metabolic profile. 	CYP1A2	1583	1589	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:10	These findings suggest that measuring the activity of CYP1A2, 2B6, 2C9, and 2C19 allowed us to accurately predict CYP2A6-, 2C8-, 2D6-, 2E1-, and 3A4/5-mediated activities in vitro and in vivo and may possibly be helpful for the assessment of an individuals drug metabolic profile. 	CYP1A2	1583	1589	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP1A2	8220	8226	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP1A2	8220	8226	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	11318	11324	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	11318	11324	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	CYP1A2	14530	14536	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	CYP1A2	14530	14536	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	CYP1A2	15024	15030	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	CYP1A2	15024	15030	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	CYP1A2	15682	15688	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	CYP1A2	15682	15688	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP1A2	16249	16255	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP1A2	16249	16255	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	16616	16622	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	16616	16622	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	16670	16676	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	16670	16676	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	17152	17158	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP1A2	17152	17158	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	24373	24379	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	24373	24379	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	27693	27699	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	CYP1A2	27693	27699	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP1A2	153	159	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP1A2	153	159	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP1A2	1177	1183	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP1A2	1177	1183	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP1A2	1352	1358	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP1A2	1352	1358	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP1A2	1796	1802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP1A2	1796	1802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP1A2	4657	4663	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP1A2	4657	4663	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP1A2	5802	5808	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP1A2	5802	5808	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	8769	8775	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	8769	8775	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	8990	8996	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	8990	8996	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	10269	10275	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	10269	10275	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	10488	10494	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP1A2	10488	10494	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:56	AHR and Pregnane X Receptor are reported to regulate the expression of CYP1A2 and CYP3A4^. 	CYP1A2	10877	10883	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:56	AHR and Pregnane X Receptor are reported to regulate the expression of CYP1A2 and CYP3A4^. 	CYP1A2	10877	10883	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP1A2	16729	16735	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP1A2	16729	16735	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17232	17238	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17232	17238	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17305	17311	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17305	17311	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17530	17536	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP1A2	17530	17536	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP1A2	17644	17650	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP1A2	17644	17650	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:94	Aryl Hydrocarbon Receptor and Pregnane X Receptor are found to be responsible for regulating the transcriptional expression of CYP1A2 and CYP3A4^,. 	CYP1A2	17912	17918	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:94	Aryl Hydrocarbon Receptor and Pregnane X Receptor are found to be responsible for regulating the transcriptional expression of CYP1A2 and CYP3A4^,. 	CYP1A2	17912	17918	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:95	In this study, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside promoted the nuclear translocation of Aryl Hydrocarbon Receptor and Pregnane X Receptor both in vivo and in vitro, which may contribute to the increased expression of CYP1A2 and CYP3A4 induced by 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside. 	CYP1A2	18165	18171	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:95	In this study, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside promoted the nuclear translocation of Aryl Hydrocarbon Receptor and Pregnane X Receptor both in vivo and in vitro, which may contribute to the increased expression of CYP1A2 and CYP3A4 induced by 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside. 	CYP1A2	18165	18171	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:97	Additionally, Aryl Hydrocarbon Receptor or Pregnane X Receptor inhibitors reduced the expression and activity of hepatic CYP1A2 and CYP3A4 in mice. 	CYP1A2	18569	18575	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:97	Additionally, Aryl Hydrocarbon Receptor or Pregnane X Receptor inhibitors reduced the expression and activity of hepatic CYP1A2 and CYP3A4 in mice. 	CYP1A2	18569	18575	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP1A2	19105	19111	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP1A2	19105	19111	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP1A2	19994	20000	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP1A2	19994	20000	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP1A2	20551	20557	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP1A2	20551	20557	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP1A2	24378	24384	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP1A2	24378	24384	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP1A2	28827	28833	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP1A2	28827	28833	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP1A2	28902	28908	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP1A2	28902	28908	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:187	The activity of 7-methoxyresorufin-O-demethylase is the diagnostic marker of CYP1A2. 	CYP1A2	29269	29275	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:187	The activity of 7-methoxyresorufin-O-demethylase is the diagnostic marker of CYP1A2. 	CYP1A2	29269	29275	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:188	The activity of CYP1A2 was determined by fluorescence value of resorufin conversed from 7-methoxyresorufin by 7-Methoxyresorufin-O-Demethylase. 	CYP1A2	29293	29299	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:188	The activity of CYP1A2 was determined by fluorescence value of resorufin conversed from 7-methoxyresorufin by 7-Methoxyresorufin-O-Demethylase. 	CYP1A2	29293	29299	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP1A2	30051	30057	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP1A2	30051	30057	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:163	Various studies highlighted the interactions between tetramethoxystilbene and the AhR-CYP1A signaling pathway and define as substrates and inhibitors of CYP1A1, CYP1A2 and CYP1B1 enzymes. 	CYP1A2	25810	25816	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:163	Various studies highlighted the interactions between tetramethoxystilbene and the AhR-CYP1A signaling pathway and define as substrates and inhibitors of CYP1A1, CYP1A2 and CYP1B1 enzymes. 	CYP1A2	25810	25816	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	CYP1A2	25979	25985	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:164	A series of stilbene derivatives were synthesized to study their role in inhibiting human recombinant cytochrome P450 (CYPs): CYP1B1, CYP1A1, CYP1A2. 	CYP1A2	25979	25985	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:165	Among all the studies, compound tetramethoxystilbene was found to be more potent and selective in inhibiting CYP1A1, CYP1A2 and CYP1B1 activities. 	CYP1A2	26104	26110	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:165	Among all the studies, compound tetramethoxystilbene was found to be more potent and selective in inhibiting CYP1A1, CYP1A2 and CYP1B1 activities. 	CYP1A2	26104	26110	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP1A2	41286	41292	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP1A2	41286	41292	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:233	Results showed potent inhibitory activity of A. Lancea on CYP1A2-mediated phenacetin O-deethylation with mean IC_50 of 0.36 g/ml (36-fold of the inhibitor ALPHA-naphthoflavone). 	CYP1A2	41452	41458	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:233	Results showed potent inhibitory activity of A. Lancea on CYP1A2-mediated phenacetin O-deethylation with mean IC_50 of 0.36 g/ml (36-fold of the inhibitor ALPHA-naphthoflavone). 	CYP1A2	41452	41458	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:234	Inhibition of CYP1A2 by A. Lancea extract should be beneficial to Compared With Human Embryonic Fibroblast Cell Oums-36t prevention and/or therapy in view of the contribution of CYP1A2 in carcinogenesis of Compared With Human Embryonic Fibroblast Cell Oums-36t. 	CYP1A2	41586	41592	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:234	Inhibition of CYP1A2 by A. Lancea extract should be beneficial to Compared With Human Embryonic Fibroblast Cell Oums-36t prevention and/or therapy in view of the contribution of CYP1A2 in carcinogenesis of Compared With Human Embryonic Fibroblast Cell Oums-36t. 	CYP1A2	41586	41592	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:234	Inhibition of CYP1A2 by A. Lancea extract should be beneficial to Compared With Human Embryonic Fibroblast Cell Oums-36t prevention and/or therapy in view of the contribution of CYP1A2 in carcinogenesis of Compared With Human Embryonic Fibroblast Cell Oums-36t. 	CYP1A2	41750	41756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:234	Inhibition of CYP1A2 by A. Lancea extract should be beneficial to Compared With Human Embryonic Fibroblast Cell Oums-36t prevention and/or therapy in view of the contribution of CYP1A2 in carcinogenesis of Compared With Human Embryonic Fibroblast Cell Oums-36t. 	CYP1A2	41750	41756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP1A2	8790	8796	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP1A2	8790	8796	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:52	CYP1A2 is a highly polymorphic enzyme responsible for the metabolism of many drugs including clozapine, mirtazapine, theophylline, tizanidine and triamterene. 	CYP1A2	10091	10097	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:52	CYP1A2 is a highly polymorphic enzyme responsible for the metabolism of many drugs including clozapine, mirtazapine, theophylline, tizanidine and triamterene. 	CYP1A2	10091	10097	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:53	CYP1A2*1F is associated with increased enzyme activity in the presence of an inducer, such as high caffeine consumption or heavy cigarette use. 	CYP1A2	10250	10256	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:53	CYP1A2*1F is associated with increased enzyme activity in the presence of an inducer, such as high caffeine consumption or heavy cigarette use. 	CYP1A2	10250	10256	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:55	found that the CYP1A2*1F allele was present at a MAF of 66.6% in the Amerindian population (Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo). 	CYP1A2	10425	10431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:55	found that the CYP1A2*1F allele was present at a MAF of 66.6% in the Amerindian population (Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo). 	CYP1A2	10425	10431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:56	Using 100 mg of caffeine, as part of a probe drug cocktail for phenotyping, no association between CYP1A2*1F and higher enzyme activity was observed. 	CYP1A2	10676	10682	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:56	Using 100 mg of caffeine, as part of a probe drug cocktail for phenotyping, no association between CYP1A2*1F and higher enzyme activity was observed. 	CYP1A2	10676	10682	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:57	However, the CYP1A2*1F variant does not confer high constitutive activity but rather increases enzyme inducibility with exposure to an inducer, so the lack of genotype-phenotype association could be due to the fact that subjects were not stratified by their level of intake of a CYP1A2 inducer, such as high dose caffeine. 	CYP1A2	10740	10746	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:57	However, the CYP1A2*1F variant does not confer high constitutive activity but rather increases enzyme inducibility with exposure to an inducer, so the lack of genotype-phenotype association could be due to the fact that subjects were not stratified by their level of intake of a CYP1A2 inducer, such as high dose caffeine. 	CYP1A2	10740	10746	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:57	However, the CYP1A2*1F variant does not confer high constitutive activity but rather increases enzyme inducibility with exposure to an inducer, so the lack of genotype-phenotype association could be due to the fact that subjects were not stratified by their level of intake of a CYP1A2 inducer, such as high dose caffeine. 	CYP1A2	11006	11012	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:57	However, the CYP1A2*1F variant does not confer high constitutive activity but rather increases enzyme inducibility with exposure to an inducer, so the lack of genotype-phenotype association could be due to the fact that subjects were not stratified by their level of intake of a CYP1A2 inducer, such as high dose caffeine. 	CYP1A2	11006	11012	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:264	For example, despite the fact that CYP1A2 is a highly polymorphic enzyme important for the metabolism of many clinical drugs, no studies to date have assessed the frequencies of CYP1A2 allelic variants in Indigenous peoples of Canada or AIAN populations. 	CYP1A2	40731	40737	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:264	For example, despite the fact that CYP1A2 is a highly polymorphic enzyme important for the metabolism of many clinical drugs, no studies to date have assessed the frequencies of CYP1A2 allelic variants in Indigenous peoples of Canada or AIAN populations. 	CYP1A2	40731	40737	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:264	For example, despite the fact that CYP1A2 is a highly polymorphic enzyme important for the metabolism of many clinical drugs, no studies to date have assessed the frequencies of CYP1A2 allelic variants in Indigenous peoples of Canada or AIAN populations. 	CYP1A2	40874	40880	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:264	For example, despite the fact that CYP1A2 is a highly polymorphic enzyme important for the metabolism of many clinical drugs, no studies to date have assessed the frequencies of CYP1A2 allelic variants in Indigenous peoples of Canada or AIAN populations. 	CYP1A2	40874	40880	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:35	Previous studies have suggested that Glycine N-Methyltransferase may participate in and serve as a cofactor for the regulation of detoxification gene expression, such as CYP 1A1 and CYP1A2, thereby decreasing the formations of BaP- and AFB1-DNA adducts^-. 	CYP1A2	6124	6130	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:35	Previous studies have suggested that Glycine N-Methyltransferase may participate in and serve as a cofactor for the regulation of detoxification gene expression, such as CYP 1A1 and CYP1A2, thereby decreasing the formations of BaP- and AFB1-DNA adducts^-. 	CYP1A2	6124	6130	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:53	CYP1A2, CYP1A1 and NQO1 have been reported to be the major enzymes involved in AAI metabolism^,,,. 	CYP1A2	8566	8572	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:53	CYP1A2, CYP1A1 and NQO1 have been reported to be the major enzymes involved in AAI metabolism^,,,. 	CYP1A2	8566	8572	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:54	To examine whether Glycine N-Methyltransferase participates in AAI-induced nephropathy, the levels of mRNA expression for Glycine N-Methyltransferase, CYP1A1, CYP1A2, and NQO1 in mouse livers and kidneys were determined using real-time quantitative PCR analysis. 	CYP1A2	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:54	To examine whether Glycine N-Methyltransferase participates in AAI-induced nephropathy, the levels of mRNA expression for Glycine N-Methyltransferase, CYP1A1, CYP1A2, and NQO1 in mouse livers and kidneys were determined using real-time quantitative PCR analysis. 	CYP1A2	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:55	In both sexes, the liver Glycine N-Methyltransferase and CYP1A2 mRNA levels decreased and liver NQO1 mRNA levels increased significantly after 3 weeks of AAI exposure. 	CYP1A2	8985	8991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:55	In both sexes, the liver Glycine N-Methyltransferase and CYP1A2 mRNA levels decreased and liver NQO1 mRNA levels increased significantly after 3 weeks of AAI exposure. 	CYP1A2	8985	8991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:68	The kidney Glycine N-Methyltransferase, NQO1 and CYP1A2 mRNA levels were decreased in all groups after AAI treatment (Supplementary Fig. 	CYP1A2	10851	10857	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:68	The kidney Glycine N-Methyltransferase, NQO1 and CYP1A2 mRNA levels were decreased in all groups after AAI treatment (Supplementary Fig. 	CYP1A2	10851	10857	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:128	In mice, CYP1A1, CYP1A2 and CYP3A44/3A41 are almost not expressed in kidney^. 	CYP1A2	22218	22224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:128	In mice, CYP1A1, CYP1A2 and CYP3A44/3A41 are almost not expressed in kidney^. 	CYP1A2	22218	22224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:6	Further analysis of other crude extracts demonstrated potent inhibition of CYP1A2 activity for a dried plant ethanol extract (1.5 g/mL), fresh plant ethanol extract (3.9 g/mL), and moderate activity for a fresh plant aqueous extract (27.8 g/mL). 	CYP1A2	882	888	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:6	Further analysis of other crude extracts demonstrated potent inhibition of CYP1A2 activity for a dried plant ethanol extract (1.5 g/mL), fresh plant ethanol extract (3.9 g/mL), and moderate activity for a fresh plant aqueous extract (27.8 g/mL). 	CYP1A2	882	888	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:9	Individual screening of these phytochemicals against the activity of CYP1A2 identified yatein as a moderate inhibitor (71.9 M), likely to contribute to the plant extracts potent bioactivity. 	CYP1A2	1439	1445	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:9	Individual screening of these phytochemicals against the activity of CYP1A2 identified yatein as a moderate inhibitor (71.9 M), likely to contribute to the plant extracts potent bioactivity. 	CYP1A2	1439	1445	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:25	This latest study set out to investigate the inhibitory impact of various extracts of H. verticillata on a number of key drug metabolizing CYP450 enzymes, its characterisation and further impact on CYP1A2, representing the first such in vitro evaluation for this plant, and to add to the growing list of screened Caribbean medicinal plants. 	CYP1A2	4320	4326	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:25	This latest study set out to investigate the inhibitory impact of various extracts of H. verticillata on a number of key drug metabolizing CYP450 enzymes, its characterisation and further impact on CYP1A2, representing the first such in vitro evaluation for this plant, and to add to the growing list of screened Caribbean medicinal plants. 	CYP1A2	4320	4326	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:38	Both fresh and dry ethanol extracts and the dry aqueous extract demonstrated potent inhibition of CYP1A2 activity with the dry plant ethanol extract demonstrating the most potent inhibition (1.5 g/mL). 	CYP1A2	6714	6720	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:38	Both fresh and dry ethanol extracts and the dry aqueous extract demonstrated potent inhibition of CYP1A2 activity with the dry plant ethanol extract demonstrating the most potent inhibition (1.5 g/mL). 	CYP1A2	6714	6720	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:39	The dry aqueous extract potently inhibited CYP1A2 activity and was close in potency at 1.9 g/mL to the dry plant ethanol extract and was more potent than the fresh plant ethanol extract (3.9 g/mL). 	CYP1A2	6861	6867	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:39	The dry aqueous extract potently inhibited CYP1A2 activity and was close in potency at 1.9 g/mL to the dry plant ethanol extract and was more potent than the fresh plant ethanol extract (3.9 g/mL). 	CYP1A2	6861	6867	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:40	The fresh plant aqueous extract moderately inhibited CYP1A2 activity (27.8 g/mL). 	CYP1A2	7069	7075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:40	The fresh plant aqueous extract moderately inhibited CYP1A2 activity (27.8 g/mL). 	CYP1A2	7069	7075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:50	Key phytochemicals were individually assessed for their impact on CYP1A2 activity. 	CYP1A2	9045	9051	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:50	Key phytochemicals were individually assessed for their impact on CYP1A2 activity. 	CYP1A2	9045	9051	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:53	The mix of five lignans demonstrated moderate inhibition against the activity of CYP1A2 (61.8 g/mL). 	CYP1A2	9382	9388	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:53	The mix of five lignans demonstrated moderate inhibition against the activity of CYP1A2 (61.8 g/mL). 	CYP1A2	9382	9388	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:54	In comparison H. verticillata aqueous extract (dried aerial plant material) demonstrated potent inhibition of CYP1A2 activity (1.9 g/mL). 	CYP1A2	9512	9518	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:54	In comparison H. verticillata aqueous extract (dried aerial plant material) demonstrated potent inhibition of CYP1A2 activity (1.9 g/mL). 	CYP1A2	9512	9518	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:55	The IC_50 values determined for-yatein (71.9 M), demonstrated moderate inhibition, and BETA-sitosterol (160.1 M) demonstrated weak inhibition against the activity of CYP1A2. 	CYP1A2	9706	9712	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:55	The IC_50 values determined for-yatein (71.9 M), demonstrated moderate inhibition, and BETA-sitosterol (160.1 M) demonstrated weak inhibition against the activity of CYP1A2. 	CYP1A2	9706	9712	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:56	In comparison, the plot and the IC_50 value for known CYP1A2 inhibitor, furafylline (1.4 M), demonstrated potent inhibition. 	CYP1A2	9768	9774	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:56	In comparison, the plot and the IC_50 value for known CYP1A2 inhibitor, furafylline (1.4 M), demonstrated potent inhibition. 	CYP1A2	9768	9774	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:58	However, it was possible to indicate that IC_50 values for both oleanolic and ursolic acid would be >100 M and for cadina-4,10(15)-dien-3-one >500 M, demonstrating weak inhibition against the activity of CYP1A2. 	CYP1A2	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:58	However, it was possible to indicate that IC_50 values for both oleanolic and ursolic acid would be >100 M and for cadina-4,10(15)-dien-3-one >500 M, demonstrating weak inhibition against the activity of CYP1A2. 	CYP1A2	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:59	Two phytochemicals, podophyllotoxin and 4-demethylpodophyllotoxin demonstrated no impact on the activity of CYP1A2. 	CYP1A2	10271	10277	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:59	Two phytochemicals, podophyllotoxin and 4-demethylpodophyllotoxin demonstrated no impact on the activity of CYP1A2. 	CYP1A2	10271	10277	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP1A2	11033	11039	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP1A2	11033	11039	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:66	CYP1A2 is important, as it metabolizes many commonly prescribed drugs including the bronchodilator theophylline, the tricyclic antidepressant imipramine, the beta blocker propranolol and the antipsychotic clozapine. 	CYP1A2	11268	11274	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:66	CYP1A2 is important, as it metabolizes many commonly prescribed drugs including the bronchodilator theophylline, the tricyclic antidepressant imipramine, the beta blocker propranolol and the antipsychotic clozapine. 	CYP1A2	11268	11274	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:71	Additional research, undertaken to assess the bioactivity of other traditionally prepared extracts, aqueous (fresh) and ethanol (dry and fresh), against the activity of the CYP enzyme most potently inhibited, in this case CYP1A2, demonstrated similar results to those originally obtained with the aqueous extract (dry plant material). 	CYP1A2	12570	12576	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:71	Additional research, undertaken to assess the bioactivity of other traditionally prepared extracts, aqueous (fresh) and ethanol (dry and fresh), against the activity of the CYP enzyme most potently inhibited, in this case CYP1A2, demonstrated similar results to those originally obtained with the aqueous extract (dry plant material). 	CYP1A2	12570	12576	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:75	CYP1A2 is an important enzyme, because it is responsible for metabolizing a number of commonly prescribed drugs, several of which are used in psychiatric medicine-drugs such as fluvoxamine, amitriptyline, clomipramine and clozapine. 	CYP1A2	13140	13146	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:75	CYP1A2 is an important enzyme, because it is responsible for metabolizing a number of commonly prescribed drugs, several of which are used in psychiatric medicine-drugs such as fluvoxamine, amitriptyline, clomipramine and clozapine. 	CYP1A2	13140	13146	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:80	CYP1A1 is particularly implicated in lung, colorectal, breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and endometrium, and CYP1A2 in colorectal, lung, and breast cancers. 	CYP1A2	14210	14216	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:80	CYP1A1 is particularly implicated in lung, colorectal, breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and endometrium, and CYP1A2 in colorectal, lung, and breast cancers. 	CYP1A2	14210	14216	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:93	Further investigations were undertaken to characterise the phytochemicals in the crude aqueous extract of the dried aerial plant material of H. verticillata, to identify the key phytochemical(s) responsible for the inhibition of CYP1A2, and to allow further assessment of the plant preparations potential to impact the activities of CYP enzymes in vivo. 	CYP1A2	16245	16251	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:93	Further investigations were undertaken to characterise the phytochemicals in the crude aqueous extract of the dried aerial plant material of H. verticillata, to identify the key phytochemical(s) responsible for the inhibition of CYP1A2, and to allow further assessment of the plant preparations potential to impact the activities of CYP enzymes in vivo. 	CYP1A2	16245	16251	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:99	Five individual phytochemicals, together with the mixture of five lignans were tested for their impact on the activity of CYP1A2. 	CYP1A2	17217	17223	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:99	Five individual phytochemicals, together with the mixture of five lignans were tested for their impact on the activity of CYP1A2. 	CYP1A2	17217	17223	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:101	The two triterpenes, oleanolic acid and ursolic acid, demonstrated weak inhibition, with IC_50 values >100 M. The remaining two individual phytochemicals, the lignans podophyllotoxin and 4-demethylpodophyllotoxin demonstrated no inhibition of CYP1A2 activity. 	CYP1A2	17621	17627	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:101	The two triterpenes, oleanolic acid and ursolic acid, demonstrated weak inhibition, with IC_50 values >100 M. The remaining two individual phytochemicals, the lignans podophyllotoxin and 4-demethylpodophyllotoxin demonstrated no inhibition of CYP1A2 activity. 	CYP1A2	17621	17627	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:102	Two further phytochemicals, cadina-4,10(15)-dien-3-one and -sitosterol were found to be weak inhibitors of CYP1A2. 	CYP1A2	17745	17751	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:102	Two further phytochemicals, cadina-4,10(15)-dien-3-one and -sitosterol were found to be weak inhibitors of CYP1A2. 	CYP1A2	17745	17751	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:104	By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against the activity of CYP1A2, and an IC_50 value of 1.4  0.15 M generated, which was consistent with values previously obtained and published by our laboratory. 	CYP1A2	18084	18090	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:104	By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against the activity of CYP1A2, and an IC_50 value of 1.4  0.15 M generated, which was consistent with values previously obtained and published by our laboratory. 	CYP1A2	18084	18090	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:104	By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against the activity of CYP1A2, and an IC_50 value of 1.4  0.15 M generated, which was consistent with values previously obtained and published by our laboratory. 	CYP1A2	18150	18156	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:104	By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against the activity of CYP1A2, and an IC_50 value of 1.4  0.15 M generated, which was consistent with values previously obtained and published by our laboratory. 	CYP1A2	18150	18156	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:106	Only two of the phytochemicals, oleanolic and ursolic acid, appear to have been previously screened against the activity of CYP1A2. 	CYP1A2	18637	18643	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:106	Only two of the phytochemicals, oleanolic and ursolic acid, appear to have been previously screened against the activity of CYP1A2. 	CYP1A2	18637	18643	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:109	Our results, reporting no inhibition by podophyllotoxin and moderate/weak inhibition by-yatein against the activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent inhibition of CYP3A4 by these two phytochemicals. 	CYP1A2	19039	19045	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:109	Our results, reporting no inhibition by podophyllotoxin and moderate/weak inhibition by-yatein against the activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent inhibition of CYP3A4 by these two phytochemicals. 	CYP1A2	19039	19045	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:110	Having confirmed the identity of seven phytochemicals in the aqueous extract of H. verticillata (dried aerial material), and screened them for their impact on the activity of CYP1A2, it appears that the bioactivity displayed by the crude aqueous extract of the plant (dried aerial material) can be attributed in part to yatein and two of the phytochemicals identified from the mixture of lignans, which displayed moderate/weak and moderate inhibition, respectively, of the same enzyme. 	CYP1A2	19353	19359	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:110	Having confirmed the identity of seven phytochemicals in the aqueous extract of H. verticillata (dried aerial material), and screened them for their impact on the activity of CYP1A2, it appears that the bioactivity displayed by the crude aqueous extract of the plant (dried aerial material) can be attributed in part to yatein and two of the phytochemicals identified from the mixture of lignans, which displayed moderate/weak and moderate inhibition, respectively, of the same enzyme. 	CYP1A2	19353	19359	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:117	In conclusion, this research presents the results of an in-depth assessment of the medicinal plant H. verticillata, its impact on a number of key CYP450 enzymes, antioxidant properties, and its characterisation and further impact on CYP1A2. 	CYP1A2	20941	20947	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:117	In conclusion, this research presents the results of an in-depth assessment of the medicinal plant H. verticillata, its impact on a number of key CYP450 enzymes, antioxidant properties, and its characterisation and further impact on CYP1A2. 	CYP1A2	20941	20947	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:120	Screening phytochemicals against the activity of CYP1A2 identified yatein as a moderate-weak contributor to the plants potent bioactivity, with potential for synergistic activity among other constituents. 	CYP1A2	21631	21637	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:120	Screening phytochemicals against the activity of CYP1A2 identified yatein as a moderate-weak contributor to the plants potent bioactivity, with potential for synergistic activity among other constituents. 	CYP1A2	21631	21637	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP1A2	23041	23047	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP1A2	23041	23047	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP1A2	29764	29770	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP1A2	29764	29770	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:185	Dimethylformamide (DMF) has been identified as one of the least inhibitory solvents towards CYP1A2. 	CYP1A2	30159	30165	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:185	Dimethylformamide (DMF) has been identified as one of the least inhibitory solvents towards CYP1A2. 	CYP1A2	30159	30165	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:186	Control assays run with DMF confirmed that no inhibition against CYP1A2 occurred at concentrations levels below 3%, demonstrating the least impact with no significant levels of inhibition or potentiation of fluorescence across the range of concentrations tested. 	CYP1A2	30232	30238	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:186	Control assays run with DMF confirmed that no inhibition against CYP1A2 occurred at concentrations levels below 3%, demonstrating the least impact with no significant levels of inhibition or potentiation of fluorescence across the range of concentrations tested. 	CYP1A2	30232	30238	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:126	A recent study has also shown in silico that the phospholipids may modulate the dynamics of access channels in human CYP1A2. 	CYP1A2	21956	21962	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:126	A recent study has also shown in silico that the phospholipids may modulate the dynamics of access channels in human CYP1A2. 	CYP1A2	21956	21962	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:127	One of the results presented shows that, during molecular dynamics simulations, a molecule of 1,2-dilauroyl-sn-glycero-3-phosphocholine can penetrate in one of the CYP1A2 access channels (namely tunnel 2d). 	CYP1A2	22128	22134	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:127	One of the results presented shows that, during molecular dynamics simulations, a molecule of 1,2-dilauroyl-sn-glycero-3-phosphocholine can penetrate in one of the CYP1A2 access channels (namely tunnel 2d). 	CYP1A2	22128	22134	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:128	The penetration progress, monitored as the time evolution of distance of 1,2-Dilauroyl-Sn-Glycero-3-Phosphocholine molecule from heme cofactor, is found to be correlated with opening/closing events of the other important channels of CYP1A2. 	CYP1A2	22404	22410	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:128	The penetration progress, monitored as the time evolution of distance of 1,2-Dilauroyl-Sn-Glycero-3-Phosphocholine molecule from heme cofactor, is found to be correlated with opening/closing events of the other important channels of CYP1A2. 	CYP1A2	22404	22410	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	CYP1A2	37751	37757	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:207	Using wild-type and artificial chimeras between human CYP1A1 and human CYP1A2, conclusive evidence were presented showing that, despite a 82% sequence identity between them, these two human P450 enzymes have a totally different affinity for the lipid rafts in mammalian cells. 	CYP1A2	37751	37757	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:242	The three-residue disruption of helix F in CYP1A2 is extended to five residues in CYP1A1. 	CYP1A2	43738	43744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:242	The three-residue disruption of helix F in CYP1A2 is extended to five residues in CYP1A1. 	CYP1A2	43738	43744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:243	This suggests that this longer break in helix F and a slightly longer helix B are the only secondary structural differences that are observed between CYP1A1 and CYP1A2. 	CYP1A2	43946	43952	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:243	This suggests that this longer break in helix F and a slightly longer helix B are the only secondary structural differences that are observed between CYP1A1 and CYP1A2. 	CYP1A2	43946	43952	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:244	Moreover, the tilt that was observed in X-ray structures between the N- and C-terminal moieties of helix Fis more pronounced in CYP1A2 than in CYP1A1. 	CYP1A2	44082	44088	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:244	Moreover, the tilt that was observed in X-ray structures between the N- and C-terminal moieties of helix Fis more pronounced in CYP1A2 than in CYP1A1. 	CYP1A2	44082	44088	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:245	This causes the mouth of one of the four channels, namely channel 3, to be smaller in CYP1A2 than in CYP1A1. 	CYP1A2	44191	44197	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:245	This causes the mouth of one of the four channels, namely channel 3, to be smaller in CYP1A2 than in CYP1A1. 	CYP1A2	44191	44197	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45454	45460	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45454	45460	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45469	45475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45469	45475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45678	45684	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45678	45684	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45759	45765	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:253	A natural genetic variant of CYP1A2, namely CYP1A2*11, was characterized for its activity towards two marker substrates, phenacetin and 7-ethoxy-resorufin, and was shown to be more impacted for phenacetin O-deethylase activity (10% of that of wild-type CYP1A2) than for ethoxyresorufin O-deethylase activity (30% of that of wild-type CYP1A2). 	CYP1A2	45759	45765	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:257	In a recent work, the aromatic residue 186 was proposed, based on molecular simulation studies, to exist in two conformational states, corresponding to the open or closed conformation of one of the several access channels of CYP1A2 network. 	CYP1A2	46323	46329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:257	In a recent work, the aromatic residue 186 was proposed, based on molecular simulation studies, to exist in two conformational states, corresponding to the open or closed conformation of one of the several access channels of CYP1A2 network. 	CYP1A2	46323	46329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP1A2	58873	58879	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP1A2	58873	58879	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A2	59226	59232	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A2	59226	59232	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A2	59337	59343	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP1A2	59337	59343	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:378	In contrast to the further above-mentioned studies CYP1A2, 2A7, 2B6 and 3A4 mRNAs were not detected in keratinocytes in this investigation (the keratinocytes were cultured for 36 h only, in presence of 1.5 mM calcium). 	CYP1A2	60917	60923	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:378	In contrast to the further above-mentioned studies CYP1A2, 2A7, 2B6 and 3A4 mRNAs were not detected in keratinocytes in this investigation (the keratinocytes were cultured for 36 h only, in presence of 1.5 mM calcium). 	CYP1A2	60917	60923	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:387	mRNA coding for CYP1A1, CYP1A2 and CYP1B1 were increased after treatment with dioxin. 	CYP1A2	62046	62052	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:387	mRNA coding for CYP1A1, CYP1A2 and CYP1B1 were increased after treatment with dioxin. 	CYP1A2	62046	62052	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:398	A considerable number of CYPs mRNAs were found in both, Full-Thickness Human Bottom Skin and EpiDerm^: CYP1A2, 1B1, 2C9, 2C18, 2J2, 2R1, 2S1, 3A5 and 4B1 and a considerable number of CYPs mRNAs were found in neither Full-Thickness Human Bottom Skin nor EpiDerm^: CYP2B6, 2C8, 2C19, 2F1, 3A4 and 3A7 (for further studies on CYPs transcripts expression in reconstructed human skin models see Hayden et al. 	CYP1A2	63663	63669	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:398	A considerable number of CYPs mRNAs were found in both, Full-Thickness Human Bottom Skin and EpiDerm^: CYP1A2, 1B1, 2C9, 2C18, 2J2, 2R1, 2S1, 3A5 and 4B1 and a considerable number of CYPs mRNAs were found in neither Full-Thickness Human Bottom Skin nor EpiDerm^: CYP2B6, 2C8, 2C19, 2F1, 3A4 and 3A7 (for further studies on CYPs transcripts expression in reconstructed human skin models see Hayden et al. 	CYP1A2	63663	63669	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP1A2	64173	64179	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP1A2	64173	64179	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP1A2	64256	64262	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP1A2	64256	64262	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:421	CYP1A2, 2E1 and 3A4 proteins were additionally sought and not found by immunoblotting (LOD 2.5 pmol/mg microsomal protein). 	CYP1A2	66394	66400	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:421	CYP1A2, 2E1 and 3A4 proteins were additionally sought and not found by immunoblotting (LOD 2.5 pmol/mg microsomal protein). 	CYP1A2	66394	66400	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:483	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) and 7-Methoxyresorufin-O-Demethylase (CYP1A2-selective) which was higher in the immortalized cell lines HaCaT and NCTC 2544 than in the primary keratinocytes NHEK. 	CYP1A2	74983	74989	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:483	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) and 7-Methoxyresorufin-O-Demethylase (CYP1A2-selective) which was higher in the immortalized cell lines HaCaT and NCTC 2544 than in the primary keratinocytes NHEK. 	CYP1A2	74983	74989	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	86974	86980	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	86974	86980	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	87019	87025	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	87019	87025	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	87107	87113	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:556	CYP1A2 The following arguments indicate that CYP1A2 is present in the human skin: several enzymatic activities which are typical for CYP1A2 have been observed in human skin, including 7-Methoxyresorufin-O-Demethylase as well as theophylline demethylation (Ademola et al.. Schober et al. 	CYP1A2	87107	87113	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:557	reported that metabolic activation of dibenzo[a,l]pyrene is catalyzed by heterologously expressed CYP1A2, albeit not as well as by human CYP1A1 or by CYP1B1, but better than by other human CYPs. 	CYP1A2	87359	87365	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:557	reported that metabolic activation of dibenzo[a,l]pyrene is catalyzed by heterologously expressed CYP1A2, albeit not as well as by human CYP1A1 or by CYP1B1, but better than by other human CYPs. 	CYP1A2	87359	87365	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:558	Other CYP1A2 substrates (as observed in skin or in other systems) include aflatoxin B1, aromatic amines and aromatic amides, caffeine, acetaminophen, phenacetin, imipramine, warfarin (Du et al. 	CYP1A2	87462	87468	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:558	Other CYP1A2 substrates (as observed in skin or in other systems) include aflatoxin B1, aromatic amines and aromatic amides, caffeine, acetaminophen, phenacetin, imipramine, warfarin (Du et al. 	CYP1A2	87462	87468	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:93	Interestingly both CYP2B4 and CYP1A2 have been shown to exist as hexamers in solution^-. 	CYP1A2	17505	17511	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:93	Interestingly both CYP2B4 and CYP1A2 have been shown to exist as hexamers in solution^-. 	CYP1A2	17505	17511	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:12	Although CYP1A2 is predominantly a hepatic isoform, CYP1A2 protein has been identified in breast cancer tissues. 	CYP1A2	1798	1804	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:12	Although CYP1A2 is predominantly a hepatic isoform, CYP1A2 protein has been identified in breast cancer tissues. 	CYP1A2	1798	1804	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:12	Although CYP1A2 is predominantly a hepatic isoform, CYP1A2 protein has been identified in breast cancer tissues. 	CYP1A2	1841	1847	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:12	Although CYP1A2 is predominantly a hepatic isoform, CYP1A2 protein has been identified in breast cancer tissues. 	CYP1A2	1841	1847	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:14	The AhR nuclear translocator (ARNT) carries the AhR-ligand complex to interact with the dioxin-responsive element (DRE) of the CYP1A1, CYP1A2 and CYP1B1 genes, resulting in transcriptional induction. 	CYP1A2	2135	2141	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:14	The AhR nuclear translocator (ARNT) carries the AhR-ligand complex to interact with the dioxin-responsive element (DRE) of the CYP1A1, CYP1A2 and CYP1B1 genes, resulting in transcriptional induction. 	CYP1A2	2135	2141	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:48	In MCF-7 cells, 24-h exposure to 2 M B(a)P potently increased CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 8-, 3- and 6-fold, respectively (A). 	CYP1A2	7061	7067	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:48	In MCF-7 cells, 24-h exposure to 2 M B(a)P potently increased CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 8-, 3- and 6-fold, respectively (A). 	CYP1A2	7061	7067	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:50	By increasing the exposure concentration to 10 M, berberine significantly elevated the CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 4-fold, 28% and 3-fold, respectively. 	CYP1A2	7336	7342	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:50	By increasing the exposure concentration to 10 M, berberine significantly elevated the CYP1A1, CYP1A2 and CYP1B1 mRNA levels by 4-fold, 28% and 3-fold, respectively. 	CYP1A2	7336	7342	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:51	Palmatine at 10 M elevated CYP1A1 and CYP1A2 mRNA levels by 2-fold, whereas CYP1B1 mRNA level remained unchanged. 	CYP1A2	7445	7451	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:51	Palmatine at 10 M elevated CYP1A1 and CYP1A2 mRNA levels by 2-fold, whereas CYP1B1 mRNA level remained unchanged. 	CYP1A2	7445	7451	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:52	Exposure to 10 M jatrorrhizine decreased CYP1A1 mRNA levels by 32% without affecting CYP1A2 or CYP1B1. 	CYP1A2	7606	7612	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:52	Exposure to 10 M jatrorrhizine decreased CYP1A1 mRNA levels by 32% without affecting CYP1A2 or CYP1B1. 	CYP1A2	7606	7612	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:54	In MB-231 cells, the CYP1A2 mRNA levels were below detectable limits. 	CYP1A2	7738	7744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:54	In MB-231 cells, the CYP1A2 mRNA levels were below detectable limits. 	CYP1A2	7738	7744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:100	This finding was consistent with that of a mouse study that showed that liver microsomal EROD activity was unaffected by berberine when CYP1A2 mRNA was elevated. 	CYP1A2	13771	13777	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:100	This finding was consistent with that of a mouse study that showed that liver microsomal EROD activity was unaffected by berberine when CYP1A2 mRNA was elevated. 	CYP1A2	13771	13777	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:155	The resulting cDNA was subjected to PCR amplification using primer sets for CYP1A2*1 (NM_000761.4), CYP1B1*1 (NM_000104.3) and BETA-actin (NM_001101). 	CYP1A2	20839	20845	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:155	The resulting cDNA was subjected to PCR amplification using primer sets for CYP1A2*1 (NM_000761.4), CYP1B1*1 (NM_000104.3) and BETA-actin (NM_001101). 	CYP1A2	20839	20845	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:157	The amplification of CYP1A1, CYP1A2, CYP1B1 and BETA-actin was carried out for 35, 40, 35 and 25 cycles, respectively. 	CYP1A2	21084	21090	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:157	The amplification of CYP1A1, CYP1A2, CYP1B1 and BETA-actin was carried out for 35, 40, 35 and 25 cycles, respectively. 	CYP1A2	21084	21090	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:8	In this study, we investigated the drug interaction potential of two selaginellins on ten P450 isoforms (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2 and 3A) and six Uridine 5-Diphosphoglucuronosyltransferase isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using human liver microsomes and liquid chromatography-tandem mass spectrometry. 	CYP1A2	963	969	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:8	In this study, we investigated the drug interaction potential of two selaginellins on ten P450 isoforms (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2 and 3A) and six Uridine 5-Diphosphoglucuronosyltransferase isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using human liver microsomes and liquid chromatography-tandem mass spectrometry. 	CYP1A2	963	969	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:11	These two selaginellins had low inhibitory potential against CYP1A2, CYP2A6, CYP2E1, and UGT1A6 (IC50 > 25 M). 	CYP1A2	1552	1558	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:11	These two selaginellins had low inhibitory potential against CYP1A2, CYP2A6, CYP2E1, and UGT1A6 (IC50 > 25 M). 	CYP1A2	1552	1558	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP1A2	9317	9323	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP1A2	9317	9323	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:189	Prediction of the ligand effect in CYP1A2 show the inhibitory effect of 1-4; this result could be explained considering the similitude between the substrates (polar heterocyclic compounds and arylamines) of cytochrome 1A2 with the indole motif of the target molecules. 	CYP1A2	32013	32019	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:189	Prediction of the ligand effect in CYP1A2 show the inhibitory effect of 1-4; this result could be explained considering the similitude between the substrates (polar heterocyclic compounds and arylamines) of cytochrome 1A2 with the indole motif of the target molecules. 	CYP1A2	32013	32019	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP1A2	20383	20389	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP1A2	20383	20389	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:47	Expression of the phase I genes CYP1A1, CYP1A2, and CYP1B1 was then quantified, using untreated samples as references. 	CYP1A2	6387	6393	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:47	Expression of the phase I genes CYP1A1, CYP1A2, and CYP1B1 was then quantified, using untreated samples as references. 	CYP1A2	6387	6393	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:60	However, contrary to skin, CYP1B1 was more upregulated than CYP1A2. 	CYP1A2	7978	7984	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:60	However, contrary to skin, CYP1B1 was more upregulated than CYP1A2. 	CYP1A2	7978	7984	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	CYP1A2	8120	8126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	CYP1A2	8120	8126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:64	Interestingly, the maximal level of adducts was not observed for the largest concentration investigated (5 M), but rather at 1 M. Exposure to Simulated Sunlight resulted in a very low overexpression of CYP1A1 and 1B1 by a factor of 2, but not of CYP1A2 (Supplementary Fig. 	CYP1A2	8701	8707	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:64	Interestingly, the maximal level of adducts was not observed for the largest concentration investigated (5 M), but rather at 1 M. Exposure to Simulated Sunlight resulted in a very low overexpression of CYP1A1 and 1B1 by a factor of 2, but not of CYP1A2 (Supplementary Fig. 	CYP1A2	8701	8707	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:70	Over the time period investigated, it was observed that Simulated Sunlight reduced the stimulation of gene expression induced by B[a]P of CYP1A1 and CYP1A2, particularly at 48 hours and to a lesser extent at 72 hours, regardless of the treatment protocol used (Figs  and. 	CYP1A2	9716	9722	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:70	Over the time period investigated, it was observed that Simulated Sunlight reduced the stimulation of gene expression induced by B[a]P of CYP1A1 and CYP1A2, particularly at 48 hours and to a lesser extent at 72 hours, regardless of the treatment protocol used (Figs  and. 	CYP1A2	9716	9722	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:100	Emphasis was placed on classical metabolic enzymes CYP1A1, CYP1B1, and CYP1A2 found in the skin and other organs^,. 	CYP1A2	14334	14340	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:100	Emphasis was placed on classical metabolic enzymes CYP1A1, CYP1B1, and CYP1A2 found in the skin and other organs^,. 	CYP1A2	14334	14340	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:103	In agreement with Costa et al.^, our RT-qPCR analyses unambiguously showed that exposure of human skin and NHK^, to B[a]P results in a time-dependent increase of CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	14760	14766	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:103	In agreement with Costa et al.^, our RT-qPCR analyses unambiguously showed that exposure of human skin and NHK^, to B[a]P results in a time-dependent increase of CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	14760	14766	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:106	Interestingly, induction of CYP1A2 in skin was found to be much larger than that of CYP1B1, whereas an opposite trend was found in Normal Human Keratinocytes, similar to other cell types^. 	CYP1A2	15040	15046	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:106	Interestingly, induction of CYP1A2 in skin was found to be much larger than that of CYP1B1, whereas an opposite trend was found in Normal Human Keratinocytes, similar to other cell types^. 	CYP1A2	15040	15046	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:124	Our experiments involving irradiation followed by B[a]P treatment rather showed that preliminary irradiation of skin explants strongly inhibited the induction of Phase I CYP1A1, CYP1A2, or CYP1B1 metabolism genes. 	CYP1A2	18038	18044	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:124	Our experiments involving irradiation followed by B[a]P treatment rather showed that preliminary irradiation of skin explants strongly inhibited the induction of Phase I CYP1A1, CYP1A2, or CYP1B1 metabolism genes. 	CYP1A2	18038	18044	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	CYP1A2	31628	31634	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	CYP1A2	31628	31634	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP1A2	3428	3434	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP1A2	3428	3434	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP1A2	4600	4606	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP1A2	4600	4606	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP1A2	64	70	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP1A2	64	70	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP1A2	689	695	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP1A2	689	695	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP1A2	4264	4270	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP1A2	4264	4270	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:29	The CYP1A2 form is relevant not only in drug metabolism (over 10% of popular drugs) but also for polycyclic aromatic hydrocarbon (PAH) metabolism, leading to metabolic activation of procarcinogens. 	CYP1A2	4489	4495	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:29	The CYP1A2 form is relevant not only in drug metabolism (over 10% of popular drugs) but also for polycyclic aromatic hydrocarbon (PAH) metabolism, leading to metabolic activation of procarcinogens. 	CYP1A2	4489	4495	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP1A2	6201	6207	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP1A2	6201	6207	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP1A2	10325	10331	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP1A2	10325	10331	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP1A2	11770	11776	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP1A2	11770	11776	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP1A2	12113	12119	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP1A2	12113	12119	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP1A2	12442	12448	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP1A2	12442	12448	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP1A2	18358	18364	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP1A2	18358	18364	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP1A2	20638	20644	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP1A2	20638	20644	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP1A2	20786	20792	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP1A2	20786	20792	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP1A2	20963	20969	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP1A2	20963	20969	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP1A2	21053	21059	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP1A2	21053	21059	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP1A2	22059	22065	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP1A2	22059	22065	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP1A2	22255	22261	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP1A2	22255	22261	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP1A2	22442	22448	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP1A2	22442	22448	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:145	In the reaction catalyzed by CYP1A2, higher inhibition at a similar level was observed for DN and GN (about 70%-80% compared to the control inhibitor, miconazole) than for GO (20%-50% inhibition). 	CYP1A2	22796	22802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:145	In the reaction catalyzed by CYP1A2, higher inhibition at a similar level was observed for DN and GN (about 70%-80% compared to the control inhibitor, miconazole) than for GO (20%-50% inhibition). 	CYP1A2	22796	22802	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:147	The inhibition rate of CYP3A4 was comparable for DN, GO and GN at all concentrations (50%-60% inhibition); however, at the highest concentration, we observed an effect similar to the one in CYP1A2. 	CYP1A2	23385	23391	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:147	The inhibition rate of CYP3A4 was comparable for DN, GO and GN at all concentrations (50%-60% inhibition); however, at the highest concentration, we observed an effect similar to the one in CYP1A2. 	CYP1A2	23385	23391	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:157	CYP1A2 expression was significantly decreased in both cell lines in the DN (45.9% and 36% of the control in HepG2 and HepaRG, respectively) and GO (50.6% and 1.7% of the control in HepG2 and HepaRG, respectively) groups, but increased in the GN group (55.8% and 138.7% more than in the control, HepG2 and HepaRG, respectively). 	CYP1A2	24564	24570	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:157	CYP1A2 expression was significantly decreased in both cell lines in the DN (45.9% and 36% of the control in HepG2 and HepaRG, respectively) and GO (50.6% and 1.7% of the control in HepG2 and HepaRG, respectively) groups, but increased in the GN group (55.8% and 138.7% more than in the control, HepG2 and HepaRG, respectively). 	CYP1A2	24564	24570	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP1A2	25828	25834	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP1A2	25828	25834	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP1A2	28384	28390	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP1A2	28384	28390	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP1A2	28529	28535	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP1A2	28529	28535	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:176	Interestingly, inhibition of CYP1A2 and CYP3A4 was lower in the presence of the highest concentration of DN and GN (100 mg/L), which could be related to the formation of nanoparticle agglomerates in higher concentrations and then reduction of their surface area available to interact. 	CYP1A2	28689	28695	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:176	Interestingly, inhibition of CYP1A2 and CYP3A4 was lower in the presence of the highest concentration of DN and GN (100 mg/L), which could be related to the formation of nanoparticle agglomerates in higher concentrations and then reduction of their surface area available to interact. 	CYP1A2	28689	28695	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:178	On the contrary, inhibition of CYP1A2 was concentration dependent in the presence of GO. 	CYP1A2	29225	29231	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:178	On the contrary, inhibition of CYP1A2 was concentration dependent in the presence of GO. 	CYP1A2	29225	29231	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP1A2	31163	31169	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP1A2	31163	31169	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:192	Interestingly, we observed induction of CYP1A2 upon treatment with GN. 	CYP1A2	31889	31895	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:192	Interestingly, we observed induction of CYP1A2 upon treatment with GN. 	CYP1A2	31889	31895	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:193	A known inducer of CYP1A2 is cigarette smoke containing a significant amount of nanoparticulated carbon black and PAH., Thus, it might be related to GN structure, more similar to compounds found in the cigarette smoke, when compared to the DN or GO used in this study, as PAH structure also consists of sp^2-hybridized carbon atoms with delocalized  electrons, which is a reason for naming PAH nanographenes or cutouts of graphene. 	CYP1A2	31939	31945	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:193	A known inducer of CYP1A2 is cigarette smoke containing a significant amount of nanoparticulated carbon black and PAH., Thus, it might be related to GN structure, more similar to compounds found in the cigarette smoke, when compared to the DN or GO used in this study, as PAH structure also consists of sp^2-hybridized carbon atoms with delocalized  electrons, which is a reason for naming PAH nanographenes or cutouts of graphene. 	CYP1A2	31939	31945	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:42	456211), CYP1A2 (Lot No. 	CYP1A2	8233	8239	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:42	456211), CYP1A2 (Lot No. 	CYP1A2	8233	8239	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12817	12823	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12817	12823	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12932	12938	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12932	12938	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP1A2	14044	14050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP1A2	14044	14050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A2	19988	19994	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A2	19988	19994	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A2	24523	24529	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A2	24523	24529	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP1A2	24649	24655	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP1A2	24649	24655	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP1A2	38313	38319	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP1A2	38313	38319	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:241	Results revealed that for predicting the site of enzyme CYP1A2, the K_m value was 28.53, 33.79, 18.55, 16.59, 7.42, 158.31 and 49.91 M, whereas the V_max constant was 1.76, 4.22, 5.34, 1.18, 1.99, 5.19 and 8.04 nM/min/nM and the C_Lint was 3.21, 6.49, 14.96, 3.69, 13.92, 1.70, and 8.37 L/min/mg for compounds F2, F3, F8, F11, F13, F20, and F21, respectively. 	CYP1A2	38942	38948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:241	Results revealed that for predicting the site of enzyme CYP1A2, the K_m value was 28.53, 33.79, 18.55, 16.59, 7.42, 158.31 and 49.91 M, whereas the V_max constant was 1.76, 4.22, 5.34, 1.18, 1.99, 5.19 and 8.04 nM/min/nM and the C_Lint was 3.21, 6.49, 14.96, 3.69, 13.92, 1.70, and 8.37 L/min/mg for compounds F2, F3, F8, F11, F13, F20, and F21, respectively. 	CYP1A2	38942	38948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP1A2	40379	40385	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP1A2	40379	40385	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:70	^, Chronic tobacco smokers have induced hepatic CYP enzymes, particularly CYP1A2. 	CYP1A2	9559	9565	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:70	^, Chronic tobacco smokers have induced hepatic CYP enzymes, particularly CYP1A2. 	CYP1A2	9559	9565	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9775	9781	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9775	9781	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9952	9958	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9952	9958	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:9	PharmG+ clozapine treated patients with CYP1A2 or CYP2C19 UM and PMs variants also showed higher reductions in UKU scores than PharmG clozapine patients in general. 	CYP1A2	1469	1475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:9	PharmG+ clozapine treated patients with CYP1A2 or CYP2C19 UM and PMs variants also showed higher reductions in UKU scores than PharmG clozapine patients in general. 	CYP1A2	1469	1475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3323	3329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3323	3329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3356	3362	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3356	3362	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP1A2	8069	8075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP1A2	8069	8075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9556	9562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9556	9562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9620	9626	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9620	9626	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP1A2	12931	12937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP1A2	12931	12937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP1A2	13857	13863	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP1A2	13857	13863	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:111	However, those differences were not statistically significant, even when considering patients with CYP1A2 or CYP2C19 UM and PMs variants (p > 0.05 in all comparisons). 	CYP1A2	18287	18293	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:111	However, those differences were not statistically significant, even when considering patients with CYP1A2 or CYP2C19 UM and PMs variants (p > 0.05 in all comparisons). 	CYP1A2	18287	18293	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP1A2	18815	18821	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP1A2	18815	18821	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP1A2	39916	39922	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP1A2	39916	39922	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	17985	17991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	17985	17991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A2	70422	70428	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A2	70422	70428	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A2	70832	70838	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A2	70832	70838	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP1A2	24750	24756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP1A2	24750	24756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP1A2	32120	32126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP1A2	32120	32126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A2	2021	2027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A2	2021	2027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2218	2224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2218	2224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2369	2375	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2369	2375	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A2	2556	2562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A2	2556	2562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A2	2845	2851	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A2	2845	2851	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A2	4942	4948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A2	4942	4948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2C19	934	941	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2C19	3555	3562	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2C19	4005	4012	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2C19	4771	4778	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:100	In addition, LD was observed between rs2153628 and rs9332168 (r^2 = 0.88) in the CYP2C9 gene, and between rs11597626 and rs12268020 (r^2 = 0.84) in CYP2C19 in the remaining SNP set. 	CYP2C19	17420	17427	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP2C19	19912	19919	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:157	Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov). 	CYP2C19	27106	27113	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP2C19	760	767	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2C19	1308	1315	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP2C19	1783	1790	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2C19	4637	4644	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2C19	5220	5227	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C19	5632	5639	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C19	5884	5891	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP2C19	6006	6013	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:22	Fargesin decreased CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pre-incubation time- and concentration-dependent manners in human liver microsomes. 	CYP2C19	6443	6450	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:23	The apparent K_i and maximal inactivation rate (k_inact) values of fargesin were 10.7 M and 0.082 min^1 for CYP2C8-catalyzed amodiaquine N-deethylation, 3.7 M and 0.102 min^1 for CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and 23.0 M and 0.050 min^1 for CYP3A4-catalyzed midazolam 1-hydroxylation, respectively, in human liver microsomes. 	CYP2C19	6807	6814	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2C19	7309	7316	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C19	7564	7571	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2C19	7682	7689	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP2C19	7961	7968	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:32	Fargesin showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pooled human liver microsomes. 	CYP2C19	8831	8838	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:34	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C19 (27.57 min^1 nM^1) was higher than those of drugs identified as mechanism-based inhibitors of CYP2C19 such as aschantin (8.28 min^1 nM^1), clopidogrel (3.90 min^1 nM^1), and fluoxetine (2.14 min^1 nM^1), but was comparable to that of ticlopidine (22.3 min^1 nM^1) in human liver microsomes. 	CYP2C19	9457	9464	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:34	The inactivation potency (k_inact/K_i ratio) of fargesin against CYP2C19 (27.57 min^1 nM^1) was higher than those of drugs identified as mechanism-based inhibitors of CYP2C19 such as aschantin (8.28 min^1 nM^1), clopidogrel (3.90 min^1 nM^1), and fluoxetine (2.14 min^1 nM^1), but was comparable to that of ticlopidine (22.3 min^1 nM^1) in human liver microsomes. 	CYP2C19	9559	9566	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2C19	11770	11777	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:64	The mechanism-based inhibition potency of fargesin against human liver microsomal CYP2C8, CYP2C19, and CYP3A4 activities was evaluated. 	CYP2C19	17083	17090	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	CYP2C19	17511	17518	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP2C19	18311	18318	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2C19	18661	18668	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP2C19	19169	19176	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP2C19	495	502	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP2C19	689	696	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP2C19	2049	2056	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP2C19	2183	2190	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP2C19	4922	4929	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:28	Concomitant treatment with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, CYP2C19, CYP3A4), significantly decreased the plasma norclozapine/clozapine ratios and patients clozapine dose requirement (;. 	CYP2C19	5488	5495	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP2C19	8325	8332	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2C19	8591	8598	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2C19	8602	8609	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2C19	8613	8620	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2C19	8624	8631	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP2C19	11178	11185	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:73	Of 92 patients, 31 carried at least one CYP2C19 loss-of-function allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the gain-of-function CYP2C19*17 allele. 	CYP2C19	13095	13102	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:73	Of 92 patients, 31 carried at least one CYP2C19 loss-of-function allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the gain-of-function CYP2C19*17 allele. 	CYP2C19	13128	13135	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:73	Of 92 patients, 31 carried at least one CYP2C19 loss-of-function allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the gain-of-function CYP2C19*17 allele. 	CYP2C19	13139	13146	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:73	Of 92 patients, 31 carried at least one CYP2C19 loss-of-function allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the gain-of-function CYP2C19*17 allele. 	CYP2C19	13153	13160	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:73	Of 92 patients, 31 carried at least one CYP2C19 loss-of-function allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the gain-of-function CYP2C19*17 allele. 	CYP2C19	13201	13208	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:74	CYP2C19 genotype seemed to influence neither the clozapine concentrations normalized by the dose nor the concentrations normalized by the dose/bodyweight. 	CYP2C19	13220	13227	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:75	No significant differences in clozapine concentrations were observed between the carriers of one or two loss-of-function alleles and the patients with CYP2C19*1/*1 genotype or those with gain-of-function allele (CYP2C19*17) associated with increased CYP2C19 expression (P=.1083). 	CYP2C19	13526	13533	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:75	No significant differences in clozapine concentrations were observed between the carriers of one or two loss-of-function alleles and the patients with CYP2C19*1/*1 genotype or those with gain-of-function allele (CYP2C19*17) associated with increased CYP2C19 expression (P=.1083). 	CYP2C19	13587	13594	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:75	No significant differences in clozapine concentrations were observed between the carriers of one or two loss-of-function alleles and the patients with CYP2C19*1/*1 genotype or those with gain-of-function allele (CYP2C19*17) associated with increased CYP2C19 expression (P=.1083). 	CYP2C19	13625	13632	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP2C19	16136	16143	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2C19	22348	22355	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2C19	22479	22486	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:121	Our results indicated that CYP2C19 and CYP2D6 were not likely to have a primary role in clozapine clearance. 	CYP2C19	22529	22536	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2C19	22893	22900	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:123	In contrast,  reported higher clozapine concentrations in patients with CYP2C19*2/*2 genotype than in those carrying non-CYP2C19*2/*2 genotypes. 	CYP2C19	23005	23012	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:123	In contrast,  reported higher clozapine concentrations in patients with CYP2C19*2/*2 genotype than in those carrying non-CYP2C19*2/*2 genotypes. 	CYP2C19	23054	23061	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP2C19	2135	2142	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2C19	38334	38341	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:1	 CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. 	CYP2C19	1	8	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:1	 CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. 	CYP2C19	15	22	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:3	CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. 	CYP2C19	381	388	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:6	CYP2C19 genotype data was available for 2 423 patients and the final sample cohort comprised 2 102 patients. 	CYP2C19	705	712	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:7	CYP2C19*2 or *19 alleles did not influence DFS. 	CYP2C19	814	821	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:8	For the CYP2C19*2 allele, the HR was 1.05 (CI 0.78-1.42) and 0.79 (CI 0.32-1.94) for hetero- and homozygote carriers, respectively. 	CYP2C19	870	877	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:9	The corresponding HR for hetero- and homozygote carriers of the CYP2C19*17 allele were 1.02 (CI 0.71-1.46) and 0.57 (CI 0.26-1.24), respectively. 	CYP2C19	1058	1065	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:11	We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment. 	CYP2C19	1274	1281	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:11	We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment. 	CYP2C19	1367	1374	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:20	CYP2C19 catalyzes the formation of a proportion of tamoxifen metabolites, including the conversion of 4-OH-TAM to endoxifen^. 	CYP2C19	2955	2962	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:21	The CYP2C19 gene is highly polymorphic. 	CYP2C19	3085	3092	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:22	Loss of enzyme activity results from the CYP2C19*2 (681 G > A, rs4244285)^,  and CYP2C19*3 (636 G > A, rs4986893) alleles^,. 	CYP2C19	3162	3169	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:22	Loss of enzyme activity results from the CYP2C19*2 (681 G > A, rs4244285)^,  and CYP2C19*3 (636 G > A, rs4986893) alleles^,. 	CYP2C19	3202	3209	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:25	CYP2C19*17 (806C > T, rs12248560 or 3402C > T, rs11188072) has been implicated in enhanced gene transcription^,. 	CYP2C19	3395	3402	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:27	Studies differ with respect to the associations observed between CYP2C19 genotypes and clinical outcomes as well as to corresponding levels of tamoxifen and its metabolites^-. 	CYP2C19	3660	3667	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:29	In some studies the CYP2C19*17 allele is associated with more favorable outcomes in breast cancer patients treated with tamoxifen^, though null results have also been found^,. 	CYP2C19	3972	3979	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:31	Given these contradictory findings, we used a large, publicly available dataset to investigate the association of CYP2C19*2 and CYP2C19*17 variants with breast cancer recurrence in both pre- and postmenopausal women treated with adjuvant tamoxifen therapy for ER-positive breast cancer. 	CYP2C19	4448	4455	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:31	Given these contradictory findings, we used a large, publicly available dataset to investigate the association of CYP2C19*2 and CYP2C19*17 variants with breast cancer recurrence in both pre- and postmenopausal women treated with adjuvant tamoxifen therapy for ER-positive breast cancer. 	CYP2C19	4462	4469	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:34	We included patients with non-metastatic, ER-positive tumors who had data on at least one CYP2C19 variant, whether a recurrence occurred, and follow-up time (Fig. 	CYP2C19	5309	5316	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:37	Genotype exposures were CYP2C19*2 and CYP2C19*17, with reference to the wild-type CYP2C19*1. 	CYP2C19	5823	5830	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:37	Genotype exposures were CYP2C19*2 and CYP2C19*17, with reference to the wild-type CYP2C19*1. 	CYP2C19	5837	5844	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:37	Genotype exposures were CYP2C19*2 and CYP2C19*17, with reference to the wild-type CYP2C19*1. 	CYP2C19	5881	5888	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:39	In three instances where multiple methods were used for a single individual and the AmpliChip blood genotype did not match the CYP2C19*2 genotype obtained with another method, preference was given to the AmpliChip data due to the high sensitivity and specificity of this test^. 	CYP2C19	6231	6238	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:40	The CYP2C19*3 allele was not assessed in this study because no variants were detected in the included data. 	CYP2C19	6386	6393	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:48	We generated a variable designating overall tamoxifen metabolic activity (high, intermediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth^. 	CYP2C19	7974	7981	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:53	Final Cox proportional hazards models included age at diagnosis of primary breast cancer (as a continuous variable), tumor stage, and ethnicity (Caucasian or Asian, for CYP2C19*2 only) as covariates. 	CYP2C19	8834	8841	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:56	To assess the potential for bias due to the use of complete case analyses, imputation of missing values for CYP2C19*2 genotype, CYP2C19*17 genotype, ethnicity, age at breast cancer diagnosis, and tumor stage was done in a supplemental analysis. 	CYP2C19	9169	9176	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:56	To assess the potential for bias due to the use of complete case analyses, imputation of missing values for CYP2C19*2 genotype, CYP2C19*17 genotype, ethnicity, age at breast cancer diagnosis, and tumor stage was done in a supplemental analysis. 	CYP2C19	9189	9196	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:65	Data on CYP2C19*2 were available from all seven study sites for 2 055 women, and data on CYP2C19*17 were reported from three sites for 1 253 women. 	CYP2C19	10174	10181	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:65	Data on CYP2C19*2 were available from all seven study sites for 2 055 women, and data on CYP2C19*17 were reported from three sites for 1 253 women. 	CYP2C19	10255	10262	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:66	Distributions and Hardy-Weinberg chi-squared statistics within each study site for the CYP2C19*2 and CYP2C19*17 genotypes and DNA sources are provided for sample and source populations in Supplementary Tables  and. 	CYP2C19	10401	10408	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:66	Distributions and Hardy-Weinberg chi-squared statistics within each study site for the CYP2C19*2 and CYP2C19*17 genotypes and DNA sources are provided for sample and source populations in Supplementary Tables  and. 	CYP2C19	10415	10422	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2C19	10610	10617	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2C19	10686	10693	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:68	Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between CYP2C19 genotype and DFS (Supplementary Table. 	CYP2C19	11022	11029	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:71	For the CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically designated high and intermediate tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45-1.66) and 0.89 (95% CI: 0.46-1.74), respectively, compared with the low metabolic activity group. 	CYP2C19	11295	11302	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:72	The corresponding adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 0.73-1.94) and 1.21 (95% CI: 0.80-1.85). 	CYP2C19	11643	11650	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:73	We found no evidence of a clinically meaningful association between CYP2C19*2 or CYP2C19*17 genotypes and DFS in tamoxifen-treated breast cancer patients in a large dataset. 	CYP2C19	11804	11811	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:73	We found no evidence of a clinically meaningful association between CYP2C19*2 or CYP2C19*17 genotypes and DFS in tamoxifen-treated breast cancer patients in a large dataset. 	CYP2C19	11817	11824	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:74	A secondary analysis of CYP2C19 genotype accounting for CYP2D6 phenotypes resulted in little change to the observation. 	CYP2C19	11934	11941	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:75	This study has the largest overall sample size of work on this topic to date and includes a larger number of CYP2C19 variants compared with prior studies. 	CYP2C19	12139	12146	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:77	Only two other studies have examined the association between CYP2C19 genotype and breast cancer recurrence within strata of menopausal status^, and those studies included a combined total of only 85 premenopausal patients. 	CYP2C19	12519	12526	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2C19	12837	12844	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2C19	12850	12857	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:83	The CYP2C19*17 was only assessed at three sites that yielded homogenous and comparable allele frequencies with one gain of function allele frequencies between 32-37%. 	CYP2C19	13393	13400	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:85	The lack of data on CYP2C19 inhibitor use could have biased our estimates towards the null. 	CYP2C19	13842	13849	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:86	CYP2C19 genotyping using tumor-derived DNA (at three sites) may introduce misclassification due to potential loss-of-heterozygosity in tumor cells^,. 	CYP2C19	13914	13921	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:87	Results of chi-squared tests for Hardy-Weinberg equilibrium indicate that loss-of-heterozygosity had a minor impact on observed CYP2C19 genotypes in this study. 	CYP2C19	14192	14199	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:88	A minor violation of HWE was observed at study site 8, which accounted for the majority of samples assessed for CYP2C19*17. 	CYP2C19	14337	14344	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:90	A violation of HWE for CYP2C19*2 was observed at study site 12, but the sample of 240 subjects contributed little to the overall analysis. 	CYP2C19	14550	14557	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:91	While previous reports have found the presence of CYP2C19*2 to be associated with superior efficacy of tamoxifen treatment^-, our results support other studies reporting no such association^, --. 	CYP2C19	14716	14723	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:92	The hazard ratio for the association of CYP2C19*17 homozygotes with a favorable DFS (HR = 0.57, 95% CI: 0.26, 1.24) is similar to the ratio found previously for the association of carrying CYP2C19*17 with relapse-free time (HR = 0.45, 95% CI: 0.21, 0.92) (31). 	CYP2C19	14902	14909	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:92	The hazard ratio for the association of CYP2C19*17 homozygotes with a favorable DFS (HR = 0.57, 95% CI: 0.26, 1.24) is similar to the ratio found previously for the association of carrying CYP2C19*17 with relapse-free time (HR = 0.45, 95% CI: 0.21, 0.92) (31). 	CYP2C19	15051	15058	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:95	Despite the biologic plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified analyses do not support this hypothesis. 	CYP2C19	15559	15566	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2C19	15764	15771	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:97	The formation of active tamoxifen metabolites in patients carrying reduced or increased CYP2C19 function alleles may be sufficiently compensated through parallel and serial metabolic pathways catalyzed by other P450 enzymes. 	CYP2C19	15960	15967	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:98	This would mitigate the net overall clinical consequence of genomic CYP2C19 variants and result in a statistical inference toward the null. 	CYP2C19	16165	16172	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:100	Several studies indicate that CYP2C19 variants are associated with differences in baseline breast cancer risk, likely due to the inherent role of CYP2C19 in the metabolism of estrogen. 	CYP2C19	16494	16501	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:100	Several studies indicate that CYP2C19 variants are associated with differences in baseline breast cancer risk, likely due to the inherent role of CYP2C19 in the metabolism of estrogen. 	CYP2C19	16610	16617	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:101	However, this association has not been consistently observed, and the fact that the minor allele frequencies observed here match population-wide benchmarks argues against CYP2C19 genotype as a selection force. 	CYP2C19	16820	16827	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:109	In conclusion, we found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients. 	CYP2C19	17806	17813	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2C19	35858	35865	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:217	In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and mitochondrial toxicity, there is a selectivity index of around 3-4 fold, thus showing an acceptable profile. 	CYP2C19	37502	37509	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2C19	467	474	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2C19	5832	5839	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:42	Next, the HS4-CAG-CYP2C9 plasmid was digested with NheI/AscI site and ligated with the HS4-CAG-CYP2C19, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 plasmid. 	CYP2C19	6593	6600	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:42	Next, the HS4-CAG-CYP2C9 plasmid was digested with NheI/AscI site and ligated with the HS4-CAG-CYP2C19, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 plasmid. 	CYP2C19	6670	6677	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2C19	6922	6929	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2C19	13139	13146	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2C19	14117	14124	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2C19	18340	18347	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:41	Another genomic position (CYP2C19*9, rs17884712) with low- quality calling was observed in a portion of the study samples (17/98). 	CYP2C19	6362	6369	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2C19	24878	24885	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2C19	4542	4549	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2C19	17056	17063	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2C19	17784	17791	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2C19	16122	16129	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C19	16486	16493	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C19	16995	17002	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2C19	17098	17105	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2C19	18762	18769	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP2C19	41294	41301	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP2C19	41891	41898	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP2C19	7845	7852	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP2C19	8751	8758	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP2C19	20564	20571	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:168	It is known that indole is oxidized to isatin by some cytochromes P450 (CYP2A6, CYP2C19, and CYP2E1) which are responsible for the metabolism of various xenobiotics. 	CYP2C19	23802	23809	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2C19	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:127	The CYP2C19 enzyme plays an important role in the metabolism of antiplatelet agents (eg, clopidogrel), proton pump inhibitors (eg, omeprazole), tricyclic antidepressants, selective serotonin reuptake inhibitors and benzodiazepines. 	CYP2C19	21071	21078	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:128	CYP2C19*2 and *3 alleles define the current PM phenotype status, with markedly different allele frequencies across different ethnic populations. 	CYP2C19	21299	21306	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:129	The CYP2C19*17 variant is a gain-of-function allele, resulting in higher enzyme activity. 	CYP2C19	21448	21455	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:130	CYP2C19 catalyzes the 4-hydroxylation of (S)-mephenytoin, a probe substrate for CYP2C19. 	CYP2C19	21534	21541	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:130	CYP2C19 catalyzes the 4-hydroxylation of (S)-mephenytoin, a probe substrate for CYP2C19. 	CYP2C19	21614	21621	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:131	The CYP2C19 PM phenotype is associated with a reduced ability to metabolize (S)-mephenytoin. 	CYP2C19	21627	21634	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:132	Thus, PMs eliminate racemic mephenytoin more slowly than EMs and urinary 4-hydroxymephenytoin and S/R mephenytoin enantiomeric ratio was used in the past to distinguish between CYP2C19 EMs and PMs. 	CYP2C19	21893	21900	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:134	reported that in FNs, the CYP2C19*2 allelic variant was found at 19.1%, while CYP2C19*3 was not detected. 	CYP2C19	21953	21960	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:134	reported that in FNs, the CYP2C19*2 allelic variant was found at 19.1%, while CYP2C19*3 was not detected. 	CYP2C19	22005	22012	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:136	conducted CYP2C19 genotyping and phenotyping, based on the mephenytoin S/R enantiomeric ratio, in Inuit peoples in Canada. 	CYP2C19	22063	22070	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:137	The CYP2C19*2 allele frequency was 12%, while CYP2C19*3 was not detected in this Inuit population. 	CYP2C19	22180	22187	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:137	The CYP2C19*2 allele frequency was 12%, while CYP2C19*3 was not detected in this Inuit population. 	CYP2C19	22222	22229	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:140	Clopidogrel is a prodrug that is bioactivated by multiple P450s enzymes (including CYP2C19) to its active metabolite, which acts as an antiplatelet agent by irreversibly inhibiting the P2Y12 adenosine diphosphate receptor on platelets. 	CYP2C19	22789	22796	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:141	CYP2C19 genetic variation has been associated with the fraction metabolized and clinical response to clopidogrel. 	CYP2C19	22942	22949	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:142	In the Oglala Sioux Tribe of South Dakota, the MAFs for CYP2C19*2, *3 and *17 were 11.2%, 0.0% and 8.7%, respectively. 	CYP2C19	23112	23119	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:145	In a study examining CYP2C19 variant alleles in AI children, the frequencies of CYP2C19*2, *4 and *17 were 11.5%, 1.3% and 11.1%, respectively. 	CYP2C19	23542	23549	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:145	In a study examining CYP2C19 variant alleles in AI children, the frequencies of CYP2C19*2, *4 and *17 were 11.5%, 1.3% and 11.1%, respectively. 	CYP2C19	23601	23608	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:146	CYP2C19*8 and CYP2C19*14 were not present in the AI population studied and CYP2C19*3 was not tested. 	CYP2C19	23665	23672	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:146	CYP2C19*8 and CYP2C19*14 were not present in the AI population studied and CYP2C19*3 was not tested. 	CYP2C19	23679	23686	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:146	CYP2C19*8 and CYP2C19*14 were not present in the AI population studied and CYP2C19*3 was not tested. 	CYP2C19	23740	23747	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:148	With regards to CYP2C19 variation in Amerindians of Mexico, Salazar-Flores et al. 	CYP2C19	23897	23904	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:150	The CYP2C19*2 MAF was reported as 31%, 5.4%, 3.6%, 5.6% and 0.0% in Tarahumaras, Purepechas, Tojolabales, Tzotziles and Tzeltales, respectively. 	CYP2C19	24124	24131	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:151	The high allele frequency in the Tarahumara population is of particular interest clinically, as this predicts that a substantial portion of the population would be CYP2C19 PMs. 	CYP2C19	24429	24436	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:152	CYP2C19*3, *4 and *5 were not detected in any of the Amerindian populations studied. 	CYP2C19	24442	24449	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:154	reported the MAFs of CYP2C19*2, *3 and *17 as 12.0%, 0.2% and 2.2%, respectively. 	CYP2C19	24687	24694	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:155	CYP2C19*4 and *5 were not detected in the population studied. 	CYP2C19	24748	24755	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:156	CYP2C19 phenotype was determined using omeprazole as a probe substrate as part of a drug cocktail. 	CYP2C19	24810	24817	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:157	The ratio of omeprazole to 5-hydroxyomeprazole was significantly greater in individuals with the PM conferring variants, CYP2C19*2 or *3, compared to those with the reference genotype. 	CYP2C19	25030	25037	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:250	In contrast, CYP2C19*2 was found at a high MAF in Tarahumaras, compared to other Indigenous peoples of Mexico. 	CYP2C19	38327	38334	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2C19	40266	40273	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2C19	58825	58832	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:617	CYP2C subfamily In contrast to other CYPs, as pointed out above, the mRNAs coding for the major human CYP2C proteins, CYP2C9, CYP2C18 and CYP2C19 were found in the skin of all individuals investigated by Yengi et al.. On the other hand, in proliferating human keratinocytes in culture CYP2C19 mRNA was found only after induction by clofibrate Gonzalez et al.. In line with the failure of finding constitutive expression in proliferating keratinocytes, the localization of CYP2C mRNAs as well as CYP2C proteins is in most cases in the outer suprabasal cell layers of the epidermis, where differentiated keratinocytes are located (Du et al.. As found in skin or other systems CYP2Cs metabolize: many physiological compounds (CYP2C9: retinoic, arachidonic and linoleic acids, 5-alpha-androstane-3-alpha,17-beta-diol; 2C18: retinoic acid, progesterone; 2C19: progesterone, testosterone, retinal, arachidonic and linoleic acids);natural compounds (2C9: limonene, capsaicin, nicotine, galangin, genistein 4-methyl ether, ochrotoxine A; 2C18: limonene; 2C19: limonene, capsaicin, nicotine, genistein 4-methyl ether, ochratoxin A, tetrahydrocannabinol);pharmaceutical drugs [2C9: (S)-warfarin, tolbutamide, diclofenac, ibuprofen, indomethacin, phenytoin; 2C19: (R)-warfarin, omeprazole, pantoprazole, lansoprazole, (S)-mephenytoin, diazepam, amitryptiline] (Du et al. 	CYP2C19	94464	94471	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:617	CYP2C subfamily In contrast to other CYPs, as pointed out above, the mRNAs coding for the major human CYP2C proteins, CYP2C9, CYP2C18 and CYP2C19 were found in the skin of all individuals investigated by Yengi et al.. On the other hand, in proliferating human keratinocytes in culture CYP2C19 mRNA was found only after induction by clofibrate Gonzalez et al.. In line with the failure of finding constitutive expression in proliferating keratinocytes, the localization of CYP2C mRNAs as well as CYP2C proteins is in most cases in the outer suprabasal cell layers of the epidermis, where differentiated keratinocytes are located (Du et al.. As found in skin or other systems CYP2Cs metabolize: many physiological compounds (CYP2C9: retinoic, arachidonic and linoleic acids, 5-alpha-androstane-3-alpha,17-beta-diol; 2C18: retinoic acid, progesterone; 2C19: progesterone, testosterone, retinal, arachidonic and linoleic acids);natural compounds (2C9: limonene, capsaicin, nicotine, galangin, genistein 4-methyl ether, ochrotoxine A; 2C18: limonene; 2C19: limonene, capsaicin, nicotine, genistein 4-methyl ether, ochratoxin A, tetrahydrocannabinol);pharmaceutical drugs [2C9: (S)-warfarin, tolbutamide, diclofenac, ibuprofen, indomethacin, phenytoin; 2C19: (R)-warfarin, omeprazole, pantoprazole, lansoprazole, (S)-mephenytoin, diazepam, amitryptiline] (Du et al. 	CYP2C19	94611	94618	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2C19	9357	9364	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:191	In the same way, 3 and 4 show inhibitory effects on CYP2C19. 	CYP2C19	32451	32458	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP2C19	20362	20369	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2C19	4616	4623	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:48	456222), CYP2C19 (Lot No. 	CYP2C19	8394	8401	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C19	12966	12973	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C19	14219	14226	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:239	Moreover, only compound F13 was found to be the substrate of CYP2C19 and compound F25 was found to be the substrate of CYP3A4. 	CYP2C19	38559	38566	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:243	Additionally, that for predicting the site of enzyme CYP2C19, the K_m value was 61.866 M, whereas the V_max constant was 2.35 nM/min/nM and the C_Lint was 0.53 L/min/mg for compound F13. 	CYP2C19	39590	39597	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:247	Whereas no compounds were found to inhibit the CYP2C19. 	CYP2C19	40507	40514	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:59	Seven variants of CYP2C19 have also been associated with slow metabolism of several antidepressants. 	CYP2C19	8402	8409	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:60	Slow recovery after overdoses is anticipated in patients with low-activity CYP2C19. 	CYP2C19	8560	8567	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:61	Slow recovery is also anticipated in patients receiving proton-pump inhibitors, particularly omeprazole and esomeprazole, as these are potent inhibitors of CYP2C19. 	CYP2C19	8725	8732	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:62	^ On the other hand, some patients are ultrafast CYP2C19 metabolizers. 	CYP2C19	8783	8790	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:160	^, Important pharmacokinetic and pharmacodynamic interactions in the use of MAOIs include inhibitory effects on hepatic CYP enzymes, in particular, CYP2C19 and 2D6, and a tyramine-induced sympathomimetic response. 	CYP2C19	22789	22796	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2C19	27726	27733	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:9	PharmG+ clozapine treated patients with CYP1A2 or CYP2C19 UM and PMs variants also showed higher reductions in UKU scores than PharmG clozapine patients in general. 	CYP2C19	1479	1486	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2C19	3334	3341	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2C19	8085	8092	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2C19	9567	9574	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2C19	12953	12960	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2C19	13875	13882	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:111	However, those differences were not statistically significant, even when considering patients with CYP1A2 or CYP2C19 UM and PMs variants (p > 0.05 in all comparisons). 	CYP2C19	18297	18304	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2C19	18834	18841	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2C19	19611	19618	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2C19	19950	19957	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP2C19	22211	22218	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2C19	39932	39939	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:335	In term of pharmacokinetics, tivantinib is metabolized by CYP2C19, CYP3A4/5, Udp Glucuronosyltransferase 1a9, and alcohol dehydrogenase isoform 4. 	CYP2C19	68231	68238	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:336	CYP2C19 shows catalytic activity for the formation of the hydroxylated metabolite (M5), whereas CYP3A4/5 catalyzes formation of M5 and its stereoisomer (M4). 	CYP2C19	68320	68327	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:339	Between 2010 and 2014, two phase I trials (NCT01069757, NCT01656265) in Japanese patients with advanced solid tumors examined the safety, pharmacokinetics, and preliminary efficacy of tivantinib as a single agent to determine recommended phase II dose according to CYP2C19 polymorphisms. 	CYP2C19	69110	69117	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:208	In fact, CYP2C19 and CYP3A4 can 21-hydroxylate progesterone and pregnenolone, possibly partially compensating mineralocorticoid deficiency in CAH due to 21-hydroxylase deficiency; however, the two enzymes are not capable of catalyzing the 21-hydroxylation of 17OHP to 11-deoxycortisol. 	CYP2C19	35294	35301	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP2C19	70359	70366	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:13	The highly polymorphic CYP2C19 isozymes are responsible for metabolizing a large portion of routinely prescribed drugs and variants contribute significantly to adverse drug reactions and therapeutic failures. 	CYP2C19	1684	1691	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:14	A limited number of CYP2C19 single nucleotide polymorphisms are involved in drug metabolism. 	CYP2C19	1890	1897	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:19	The aim of this study is to better understand and provide further knowledge about the metabolism and interactions between phenobarbital and CYP2C19 polymorphisms in children with epilepsy, interplay between sleep, and Eversus Understanding this interplay between epilepsy and sleep is helpful in the optimal treatment of all patients with epileptic seizures. 	CYP2C19	2620	2627	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2C19	24766	24773	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:137	In the report we will only discuss the CYP2C19 gene as outlined in. 	CYP2C19	25683	25690	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	CYP2C19	25772	25779	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	CYP2C19	25840	25847	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:139	CYP2C19 is expressed in the liver and to a lesser extent in the small intestine, contributing to the metabolism of a large number of clinically relevant drugs and drug classes including phenytoin and phenobarbital. 	CYP2C19	25964	25971	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C19	26183	26190	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C19	26276	26283	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:141	This CYP2C19 gene encompasses 90,637 bases and is composed of nine exons encoding 490 amino acids. 	CYP2C19	26291	26298	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	CYP2C19	26494	26501	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:144	Understanding the biological function of CYP2C19 gene can provide a good foundation for subsequently interpreting the potential influence of genetic associations on a disease phenotype and so can greatly support any identified genetic association. 	CYP2C19	27048	27055	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:151	Potential binding sites for the transcription factors such as GATA proteins, progesterone receptor, TATA box elements and nuclear factors in CYP2C19 promoter region has been described. 	CYP2C19	28169	28176	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:153	This CYP2C19 gene (RefSeq accession number NM_000769.4) has three promoter regions. 	CYP2C19	28374	28381	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:154	As shown in, CYP2C19-201 has nine exons and eight introns and consists of 490 amino acids, while CYP2C10-202 has 162 amino acids, however, CYP2C19-203 does not produce protein products. 	CYP2C19	28466	28473	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:154	As shown in, CYP2C19-201 has nine exons and eight introns and consists of 490 amino acids, while CYP2C10-202 has 162 amino acids, however, CYP2C19-203 does not produce protein products. 	CYP2C19	28592	28599	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28674	28681	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28703	28710	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28825	28832	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28934	28941	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	29131	29138	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:157	For the cellular component, the CYP2C19 gene is found in different part of the cells: cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), and organelle membrane (GO:0031090). 	CYP2C19	29691	29698	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:160	Next, we used STRING software to build a gene network of the CYP2C19 gene and other neighbor genes using https://string-db.org/ as shown in. 	CYP2C19	30454	30461	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:161	This network shows high interaction between CYP2C19 and other genes such as glutathione S-transferase mu 1, glutathione S-transferase mu 2 (muscle), glutathione S-transferase mu 3 (brain), glutathione S-transferase theta 1. 	CYP2C19	30578	30585	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:165	Next, we used genome at USSC to find out the CYP2C19 tagged Single Nucleotide Polymorphisms (https://genome.ucsc.edu/cgi-bin/hgGateway). 	CYP2C19	31410	31417	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:166	The tagged Single Nucleotide Polymorphisms associated with the CYP2C19 gene are shown in. 	CYP2C19	31565	31572	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:168	In this report, we will focus only on CYP2C19 Single Nucleotide Polymorphisms that has been reported to be associated with drug metabolism as shown in. 	CYP2C19	31805	31812	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32157	32164	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32221	32228	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32285	32292	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2D6	943	949	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2D6	943	949	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2D6	943	949	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2D6	943	949	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2D6	3564	3570	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2D6	3564	3570	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2D6	3564	3570	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2D6	3564	3570	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2D6	4030	4036	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2D6	4030	4036	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2D6	4030	4036	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:24	Similarly, SNPs in CYP2C9 (rs1799853 and rs1057910) have been associated with PHT dose requirement, and SNPs in CYP2C19 (rs12248560) and CYP2D6 have been considered pharmacogenomic biomarkers for neurologic and psychiatric therapeutic drugs, including clobazam (CLB) and diazepam, receiving approval for use by the U.S. 	CYP2D6	4030	4036	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2D6	4780	4786	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2D6	4780	4786	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2D6	4780	4786	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2D6	4780	4786	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:157	Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov). 	CYP2D6	27118	27124	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:157	Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov). 	CYP2D6	27118	27124	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:157	Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov). 	CYP2D6	27118	27124	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:157	Genotyping kits for specific alleles in CYP2C19 and CYP2D6 genes have been approved by the US-FDA to be used as pharmacogenetic biomarkers (www.fda.gov). 	CYP2D6	27118	27124	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:158	However, SNPs in CYP2C9 and CYP2D6 present an average MAF = 0.06, significantly limiting their use in clinical practice, since they can only be detected in a small fraction of the population. 	CYP2D6	27248	27254	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:158	However, SNPs in CYP2C9 and CYP2D6 present an average MAF = 0.06, significantly limiting their use in clinical practice, since they can only be detected in a small fraction of the population. 	CYP2D6	27248	27254	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:158	However, SNPs in CYP2C9 and CYP2D6 present an average MAF = 0.06, significantly limiting their use in clinical practice, since they can only be detected in a small fraction of the population. 	CYP2D6	27248	27254	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:158	However, SNPs in CYP2C9 and CYP2D6 present an average MAF = 0.06, significantly limiting their use in clinical practice, since they can only be detected in a small fraction of the population. 	CYP2D6	27248	27254	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2D6	1191	1197	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2D6	1191	1197	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2D6	1191	1197	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2D6	1191	1197	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2D6	1432	1438	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2D6	1432	1438	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2D6	1432	1438	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2D6	1432	1438	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2D6	4983	4989	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2D6	4983	4989	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2D6	4983	4989	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2D6	4983	4989	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2D6	5229	5235	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2D6	5229	5235	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2D6	5229	5235	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2D6	5229	5235	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2D6	7382	7388	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2D6	7382	7388	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2D6	7382	7388	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2D6	7382	7388	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2D6	7573	7579	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2D6	7573	7579	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2D6	7573	7579	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2D6	7573	7579	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2D6	11779	11785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2D6	11779	11785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2D6	11779	11785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP2D6	11779	11785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18595	18601	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18595	18601	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18595	18601	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18595	18601	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18786	18792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18786	18792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18786	18792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2D6	18786	18792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP2D6	504	510	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP2D6	504	510	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP2D6	504	510	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP2D6	504	510	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP2D6	700	706	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP2D6	700	706	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP2D6	700	706	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP2D6	700	706	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP2D6	2058	2064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP2D6	2058	2064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP2D6	2058	2064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP2D6	2058	2064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP2D6	2195	2201	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP2D6	2195	2201	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP2D6	2195	2201	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:11	The patients CYP2C19 and CYP2D6 genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced neither the clozapine levels nor the norclozapine/clozapine ratio. 	CYP2D6	2195	2201	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP2D6	4931	4937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP2D6	4931	4937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP2D6	4931	4937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP2D6	4931	4937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP2D6	8334	8340	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP2D6	8334	8340	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP2D6	8334	8340	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP2D6	8334	8340	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8636	8642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8636	8642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8636	8642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8636	8642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8646	8652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8646	8652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8646	8652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8646	8652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8656	8662	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8656	8662	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8656	8662	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8656	8662	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8666	8672	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8666	8672	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8666	8672	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8666	8672	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8677	8683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8677	8683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8677	8683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP2D6	8677	8683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:49	CYP2D6*5 (gene deletion) and CYP2D6 duplication were analyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, Waltham, MA). 	CYP2D6	8824	8830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP2D6	11187	11193	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP2D6	11187	11193	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP2D6	11187	11193	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP2D6	11187	11193	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:76	Furthermore, no significant association was found between the normalized clozapine concentrations and the patients CYP2D6 genotypes (P=.8881). 	CYP2D6	13770	13776	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:76	Furthermore, no significant association was found between the normalized clozapine concentrations and the patients CYP2D6 genotypes (P=.8881). 	CYP2D6	13770	13776	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:76	Furthermore, no significant association was found between the normalized clozapine concentrations and the patients CYP2D6 genotypes (P=.8881). 	CYP2D6	13770	13776	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:76	Furthermore, no significant association was found between the normalized clozapine concentrations and the patients CYP2D6 genotypes (P=.8881). 	CYP2D6	13770	13776	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP2D6	16147	16153	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP2D6	16147	16153	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP2D6	16147	16153	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP2D6	16147	16153	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22369	22375	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22369	22375	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22369	22375	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22369	22375	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22491	22497	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22491	22497	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22491	22497	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP2D6	22491	22497	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:121	Our results indicated that CYP2C19 and CYP2D6 were not likely to have a primary role in clozapine clearance. 	CYP2D6	22541	22547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:121	Our results indicated that CYP2C19 and CYP2D6 were not likely to have a primary role in clozapine clearance. 	CYP2D6	22541	22547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:121	Our results indicated that CYP2C19 and CYP2D6 were not likely to have a primary role in clozapine clearance. 	CYP2D6	22541	22547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:121	Our results indicated that CYP2C19 and CYP2D6 were not likely to have a primary role in clozapine clearance. 	CYP2D6	22541	22547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22765	22771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22765	22771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22765	22771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22765	22771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22883	22889	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22883	22889	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22883	22889	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:122	These findings are consistent with the results of previous studies showing that the patients response to clozapine treatment did not correlate with their CYP2D6 genotype, and the association between clozapine clearance in patients and the polymorphic expression of either CYP2D6 or CYP2C19 have failed to be demonstrated. 	CYP2D6	22883	22889	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26734	26740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26734	26740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26734	26740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26734	26740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26797	26803	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26797	26803	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26797	26803	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26797	26803	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26907	26913	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26907	26913	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26907	26913	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:140	Haloperidol, risperidone, and propranolol are potent CYP2D6 inhibitors that may influence the minor contribution of CYP2D6 to clozapine clearance; however, most of the patients who were co-treated with these drugs carried the CYP2D6 loss-of-function allele. 	CYP2D6	26907	26913	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:141	Genetic factors and/or co-medication therefore could result in CYP2D6 poor metabolism. 	CYP2D6	27002	27008	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:141	Genetic factors and/or co-medication therefore could result in CYP2D6 poor metabolism. 	CYP2D6	27002	27008	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:141	Genetic factors and/or co-medication therefore could result in CYP2D6 poor metabolism. 	CYP2D6	27002	27008	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:141	Genetic factors and/or co-medication therefore could result in CYP2D6 poor metabolism. 	CYP2D6	27002	27008	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:142	According to the guidance of the Pharmacogenetic Working Group of the Royal Dutch Pharmacists Association, no clozapine dose adjustment is needed for patients with CYP2D6 poor metabolism. 	CYP2D6	27190	27196	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:142	According to the guidance of the Pharmacogenetic Working Group of the Royal Dutch Pharmacists Association, no clozapine dose adjustment is needed for patients with CYP2D6 poor metabolism. 	CYP2D6	27190	27196	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:142	According to the guidance of the Pharmacogenetic Working Group of the Royal Dutch Pharmacists Association, no clozapine dose adjustment is needed for patients with CYP2D6 poor metabolism. 	CYP2D6	27190	27196	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:142	According to the guidance of the Pharmacogenetic Working Group of the Royal Dutch Pharmacists Association, no clozapine dose adjustment is needed for patients with CYP2D6 poor metabolism. 	CYP2D6	27190	27196	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2D6	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2D6	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2D6	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP2D6	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:3	CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. 	CYP2D6	327	333	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:3	CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. 	CYP2D6	327	333	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:3	CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. 	CYP2D6	327	333	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:3	CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. 	CYP2D6	327	333	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:10	Accounting for CYP2D6 genotype status did not change these estimates. 	CYP2D6	1155	1161	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:10	Accounting for CYP2D6 genotype status did not change these estimates. 	CYP2D6	1155	1161	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:10	Accounting for CYP2D6 genotype status did not change these estimates. 	CYP2D6	1155	1161	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:10	Accounting for CYP2D6 genotype status did not change these estimates. 	CYP2D6	1155	1161	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2546	2552	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2546	2552	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2546	2552	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2546	2552	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:18	CYP2D6 is the principal enzyme catalyzing the conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome of tamoxifen treatment has been extensively studied^,. 	CYP2D6	2677	2683	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:19	Two of the largest datasets reported a null-association, but contradictory findings have led to ongoing controversy over the value of using CYP2D6 genotyping to guide the prescription of tamoxifen^-. 	CYP2D6	2895	2901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:19	Two of the largest datasets reported a null-association, but contradictory findings have led to ongoing controversy over the value of using CYP2D6 genotyping to guide the prescription of tamoxifen^-. 	CYP2D6	2895	2901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:19	Two of the largest datasets reported a null-association, but contradictory findings have led to ongoing controversy over the value of using CYP2D6 genotyping to guide the prescription of tamoxifen^-. 	CYP2D6	2895	2901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:19	Two of the largest datasets reported a null-association, but contradictory findings have led to ongoing controversy over the value of using CYP2D6 genotyping to guide the prescription of tamoxifen^-. 	CYP2D6	2895	2901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:41	Potential covariates of interest were: age, ethnicity, menopausal status, tumor grade and stage, progesterone receptor (PR) status, use of other adjuvant therapies (radiation and chemotherapy), and CYP2D6 metabolizer phenotype. 	CYP2D6	6688	6694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:41	Potential covariates of interest were: age, ethnicity, menopausal status, tumor grade and stage, progesterone receptor (PR) status, use of other adjuvant therapies (radiation and chemotherapy), and CYP2D6 metabolizer phenotype. 	CYP2D6	6688	6694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:41	Potential covariates of interest were: age, ethnicity, menopausal status, tumor grade and stage, progesterone receptor (PR) status, use of other adjuvant therapies (radiation and chemotherapy), and CYP2D6 metabolizer phenotype. 	CYP2D6	6688	6694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:41	Potential covariates of interest were: age, ethnicity, menopausal status, tumor grade and stage, progesterone receptor (PR) status, use of other adjuvant therapies (radiation and chemotherapy), and CYP2D6 metabolizer phenotype. 	CYP2D6	6688	6694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7640	7646	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7640	7646	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7640	7646	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7640	7646	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7813	7819	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7813	7819	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7813	7819	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:47	A variable encoding individuals CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of CYP2D6-inhibiting drugs. 	CYP2D6	7813	7819	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:48	We generated a variable designating overall tamoxifen metabolic activity (high, intermediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth^. 	CYP2D6	7952	7958	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:48	We generated a variable designating overall tamoxifen metabolic activity (high, intermediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth^. 	CYP2D6	7952	7958	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:48	We generated a variable designating overall tamoxifen metabolic activity (high, intermediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth^. 	CYP2D6	7952	7958	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:48	We generated a variable designating overall tamoxifen metabolic activity (high, intermediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth^. 	CYP2D6	7952	7958	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:54	Supplemental analyses stratified by CYP2D6 phenotype and menopausal status were also performed. 	CYP2D6	8901	8907	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:54	Supplemental analyses stratified by CYP2D6 phenotype and menopausal status were also performed. 	CYP2D6	8901	8907	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:54	Supplemental analyses stratified by CYP2D6 phenotype and menopausal status were also performed. 	CYP2D6	8901	8907	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:54	Supplemental analyses stratified by CYP2D6 phenotype and menopausal status were also performed. 	CYP2D6	8901	8907	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2D6	10646	10652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2D6	10646	10652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2D6	10646	10652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:67	Both variants were in Hardy-Weinberg equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005) For the CYP2C19*2 allele, adjusted hazard ratios for associations between variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), respectively and 0.57 (0.26, 1.24), respectively (Table. 	CYP2D6	10646	10652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:68	Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between CYP2C19 genotype and DFS (Supplementary Table. 	CYP2D6	10958	10964	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:68	Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between CYP2C19 genotype and DFS (Supplementary Table. 	CYP2D6	10958	10964	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:68	Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between CYP2C19 genotype and DFS (Supplementary Table. 	CYP2D6	10958	10964	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:68	Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between CYP2C19 genotype and DFS (Supplementary Table. 	CYP2D6	10958	10964	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:71	For the CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically designated high and intermediate tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45-1.66) and 0.89 (95% CI: 0.46-1.74), respectively, compared with the low metabolic activity group. 	CYP2D6	11278	11284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:71	For the CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically designated high and intermediate tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45-1.66) and 0.89 (95% CI: 0.46-1.74), respectively, compared with the low metabolic activity group. 	CYP2D6	11278	11284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:71	For the CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically designated high and intermediate tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45-1.66) and 0.89 (95% CI: 0.46-1.74), respectively, compared with the low metabolic activity group. 	CYP2D6	11278	11284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:71	For the CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically designated high and intermediate tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45-1.66) and 0.89 (95% CI: 0.46-1.74), respectively, compared with the low metabolic activity group. 	CYP2D6	11278	11284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:72	The corresponding adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 0.73-1.94) and 1.21 (95% CI: 0.80-1.85). 	CYP2D6	11626	11632	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:72	The corresponding adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 0.73-1.94) and 1.21 (95% CI: 0.80-1.85). 	CYP2D6	11626	11632	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:72	The corresponding adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 0.73-1.94) and 1.21 (95% CI: 0.80-1.85). 	CYP2D6	11626	11632	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:72	The corresponding adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 0.73-1.94) and 1.21 (95% CI: 0.80-1.85). 	CYP2D6	11626	11632	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:74	A secondary analysis of CYP2C19 genotype accounting for CYP2D6 phenotypes resulted in little change to the observation. 	CYP2D6	11966	11972	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:74	A secondary analysis of CYP2C19 genotype accounting for CYP2D6 phenotypes resulted in little change to the observation. 	CYP2D6	11966	11972	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:74	A secondary analysis of CYP2C19 genotype accounting for CYP2D6 phenotypes resulted in little change to the observation. 	CYP2D6	11966	11972	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:74	A secondary analysis of CYP2C19 genotype accounting for CYP2D6 phenotypes resulted in little change to the observation. 	CYP2D6	11966	11972	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2D6	12826	12832	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2D6	12826	12832	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2D6	12826	12832	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:79	Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth et al.^) did not suggest that this is of clinical relevance which yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. 	CYP2D6	12826	12832	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:94	Our findings for the *17 allele are consistent with results from a smaller, similar study, which reported a hazard ratio of 0.93 (95% CI = 0.64, 1.37) and found a near-null association among those with impaired CYP2D6^. 	CYP2D6	15513	15519	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:94	Our findings for the *17 allele are consistent with results from a smaller, similar study, which reported a hazard ratio of 0.93 (95% CI = 0.64, 1.37) and found a near-null association among those with impaired CYP2D6^. 	CYP2D6	15513	15519	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:94	Our findings for the *17 allele are consistent with results from a smaller, similar study, which reported a hazard ratio of 0.93 (95% CI = 0.64, 1.37) and found a near-null association among those with impaired CYP2D6^. 	CYP2D6	15513	15519	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:94	Our findings for the *17 allele are consistent with results from a smaller, similar study, which reported a hazard ratio of 0.93 (95% CI = 0.64, 1.37) and found a near-null association among those with impaired CYP2D6^. 	CYP2D6	15513	15519	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:95	Despite the biologic plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified analyses do not support this hypothesis. 	CYP2D6	15618	15624	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:95	Despite the biologic plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified analyses do not support this hypothesis. 	CYP2D6	15618	15624	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:95	Despite the biologic plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified analyses do not support this hypothesis. 	CYP2D6	15618	15624	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:95	Despite the biologic plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified analyses do not support this hypothesis. 	CYP2D6	15618	15624	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2D6	15791	15797	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2D6	15791	15797	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2D6	15791	15797	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2D6	15791	15797	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:104	analyzed the ITPC dataset and reported poorer disease-free survival among CYP2D6 poor metabolizers and a weak association between poor metabolizer status and a shorter breast cancer-free interval^. 	CYP2D6	17113	17119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:104	analyzed the ITPC dataset and reported poorer disease-free survival among CYP2D6 poor metabolizers and a weak association between poor metabolizer status and a shorter breast cancer-free interval^. 	CYP2D6	17113	17119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:104	analyzed the ITPC dataset and reported poorer disease-free survival among CYP2D6 poor metabolizers and a weak association between poor metabolizer status and a shorter breast cancer-free interval^. 	CYP2D6	17113	17119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:104	analyzed the ITPC dataset and reported poorer disease-free survival among CYP2D6 poor metabolizers and a weak association between poor metabolizer status and a shorter breast cancer-free interval^. 	CYP2D6	17113	17119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP2D6	2186	2192	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP2D6	2186	2192	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP2D6	2186	2192	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP2D6	2186	2192	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2D6	35867	35873	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2D6	35867	35873	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2D6	35867	35873	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP2D6	35867	35873	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:211	Some compounds in series 4 showed a liability risk for their effects on hERG, CYP2D6, and WI-38 cells, which appears to be due to the introduction of the second nitrogen atom that can induce a toxic effect on the thiadiazole core. 	CYP2D6	36610	36616	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:211	Some compounds in series 4 showed a liability risk for their effects on hERG, CYP2D6, and WI-38 cells, which appears to be due to the introduction of the second nitrogen atom that can induce a toxic effect on the thiadiazole core. 	CYP2D6	36610	36616	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:211	Some compounds in series 4 showed a liability risk for their effects on hERG, CYP2D6, and WI-38 cells, which appears to be due to the introduction of the second nitrogen atom that can induce a toxic effect on the thiadiazole core. 	CYP2D6	36610	36616	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:211	Some compounds in series 4 showed a liability risk for their effects on hERG, CYP2D6, and WI-38 cells, which appears to be due to the introduction of the second nitrogen atom that can induce a toxic effect on the thiadiazole core. 	CYP2D6	36610	36616	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:217	In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and mitochondrial toxicity, there is a selectivity index of around 3-4 fold, thus showing an acceptable profile. 	CYP2D6	37486	37492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:217	In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and mitochondrial toxicity, there is a selectivity index of around 3-4 fold, thus showing an acceptable profile. 	CYP2D6	37486	37492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:217	In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and mitochondrial toxicity, there is a selectivity index of around 3-4 fold, thus showing an acceptable profile. 	CYP2D6	37486	37492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:217	In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and mitochondrial toxicity, there is a selectivity index of around 3-4 fold, thus showing an acceptable profile. 	CYP2D6	37486	37492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2D6	476	482	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2D6	476	482	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2D6	476	482	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP2D6	476	482	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2D6	5841	5847	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2D6	5841	5847	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2D6	5841	5847	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP2D6	5841	5847	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6888	6894	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6888	6894	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6888	6894	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP2D6	6888	6894	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2D6	6976	6982	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2D6	6976	6982	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2D6	6976	6982	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP2D6	6976	6982	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2D6	13148	13154	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2D6	13148	13154	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2D6	13148	13154	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP2D6	13148	13154	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2D6	14126	14132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2D6	14126	14132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2D6	14126	14132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP2D6	14126	14132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2D6	18375	18381	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2D6	18375	18381	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2D6	18375	18381	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP2D6	18375	18381	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:5	We used targeted genotyping data as a benchmark to assess accuracy of variant calling, and to identify copy number variations of the CYP2D6 gene. 	CYP2D6	690	696	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:5	We used targeted genotyping data as a benchmark to assess accuracy of variant calling, and to identify copy number variations of the CYP2D6 gene. 	CYP2D6	690	696	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:5	We used targeted genotyping data as a benchmark to assess accuracy of variant calling, and to identify copy number variations of the CYP2D6 gene. 	CYP2D6	690	696	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:5	We used targeted genotyping data as a benchmark to assess accuracy of variant calling, and to identify copy number variations of the CYP2D6 gene. 	CYP2D6	690	696	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	849	855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	849	855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	849	855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	849	855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	1104	1110	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	1104	1110	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	1104	1110	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:8	Concordance of CYP2D6 predicted phenotype between estimates of whole-genome sequencing and targeted genotyping panel were 90%; a result from a lower coverage depth or variant calling difficulties in our whole-genome sequencing data when copy number variation and/or the CYP2D6*4 haplotype were present. 	CYP2D6	1104	1110	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:29	We also compared estimates of CYP2D6 gene copy number between WGS and targeted genotyping. 	CYP2D6	4767	4773	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:29	We also compared estimates of CYP2D6 gene copy number between WGS and targeted genotyping. 	CYP2D6	4767	4773	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:29	We also compared estimates of CYP2D6 gene copy number between WGS and targeted genotyping. 	CYP2D6	4767	4773	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:29	We also compared estimates of CYP2D6 gene copy number between WGS and targeted genotyping. 	CYP2D6	4767	4773	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:34	We used the targeted genotyping data as a benchmark to assess variant calling and to predict copy number status of the CYP2D6 gene. 	CYP2D6	5694	5700	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:34	We used the targeted genotyping data as a benchmark to assess variant calling and to predict copy number status of the CYP2D6 gene. 	CYP2D6	5694	5700	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:34	We used the targeted genotyping data as a benchmark to assess variant calling and to predict copy number status of the CYP2D6 gene. 	CYP2D6	5694	5700	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:34	We used the targeted genotyping data as a benchmark to assess variant calling and to predict copy number status of the CYP2D6 gene. 	CYP2D6	5694	5700	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5821	5827	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5821	5827	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5821	5827	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5821	5827	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5848	5854	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5848	5854	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5848	5854	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:36	We genotyped 98 subjects with the iPLEX ADME CYP2D6 Panel, analyzing 29 CYP2D6 SNP and indel variants, with a 99.8% success rate (2835 genotypes). 	CYP2D6	5848	5854	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:40	This metric was over 99% in non-CYP2D6 positions. 	CYP2D6	6318	6324	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:40	This metric was over 99% in non-CYP2D6 positions. 	CYP2D6	6318	6324	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:40	This metric was over 99% in non-CYP2D6 positions. 	CYP2D6	6318	6324	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:40	This metric was over 99% in non-CYP2D6 positions. 	CYP2D6	6318	6324	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6486	6492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6486	6492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6486	6492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6486	6492	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6621	6627	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6621	6627	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6621	6627	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:42	Seven positions in CYP2D6 were missing calls in more than 10 patients in WGS due to low-confidence calling; rs16947, a common CYP2D6 variant found in the CYP2D6*2 haplotype among others, was the most frequently missed position (60 of the 98 subjects). 	CYP2D6	6621	6627	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6924	6930	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6924	6930	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6924	6930	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6924	6930	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6993	6999	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6993	6999	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6993	6999	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	6993	6999	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7058	7064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7058	7064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7058	7064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7058	7064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7159	7165	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7159	7165	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7159	7165	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:44	For subjects missing a call for rs16947 and/or additional variants, the most likely CYP2D6 diplotype was manually and individually assigned by using the CYP2D6 star nomenclature^ carried rs3892097 variant defining the CYP2D6*4 haplotype and seven subjects (Patient ID: 1039, 1053, 1063, 1086, 1090, 1093, and 1096) had CYP2D6 copy number gains or losses (described below). 	CYP2D6	7159	7165	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:45	One sample (Patient ID 1093) carried a combination of both (copy number gain + CYP2D6*4). 	CYP2D6	7292	7298	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:45	One sample (Patient ID 1093) carried a combination of both (copy number gain + CYP2D6*4). 	CYP2D6	7292	7298	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:45	One sample (Patient ID 1093) carried a combination of both (copy number gain + CYP2D6*4). 	CYP2D6	7292	7298	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:45	One sample (Patient ID 1093) carried a combination of both (copy number gain + CYP2D6*4). 	CYP2D6	7292	7298	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:46	Lastly, we looked at coding variants in the CYP2D6 gene outside of the set examined here were investigated further because of their potential to affect metabolizer status depending on the allele they occur in. 	CYP2D6	7347	7353	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:46	Lastly, we looked at coding variants in the CYP2D6 gene outside of the set examined here were investigated further because of their potential to affect metabolizer status depending on the allele they occur in. 	CYP2D6	7347	7353	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:46	Lastly, we looked at coding variants in the CYP2D6 gene outside of the set examined here were investigated further because of their potential to affect metabolizer status depending on the allele they occur in. 	CYP2D6	7347	7353	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:46	Lastly, we looked at coding variants in the CYP2D6 gene outside of the set examined here were investigated further because of their potential to affect metabolizer status depending on the allele they occur in. 	CYP2D6	7347	7353	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8043	8049	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8043	8049	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8043	8049	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8043	8049	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8138	8144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8138	8144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8138	8144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:51	CNV in CYP2D6 is relatively common, and has been established as important accompanying information in CYP2D6 typing. 	CYP2D6	8138	8144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8172	8178	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8172	8178	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8172	8178	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8172	8178	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8343	8349	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8343	8349	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8343	8349	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:52	^ When we examined CYP2D6-overlapping CNVs in the Complete Genomics cnvSegmentsDiploidBeta and high ConfidenceSVEventsBeta files, only one sample was flagged as having a copy number gain of CYP2D6. 	CYP2D6	8343	8349	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:53	We instead extracted relative coverage (defined as normalized coverage level under a diploid model, a value of 1 being 2-copy) for a 6 kb window containing CYP2D6. 	CYP2D6	8507	8513	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:53	We instead extracted relative coverage (defined as normalized coverage level under a diploid model, a value of 1 being 2-copy) for a 6 kb window containing CYP2D6. 	CYP2D6	8507	8513	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:53	We instead extracted relative coverage (defined as normalized coverage level under a diploid model, a value of 1 being 2-copy) for a 6 kb window containing CYP2D6. 	CYP2D6	8507	8513	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:53	We instead extracted relative coverage (defined as normalized coverage level under a diploid model, a value of 1 being 2-copy) for a 6 kb window containing CYP2D6. 	CYP2D6	8507	8513	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:57	A subset of nine samples was inconclusive for copy number by this method, as they exhibited intermediate values of average relative coverage (between 0.5 and 1 or between 1 and 1.5) contain the CYP2D6*4 variant rs3892097 in this way. 	CYP2D6	9137	9143	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:57	A subset of nine samples was inconclusive for copy number by this method, as they exhibited intermediate values of average relative coverage (between 0.5 and 1 or between 1 and 1.5) contain the CYP2D6*4 variant rs3892097 in this way. 	CYP2D6	9137	9143	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:57	A subset of nine samples was inconclusive for copy number by this method, as they exhibited intermediate values of average relative coverage (between 0.5 and 1 or between 1 and 1.5) contain the CYP2D6*4 variant rs3892097 in this way. 	CYP2D6	9137	9143	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:57	A subset of nine samples was inconclusive for copy number by this method, as they exhibited intermediate values of average relative coverage (between 0.5 and 1 or between 1 and 1.5) contain the CYP2D6*4 variant rs3892097 in this way. 	CYP2D6	9137	9143	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:59	Of the nine samples (Patient ID: 1009, 1025, 1031, 1043, 1068, 1070, 1072, 1074, 1112) inconclusive for genomic copy number of CYP2D6 in WGS data, one sample (Patient ID: 1074) was estimated to be one copy while the other eight samples were classified as a two copy using the targeted genotyping panel (Table. 	CYP2D6	9629	9635	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:59	Of the nine samples (Patient ID: 1009, 1025, 1031, 1043, 1068, 1070, 1072, 1074, 1112) inconclusive for genomic copy number of CYP2D6 in WGS data, one sample (Patient ID: 1074) was estimated to be one copy while the other eight samples were classified as a two copy using the targeted genotyping panel (Table. 	CYP2D6	9629	9635	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:59	Of the nine samples (Patient ID: 1009, 1025, 1031, 1043, 1068, 1070, 1072, 1074, 1112) inconclusive for genomic copy number of CYP2D6 in WGS data, one sample (Patient ID: 1074) was estimated to be one copy while the other eight samples were classified as a two copy using the targeted genotyping panel (Table. 	CYP2D6	9629	9635	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:59	Of the nine samples (Patient ID: 1009, 1025, 1031, 1043, 1068, 1070, 1072, 1074, 1112) inconclusive for genomic copy number of CYP2D6 in WGS data, one sample (Patient ID: 1074) was estimated to be one copy while the other eight samples were classified as a two copy using the targeted genotyping panel (Table. 	CYP2D6	9629	9635	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:61	In the 12 WES samples, the 67 loci were sequenced to an average depth of 140X, and there were no missing calls for variants in exonic regions were not covered by this WES data set, however, all other CYP2D6 positions were successfully genotyped. 	CYP2D6	10122	10128	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:61	In the 12 WES samples, the 67 loci were sequenced to an average depth of 140X, and there were no missing calls for variants in exonic regions were not covered by this WES data set, however, all other CYP2D6 positions were successfully genotyped. 	CYP2D6	10122	10128	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:61	In the 12 WES samples, the 67 loci were sequenced to an average depth of 140X, and there were no missing calls for variants in exonic regions were not covered by this WES data set, however, all other CYP2D6 positions were successfully genotyped. 	CYP2D6	10122	10128	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:61	In the 12 WES samples, the 67 loci were sequenced to an average depth of 140X, and there were no missing calls for variants in exonic regions were not covered by this WES data set, however, all other CYP2D6 positions were successfully genotyped. 	CYP2D6	10122	10128	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:75	However, we also found WGS was not able to accurately genotype several positions in CYP2D6. 	CYP2D6	12825	12831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:75	However, we also found WGS was not able to accurately genotype several positions in CYP2D6. 	CYP2D6	12825	12831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:75	However, we also found WGS was not able to accurately genotype several positions in CYP2D6. 	CYP2D6	12825	12831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:75	However, we also found WGS was not able to accurately genotype several positions in CYP2D6. 	CYP2D6	12825	12831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:76	In particular, genotype information for the rs16947 SNP that defines CYP2D6*2-related haplotypes was absent in the majority of subjects (60/98) with WGS data. 	CYP2D6	12902	12908	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:76	In particular, genotype information for the rs16947 SNP that defines CYP2D6*2-related haplotypes was absent in the majority of subjects (60/98) with WGS data. 	CYP2D6	12902	12908	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:76	In particular, genotype information for the rs16947 SNP that defines CYP2D6*2-related haplotypes was absent in the majority of subjects (60/98) with WGS data. 	CYP2D6	12902	12908	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:76	In particular, genotype information for the rs16947 SNP that defines CYP2D6*2-related haplotypes was absent in the majority of subjects (60/98) with WGS data. 	CYP2D6	12902	12908	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:78	In a clinical setting, these individuals would require reflexed testing using targeted genotyping of the CYP2D6 gene. 	CYP2D6	13221	13227	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:78	In a clinical setting, these individuals would require reflexed testing using targeted genotyping of the CYP2D6 gene. 	CYP2D6	13221	13227	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:78	In a clinical setting, these individuals would require reflexed testing using targeted genotyping of the CYP2D6 gene. 	CYP2D6	13221	13227	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:78	In a clinical setting, these individuals would require reflexed testing using targeted genotyping of the CYP2D6 gene. 	CYP2D6	13221	13227	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13287	13293	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13287	13293	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13287	13293	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13287	13293	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13400	13406	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13400	13406	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13400	13406	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:79	We found that individuals with an rs3892097 variant (CYP2D6*4) were more likely to have ambiguous calling (no call or only one allele confidently called) for several CYP2D6 positions. 	CYP2D6	13400	13406	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13673	13679	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13673	13679	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13673	13679	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13673	13679	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13805	13811	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13805	13811	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13805	13811	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:81	Our findings are also consistent with in silico modeling showing that short reads of CYP2D6 multi-align to the highly similar CYP2D7 and CYP2D8 genes,^ leading to the reasonable assumption that WGS variant calling in CYP2D6 will be platform-dependent because of variations in sequence coverage due to chemistry, read length and downstream bioinformatics tools. 	CYP2D6	13805	13811	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:82	^ At this time, we recommend pursuing additional targeted testing for the CYP2D6 gene to confirm WGS data. 	CYP2D6	14023	14029	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:82	^ At this time, we recommend pursuing additional targeted testing for the CYP2D6 gene to confirm WGS data. 	CYP2D6	14023	14029	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:82	^ At this time, we recommend pursuing additional targeted testing for the CYP2D6 gene to confirm WGS data. 	CYP2D6	14023	14029	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:82	^ At this time, we recommend pursuing additional targeted testing for the CYP2D6 gene to confirm WGS data. 	CYP2D6	14023	14029	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:85	In five samples with a copy number gain (Patient ID: 1012, 1018, 1020, 1061, 1085) the prediction of CYP2D6 metabolizer status changed when compared to an individual of the same genotype without a duplication from 12 individuals of our patient cohort and compared the variant calling data for the 67 positions to targeted genotyping data. 	CYP2D6	14734	14740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:85	In five samples with a copy number gain (Patient ID: 1012, 1018, 1020, 1061, 1085) the prediction of CYP2D6 metabolizer status changed when compared to an individual of the same genotype without a duplication from 12 individuals of our patient cohort and compared the variant calling data for the 67 positions to targeted genotyping data. 	CYP2D6	14734	14740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:85	In five samples with a copy number gain (Patient ID: 1012, 1018, 1020, 1061, 1085) the prediction of CYP2D6 metabolizer status changed when compared to an individual of the same genotype without a duplication from 12 individuals of our patient cohort and compared the variant calling data for the 67 positions to targeted genotyping data. 	CYP2D6	14734	14740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:85	In five samples with a copy number gain (Patient ID: 1012, 1018, 1020, 1061, 1085) the prediction of CYP2D6 metabolizer status changed when compared to an individual of the same genotype without a duplication from 12 individuals of our patient cohort and compared the variant calling data for the 67 positions to targeted genotyping data. 	CYP2D6	14734	14740	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:86	Although we anticipated similar variant calling issues as observed in the WGS data, interestingly, WES variant calling in CYP2D6 was highly concordant to targeted genotyping and no position exhibited similar rates of missing data. 	CYP2D6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:86	Although we anticipated similar variant calling issues as observed in the WGS data, interestingly, WES variant calling in CYP2D6 was highly concordant to targeted genotyping and no position exhibited similar rates of missing data. 	CYP2D6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:86	Although we anticipated similar variant calling issues as observed in the WGS data, interestingly, WES variant calling in CYP2D6 was highly concordant to targeted genotyping and no position exhibited similar rates of missing data. 	CYP2D6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:86	Although we anticipated similar variant calling issues as observed in the WGS data, interestingly, WES variant calling in CYP2D6 was highly concordant to targeted genotyping and no position exhibited similar rates of missing data. 	CYP2D6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:87	Two SNPs outside of exons (rs28735595, rs1080985) that are traditionally examined to assign CYP2D6 haplotypes were not captured was covered at a sufficient depth for variant calling (average 47X) indicating that some commercial bait sets may be supplemented to capture intronic regions. 	CYP2D6	15295	15301	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:87	Two SNPs outside of exons (rs28735595, rs1080985) that are traditionally examined to assign CYP2D6 haplotypes were not captured was covered at a sufficient depth for variant calling (average 47X) indicating that some commercial bait sets may be supplemented to capture intronic regions. 	CYP2D6	15295	15301	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:87	Two SNPs outside of exons (rs28735595, rs1080985) that are traditionally examined to assign CYP2D6 haplotypes were not captured was covered at a sufficient depth for variant calling (average 47X) indicating that some commercial bait sets may be supplemented to capture intronic regions. 	CYP2D6	15295	15301	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:87	Two SNPs outside of exons (rs28735595, rs1080985) that are traditionally examined to assign CYP2D6 haplotypes were not captured was covered at a sufficient depth for variant calling (average 47X) indicating that some commercial bait sets may be supplemented to capture intronic regions. 	CYP2D6	15295	15301	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:107	However, it is important to note that variant calling, especially in the CYP2D6 gene, could be challenging depending on sequencing platform used. 	CYP2D6	19049	19055	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:107	However, it is important to note that variant calling, especially in the CYP2D6 gene, could be challenging depending on sequencing platform used. 	CYP2D6	19049	19055	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:107	However, it is important to note that variant calling, especially in the CYP2D6 gene, could be challenging depending on sequencing platform used. 	CYP2D6	19049	19055	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:107	However, it is important to note that variant calling, especially in the CYP2D6 gene, could be challenging depending on sequencing platform used. 	CYP2D6	19049	19055	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:108	For CYP2D6, manual interpretation of WGS data in the form of targeted CNV analysis, inspection of allelic read depth and decision-making surrounding missing markers, was necessary here with data generated on the Complete Genomics platform. 	CYP2D6	19126	19132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:108	For CYP2D6, manual interpretation of WGS data in the form of targeted CNV analysis, inspection of allelic read depth and decision-making surrounding missing markers, was necessary here with data generated on the Complete Genomics platform. 	CYP2D6	19126	19132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:108	For CYP2D6, manual interpretation of WGS data in the form of targeted CNV analysis, inspection of allelic read depth and decision-making surrounding missing markers, was necessary here with data generated on the Complete Genomics platform. 	CYP2D6	19126	19132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:108	For CYP2D6, manual interpretation of WGS data in the form of targeted CNV analysis, inspection of allelic read depth and decision-making surrounding missing markers, was necessary here with data generated on the Complete Genomics platform. 	CYP2D6	19126	19132	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:109	Further PCR-based testing could also be done on some subjects to determine if they harbor structural variants of CYP2D6 not detectable by the methods here. 	CYP2D6	19475	19481	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:109	Further PCR-based testing could also be done on some subjects to determine if they harbor structural variants of CYP2D6 not detectable by the methods here. 	CYP2D6	19475	19481	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:109	Further PCR-based testing could also be done on some subjects to determine if they harbor structural variants of CYP2D6 not detectable by the methods here. 	CYP2D6	19475	19481	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:109	Further PCR-based testing could also be done on some subjects to determine if they harbor structural variants of CYP2D6 not detectable by the methods here. 	CYP2D6	19475	19481	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:112	In the case of CYP2D6, the copy number status is an integral part of typing an individual so this testing would need to be done separately via quantitative PCR or other method. 	CYP2D6	19859	19865	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:112	In the case of CYP2D6, the copy number status is an integral part of typing an individual so this testing would need to be done separately via quantitative PCR or other method. 	CYP2D6	19859	19865	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:112	In the case of CYP2D6, the copy number status is an integral part of typing an individual so this testing would need to be done separately via quantitative PCR or other method. 	CYP2D6	19859	19865	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:112	In the case of CYP2D6, the copy number status is an integral part of typing an individual so this testing would need to be done separately via quantitative PCR or other method. 	CYP2D6	19859	19865	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23132	23138	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23132	23138	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23132	23138	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23132	23138	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23185	23191	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23185	23191	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23185	23191	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:134	Twenty-nine SNP and indel variants as well as copy number status of the CYP2D6 gene were analyzed using the Agena iPLEX ADME CYP2D6 Panel v1.0, which is a 3-well assay combining genotyping for SNP and indel variants as well as five assays to determine genomic copy number. 	CYP2D6	23185	23191	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:136	^ CYP2D6 diplotypes and CNV calling for MassArray data were determined using the Agena PGx Report 2.0 Reporter plugin for the Typer Analyzer software (Agena Bioscience). 	CYP2D6	23471	23477	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:136	^ CYP2D6 diplotypes and CNV calling for MassArray data were determined using the Agena PGx Report 2.0 Reporter plugin for the Typer Analyzer software (Agena Bioscience). 	CYP2D6	23471	23477	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:136	^ CYP2D6 diplotypes and CNV calling for MassArray data were determined using the Agena PGx Report 2.0 Reporter plugin for the Typer Analyzer software (Agena Bioscience). 	CYP2D6	23471	23477	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:136	^ CYP2D6 diplotypes and CNV calling for MassArray data were determined using the Agena PGx Report 2.0 Reporter plugin for the Typer Analyzer software (Agena Bioscience). 	CYP2D6	23471	23477	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23639	23645	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23639	23645	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23639	23645	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23639	23645	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23732	23738	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23732	23738	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23732	23738	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23732	23738	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23816	23822	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23816	23822	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23816	23822	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:137	CYP2D6 copy number was estimated from the five copy number assays that are integrated in the CYP2D6 genotyping panel, which is calculated from informative polymorphisms between CYP2D6 and CYP2D7. 	CYP2D6	23816	23822	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2D6	24862	24868	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2D6	24862	24868	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2D6	24862	24868	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP2D6	24862	24868	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:145	Furthermore, phenotype assignments such as poor, intermediate, extensive, and ultrarapid metabolizers were determined by utilizing the corresponding published CPIC guidelines^- and for CYP2D6, the activity score system as described elsewhere. 	CYP2D6	25139	25145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:145	Furthermore, phenotype assignments such as poor, intermediate, extensive, and ultrarapid metabolizers were determined by utilizing the corresponding published CPIC guidelines^- and for CYP2D6, the activity score system as described elsewhere. 	CYP2D6	25139	25145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:145	Furthermore, phenotype assignments such as poor, intermediate, extensive, and ultrarapid metabolizers were determined by utilizing the corresponding published CPIC guidelines^- and for CYP2D6, the activity score system as described elsewhere. 	CYP2D6	25139	25145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:145	Furthermore, phenotype assignments such as poor, intermediate, extensive, and ultrarapid metabolizers were determined by utilizing the corresponding published CPIC guidelines^- and for CYP2D6, the activity score system as described elsewhere. 	CYP2D6	25139	25145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP2D6	3664	3670	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP2D6	3664	3670	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP2D6	3664	3670	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP2D6	3664	3670	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2D6	4551	4557	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2D6	4551	4557	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2D6	4551	4557	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP2D6	4551	4557	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP2D6	5661	5667	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP2D6	5661	5667	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP2D6	5661	5667	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP2D6	5661	5667	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2D6	16554	16560	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2D6	16554	16560	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2D6	16554	16560	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:125	In fact, the influence of ethanol on CYP2C9 activity seems to be substrate dependent, with a significant inhibition on warfarin metabolism at 0.1 vol% and no inhibition of diclofenac metabolism at 1 vol% (Tatsumi et al.. In general, the influence of ethanol on CYP2C9 differs from that on CYP2D6, where Hellum and Nilsen found a biphasic effect with a small inhibition at 0.1%, a significant activation at 0.5%, 0.8%, 1.1%, 1.5%, and 5%, and a significant inhibition at 8% and 15%. 	CYP2D6	16554	16560	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2D6	17069	17075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2D6	17069	17075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2D6	17069	17075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2D6	17069	17075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP2D6	17466	17472	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP2D6	17466	17472	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP2D6	17466	17472	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP2D6	17466	17472	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2D6	17793	17799	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2D6	17793	17799	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2D6	17793	17799	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP2D6	17793	17799	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21679	21685	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21679	21685	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21679	21685	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21679	21685	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21824	21830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21824	21830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21824	21830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP2D6	21824	21830	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2D6	8264	8270	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2D6	8264	8270	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2D6	8264	8270	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2D6	8264	8270	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2D6	16144	16150	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2D6	16144	16150	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2D6	16144	16150	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2D6	16144	16150	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2D6	16538	16544	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2D6	16538	16544	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2D6	16538	16544	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2D6	16538	16544	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2D6	17536	17542	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2D6	17536	17542	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2D6	17536	17542	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2D6	17536	17542	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:94	Nevertheless, the predicted CL_int values of CYP2D6 (P=0.003) and 3A4/5 (P=0.014) were significantly higher than the measured values. 	CYP2D6	17962	17968	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:94	Nevertheless, the predicted CL_int values of CYP2D6 (P=0.003) and 3A4/5 (P=0.014) were significantly higher than the measured values. 	CYP2D6	17962	17968	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:94	Nevertheless, the predicted CL_int values of CYP2D6 (P=0.003) and 3A4/5 (P=0.014) were significantly higher than the measured values. 	CYP2D6	17962	17968	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:94	Nevertheless, the predicted CL_int values of CYP2D6 (P=0.003) and 3A4/5 (P=0.014) were significantly higher than the measured values. 	CYP2D6	17962	17968	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2D6	18743	18749	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2D6	18743	18749	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2D6	18743	18749	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP2D6	18743	18749	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP2D6	41303	41309	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP2D6	41303	41309	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP2D6	41303	41309	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP2D6	41303	41309	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP2D6	41879	41885	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP2D6	41879	41885	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP2D6	41879	41885	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP2D6	41879	41885	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2D6	8831	8837	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2D6	8831	8837	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2D6	8831	8837	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2D6	8831	8837	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:159	The CYP2D6 enzyme metabolizes many basic drugs including opioids, antidepressants (eg, nortriptyline and fluoxetine), antipsychotics (eg, risperidone) and -blockers (eg, metoprolol). 	CYP2D6	25285	25291	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:159	The CYP2D6 enzyme metabolizes many basic drugs including opioids, antidepressants (eg, nortriptyline and fluoxetine), antipsychotics (eg, risperidone) and -blockers (eg, metoprolol). 	CYP2D6	25285	25291	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:159	The CYP2D6 enzyme metabolizes many basic drugs including opioids, antidepressants (eg, nortriptyline and fluoxetine), antipsychotics (eg, risperidone) and -blockers (eg, metoprolol). 	CYP2D6	25285	25291	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:159	The CYP2D6 enzyme metabolizes many basic drugs including opioids, antidepressants (eg, nortriptyline and fluoxetine), antipsychotics (eg, risperidone) and -blockers (eg, metoprolol). 	CYP2D6	25285	25291	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25709	25715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25709	25715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25709	25715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25709	25715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25787	25793	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25787	25793	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25787	25793	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25787	25793	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25829	25835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25829	25835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25829	25835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:161	Individuals homozygous or compound heterozygous for the CYP2D6*3, *4, *5, or *6 variants exhibit no enzyme activity, while those with CYP2D6*1 or *2 gene duplication have more CYP2D6 protein with resulting higher enzymatic activity. 	CYP2D6	25829	25835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:162	This is clinically relevant for codeine, which is metabolized to morphine by CYP2D6. 	CYP2D6	25963	25969	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:162	This is clinically relevant for codeine, which is metabolized to morphine by CYP2D6. 	CYP2D6	25963	25969	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:162	This is clinically relevant for codeine, which is metabolized to morphine by CYP2D6. 	CYP2D6	25963	25969	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:162	This is clinically relevant for codeine, which is metabolized to morphine by CYP2D6. 	CYP2D6	25963	25969	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:163	CYP2D6 PMs may experience an inadequate analgesic effect while UMs are at risk of morphine toxicity. 	CYP2D6	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:163	CYP2D6 PMs may experience an inadequate analgesic effect while UMs are at risk of morphine toxicity. 	CYP2D6	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:163	CYP2D6 PMs may experience an inadequate analgesic effect while UMs are at risk of morphine toxicity. 	CYP2D6	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:163	CYP2D6 PMs may experience an inadequate analgesic effect while UMs are at risk of morphine toxicity. 	CYP2D6	25971	25977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26331	26337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26331	26337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26331	26337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26331	26337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26443	26449	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26443	26449	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26443	26449	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:165	A structurally related drug, dextromethorphan (DEX), is O-demethylated by CYP2D6 to dextrorphan (DXO) and, therefore, the metabolic ratio of DEX/DXO can be used to differentiate between CYP2D6 phenotypes. 	CYP2D6	26443	26449	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26514	26520	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26514	26520	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26514	26520	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26514	26520	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26541	26547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26541	26547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26541	26547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26541	26547	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26572	26578	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26572	26578	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26572	26578	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:166	In Inuit peoples in Canada, the allele frequency of CYP2D6*4 was 6.7-8.3%; the CYP2D6*10 MAF was 2.2% and the CYP2D6*3 and *6 alleles were not detected. 	CYP2D6	26572	26578	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:169	Phenotype results were in agreement with genotype and furthermore, individuals classified as PMs had lower recoveries of DXO as well as other CYP2D6-mediated metabolites, compared to EMs. 	CYP2D6	26948	26954	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:169	Phenotype results were in agreement with genotype and furthermore, individuals classified as PMs had lower recoveries of DXO as well as other CYP2D6-mediated metabolites, compared to EMs. 	CYP2D6	26948	26954	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:169	Phenotype results were in agreement with genotype and furthermore, individuals classified as PMs had lower recoveries of DXO as well as other CYP2D6-mediated metabolites, compared to EMs. 	CYP2D6	26948	26954	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:169	Phenotype results were in agreement with genotype and furthermore, individuals classified as PMs had lower recoveries of DXO as well as other CYP2D6-mediated metabolites, compared to EMs. 	CYP2D6	26948	26954	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:170	Notably, the frequency of the CYP2D6*4 allele in the Inuit population was significantly lower than the MAF reported in the European population (23%) and significantly greater than in the Asian population (<1.0%). 	CYP2D6	27024	27030	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:170	Notably, the frequency of the CYP2D6*4 allele in the Inuit population was significantly lower than the MAF reported in the European population (23%) and significantly greater than in the Asian population (<1.0%). 	CYP2D6	27024	27030	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:170	Notably, the frequency of the CYP2D6*4 allele in the Inuit population was significantly lower than the MAF reported in the European population (23%) and significantly greater than in the Asian population (<1.0%). 	CYP2D6	27024	27030	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:170	Notably, the frequency of the CYP2D6*4 allele in the Inuit population was significantly lower than the MAF reported in the European population (23%) and significantly greater than in the Asian population (<1.0%). 	CYP2D6	27024	27030	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:171	CYP2D6 genotype, as well as phenotype using the O-demethylation ratio of DEX, was determined in a FN population. 	CYP2D6	27207	27213	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:171	CYP2D6 genotype, as well as phenotype using the O-demethylation ratio of DEX, was determined in a FN population. 	CYP2D6	27207	27213	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:171	CYP2D6 genotype, as well as phenotype using the O-demethylation ratio of DEX, was determined in a FN population. 	CYP2D6	27207	27213	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:171	CYP2D6 genotype, as well as phenotype using the O-demethylation ratio of DEX, was determined in a FN population. 	CYP2D6	27207	27213	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:172	The MAFs of CYP2D6*3, *4 and *10 were 0.0, 3.0 and 3.0%, respectively. 	CYP2D6	27332	27338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:172	The MAFs of CYP2D6*3, *4 and *10 were 0.0, 3.0 and 3.0%, respectively. 	CYP2D6	27332	27338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:172	The MAFs of CYP2D6*3, *4 and *10 were 0.0, 3.0 and 3.0%, respectively. 	CYP2D6	27332	27338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:172	The MAFs of CYP2D6*3, *4 and *10 were 0.0, 3.0 and 3.0%, respectively. 	CYP2D6	27332	27338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27441	27447	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27441	27447	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27441	27447	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27441	27447	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27499	27505	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27499	27505	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27499	27505	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:173	Interestingly, the one individual identified as a CYP2D6 PM by phenotyping with DEX was not found to have a CYP2D6*4/*4 genotype. 	CYP2D6	27499	27505	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27688	27694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27688	27694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27688	27694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27688	27694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27718	27724	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27718	27724	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27718	27724	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:175	In the CSKT population, the CYP2D6*1 frequency was 37.6%, CYP2D6*2 occurred at a frequency of 23.4% and copy number variation conferring UM phenotype had a frequency of 1.1%. 	CYP2D6	27718	27724	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:176	The reported frequencies of the PM conferring variants CYP2D6*3, *4, *5 and *6 were 0.3%, 20.9%, 1.3% and 0.0%, respectively. 	CYP2D6	27890	27896	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:176	The reported frequencies of the PM conferring variants CYP2D6*3, *4, *5 and *6 were 0.3%, 20.9%, 1.3% and 0.0%, respectively. 	CYP2D6	27890	27896	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:176	The reported frequencies of the PM conferring variants CYP2D6*3, *4, *5 and *6 were 0.3%, 20.9%, 1.3% and 0.0%, respectively. 	CYP2D6	27890	27896	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:176	The reported frequencies of the PM conferring variants CYP2D6*3, *4, *5 and *6 were 0.3%, 20.9%, 1.3% and 0.0%, respectively. 	CYP2D6	27890	27896	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:177	The reduced activity variants conferring IM phenotype, CYP2D6*10, *17 and *41, had frequencies of 1.3%, 0.0% and 11.2%, respectively. 	CYP2D6	28016	28022	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:177	The reduced activity variants conferring IM phenotype, CYP2D6*10, *17 and *41, had frequencies of 1.3%, 0.0% and 11.2%, respectively. 	CYP2D6	28016	28022	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:177	The reduced activity variants conferring IM phenotype, CYP2D6*10, *17 and *41, had frequencies of 1.3%, 0.0% and 11.2%, respectively. 	CYP2D6	28016	28022	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:177	The reduced activity variants conferring IM phenotype, CYP2D6*10, *17 and *41, had frequencies of 1.3%, 0.0% and 11.2%, respectively. 	CYP2D6	28016	28022	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:178	These allele frequencies are similar to the findings of McGrane and Loveland who performed pharmacogenetic testing in Northwest AI youth and reported MAFs of CYP2D6*3, *4, *5, *6, *10, *17 and *41 as 0.0%, 14.6%, 2.8%, 0.8%, 2.0%, 0.0% and 6.9%, respectively. 	CYP2D6	28253	28259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:178	These allele frequencies are similar to the findings of McGrane and Loveland who performed pharmacogenetic testing in Northwest AI youth and reported MAFs of CYP2D6*3, *4, *5, *6, *10, *17 and *41 as 0.0%, 14.6%, 2.8%, 0.8%, 2.0%, 0.0% and 6.9%, respectively. 	CYP2D6	28253	28259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:178	These allele frequencies are similar to the findings of McGrane and Loveland who performed pharmacogenetic testing in Northwest AI youth and reported MAFs of CYP2D6*3, *4, *5, *6, *10, *17 and *41 as 0.0%, 14.6%, 2.8%, 0.8%, 2.0%, 0.0% and 6.9%, respectively. 	CYP2D6	28253	28259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:178	These allele frequencies are similar to the findings of McGrane and Loveland who performed pharmacogenetic testing in Northwest AI youth and reported MAFs of CYP2D6*3, *4, *5, *6, *10, *17 and *41 as 0.0%, 14.6%, 2.8%, 0.8%, 2.0%, 0.0% and 6.9%, respectively. 	CYP2D6	28253	28259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28391	28397	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28391	28397	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28391	28397	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28391	28397	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28404	28410	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28404	28410	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28404	28410	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28404	28410	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28508	28514	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28508	28514	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28508	28514	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:179	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 could have clinical implications, particularly with medications that require bioactivation by CYP2D6 to an active metabolite to be clinically effective. 	CYP2D6	28508	28514	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:181	CYP2D6 is the primary enzyme responsible for metabolizing tamoxifen to endoxifen, a major active metabolite responsible for much of tamoxifens therapeutic effect. 	CYP2D6	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:181	CYP2D6 is the primary enzyme responsible for metabolizing tamoxifen to endoxifen, a major active metabolite responsible for much of tamoxifens therapeutic effect. 	CYP2D6	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:181	CYP2D6 is the primary enzyme responsible for metabolizing tamoxifen to endoxifen, a major active metabolite responsible for much of tamoxifens therapeutic effect. 	CYP2D6	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:181	CYP2D6 is the primary enzyme responsible for metabolizing tamoxifen to endoxifen, a major active metabolite responsible for much of tamoxifens therapeutic effect. 	CYP2D6	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:182	Therefore, it is important to understand the distribution of CYP2D6 activity within different patient populations. 	CYP2D6	28931	28937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:182	Therefore, it is important to understand the distribution of CYP2D6 activity within different patient populations. 	CYP2D6	28931	28937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:182	Therefore, it is important to understand the distribution of CYP2D6 activity within different patient populations. 	CYP2D6	28931	28937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:182	Therefore, it is important to understand the distribution of CYP2D6 activity within different patient populations. 	CYP2D6	28931	28937	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:183	In the Northwest CSKT and AI youth populations, the overall prevalence of low activity CYP2D6, including both PMs and IMs, was 9.1% and 20.3%, respectively. 	CYP2D6	29072	29078	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:183	In the Northwest CSKT and AI youth populations, the overall prevalence of low activity CYP2D6, including both PMs and IMs, was 9.1% and 20.3%, respectively. 	CYP2D6	29072	29078	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:183	In the Northwest CSKT and AI youth populations, the overall prevalence of low activity CYP2D6, including both PMs and IMs, was 9.1% and 20.3%, respectively. 	CYP2D6	29072	29078	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:183	In the Northwest CSKT and AI youth populations, the overall prevalence of low activity CYP2D6, including both PMs and IMs, was 9.1% and 20.3%, respectively. 	CYP2D6	29072	29078	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:185	performed CYP2D6 genotyping in Tarahumaras from Chihuahua, Purepechas from Michoacn, Tojolabales, Tzotziles and Tzeltales from Chiapas and Tepehuanos from Durango. 	CYP2D6	29174	29180	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:185	performed CYP2D6 genotyping in Tarahumaras from Chihuahua, Purepechas from Michoacn, Tojolabales, Tzotziles and Tzeltales from Chiapas and Tepehuanos from Durango. 	CYP2D6	29174	29180	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:185	performed CYP2D6 genotyping in Tarahumaras from Chihuahua, Purepechas from Michoacn, Tojolabales, Tzotziles and Tzeltales from Chiapas and Tepehuanos from Durango. 	CYP2D6	29174	29180	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:185	performed CYP2D6 genotyping in Tarahumaras from Chihuahua, Purepechas from Michoacn, Tojolabales, Tzotziles and Tzeltales from Chiapas and Tepehuanos from Durango. 	CYP2D6	29174	29180	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:186	The MAFs reported for CYP2D6*4 were 7.3%, 2.9%, 1.2%, 2.7% and 5.3% for Tarahumaras, Purepechas, Tojolabales, Tzotziles and Tzeltales, respectively. 	CYP2D6	29350	29356	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:186	The MAFs reported for CYP2D6*4 were 7.3%, 2.9%, 1.2%, 2.7% and 5.3% for Tarahumaras, Purepechas, Tojolabales, Tzotziles and Tzeltales, respectively. 	CYP2D6	29350	29356	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:186	The MAFs reported for CYP2D6*4 were 7.3%, 2.9%, 1.2%, 2.7% and 5.3% for Tarahumaras, Purepechas, Tojolabales, Tzotziles and Tzeltales, respectively. 	CYP2D6	29350	29356	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:186	The MAFs reported for CYP2D6*4 were 7.3%, 2.9%, 1.2%, 2.7% and 5.3% for Tarahumaras, Purepechas, Tojolabales, Tzotziles and Tzeltales, respectively. 	CYP2D6	29350	29356	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:187	CYP2D6*3, *6, *7 and *8 were not detected in any of the Amerindian populations studied. 	CYP2D6	29477	29483	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:187	CYP2D6*3, *6, *7 and *8 were not detected in any of the Amerindian populations studied. 	CYP2D6	29477	29483	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:187	CYP2D6*3, *6, *7 and *8 were not detected in any of the Amerindian populations studied. 	CYP2D6	29477	29483	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:187	CYP2D6*3, *6, *7 and *8 were not detected in any of the Amerindian populations studied. 	CYP2D6	29477	29483	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:188	The CYP2D6 genotype results from Perez-Paramo et al. 	CYP2D6	29569	29575	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:188	The CYP2D6 genotype results from Perez-Paramo et al. 	CYP2D6	29569	29575	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:188	The CYP2D6 genotype results from Perez-Paramo et al. 	CYP2D6	29569	29575	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:188	The CYP2D6 genotype results from Perez-Paramo et al. 	CYP2D6	29569	29575	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:192	in Tepehuanos further support previous findings that the frequency of CYP2D6 inactive alleles is low in most Amerindian populations. 	CYP2D6	29904	29910	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:192	in Tepehuanos further support previous findings that the frequency of CYP2D6 inactive alleles is low in most Amerindian populations. 	CYP2D6	29904	29910	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:192	in Tepehuanos further support previous findings that the frequency of CYP2D6 inactive alleles is low in most Amerindian populations. 	CYP2D6	29904	29910	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:192	in Tepehuanos further support previous findings that the frequency of CYP2D6 inactive alleles is low in most Amerindian populations. 	CYP2D6	29904	29910	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:193	These MAFs predict a low frequency of CYP2D6 PMs in these Amerindian populations. 	CYP2D6	30005	30011	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:193	These MAFs predict a low frequency of CYP2D6 PMs in these Amerindian populations. 	CYP2D6	30005	30011	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:193	These MAFs predict a low frequency of CYP2D6 PMs in these Amerindian populations. 	CYP2D6	30005	30011	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:193	These MAFs predict a low frequency of CYP2D6 PMs in these Amerindian populations. 	CYP2D6	30005	30011	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30108	30114	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30108	30114	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30108	30114	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30108	30114	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30217	30223	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30217	30223	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30217	30223	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:196	investigated the CYP2D6 phenotype in Tepehuanos using DEX/DXO metabolic ratio and found that no Tepehuanos were classified as CYP2D6 PMs, as expected based on the allele frequencies reported by multiple studies. 	CYP2D6	30217	30223	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30320	30326	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30320	30326	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30320	30326	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30320	30326	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30341	30347	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30341	30347	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30341	30347	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:197	The frequency of CYP2D6 UMs, based on CYP2D6*1 or *2 gene duplication, varied depending on the Amerindian population studied and the location of the reference Mestizo population. 	CYP2D6	30341	30347	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:199	in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups, were consistent with previously published findings that CYP2D6 variants conferring PM status are rare in the Amerindian population. 	CYP2D6	30710	30716	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:199	in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups, were consistent with previously published findings that CYP2D6 variants conferring PM status are rare in the Amerindian population. 	CYP2D6	30710	30716	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:199	in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups, were consistent with previously published findings that CYP2D6 variants conferring PM status are rare in the Amerindian population. 	CYP2D6	30710	30716	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:199	in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups, were consistent with previously published findings that CYP2D6 variants conferring PM status are rare in the Amerindian population. 	CYP2D6	30710	30716	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:200	Regarding CYP2D6 multiplications, the frequency of wtxN, *2xN and *4xN were 4.7, 1.1 and 0.1%, respectively. 	CYP2D6	30796	30802	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:200	Regarding CYP2D6 multiplications, the frequency of wtxN, *2xN and *4xN were 4.7, 1.1 and 0.1%, respectively. 	CYP2D6	30796	30802	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:200	Regarding CYP2D6 multiplications, the frequency of wtxN, *2xN and *4xN were 4.7, 1.1 and 0.1%, respectively. 	CYP2D6	30796	30802	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:200	Regarding CYP2D6 multiplications, the frequency of wtxN, *2xN and *4xN were 4.7, 1.1 and 0.1%, respectively. 	CYP2D6	30796	30802	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	30895	30901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	30895	30901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	30895	30901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	30895	30901	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	31059	31065	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	31059	31065	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	31059	31065	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:201	CYP2D6 phenotype was also determined using the DEX/DXO ratio, with a significantly greater parent to metabolite ratio for individuals with reduced activity or null CYP2D6 variants. 	CYP2D6	31059	31065	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:203	Further studies are necessary to identify and characterize variants that may impact the activity of important drug metabolizing enzymes including CYP2D6. 	CYP2D6	31355	31361	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:203	Further studies are necessary to identify and characterize variants that may impact the activity of important drug metabolizing enzymes including CYP2D6. 	CYP2D6	31355	31361	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:203	Further studies are necessary to identify and characterize variants that may impact the activity of important drug metabolizing enzymes including CYP2D6. 	CYP2D6	31355	31361	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:203	Further studies are necessary to identify and characterize variants that may impact the activity of important drug metabolizing enzymes including CYP2D6. 	CYP2D6	31355	31361	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38461	38467	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38461	38467	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38461	38467	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38461	38467	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38474	38480	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38474	38480	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38474	38480	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38474	38480	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38543	38549	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38543	38549	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38543	38549	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:251	The relatively high frequencies for CYP2D6*4 and CYP2D6*41 in the CSKT and AI youth may be important to consider with CYP2D6 substrates such as codeine, tamoxifen and antidepressants. 	CYP2D6	38543	38549	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:252	Conversely, certain subgroups in the Amerindian population (Tepehuano, Purepecha, Tojolabal, Tzotzil, Mexicanera, Cora and Guarijo) had a low proportion of CYP2D6 variants conferring PM status. 	CYP2D6	38765	38771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:252	Conversely, certain subgroups in the Amerindian population (Tepehuano, Purepecha, Tojolabal, Tzotzil, Mexicanera, Cora and Guarijo) had a low proportion of CYP2D6 variants conferring PM status. 	CYP2D6	38765	38771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:252	Conversely, certain subgroups in the Amerindian population (Tepehuano, Purepecha, Tojolabal, Tzotzil, Mexicanera, Cora and Guarijo) had a low proportion of CYP2D6 variants conferring PM status. 	CYP2D6	38765	38771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:252	Conversely, certain subgroups in the Amerindian population (Tepehuano, Purepecha, Tojolabal, Tzotzil, Mexicanera, Cora and Guarijo) had a low proportion of CYP2D6 variants conferring PM status. 	CYP2D6	38765	38771	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2D6	40278	40284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2D6	40278	40284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2D6	40278	40284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:262	where the CYP2C9, CYP2C19, or CYP2D6 phenotype for some Amerindians could not be accurately predicted based on genotype, possibly due to the presence of novel rare variation in these pharmacogenes. 	CYP2D6	40278	40284	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:108	^, However, incubation of the antiestrogenic precursor drug tamoxifen did not lead to an increased antiestrogenic response (data not shown) despite the presence of CYP2D6 in S9-mix which increases the potency of tamoxifen 30-100 fold through formation of the active metabolite 4-hydroxytamoxifen. 	CYP2D6	23605	23611	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:108	^, However, incubation of the antiestrogenic precursor drug tamoxifen did not lead to an increased antiestrogenic response (data not shown) despite the presence of CYP2D6 in S9-mix which increases the potency of tamoxifen 30-100 fold through formation of the active metabolite 4-hydroxytamoxifen. 	CYP2D6	23605	23611	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:108	^, However, incubation of the antiestrogenic precursor drug tamoxifen did not lead to an increased antiestrogenic response (data not shown) despite the presence of CYP2D6 in S9-mix which increases the potency of tamoxifen 30-100 fold through formation of the active metabolite 4-hydroxytamoxifen. 	CYP2D6	23605	23611	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:108	^, However, incubation of the antiestrogenic precursor drug tamoxifen did not lead to an increased antiestrogenic response (data not shown) despite the presence of CYP2D6 in S9-mix which increases the potency of tamoxifen 30-100 fold through formation of the active metabolite 4-hydroxytamoxifen. 	CYP2D6	23605	23611	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:109	^, Therefore, formation of 4-hydroxytamoxifen by endogenously expressed CYP2D6 in MCF-7 cells^, could explain the lack of increased potency following treatment with S9-mix. 	CYP2D6	23810	23816	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:109	^, Therefore, formation of 4-hydroxytamoxifen by endogenously expressed CYP2D6 in MCF-7 cells^, could explain the lack of increased potency following treatment with S9-mix. 	CYP2D6	23810	23816	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:109	^, Therefore, formation of 4-hydroxytamoxifen by endogenously expressed CYP2D6 in MCF-7 cells^, could explain the lack of increased potency following treatment with S9-mix. 	CYP2D6	23810	23816	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:109	^, Therefore, formation of 4-hydroxytamoxifen by endogenously expressed CYP2D6 in MCF-7 cells^, could explain the lack of increased potency following treatment with S9-mix. 	CYP2D6	23810	23816	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:36	It was not possible to measure the aqueous extracts impact on CYP2D6 due to a high level of background fluorescence produced by the extract (A,B). 	CYP2D6	6283	6289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:36	It was not possible to measure the aqueous extracts impact on CYP2D6 due to a high level of background fluorescence produced by the extract (A,B). 	CYP2D6	6283	6289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:36	It was not possible to measure the aqueous extracts impact on CYP2D6 due to a high level of background fluorescence produced by the extract (A,B). 	CYP2D6	6283	6289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:36	It was not possible to measure the aqueous extracts impact on CYP2D6 due to a high level of background fluorescence produced by the extract (A,B). 	CYP2D6	6283	6289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP2D6	11014	11020	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP2D6	11014	11020	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP2D6	11014	11020	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP2D6	11014	11020	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP2D6	11106	11112	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP2D6	11106	11112	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP2D6	11106	11112	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP2D6	11106	11112	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP2D6	18912	18918	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP2D6	18912	18918	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP2D6	18912	18918	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP2D6	18912	18918	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP2D6	23069	23075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP2D6	23069	23075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP2D6	23069	23075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP2D6	23069	23075	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP2D6	29462	29468	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP2D6	29462	29468	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP2D6	29462	29468	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP2D6	29462	29468	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP2D6	29786	29792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP2D6	29786	29792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP2D6	29786	29792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP2D6	29786	29792	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2D6	12139	12145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2D6	12139	12145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2D6	12139	12145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2D6	12139	12145	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2D6	58768	58774	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2D6	58768	58774	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2D6	58768	58774	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2D6	58768	58774	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:397	mRNAs for CYP2D6, 2U1 and 2W1 were present in Full-Thickness Human Bottom Skin, but variable between individual EpiDerm^ samples. 	CYP2D6	63440	63446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:397	mRNAs for CYP2D6, 2U1 and 2W1 were present in Full-Thickness Human Bottom Skin, but variable between individual EpiDerm^ samples. 	CYP2D6	63440	63446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:397	mRNAs for CYP2D6, 2U1 and 2W1 were present in Full-Thickness Human Bottom Skin, but variable between individual EpiDerm^ samples. 	CYP2D6	63440	63446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:397	mRNAs for CYP2D6, 2U1 and 2W1 were present in Full-Thickness Human Bottom Skin, but variable between individual EpiDerm^ samples. 	CYP2D6	63440	63446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:403	The expression of CYP2D6 was very low or nil. 	CYP2D6	64505	64511	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:403	The expression of CYP2D6 was very low or nil. 	CYP2D6	64505	64511	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:403	The expression of CYP2D6 was very low or nil. 	CYP2D6	64505	64511	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:403	The expression of CYP2D6 was very low or nil. 	CYP2D6	64505	64511	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95772	95778	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95772	95778	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95772	95778	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95772	95778	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95865	95871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95865	95871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95865	95871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:620	reported that they found CYP2D6 mRNA in the skin biopsies of all 27 human individuals investigated, the levels of the CYP2D6 mRNA being among the highest of all 10 CYPs studied. 	CYP2D6	95865	95871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:622	reported that the CYP2D6-catalyzed metabolism of bufuralol did not reach the Limit Of Quantitation of 1.08 pmol. 	CYP2D6	95977	95983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:622	reported that the CYP2D6-catalyzed metabolism of bufuralol did not reach the Limit Of Quantitation of 1.08 pmol. 	CYP2D6	95977	95983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:622	reported that the CYP2D6-catalyzed metabolism of bufuralol did not reach the Limit Of Quantitation of 1.08 pmol. 	CYP2D6	95977	95983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:622	reported that the CYP2D6-catalyzed metabolism of bufuralol did not reach the Limit Of Quantitation of 1.08 pmol. 	CYP2D6	95977	95983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:624	reported that they observed CYP2D6 mRNA in human dermal fibroblasts, but not in proliferating human keratinocytes in culture. 	CYP2D6	96113	96119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:624	reported that they observed CYP2D6 mRNA in human dermal fibroblasts, but not in proliferating human keratinocytes in culture. 	CYP2D6	96113	96119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:624	reported that they observed CYP2D6 mRNA in human dermal fibroblasts, but not in proliferating human keratinocytes in culture. 	CYP2D6	96113	96119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:624	reported that they observed CYP2D6 mRNA in human dermal fibroblasts, but not in proliferating human keratinocytes in culture. 	CYP2D6	96113	96119	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:626	CYP2D6 mRNA was neither detected in the dermis of native human skin nor in monolayer fibroblasts derived from the same donors nor in the dermis of the three-dimensional full skin model Phenion FT Skin, but was consistently expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors. 	CYP2D6	96283	96289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:626	CYP2D6 mRNA was neither detected in the dermis of native human skin nor in monolayer fibroblasts derived from the same donors nor in the dermis of the three-dimensional full skin model Phenion FT Skin, but was consistently expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors. 	CYP2D6	96283	96289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:626	CYP2D6 mRNA was neither detected in the dermis of native human skin nor in monolayer fibroblasts derived from the same donors nor in the dermis of the three-dimensional full skin model Phenion FT Skin, but was consistently expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors. 	CYP2D6	96283	96289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:626	CYP2D6 mRNA was neither detected in the dermis of native human skin nor in monolayer fibroblasts derived from the same donors nor in the dermis of the three-dimensional full skin model Phenion FT Skin, but was consistently expressed in the three-dimensional epidermal reconstructed model OS-REp derived from any of the three donors. 	CYP2D6	96283	96289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:628	It was not expressed in native human skin, neither in the epidermis nor in the dermis (Wiegand et al.. The substrate specificity of CYP2D6 protein (investigated in organs other than the skin) includes: physiological substrates (eg, progesterone, testosterone, retinal, tryptoptamine),natural compounds (eg, aflatoxin B_1, nicotine, ochratoxin A, capsaicin, curcumin, emetine, genistein 4-methyl ether, sparteine),pharmaceutical drugs (eg, debrisoquine, bufuralol, propranolol, dextromethorphan, fluoxetine) (Du et al. 	CYP2D6	96842	96848	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:628	It was not expressed in native human skin, neither in the epidermis nor in the dermis (Wiegand et al.. The substrate specificity of CYP2D6 protein (investigated in organs other than the skin) includes: physiological substrates (eg, progesterone, testosterone, retinal, tryptoptamine),natural compounds (eg, aflatoxin B_1, nicotine, ochratoxin A, capsaicin, curcumin, emetine, genistein 4-methyl ether, sparteine),pharmaceutical drugs (eg, debrisoquine, bufuralol, propranolol, dextromethorphan, fluoxetine) (Du et al. 	CYP2D6	96842	96848	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:628	It was not expressed in native human skin, neither in the epidermis nor in the dermis (Wiegand et al.. The substrate specificity of CYP2D6 protein (investigated in organs other than the skin) includes: physiological substrates (eg, progesterone, testosterone, retinal, tryptoptamine),natural compounds (eg, aflatoxin B_1, nicotine, ochratoxin A, capsaicin, curcumin, emetine, genistein 4-methyl ether, sparteine),pharmaceutical drugs (eg, debrisoquine, bufuralol, propranolol, dextromethorphan, fluoxetine) (Du et al. 	CYP2D6	96842	96848	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:628	It was not expressed in native human skin, neither in the epidermis nor in the dermis (Wiegand et al.. The substrate specificity of CYP2D6 protein (investigated in organs other than the skin) includes: physiological substrates (eg, progesterone, testosterone, retinal, tryptoptamine),natural compounds (eg, aflatoxin B_1, nicotine, ochratoxin A, capsaicin, curcumin, emetine, genistein 4-methyl ether, sparteine),pharmaceutical drugs (eg, debrisoquine, bufuralol, propranolol, dextromethorphan, fluoxetine) (Du et al. 	CYP2D6	96842	96848	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2D6	9366	9372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2D6	9366	9372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2D6	9366	9372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2D6	9366	9372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP2D6	32531	32537	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP2D6	32531	32537	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP2D6	32531	32537	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP2D6	32531	32537	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP2D6	3396	3402	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP2D6	3396	3402	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP2D6	3396	3402	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP2D6	3396	3402	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2D6	4625	4631	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2D6	4625	4631	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2D6	4625	4631	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2D6	4625	4631	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2D6	11167	11173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2D6	11167	11173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2D6	11167	11173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP2D6	11167	11173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:8	EtOH increased mRNA and protein levels of CYP2D6 by 73% and 60% respectively. 	CYP2D6	930	936	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:8	EtOH increased mRNA and protein levels of CYP2D6 by 73% and 60% respectively. 	CYP2D6	930	936	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:8	EtOH increased mRNA and protein levels of CYP2D6 by 73% and 60% respectively. 	CYP2D6	930	936	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:8	EtOH increased mRNA and protein levels of CYP2D6 by 73% and 60% respectively. 	CYP2D6	930	936	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:12	Finally, CYP2D6 localized at mitochondria and Endoplasmic Reticulum. 	CYP2D6	1317	1323	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:12	Finally, CYP2D6 localized at mitochondria and Endoplasmic Reticulum. 	CYP2D6	1317	1323	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:12	Finally, CYP2D6 localized at mitochondria and Endoplasmic Reticulum. 	CYP2D6	1317	1323	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:12	Finally, CYP2D6 localized at mitochondria and Endoplasmic Reticulum. 	CYP2D6	1317	1323	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:36	CYP2D6 is one of the most expressed isoforms in brain cells and plays a key role in Central Nervous System homeostasis. 	CYP2D6	4774	4780	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:36	CYP2D6 is one of the most expressed isoforms in brain cells and plays a key role in Central Nervous System homeostasis. 	CYP2D6	4774	4780	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:36	CYP2D6 is one of the most expressed isoforms in brain cells and plays a key role in Central Nervous System homeostasis. 	CYP2D6	4774	4780	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:36	CYP2D6 is one of the most expressed isoforms in brain cells and plays a key role in Central Nervous System homeostasis. 	CYP2D6	4774	4780	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:38	CYP2D6 is also involved in an alternative anabolic pathway of dopamine, thus taking part in important aspects of brain health and neurotoxicity. 	CYP2D6	5058	5064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:38	CYP2D6 is also involved in an alternative anabolic pathway of dopamine, thus taking part in important aspects of brain health and neurotoxicity. 	CYP2D6	5058	5064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:38	CYP2D6 is also involved in an alternative anabolic pathway of dopamine, thus taking part in important aspects of brain health and neurotoxicity. 	CYP2D6	5058	5064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:38	CYP2D6 is also involved in an alternative anabolic pathway of dopamine, thus taking part in important aspects of brain health and neurotoxicity. 	CYP2D6	5058	5064	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:39	Recently, it has been shown that CYP2D6-polymorphism affects dopamine formation through drug interaction, and therefore, may contribute to neurodegeneration. 	CYP2D6	5236	5242	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:39	Recently, it has been shown that CYP2D6-polymorphism affects dopamine formation through drug interaction, and therefore, may contribute to neurodegeneration. 	CYP2D6	5236	5242	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:39	Recently, it has been shown that CYP2D6-polymorphism affects dopamine formation through drug interaction, and therefore, may contribute to neurodegeneration. 	CYP2D6	5236	5242	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:39	Recently, it has been shown that CYP2D6-polymorphism affects dopamine formation through drug interaction, and therefore, may contribute to neurodegeneration. 	CYP2D6	5236	5242	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:40	Individuals with CYP2D6-poor metabolism are related to a higher risk of Parkinsons Disease. 	CYP2D6	5378	5384	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:40	Individuals with CYP2D6-poor metabolism are related to a higher risk of Parkinsons Disease. 	CYP2D6	5378	5384	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:40	Individuals with CYP2D6-poor metabolism are related to a higher risk of Parkinsons Disease. 	CYP2D6	5378	5384	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:40	Individuals with CYP2D6-poor metabolism are related to a higher risk of Parkinsons Disease. 	CYP2D6	5378	5384	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2D6	5980	5986	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2D6	5980	5986	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2D6	5980	5986	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2D6	5980	5986	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:57	We found that CYP2D6 can play an important role in the metabolism of xenobiotics in this cell line. 	CYP2D6	8188	8194	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:57	We found that CYP2D6 can play an important role in the metabolism of xenobiotics in this cell line. 	CYP2D6	8188	8194	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:57	We found that CYP2D6 can play an important role in the metabolism of xenobiotics in this cell line. 	CYP2D6	8188	8194	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:57	We found that CYP2D6 can play an important role in the metabolism of xenobiotics in this cell line. 	CYP2D6	8188	8194	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:61	In undifferentiated cells, the mRNA levels of CYP2D6 were not significantly affected by BETA-NF treatment, yet EtOH promoted a significative 1.7-fold increase (a). 	CYP2D6	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:61	In undifferentiated cells, the mRNA levels of CYP2D6 were not significantly affected by BETA-NF treatment, yet EtOH promoted a significative 1.7-fold increase (a). 	CYP2D6	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:61	In undifferentiated cells, the mRNA levels of CYP2D6 were not significantly affected by BETA-NF treatment, yet EtOH promoted a significative 1.7-fold increase (a). 	CYP2D6	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:61	In undifferentiated cells, the mRNA levels of CYP2D6 were not significantly affected by BETA-NF treatment, yet EtOH promoted a significative 1.7-fold increase (a). 	CYP2D6	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:66	In the undifferentiated phenotype, the protein levels of CYP2D6 revealed that EtOH was the most potent inducer, showing a 1.6-fold increase compared to control, while BETA-NF did not significantly affect the expression of this protein (a). 	CYP2D6	9581	9587	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:66	In the undifferentiated phenotype, the protein levels of CYP2D6 revealed that EtOH was the most potent inducer, showing a 1.6-fold increase compared to control, while BETA-NF did not significantly affect the expression of this protein (a). 	CYP2D6	9581	9587	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:66	In the undifferentiated phenotype, the protein levels of CYP2D6 revealed that EtOH was the most potent inducer, showing a 1.6-fold increase compared to control, while BETA-NF did not significantly affect the expression of this protein (a). 	CYP2D6	9581	9587	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:66	In the undifferentiated phenotype, the protein levels of CYP2D6 revealed that EtOH was the most potent inducer, showing a 1.6-fold increase compared to control, while BETA-NF did not significantly affect the expression of this protein (a). 	CYP2D6	9581	9587	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:77	The dextromethorphan is metabolized mainly by CYP2D6, which promotes the formation of dextrorphan by an O-demethylation reaction. 	CYP2D6	11052	11058	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:77	The dextromethorphan is metabolized mainly by CYP2D6, which promotes the formation of dextrorphan by an O-demethylation reaction. 	CYP2D6	11052	11058	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:77	The dextromethorphan is metabolized mainly by CYP2D6, which promotes the formation of dextrorphan by an O-demethylation reaction. 	CYP2D6	11052	11058	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:77	The dextromethorphan is metabolized mainly by CYP2D6, which promotes the formation of dextrorphan by an O-demethylation reaction. 	CYP2D6	11052	11058	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:82	Interestingly, the expression of CYP2D6 after treatments correlated with mitochondria, while it presented less localization in Endoplasmic Reticulum. 	CYP2D6	11892	11898	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:82	Interestingly, the expression of CYP2D6 after treatments correlated with mitochondria, while it presented less localization in Endoplasmic Reticulum. 	CYP2D6	11892	11898	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:82	Interestingly, the expression of CYP2D6 after treatments correlated with mitochondria, while it presented less localization in Endoplasmic Reticulum. 	CYP2D6	11892	11898	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:82	Interestingly, the expression of CYP2D6 after treatments correlated with mitochondria, while it presented less localization in Endoplasmic Reticulum. 	CYP2D6	11892	11898	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:84	Localization between CYP2D6 and Endoplasmic Reticulum was lower, as observed by their R Pearson coefficients (BETA-NF, 0.43; EtOH, 0.37). 	CYP2D6	12138	12144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:84	Localization between CYP2D6 and Endoplasmic Reticulum was lower, as observed by their R Pearson coefficients (BETA-NF, 0.43; EtOH, 0.37). 	CYP2D6	12138	12144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:84	Localization between CYP2D6 and Endoplasmic Reticulum was lower, as observed by their R Pearson coefficients (BETA-NF, 0.43; EtOH, 0.37). 	CYP2D6	12138	12144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:84	Localization between CYP2D6 and Endoplasmic Reticulum was lower, as observed by their R Pearson coefficients (BETA-NF, 0.43; EtOH, 0.37). 	CYP2D6	12138	12144	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:88	Similar to CYP2D6, the R Pearson coefficient was not able to be calculated in control conditions due to the low fluorescent intensity. 	CYP2D6	12849	12855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:88	Similar to CYP2D6, the R Pearson coefficient was not able to be calculated in control conditions due to the low fluorescent intensity. 	CYP2D6	12849	12855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:88	Similar to CYP2D6, the R Pearson coefficient was not able to be calculated in control conditions due to the low fluorescent intensity. 	CYP2D6	12849	12855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:88	Similar to CYP2D6, the R Pearson coefficient was not able to be calculated in control conditions due to the low fluorescent intensity. 	CYP2D6	12849	12855	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP2D6	13380	13386	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP2D6	13380	13386	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP2D6	13380	13386	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:91	Similar to CYP2D6 and 2E1, the low expression of CYP1A1 in the control condition did not allow us to calculate the R Pearson coefficient. 	CYP2D6	13380	13386	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:94	The role of CYP2D6 and 2E1 in neurodegeneration is important for developing new therapeutic approaches. 	CYP2D6	13825	13831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:94	The role of CYP2D6 and 2E1 in neurodegeneration is important for developing new therapeutic approaches. 	CYP2D6	13825	13831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:94	The role of CYP2D6 and 2E1 in neurodegeneration is important for developing new therapeutic approaches. 	CYP2D6	13825	13831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:94	The role of CYP2D6 and 2E1 in neurodegeneration is important for developing new therapeutic approaches. 	CYP2D6	13825	13831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:105	Our results demonstrate that CYP2D6 and 2E1 can be increased in terms of mRNA, proteins, and activities by incubating undifferentiated SH-SY5Y cells with two well-known inducer compounds in the liver, BETA-NF and EtOH. 	CYP2D6	15275	15281	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:105	Our results demonstrate that CYP2D6 and 2E1 can be increased in terms of mRNA, proteins, and activities by incubating undifferentiated SH-SY5Y cells with two well-known inducer compounds in the liver, BETA-NF and EtOH. 	CYP2D6	15275	15281	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:105	Our results demonstrate that CYP2D6 and 2E1 can be increased in terms of mRNA, proteins, and activities by incubating undifferentiated SH-SY5Y cells with two well-known inducer compounds in the liver, BETA-NF and EtOH. 	CYP2D6	15275	15281	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:105	Our results demonstrate that CYP2D6 and 2E1 can be increased in terms of mRNA, proteins, and activities by incubating undifferentiated SH-SY5Y cells with two well-known inducer compounds in the liver, BETA-NF and EtOH. 	CYP2D6	15275	15281	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:107	Moreover, different studies suggested that, inconsistent with what has been observed in the liver, CYP2D6 is inducible in the brain and in SH-SY5Y. 	CYP2D6	15704	15710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:107	Moreover, different studies suggested that, inconsistent with what has been observed in the liver, CYP2D6 is inducible in the brain and in SH-SY5Y. 	CYP2D6	15704	15710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:107	Moreover, different studies suggested that, inconsistent with what has been observed in the liver, CYP2D6 is inducible in the brain and in SH-SY5Y. 	CYP2D6	15704	15710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:107	Moreover, different studies suggested that, inconsistent with what has been observed in the liver, CYP2D6 is inducible in the brain and in SH-SY5Y. 	CYP2D6	15704	15710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:108	Therefore, we have also investigated the effects of BETA-NF and EtOH on CYP2D6. 	CYP2D6	15825	15831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:108	Therefore, we have also investigated the effects of BETA-NF and EtOH on CYP2D6. 	CYP2D6	15825	15831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:108	Therefore, we have also investigated the effects of BETA-NF and EtOH on CYP2D6. 	CYP2D6	15825	15831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:108	Therefore, we have also investigated the effects of BETA-NF and EtOH on CYP2D6. 	CYP2D6	15825	15831	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:109	Under our experimental conditions, CYP2D6 seems to be inducible by EtOH in terms of mRNA and protein levels, and not by BETA-NF, while in differentiated cells, both BETA-NF and EtOH were able to increase the protein levels. 	CYP2D6	15868	15874	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:109	Under our experimental conditions, CYP2D6 seems to be inducible by EtOH in terms of mRNA and protein levels, and not by BETA-NF, while in differentiated cells, both BETA-NF and EtOH were able to increase the protein levels. 	CYP2D6	15868	15874	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:109	Under our experimental conditions, CYP2D6 seems to be inducible by EtOH in terms of mRNA and protein levels, and not by BETA-NF, while in differentiated cells, both BETA-NF and EtOH were able to increase the protein levels. 	CYP2D6	15868	15874	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:109	Under our experimental conditions, CYP2D6 seems to be inducible by EtOH in terms of mRNA and protein levels, and not by BETA-NF, while in differentiated cells, both BETA-NF and EtOH were able to increase the protein levels. 	CYP2D6	15868	15874	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:119	On the other hand, the EtOH induction of CYP2D6 observed in these results is in agreement with other studies, where an in vitro induction of this isoform by the same compound has been reported. 	CYP2D6	17502	17508	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:119	On the other hand, the EtOH induction of CYP2D6 observed in these results is in agreement with other studies, where an in vitro induction of this isoform by the same compound has been reported. 	CYP2D6	17502	17508	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:119	On the other hand, the EtOH induction of CYP2D6 observed in these results is in agreement with other studies, where an in vitro induction of this isoform by the same compound has been reported. 	CYP2D6	17502	17508	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:119	On the other hand, the EtOH induction of CYP2D6 observed in these results is in agreement with other studies, where an in vitro induction of this isoform by the same compound has been reported. 	CYP2D6	17502	17508	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:120	Furthermore, the in vivo treatment of African green monkeys with nicotine also demonstrated that CYP2D6 can be inducible in brain while remaining unchanged in the liver. 	CYP2D6	17752	17758	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:120	Furthermore, the in vivo treatment of African green monkeys with nicotine also demonstrated that CYP2D6 can be inducible in brain while remaining unchanged in the liver. 	CYP2D6	17752	17758	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:120	Furthermore, the in vivo treatment of African green monkeys with nicotine also demonstrated that CYP2D6 can be inducible in brain while remaining unchanged in the liver. 	CYP2D6	17752	17758	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:120	Furthermore, the in vivo treatment of African green monkeys with nicotine also demonstrated that CYP2D6 can be inducible in brain while remaining unchanged in the liver. 	CYP2D6	17752	17758	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:121	The evidence of the induction of CYP2D6 in SH-SY5Y cells, in conflict with that observed in hepatocytes, suggests that this isoform has a different regulation in the neuroblastoma cell line. 	CYP2D6	17858	17864	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:121	The evidence of the induction of CYP2D6 in SH-SY5Y cells, in conflict with that observed in hepatocytes, suggests that this isoform has a different regulation in the neuroblastoma cell line. 	CYP2D6	17858	17864	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:121	The evidence of the induction of CYP2D6 in SH-SY5Y cells, in conflict with that observed in hepatocytes, suggests that this isoform has a different regulation in the neuroblastoma cell line. 	CYP2D6	17858	17864	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:121	The evidence of the induction of CYP2D6 in SH-SY5Y cells, in conflict with that observed in hepatocytes, suggests that this isoform has a different regulation in the neuroblastoma cell line. 	CYP2D6	17858	17864	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:123	suggested the involvement of PPARs in the regulation of CYP2D6 in brain and SH-SY5Y cells. 	CYP2D6	18096	18102	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:123	suggested the involvement of PPARs in the regulation of CYP2D6 in brain and SH-SY5Y cells. 	CYP2D6	18096	18102	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:123	suggested the involvement of PPARs in the regulation of CYP2D6 in brain and SH-SY5Y cells. 	CYP2D6	18096	18102	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:123	suggested the involvement of PPARs in the regulation of CYP2D6 in brain and SH-SY5Y cells. 	CYP2D6	18096	18102	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:128	As shown in Western Blot experiments, the expression of CYP2D6 and 2E1 proteins can be increased by at least one compound used in this study in both undifferentiated and differentiated phenotypes. 	CYP2D6	18724	18730	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:128	As shown in Western Blot experiments, the expression of CYP2D6 and 2E1 proteins can be increased by at least one compound used in this study in both undifferentiated and differentiated phenotypes. 	CYP2D6	18724	18730	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:128	As shown in Western Blot experiments, the expression of CYP2D6 and 2E1 proteins can be increased by at least one compound used in this study in both undifferentiated and differentiated phenotypes. 	CYP2D6	18724	18730	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:128	As shown in Western Blot experiments, the expression of CYP2D6 and 2E1 proteins can be increased by at least one compound used in this study in both undifferentiated and differentiated phenotypes. 	CYP2D6	18724	18730	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP2D6	18925	18931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP2D6	18925	18931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP2D6	18925	18931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:129	In general terms, these results support the inducibility of CYP2D6 and 2E1 in our in vitro model, in contrast to other isoforms such as CYP1A1 and 3A4. 	CYP2D6	18925	18931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:131	The role of CYP2D6 in Parkinsons Disease is still under debate. 	CYP2D6	19269	19275	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:131	The role of CYP2D6 in Parkinsons Disease is still under debate. 	CYP2D6	19269	19275	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:131	The role of CYP2D6 in Parkinsons Disease is still under debate. 	CYP2D6	19269	19275	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:131	The role of CYP2D6 in Parkinsons Disease is still under debate. 	CYP2D6	19269	19275	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:132	In fact, a pharmacogenetic study of 70 individuals with Parkinsons Disease showed that a lower metabolic rate of CYP2D6 was associated with a higher risk of developing this disease. 	CYP2D6	19434	19440	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:132	In fact, a pharmacogenetic study of 70 individuals with Parkinsons Disease showed that a lower metabolic rate of CYP2D6 was associated with a higher risk of developing this disease. 	CYP2D6	19434	19440	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:132	In fact, a pharmacogenetic study of 70 individuals with Parkinsons Disease showed that a lower metabolic rate of CYP2D6 was associated with a higher risk of developing this disease. 	CYP2D6	19434	19440	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:132	In fact, a pharmacogenetic study of 70 individuals with Parkinsons Disease showed that a lower metabolic rate of CYP2D6 was associated with a higher risk of developing this disease. 	CYP2D6	19434	19440	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:133	However, other groups state that the association between Parkinsons Disease and mutations of CYP2D6 is most likely the result of interactions between multiple genetic and environmental factors. 	CYP2D6	19596	19602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:133	However, other groups state that the association between Parkinsons Disease and mutations of CYP2D6 is most likely the result of interactions between multiple genetic and environmental factors. 	CYP2D6	19596	19602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:133	However, other groups state that the association between Parkinsons Disease and mutations of CYP2D6 is most likely the result of interactions between multiple genetic and environmental factors. 	CYP2D6	19596	19602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:133	However, other groups state that the association between Parkinsons Disease and mutations of CYP2D6 is most likely the result of interactions between multiple genetic and environmental factors. 	CYP2D6	19596	19602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:140	However, CYP2D6 is one of the most expressed isoforms in dopaminergic neurons, and therefore, the evidence that our treatments in SH-SY5Y cells increased 7-hydroxycumarin formation clearly indicated that the induction of CYP(s) proteins also corresponded to an increase in the CYP-dependent metabolism. 	CYP2D6	20940	20946	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:140	However, CYP2D6 is one of the most expressed isoforms in dopaminergic neurons, and therefore, the evidence that our treatments in SH-SY5Y cells increased 7-hydroxycumarin formation clearly indicated that the induction of CYP(s) proteins also corresponded to an increase in the CYP-dependent metabolism. 	CYP2D6	20940	20946	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:140	However, CYP2D6 is one of the most expressed isoforms in dopaminergic neurons, and therefore, the evidence that our treatments in SH-SY5Y cells increased 7-hydroxycumarin formation clearly indicated that the induction of CYP(s) proteins also corresponded to an increase in the CYP-dependent metabolism. 	CYP2D6	20940	20946	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:140	However, CYP2D6 is one of the most expressed isoforms in dopaminergic neurons, and therefore, the evidence that our treatments in SH-SY5Y cells increased 7-hydroxycumarin formation clearly indicated that the induction of CYP(s) proteins also corresponded to an increase in the CYP-dependent metabolism. 	CYP2D6	20940	20946	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:142	The results demonstrate that cells are able to promote the CYP2D6-dependent metabolism of the compound although its induction does not lead to a statistically significant increase compared to control. 	CYP2D6	21377	21383	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:142	The results demonstrate that cells are able to promote the CYP2D6-dependent metabolism of the compound although its induction does not lead to a statistically significant increase compared to control. 	CYP2D6	21377	21383	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:142	The results demonstrate that cells are able to promote the CYP2D6-dependent metabolism of the compound although its induction does not lead to a statistically significant increase compared to control. 	CYP2D6	21377	21383	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:142	The results demonstrate that cells are able to promote the CYP2D6-dependent metabolism of the compound although its induction does not lead to a statistically significant increase compared to control. 	CYP2D6	21377	21383	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:143	This can be explained by the fact that dextromethorphan is only metabolized by CYP2D6, unlike 7-ethoxycoumarin, and its low concentration in our cellular preparations, even in the case of induction, is not sufficient to increase the formation of dextrorphane in a statistically significant manner. 	CYP2D6	21598	21604	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:143	This can be explained by the fact that dextromethorphan is only metabolized by CYP2D6, unlike 7-ethoxycoumarin, and its low concentration in our cellular preparations, even in the case of induction, is not sufficient to increase the formation of dextrorphane in a statistically significant manner. 	CYP2D6	21598	21604	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:143	This can be explained by the fact that dextromethorphan is only metabolized by CYP2D6, unlike 7-ethoxycoumarin, and its low concentration in our cellular preparations, even in the case of induction, is not sufficient to increase the formation of dextrorphane in a statistically significant manner. 	CYP2D6	21598	21604	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:143	This can be explained by the fact that dextromethorphan is only metabolized by CYP2D6, unlike 7-ethoxycoumarin, and its low concentration in our cellular preparations, even in the case of induction, is not sufficient to increase the formation of dextrorphane in a statistically significant manner. 	CYP2D6	21598	21604	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:149	Our study showed by confocal microscopy analysis that CYP2D6 in treated cells also localized at mitochondria, and at a minor level, at Endoplasmic Reticulum. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:149	Our study showed by confocal microscopy analysis that CYP2D6 in treated cells also localized at mitochondria, and at a minor level, at Endoplasmic Reticulum. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:149	Our study showed by confocal microscopy analysis that CYP2D6 in treated cells also localized at mitochondria, and at a minor level, at Endoplasmic Reticulum. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:149	Our study showed by confocal microscopy analysis that CYP2D6 in treated cells also localized at mitochondria, and at a minor level, at Endoplasmic Reticulum. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:151	Targeting this organelle is a key feature for the implications of CYP2D6 in neurodegeneration. 	CYP2D6	22751	22757	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:151	Targeting this organelle is a key feature for the implications of CYP2D6 in neurodegeneration. 	CYP2D6	22751	22757	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:151	Targeting this organelle is a key feature for the implications of CYP2D6 in neurodegeneration. 	CYP2D6	22751	22757	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:151	Targeting this organelle is a key feature for the implications of CYP2D6 in neurodegeneration. 	CYP2D6	22751	22757	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:152	Some polymorphisms have been found in liver mitochondria, and, in other in vitro studies, neurons have been transduced to overexpress a mitochondrially-targeted CYP2D6. 	CYP2D6	22941	22947	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:152	Some polymorphisms have been found in liver mitochondria, and, in other in vitro studies, neurons have been transduced to overexpress a mitochondrially-targeted CYP2D6. 	CYP2D6	22941	22947	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:152	Some polymorphisms have been found in liver mitochondria, and, in other in vitro studies, neurons have been transduced to overexpress a mitochondrially-targeted CYP2D6. 	CYP2D6	22941	22947	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:152	Some polymorphisms have been found in liver mitochondria, and, in other in vitro studies, neurons have been transduced to overexpress a mitochondrially-targeted CYP2D6. 	CYP2D6	22941	22947	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:153	This experimental evidence may represent another important perspective of the role of CYP2D6 in detoxification processes, since this isoform is proposed to be neuroprotective against xenobiotics that target the mitochondria, such as the MPP^+. 	CYP2D6	23035	23041	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:153	This experimental evidence may represent another important perspective of the role of CYP2D6 in detoxification processes, since this isoform is proposed to be neuroprotective against xenobiotics that target the mitochondria, such as the MPP^+. 	CYP2D6	23035	23041	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:153	This experimental evidence may represent another important perspective of the role of CYP2D6 in detoxification processes, since this isoform is proposed to be neuroprotective against xenobiotics that target the mitochondria, such as the MPP^+. 	CYP2D6	23035	23041	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:153	This experimental evidence may represent another important perspective of the role of CYP2D6 in detoxification processes, since this isoform is proposed to be neuroprotective against xenobiotics that target the mitochondria, such as the MPP^+. 	CYP2D6	23035	23041	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:162	However, the expression of the four isoforms in general can vary depending on the brain area and cellular type, and the only expression of CYP2D6 at mitochondrial level highlights the importance of this isoform only in neuroblastoma SH-SY5Y cells. 	CYP2D6	24704	24710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:162	However, the expression of the four isoforms in general can vary depending on the brain area and cellular type, and the only expression of CYP2D6 at mitochondrial level highlights the importance of this isoform only in neuroblastoma SH-SY5Y cells. 	CYP2D6	24704	24710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:162	However, the expression of the four isoforms in general can vary depending on the brain area and cellular type, and the only expression of CYP2D6 at mitochondrial level highlights the importance of this isoform only in neuroblastoma SH-SY5Y cells. 	CYP2D6	24704	24710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:162	However, the expression of the four isoforms in general can vary depending on the brain area and cellular type, and the only expression of CYP2D6 at mitochondrial level highlights the importance of this isoform only in neuroblastoma SH-SY5Y cells. 	CYP2D6	24704	24710	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:164	Finally, our results in cell viability suggest that the induction of CYP2D6 and 2E1 might have a protective role against the toxicity promoted by MPP^+. 	CYP2D6	25090	25096	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:164	Finally, our results in cell viability suggest that the induction of CYP2D6 and 2E1 might have a protective role against the toxicity promoted by MPP^+. 	CYP2D6	25090	25096	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:164	Finally, our results in cell viability suggest that the induction of CYP2D6 and 2E1 might have a protective role against the toxicity promoted by MPP^+. 	CYP2D6	25090	25096	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:164	Finally, our results in cell viability suggest that the induction of CYP2D6 and 2E1 might have a protective role against the toxicity promoted by MPP^+. 	CYP2D6	25090	25096	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:166	Indeed, the partial neuroprotection showed by BETA-NF and EtOH treatments agree with other MTT experiments, where the inhibition of CYP2D6 increased the toxic effect of MPP^+ in SH-SY5Y cells. 	CYP2D6	25387	25393	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:166	Indeed, the partial neuroprotection showed by BETA-NF and EtOH treatments agree with other MTT experiments, where the inhibition of CYP2D6 increased the toxic effect of MPP^+ in SH-SY5Y cells. 	CYP2D6	25387	25393	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:166	Indeed, the partial neuroprotection showed by BETA-NF and EtOH treatments agree with other MTT experiments, where the inhibition of CYP2D6 increased the toxic effect of MPP^+ in SH-SY5Y cells. 	CYP2D6	25387	25393	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:166	Indeed, the partial neuroprotection showed by BETA-NF and EtOH treatments agree with other MTT experiments, where the inhibition of CYP2D6 increased the toxic effect of MPP^+ in SH-SY5Y cells. 	CYP2D6	25387	25393	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:173	Other groups have shown that the active site of CYP2D6 is large enough to allow MPP^+ to enter into it, suggesting that the metabolism of this toxin can be carried out by this isoform. 	CYP2D6	26405	26411	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:173	Other groups have shown that the active site of CYP2D6 is large enough to allow MPP^+ to enter into it, suggesting that the metabolism of this toxin can be carried out by this isoform. 	CYP2D6	26405	26411	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:173	Other groups have shown that the active site of CYP2D6 is large enough to allow MPP^+ to enter into it, suggesting that the metabolism of this toxin can be carried out by this isoform. 	CYP2D6	26405	26411	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:173	Other groups have shown that the active site of CYP2D6 is large enough to allow MPP^+ to enter into it, suggesting that the metabolism of this toxin can be carried out by this isoform. 	CYP2D6	26405	26411	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:174	Since CYP2D6 and MPP^+ target mitochondria, we expect that the toxic effect and the protection by CYPs observed here will affect mitochondrial function. 	CYP2D6	26548	26554	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:174	Since CYP2D6 and MPP^+ target mitochondria, we expect that the toxic effect and the protection by CYPs observed here will affect mitochondrial function. 	CYP2D6	26548	26554	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:174	Since CYP2D6 and MPP^+ target mitochondria, we expect that the toxic effect and the protection by CYPs observed here will affect mitochondrial function. 	CYP2D6	26548	26554	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:174	Since CYP2D6 and MPP^+ target mitochondria, we expect that the toxic effect and the protection by CYPs observed here will affect mitochondrial function. 	CYP2D6	26548	26554	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2D6	28779	28785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2D6	28779	28785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2D6	28779	28785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2D6	28779	28785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2D6	30783	30789	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2D6	30783	30789	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2D6	30783	30789	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2D6	30783	30789	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	CYP2D6	31794	31800	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	CYP2D6	31794	31800	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	CYP2D6	31794	31800	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	CYP2D6	31794	31800	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2D6	36127	36133	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2D6	36127	36133	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2D6	36127	36133	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2D6	36127	36133	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:234	We also propose a primary role of CYP2D6 toward the metabolism of compounds related to Parkinsons Disease due its presence in mitochondria and suggest that SH-SY5Y cells can be a useful in vitro experimental method to clarify the overall role of CYPs at neuronal level.	CYP2D6	36223	36229	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:234	We also propose a primary role of CYP2D6 toward the metabolism of compounds related to Parkinsons Disease due its presence in mitochondria and suggest that SH-SY5Y cells can be a useful in vitro experimental method to clarify the overall role of CYPs at neuronal level.	CYP2D6	36223	36229	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:234	We also propose a primary role of CYP2D6 toward the metabolism of compounds related to Parkinsons Disease due its presence in mitochondria and suggest that SH-SY5Y cells can be a useful in vitro experimental method to clarify the overall role of CYPs at neuronal level.	CYP2D6	36223	36229	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:234	We also propose a primary role of CYP2D6 toward the metabolism of compounds related to Parkinsons Disease due its presence in mitochondria and suggest that SH-SY5Y cells can be a useful in vitro experimental method to clarify the overall role of CYPs at neuronal level.	CYP2D6	36223	36229	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP2D6	72	78	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP2D6	72	78	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP2D6	72	78	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP2D6	72	78	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP2D6	697	703	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP2D6	697	703	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP2D6	697	703	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP2D6	697	703	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP2D6	4253	4259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP2D6	4253	4259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP2D6	4253	4259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:27	Other important isoenzymes highly engaged in drug and xenobiotic metabolism are CYP2D6 and CYP1A2. 	CYP2D6	4253	4259	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:28	CYP2D6 metabolizes about 20% of clinically relevant drugs, and its characteristic feature is a possible duplication of an encoding gene, which has an impact on the different metabolism of drugs among populations. 	CYP2D6	4272	4278	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:28	CYP2D6 metabolizes about 20% of clinically relevant drugs, and its characteristic feature is a possible duplication of an encoding gene, which has an impact on the different metabolism of drugs among populations. 	CYP2D6	4272	4278	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:28	CYP2D6 metabolizes about 20% of clinically relevant drugs, and its characteristic feature is a possible duplication of an encoding gene, which has an impact on the different metabolism of drugs among populations. 	CYP2D6	4272	4278	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:28	CYP2D6 metabolizes about 20% of clinically relevant drugs, and its characteristic feature is a possible duplication of an encoding gene, which has an impact on the different metabolism of drugs among populations. 	CYP2D6	4272	4278	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP2D6	6209	6215	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP2D6	6209	6215	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP2D6	6209	6215	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP2D6	6209	6215	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP2D6	10333	10339	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP2D6	10333	10339	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP2D6	10333	10339	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP2D6	10333	10339	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP2D6	11792	11798	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP2D6	11792	11798	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP2D6	11792	11798	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP2D6	11792	11798	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP2D6	12124	12130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP2D6	12124	12130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP2D6	12124	12130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP2D6	12124	12130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2E1	951	957	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP2E1	951	957	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2E1	3599	3605	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP2E1	3599	3605	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2E1	4788	4794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP2E1	4788	4794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP2E1	19862	19868	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP2E1	19862	19868	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:164	In agreement with our current findings in male mice, we have previously demonstrated that acute Doxorubicin cardiotoxicity did not change CYP2E1 expression in the hearts of male Sprague Dawley rats. 	CYP2E1	29459	29465	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:164	In agreement with our current findings in male mice, we have previously demonstrated that acute Doxorubicin cardiotoxicity did not change CYP2E1 expression in the hearts of male Sprague Dawley rats. 	CYP2E1	29459	29465	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:165	However, Doxorubicin induced CYP2E1 in a concentration-dependent manner in H9c2 cardiomyoblasts in vitro. 	CYP2E1	29549	29555	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:165	However, Doxorubicin induced CYP2E1 in a concentration-dependent manner in H9c2 cardiomyoblasts in vitro. 	CYP2E1	29549	29555	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2E1	16207	16213	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2E1	16207	16213	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2E1	16581	16587	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2E1	16581	16587	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2E1	17063	17069	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2E1	17063	17069	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2E1	17552	17558	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP2E1	17552	17558	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP2E1	134	140	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP2E1	134	140	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP2E1	1158	1164	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP2E1	1158	1164	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP2E1	1333	1339	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP2E1	1333	1339	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP2E1	1785	1791	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP2E1	1785	1791	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP2E1	4638	4644	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP2E1	4638	4644	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP2E1	5783	5789	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP2E1	5783	5789	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9061	9067	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9061	9067	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9287	9293	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9287	9293	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9672	9678	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9672	9678	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9891	9897	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP2E1	9891	9897	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP2E1	16737	16743	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP2E1	16737	16743	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17224	17230	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17224	17230	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17297	17303	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17297	17303	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17522	17528	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP2E1	17522	17528	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP2E1	17652	17658	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP2E1	17652	17658	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP2E1	19116	19122	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP2E1	19116	19122	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP2E1	20002	20008	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP2E1	20002	20008	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP2E1	20560	20566	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP2E1	20560	20566	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP2E1	24386	24392	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP2E1	24386	24392	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP2E1	28835	28841	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP2E1	28835	28841	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP2E1	28910	28916	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP2E1	28910	28916	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:189	The activity of 7-methoxy-4-trifluoromethylcoumarin dealkylation is the diagnostic marker of CYP2E1. 	CYP2E1	29514	29520	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:189	The activity of 7-methoxy-4-trifluoromethylcoumarin dealkylation is the diagnostic marker of CYP2E1. 	CYP2E1	29514	29520	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:190	The activity of CYP2E1 was determined by fluorescence value of 7-hydroxy-4-trifluoromethylcoumarin conversed from 7-methoxy-4-trifluoromethyl-coumarin by 7-Methoxy-4-Trifluoromethylcoumarin Dealkylation. 	CYP2E1	29538	29544	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:190	The activity of CYP2E1 was determined by fluorescence value of 7-hydroxy-4-trifluoromethylcoumarin conversed from 7-methoxy-4-trifluoromethyl-coumarin by 7-Methoxy-4-Trifluoromethylcoumarin Dealkylation. 	CYP2E1	29538	29544	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP2E1	30059	30065	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP2E1	30059	30065	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:7	Sort=Bait protein partners were identified, including the components regulating cytoskeleton organization (BBIP1 and ANKMY1), components of the coagulation cascade of human blood (SERPINA1, SERPINA3, APOH, FGA, and FN1), and the enzyme involved in the metabolism of xenobiotics and endogenous bioregulators (CYP2E1). 	CYP2E1	1224	1230	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:7	Sort=Bait protein partners were identified, including the components regulating cytoskeleton organization (BBIP1 and ANKMY1), components of the coagulation cascade of human blood (SERPINA1, SERPINA3, APOH, FGA, and FN1), and the enzyme involved in the metabolism of xenobiotics and endogenous bioregulators (CYP2E1). 	CYP2E1	1224	1230	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:8	Surface Plasmon Resonance validation on the Biacore 3000 biosensor confirmed the effectiveness of the interaction between CYP2E1 (the enzyme that converts prostaglandin H2 to 12-HHT/thromboxane A2 proantagonist) and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	1355	1361	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:8	Surface Plasmon Resonance validation on the Biacore 3000 biosensor confirmed the effectiveness of the interaction between CYP2E1 (the enzyme that converts prostaglandin H2 to 12-HHT/thromboxane A2 proantagonist) and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	1355	1361	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:10	Importantly, the TBXAS1CYP2E1 complex formation increases fivefold in the presence of isatin (indole-2,3-dione, a low-molecular nonpeptide endogenous bioregulator, a product of CYP2E1). 	CYP2E1	1573	1579	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:10	Importantly, the TBXAS1CYP2E1 complex formation increases fivefold in the presence of isatin (indole-2,3-dione, a low-molecular nonpeptide endogenous bioregulator, a product of CYP2E1). 	CYP2E1	1573	1579	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:10	Importantly, the TBXAS1CYP2E1 complex formation increases fivefold in the presence of isatin (indole-2,3-dione, a low-molecular nonpeptide endogenous bioregulator, a product of CYP2E1). 	CYP2E1	1727	1733	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:10	Importantly, the TBXAS1CYP2E1 complex formation increases fivefold in the presence of isatin (indole-2,3-dione, a low-molecular nonpeptide endogenous bioregulator, a product of CYP2E1). 	CYP2E1	1727	1733	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:52	Sort=Bait using a LC-MS/MS-analysis, one of which was cytochrome P450 (CYP2E1). 	CYP2E1	7528	7534	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:52	Sort=Bait using a LC-MS/MS-analysis, one of which was cytochrome P450 (CYP2E1). 	CYP2E1	7528	7534	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	7963	7969	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	7963	7969	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	8168	8174	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	8168	8174	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:59	Sort=Bait  CYP2E1 interaction and does not affect the Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	8413	8419	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:59	Sort=Bait  CYP2E1 interaction and does not affect the Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	8413	8419	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP2E1	8986	8992	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP2E1	8986	8992	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:130	The presence of CYP2E1, which belongs to the cytochromes P450 superfamily, in the list of fished proteins is of particular interest. 	CYP2E1	18746	18752	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:130	The presence of CYP2E1, which belongs to the cytochromes P450 superfamily, in the list of fished proteins is of particular interest. 	CYP2E1	18746	18752	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:131	A functional relationship between CYP2E1 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	18897	18903	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:131	A functional relationship between CYP2E1 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	18897	18903	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:133	As it is known, CYP2E1 is characterized by broad substrate specificity and a broad tissue localization profile, including the liver. 	CYP2E1	19104	19110	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:133	As it is known, CYP2E1 is characterized by broad substrate specificity and a broad tissue localization profile, including the liver. 	CYP2E1	19104	19110	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:134	For example, CYP2E1 can oxidize arachidonic acid (via -1-hydroxylation) and prostaglandin H2 to form side metabolites, which, in turn, are formed in the prostaglandin H2 to thromboxane A2 isomerization reactions. 	CYP2E1	19234	19240	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:134	For example, CYP2E1 can oxidize arachidonic acid (via -1-hydroxylation) and prostaglandin H2 to form side metabolites, which, in turn, are formed in the prostaglandin H2 to thromboxane A2 isomerization reactions. 	CYP2E1	19234	19240	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:137	Sort=Bait, synthesizing thromboxane A2, and CYP2E1 could serve as an additional mechanism regulating the effectiveness of enzymatic conversion of common substrates. 	CYP2E1	19752	19758	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:137	Sort=Bait, synthesizing thromboxane A2, and CYP2E1 could serve as an additional mechanism regulating the effectiveness of enzymatic conversion of common substrates. 	CYP2E1	19752	19758	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:141	Sort=Bait  CYP2E1 complex in direct Surface Plasmon Resonance experiments. 	CYP2E1	20289	20295	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:141	Sort=Bait  CYP2E1 complex in direct Surface Plasmon Resonance experiments. 	CYP2E1	20289	20295	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP2E1	20454	20460	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP2E1	20454	20460	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	21381	21387	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	21381	21387	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:153	Sort=Bait  CYP2E1 complex formation were (6.9  0.3)  10^-7 M and (4.3  0.4)  10^-7 M, respectively. 	CYP2E1	21689	21695	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:153	Sort=Bait  CYP2E1 complex formation were (6.9  0.3)  10^-7 M and (4.3  0.4)  10^-7 M, respectively. 	CYP2E1	21689	21695	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:157	Sort=Bait  CYP2E1 interactions are very different in their kinetic parameters. 	CYP2E1	22178	22184	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:157	Sort=Bait  CYP2E1 interactions are very different in their kinetic parameters. 	CYP2E1	22178	22184	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:159	Sort=Bait  CYP2E1 occur about an order of magnitude slower compared to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	22353	22359	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:159	Sort=Bait  CYP2E1 occur about an order of magnitude slower compared to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	22353	22359	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:168	It is known that indole is oxidized to isatin by some cytochromes P450 (CYP2A6, CYP2C19, and CYP2E1) which are responsible for the metabolism of various xenobiotics. 	CYP2E1	23815	23821	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:168	It is known that indole is oxidized to isatin by some cytochromes P450 (CYP2A6, CYP2C19, and CYP2E1) which are responsible for the metabolism of various xenobiotics. 	CYP2E1	23815	23821	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:170	Since CYP2E1 turned out to be one of the proteins that interact with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	24083	24089	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:170	Since CYP2E1 turned out to be one of the proteins that interact with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	24083	24089	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:172	Sort=Bait  CYP2E1 complex formation. 	CYP2E1	24330	24336	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:172	Sort=Bait  CYP2E1 complex formation. 	CYP2E1	24330	24336	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:174	Sort=Bait and CYP2E1 in the absence and presence of isatin. 	CYP2E1	24527	24533	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:174	Sort=Bait and CYP2E1 in the absence and presence of isatin. 	CYP2E1	24527	24533	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:176	Sort=Bait  CYP2E1 complex formation, but it has no effect on the Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	24684	24690	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:176	Sort=Bait  CYP2E1 complex formation, but it has no effect on the Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP2E1	24684	24690	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:179	Sort=Bait  CYP2E1 in the presence of isatin is due to both a twofold increase in k_on values and a 2.5-fold decrease in k_off. 	CYP2E1	24982	24988	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:179	Sort=Bait  CYP2E1 in the presence of isatin is due to both a twofold increase in k_on values and a 2.5-fold decrease in k_off. 	CYP2E1	24982	24988	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP2E1	25445	25451	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP2E1	25445	25451	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP2E1	25493	25499	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP2E1	25493	25499	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:18	The most robust evidence supporting this hypothesis is found in short-term oral or intraperitoneal dose mode of action studies in which the lung toxicity of styrene and a previously postulated putative lung toxic metabolite, styrene oxide (a primary metabolite of CYP2E1 metabolism; ), was completely attenuated in CYP2F2 knockout mice and in mice in which human CYP2F1 was inserted as a transgene in the knockout mouse strain. 	CYP2E1	3071	3077	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:18	The most robust evidence supporting this hypothesis is found in short-term oral or intraperitoneal dose mode of action studies in which the lung toxicity of styrene and a previously postulated putative lung toxic metabolite, styrene oxide (a primary metabolite of CYP2E1 metabolism; ), was completely attenuated in CYP2F2 knockout mice and in mice in which human CYP2F1 was inserted as a transgene in the knockout mouse strain. 	CYP2E1	3071	3077	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:19	Despite robust mode of action data indicating the essential role of styrene CYP2F2 metabolism in mediating the lung toxicity of styrene, these data do not fully address the possibility that alternative and potentially human-relevant mode(s) of action outside of CYP2F2 metabolism, eg, styrene oxide formation by CYP2E1, might be contributing to styrene-induced mouse lung tumors. 	CYP2E1	3547	3553	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:19	Despite robust mode of action data indicating the essential role of styrene CYP2F2 metabolism in mediating the lung toxicity of styrene, these data do not fully address the possibility that alternative and potentially human-relevant mode(s) of action outside of CYP2F2 metabolism, eg, styrene oxide formation by CYP2E1, might be contributing to styrene-induced mouse lung tumors. 	CYP2E1	3547	3553	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:150	As CYP2F2 KO mice express equal amounts of CYP2E1 protein in WT and KO mice, these mice strains are capable of generating styrene oxide. 	CYP2E1	21036	21042	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:150	As CYP2F2 KO mice express equal amounts of CYP2E1 protein in WT and KO mice, these mice strains are capable of generating styrene oxide. 	CYP2E1	21036	21042	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:152	In addition, styrene oxide lung toxicity was completely attenuated in CYP2F2 KO mice, indicating that this primary metabolite product of CYP2E1 metabolism is not the proximate lung toxic metabolite of styrene. 	CYP2E1	21428	21434	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:152	In addition, styrene oxide lung toxicity was completely attenuated in CYP2F2 KO mice, indicating that this primary metabolite product of CYP2E1 metabolism is not the proximate lung toxic metabolite of styrene. 	CYP2E1	21428	21434	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:153	The lack of a role for CYP2E1 generated styrene oxide in lung toxicity is consistent with the observation that styrene lung toxicity was comparable in both WT and CYP2E1 KO mice. 	CYP2E1	21524	21530	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:153	The lack of a role for CYP2E1 generated styrene oxide in lung toxicity is consistent with the observation that styrene lung toxicity was comparable in both WT and CYP2E1 KO mice. 	CYP2E1	21524	21530	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:153	The lack of a role for CYP2E1 generated styrene oxide in lung toxicity is consistent with the observation that styrene lung toxicity was comparable in both WT and CYP2E1 KO mice. 	CYP2E1	21664	21670	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:153	The lack of a role for CYP2E1 generated styrene oxide in lung toxicity is consistent with the observation that styrene lung toxicity was comparable in both WT and CYP2E1 KO mice. 	CYP2E1	21664	21670	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:159	These multiple rodent bioassays support a conclusion that styrene, via CYP2E1-mediated styrene oxide formation or ring-oxidized metabolite(s) from CYP2F metabolism, has a very low potential for inducing cancer in any tissue other than mouse lung. 	CYP2E1	22797	22803	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:159	These multiple rodent bioassays support a conclusion that styrene, via CYP2E1-mediated styrene oxide formation or ring-oxidized metabolite(s) from CYP2F metabolism, has a very low potential for inducing cancer in any tissue other than mouse lung. 	CYP2E1	22797	22803	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:162	In these genetically modified mice, possible styrene metabolism by the human CYP2F isoform or that of native CYP2E1 in the CYP2F2-KO mice, also is insufficient to initiate any pre-neoplastic events resulting in potential cancer outcomes. 	CYP2E1	23628	23634	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:162	In these genetically modified mice, possible styrene metabolism by the human CYP2F isoform or that of native CYP2E1 in the CYP2F2-KO mice, also is insufficient to initiate any pre-neoplastic events resulting in potential cancer outcomes. 	CYP2E1	23628	23634	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2E1	8839	8845	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2E1	8839	8845	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:204	The CYP2E1 enzyme metabolizes ethanol, tobacco-related nitrosamines, as well as other xenobiotics (eg, acetaminophen). 	CYP2E1	31367	31373	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:204	The CYP2E1 enzyme metabolizes ethanol, tobacco-related nitrosamines, as well as other xenobiotics (eg, acetaminophen). 	CYP2E1	31367	31373	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:205	CYP2E1 is also induced by ethanol, increasing alcohol metabolism in cases of chronic ethanol consumption. 	CYP2E1	31482	31488	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:205	CYP2E1 is also induced by ethanol, increasing alcohol metabolism in cases of chronic ethanol consumption. 	CYP2E1	31482	31488	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:206	CYP2E1*1D has been associated with greater CYP2E1 induction by ethanol in individuals with at least one copy of the allele. 	CYP2E1	31588	31594	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:206	CYP2E1*1D has been associated with greater CYP2E1 induction by ethanol in individuals with at least one copy of the allele. 	CYP2E1	31588	31594	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:206	CYP2E1*1D has been associated with greater CYP2E1 induction by ethanol in individuals with at least one copy of the allele. 	CYP2E1	31631	31637	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:206	CYP2E1*1D has been associated with greater CYP2E1 induction by ethanol in individuals with at least one copy of the allele. 	CYP2E1	31631	31637	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:207	The CYP2E1*5B allele, also referred to as CYP2E1*c2, has been associated with increased enzyme activity. 	CYP2E1	31716	31722	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:207	The CYP2E1*5B allele, also referred to as CYP2E1*c2, has been associated with increased enzyme activity. 	CYP2E1	31716	31722	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:207	The CYP2E1*5B allele, also referred to as CYP2E1*c2, has been associated with increased enzyme activity. 	CYP2E1	31754	31760	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:207	The CYP2E1*5B allele, also referred to as CYP2E1*c2, has been associated with increased enzyme activity. 	CYP2E1	31754	31760	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:208	The frequency of CYP2E1*1D was reported to be 9.3% in the FN population, which is significantly higher than that seen in European Canadians (2.1%). 	CYP2E1	31834	31840	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:208	The frequency of CYP2E1*1D was reported to be 9.3% in the FN population, which is significantly higher than that seen in European Canadians (2.1%). 	CYP2E1	31834	31840	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:209	Furthermore, FN individuals dependent on alcohol (as defined by DSM-IV) had a higher frequency of the CYP2E1*1D allele, compared to non-alcohol dependent FNs. 	CYP2E1	32067	32073	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:209	Furthermore, FN individuals dependent on alcohol (as defined by DSM-IV) had a higher frequency of the CYP2E1*1D allele, compared to non-alcohol dependent FNs. 	CYP2E1	32067	32073	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:211	CYP2E1*1D genotype was also associated with nicotine dependence in FNs, however further studies are needed to elucidate potential mechanisms responsible for this relationship. 	CYP2E1	32185	32191	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:211	CYP2E1*1D genotype was also associated with nicotine dependence in FNs, however further studies are needed to elucidate potential mechanisms responsible for this relationship. 	CYP2E1	32185	32191	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:212	The MAF of the CYP2E1 1295G>C variant was determined to be 51.5% in Huichols, an Amerindian population of Western-Central Mexico. 	CYP2E1	32376	32382	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:212	The MAF of the CYP2E1 1295G>C variant was determined to be 51.5% in Huichols, an Amerindian population of Western-Central Mexico. 	CYP2E1	32376	32382	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32598	32604	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32598	32604	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32697	32703	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32697	32703	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32790	32796	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:214	The CYP2E1 1295G>C variant is of interest when considering the metabolism of ethanol, as well as other CYP2E1 substrates and further studies would be useful to establish the clinical relevance of CYP2E1 variation across diverse populations. 	CYP2E1	32790	32796	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:134	It has been reported that elevated concentration of S-Adenosylmethionine reduces CYP2E1^ and CYP39A^, but markedly induces CYP4A^ in Glycine N-Methyltransferase Knockout mice. 	CYP2E1	23159	23165	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:134	It has been reported that elevated concentration of S-Adenosylmethionine reduces CYP2E1^ and CYP39A^, but markedly induces CYP4A^ in Glycine N-Methyltransferase Knockout mice. 	CYP2E1	23159	23165	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:66	reported the presence of the following CYPs in rat skin microsomes: CYP2B, CYP2C13, CYP2D1, CYP2D4, CYP2E1, CYP3A1, and CYP3A2, their levels being much lower than in the liver (except CYP2D4, which was not observed in the liver). 	CYP2E1	10030	10036	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:66	reported the presence of the following CYPs in rat skin microsomes: CYP2B, CYP2C13, CYP2D1, CYP2D4, CYP2E1, CYP3A1, and CYP3A2, their levels being much lower than in the liver (except CYP2D4, which was not observed in the liver). 	CYP2E1	10030	10036	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:70	This CYP turned out to be an arachidonic acid 8,9- and 11,12-epoxygenase present exclusively in sebocytes (Keeney et al.. The temporal development of CYPs in rat keratinocyte monolayer cultures (serum-free) appears to provide temporal limitations of usefulness for predictions of metabolism-dependent toxicities: CYPs 3A1 and 3A2 proteins were very low, CYP2E1 below detection on day 0, while near confluency of the keratinocytes between days 10 and 14, their levels became similar to those in native skin (Zhu et al.. CYP reductase (NADPH CYP oxidoreductase) protein (required for CYP activity) has been shown to be present in the rat skin, predominantly in the epidermis (Takahara et al.. See also Table. 	CYP2E1	10719	10725	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:70	This CYP turned out to be an arachidonic acid 8,9- and 11,12-epoxygenase present exclusively in sebocytes (Keeney et al.. The temporal development of CYPs in rat keratinocyte monolayer cultures (serum-free) appears to provide temporal limitations of usefulness for predictions of metabolism-dependent toxicities: CYPs 3A1 and 3A2 proteins were very low, CYP2E1 below detection on day 0, while near confluency of the keratinocytes between days 10 and 14, their levels became similar to those in native skin (Zhu et al.. CYP reductase (NADPH CYP oxidoreductase) protein (required for CYP activity) has been shown to be present in the rat skin, predominantly in the epidermis (Takahara et al.. See also Table. 	CYP2E1	10719	10725	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2E1	12200	12206	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP2E1	12200	12206	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:88	), increased para-nitrophenol hydroxylation (CYP2E1-selective) after treatment of the rat skin with clotrimazole (Merk et al. 	CYP2E1	13788	13794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:88	), increased para-nitrophenol hydroxylation (CYP2E1-selective) after treatment of the rat skin with clotrimazole (Merk et al. 	CYP2E1	13788	13794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP2E1	33679	33685	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP2E1	33679	33685	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2E1	58834	58840	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2E1	58834	58840	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP2E1	70352	70358	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP2E1	70352	70358	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:468	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP 1-selective): 10.7 pmol/min/mg protein, PROD (CYP2B-selective): 1.43 pmol/min/mg protein, para-nitrophenol hydroxylase (CYP2E1-selective): 1.81 nmol/min/mg protein, erythromycin N-demethylase (CYP 3A-selective): 3.26 nmol/min/mg protein. 	CYP2E1	73165	73171	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:468	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP 1-selective): 10.7 pmol/min/mg protein, PROD (CYP2B-selective): 1.43 pmol/min/mg protein, para-nitrophenol hydroxylase (CYP2E1-selective): 1.81 nmol/min/mg protein, erythromycin N-demethylase (CYP 3A-selective): 3.26 nmol/min/mg protein. 	CYP2E1	73165	73171	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:581	Since basal CYP2E1 expression was absent in these ORS-RHE models, they concluded that the CYP responsible for the biotransformation of 7-ethoxycoumarin to 7-hydroxycoumarin was likely to be CYP1B1, which they had found to be expressed at good levels. 	CYP2E1	89888	89894	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:581	Since basal CYP2E1 expression was absent in these ORS-RHE models, they concluded that the CYP responsible for the biotransformation of 7-ethoxycoumarin to 7-hydroxycoumarin was likely to be CYP1B1, which they had found to be expressed at good levels. 	CYP2E1	89888	89894	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:630	CYP2E subfamily CYP2E1 transcripts were noted in human keratinocytes, melanocytes, Langerhans cells and fibroblasts (Baron et al. 	CYP2E1	97276	97282	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:630	CYP2E subfamily CYP2E1 transcripts were noted in human keratinocytes, melanocytes, Langerhans cells and fibroblasts (Baron et al. 	CYP2E1	97276	97282	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:633	CYP2E1 mRNA was expressed in native human skin, both, in the epidermis and in the dermis. 	CYP2E1	97509	97515	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:633	CYP2E1 mRNA was expressed in native human skin, both, in the epidermis and in the dermis. 	CYP2E1	97509	97515	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:636	CYP2E1-typical enzymatic activity in the human skin was observed toward the substrates chlorzoxazone and toward para-nitrophenol in microsomes derived from the total human skin by Rolsted et al. 	CYP2E1	97921	97927	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:636	CYP2E1-typical enzymatic activity in the human skin was observed toward the substrates chlorzoxazone and toward para-nitrophenol in microsomes derived from the total human skin by Rolsted et al. 	CYP2E1	97921	97927	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:638	Some examples of CYP2E1 substrates: ethanol, chlorzoxazone, benzene, 17BETA-estradiol, estrone, retinoic acid, fatty acids, aflatoxin B_1, nicotine, capsaicin, curcumin, short-chain N-nitrosamines (Du et al. 	CYP2E1	98227	98233	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:638	Some examples of CYP2E1 substrates: ethanol, chlorzoxazone, benzene, 17BETA-estradiol, estrone, retinoic acid, fatty acids, aflatoxin B_1, nicotine, capsaicin, curcumin, short-chain N-nitrosamines (Du et al. 	CYP2E1	98227	98233	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:11	These two selaginellins had low inhibitory potential against CYP1A2, CYP2A6, CYP2E1, and UGT1A6 (IC50 > 25 M). 	CYP2E1	1568	1574	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:11	These two selaginellins had low inhibitory potential against CYP1A2, CYP2A6, CYP2E1, and UGT1A6 (IC50 > 25 M). 	CYP2E1	1568	1574	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:41	The effects on CYP1A1, CYP2A6, CYP2E1, and UGT1A6 activities were assumed to be a negligible (IC_50 > 25 M). 	CYP2E1	6570	6576	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:41	The effects on CYP1A1, CYP2A6, CYP2E1, and UGT1A6 activities were assumed to be a negligible (IC_50 > 25 M). 	CYP2E1	6570	6576	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:42	These findings suggest that clinical interactions between these compounds and CYP1A1, CYP2A6, CYP2E1, or UGT1A6 would not occur. 	CYP2E1	6742	6748	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:42	These findings suggest that clinical interactions between these compounds and CYP1A1, CYP2A6, CYP2E1, or UGT1A6 would not occur. 	CYP2E1	6742	6748	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2E1	9374	9380	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2E1	9374	9380	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	CYP2E1	91	97	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	CYP2E1	91	97	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:2	Incubation systems were established to investigate the effects of quercetin, kaempferol, isoquercitrin and astragalin in Lysimachia clethroides Duby on the activities of CYP2E1 and CYP3A4 in rat liver microsomes in vitro. 	CYP2E1	304	310	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:2	Incubation systems were established to investigate the effects of quercetin, kaempferol, isoquercitrin and astragalin in Lysimachia clethroides Duby on the activities of CYP2E1 and CYP3A4 in rat liver microsomes in vitro. 	CYP2E1	304	310	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:5	The results suggested that kaempferol exhibited a weak inhibition of CYP2E1 activity with an IC50 of 60.26  2.54 M, while quercetin and kaempferol caused a moderate inhibition of CYP3A4 activity with IC50 values of 18.77  1.69 M and 32.65  1.32 M, respectively. 	CYP2E1	711	717	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:5	The results suggested that kaempferol exhibited a weak inhibition of CYP2E1 activity with an IC50 of 60.26  2.54 M, while quercetin and kaempferol caused a moderate inhibition of CYP3A4 activity with IC50 values of 18.77  1.69 M and 32.65  1.32 M, respectively. 	CYP2E1	711	717	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:6	Isoquercitrin and astragalin had no effects on the activities of either CYP2E1 or CYP3A4. 	CYP2E1	976	982	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:6	Isoquercitrin and astragalin had no effects on the activities of either CYP2E1 or CYP3A4. 	CYP2E1	976	982	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:7	It could be speculated from these results that the inhibitory effects of quercetin and kaempferol on the activities of CYP2E1 and CYP3A4 could be the mechanisms underlying the hepatoprotective effects of L. clethroides. 	CYP2E1	1113	1119	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:7	It could be speculated from these results that the inhibitory effects of quercetin and kaempferol on the activities of CYP2E1 and CYP3A4 could be the mechanisms underlying the hepatoprotective effects of L. clethroides. 	CYP2E1	1113	1119	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:17	It has been shown by studies in the literature that the enzyme CYP2E1 which mediates the hepatocyte damage caused by a variety of compounds, such as ethanol and CCl_4, is considered to be an important determinant of human susceptibility to toxicity and carcinogenicity caused by the industrial and environmental chemicals. 	CYP2E1	2872	2878	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:17	It has been shown by studies in the literature that the enzyme CYP2E1 which mediates the hepatocyte damage caused by a variety of compounds, such as ethanol and CCl_4, is considered to be an important determinant of human susceptibility to toxicity and carcinogenicity caused by the industrial and environmental chemicals. 	CYP2E1	2872	2878	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:19	CYP2E1 and CYP3A4 are not only the metabolic enzymes directly involved in hepatic oxidative damage, but they also are two important targets of the oxidation mechanism of acute liver injury. 	CYP2E1	3262	3268	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:19	CYP2E1 and CYP3A4 are not only the metabolic enzymes directly involved in hepatic oxidative damage, but they also are two important targets of the oxidation mechanism of acute liver injury. 	CYP2E1	3262	3268	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:21	On the basis of previous studies, the impacts of quercetin, kaempferol, isoquercitrin and astragalin on the activities of enzymes CYP2E1 and CYP3A4 in rat liver microsomes were examined, aiming to investigate the correlation between the hepatoprotective effects of L. clethroides and the antioxidant activities of these four compounds. 	CYP2E1	3938	3944	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:21	On the basis of previous studies, the impacts of quercetin, kaempferol, isoquercitrin and astragalin on the activities of enzymes CYP2E1 and CYP3A4 in rat liver microsomes were examined, aiming to investigate the correlation between the hepatoprotective effects of L. clethroides and the antioxidant activities of these four compounds. 	CYP2E1	3938	3944	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:36	The regressive equations obtained by the Lineweaver-Burk method for CYP2E1 and CYP3A4 were Y = 835.9883X + 9.1943 (r = 0.9864) and Y = 2388.0110X + 14.1598 (r = 0.9961) respetively. 	CYP2E1	6007	6013	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:36	The regressive equations obtained by the Lineweaver-Burk method for CYP2E1 and CYP3A4 were Y = 835.9883X + 9.1943 (r = 0.9864) and Y = 2388.0110X + 14.1598 (r = 0.9961) respetively. 	CYP2E1	6007	6013	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:39	The effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides and clomethiazole (positive control) on CYP2E1 activity are shown in  and. 	CYP2E1	6484	6490	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:39	The effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides and clomethiazole (positive control) on CYP2E1 activity are shown in  and. 	CYP2E1	6484	6490	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:40	Clomethiazole inhibited the production of 4-nitrocatechol with an IC_50 of 1.07  0.01 M. The effects of quercetin, kaempferol, isoquercitrin and astragalin on CYP2E1 acivity were very weak and their IC_50 values could not be calculated. 	CYP2E1	6678	6684	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:40	Clomethiazole inhibited the production of 4-nitrocatechol with an IC_50 of 1.07  0.01 M. The effects of quercetin, kaempferol, isoquercitrin and astragalin on CYP2E1 acivity were very weak and their IC_50 values could not be calculated. 	CYP2E1	6678	6684	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:45	CYP2E1 and CYP3A4 are two important metabolic enzymes involved in liver injury. 	CYP2E1	7637	7643	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:45	CYP2E1 and CYP3A4 are two important metabolic enzymes involved in liver injury. 	CYP2E1	7637	7643	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:46	Total alkaloids of Rubus alceaefolius Poir could significantly reduce the levels of GOT and GPT, protect liver cells from injury, and inhibit the mRNA expressions of CYP2E1 and CYP3A1 in liver tissue. 	CYP2E1	7883	7889	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:46	Total alkaloids of Rubus alceaefolius Poir could significantly reduce the levels of GOT and GPT, protect liver cells from injury, and inhibit the mRNA expressions of CYP2E1 and CYP3A1 in liver tissue. 	CYP2E1	7883	7889	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:47	It has been indicated that Gegen powder possesses therapeutic effects on acute alcohol-induced liver injury, by increasing the content of CYP450 and reducing the activity of CYP2E1. 	CYP2E1	8092	8098	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:47	It has been indicated that Gegen powder possesses therapeutic effects on acute alcohol-induced liver injury, by increasing the content of CYP450 and reducing the activity of CYP2E1. 	CYP2E1	8092	8098	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:48	Radix Glycyrrhizae could protect the liver injury caused by Rhizoma dioscorea bulbifera, possibly due to its induction of activity of CYP2E1 and CYP3A4 and inhibition of the mRNA expression. 	CYP2E1	8234	8240	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:48	Radix Glycyrrhizae could protect the liver injury caused by Rhizoma dioscorea bulbifera, possibly due to its induction of activity of CYP2E1 and CYP3A4 and inhibition of the mRNA expression. 	CYP2E1	8234	8240	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:49	Clomethiazole and ketoconazole act as the positive inhibitors for CYP2E1 and CYP3A4 can significantly inhibit the formation of metabolites. 	CYP2E1	8357	8363	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:49	Clomethiazole and ketoconazole act as the positive inhibitors for CYP2E1 and CYP3A4 can significantly inhibit the formation of metabolites. 	CYP2E1	8357	8363	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:50	The IC_50 values of clomethiazole and ketoconazole were 1.07  0.01 M and 0.25  0.01 M, respectively, which are consistent with literature values, suggesting that the incubation systems in vitro can meet the activities of measurement of CYP2E1 and CYP3A4. 	CYP2E1	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:50	The IC_50 values of clomethiazole and ketoconazole were 1.07  0.01 M and 0.25  0.01 M, respectively, which are consistent with literature values, suggesting that the incubation systems in vitro can meet the activities of measurement of CYP2E1 and CYP3A4. 	CYP2E1	8667	8673	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:52	Thus, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol have moderate inhibitory effects on CYP3A4. 	CYP2E1	8941	8947	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:52	Thus, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol have moderate inhibitory effects on CYP3A4. 	CYP2E1	8941	8947	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:53	The results of this study showed that the two flavone glycosides (isoquercitrin and astragalin) had no effect on the activities of CYP2E1 and CYP3A4. 	CYP2E1	9155	9161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:53	The results of this study showed that the two flavone glycosides (isoquercitrin and astragalin) had no effect on the activities of CYP2E1 and CYP3A4. 	CYP2E1	9155	9161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:59	Cytochromes P450, especially CYP2E1 and CYP3A4, are responsible for metabolism of ethanol, CCl_4 and other solvents in the body. 	CYP2E1	9929	9935	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:59	Cytochromes P450, especially CYP2E1 and CYP3A4, are responsible for metabolism of ethanol, CCl_4 and other solvents in the body. 	CYP2E1	9929	9935	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:60	In the model of alcohol-induced liver injury, the expression levels of CYP2E1 and CYP3A4 were enhanced. 	CYP2E1	10100	10106	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:60	In the model of alcohol-induced liver injury, the expression levels of CYP2E1 and CYP3A4 were enhanced. 	CYP2E1	10100	10106	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10155	10161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10202	10208	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10202	10208	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10400	10406	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10400	10406	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10435	10441	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:61	Researchers have used CYP2E1 knockout mice to evaluate the effect of CYP2E1 on ethanol-induced chronic liver injury, and the results showed that the fatty liver production and ethanol-induced oxidative stress of wild-type mice were significantly higher than those in CYP2E1 knockout mice, showing that CYP2E1 is involved in the oxidative stress of the body, increasing the severity of liver damage. 	CYP2E1	10435	10441	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:62	As a typical poison, CC1_4 is activated by CYP2E1 and metabolized to a series of highly reactive free radicals. 	CYP2E1	10575	10581	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:62	As a typical poison, CC1_4 is activated by CYP2E1 and metabolized to a series of highly reactive free radicals. 	CYP2E1	10575	10581	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:66	The occurrence of liver injury can be reduced or even suppressed by minimizing the activities of CYP2E1 and CYP3A4, making the discovery of more compounds with anti-oxidative stress from natural products of important significance. 	CYP2E1	11144	11150	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:66	The occurrence of liver injury can be reduced or even suppressed by minimizing the activities of CYP2E1 and CYP3A4, making the discovery of more compounds with anti-oxidative stress from natural products of important significance. 	CYP2E1	11144	11150	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:104	The in vitro incubation system of CYP2E1 contained liver microsomes, MgCl_2 (5 mM), 4-nitrophenol (probe substrate) and phosphate buffer (pH 7.4) in a final volume of 200 L. The mixture was pre-incubated 5 min at 37 C thermostatic constant incubator, the reaction was initiated by adding NADPH (1 mM). 	CYP2E1	15012	15018	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:104	The in vitro incubation system of CYP2E1 contained liver microsomes, MgCl_2 (5 mM), 4-nitrophenol (probe substrate) and phosphate buffer (pH 7.4) in a final volume of 200 L. The mixture was pre-incubated 5 min at 37 C thermostatic constant incubator, the reaction was initiated by adding NADPH (1 mM). 	CYP2E1	15012	15018	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:127	To evaluate whether quercetin, kaempferol, isoquercitrin and astragalin affect the activity of CYP2E1, the studies were carried out in three groups. 	CYP2E1	18503	18509	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:127	To evaluate whether quercetin, kaempferol, isoquercitrin and astragalin affect the activity of CYP2E1, the studies were carried out in three groups. 	CYP2E1	18503	18509	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:133	The effects of flavonoids in L. clethroides on CYP3A4 activity were basically the same as CYP2E1. 	CYP2E1	19410	19416	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:133	The effects of flavonoids in L. clethroides on CYP3A4 activity were basically the same as CYP2E1. 	CYP2E1	19410	19416	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:134	The positive control was ketoconazole, and Groups 2 and 3 experiments were performed at concentrations of 0.02, 0.1, 0.2, 1 and 5 M. In vitro rat liver microsomes incubation assay methods were adopted for determining the effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides on the activities of CYP2E1 and CYP3A4. 	CYP2E1	19741	19747	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:134	The positive control was ketoconazole, and Groups 2 and 3 experiments were performed at concentrations of 0.02, 0.1, 0.2, 1 and 5 M. In vitro rat liver microsomes incubation assay methods were adopted for determining the effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides on the activities of CYP2E1 and CYP3A4. 	CYP2E1	19741	19747	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:135	In conclusion, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol had moderate inhibitory effects on CYP3A4 activity. 	CYP2E1	19820	19826	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:135	In conclusion, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol had moderate inhibitory effects on CYP3A4 activity. 	CYP2E1	19820	19826	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:136	Based on these results, it can be speculated that the active hepatoprotective ingredients of L. clethroides include quercetin and kaempferol, which confer the inhibitory effects on the activities of CYP2E1 and CYP3A4. 	CYP2E1	20110	20116	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:136	Based on these results, it can be speculated that the active hepatoprotective ingredients of L. clethroides include quercetin and kaempferol, which confer the inhibitory effects on the activities of CYP2E1 and CYP3A4. 	CYP2E1	20110	20116	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:137	The reduction of CYP2E1 and CYP3A4 activities can mitigate the biotransformation of CC1_4 and prevent the production of liver damaging substances to exert a liver protective role. 	CYP2E1	20146	20152	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:137	The reduction of CYP2E1 and CYP3A4 activities can mitigate the biotransformation of CC1_4 and prevent the production of liver damaging substances to exert a liver protective role. 	CYP2E1	20146	20152	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2E1	4633	4639	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP2E1	4633	4639	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:9	Both BETA-NF and EtOH increased CYP2E1 mRNA (4- and 1.4-fold, respectively) and protein levels (64% both). 	CYP2E1	998	1004	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:9	Both BETA-NF and EtOH increased CYP2E1 mRNA (4- and 1.4-fold, respectively) and protein levels (64% both). 	CYP2E1	998	1004	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:43	Another important isoform in the Central Nervous System is CYP2E1, which can metabolize l-deprenyl in C57BL mice but not in monkeys, either in the liver or brain. 	CYP2E1	5811	5817	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:43	Another important isoform in the Central Nervous System is CYP2E1, which can metabolize l-deprenyl in C57BL mice but not in monkeys, either in the liver or brain. 	CYP2E1	5811	5817	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2E1	6008	6014	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:44	Despite that its mRNA expression is lower than that observed for CYP2D6 in substantia nigra, CYP2E1 is important for many key biological processes. 	CYP2E1	6008	6014	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:46	In the brain of Parkinsons Disease patients, the CYP2E1 gene seems to be less methylated compared to healthy brains, leading to a higher expression of this isoform. 	CYP2E1	6278	6284	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:46	In the brain of Parkinsons Disease patients, the CYP2E1 gene seems to be less methylated compared to healthy brains, leading to a higher expression of this isoform. 	CYP2E1	6278	6284	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:47	CYP2E1 has been proposed to play a role in the development of Parkinsons Disease due to its capability to be induced, its ability to metabolize several xenobiotics that are able to cross the blood-brain barrier, and the high level of ROS production during its metabolic reactions. 	CYP2E1	6394	6400	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:47	CYP2E1 has been proposed to play a role in the development of Parkinsons Disease due to its capability to be induced, its ability to metabolize several xenobiotics that are able to cross the blood-brain barrier, and the high level of ROS production during its metabolic reactions. 	CYP2E1	6394	6400	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:48	Moreover, CYP2E1 also present polymorphisms, where the 5 flanking region seems to be important for the metabolism of drugs. 	CYP2E1	6685	6691	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:48	Moreover, CYP2E1 also present polymorphisms, where the 5 flanking region seems to be important for the metabolism of drugs. 	CYP2E1	6685	6691	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:55	EtOH is the most studied compound for CYP2E1 induction in both in vitro and in vivo experiments. 	CYP2E1	7920	7926	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:55	EtOH is the most studied compound for CYP2E1 induction in both in vitro and in vivo experiments. 	CYP2E1	7920	7926	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:62	Moreover, CYP2E1 promoted an increase of 4-fold changes after BETA-NF treatment while EtOH only showed a nonsignificant 1.4-fold change (b). 	CYP2E1	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:62	Moreover, CYP2E1 promoted an increase of 4-fold changes after BETA-NF treatment while EtOH only showed a nonsignificant 1.4-fold change (b). 	CYP2E1	8795	8801	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:67	Moreover, CYP2E1 showed to be inducible by both BETA-NF and EtOH by about 1.7-fold (b). 	CYP2E1	9774	9780	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:67	Moreover, CYP2E1 showed to be inducible by both BETA-NF and EtOH by about 1.7-fold (b). 	CYP2E1	9774	9780	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:86	The analysis of the CYP2E1 fluorescence revealed that this isoform was localized with Endoplasmic Reticulum and not with mitochondria. 	CYP2E1	12489	12495	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:86	The analysis of the CYP2E1 fluorescence revealed that this isoform was localized with Endoplasmic Reticulum and not with mitochondria. 	CYP2E1	12489	12495	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:106	BETA-NF is known to induce Cytochrome P450 isoforms belonging to the family 1A and 1B, while EtOH induces the expression of CYP2E1 isoform. 	CYP2E1	15589	15595	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:106	BETA-NF is known to induce Cytochrome P450 isoforms belonging to the family 1A and 1B, while EtOH induces the expression of CYP2E1 isoform. 	CYP2E1	15589	15595	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:110	Moreover, CYP2E1 mRNA levels were statistically increased by BETA-NF and not by EtOH. 	CYP2E1	16067	16073	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:110	Moreover, CYP2E1 mRNA levels were statistically increased by BETA-NF and not by EtOH. 	CYP2E1	16067	16073	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:111	However, both treatments were able to increase the CYP2E1 proteins as observed by Western Blot analysis in undifferentiated cells, while only EtOH promoted this expression in the differentiated phenotype. 	CYP2E1	16194	16200	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:111	However, both treatments were able to increase the CYP2E1 proteins as observed by Western Blot analysis in undifferentiated cells, while only EtOH promoted this expression in the differentiated phenotype. 	CYP2E1	16194	16200	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:124	Conversely, the treatment with EtOH did not show a significant increase of the CYP2E1 mRNA levels, while in Western Blot analysis we observed a statistical increase of protein levels. 	CYP2E1	18210	18216	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:124	Conversely, the treatment with EtOH did not show a significant increase of the CYP2E1 mRNA levels, while in Western Blot analysis we observed a statistical increase of protein levels. 	CYP2E1	18210	18216	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:125	These results are justified by the evidence that EtOH promotes CYP2E1 protein stabilization, rather than regulation via receptor activation. 	CYP2E1	18378	18384	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:125	These results are justified by the evidence that EtOH promotes CYP2E1 protein stabilization, rather than regulation via receptor activation. 	CYP2E1	18378	18384	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:127	CYP2E1 induction was also observed in vivo, where rats treated with EtOH and nicotine had increased brain levels of this isoform. 	CYP2E1	18538	18544	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:127	CYP2E1 induction was also observed in vivo, where rats treated with EtOH and nicotine had increased brain levels of this isoform. 	CYP2E1	18538	18544	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:134	It is also important to underline the contrasting results in the literature on the role of CYP2E1 in the brain. 	CYP2E1	19788	19794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:134	It is also important to underline the contrasting results in the literature on the role of CYP2E1 in the brain. 	CYP2E1	19788	19794	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:136	However, in another study by the same group, the knockout mice of CYP2E1^/ were shown to have a lower degeneration of dopaminergic neurons after acute administration of this toxin. 	CYP2E1	19982	19988	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:136	However, in another study by the same group, the knockout mice of CYP2E1^/ were shown to have a lower degeneration of dopaminergic neurons after acute administration of this toxin. 	CYP2E1	19982	19988	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:137	On the other hand, a study of six Parkinsons Disease patients showed a lower DNA methylation at the promoter region of CYP2E1 gene in both cortex and putamen, and an increase of mRNA levels in cortex, suggesting that epigenetic variations of this isoform may contribute to Parkinsons Disease susceptibility, but they did not study the correlation between mRNA levels and proteins or enzymatic activity. 	CYP2E1	20216	20222	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:137	On the other hand, a study of six Parkinsons Disease patients showed a lower DNA methylation at the promoter region of CYP2E1 gene in both cortex and putamen, and an increase of mRNA levels in cortex, suggesting that epigenetic variations of this isoform may contribute to Parkinsons Disease susceptibility, but they did not study the correlation between mRNA levels and proteins or enzymatic activity. 	CYP2E1	20216	20222	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:155	In contrast, CYP2E1 appeared to partially localize in the Endoplasmic Reticulum, as it has been reported in other cell types and tissues. 	CYP2E1	23496	23502	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:155	In contrast, CYP2E1 appeared to partially localize in the Endoplasmic Reticulum, as it has been reported in other cell types and tissues. 	CYP2E1	23496	23502	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:158	Moreover, other groups have indicated the possibility that CYP2E1, and other isoforms, may target the mitochondria in other in vitro and in vivo models. 	CYP2E1	24023	24029	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:158	Moreover, other groups have indicated the possibility that CYP2E1, and other isoforms, may target the mitochondria in other in vitro and in vivo models. 	CYP2E1	24023	24029	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:159	However, the intracellular location of CYP2E1 is still a subject of debate. 	CYP2E1	24156	24162	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:159	However, the intracellular location of CYP2E1 is still a subject of debate. 	CYP2E1	24156	24162	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:167	On the other hand, CYP2E1 has been proposed to be involved in the intracellular accumulation of this toxin rather than in the metabolism itself. 	CYP2E1	25467	25473	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:167	On the other hand, CYP2E1 has been proposed to be involved in the intracellular accumulation of this toxin rather than in the metabolism itself. 	CYP2E1	25467	25473	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2E1	28846	28852	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2E1	28846	28852	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2E1	30855	30861	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2E1	30855	30861	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2E1	36161	36167	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2E1	36161	36167	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2E1	18453	18459	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2E1	18453	18459	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2E1	31205	31211	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2E1	31205	31211	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:50	456217), CYP2E1 (Lot No. 	CYP2E1	8447	8453	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:50	456217), CYP2E1 (Lot No. 	CYP2E1	8447	8453	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2E1	13027	13033	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2E1	13027	13033	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2E1	14292	14298	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2E1	14292	14298	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2E1	19953	19959	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2E1	19953	19959	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2E1	24539	24545	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2E1	24539	24545	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:8	Employing mice with genetic ablation of CHIP and gp78/AMFR E3 ubiquitin-ligases that stabilize hepatic CYP2E1, we document why this stabilization not always leads to non-alcoholic fatty liver disease: It requires concomitantly enhanced hepatic lipogenesis.Image 1 The ubiquitous hemoproteins cytochromes P450 (P450s or CYPs; MW 50 kDa) are enzymes engaged both in synthetic and degradative functions critically important to the cellular integrity, physiology and defense,. 	CYP2E1	1869	1875	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:8	Employing mice with genetic ablation of CHIP and gp78/AMFR E3 ubiquitin-ligases that stabilize hepatic CYP2E1, we document why this stabilization not always leads to non-alcoholic fatty liver disease: It requires concomitantly enhanced hepatic lipogenesis.Image 1 The ubiquitous hemoproteins cytochromes P450 (P450s or CYPs; MW 50 kDa) are enzymes engaged both in synthetic and degradative functions critically important to the cellular integrity, physiology and defense,. 	CYP2E1	1869	1875	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP2E1	5137	5143	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP2E1	5137	5143	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP2E1	5343	5349	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP2E1	5343	5349	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:28	Hepatic CYP2E1 similarly exhibits a high propensity for ROS generation and is labile in the absence of relevant substrates and/or inducers that stabilize the protein,. 	CYP2E1	5990	5996	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:28	Hepatic CYP2E1 similarly exhibits a high propensity for ROS generation and is labile in the absence of relevant substrates and/or inducers that stabilize the protein,. 	CYP2E1	5990	5996	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:30	Systematic dissection of the hepatic CYP3A and CYP2E1 ERAD-C process employing various in vivo and in vitro reconstituted eukaryotic systems has revealed that it involves initial post-translational phosphorylation by cytosolic protein kinases A and C of P450 Ser/Thr residues,. 	CYP2E1	6282	6288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:30	Systematic dissection of the hepatic CYP3A and CYP2E1 ERAD-C process employing various in vivo and in vitro reconstituted eukaryotic systems has revealed that it involves initial post-translational phosphorylation by cytosolic protein kinases A and C of P450 Ser/Thr residues,. 	CYP2E1	6282	6288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9257	9263	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9257	9263	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9392	9398	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9392	9398	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:50	The individual roles of CHIP and gp78 in CYP3A and CYP2E1 ubiquitination and Endoplasmic Reticulum-Associated Degradation were verified upon lentiviral shRNA interference analyses targeted individually against each of these E3s in cultured rat hepatocytes,. 	CYP2E1	11378	11384	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP3A	959	964	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP3A	971	976	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP3A	3572	3577	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP3A	3580	3585	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP3A	4796	4801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP3A	4808	4813	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP3A	19870	19875	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP3A	19882	19887	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:167	For instance,  reported that curcumin and its derivatives inhibit the activity of CYP3A4 and other drug-metabolizing enzymes such as: glutathione-S-transferase and UDP-glucuronosyltransferase. 	CYP3A	33448	33453	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:168	These authors reported that inhibition by curcumin, alone or in combination with piperine, of CYP3A4 could be harmful, especially during prolonged usage. 	CYP3A	33653	33658	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:169	in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity in vitro which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. 	CYP3A	33783	33788	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:169	in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity in vitro which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. 	CYP3A	33948	33953	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:170	Similarly, the-flavonols kaempferol, quercetin, and galangin were reported to inhibit CYP3A4-mediated metabolism of xenobiotics in vitro (;. 	CYP3A	34151	34156	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:171	Furthermore, inhibitory effects of catechins on CYP3A4 were reported in some studies, although no specific mechanisms of action were reported in these studies. 	CYP3A	34254	34259	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP3A	925	930	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP3A	1444	1449	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP3A	1796	1801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP3A	5031	5036	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP3A	5241	5246	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A	5687	5692	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A	5920	5925	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A	6019	6024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:22	Fargesin decreased CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pre-incubation time- and concentration-dependent manners in human liver microsomes. 	CYP3A	6498	6503	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:23	The apparent K_i and maximal inactivation rate (k_inact) values of fargesin were 10.7 M and 0.082 min^1 for CYP2C8-catalyzed amodiaquine N-deethylation, 3.7 M and 0.102 min^1 for CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and 23.0 M and 0.050 min^1 for CYP3A4-catalyzed midazolam 1-hydroxylation, respectively, in human liver microsomes. 	CYP3A	6889	6894	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP3A	7394	7399	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP3A	7585	7590	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP3A	7703	7708	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP3A	7974	7979	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:29	Other methylenedioxyphenyl compounds such as myristicin and podophyllotoxin exhibited mechanism-based inactivation of CYP1A2 and CYP3A4, respectively, in human liver microsomes. 	CYP3A	8304	8309	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:32	Fargesin showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pooled human liver microsomes. 	CYP3A	8886	8891	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:35	The CYP3A4 inactivation potency (k_inact/K_i ratio) of fargesin (2.17 min^1 nM^1) was comparable with those reported for some phytochemicals identified as mechanism-based inhibitors of CYP3A4 including aschantin (4.92 min^1 nM^1), bergamottin (2 min^1 nM^1), and rutaecarpine (3.59 min^1 nM^1), but much lower than those reported for podophyllotoxin (13.63 min^1 nM^1), phyllanthin (131.88 min^1 nM^1) and hypophyllanthin (83.21 min^1 nM^1) in human liver microsomes. 	CYP3A	9760	9765	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:35	The CYP3A4 inactivation potency (k_inact/K_i ratio) of fargesin (2.17 min^1 nM^1) was comparable with those reported for some phytochemicals identified as mechanism-based inhibitors of CYP3A4 including aschantin (4.92 min^1 nM^1), bergamottin (2 min^1 nM^1), and rutaecarpine (3.59 min^1 nM^1), but much lower than those reported for podophyllotoxin (13.63 min^1 nM^1), phyllanthin (131.88 min^1 nM^1) and hypophyllanthin (83.21 min^1 nM^1) in human liver microsomes. 	CYP3A	9941	9946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:36	The k_inact/K_i ratio of fargesin against CYP3A4 was comparable to those of therapeutic drugs known as mechanism-based CYP3A4 inhibitors such as clarithromycin (1-13 min^1 nM^1), erythromycin (3-9 min^1 nM^1), amiodarone (4.5 min^1 nM^1), and fluoxetine (3.2 min^1 nM^1) in human liver microsomes. 	CYP3A	10266	10271	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:36	The k_inact/K_i ratio of fargesin against CYP3A4 was comparable to those of therapeutic drugs known as mechanism-based CYP3A4 inhibitors such as clarithromycin (1-13 min^1 nM^1), erythromycin (3-9 min^1 nM^1), amiodarone (4.5 min^1 nM^1), and fluoxetine (3.2 min^1 nM^1) in human liver microsomes. 	CYP3A	10343	10348	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP3A	11791	11796	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:64	The mechanism-based inhibition potency of fargesin against human liver microsomal CYP2C8, CYP2C19, and CYP3A4 activities was evaluated. 	CYP3A	17096	17101	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	CYP3A	17541	17546	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP3A	18411	18416	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP3A	18798	18803	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP3A	19182	19187	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:1	 Potential Role of Patients CYP3A-Status in Clozapine Pharmacokinetics. 	CYP3A	28	33	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:4	Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. 	CYP3A	515	520	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A	806	811	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:6	The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. 	CYP3A	1093	1098	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:6	The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. 	CYP3A	1186	1191	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:7	The dose requirement for the therapeutic concentration of clozapine was substantially lower in low CYP3A4 expresser patients than in normal/high expressers (2.180.64 vs 4.981.40 mg/kg, P<.0001). 	CYP3A	1307	1312	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:8	Furthermore, significantly higher plasma concentration ratios of norclozapine/clozapine and clozapine N-oxide/clozapine were observed in the patients displaying normal/high CYP3A4 expression than in the low expressers. 	CYP3A	1576	1581	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A	1646	1651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A	1660	1665	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A	1679	1684	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A	1924	1929	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP3A	2041	2046	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A	2490	2495	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A	2504	2509	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A	2526	2531	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A	2766	2771	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A	2848	2853	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A	2870	2875	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A	2916	2921	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:14	Personalized medication taking patients CYP3A status into account may facilitate the improvement of individual clozapine therapy, leading to the dosage optimization for a more effective therapy. 	CYP3A	2976	2981	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP3A	4939	4944	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:26	CYP3A4 seems to catalyze N-oxidation of clozapine, whereas the formation of norclozapine appears to be more complex. 	CYP3A	5080	5085	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:27	CYP1A2 and CYP3A4 were assumed to be the major enzymes responsible for the N-demethylation pathway, and several clinical reports provided indirect evidence for their participation in clozapine metabolism. 	CYP3A	5208	5213	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:28	Concomitant treatment with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, CYP2C19, CYP3A4), significantly decreased the plasma norclozapine/clozapine ratios and patients clozapine dose requirement (;. 	CYP3A	5497	5502	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:30	In vitro studies have demonstrated that at high clozapine concentrations, CYP3A4 plays a primary role in N-demethylation can modify CYP activities, resulting in transient poor (or extensive) metabolism. 	CYP3A	5854	5859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP3A	6596	6601	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP3A	6680	6685	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A	8342	8347	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A	8354	8359	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A	8400	8405	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A	8688	8693	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A	8699	8704	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A	8714	8719	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:52	The quantities of CYP1A2 and CYP3A4 mRNAs relative to that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined. 	CYP3A	9472	9477	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:55	The cut-off values for CYP mRNA levels in leukocytes have been previously established on the basis of the cut-off values for the hepatic CYP enzyme activities (CYP1A2: phenacetin O-dealkylation; CYP3A4: nifedipine oxidation or midazolam 1- and 4-hydroxylation). 	CYP3A	10065	10070	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:56	The cut-off values for CYP1A2 (10^-5 and 5*10^-4) and CYP3A4 (10^-6 and 10^-4) allowed a distinction between low, normal, and high expressers. 	CYP3A	10186	10191	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP3A	11158	11163	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP3A	11198	11203	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:64	The dose and patients CYP3A4 expression were identified as significant parameters for clozapine concentration (P<.0001). 	CYP3A	11763	11768	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:67	Model parameters k_0 and k_1 were estimated for low and normal/high CYP3A4 expressers individually. 	CYP3A	12293	12298	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:80	The role of CYP3A4 in the metabolism of clozapine at therapeutic or higher concentrations has been demonstrated; however, the contribution of the highly polymorphic CYP3A5 must be clarified. 	CYP3A	14409	14414	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:80	The role of CYP3A4 in the metabolism of clozapine at therapeutic or higher concentrations has been demonstrated; however, the contribution of the highly polymorphic CYP3A5 must be clarified. 	CYP3A	14562	14567	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A	14645	14650	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A	14696	14701	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A	14718	14723	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A	14782	14787	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A	14824	14829	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A	14837	14842	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A	14904	14909	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A	15000	15005	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A	15069	15074	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A	15133	15138	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A	15162	15167	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A	15181	15186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A	15263	15268	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A	15313	15318	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A	15362	15367	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:85	One of the high CYP3A4 expressers carried CYP3A5*1, anticipating rapid metabolism of CYP3A substrates. 	CYP3A	15397	15402	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:85	One of the high CYP3A4 expressers carried CYP3A5*1, anticipating rapid metabolism of CYP3A substrates. 	CYP3A	15423	15428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:85	One of the high CYP3A4 expressers carried CYP3A5*1, anticipating rapid metabolism of CYP3A substrates. 	CYP3A	15466	15471	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:86	Strong association was found between the patients CYP3A4 expression and normalized clozapine serum levels. 	CYP3A	15534	15539	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A	15594	15599	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A	15696	15701	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A	15738	15743	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:88	The patients CYP3A5 genotype was significantly associated with clozapine concentrations in those patients who expressed CYP3A4 at low levels (P<.0001). 	CYP3A	15836	15841	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:88	The patients CYP3A5 genotype was significantly associated with clozapine concentrations in those patients who expressed CYP3A4 at low levels (P<.0001). 	CYP3A	15943	15948	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:89	Further confirmation of the role of CYP3A5 is needed because of the relatively small number of CYP3A5 expressers. 	CYP3A	16011	16016	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:89	Further confirmation of the role of CYP3A5 is needed because of the relatively small number of CYP3A5 expressers. 	CYP3A	16070	16075	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP3A	16248	16253	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A	16386	16391	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A	16403	16408	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A	16441	16446	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:92	Significantly higher (about 2-fold) clozapine concentration was observed in CYP3A5 nonexpresser patients displaying low CYP3A4 expression than in all the others. 	CYP3A	16560	16565	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:92	Significantly higher (about 2-fold) clozapine concentration was observed in CYP3A5 nonexpresser patients displaying low CYP3A4 expression than in all the others. 	CYP3A	16604	16609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:93	However, modelling of the association between CYP3A4 expression and clozapine concentrations identified only 2 groups. 	CYP3A	16692	16697	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A	16798	16803	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A	16828	16833	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A	16902	16907	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A	16925	16930	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A	16965	16970	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:96	The models were able to predict the normalized clozapine concentrations with the standard deviations of 15.68 and 6.65 ng/mL for the low CYP3A4 expressers with CYP3A5*3/*3 genotype and the rest of the patients, respectively. 	CYP3A	17352	17357	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:96	The models were able to predict the normalized clozapine concentrations with the standard deviations of 15.68 and 6.65 ng/mL for the low CYP3A4 expressers with CYP3A5*3/*3 genotype and the rest of the patients, respectively. 	CYP3A	17375	17380	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:99	The 2 models for prediction of clozapine concentration in the patients expressing CYP3A4 at low or normal/high levels had comparable prediction quality and were found to be applicable for prediction of optimal dosing. 	CYP3A	17876	17881	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A	18319	18324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A	18373	18378	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A	18400	18405	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A	18544	18549	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A	18573	18578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:103	Underdosing occurred more frequently, primarily in the patients expressing CYP3A4 at a normal/high level or in CYP3A5 expressers. 	CYP3A	18925	18930	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:103	Underdosing occurred more frequently, primarily in the patients expressing CYP3A4 at a normal/high level or in CYP3A5 expressers. 	CYP3A	18961	18966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:104	Moreover, the routine dosing regimen appears to be appropriate for the patients with low CYP3A4 mRNA levels rather than for normal/high expressers. 	CYP3A	19069	19074	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:105	Seven of the 24 low expresser patients were overdosed, whereas the clozapine therapy of 17 patients (71%) in the low CYP3A4 expresser group resulted in therapeutic concentrations of clozapine. 	CYP3A	19245	19250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:106	The mathematical model displayed clozapine dosing to be optimal for 40 patients in the normal/high CYP3A4 expresser and CYP3A5 expresser groups (n=68), whereas 41% were underdosed. 	CYP3A	19420	19425	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:106	The mathematical model displayed clozapine dosing to be optimal for 40 patients in the normal/high CYP3A4 expresser and CYP3A5 expresser groups (n=68), whereas 41% were underdosed. 	CYP3A	19441	19446	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:108	The low CYP3A4 expresser patients required a significantly lower (50%) dose of clozapine for the optimal serum level than normal/high CYP3A4 expressers (2.180.64 mg/kg vs 4.981.40 mg/kg; P<.0001). 	CYP3A	19788	19793	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:108	The low CYP3A4 expresser patients required a significantly lower (50%) dose of clozapine for the optimal serum level than normal/high CYP3A4 expressers (2.180.64 mg/kg vs 4.981.40 mg/kg; P<.0001). 	CYP3A	19914	19919	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:109	Several CYPs are assumed to be responsible for the formation of norclozapine, while CYP3A4 is likely to catalyze the clozapine N-oxidation. 	CYP3A	20061	20066	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:110	The formation of both principal metabolites widely varied in individuals; however, the serum concentrations of clozapine metabolites appeared to be associated merely with the patients CYP3A4 expression and not with CYP1A2 mRNA levels. 	CYP3A	20301	20306	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:111	Strong association was observed between the metabolite/clozapine ratios and CYP3A4 mRNA levels. 	CYP3A	20428	20433	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A	20475	20480	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A	20566	20571	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A	20615	20620	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:113	Furthermore, significantly lower clozapine N-oxide/clozapine ratios were observed in the patients displaying low CYP3A4 expression than in CYP3A4 normal/high expressers (0.22790.0887 vs 0.56590.1960, P<.0001). 	CYP3A	20778	20783	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:113	Furthermore, significantly lower clozapine N-oxide/clozapine ratios were observed in the patients displaying low CYP3A4 expression than in CYP3A4 normal/high expressers (0.22790.0887 vs 0.56590.1960, P<.0001). 	CYP3A	20804	20809	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:114	The strong association between the patients CYP3A status and the serum clozapine concentrations or the metabolite/clozapine ratios demonstrated the potential role of CYP3A enzymes in clozapine clearance. 	CYP3A	20919	20924	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:114	The strong association between the patients CYP3A status and the serum clozapine concentrations or the metabolite/clozapine ratios demonstrated the potential role of CYP3A enzymes in clozapine clearance. 	CYP3A	21041	21046	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP3A	22357	22362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:130	It should be noted that fluvoxamine is not a CYP1A2-selective inhibitor, but significantly blocks the activities of other CYPs, notably it irreversibly inhibits CYP3A4 by forming a metabolic intermediate complex. 	CYP3A	24436	24441	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:131	The clinical observations on the dominant role of CYP1A2 were not confirmed by our findings that the patients CYP3A status rather than their CYP1A2 expression was associated with normalized clozapine concentrations. 	CYP3A	24598	24603	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:132	The relative importance of CYP3A4 in clozapine clearance, particularly in patients with low CYP1A2 activity, may be higher than it has been previously considered (;.  	CYP3A	24731	24736	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A	25115	25120	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A	25199	25204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A	25268	25273	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A	25423	25428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP3A	25579	25584	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP3A	25667	25672	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A	26093	26098	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A	26147	26152	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A	26240	26245	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:138	Therefore, the relative CYP activities predicted the potential role of CYP3A4/5 in clozapine clearance, which was confirmed by the 2-fold higher normalized clozapine concentrations and by the halved dose-requirement in low CYP3A4 expressers. 	CYP3A	26328	26333	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:138	Therefore, the relative CYP activities predicted the potential role of CYP3A4/5 in clozapine clearance, which was confirmed by the 2-fold higher normalized clozapine concentrations and by the halved dose-requirement in low CYP3A4 expressers. 	CYP3A	26480	26485	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:143	Valproate has been proved to transcriptionally induce CYP3A4 expression; consequently, the patients CYP3A4 mRNA levels captured the influence of valproate treatment. 	CYP3A	27268	27273	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:143	Valproate has been proved to transcriptionally induce CYP3A4 expression; consequently, the patients CYP3A4 mRNA levels captured the influence of valproate treatment. 	CYP3A	27314	27319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:148	Additionally, the normal/high CYP3A4 activity was associated with increased metabolite formation, that is, the concentrations of norclozapine and clozapine N-oxide were close to or even exceeded clozapine concentrations. 	CYP3A	28068	28073	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:154	Although the present work involved a limited number of patients and further investigation enrolling larger cohort is required, it clearly demonstrated that CYP3A status could be the major determinant of normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A	29348	29353	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A	29628	29633	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A	29650	29655	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A	29681	29686	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:156	Tailored medication controlled by patients CYP3A4 expression and CYP3A5 genotype may facilitate the improvement of the individual clozapine therapy, leading to the dosage optimization for a more effective therapy. 	CYP3A	29743	29748	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:156	Tailored medication controlled by patients CYP3A4 expression and CYP3A5 genotype may facilitate the improvement of the individual clozapine therapy, leading to the dosage optimization for a more effective therapy. 	CYP3A	29765	29770	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP3A	2144	2149	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:3	In this study, we present the design and evaluation of bio-compatible nanocarriers trapping a natural CYP3A4-inhibiting compound. 	CYP3A	290	295	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	CYP3A	374	379	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	CYP3A	4210	4215	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	CYP3A	14314	14319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	CYP3A	35625	35630	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP3A	38302	38307	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP3A	15781	15786	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5570141_OgerInput.txtOger_out.csv:107	This search provided further details on other sildenafil-related compounds: primary metabolite (N-desmethylsildenafil), drug-drug interactions with CYP3A4 inhibitors (eg ketoconazole, itraconazole, ritonavir and indinavir) and other PDE5 inhibitors (vardenafil). 	CYP3A	16986	16991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:12	The main Gr-drug interaction mechanism is inactivation of the enzyme CYP3A4 by furanocoumarins. 	CYP3A	1432	1437	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:13	CYP3A4 enzyme participates in the inactivation of various drugs; it is located in the intestinal epithelium and the liver. 	CYP3A	1459	1464	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP3A	2047	2052	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP3A	2166	2171	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:22	The interacting drugs are generally characterized by the oral intake, low to intermediate bioavailability, and inactivation by the CYP3A4 enzyme. 	CYP3A	2903	2908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:23	Patients with higher levels of CYP3A4 determined in intestinal biopsies may require higher doses of corresponding drugs, the size of the Gr effect being generally higher in such patients. 	CYP3A	2949	2954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:45	Artemether is an effective medication against malaria; however, relapses may occur presumably as a result of the drug metabolism by CYP3A4. 	CYP3A	6109	6114	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP3A	35879	35884	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:2	Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. 	CYP3A	269	274	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	CYP3A	470	475	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:6	Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. 	CYP3A	980	985	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:8	Human CYP3A4 in Supersomes generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. 	CYP3A	1247	1252	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:9	Using the 32P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. 	CYP3A	1468	1473	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:11	In the presence of NADPH or NADH, cytochrome b 5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. 	CYP3A	1711	1716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A	1979	1984	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A	2050	2055	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A	2331	2336	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:17	Of the CYP enzymes investigated, human CYP3A4 is the most active enzyme oxidizing ellipticine to 12-hydroxy- and 13-hydroxyellipticine, reactive metabolites that dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind to DNA (see Fig ) [,. 	CYP3A	2987	2992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:18	The CYP3A4 isoform also forms other ellipticine metabolites, including 9-hydroxyellipticine, which is a detoxification product, as well as 7-hydroxyellipticine and ellipticine N ^2-oxide as minor metabolites [,. 	CYP3A	3205	3210	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:19	CYP enzymes, including CYP3A4, are components of the monooxygenase system located in the membrane of the endoplasmic reticulum (microsomes). 	CYP3A	3436	3441	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:24	Cytochrome b _5 has been reported to stimulate the oxidation of a variety of CYP3A4 substrates, including ellipticine. 	CYP3A	4478	4483	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:25	Interestingly, in the case of ellipticine, cytochrome b _5, when reconstituted with CYP3A4 and POR, alters the ratio of ellipticine metabolites formed by this CYP. 	CYP3A	4604	4609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:28	Hence, cytochrome b _5 seems to play a key role in the CYP3A4-mediated DNA-damage caused by these ellipticine metabolites [,. 	CYP3A	5199	5204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	CYP3A	5270	5275	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A	5573	5578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A	5612	5617	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:31	They also showed that this heme protein with NADH:cytochrome b _5 reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. 	CYP3A	5806	5811	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:33	This NADH-dependent system can, therefore, function as a sole electron donor for both reduction steps in the reaction cycles of CYP1A1 and CYP3A4 [,. 	CYP3A	6223	6228	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	CYP3A	6381	6386	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	CYP3A	6524	6529	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	CYP3A	7260	7265	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	CYP3A	7467	7472	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:43	Here, we show that three of these metabolites are also formed in human hepatic microsomes in the presence of NADH instead of NADPH were found when NADPH or NADH was omitted from the incubation mixtures containing human hepatic microsomes and (iii)] for our experiments, we first tested whether they are functionally active by testing the CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A	8519	8524	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A	8617	8622	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A	8822	8827	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A	8857	8862	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A	8919	8924	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	CYP3A	9400	9405	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	CYP3A	9484	9489	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	CYP3A	9639	9644	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	CYP3A	9804	9809	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	CYP3A	10356	10361	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	CYP3A	10593	10598	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	CYP3A	10803	10808	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:55	This finding demonstrated that cytochrome b _5 influences the CYP3A4 catalytic activity in at least two ways. 	CYP3A	11223	11228	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:56	First, this heme protein can mediate CYP3A4 enzyme activity even in the absence of the NADPH/POR system, by donating both the first and second electron from NADH to CY3A4 in the catalytic cycle. 	CYP3A	11308	11313	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	CYP3A	11720	11725	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:58	Second, cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, resulting in changes in profile of ellipticine metabolite formation. 	CYP3A	11863	11868	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:59	In further experiments, DNA adduct formation was analyzed in incubations with ellipticine and human hepatic microsomes or human CYP3A4 in Supersomes in the presence of DNA. 	CYP3A	12076	12081	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:60	Two DNA adducts were detected by the ^32P-postlabeling method derived from ellipticine activated with human hepatic microsomes or CYP3A4-Supersomes, both in the presence of NADPH and NADH was previously shown to be generated by the reaction of guanine in DNA with ellipticine-13-ylium which is formed by the decomposition of 13-hydroxyellipticine was previously shown to be generated by reaction of guanine in DNA with ellipticine-12-ylium formed from 12-hydroxyellipticine and tumor tissues in vivo. 	CYP3A	12251	12256	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:61	The levels of ellipticine-derived adduct 1 (formed predominantly by CYP3A4) generated in human microsomes were 2.8-fold lower with NADH than with NADPH as the cofactor, which is in agreement with a 2.6-fold lower efficiency of ellipticine oxidation to 13-hydroxyellipticine by human microsomes in the presence of NADH, indicating that adduct 2 might be also formed by autooxidation as reported previously [,. 	CYP3A	12690	12695	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:62	With human recombinant CYP3A4 expressed in Supersomes the adducts formed were the same as those generated by human hepatic microsomes, both in the presence of NADPH and NADH. 	CYP3A	13054	13059	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:64	When NADPH or NADH was omitted from the incubation mixtures containing CYP3A4-Supersomes, only low amounts of adduct spot 2 were detected (Fig. 	CYP3A	13342	13347	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	CYP3A	13484	13489	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	CYP3A	13594	13599	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:66	The present study was aimed to advance our knowledge regarding the role of cytochrome b _5 in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. 	CYP3A	13826	13831	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	CYP3A	14033	14038	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	CYP3A	14535	14540	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	CYP3A	14782	14787	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:75	Here, we showed that if NADPH is substituted by NADH, ellipticine oxidation is catalyzed by experimental CYP3A4 enzymatic systems. 	CYP3A	15603	15608	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:76	Such NADH-mediated activity of the employed CYP3A4 systems was proven by the formation of oxidized ellipticine metabolites as well as by the generation of ellipticine-derived DNA adducts, which were the same as in the system where NADPH was used as electron donor. 	CYP3A	15673	15678	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	CYP3A	16023	16028	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:78	Specifically, as shown here, (i) it acts as a sole electron donor to CYP3A4 during its reaction cycle and (ii) it can also act as an allosteric modifier of CYP3A4 oxygenase. 	CYP3A	16134	16139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:78	Specifically, as shown here, (i) it acts as a sole electron donor to CYP3A4 during its reaction cycle and (ii) it can also act as an allosteric modifier of CYP3A4 oxygenase. 	CYP3A	16221	16226	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	CYP3A	16422	16427	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:83	CYP3A4-Supersomes, microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4 and POR that are, therefore, over-expressed in these microsomes, were purchased from the Gentest Corp. 	CYP3A	16842	16847	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:83	CYP3A4-Supersomes, microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4 and POR that are, therefore, over-expressed in these microsomes, were purchased from the Gentest Corp. 	CYP3A	16965	16970	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	CYP3A	17401	17406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	CYP3A	17492	17497	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	CYP3A	18016	18021	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	CYP3A	19382	19387	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:100	Negative control reactions lacked either CYP3A4-Supersomes systems, cofactors or testosterone. 	CYP3A	19632	19637	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	CYP3A	20646	20651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:110	Control incubations were carried out either without human hepatic microsomes or CYP3A4 in Supersomes without NADPH (or NADH), without DNA, or without ellipticine. 	CYP3A	21140	21145	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP3A	488	493	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP3A	5849	5854	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP3A	6797	6802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP3A	6873	6878	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP3A	6961	6966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP3A	13156	13161	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP3A	14134	14139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:113	Assessment of the inhibitory effect of clarithromycin on CYP3A4 in three TC-HepG2 cells indicated that there was a concentration-dependent inhibitory effect on metabolic activity. 	CYP3A	15859	15864	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP3A	18198	18203	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:134	Specifically, increasing concentrations of the inhibitors (0, 5, 10, 20, 40, or 100 M) were added 10, 20, or 30 min prior to the addition of the luminescent CYP3A4 substrate, and the luminescence levels in culture media were used to determine metabolite levels.  	CYP3A	19340	19345	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:139	Further, because the CYP3A4 activity level in TC-HepG2 cells was higher than that in human hepatocytes, the rate of metabolic reduction by the inhibitors may be detected with high sensitivity.  	CYP3A	20004	20009	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:147	Both aflatoxin B1 and sterigmatocystin convert to active metabolites via CYP3A4 and exert hepatotoxicity through DNA damage [,. 	CYP3A	21141	21146	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:185	The aflatoxin B1 forms DNA adduct as a result of metabolic activation induced mainly by CYP3A4. 	CYP3A	27026	27031	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP3A	24891	24896	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP3A	3368	3373	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP3A	3676	3681	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP3A	4563	4568	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP3A	5672	5677	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP3A	17012	17017	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP3A	17478	17483	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP3A	17805	17810	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:131	Similar findings have been demonstrated for milk thistle, where in vitro CYP3A4 inhibition by its constituents silymarin and silibinin produced IC_50 values ranging from 27 to 60 mol/L. 	CYP3A	18177	18182	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:153	examined whether the concentration of the supposed bioactive constituents could be correlated with CYP3A4 enzyme inhibition, but with no significant findings. 	CYP3A	21529	21534	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP3A	21691	21696	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP3A	16365	16370	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP3A	16633	16638	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP3A	17115	17120	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP3A	17484	17489	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:141	For example, different probe substrates could result in different observations in CYP3A4 activities due to different substrate binding sites. 	CYP3A	26846	26851	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP3A	142	147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP3A	1166	1171	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP3A	1341	1346	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP3A	1777	1782	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP3A	4646	4651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP3A	5791	5796	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A	8400	8405	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A	9350	9355	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A	9571	9576	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A	9968	9973	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A	10187	10192	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:56	AHR and Pregnane X Receptor are reported to regulate the expression of CYP1A2 and CYP3A4^. 	CYP3A	10888	10893	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP3A	16748	16753	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A	17243	17248	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A	17316	17321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A	17541	17546	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP3A	17663	17668	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:94	Aryl Hydrocarbon Receptor and Pregnane X Receptor are found to be responsible for regulating the transcriptional expression of CYP1A2 and CYP3A4^,. 	CYP3A	17923	17928	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:95	In this study, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside promoted the nuclear translocation of Aryl Hydrocarbon Receptor and Pregnane X Receptor both in vivo and in vitro, which may contribute to the increased expression of CYP1A2 and CYP3A4 induced by 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside. 	CYP3A	18176	18181	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:97	Additionally, Aryl Hydrocarbon Receptor or Pregnane X Receptor inhibitors reduced the expression and activity of hepatic CYP1A2 and CYP3A4 in mice. 	CYP3A	18580	18585	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP3A	19097	19102	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP3A	20013	20018	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP3A	20569	20574	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP3A	24397	24402	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP3A	28846	28851	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP3A	28921	28926	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:191	The activity of 7-benzyloxy-4trifluoromethylcoumarin dealkylation is the diagnostic marker of CYP3A4. 	CYP3A	29820	29825	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:192	The activity of CYP3A4 was determined by fluorescence value of 7-Hydroxy-4-Trifluoromethylcoumarin conversed from 7-benzyloxy-4-trifluoromethyl-coumarin by 7-Benzyloxy-4trifluoromethylcoumarin Dealkylation. 	CYP3A	29844	29849	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP3A	30070	30075	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:1	 Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. 	CYP3A	26	31	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:4	So far, there are few reports about the functional characterization of CYP3A4 variants in terms of specific substrates. 	CYP3A	341	346	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:5	The aim of this study was to systematically investigate the genetic polymorphisms of 23 CYP3A4 alleles and evaluate their catalytic activities on the metabolism of lidocaine in vitro. 	CYP3A	478	483	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:6	The wild-type and 22 CYP3A4 variants were expressed in Spodoptera frugiperda 21 insect cells. 	CYP3A	595	600	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:7	Then the insect microsomes were incubated with the CYP3A4-specific substrate lidocaine. 	CYP3A	719	724	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	970	975	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1014	1019	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1028	1033	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1090	1095	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1100	1105	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1110	1115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1120	1125	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1134	1139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A	1227	1232	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:11	As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. 	CYP3A	1269	1274	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:11	As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. 	CYP3A	1429	1434	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	CYP3A	2511	2516	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	CYP3A	2642	2647	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A	2802	2807	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A	3122	3127	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A	3193	3198	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:20	Recently, increasing evidence has shown that genetic polymorphisms of CYP3A4 significantly contribute to the wide inter-individual variability of enzyme activity. 	CYP3A	3312	3317	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:21	The enormous variation observed in drug metabolism may result in undesirable adverse side effects or therapeutic failure, thus more attention should be paid to genetic polymorphism of CYP3A4. 	CYP3A	3589	3594	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:22	To date, 46 different types of CYP3A4 allelic variants have been identified in the Human CYP Allele Nomenclature Committee website (http://www.cypalleles.ki.se/cyp3a4.htm). 	CYP3A	3628	3633	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:23	In our previous study, Hu et al sequenced the promoter regions and 13 exon junctions of CYP3A4 in DNA from 1,114 healthy subjects from the southern region of China. 	CYP3A	3858	3863	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:24	Five previously reported alleles (CYP3A4*1G, *4, *5, *18B and *23) were detected. 	CYP3A	3969	3974	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:25	In addition, a total of 7 novel exonic variants were also detected and further named as new alleles CYP3A4*28-*34 by the Human CYP Allele Nomenclature Committee. 	CYP3A	4117	4122	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A	4210	4215	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A	4294	4299	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A	4310	4315	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:37	The open reading frame (ORF) fragments for each CYP3A4 variants were constructed by the overlap extension polymerase chain reaction (PCR) amplification method using the primers that are listed in, and then isolated ORF fragments by PCR amplification using the forward primer 3A4-SALF (5-ACCAGTCGACATGG CTCTCATCCCAGAC-3, introducing 1 Sal site) and the reverse primer 3A4-SR (5-CCAAACTAGTTCAGGCT CCACTTACGGT-3, introducing 1 Spe site). 	CYP3A	5937	5942	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:38	These full-length PCR products for each of the CYP3A4 variants were digested and ligated to the pFastBac-OR receptor vector to produce the ultimate dual-expression vector pFastBac-OR-CYP3A4. 	CYP3A	6371	6376	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:38	These full-length PCR products for each of the CYP3A4 variants were digested and ligated to the pFastBac-OR receptor vector to produce the ultimate dual-expression vector pFastBac-OR-CYP3A4. 	CYP3A	6507	6512	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:49	CYP3A4 expression levels were determined by measured difference spectra. 	CYP3A	8280	8285	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	CYP3A	8402	8407	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	CYP3A	8420	8425	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:51	The addition of b5 was to deliver electrons and support CYP3A4 enzymatic activities. 	CYP3A	8585	8590	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A	11874	11879	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A	11927	11932	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A	11963	11968	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:76	The ratio of V_max/K_m represents the intrinsic clearance (C_Lint), which can evaluate the enzymatic activity of each CYP3A4 allelic variant as an evaluation criteria. 	CYP3A	12116	12121	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:77	Michaelis-Menten plots of lidocaine for the tested 23 CYP3A4 enzymes are shown in, and the corresponding kinetic parameters are summarized in. 	CYP3A	12220	12225	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A	12378	12383	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A	12392	12397	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A	12489	12494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A	12503	12508	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12570	12575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12584	12589	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12701	12706	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12727	12732	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12737	12742	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12747	12752	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12762	12767	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12821	12826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12831	12836	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12841	12846	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12852	12857	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12863	12868	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A	12878	12883	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13064	13069	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13074	13079	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13084	13089	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13094	13099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13104	13109	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13119	13124	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13196	13201	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13221	13226	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13232	13237	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13243	13248	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13254	13259	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13265	13270	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13276	13281	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A	13291	13296	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A	13432	13437	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A	13500	13505	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A	13671	13676	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A	13748	13753	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:82	Another 5 variants (CYP3A4*3, *4, *10, *28, and *33) were without statistical significance. 	CYP3A	13813	13818	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:83	In addition, to investigate the enzymatic abilities of 23 CYP3A4 variants between different substrate, lidocaine and 1 typical probing substrate for the CYP3A4 enzyme were used in the in vitro functional analysis. 	CYP3A	13943	13948	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:83	In addition, to investigate the enzymatic abilities of 23 CYP3A4 variants between different substrate, lidocaine and 1 typical probing substrate for the CYP3A4 enzyme were used in the in vitro functional analysis. 	CYP3A	14038	14043	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:84	As shown in,  variants, CYP3A4*17 and CYP3A4*30, exhibited extremely low enzymatic activity or null function for both substrates. 	CYP3A	14123	14128	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:84	As shown in,  variants, CYP3A4*17 and CYP3A4*30, exhibited extremely low enzymatic activity or null function for both substrates. 	CYP3A	14137	14142	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14245	14250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14255	14260	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14265	14270	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14276	14281	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14287	14292	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14298	14303	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14309	14314	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14320	14325	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14335	14340	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A	14413	14418	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14480	14485	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14508	14513	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14518	14523	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14529	14534	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14540	14545	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14551	14556	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A	14566	14571	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:87	CYP3A4 exhibits remarkable individual variation in expression levels, which may be caused by genetic, environmental, pathological, hormonal, and dietary factors. 	CYP3A	14646	14651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:88	Increasing evidence suggests that genetic polymorphism is a primary source of inter-individual difference in drug metabolism., Genetic polymorphism of CYP3A4 can greatly influence the rate of elimination of lidocaine, thereby may result in adverse effects or therapeutic failures. 	CYP3A	14959	14964	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:90	Therefore, it is of great significance to functionally characterize the enzymatic activity of CYP3A4 variants in the metabolism of lidocaine in vitro. 	CYP3A	15330	15335	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A	15423	15428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A	15506	15511	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A	15522	15527	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A	15593	15598	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A	15649	15654	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:92	The enzymatic activity of CYP3A4*1 was used as a control group. 	CYP3A	15785	15790	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:93	As a novel allelic variant, the CYP3A4*30 (R130STOP), which contains the premature stop codon, produces a nonfunctional protein with a shorter peptide. 	CYP3A	15855	15860	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:94	As a consequence, the kinetic parameters of CYP3A4*30 could not be detected and it showed no catalytic activity on lidocaine metabolism. 	CYP3A	16019	16024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:95	Similar to CYP3A4*30, CYP3A4*17 exhibited extremely low enzymatic activity toward lidocaine. 	CYP3A	16123	16128	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:95	Similar to CYP3A4*30, CYP3A4*17 exhibited extremely low enzymatic activity toward lidocaine. 	CYP3A	16134	16139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16236	16241	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16426	16431	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16440	16445	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16473	16478	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16565	16570	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A	16663	16668	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:98	Therefore, patients carrying the CYP3A4*2, *5, *9, *16, *17, *24, or *30 should pay more attention to the dose of lidocaine, in order to avoid lidocaine-induced toxicity or delayed emergence from anesthesia. 	CYP3A	16825	16830	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:99	Four (CYP3A4*29, *31, *32, and *34) of novel alleles exhibited significantly increased intrinsic clearance value for lidocaine from 141.84% to 197.87% of wild-type CYP3A4*1. 	CYP3A	17006	17011	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:99	Four (CYP3A4*29, *31, *32, and *34) of novel alleles exhibited significantly increased intrinsic clearance value for lidocaine from 141.84% to 197.87% of wild-type CYP3A4*1. 	CYP3A	17164	17169	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:100	CYP3A4*28 showed both lower V_max and K_m values so that the intrinsic clearance showed no significant difference to that of the CYP3A4*1. 	CYP3A	17174	17179	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:100	CYP3A4*28 showed both lower V_max and K_m values so that the intrinsic clearance showed no significant difference to that of the CYP3A4*1. 	CYP3A	17303	17308	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A	17333	17338	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A	17351	17356	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A	17373	17378	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:102	However, as for our result that these alleles exhibited higher catalytic activity than wild type in our study, it may be interpreted that His324 and Ile335 are not involved in the active site for drug-substrate binding according to previously reported crystal structures of the CYP3A4 enzyme. 	CYP3A	17698	17703	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:103	CYP3A4*18, contains a nucleotide substitution of T>C at position 878 of the cDNA of CYP3A4 and results in an amino acid change of Leu to Pro at codon 293, is commonly detected in Asians. 	CYP3A	17713	17718	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:103	CYP3A4*18, contains a nucleotide substitution of T>C at position 878 of the cDNA of CYP3A4 and results in an amino acid change of Leu to Pro at codon 293, is commonly detected in Asians. 	CYP3A	17797	17802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:104	According to previous study, CYP3A4*18 exhibited increased turnover numbers for testosterone and chlorpyrifos in vitro. 	CYP3A	17929	17934	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:105	Similarly, in our study, CYP3A4*18, with a distinctly increased V_max, showed significantly increased relative clearance compared with CYP3A4*1. 	CYP3A	18045	18050	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:105	Similarly, in our study, CYP3A4*18, with a distinctly increased V_max, showed significantly increased relative clearance compared with CYP3A4*1. 	CYP3A	18155	18160	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:106	These results are consistent with the previous study of testosterone and chlorpyrifos, 2 typical probing substrates for CYP3A4, thus indicating that our CYP expression and in vitro metabolism system were suitable for analyzing the catalytic activities of the CYP3A4 allelic variants. 	CYP3A	18285	18290	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:106	These results are consistent with the previous study of testosterone and chlorpyrifos, 2 typical probing substrates for CYP3A4, thus indicating that our CYP expression and in vitro metabolism system were suitable for analyzing the catalytic activities of the CYP3A4 allelic variants. 	CYP3A	18424	18429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:107	In addition, CYP3A4*23 was reported by Hu et al for the first time in the Chinese population. 	CYP3A	18462	18467	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:108	In our work, CYP3A4*23 exhibited significantly increased intrinsic clearance value (206.96% of CYP3A4*1) owing to marked increase in V_max and huge decrease in K_m. 	CYP3A	18556	18561	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:108	In our work, CYP3A4*23 exhibited significantly increased intrinsic clearance value (206.96% of CYP3A4*1) owing to marked increase in V_max and huge decrease in K_m. 	CYP3A	18638	18643	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A	19055	19060	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A	19100	19105	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A	19210	19215	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A	19405	19410	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A	19468	19473	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A	19537	19542	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19614	19619	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19742	19747	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19752	19757	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19763	19768	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19774	19779	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A	19789	19794	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:112	These results suggested that CYP3A4 also had substrate-specific alterations in metabolic activity and we infer that amino acid substitution in these sites might have different impacts for different substrate of CYP3A4. 	CYP3A	19885	19890	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:112	These results suggested that CYP3A4 also had substrate-specific alterations in metabolic activity and we infer that amino acid substitution in these sites might have different impacts for different substrate of CYP3A4. 	CYP3A	20067	20072	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:113	Moreover, genetic polymorphism and substrate-specificity of CYP3A4 need further study on daily used drugs in order to help in personalized medicine for patients in a safe and reduced toxicity reaction. 	CYP3A	20135	20140	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:114	In summary, this study provides functional assessment of 23 CYP3A4 variants on lidocaine metabolism in vitro for the first time. 	CYP3A	20337	20342	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:116	As the first study of all these alleles on lidocaine metabolism, the research may help to improve our understanding of the polymorphism of CYP3A4; on the other hand, this study could help clinical assessment of the lidocaine metabolism and aid the application of this knowledge in clinical practice. 	CYP3A	20766	20771	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:117	However, further studies are required to examine a wider range of CYP3A4 substrates, including clinically used drugs.	CYP3A	20993	20998	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:227	Among all human CYPs, CYP3A4 is reported to be involved in the metabolism of 50% of all pharmaceuticals; it is therefore an enzyme of general interest for herb-drug interactions. 	CYP3A	40767	40772	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:228	Several herbs and natural remedies have been reported to induce or inhibit CYP3A4. 	CYP3A	40999	41004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP3A	41315	41320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP3A	41871	41876	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP3A	7872	7877	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP3A	7880	7885	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP3A	8907	8912	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP3A	8948	8953	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP3A	20573	20578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP3A	20581	20586	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:10	This observation was further supported by consistent CYP3A4 expression across all treatment groups. 	CYP3A	1902	1907	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:26	Indeed, Berberine has been shown to affect the metabolism of drugs through changes in CYP3A4 expression. 	CYP3A	4646	4651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:27	The effects of Berberine on CYP3A4-mediated drug metabolism is of particular interest as this enzyme degrades several widely used statin drugs (eg simvastatin and lovastatin) that may be concomitantly used with Berberine to treat dyslipidemia or hypercholesterolemia. 	CYP3A	4693	4698	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:118	Two livers per treatment group were evaluated for CYP3A4 and HMG-CoA reductase using a combination of enzyme-linked immunosorbent assays and western blot techniques. 	CYP3A	19191	19196	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:122	For Enzyme-Linked Immunosorbent Assays quantification of CYP3A4 and HMG-CoA reductase were performed according to manufacturers instructions (LifeSpan BioSciences LS-F22383 and LifeSpan BioSciences LS-F15758). 	CYP3A	19759	19764	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:207	This decrease in Demethylene Berberine Glucuronide may reflect an alteration in hepatic function such as changes in enzymes responsible for berberine metabolism, of which CYP3A4 is a significant player. 	CYP3A	33531	33536	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:208	To address this possibility, liver samples from chronically treated animals (14 days) were dissected and CYP3A4 was quantified by Enzyme-Linked Immunosorbent Assays and western blot. 	CYP3A	33668	33673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:209	No differences in CYP3A4 expression were observed between treatment groups. 	CYP3A	33764	33769	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:217	Simvastatin and berberine both undergo metabolism in the liver primarily through CYP3A4. 	CYP3A	34804	34809	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:229	While transdermal dihydroberberine unequivocally increased berberine levels in circulation this increase had no effect on liver or kidney function nor altered the expression of hepatic enzymes CYP3A4 and HMG-CoA reductase. 	CYP3A	37108	37113	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP3A	8847	8852	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP3A	8855	8860	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:215	The CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and together, they control the clearance of approximately 50% of all drugs eliminated primarily through P450-mediated biotransformation. 	CYP3A	32839	32844	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:215	The CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and together, they control the clearance of approximately 50% of all drugs eliminated primarily through P450-mediated biotransformation. 	CYP3A	32850	32855	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:216	CYP3A4 protein is present in almost all adults, whereas CYP3A5 protein expression varies across different ethnic groups; polymorphisms in the genes encoding these proteins are shown in  and. 	CYP3A	33041	33046	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:216	CYP3A4 protein is present in almost all adults, whereas CYP3A5 protein expression varies across different ethnic groups; polymorphisms in the genes encoding these proteins are shown in  and. 	CYP3A	33097	33102	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A	33236	33241	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A	33298	33303	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A	33354	33359	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:218	The CYP3A4*22 variant is also associated with reduced CYP3A4 protein levels and enzyme function, as are rare deleterious coding variants. 	CYP3A	33501	33506	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:218	The CYP3A4*22 variant is also associated with reduced CYP3A4 protein levels and enzyme function, as are rare deleterious coding variants. 	CYP3A	33551	33556	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A	33639	33644	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A	33653	33658	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A	33836	33841	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:220	In the CSKT population, resequencing followed by subsequent genotyping identified four novel CYP3A4 SNVs-three intronic and one in the 5 UTR region. 	CYP3A	33939	33944	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:221	The known CYP3A4 variants, *1B, *22 and *1G were found at frequencies of 2.2%, 2.4% and 26.8%, respectively. 	CYP3A	34005	34010	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A	34247	34252	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A	34278	34283	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A	34324	34329	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A	34349	34354	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:224	These data suggest that 14.9% of CSKT individuals express CYP3A5, contributing to their total CYP3A metabolic activity. 	CYP3A	34442	34447	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:224	These data suggest that 14.9% of CSKT individuals express CYP3A5, contributing to their total CYP3A metabolic activity. 	CYP3A	34478	34483	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:226	determined the MAFs of CYP3A4 variants in the Tepehuano and Mestizo populations and found that the frequencies were not significantly different between these two group. 	CYP3A	34549	34554	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:227	The MAFs of CYP3A4*1B was 8.0% in Tepehuanos, compared to 8.8% in Mestizos and CYP3A4*2 was not detected in the Tepehuanos but was found at a low frequency of 0.5% in Mestizos. 	CYP3A	34707	34712	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:227	The MAFs of CYP3A4*1B was 8.0% in Tepehuanos, compared to 8.8% in Mestizos and CYP3A4*2 was not detected in the Tepehuanos but was found at a low frequency of 0.5% in Mestizos. 	CYP3A	34774	34779	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:228	CYP3A4*4, *5 and *18 were not found in either population. 	CYP3A	34872	34877	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:229	Although the variant allele frequencies were similar between Tepehuanos and Mestizos for CYP3A4, it is important to consider that these populations may share similar allele frequencies in other P450 genes. 	CYP3A	35019	35024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:231	found that the CYP3A4*1B MAF was 4.8% in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups. 	CYP3A	35167	35172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:232	The CYP3A4*1B allele did not significantly affect the parent to metabolite ratio of dextromethorphan to 3-methoxymorphinan, a CYP3A4 mediated pathway. 	CYP3A	35317	35322	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:232	The CYP3A4*1B allele did not significantly affect the parent to metabolite ratio of dextromethorphan to 3-methoxymorphinan, a CYP3A4 mediated pathway. 	CYP3A	35439	35444	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:253	About 15% of the CSKT population would be expected to express CYP3A5, based on the CYP3A5*1 allele frequency. 	CYP3A	38865	38870	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:253	About 15% of the CSKT population would be expected to express CYP3A5, based on the CYP3A5*1 allele frequency. 	CYP3A	38886	38891	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:209	In the same way, PAH such BaP, and their dihydrodiol metabolites, were able to activate PXR and enhance CYP3A4 expression in human cell lines (HepG2 and HEK-293 cells). 	CYP3A	31703	31708	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:1	 Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes. 	CYP3A	82	87	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:8	Mechanism-wise, AAI enhanced Glycine N-Methyltransferase nuclear translocation, resulting in Glycine N-Methyltransferase interaction with the promoter region of the genes encoding Nuclear Factor-E2-Related Factor 2 and CAR/PXR, the transcription factors for NQO1 and CYP3A44/3A41, respectively. 	CYP3A	1460	1465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:9	Unlike the preference for Nrf2/NQO1 transcriptions at lower levels of Glycine N-Methyltransferase, overexpression of Glycine N-Methyltransferase preferred CAR/PXR/CYP3A44/3A41 transcriptions and alleviated kidney injury upon AAI treatment. 	CYP3A	1651	1656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:10	In summary, hepatic Glycine N-Methyltransferase protected mice from AAI nephropathy by enhancing CAR/PXR/CYP3A44/3A41 transcriptions and reducing Nrf2/NQO1 transcriptions. 	CYP3A	1833	1838	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:38	In our Gnmt genetically-modified mouse models, we were able to induce Aristolochic Acids nephropathy in a C57BL/6 background which was similar to the human histopathology^, and demostrated that Glycine N-Methyltransferase protected mice from AAI-induced kidney injury by increasing CAR/PXR and CYP3A44/3A41 transcriptions and decreasing NRF2/NQO1 transcriptions in female mouse hepatocytes. 	CYP3A	6723	6728	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:71	These results may explain the sex difference in AAI tolerance and suggest that Glycine N-Methyltransferase reduced AAI nephrotoxicity by regulating female-specific CYP3A44 and CYP3A41. 	CYP3A	11587	11592	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:71	These results may explain the sex difference in AAI tolerance and suggest that Glycine N-Methyltransferase reduced AAI nephrotoxicity by regulating female-specific CYP3A44 and CYP3A41. 	CYP3A	11599	11604	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:81	Also, compared to Wild-Type control female mice, CYP3A44 and CYP3A41 expressions were significantly decreased in Glycine N-Methyltransferase Knockout control female mice (Fig. 	CYP3A	13188	13193	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:81	Also, compared to Wild-Type control female mice, CYP3A44 and CYP3A41 expressions were significantly decreased in Glycine N-Methyltransferase Knockout control female mice (Fig. 	CYP3A	13200	13205	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:82	The CYP3A44 and CYP3A41 expression levels increased in low-dose AAI-treated Wild-Type female mice (Fig. 	CYP3A	13319	13324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:82	The CYP3A44 and CYP3A41 expression levels increased in low-dose AAI-treated Wild-Type female mice (Fig. 	CYP3A	13331	13336	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:84	These results further support that Glycine N-Methyltransferase protects female mice from AAI-induced renal damage via increasing CYP3A44/41 expression. 	CYP3A	13745	13750	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:90	In all mice after AAV-GNMT gene therapy, Glycine N-Methyltransferase was expressed in the liver but not in the kidneys to reduce the NQO1 mRNA level and increase CYP3A44 and CYP3A41 mRNA levels in the corn oil-treated (vehicle control) mice. 	CYP3A	15013	15018	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:90	In all mice after AAV-GNMT gene therapy, Glycine N-Methyltransferase was expressed in the liver but not in the kidneys to reduce the NQO1 mRNA level and increase CYP3A44 and CYP3A41 mRNA levels in the corn oil-treated (vehicle control) mice. 	CYP3A	15025	15030	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:91	After AAI exposure, the NQO1 was upregulated and CYP3A44 and 3A41 were downregulated in AAV-GNMT-treated female Knockout mice. 	CYP3A	15142	15147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:92	However, the CYP3A44 and CYP3A41 mRNA levels in AAV-GNMT-treated female Knockout mice remained higher than that in AAV-eGFP-treated female Knockout mice after AAI exposure (Fig. 	CYP3A	15233	15238	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:92	However, the CYP3A44 and CYP3A41 mRNA levels in AAV-GNMT-treated female Knockout mice remained higher than that in AAV-eGFP-treated female Knockout mice after AAI exposure (Fig. 	CYP3A	15245	15250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:93	In summary, Glycine N-Methyltransferase serves as a protector to prevent kidney injury from AAI toxicity by upregulating CYP3A44 and CYP3A41 in mouse liver. 	CYP3A	15519	15524	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:93	In summary, Glycine N-Methyltransferase serves as a protector to prevent kidney injury from AAI toxicity by upregulating CYP3A44 and CYP3A41 in mouse liver. 	CYP3A	15531	15536	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:104	The Chromatin Immunoprecipitation data indicated that GNMT-CAR and GNMT-PXR were higher at low AAI concentration than at higher concentration, resulting in increases in CYP3A44/3A41 mRNA levels and minor kidney injuries, upregulated NQO1 mRNA levels and damaged kidney severely (Fig. 	CYP3A	18289	18294	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:106	In this study, we revealed that AAI promotes Glycine N-Methyltransferase nuclear translocation and nuclear Glycine N-Methyltransferase can bind to the promoter regions of NRF2 and CAR/PXR and enhance subsequent NQO1 and CYP3A44/3A41 transcriptions, respectively. 	CYP3A	18751	18756	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:109	In Wild-Type female mice, AAI exposure increased GNMT-Nrf2, resulting in the elevated NOQ1 transcription, and decreased GNMT-CAR and GNMT-PXR, resulting in a reduction of CYP3A44/CYP3A41 transcripts. 	CYP3A	19223	19228	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:109	In Wild-Type female mice, AAI exposure increased GNMT-Nrf2, resulting in the elevated NOQ1 transcription, and decreased GNMT-CAR and GNMT-PXR, resulting in a reduction of CYP3A44/CYP3A41 transcripts. 	CYP3A	19231	19236	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:111	Our findings suggest that CYP3A44/3A41 regulated by Glycine N-Methyltransferase is highly related to reduced AAI nephropathy in mice, although the catalytic activities of mouse CYP3A44/CYP3A41 towards AAI have never been reported. 	CYP3A	19445	19450	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:111	Our findings suggest that CYP3A44/3A41 regulated by Glycine N-Methyltransferase is highly related to reduced AAI nephropathy in mice, although the catalytic activities of mouse CYP3A44/CYP3A41 towards AAI have never been reported. 	CYP3A	19596	19601	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:111	Our findings suggest that CYP3A44/3A41 regulated by Glycine N-Methyltransferase is highly related to reduced AAI nephropathy in mice, although the catalytic activities of mouse CYP3A44/CYP3A41 towards AAI have never been reported. 	CYP3A	19604	19609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:112	Human CYP3A4 is the homologue of mouse CYP3A44/CYP3A41, a protein mainly expressed in the liver and small intestine and responsible for the metabolism of many drugs. 	CYP3A	19656	19661	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:112	Human CYP3A4 is the homologue of mouse CYP3A44/CYP3A41, a protein mainly expressed in the liver and small intestine and responsible for the metabolism of many drugs. 	CYP3A	19689	19694	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:112	Human CYP3A4 is the homologue of mouse CYP3A44/CYP3A41, a protein mainly expressed in the liver and small intestine and responsible for the metabolism of many drugs. 	CYP3A	19697	19702	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:113	Women have higher CYP3A4 activity than men^,; thus, many drugs metabolized by CYP3A4 clear faster in women than men^,. 	CYP3A	19834	19839	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:113	Women have higher CYP3A4 activity than men^,; thus, many drugs metabolized by CYP3A4 clear faster in women than men^,. 	CYP3A	19894	19899	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:127	CYP1A1, 1A2 and CYP2C9 are not expressed in human kidney, whereas the CYP3A4 expression in kidney is highly variable and remains to be elucidated^. 	CYP3A	22123	22128	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:128	In mice, CYP1A1, CYP1A2 and CYP3A44/3A41 are almost not expressed in kidney^. 	CYP3A	22229	22234	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:139	Glycine N-Methyltransferase protects mice from AAI-induced kidney injury by increasing CAR/PXR/CYP3A44/3A41 transcription and decreasing Nrf2/NQO1 transcription in female hepatocytes. 	CYP3A	23873	23878	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP3A	10998	11003	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP3A	11041	11046	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP3A	18829	18834	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:109	Our results, reporting no inhibition by podophyllotoxin and moderate/weak inhibition by-yatein against the activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent inhibition of CYP3A4 by these two phytochemicals. 	CYP3A	19142	19147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP3A	23057	23062	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP3A	29369	29374	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP3A	29815	29820	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017738_OgerInput.txtOger_out.csv:27	In terms of Rheumatoid Arthritis, hepatic CYP1A, CYP3A, and CYP2B subfamily enzymes was found to decrease during the development of arthritis and was accompanied by a increase in tumor necrosis factor (TNF-ALPHA) and interleukin-1BETA (IL-1BETA). 	CYP3A	4732	4737	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6017738_OgerInput.txtOger_out.csv:28	The metabolism of liquiritigenin and glycyrrhetinic acid were mediated by CYP1A and CYP3A, respectively, and glycyrrhetinic acid could be formed from hydrolysis of glycyrrhizin in intestinal flora according to this summary, while the effect of CYPs on the compounds in Zushima was not reported. 	CYP3A	5014	5019	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:88	Alternatively, some crystal P450 structures present a protein that exhibits several molecules of tightly bound ligands, as, for instance, the case of human CYP3A4 with a metyrapone molecule bound within the catalytic cavity and a progesterone molecule bound at its surface.  	CYP3A	15125	15130	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:90	It appears that the inhibitor metyrapone binds the heme iron ion by one of its pyridine nitrogen, and that the progesterone is bound on the CYP3A4 surface to a pocket made by the F/G region, and which colocalized with the mouth of either CAVER channel 3 or 4 in P450 enzymes. 	CYP3A	15465	15470	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:93	have demonstrated that the drug-drug interaction existing between atorvatstatin, which is a cholesterol-lowering drug, and dronedarone, an antiarrythmic drug, on CYP3A4 was indeed taking place by a crosstalk between a site on the surface of the enzyme, at which progesterone is seen bound in the crystal structure, and the buried active site. 	CYP3A	15925	15930	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:130	In the same regard, Otyepka and his collaborators used a synergy of MOLE, the standard structure-based approach for identifying access channel, and a bias-exchange molecular metadynamics (BE-META) to study in silico the mechanism(s) of ligand passage through the flexible channels of CYP3A4 embedded in a 1,2-dioleoyl-sn-glycero-3-phosphocholine membrane environment. 	CYP3A	22843	22848	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:133	A CYP3A4 channel, namely 2af, seems to not permit exiting through it due to a very high free energy at its mouth for the passage of the product. 	CYP3A	23318	23323	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:135	These results provide new insights into the mechanism of ligand release from CYP3A4. 	CYP3A	23744	23749	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:150	Moreover, the shift of the F-helix and of the F/F loop in CYP2C9 in high-temperature molecular dynamics simulations are shown to close the solvent channel and to open the channel 2b.. A large conformational shift of the F/F loop is also seen in CYP3A4 crystal structures complexed with ketoconazole (a P450 inhibitor) or erythromycin (a CYP3A4 substrate). 	CYP3A	26024	26029	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:150	Moreover, the shift of the F-helix and of the F/F loop in CYP2C9 in high-temperature molecular dynamics simulations are shown to close the solvent channel and to open the channel 2b.. A large conformational shift of the F/F loop is also seen in CYP3A4 crystal structures complexed with ketoconazole (a P450 inhibitor) or erythromycin (a CYP3A4 substrate). 	CYP3A	26116	26121	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:157	However, the movements of the different elements forming the F/G region are not always easy to identify or to simulate in molecular dynamics, since, for instance, four of the 24 crystal structures of CYP3A4 available in the Protein Data Bank have missing residues in the F and F helices. 	CYP3A	27463	27468	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:159	It has been shown that one of them, channel 4, couldbe predominantly a metabolite egress channel in CYP3A4. 	CYP3A	27949	27954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:165	In a recent study, Petitjean and his collaborators have analyzed 24 crystal structures of human CYP3A4 with their newly developed algorithm Computing Cavities, Channels, Pores And Pockets (Computing Cavities, Channels, Pores and Pockets) that finds out the different ways used by a cylinder to escape the catalytic cavity. 	CYP3A	28854	28859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:166	They choose CYP3A4 because its numerous crystal structures are showing an impressive flexibility of some parts of the protein, suggesting that the ligand access and the exit routes might differ from a P450 structure to the next, and that these differences might be correlated to ligand physicochemical properties. 	CYP3A	29093	29098	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:167	By doing so, they have classified the 24 crystal structures in three groups of different conformations, on closed, named C, in which a substrate-free CYP3A4 structure is found, and two open conformations, named O1 and O2. 	CYP3A	29545	29550	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:168	They have also identified a series of crucial physicochemical properties for a molecule to be a CYP3A4 ligand, namely its hydrophobicity (LogP), the flatness of the cylinder that describes it, its ability to - interactions, as measured by the Hckel -energy, and the number of ligand molecules that can bind simultaneously to CYP3A4. 	CYP3A	29713	29718	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:168	They have also identified a series of crucial physicochemical properties for a molecule to be a CYP3A4 ligand, namely its hydrophobicity (LogP), the flatness of the cylinder that describes it, its ability to - interactions, as measured by the Hckel -energy, and the number of ligand molecules that can bind simultaneously to CYP3A4. 	CYP3A	29942	29947	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:169	In this interesting in silico study, they have highlighted the key role of two amino acid residues, Leu212 and Phe213, in triggering and controlling the shift between the three different conformations of CYP3A4. 	CYP3A	30154	30159	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:170	Phe213 has been also identified independently as a critical residue in allosteric regulations that were observed with CYP3A4 when two substrates, carbamazepine and progesterone, were mixed. 	CYP3A	30280	30285	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:173	By molecular dynamic simulations of human CYP3A4, it was predicted that the monooxygenation products of temazepam, which is a benzodiazepine hypnotic, and testosterone are each using a different channel for exiting the catalytic cavity once produced. 	CYP3A	30985	30990	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:176	Two phenylalanine residues were prominent in that control in CYP3A4, Phe215, and Phe220. 	CYP3A	31562	31567	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:177	In a recent study of the binding of metconazole, an enantiomeric P450 inhibitor, to CYP3A4, it was shown that two aromatic residues were involved in the differential binding of the RS and SR enantiomers within the catalytic cavity. 	CYP3A	31674	31679	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:181	This again suggests that the different positioning of each enantiomer within CYP3A4 active site could result from each eniantomer using different access channels. 	CYP3A	32471	32476	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:196	The atomic models of six human P450 enzymes including CYP3A4 anchored to a lipid bilayer were constructed and investigated by molecular dynamics simulations for the position and orientation of the P450 protein on the model membrane. 	CYP3A	35573	35578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:209	A molecular dynamics study of CYP3A4 embedded in bilayer environments presenting increased levels of cholesterol (from 0% up to 50%) shows that, as cholesterol amounts increase, the immersion an inclination of the CYP3A4 catalytic domain change relatively to the membrane. 	CYP3A	38207	38212	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:209	A molecular dynamics study of CYP3A4 embedded in bilayer environments presenting increased levels of cholesterol (from 0% up to 50%) shows that, as cholesterol amounts increase, the immersion an inclination of the CYP3A4 catalytic domain change relatively to the membrane. 	CYP3A	38391	38396	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:210	moreover, the pattern of CYP3A4 accessible channels is altered. 	CYP3A	38475	38480	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:66	reported the presence of the following CYPs in rat skin microsomes: CYP2B, CYP2C13, CYP2D1, CYP2D4, CYP2E1, CYP3A1, and CYP3A2, their levels being much lower than in the liver (except CYP2D4, which was not observed in the liver). 	CYP3A	10038	10043	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:66	reported the presence of the following CYPs in rat skin microsomes: CYP2B, CYP2C13, CYP2D1, CYP2D4, CYP2E1, CYP3A1, and CYP3A2, their levels being much lower than in the liver (except CYP2D4, which was not observed in the liver). 	CYP3A	10050	10055	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	CYP3A	12303	12308	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:89	), increased erythromycin demethylase (CYP3A-selective) after irradiation with UVB (Goerz et al.. Experiments with submerged cultures of skin cells from newborn rats showed that six- to sevenfold increases in Aryl Hydrocarbon Hydroxylase and in CYP protein after in vitro exposure to benz[a]anthracene. 	CYP3A	13908	13913	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP3A	33745	33750	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP3A	58776	58781	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP3A	58845	58850	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP3A	59405	59410	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP3A	60788	60793	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A	64198	64203	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A	64272	64277	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A	64298	64303	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A	64417	64422	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:423	reported that they did not find CYP1, CYP2B6 or CYP3A proteins In the reconstructed human skin models EpiDerm, EpiSkin^ and SkinEthik^ RHE. 	CYP3A	66589	66594	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP3A	70427	70432	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:445	noticed in human skin microsomes very low CYP3A activities (just exceeding the LOD) using 7-benzyloxyquinoline as selective CYP3A substrate and using the luminescent Luc-BE CYP3A-assay. 	CYP3A	70527	70532	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:445	noticed in human skin microsomes very low CYP3A activities (just exceeding the LOD) using 7-benzyloxyquinoline as selective CYP3A substrate and using the luminescent Luc-BE CYP3A-assay. 	CYP3A	70609	70614	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:445	noticed in human skin microsomes very low CYP3A activities (just exceeding the LOD) using 7-benzyloxyquinoline as selective CYP3A substrate and using the luminescent Luc-BE CYP3A-assay. 	CYP3A	70658	70663	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:502	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-Methoxyresorufin-O-Demethylase and PROD < 0.2 pmolminmg protein), while very low CYP3A activities were detected (Gtz et al.. These activities and lack of observed activities, respectively, were similar as the results obtained by the same authors in human skin (presented above under Human skin). 	CYP3A	77570	77575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:508	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin in SkinEthik^ RHE: 2.8, in Episkin^: 9.1, in Episkin^ FTM: 2.6, compared with human skin: 3.0;7-benzoxy 4-trifluoromethylcoumarin O-deethylase activities (CYP3A5/3A7-selective) in SkinEthik^ RHE: 13.3, in Episkin^: 3.6, in Episkin^ FTM: 3.3, compared with human skin: 3.8;7-methoxy-4-trifluoromethylcoumarin O-dealkylase activity was close to the Limit Of Quantitation of 0.5 in all three skin models and in human skin. 	CYP3A	78751	78756	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:514	)], 6BETA-hydroxytestosterone [produced by CYP1A1/2, CYP3A4/5/7 and CYP3A43 (Soucek et al. 	CYP3A	79574	79579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:514	)], 6BETA-hydroxytestosterone [produced by CYP1A1/2, CYP3A4/5/7 and CYP3A43 (Soucek et al. 	CYP3A	79589	79594	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:518	; Oesch and Arand ] and in part by CYP2C9, and CYP3A48; (Gautier et al. 	CYP3A	80105	80110	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:668	CYP3A4 and CYP3A5 Baron et al. 	CYP3A	102313	102318	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:668	CYP3A4 and CYP3A5 Baron et al. 	CYP3A	102324	102329	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A	102356	102361	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A	102372	102377	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A	102489	102494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:671	Cyp3A4 mRNA was very variably expressed in various skin systems, whereby it was not clear whether CYP3A4 was distinguished from CYP3A5. 	CYP3A	102680	102685	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:671	Cyp3A4 mRNA was very variably expressed in various skin systems, whereby it was not clear whether CYP3A4 was distinguished from CYP3A5. 	CYP3A	102710	102715	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:672	The authors report that CYP3A4 was expressed in native human skin, both in the epidermis (moderate expression in the epidermis of all three donors investigated) and in the dermis (weak expression in the dermis from one out of the three donors). 	CYP3A	102742	102747	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:675	showed that CYP3A protein was present in human skin. 	CYP3A	103422	103427	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:677	observed that in human skin testosterone was transformed to 6-BETA-hydroxytestosterone, a CYP3A-selective activity. 	CYP3A	103566	103571	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	CYP3A	103667	103672	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	CYP3A	103790	103795	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:681	observed in proliferating human skin keratinocytes in culture constitutive demethylation of the CYP3A-selective substrate erythromycin which was increased by treatment with dexamethasone. 	CYP3A	104076	104081	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:683	reported that the hydroxylation of the CYP3A-selective substrate cyclosporine A was predominantly occurring in human dermis-derived cultures. 	CYP3A	104222	104227	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:684	Some examples of CYP3A substrates, as observed in skin or other systems: 17BETA-estadiol, ethinylestradiol, progesterone, levonorgestrel, testosterone, dehydroepiandrosterone, cortisol, dexamethasone, acetaminophen, benzphetamine, nifedipine, midazolam, aflatoxin B_1 (Oesch-Bartlomowicz and Oesch. 	CYP3A	104342	104347	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:1	 Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. 	CYP3A	88	93	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:4	Here we have determined the effect of eight CYP3A4 and seven CYP2C9 Single Nucleotide Polymorphisms on the thermostability of proteins in solution to test these predictions. 	CYP3A	642	647	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:5	Thermostability assays revealed distinct Cytochrome P450 sub-populations with only 65-70% of wild-type CYP3A4 and CYP2C9 susceptible to rapid heat-induced P450 to P420 conversion. 	CYP3A	875	880	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:6	CYP3A4 mutations G56D, P218R, S222P, I223R, L373F and M445T and CYP2C9 mutations V76M, I359L and I359T were destabilising, increasing the proportion of protein sensitive to the rapid heat-induced P450 to P420 conversion and/or reducing the half-life of this conversion. 	CYP3A	952	957	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:14	Over 100 non-synonymous single amino acid substitutions have been reported for isoforms CYP3A4 and CYP2C9 alone^,; these two isoforms are jointly responsible for nearly half of Cytochrome P450 mediated drug metabolism^. 	CYP3A	2506	2511	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:38	The aim of this study was to test our previous in silico stability prediction in vitro, using a selection of recombinantly expressed CYP3A4 and CYP2C9 mutants. 	CYP3A	8280	8285	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:39	The 8 CYP3A4 and 7 CYP2C9 variants tested included mutations previously predicted to be neutral, stabilising and destabilising, falling within both functional and undefined regions of the protein structure^. 	CYP3A	8313	8318	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:40	The positions of the CYP3A4 and CYP2C9 variants selected for in vitro testing are shown in Fig. 	CYP3A	8536	8541	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:41	Recombinant wild-type and variant His-tagged CYP3A4 and CYP2C9 proteins were expressed in E. coli and purified using immobilized metal affinity chromatography. 	CYP3A	8656	8661	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:42	The specific holoprotein content of each CYP3A4 and CYP2C9 variant protein sample was determined using carbon monoxide P450 spectral assays^,. 	CYP3A	8812	8817	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:45	To test the thermostability of the CYP3A4 and CYP2C9, Wild-Type and variant proteins, Carbon Monoxide P450 difference spectra were used to measure the decrease in P450 content at an elevated temperature as a function of time. 	CYP3A	9358	9363	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:47	Different temperatures were tested to ensure the decrease in P450 could be monitored at a constant temperature over a 30-minute period: 34 C was chosen for CYP3A4 proteins and 48 C for the more stable CYP2C9 proteins. 	CYP3A	9900	9905	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:48	CYP3A4 and CYP2C9 Wild-Type protein samples both showed an exponential decrease in P450 content, although the graphs did not tend to zero, suggesting either the presence of a stable P450 sub-population or background signal. 	CYP3A	9962	9967	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:51	Figure  shows the thermostability results for the CYP3A4 Wild-Type and variant proteins. 	CYP3A	10542	10547	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:56	To determine the effect of polymorphic variation on CYP3A4 stability, the effect of mutations on the half-life of the unstable sub-population and the effect of mutations on the plateau - the proportion of P450 making up the stable sub-population - were considered. 	CYP3A	11371	11376	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:67	Size exclusion chromatography was carried out on CYP3A4 and CYP2C9 Wild-Type protein samples to determine whether protein oligomerisation could provide an explanation for the presence of P450 sub-populations with different stabilities in solution. 	CYP3A	13036	13041	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:69	Figure  shows the elution profiles for CYP3A4 and CYP2C9 Wild-Type proteins monitored at 410 nm, the maximum absorbance wavelength of the haem-bound protein. 	CYP3A	13374	13379	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:71	The data provides evidence that both isoforms do indeed oligomerise in solution; the major peak for both CYP3A4 (66 kDa in monomeric form) and CYP2C9 (63 kDa in monomeric form) correspond roughly to oligomeric structures made up of 9 and 8 subunits respectively. 	CYP3A	13716	13721	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:72	The major CYP3A4 peak has a shoulder corresponding roughly to a trimeric or tetrameric protein. 	CYP3A	13884	13889	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:74	In order to test previous in silico predictions on the effects of Single Nucleotide Polymorphisms on Cytochrome P450 stability, recombinant soluble CYP2C9 and CYP3A4 Wild-Type and variant proteins, lacking their N-terminal membrane binding region, were expressed in E. coli and purified from the cell lysate. 	CYP3A	14385	14390	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP3A	14635	14640	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP3A	14662	14667	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:77	Notably, the P420 form of the protein was not detected in any of the CYP2C9 samples, while the P420 form was present in all CYP3A4 samples. 	CYP3A	14968	14973	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:78	Exponential decay curves for both CYP3A4 and CYP2C9 indicated energetically distinct P450 sub-populations that did not interconvert between each other during the course of the assay. 	CYP3A	15018	15023	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:79	In support of this idea, previous published studies examining the binding kinetics of Carbon Monoxide to CYP3A4 using flash photolysis have argued that there are two kinetically distinct pools of P450, both in the membrane and in solution^,. 	CYP3A	15272	15277	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:80	Other studies have also observed conformational heterogeneity for CYP2B4^, and CYP3A4 proteins^ using hydrostatic pressure spectroscopy. 	CYP3A	15488	15493	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:85	In another study it was shown that 70% of CYP3A4 in solution and 50% in microsomes was susceptible to substrate-induced spin shifts and rapid, reversible pressure-induced P450 to P420 conversions^. 	CYP3A	16261	16266	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:87	In solution, this remaining fraction was subject to slow, irreversible inactivation at high pressures indicating that the pressure induced P450 to P420 conversion of CYP3A4 was biphasic consisting of a fast-reversible phase and a slow-irreversible phase. 	CYP3A	16663	16668	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:91	Similarly to CYP2B4, the addition of detergents known to break up oligomers has been reported to reduce the heterogeneity of CYP3A4 observed in solution. 	CYP3A	17262	17267	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:95	probed the geometry of CYP3A4 oligomers in microsomes using luminescence energy transfer and intermolecular cross-linking experiments^. 	CYP3A	17626	17631	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:96	Their results suggest that the most likely size of the CYP3A4 oligomer in solution and in the membrane is a trimer (or multiples of this), involving two different types of interaction interfaces between subunits, one of which is similar to the subunit interface observed in the progesterone-bound CYP3A4 crystal structure (PDB code 1W0F)^. 	CYP3A	17794	17799	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:96	Their results suggest that the most likely size of the CYP3A4 oligomer in solution and in the membrane is a trimer (or multiples of this), involving two different types of interaction interfaces between subunits, one of which is similar to the subunit interface observed in the progesterone-bound CYP3A4 crystal structure (PDB code 1W0F)^. 	CYP3A	18036	18041	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:98	In this study we observed similar conformational heterogeneity for both CYP3A4 and CYP2C9 in solution; only 65-70% of the P450 was susceptible to rapid heat-induced P450 to P420 conversion at a constant elevated temperature while the remaining fraction was much more stable, consistent with the literature. 	CYP3A	18451	18456	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:99	Size exclusion chromatography experiments confirmed that both CYP3A4 and CYP2C9 were predominantly in the oligomeric form in solution. 	CYP3A	18748	18753	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:100	The estimated molecular weight of the major CYP3A4 oligomer species were 583 and 239 kDa corresponded most closely to a nonamer and a tetramer, respectively. 	CYP3A	18865	18870	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:102	work which suggests that CYP3A4 oligomers are made up of trimers and would explain the 1:2 conformer distribution observed for CYP3A4, where 3 of the monomeric subunits are more stable than the other 6. 	CYP3A	19105	19110	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:102	work which suggests that CYP3A4 oligomers are made up of trimers and would explain the 1:2 conformer distribution observed for CYP3A4, where 3 of the monomeric subunits are more stable than the other 6. 	CYP3A	19207	19212	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:103	A previous study observed at least three major CYP3A4 oligomers in solution with molecular masses of 215, 290, and 450 kDa using continuous molecular weight distribution analysis^. 	CYP3A	19330	19335	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:110	Mutations in close proximity to the haem-binding region, such as L373F (haem contact) and M445T (predicted to be destabilising by SDM) in CYP3A4, destabilise the haem significantly in both conformers, increasing the proportion of protein sensitive to rapid heat-induced conversion to P420 and decreasing the half-life of this conversion. 	CYP3A	20751	20756	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:116	While this residue does not fall within a substrate recognition site, it is solvent accessible and is predicted to form part of the CYP3A4:CPR interface so any destabilising effects in this region may also alter interactions with Cytochrome P450 Reductase. 	CYP3A	21837	21842	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:119	CYP3A4 mutation G56D had a similar effect to the L373F mutation; while Gly 56 is not in close proximity to the haem-binding region, it was predicted to be a destabilising mutation by Site Directed Mutator and falls within SRS1a. 	CYP3A	22423	22428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:121	For reasons less immediately apparent, P218R and S222P had a significant effect on the thermostability of CYP3A4; P218R and S222P were both predicted to be neutral by Site Directed Mutator and fall within the flexible F-G loop, which is far away from the haem-binding site but forms part of substrate recognition site (2,3) at the proposed interface of the interacting Cytochrome P450 subunits, close to the peripheral effector site acts as a lid over the active site cavity and is comprised of the F and G helix connected by the F-G loop. 	CYP3A	22988	22993	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:135	Unlike Pro 218 and Ser 222, which are both solvent exposed residues with side chains orientated towards the bulk solvent, Ile 223 is buried indicating that it is unlikely to interact with other CYP3A4 molecules directly without a substantial change in protein conformation. 	CYP3A	26110	26115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:143	A recently reported crystal structure of the CYP3A4 I359L variant suggests that this mutation has long range effects - transduced along the I-helix - on the orientation of active site residues, altering the binding mode of losartan within the active site compared to the wild-type structure^. 	CYP3A	28085	28090	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A	31614	31619	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A	31715	31720	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A	31826	31831	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	CYP3A	32859	32864	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:168	pBJW102.2 vectors containing the N-terminal truncated CYP3A4 and CYP2C9 cDNA sequences were a gift from Procognia Ltd, Maidenhead, UK. 	CYP3A	33538	33543	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:170	The translated CYP3A4 and CYP2C9 proteins had a 24 amino acid and 28 amino acid deletion at the N-terminus respectively. 	CYP3A	33903	33908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP3A	34035	34040	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP3A	34112	34117	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:185	CYP3A4 and CYP2C9 holo P450 protein content in the enriched protein samples was determined using carbon monoxide spectral assays^. 	CYP3A	36551	36556	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:195	The cuvettes were then placed back into the spectrophotometer maintained at a constant temperature of 34 C (for CYP3A4 samples) or 48 C (for CYP2C9 samples) by circulating water from a heated water bath through the cell holder. 	CYP3A	38149	38154	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:206	CYP3A4 and CYP2C9 Wild-Type protein samples were separated using the BioSep-SEC-S3000 column with exclusion range of 5 kDa to 700 kDa. 	CYP3A	39622	39627	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:25	For example, bergamottin is reported to increase the blood concentration of drugs through inhibition of hepatic CYP3A activity, thereby enhancing the toxicity of drugs such as atorvastatin, felodipine, and verapamil. 	CYP3A	3502	3507	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP3A	9385	9390	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:186	The substrate behavior prediction in the CYP3A4 indicated that only 1 and 2 could be substrates, because these molecules meet the characteristics of the pharmacophore model for this cytochrome. 	CYP3A	31436	31441	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP3A	32542	32547	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:112	used NMR-based metabolomics to identify a metabolic signature associated with a variation in induced CYP3A4 activity. 	CYP3A	17302	17307	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:115	Ultraperformance liquid chromatography combined with mass spectrometry was performed to obtain a marker for CYP3A4 induction: the ratio of 3-hydroxyquinine to quinine (3OH-Q/Q). 	CYP3A	17565	17570	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:117	showed that the plasma concentrations of 4b-hydroxycholesterol increased after complete induction of CYP3A4/5 by carbamazepine or rifampicin. 	CYP3A	17770	17775	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:118	The authors suggested that 4b-hydroxycholesterol may be used as an endogenous marker of CYP3A activity. 	CYP3A	17899	17904	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:119	Such information can help to predict CYP3A activity and the metabolism level of CYP3A-mediated drugs prior to administration. 	CYP3A	17952	17957	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:119	Such information can help to predict CYP3A activity and the metabolism level of CYP3A-mediated drugs prior to administration. 	CYP3A	17995	18000	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP3A	20371	20376	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:146	One example of the modifying influence of external factors is the effect of grapefruit juice components on the expression of cytochrome P-450 (CYP3A4) and, accordingly, on the pharmacokinetics of CYP3A-mediated drugs. 	CYP3A	22336	22341	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:146	One example of the modifying influence of external factors is the effect of grapefruit juice components on the expression of cytochrome P-450 (CYP3A4) and, accordingly, on the pharmacokinetics of CYP3A-mediated drugs. 	CYP3A	22389	22394	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:1	 The Inhibitory Effect of Flavonoid Aglycones on the Metabolic Activity of CYP3A4 Enzyme. 	CYP3A	75	80	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:5	The aim of this study was to focus on possible interactions between the 30 most commonly encountered flavonoid aglycones on the metabolic activity of CYP3A4 enzyme. 	CYP3A	569	574	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:6	6BETA-hydroxylation of testosterone was used as marker reaction of CYP3A4 activity. 	CYP3A	651	656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:9	Out of the 30 flavonoids tested, 7 significantly inhibited CYP3A4, most prominent being acacetin that inhibited 95% of enzyme activity at 1 M concentration. 	CYP3A	940	945	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:11	These results alert on possible flavonoid-drug interactions on the level of CYP3A4. 	CYP3A	1338	1343	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP3A	3366	3371	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:27	The aim of the present study was to evaluate the inhibitory effect of thirty flavonoid aglycones, most commonly found in herbal drugs and propolis, on the most important drug metabolizing enzyme CYP3A4. 	CYP3A	3801	3806	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:31	For enzyme activity assessment testosterone 6BETA-hydroxylation was used as it represents a marker reaction of CYP3A4 activity. 	CYP3A	4314	4319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:34	To test the CYP3A4 enzyme inhibition, residual activity was assessed based on the product of the marker reaction generated by monitoring incubations with addition of flavonoid, as a potential inhibitor, versus incubations without inhibitor.  	CYP3A	4631	4636	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:37	Negative control (incubation with substrate and without the NADPH generating system) shows no product generation, confirming that 6BETA-hydroxytestosterone is product of generated by CYP3A4 enzyme. 	CYP3A	5271	5276	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A	5486	5491	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A	5573	5578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A	5641	5646	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:41	Seven flavonoids have been shown to inhibit CYP3A4 with statistical significance p < 0.05. 	CYP3A	6028	6033	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:46	However, there are no reports on CYP3A4 inhibition. 	CYP3A	6491	6496	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:49	Although pharmacokinetic of pinocembrin was studied, no CYP3A4 inhibition was reported. 	CYP3A	6839	6844	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:51	Residual activity of CYP3A4 after incubations with flavones apigenin, chrysin, chrysin dimethyl ether, and tangerine was 24%, 17%, 61%, and 42%. 	CYP3A	6953	6958	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:54	Reversible inhibition of CYP3A4 by apigenin was reported by Li et al. 	CYP3A	7348	7353	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:58	However, based on our study metabolism dependent inhibition of CYP3A4 by apigenin, here reported for the first time, is of greater importance. 	CYP3A	7609	7614	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:60	Neither chrysin, nor chrysin dimethylether were reported as inhibitors of CYP3A4 previously. 	CYP3A	8053	8058	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:61	Although the effect of chrysin on 1-hydroxilation of midazolam (another marker reaction of CYP3A4 enzyme) was studied, inhibition of CYP3A4 activity was not observed. 	CYP3A	8163	8168	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:61	Although the effect of chrysin on 1-hydroxilation of midazolam (another marker reaction of CYP3A4 enzyme) was studied, inhibition of CYP3A4 activity was not observed. 	CYP3A	8205	8210	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:65	However, in our study in which residual activity of CYP3A4 was studied on testosterone as marker substrate, an inhibitory effect was observed. 	CYP3A	8672	8677	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:67	who reported that tangeretin inhibited CYP3A4 mediated nifedipine oxidation in human liver microsomes in an uncompetitive manner with inhibition constant of 72 M. Lastly, Takanaga et al. 	CYP3A	8854	8859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:68	reported no influence of tangeretin, neither activation, nor inhibition, on CYP3A4 activity when using testosterone as marker substrate on human liver microsomes and recombinant CYP3A4 systems. 	CYP3A	9078	9083	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:68	reported no influence of tangeretin, neither activation, nor inhibition, on CYP3A4 activity when using testosterone as marker substrate on human liver microsomes and recombinant CYP3A4 systems. 	CYP3A	9180	9185	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:69	Observed difference justifies recommendations of medicinal products regulatory agencies to use at least two marker substrates when studding CYP3A4 activity. 	CYP3A	9336	9341	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:74	did not observe change in activity of CYP3A4 treated with isorhamnetin on hepatocyte carcinoma cell line HepG2. 	CYP3A	9853	9858	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:80	Interestingly, stimulation of enzyme activity of CYP3A4 was observed with tamarixetin; observed residual activity was 195%. 	CYP3A	10452	10457	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:84	have shown that tamarixetin has no influence on CYP3A4 induction through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor. 	CYP3A	10783	10788	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:85	Our observation of stimulation of CYP3A4 activity by tamarixetin is in contrast to von Moltke et al. 	CYP3A	10928	10933	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:87	Although stimulation in vitro (not mediated by increased induction of enzyme in vivo) is rarely observed, it has been reported that anticancer drug gefitinib is a potent stimulator of CYP3A4. 	CYP3A	11234	11239	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:88	Looking at the structural features responsible for the inhibitory effect, it can be observed that flavanones and flavones hydroxylated at the positions 5 and 7 of the A ring, and monosubstituted at the position 4 of the B ring, decrease CYP3A4 enzyme activity regardless of group present (methoxy or hydroxyl) eg, acacetin and apigenin. 	CYP3A	11479	11484	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:89	As the hydroxyl group at the B ring is nonionizable under the physiological pH, hydrophobic interactions of the flavonoid with the CYP3A4 are probably of importance. 	CYP3A	11710	11715	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:91	However, in that instance hydroxyl group should not be methylated, and susceptible to ionization under physiological conditions, indicating importance of ion-ion interactions between flavanones and CYP3A4 enzyme. 	CYP3A	12126	12131	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:94	To distinguish if the observed metabolism dependent inhibition (of the seven confirmed inhibitors of CYP3A4 in this study) was a result of time dependent inhibition, in which additional time is needed for the inhibitor to interact with enzyme to cause the inhibition, preincubations were conducted without presence of NADPH coenzyme. 	CYP3A	12838	12843	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:95	In this way, no reduction of CYP3A4 heme iron to Fe^2+ form occurred, giving sufficient time for the potential inhibitor to interact with the enzyme. 	CYP3A	13100	13105	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:97	Residual CYP3A4 activity was 57  10% (p = 0.047), 34  10% (p = 0.005), and 45  3% (p = 0.019), respectively. 	CYP3A	13328	13333	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:98	However, no statistical difference was observed in residual activity of CYP3A4 enzyme for apigenin between metabolism and time dependent inhibition assays, indicating that apigenin is pure reversible inhibitor of CYP3A4. 	CYP3A	13500	13505	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:98	However, no statistical difference was observed in residual activity of CYP3A4 enzyme for apigenin between metabolism and time dependent inhibition assays, indicating that apigenin is pure reversible inhibitor of CYP3A4. 	CYP3A	13641	13646	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:99	No time dependent inhibition was observed with chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin, and this was confirmed in direct inhibition assay, indicating these four flavonoids are irreversible inhibitors of CYP3A4. 	CYP3A	13877	13882	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:101	Direct inhibition assay showed inhibitory effect of acacetin, apigenin, and chrysin on CYP3A4 by decreasing residual enzyme activity to 46  6% (p = 0.005), 35  18% (p = 0.049), and 54  23% (p = 0.044), respectively. 	CYP3A	14181	14186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:102	These results show that no real time dependent inhibition is present, and observed inhibition of CYP3A4 in time dependent inhibition assay is consequence of the direct inhibition. 	CYP3A	14407	14412	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:103	Time dependent inhibition is extremely rare for human cytochromes P450 and has been previously reported only for cilengitide, an experimental anticancer drug used for treatment of glioblastoma, and CYP3A4 enzyme in which inhibitor was in extremely high millimolar concentration. 	CYP3A	14688	14693	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:111	Moreover, data published is not always confirmed by subsequent studies, eg, tamarixetin is activator of CYP3A4 in our study, while previously it has been reported that it either has no effect or it inhibits CYP3A4. 	CYP3A	16240	16245	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:111	Moreover, data published is not always confirmed by subsequent studies, eg, tamarixetin is activator of CYP3A4 in our study, while previously it has been reported that it either has no effect or it inhibits CYP3A4. 	CYP3A	16343	16348	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:112	For the first time we have reported inhibition of CYP3A4 by acacetin, pinocembrin, chrysin, and chrysin dimethylether, and we have also shown that pinocembrin and isorhamnetin act as irreversible inhibitors of CYP3A4. 	CYP3A	16401	16406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:112	For the first time we have reported inhibition of CYP3A4 by acacetin, pinocembrin, chrysin, and chrysin dimethylether, and we have also shown that pinocembrin and isorhamnetin act as irreversible inhibitors of CYP3A4. 	CYP3A	16561	16566	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:116	Sometimes inhibitors can have both reversible and irreversible effect on the enzyme as it has been shown with cilengitide and CYP3A4. 	CYP3A	17143	17148	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	CYP3A	17249	17254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:120	For the evaluation of activity of CYP3A4 testosterone was used as marker substrate (Sigma-Aldrich). 	CYP3A	18042	18047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	CYP3A	18399	18404	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:128	6BETA-Hydroxylation of testosterone was used as marker reaction to monitor activity of the CYP3A4 enzyme. 	CYP3A	18986	18991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:130	Incubation mixture contained 5 pmol of the CYP3A4 enzyme. 	CYP3A	19193	19198	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:147	Out of 30 flavonoids screened for potential CYP3A4 enzyme inhibition, 7 showed statistically significant inhibition. 	CYP3A	21658	21663	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:149	These results bring attention to possible flavonoid-drug interactions on the level of CYP3A4. 	CYP3A	22041	22046	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:150	As CYP3A4 is the most significant enzyme for the metabolism of xenobiotics including drugs, further in vivo studies are needed to assess clinical significance of the observed inhibitions, and possible drug-flavonoid interactions.	CYP3A	22052	22057	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	CYP3A	102	107	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:2	Incubation systems were established to investigate the effects of quercetin, kaempferol, isoquercitrin and astragalin in Lysimachia clethroides Duby on the activities of CYP2E1 and CYP3A4 in rat liver microsomes in vitro. 	CYP3A	315	320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:5	The results suggested that kaempferol exhibited a weak inhibition of CYP2E1 activity with an IC50 of 60.26  2.54 M, while quercetin and kaempferol caused a moderate inhibition of CYP3A4 activity with IC50 values of 18.77  1.69 M and 32.65  1.32 M, respectively. 	CYP3A	821	826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:6	Isoquercitrin and astragalin had no effects on the activities of either CYP2E1 or CYP3A4. 	CYP3A	986	991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:7	It could be speculated from these results that the inhibitory effects of quercetin and kaempferol on the activities of CYP2E1 and CYP3A4 could be the mechanisms underlying the hepatoprotective effects of L. clethroides. 	CYP3A	1124	1129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:18	CYP3A4, a major enzyme that is expressed in adult liver, has been considered to be an important factor affecting drug absorption. 	CYP3A	3132	3137	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:19	CYP2E1 and CYP3A4 are not only the metabolic enzymes directly involved in hepatic oxidative damage, but they also are two important targets of the oxidation mechanism of acute liver injury. 	CYP3A	3273	3278	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:21	On the basis of previous studies, the impacts of quercetin, kaempferol, isoquercitrin and astragalin on the activities of enzymes CYP2E1 and CYP3A4 in rat liver microsomes were examined, aiming to investigate the correlation between the hepatoprotective effects of L. clethroides and the antioxidant activities of these four compounds. 	CYP3A	3949	3954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:36	The regressive equations obtained by the Lineweaver-Burk method for CYP2E1 and CYP3A4 were Y = 835.9883X + 9.1943 (r = 0.9864) and Y = 2388.0110X + 14.1598 (r = 0.9961) respetively. 	CYP3A	6018	6023	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:42	The effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides and ketoconazole (positive control) on CYP3A4 activity are shown in  and. 	CYP3A	7139	7144	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:43	Ketoconazole strongly inhibited the production of 6BETA-hydroxytestosterone (IC_50 = 0.25  0.01 M), but the effects of the four flavonoids in L. clethroides on CYP3A4 were very weak and their IC_50 values could not be calculated. 	CYP3A	7334	7339	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:45	CYP2E1 and CYP3A4 are two important metabolic enzymes involved in liver injury. 	CYP3A	7648	7653	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:46	Total alkaloids of Rubus alceaefolius Poir could significantly reduce the levels of GOT and GPT, protect liver cells from injury, and inhibit the mRNA expressions of CYP2E1 and CYP3A1 in liver tissue. 	CYP3A	7894	7899	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:48	Radix Glycyrrhizae could protect the liver injury caused by Rhizoma dioscorea bulbifera, possibly due to its induction of activity of CYP2E1 and CYP3A4 and inhibition of the mRNA expression. 	CYP3A	8245	8250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:49	Clomethiazole and ketoconazole act as the positive inhibitors for CYP2E1 and CYP3A4 can significantly inhibit the formation of metabolites. 	CYP3A	8368	8373	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:50	The IC_50 values of clomethiazole and ketoconazole were 1.07  0.01 M and 0.25  0.01 M, respectively, which are consistent with literature values, suggesting that the incubation systems in vitro can meet the activities of measurement of CYP2E1 and CYP3A4. 	CYP3A	8678	8683	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:52	Thus, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol have moderate inhibitory effects on CYP3A4. 	CYP3A	9016	9021	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:53	The results of this study showed that the two flavone glycosides (isoquercitrin and astragalin) had no effect on the activities of CYP2E1 and CYP3A4. 	CYP3A	9166	9171	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:59	Cytochromes P450, especially CYP2E1 and CYP3A4, are responsible for metabolism of ethanol, CCl_4 and other solvents in the body. 	CYP3A	9940	9945	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:60	In the model of alcohol-induced liver injury, the expression levels of CYP2E1 and CYP3A4 were enhanced. 	CYP3A	10111	10116	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:66	The occurrence of liver injury can be reduced or even suppressed by minimizing the activities of CYP2E1 and CYP3A4, making the discovery of more compounds with anti-oxidative stress from natural products of important significance. 	CYP3A	11155	11160	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:112	The incubation conditions of CYP3A4 were basically the same as those described in  but the volume of incubation mixture was 500 L and the reactions were terminated by adding 700 L of ice-cold acetonitrile containing 25 M phenacetin. 	CYP3A	16109	16114	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:133	The effects of flavonoids in L. clethroides on CYP3A4 activity were basically the same as CYP2E1. 	CYP3A	19367	19372	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:134	The positive control was ketoconazole, and Groups 2 and 3 experiments were performed at concentrations of 0.02, 0.1, 0.2, 1 and 5 M. In vitro rat liver microsomes incubation assay methods were adopted for determining the effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides on the activities of CYP2E1 and CYP3A4. 	CYP3A	19752	19757	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:135	In conclusion, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol had moderate inhibitory effects on CYP3A4 activity. 	CYP3A	19894	19899	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:136	Based on these results, it can be speculated that the active hepatoprotective ingredients of L. clethroides include quercetin and kaempferol, which confer the inhibitory effects on the activities of CYP2E1 and CYP3A4. 	CYP3A	20121	20126	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:137	The reduction of CYP2E1 and CYP3A4 activities can mitigate the biotransformation of CC1_4 and prevent the production of liver damaging substances to exert a liver protective role. 	CYP3A	20157	20162	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP3A	505	510	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:6	Unfermented (GRT) and fermented (FRE) rooibos extracts inhibited the activity of CYP2C8 (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) and CYP3A4 (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) based on their respective IC50 concentrations. 	CYP3A	1100	1105	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:8	CYP3A4 showed concentration-dependent inhibition by ASP, GRT, and FRE at 25, 50, and 100 g/mL concentrations. 	CYP3A	1320	1325	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:9	ASP, GRT, and FRE time-dependently inhibited CYP3A4 activity with GRT and FRE showing a more potent time-dependent inhibition, comparable to erythromycin. 	CYP3A	1475	1480	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP3A	4645	4650	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP3A	4784	4789	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP3A	4887	4892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:32	Atorvastatin used to treat hypercholesterolemia is metabolized by CYP3A4. 	CYP3A	4973	4978	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:35	Most drugs and xenobiotics including dietary polyphenols have the ability to bind to CYP3A4 as substrates. 	CYP3A	5540	5545	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP3A	5801	5806	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP3A	6319	6324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP3A	7235	7240	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP3A	7466	7471	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP3A	7551	7556	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:54	ASP showed 24% inhibition of CYP2C9 at 100 g/mL and 23% inhibition of CYP3A4 at 200 g/mL activity, while PPAG had no effect on any of these enzymes. 	CYP3A	7659	7664	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A	7886	7891	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A	8000	8005	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:60	ASP, GRT, and FRE reduced CYP3A4 activity at 25 g/mL (62.9%, 36.9% and 61.4%, respectively; p < 0.001), 50 g/mL (44.5%, 13.5% and 29.7%, respectively; p < 0.001), and 100 g/mL (28.1%, 1.7% and 9.2%, respectively; p < 0.001) (c). 	CYP3A	8574	8579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:64	PPAG demonstrated time-dependent inhibition (p < 0.05) of only CYP3A4 (c). 	CYP3A	9248	9253	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:66	An interesting finding, however, is the time-dependent inhibition of CYP3A4 activity by GRT (p < 0.01) and FRE (p < 0.01), displaying a similar effect to that of erythromycin (c). 	CYP3A	9382	9387	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:70	These constituents include various bioactive compounds that can either activate or inhibit CYP3A4. 	CYP3A	10094	10099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A	10275	10280	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A	10356	10361	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP3A	10840	10845	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP3A	11179	11184	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:76	Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications. 	CYP3A	11197	11202	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:78	for rats ingesting rooibos tea for two weeks suggested a possible interaction between rooibos tea and medicines mediated by CYP3A. 	CYP3A	11476	11481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:81	GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC_50 values of 31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively. 	CYP3A	11865	11870	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:82	ASP, as the major compound, moderately inhibited CYP3A4 activity with an IC_50 value of 69.57  4.03 g/mL. 	CYP3A	12013	12018	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:83	Luteolin, the aglycone of rooibos flavone glucosides, orientin and isoorientin, and quercetin, the aglycone of rooibos flavonol glycosides, quercetin-3-O-robinobioside, rutin, hyperoside, and isoquercitrin, have previously been shown to inhibit CYP3A4. 	CYP3A	12315	12320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:84	Quercetin is a more effective inhibitor of CYP3A4 than its 3-O-rutinoside, rutin. 	CYP3A	12366	12371	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:85	The inhibition of CYP3A4 was also demonstrated to be both dose- and time-dependent. 	CYP3A	12423	12428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:86	Therefore, they could potentially interfere with the metabolism and alter the pharmacodynamics of drugs, such as atorvastatin, cyclosporine, felodopine, simvastatin, midazolam, erythromycin, and doxorubicin, known to be metabolized by CYP3A4. 	CYP3A	12724	12729	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP3A	15300	15305	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:105	ASP could only be implicated in CYP3A4 inhibition. 	CYP3A	15453	15458	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP3A	17181	17186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP3A	17557	17562	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP3A	17948	17953	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP3A	18718	18723	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP3A	18989	18994	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP3A	19249	19254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP3A	19460	19465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP3A	19895	19900	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP3A	20045	20050	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A	20159	20164	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A	20496	20501	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP3A	20878	20883	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP3A	20986	20991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP3A	21599	21604	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP3A	22151	22156	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP3A	22957	22962	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:33	CYP3A4 is a well-known oxidative enzyme that is mostly involved in the metabolism of xenobiotics, and is the most expressed isoform in human liver. 	CYP3A	4290	4295	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:64	CYP3A4 was not analyzed because it was included in the study during the Western Blot analysis and we did not find any change of expression with the treatments. 	CYP3A	9081	9086	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP3A	9960	9965	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP3A	10328	10333	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:92	We also observed that the fluorescent images of CYP3A4 did not report a preferential localization between mitochondria and Endoplasmic Reticulum. 	CYP3A	13555	13560	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP3A	30930	30935	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP3A	83	88	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP3A	708	713	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A	4071	4076	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A	4098	4103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:31	The problem with disturbances of CYP reactions caused by nanomaterials is a new topic, studied most recently on metallic nanoparticles (gold or silver) and using the CYP3A4 isoform. 	CYP3A	4934	4939	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:37	Single-walled carbon nanotubes (SWCNT) inhibited the activity of the CYP3A4 enzyme by direct interaction between SWCNT and the enzyme. 	CYP3A	5631	5636	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP3A	6220	6225	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP3A	10344	10349	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP3A	11820	11825	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP3A	12142	12147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP3A	12460	12465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP3A	18377	18382	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A	20657	20662	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A	20797	20802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A	20982	20987	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A	21072	21077	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP3A	22077	22082	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP3A	22274	22279	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP3A	22461	22466	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:147	The inhibition rate of CYP3A4 was comparable for DN, GO and GN at all concentrations (50%-60% inhibition); however, at the highest concentration, we observed an effect similar to the one in CYP1A2. 	CYP3A	23218	23223	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:159	The level of CYP3A4 was decreased in all nanostructure groups in both cell lines (<40% of the control, reaching only 1% in the GO group in HepaRG cells), except the GN group in HepaRG cells, where no changes occurred. 	CYP3A	25136	25141	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP3A	25847	25852	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP3A	28403	28408	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP3A	28591	28596	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:176	Interestingly, inhibition of CYP1A2 and CYP3A4 was lower in the presence of the highest concentration of DN and GN (100 mg/L), which could be related to the formation of nanoparticle agglomerates in higher concentrations and then reduction of their surface area available to interact. 	CYP3A	28700	28705	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP3A	31174	31179	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:202	It was previously reported that SWCNT inhibited the most important of the isoenzymes, CYP3A4, mostly due to the occurrence of - stacking interactions between the nanotube walls and aromatic residues of the enzyme. 	CYP3A	33903	33908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:155	These two encoding enzymes were highly expressed in roots than stems, followed by CYP3A family members (6.1%) and CYP4 family members (4.8%). 	CYP3A	23319	23324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:234	The CYP3A subfamily of enzymes is the most important to drug metabolism in humans because these enzymes metabolize the majority of commercially available drugs. 	CYP3A	35522	35527	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP3A	703	708	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP3A	711	716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	853	858	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	861	866	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:6	Surprisingly, sulfaphenazole appeared to be a potent inhibitor of 5hydroxylation of flucloxacillin by both recombinant CYP3A4 and CYP3A7. 	CYP3A	999	1004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:6	Surprisingly, sulfaphenazole appeared to be a potent inhibitor of 5hydroxylation of flucloxacillin by both recombinant CYP3A4 and CYP3A7. 	CYP3A	1010	1015	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	1112	1117	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	1120	1125	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:10	There are large interindividual differences in plasma concentrations of flucloxacillin and 5hydroxymethyl flucloxacillin.5Hydroxymethyl flucloxacillin is much more toxic to biliary epithelial cells than flucloxacillin.A previous study on four human CYPs showed that CYP3A4 exerted the highest activity of flucloxacillin hydroxylation. 	CYP3A	1812	1817	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP3A	2154	2159	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP3A	2162	2167	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP3A	2433	2438	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP3A	2441	2446	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:29	Nonrenal clearance of flucloxacillin occurs predominantly by cytochrome P450mediated hydroxylation of flucloxacillin to 5HMFLX and partly by hydrolysis to the corresponding penicilloic acid, showed that CYP3A4 was able to catalyse the 5hydroxylation of flucloxacillin. 	CYP3A	6146	6151	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:31	Another study showed that flucloxacillin induces CYP3A4 in cell lines exposed to 200-400 M flucloxacillin (Huwyler et al.,. 	CYP3A	6398	6403	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:36	Furthermore, a major involvement of CYP3A4 in drug metabolism complicates prediction of pharmacokinetics based on enzyme kinetics because of the occurrence of atypical enzyme kinetics, such as substrate activation (Houston and Kenworthy, ; Ekins et al., ; Atkins, ; Houston and Galetin,. 	CYP3A	7245	7250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:37	Furthermore, inhibition of CYP3A4 by drugs appears to be substratedependent, further complicating prediction of drug-drug interactions (Stresser et al.,. 	CYP3A	7524	7529	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:52	456264), CYP3A4 (Lot No. 	CYP3A	8497	8502	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:53	456207), CYP3A5 (Lot No. 	CYP3A	8522	8527	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:54	456256) and CYP3A7 (Lot No. 	CYP3A	8550	8555	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP3A	12223	12228	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP3A	12231	12236	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13056	13061	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13081	13086	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13107	13112	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13124	13129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP3A	13733	13738	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP3A	13744	13749	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP3A	14334	14339	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP3A	19651	19656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP3A	19659	19664	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:119	At 100 M flucloxacillin, CYP3A7 was the most active CYP followed by CYP3A4. 	CYP3A	19787	19792	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:119	At 100 M flucloxacillin, CYP3A7 was the most active CYP followed by CYP3A4. 	CYP3A	19830	19835	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP3A	19961	19966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP3A	19999	20004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP3A	20007	20012	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP3A	20348	20353	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP3A	20407	20412	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:125	The three inhibitors of CYP3A isoforms, KCZ, miconazole and troleandomycin, showed a relatively modest and differential inhibitory effect on 5HMFLX formation. 	CYP3A	20677	20682	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:126	Even at the highest concentration of ketoconazole, which inhibits the CYP3A family, still only 50% inhibition was observed at both concentrations of flucloxacillin. 	CYP3A	20882	20887	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:127	The other CYP3A4 inhibitors showed only 20 to 40% inhibition at 10 M flucloxacillin concentration. 	CYP3A	20987	20992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP3A	21148	21153	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:130	To study whether sulfaphenazole has the ability to inhibit CYP3Amediated hydroxylation of flucloxacillin, the inhibitor was added at different concentrations to incubations of CYP3A4 and CYP3A7, with flucloxacillin and testosterone as substrates. 	CYP3A	21593	21598	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:130	To study whether sulfaphenazole has the ability to inhibit CYP3Amediated hydroxylation of flucloxacillin, the inhibitor was added at different concentrations to incubations of CYP3A4 and CYP3A7, with flucloxacillin and testosterone as substrates. 	CYP3A	21604	21609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:131	As shown in Figure A, B, sulfaphenazole appeared to be a potent inhibitor of flucloxacillin hydroxylation by recombinant CYP3A4 and CYP3A7 with an IC_50 of 4.1  0.4 M and 6.1  0.5 M respectively. 	CYP3A	21785	21790	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:131	As shown in Figure A, B, sulfaphenazole appeared to be a potent inhibitor of flucloxacillin hydroxylation by recombinant CYP3A4 and CYP3A7 with an IC_50 of 4.1  0.4 M and 6.1  0.5 M respectively. 	CYP3A	21796	21801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:132	At these sulfaphenazole concentrations, no inhibition of CYP3A4catalysed 6BETAhydroxylation of testosterone was observed. 	CYP3A	21917	21922	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:145	By using recombinant CYPs, at both substrate concentrations used, CYP3A4 and CYP3A7 appeared to be the most active enzymes. 	CYP3A	24325	24330	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:145	By using recombinant CYPs, at both substrate concentrations used, CYP3A4 and CYP3A7 appeared to be the most active enzymes. 	CYP3A	24336	24341	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP3A	24558	24563	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP3A	24668	24673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:152	that CYP3A4 is likely to play a major role in the formation of 5HMFLX, as it is, on average, the most abundant CYP in human liver (mean 93 pmolmg^1 protein) (Achour et al.,. 	CYP3A	25138	25143	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP3A4	959	965	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP3A4	3572	3578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP3A4	4796	4802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP3A4	19870	19876	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:167	For instance,  reported that curcumin and its derivatives inhibit the activity of CYP3A4 and other drug-metabolizing enzymes such as: glutathione-S-transferase and UDP-glucuronosyltransferase. 	CYP3A4	33448	33454	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:168	These authors reported that inhibition by curcumin, alone or in combination with piperine, of CYP3A4 could be harmful, especially during prolonged usage. 	CYP3A4	33653	33659	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:169	in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity in vitro which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. 	CYP3A4	33783	33789	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:169	in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity in vitro which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. 	CYP3A4	33948	33954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:170	Similarly, the-flavonols kaempferol, quercetin, and galangin were reported to inhibit CYP3A4-mediated metabolism of xenobiotics in vitro (;. 	CYP3A4	34151	34157	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:171	Furthermore, inhibitory effects of catechins on CYP3A4 were reported in some studies, although no specific mechanisms of action were reported in these studies. 	CYP3A4	34254	34260	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:4	Fargesin inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with a Ki value of 16.3 M, and it exhibited mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation (Ki, 3.7 M; kinact, 0.102 min1), CYP2C8-catalyzed amodiaquine N-deethylation (Ki, 10.7 M; kinact, 0.082 min1), and CYP3A4-catalyzed midazolam 1-hydroxylation (Ki, 23.0 M; kinact, 0.050 min1) in human liver microsomes. 	CYP3A4	925	931	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP3A4	1444	1450	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:7	These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. 	CYP3A4	1796	1802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP3A4	5031	5037	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP3A4	5241	5247	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A4	5687	5693	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A4	5920	5926	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:19	However, 30 min pre-incubation of human liver microsomes with fargesin and NADPH lowered the IC_50 values of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities by more than 2.5-fold in comparison with the IC_50 values obtained without pre-incubation (34.9 versus 4.0 M for CYP2C8, 30.2 versus 1.6 M for CYP2C19, and >100 versus 17.9 M for CYP3A4), indicating that fargesin causes potent mechanism-based inhibition of CYP2C8, CYP2C19, and CYP3A4 enzymes in human liver microsomes. 	CYP3A4	6019	6025	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:22	Fargesin decreased CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pre-incubation time- and concentration-dependent manners in human liver microsomes. 	CYP3A4	6498	6504	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:23	The apparent K_i and maximal inactivation rate (k_inact) values of fargesin were 10.7 M and 0.082 min^1 for CYP2C8-catalyzed amodiaquine N-deethylation, 3.7 M and 0.102 min^1 for CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and 23.0 M and 0.050 min^1 for CYP3A4-catalyzed midazolam 1-hydroxylation, respectively, in human liver microsomes. 	CYP3A4	6889	6895	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP3A4	7394	7400	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP3A4	7585	7591	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP3A4	7703	7709	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:27	Aschantin, a chemical derivative of fargesin, with a methylenedioxyphenyl moiety also exhibited the reversible and time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 	CYP3A4	7974	7980	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:29	Other methylenedioxyphenyl compounds such as myristicin and podophyllotoxin exhibited mechanism-based inactivation of CYP1A2 and CYP3A4, respectively, in human liver microsomes. 	CYP3A4	8304	8310	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:32	Fargesin showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation, CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation in pooled human liver microsomes. 	CYP3A4	8886	8892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:35	The CYP3A4 inactivation potency (k_inact/K_i ratio) of fargesin (2.17 min^1 nM^1) was comparable with those reported for some phytochemicals identified as mechanism-based inhibitors of CYP3A4 including aschantin (4.92 min^1 nM^1), bergamottin (2 min^1 nM^1), and rutaecarpine (3.59 min^1 nM^1), but much lower than those reported for podophyllotoxin (13.63 min^1 nM^1), phyllanthin (131.88 min^1 nM^1) and hypophyllanthin (83.21 min^1 nM^1) in human liver microsomes. 	CYP3A4	9760	9766	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:35	The CYP3A4 inactivation potency (k_inact/K_i ratio) of fargesin (2.17 min^1 nM^1) was comparable with those reported for some phytochemicals identified as mechanism-based inhibitors of CYP3A4 including aschantin (4.92 min^1 nM^1), bergamottin (2 min^1 nM^1), and rutaecarpine (3.59 min^1 nM^1), but much lower than those reported for podophyllotoxin (13.63 min^1 nM^1), phyllanthin (131.88 min^1 nM^1) and hypophyllanthin (83.21 min^1 nM^1) in human liver microsomes. 	CYP3A4	9941	9947	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:36	The k_inact/K_i ratio of fargesin against CYP3A4 was comparable to those of therapeutic drugs known as mechanism-based CYP3A4 inhibitors such as clarithromycin (1-13 min^1 nM^1), erythromycin (3-9 min^1 nM^1), amiodarone (4.5 min^1 nM^1), and fluoxetine (3.2 min^1 nM^1) in human liver microsomes. 	CYP3A4	10266	10272	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:36	The k_inact/K_i ratio of fargesin against CYP3A4 was comparable to those of therapeutic drugs known as mechanism-based CYP3A4 inhibitors such as clarithromycin (1-13 min^1 nM^1), erythromycin (3-9 min^1 nM^1), amiodarone (4.5 min^1 nM^1), and fluoxetine (3.2 min^1 nM^1) in human liver microsomes. 	CYP3A4	10343	10349	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	CYP3A4	11791	11797	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:64	The mechanism-based inhibition potency of fargesin against human liver microsomal CYP2C8, CYP2C19, and CYP3A4 activities was evaluated. 	CYP3A4	17096	17102	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	CYP3A4	17541	17547	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:74	Fargesin competitively inhibited CYP2C9-catalyzed diclofenac 4-hydroxylation with K_i value of 16.3 M and exhibited the mechanism-based inhibition of CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation, CYP2C8-catalyzed amodiaquine N-deethylation, and CYP3A4-catalyzed midazolam 1-hydroxylation with K_i values of 3.7, 10.7, and 23.0 M, respectively, in human liver microsomes. 	CYP3A4	18411	18417	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP3A4	18798	18804	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:77	These in vitro results suggest that it is necessary to investigate fargesin-induced in vivo drug interaction studies via the inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 activities.	CYP3A4	19182	19188	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:5	The patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.5356.53 in low expressers vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A4	806	812	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:6	The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. 	CYP3A4	1186	1192	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:7	The dose requirement for the therapeutic concentration of clozapine was substantially lower in low CYP3A4 expresser patients than in normal/high expressers (2.180.64 vs 4.981.40 mg/kg, P<.0001). 	CYP3A4	1307	1313	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:8	Furthermore, significantly higher plasma concentration ratios of norclozapine/clozapine and clozapine N-oxide/clozapine were observed in the patients displaying normal/high CYP3A4 expression than in the low expressers. 	CYP3A4	1576	1582	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A4	1660	1666	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:10	Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to substantial differences in clozapine plasma concentrations and in drug response. 	CYP3A4	2041	2047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A4	2504	2510	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A4	2848	2854	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A4	2916	2922	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:25	Various cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demonstrated to be involved in clozapine metabolism; however, the clinical relevance of these enzymes has to be clarified. 	CYP3A4	4939	4945	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:26	CYP3A4 seems to catalyze N-oxidation of clozapine, whereas the formation of norclozapine appears to be more complex. 	CYP3A4	5080	5086	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:27	CYP1A2 and CYP3A4 were assumed to be the major enzymes responsible for the N-demethylation pathway, and several clinical reports provided indirect evidence for their participation in clozapine metabolism. 	CYP3A4	5208	5214	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:28	Concomitant treatment with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, CYP2C19, CYP3A4), significantly decreased the plasma norclozapine/clozapine ratios and patients clozapine dose requirement (;. 	CYP3A4	5497	5503	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:30	In vitro studies have demonstrated that at high clozapine concentrations, CYP3A4 plays a primary role in N-demethylation can modify CYP activities, resulting in transient poor (or extensive) metabolism. 	CYP3A4	5854	5860	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP3A4	6596	6602	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:35	CYP3A4 and CYP1A2 mRNA levels in leukocytes were proven to inform about the hepatic CYP3A4 and CYP1A2 activities. 	CYP3A4	6680	6686	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A4	8342	8348	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A4	8400	8406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A4	8688	8694	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A4	8699	8705	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:52	The quantities of CYP1A2 and CYP3A4 mRNAs relative to that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined. 	CYP3A4	9472	9478	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:55	The cut-off values for CYP mRNA levels in leukocytes have been previously established on the basis of the cut-off values for the hepatic CYP enzyme activities (CYP1A2: phenacetin O-dealkylation; CYP3A4: nifedipine oxidation or midazolam 1- and 4-hydroxylation). 	CYP3A4	10065	10071	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:56	The cut-off values for CYP1A2 (10^-5 and 5*10^-4) and CYP3A4 (10^-6 and 10^-4) allowed a distinction between low, normal, and high expressers. 	CYP3A4	10186	10192	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP3A4	11158	11164	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:64	The dose and patients CYP3A4 expression were identified as significant parameters for clozapine concentration (P<.0001). 	CYP3A4	11763	11769	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:67	Model parameters k_0 and k_1 were estimated for low and normal/high CYP3A4 expressers individually. 	CYP3A4	12293	12299	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:80	The role of CYP3A4 in the metabolism of clozapine at therapeutic or higher concentrations has been demonstrated; however, the contribution of the highly polymorphic CYP3A5 must be clarified. 	CYP3A4	14409	14415	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A4	14824	14830	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A4	14837	14843	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A4	14904	14910	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:82	Of 92 patients, 18 carried CYP3A4*22 or CYP3A4*1B alleles, resulting in reduced or increased expression of CYP3A4, respectively; however, these alleles cannot explain the inter-individual differences in CYP3A4 mRNA levels. 	CYP3A4	15000	15006	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A4	15069	15075	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A4	15133	15139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:83	For the categorization of the patients regarding CYP3A4 expression, more useful information can be obtained from CYP3A4 mRNA levels than from CYP3A4 genotyping. 	CYP3A4	15162	15168	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A4	15181	15187	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A4	15263	15269	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A4	15313	15319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:84	CYP3A4 expression assays revealed that about two-thirds of the patients expressed CYP3A4 at normal level, approximately 30% was low CYP3A4 expressers, and 3 patients displayed high CYP3A4 expression. 	CYP3A4	15362	15368	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:85	One of the high CYP3A4 expressers carried CYP3A5*1, anticipating rapid metabolism of CYP3A substrates. 	CYP3A4	15397	15403	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:86	Strong association was found between the patients CYP3A4 expression and normalized clozapine serum levels. 	CYP3A4	15534	15540	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A4	15696	15702	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A4	15738	15744	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:88	The patients CYP3A5 genotype was significantly associated with clozapine concentrations in those patients who expressed CYP3A4 at low levels (P<.0001). 	CYP3A4	15943	15949	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:90	According to the present results, the patients CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine concentrations, whereas CYP3A4 expression significantly influenced the steady-state levels of clozapine. 	CYP3A4	16248	16254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A4	16441	16447	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:92	Significantly higher (about 2-fold) clozapine concentration was observed in CYP3A5 nonexpresser patients displaying low CYP3A4 expression than in all the others. 	CYP3A4	16604	16610	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:93	However, modelling of the association between CYP3A4 expression and clozapine concentrations identified only 2 groups. 	CYP3A4	16692	16698	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A4	16828	16834	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A4	16902	16908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:96	The models were able to predict the normalized clozapine concentrations with the standard deviations of 15.68 and 6.65 ng/mL for the low CYP3A4 expressers with CYP3A5*3/*3 genotype and the rest of the patients, respectively. 	CYP3A4	17352	17358	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:99	The 2 models for prediction of clozapine concentration in the patients expressing CYP3A4 at low or normal/high levels had comparable prediction quality and were found to be applicable for prediction of optimal dosing. 	CYP3A4	17876	17882	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A4	18319	18325	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A4	18373	18379	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A4	18544	18550	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:103	Underdosing occurred more frequently, primarily in the patients expressing CYP3A4 at a normal/high level or in CYP3A5 expressers. 	CYP3A4	18925	18931	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:104	Moreover, the routine dosing regimen appears to be appropriate for the patients with low CYP3A4 mRNA levels rather than for normal/high expressers. 	CYP3A4	19069	19075	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:105	Seven of the 24 low expresser patients were overdosed, whereas the clozapine therapy of 17 patients (71%) in the low CYP3A4 expresser group resulted in therapeutic concentrations of clozapine. 	CYP3A4	19245	19251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:106	The mathematical model displayed clozapine dosing to be optimal for 40 patients in the normal/high CYP3A4 expresser and CYP3A5 expresser groups (n=68), whereas 41% were underdosed. 	CYP3A4	19420	19426	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:108	The low CYP3A4 expresser patients required a significantly lower (50%) dose of clozapine for the optimal serum level than normal/high CYP3A4 expressers (2.180.64 mg/kg vs 4.981.40 mg/kg; P<.0001). 	CYP3A4	19788	19794	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:108	The low CYP3A4 expresser patients required a significantly lower (50%) dose of clozapine for the optimal serum level than normal/high CYP3A4 expressers (2.180.64 mg/kg vs 4.981.40 mg/kg; P<.0001). 	CYP3A4	19914	19920	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:109	Several CYPs are assumed to be responsible for the formation of norclozapine, while CYP3A4 is likely to catalyze the clozapine N-oxidation. 	CYP3A4	20061	20067	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:110	The formation of both principal metabolites widely varied in individuals; however, the serum concentrations of clozapine metabolites appeared to be associated merely with the patients CYP3A4 expression and not with CYP1A2 mRNA levels. 	CYP3A4	20301	20307	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:111	Strong association was observed between the metabolite/clozapine ratios and CYP3A4 mRNA levels. 	CYP3A4	20428	20434	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A4	20475	20481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A4	20566	20572	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:113	Furthermore, significantly lower clozapine N-oxide/clozapine ratios were observed in the patients displaying low CYP3A4 expression than in CYP3A4 normal/high expressers (0.22790.0887 vs 0.56590.1960, P<.0001). 	CYP3A4	20778	20784	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:113	Furthermore, significantly lower clozapine N-oxide/clozapine ratios were observed in the patients displaying low CYP3A4 expression than in CYP3A4 normal/high expressers (0.22790.0887 vs 0.56590.1960, P<.0001). 	CYP3A4	20804	20810	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:120	In vitro studies using cDNA-expressed CYP enzymes have demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, and CYP2D6 to clozapine metabolism; however, hepatic microsomal metabolism hardly supported a significant role of CYP2C19 and CYP2D6 (;. 	CYP3A4	22357	22363	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:130	It should be noted that fluvoxamine is not a CYP1A2-selective inhibitor, but significantly blocks the activities of other CYPs, notably it irreversibly inhibits CYP3A4 by forming a metabolic intermediate complex. 	CYP3A4	24436	24442	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:132	The relative importance of CYP3A4 in clozapine clearance, particularly in patients with low CYP1A2 activity, may be higher than it has been previously considered (;.  	CYP3A4	24731	24737	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A4	25115	25121	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A4	25199	25205	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A4	25268	25274	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:134	The following indirect evidences can predict the potential role of CYP3A4: (1) clozapine N-demethylation to norclozapine significantly correlated with CYP3A4-selective midazolam clearance; (2) concomitant treatment with CYP3A4 inducers, such as carbamazepine, rifampicin, or phenytoin, was observed to substantially reduce clozapine concentrations; and (3) initiation of the CYP3A4 inhibitor erythromycin therapy increased clozapine levels and evoked toxic symptoms. 	CYP3A4	25423	25429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP3A4	25579	25585	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:135	Furthermore,  provided support for the functional roles of both CYP3A4 and CYP1A2 in clozapine clearance, and suggested that the relative activities of CYP3A4 and CYP1A2 in patients might determine the clearance pathways. 	CYP3A4	25667	25673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A4	26093	26099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A4	26147	26153	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:138	Therefore, the relative CYP activities predicted the potential role of CYP3A4/5 in clozapine clearance, which was confirmed by the 2-fold higher normalized clozapine concentrations and by the halved dose-requirement in low CYP3A4 expressers. 	CYP3A4	26328	26334	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:138	Therefore, the relative CYP activities predicted the potential role of CYP3A4/5 in clozapine clearance, which was confirmed by the 2-fold higher normalized clozapine concentrations and by the halved dose-requirement in low CYP3A4 expressers. 	CYP3A4	26480	26486	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:143	Valproate has been proved to transcriptionally induce CYP3A4 expression; consequently, the patients CYP3A4 mRNA levels captured the influence of valproate treatment. 	CYP3A4	27268	27274	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:143	Valproate has been proved to transcriptionally induce CYP3A4 expression; consequently, the patients CYP3A4 mRNA levels captured the influence of valproate treatment. 	CYP3A4	27314	27320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:148	Additionally, the normal/high CYP3A4 activity was associated with increased metabolite formation, that is, the concentrations of norclozapine and clozapine N-oxide were close to or even exceeded clozapine concentrations. 	CYP3A4	28068	28074	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A4	29628	29634	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A4	29681	29687	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:156	Tailored medication controlled by patients CYP3A4 expression and CYP3A5 genotype may facilitate the improvement of the individual clozapine therapy, leading to the dosage optimization for a more effective therapy. 	CYP3A4	29743	29749	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:3	In this study, we present the design and evaluation of bio-compatible nanocarriers trapping a natural CYP3A4-inhibiting compound. 	CYP3A4	290	296	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	CYP3A4	374	380	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	CYP3A4	4210	4216	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	CYP3A4	14314	14320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	CYP3A4	35625	35631	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:251	Furanocoumarins inhibit several CYP450 (CYP3A4, CYP1A2, CYP1B1, CYP2C9, CYP2C19 and CYP2D6),, but other CYP450 are involved in common drug metabolism. 	CYP3A4	38302	38308	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP3A4	15781	15787	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5570141_OgerInput.txtOger_out.csv:107	This search provided further details on other sildenafil-related compounds: primary metabolite (N-desmethylsildenafil), drug-drug interactions with CYP3A4 inhibitors (eg ketoconazole, itraconazole, ritonavir and indinavir) and other PDE5 inhibitors (vardenafil). 	CYP3A4	16986	16992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:12	The main Gr-drug interaction mechanism is inactivation of the enzyme CYP3A4 by furanocoumarins. 	CYP3A4	1432	1438	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:13	CYP3A4 enzyme participates in the inactivation of various drugs; it is located in the intestinal epithelium and the liver. 	CYP3A4	1459	1465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP3A4	2047	2053	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:18	Apart from CYP3A4, constituents of Gr, for example, furanocoumarins or bergamottin, can inhibit other cytochrome P450 isoenzymes (CYP3A4, CYP2C9, and CYP2D6) and transporters in the intestine such as P-glycoproteins. 	CYP3A4	2166	2172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:22	The interacting drugs are generally characterized by the oral intake, low to intermediate bioavailability, and inactivation by the CYP3A4 enzyme. 	CYP3A4	2903	2909	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:23	Patients with higher levels of CYP3A4 determined in intestinal biopsies may require higher doses of corresponding drugs, the size of the Gr effect being generally higher in such patients. 	CYP3A4	2949	2955	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5580961_OgerInput.txtOger_out.csv:45	Artemether is an effective medication against malaria; however, relapses may occur presumably as a result of the drug metabolism by CYP3A4. 	CYP3A4	6109	6115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:207	Independent of the effect of any antiparasitic potential of compounds, they were evaluated using a panel of early-toxicity assays comprising cytotoxicity (A549, human lung adenocarcinoma epithelial cell line and WI-38, human lung fibroblasts), mitochondrial toxicity (786-O, human renal carcinoma cell line), hERG inhibition,^ cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4),^ and Aurora B kinase inhibition. 	CYP3A4	35879	35885	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:2	Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. 	CYP3A4	269	275	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	CYP3A4	470	476	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:6	Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. 	CYP3A4	980	986	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:8	Human CYP3A4 in Supersomes generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. 	CYP3A4	1247	1253	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:9	Using the 32P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. 	CYP3A4	1468	1474	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:11	In the presence of NADPH or NADH, cytochrome b 5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. 	CYP3A4	1711	1717	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A4	1979	1985	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A4	2050	2056	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	CYP3A4	2331	2337	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:17	Of the CYP enzymes investigated, human CYP3A4 is the most active enzyme oxidizing ellipticine to 12-hydroxy- and 13-hydroxyellipticine, reactive metabolites that dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind to DNA (see Fig ) [,. 	CYP3A4	2987	2993	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:18	The CYP3A4 isoform also forms other ellipticine metabolites, including 9-hydroxyellipticine, which is a detoxification product, as well as 7-hydroxyellipticine and ellipticine N ^2-oxide as minor metabolites [,. 	CYP3A4	3205	3211	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:19	CYP enzymes, including CYP3A4, are components of the monooxygenase system located in the membrane of the endoplasmic reticulum (microsomes). 	CYP3A4	3436	3442	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:24	Cytochrome b _5 has been reported to stimulate the oxidation of a variety of CYP3A4 substrates, including ellipticine. 	CYP3A4	4478	4484	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:25	Interestingly, in the case of ellipticine, cytochrome b _5, when reconstituted with CYP3A4 and POR, alters the ratio of ellipticine metabolites formed by this CYP. 	CYP3A4	4604	4610	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:28	Hence, cytochrome b _5 seems to play a key role in the CYP3A4-mediated DNA-damage caused by these ellipticine metabolites [,. 	CYP3A4	5199	5205	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	CYP3A4	5270	5276	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A4	5573	5579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A4	5612	5618	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:31	They also showed that this heme protein with NADH:cytochrome b _5 reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. 	CYP3A4	5806	5812	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:33	This NADH-dependent system can, therefore, function as a sole electron donor for both reduction steps in the reaction cycles of CYP1A1 and CYP3A4 [,. 	CYP3A4	6223	6229	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	CYP3A4	6381	6387	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	CYP3A4	6524	6530	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	CYP3A4	7260	7266	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	CYP3A4	7467	7473	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:43	Here, we show that three of these metabolites are also formed in human hepatic microsomes in the presence of NADH instead of NADPH were found when NADPH or NADH was omitted from the incubation mixtures containing human hepatic microsomes and (iii)] for our experiments, we first tested whether they are functionally active by testing the CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	CYP3A4	8519	8525	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A4	8617	8623	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A4	8822	8828	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A4	8857	8863	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	CYP3A4	8919	8925	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	CYP3A4	9400	9406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	CYP3A4	9484	9490	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	CYP3A4	9639	9645	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	CYP3A4	9804	9810	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	CYP3A4	10356	10362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	CYP3A4	10593	10599	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	CYP3A4	10803	10809	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:55	This finding demonstrated that cytochrome b _5 influences the CYP3A4 catalytic activity in at least two ways. 	CYP3A4	11223	11229	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:56	First, this heme protein can mediate CYP3A4 enzyme activity even in the absence of the NADPH/POR system, by donating both the first and second electron from NADH to CY3A4 in the catalytic cycle. 	CYP3A4	11308	11314	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	CYP3A4	11720	11726	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:58	Second, cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, resulting in changes in profile of ellipticine metabolite formation. 	CYP3A4	11863	11869	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:59	In further experiments, DNA adduct formation was analyzed in incubations with ellipticine and human hepatic microsomes or human CYP3A4 in Supersomes in the presence of DNA. 	CYP3A4	12076	12082	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:60	Two DNA adducts were detected by the ^32P-postlabeling method derived from ellipticine activated with human hepatic microsomes or CYP3A4-Supersomes, both in the presence of NADPH and NADH was previously shown to be generated by the reaction of guanine in DNA with ellipticine-13-ylium which is formed by the decomposition of 13-hydroxyellipticine was previously shown to be generated by reaction of guanine in DNA with ellipticine-12-ylium formed from 12-hydroxyellipticine and tumor tissues in vivo. 	CYP3A4	12251	12257	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:61	The levels of ellipticine-derived adduct 1 (formed predominantly by CYP3A4) generated in human microsomes were 2.8-fold lower with NADH than with NADPH as the cofactor, which is in agreement with a 2.6-fold lower efficiency of ellipticine oxidation to 13-hydroxyellipticine by human microsomes in the presence of NADH, indicating that adduct 2 might be also formed by autooxidation as reported previously [,. 	CYP3A4	12690	12696	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:62	With human recombinant CYP3A4 expressed in Supersomes the adducts formed were the same as those generated by human hepatic microsomes, both in the presence of NADPH and NADH. 	CYP3A4	13054	13060	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:64	When NADPH or NADH was omitted from the incubation mixtures containing CYP3A4-Supersomes, only low amounts of adduct spot 2 were detected (Fig. 	CYP3A4	13342	13348	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	CYP3A4	13484	13490	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	CYP3A4	13594	13600	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:66	The present study was aimed to advance our knowledge regarding the role of cytochrome b _5 in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. 	CYP3A4	13826	13832	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	CYP3A4	14033	14039	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	CYP3A4	14535	14541	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	CYP3A4	14782	14788	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:75	Here, we showed that if NADPH is substituted by NADH, ellipticine oxidation is catalyzed by experimental CYP3A4 enzymatic systems. 	CYP3A4	15603	15609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:76	Such NADH-mediated activity of the employed CYP3A4 systems was proven by the formation of oxidized ellipticine metabolites as well as by the generation of ellipticine-derived DNA adducts, which were the same as in the system where NADPH was used as electron donor. 	CYP3A4	15673	15679	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	CYP3A4	16023	16029	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:78	Specifically, as shown here, (i) it acts as a sole electron donor to CYP3A4 during its reaction cycle and (ii) it can also act as an allosteric modifier of CYP3A4 oxygenase. 	CYP3A4	16134	16140	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:78	Specifically, as shown here, (i) it acts as a sole electron donor to CYP3A4 during its reaction cycle and (ii) it can also act as an allosteric modifier of CYP3A4 oxygenase. 	CYP3A4	16221	16227	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	CYP3A4	16422	16428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:83	CYP3A4-Supersomes, microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4 and POR that are, therefore, over-expressed in these microsomes, were purchased from the Gentest Corp. 	CYP3A4	16842	16848	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:83	CYP3A4-Supersomes, microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4 and POR that are, therefore, over-expressed in these microsomes, were purchased from the Gentest Corp. 	CYP3A4	16965	16971	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	CYP3A4	17401	17407	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	CYP3A4	17492	17498	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	CYP3A4	18016	18022	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	CYP3A4	19382	19388	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:100	Negative control reactions lacked either CYP3A4-Supersomes systems, cofactors or testosterone. 	CYP3A4	19632	19638	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	CYP3A4	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:110	Control incubations were carried out either without human hepatic microsomes or CYP3A4 in Supersomes without NADPH (or NADH), without DNA, or without ellipticine. 	CYP3A4	21140	21146	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	CYP3A4	488	494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	CYP3A4	5849	5855	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP3A4	6797	6803	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:43	Similarly, the HS4-CAG-CYP2D6 plasmid was digested with NheI/AscI and ligated with the HS4-CAG-CYP3A4, which was digested with AscI/AvrII, for the construction of HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmid. 	CYP3A4	6873	6879	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:44	Then, the HS4-CAG-CYP2C19-HS4-CAG-CYP2C9 and the HS4-CAG-CYP3A4-HS4-CAG-CYP2D6 plasmids were digested with AscI/AvrII and ligated in sequence to the HS4-HPRT-loxP-PAC vector, which was digested with NheI/AscI, for the construction of the P1-Derived Artificial Chromosome vector containing all four CYPs. 	CYP3A4	6961	6967	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:93	Analysis by RT-qPCR confirmed the expression of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR, and representative three clones were selected. 	CYP3A4	13156	13162	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:101	Genomic PCR determined that all of these clones expressed CYP2C9, CYP2C19, CYP2D6, CYP3A4, and POR genes. 	CYP3A4	14134	14140	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:113	Assessment of the inhibitory effect of clarithromycin on CYP3A4 in three TC-HepG2 cells indicated that there was a concentration-dependent inhibitory effect on metabolic activity. 	CYP3A4	15859	15865	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:129	The inhibitors used in these experiments included CYP3A4 inhibitors ethinylestradiol, ritonavir, mifepristone, erythromycin, clarithromycin, and roxithromycin; CYP2C9 inhibitor tienilic acid; CYP2C19 inhibitor ticlopidine; and CYP2D6 inhibitor paroxetine. 	CYP3A4	18198	18204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:134	Specifically, increasing concentrations of the inhibitors (0, 5, 10, 20, 40, or 100 M) were added 10, 20, or 30 min prior to the addition of the luminescent CYP3A4 substrate, and the luminescence levels in culture media were used to determine metabolite levels.  	CYP3A4	19340	19346	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:139	Further, because the CYP3A4 activity level in TC-HepG2 cells was higher than that in human hepatocytes, the rate of metabolic reduction by the inhibitors may be detected with high sensitivity.  	CYP3A4	20004	20010	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:147	Both aflatoxin B1 and sterigmatocystin convert to active metabolites via CYP3A4 and exert hepatotoxicity through DNA damage [,. 	CYP3A4	21141	21147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:185	The aflatoxin B1 forms DNA adduct as a result of metabolic activation induced mainly by CYP3A4. 	CYP3A4	27026	27032	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP3A4	3368	3374	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:28	A previously published study from our group found an in vitro inhibition of CYP3A4 enzyme activity by extracts of six R. rosea clones, with IC_50 values (extract concentration yielding 50% reduction in enzyme activity) ranging from 1.7 to 3.1 g/mL (Hellum et al.. We have also evaluated the in vitro inhibition potential of several commercial R. rosea products on CYP1A2, CYP2D6, and CYP3A4 activities, which produced IC_50 values ranging from 7.2 to 186 g/mL (Thu et al.. The in vivo interaction potential of R. rosea has also been studied by some groups. 	CYP3A4	3676	3682	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:33	Recently, our group published a study evaluating CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 interaction in man by a commercially available R. rosea product similar to that used by Spanakis et al. 	CYP3A4	4563	4569	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	CYP3A4	5672	5678	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP3A4	17012	17018	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:129	In a previous investigation of the inhibition of six commercial R. rosea products including Arctic Root on CYP1A2, CYP2D6, and CYP3A4, IC_50 values of 19.5  5, 30.1  3.6, and 11.6  1.1 g/mL, respectively, were found (Thu et al.. This places the in vitro CYP2C9 inhibition potential in line with our previous study. 	CYP3A4	17478	17484	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:130	However, CYP2C9 was the only affected enzyme in an in vivo experiment investigating interactions with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in man using Arctic Root as test compound (Thu et al.. One would perhaps expect a more potent in vitro CYP2C9 inhibition based on the in vivo results, but the present result illustrates the challenges of predicting possible in vivo interactions by interpretation of in vitro inhibitory data. 	CYP3A4	17805	17811	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:131	Similar findings have been demonstrated for milk thistle, where in vitro CYP3A4 inhibition by its constituents silymarin and silibinin produced IC_50 values ranging from 27 to 60 mol/L. 	CYP3A4	18177	18183	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:153	examined whether the concentration of the supposed bioactive constituents could be correlated with CYP3A4 enzyme inhibition, but with no significant findings. 	CYP3A4	21529	21535	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:154	Moreover, no correlation between the supposed bioactive constituents and in vitro CYP1A2, CYP2D6, and CYP3A4 enzyme activities was found in a previous publication from our group (Thu et al.. However, a moderate noncompetitive in vitro CYP2D6 inhibition by the relatively unknown R. rosea constituents rhodiosin and rhodionin has recently been published with IC_50 values of 0.47 and 0.19 g/mL, respectively (Xu et al.. For better prediction of the potential in vivo inhibition of commercial R. rosea products, the specific constituents responsible for the inhibition must be identified. 	CYP3A4	21691	21697	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP3A4	16365	16371	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP3A4	16633	16639	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP3A4	17115	17121	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:91	The biggest individual variations in predicted CL_int took place in the CYP3A4/5, reaching to 4.1-fold, followed by that of CYP2D6, CYP2C8, CYP2E1, and CYP2A6, demonstrating the fold-change of 3.1, 2.9, 2.6, and 1.6 respectively. 	CYP3A4	17484	17490	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:141	For example, different probe substrates could result in different observations in CYP3A4 activities due to different substrate binding sites. 	CYP3A4	26846	26852	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:1	 2,3,4,5-tetrahydroxystilbene-2-O-BETA-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. 	CYP3A4	142	148	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:8	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased the expression of CYP2E1, CYP3A4 and CYP1A2 both in mice and in human normal liver L-02 hepatocytes. 	CYP3A4	1166	1172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:9	2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced liver catalytic activity of CYP2E1, CYP3A4 and CYP1A2 in mice. 	CYP3A4	1341	1347	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:11	In summary, our results demonstrate that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside enhances hepatic expression of CYP3A4, CYP2E1 and CYP1A2, and thus exacerbates the hepatotoxicity induced by APAP in mice. 	CYP3A4	1777	1783	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	CYP3A4	4646	4652	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:43	In this study, the aggravation of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on APAP-induced liver injury by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2 was investigated. 	CYP3A4	5791	5797	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A4	8400	8406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A4	9350	9356	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A4	9571	9577	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A4	9968	9974	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:54	TSG (400, 800 mg/kg) enhanced liver CYP2E1 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP2E1 catalytic activity after treated mice for 8 h and 12 h enhanced liver CYP3A4 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP3A4 catalytic activity after treated mice for 4 h, 8 h and 12 h enhanced liver CYP1A2 catalytic activity when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased liver CYP1A2 catalytic activity after treated mice for 4 h, 8 h and 12 h (Fig. 	CYP3A4	10187	10193	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:56	AHR and Pregnane X Receptor are reported to regulate the expression of CYP1A2 and CYP3A4^. 	CYP3A4	10888	10894	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	CYP3A4	16748	16754	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A4	17243	17249	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:91	In this study, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic expression of CYP2E1, CYP1A2 and CYP3A4, and also elevated liver catalytic activity of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A4	17316	17322	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:92	Moreover, when mice were treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 5 consecutive days, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside also enhanced hepatic expression of CYP2E1, CYP1A2 and CYP3A4. 	CYP3A4	17541	17547	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:93	All these results indicate that TSG-induced the increased expression and catalytic activity of CYP1A2, CYP2E1 and CYP3A4 may contribute to its augmentation on APAP-induced hepatotoxicity via elevating its metabolic activation in liver. 	CYP3A4	17663	17669	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:94	Aryl Hydrocarbon Receptor and Pregnane X Receptor are found to be responsible for regulating the transcriptional expression of CYP1A2 and CYP3A4^,. 	CYP3A4	17923	17929	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:95	In this study, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside promoted the nuclear translocation of Aryl Hydrocarbon Receptor and Pregnane X Receptor both in vivo and in vitro, which may contribute to the increased expression of CYP1A2 and CYP3A4 induced by 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside. 	CYP3A4	18176	18182	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:97	Additionally, Aryl Hydrocarbon Receptor or Pregnane X Receptor inhibitors reduced the expression and activity of hepatic CYP1A2 and CYP3A4 in mice. 	CYP3A4	18580	18586	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:100	Next, this study showed that 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside augmented APAP-induced liver injury by increasing the expression and catalytic activation of liver CYP3A4, CYP1A2 and CYP2E1. 	CYP3A4	19097	19103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:112	Kits for detecting CYP1A2, CYP2E1 and CYP3A4 catalytic activity were purchased from Shanghai GENMED gene Pharmaceutical Technology Co. 	CYP3A4	20013	20019	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:119	Antibodies including anti-CYP1A2, -CYP2E1, -CYP3A4, -AHR and -PXR were all purchased from Beijing biosynthesis biotechnology CO., LTD (Beijing, China) (all 1:1000 dilution). 	CYP3A4	20569	20575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:147	For analyzing the effects of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside on the expression and activity of CYP1A2, CYP2E1 and CYP3A4, two batches of mice experiments were implemented. 	CYP3A4	24397	24403	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP3A4	28846	28852	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:184	CYP1A2, CYP2E1 and CYP3A4 catalytic activity were detected by using GENMED CYP1A2, CYP2E1 and CYP3A4 Kits. 	CYP3A4	28921	28927	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:191	The activity of 7-benzyloxy-4trifluoromethylcoumarin dealkylation is the diagnostic marker of CYP3A4. 	CYP3A4	29820	29826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:192	The activity of CYP3A4 was determined by fluorescence value of 7-Hydroxy-4-Trifluoromethylcoumarin conversed from 7-benzyloxy-4-trifluoromethyl-coumarin by 7-Benzyloxy-4trifluoromethylcoumarin Dealkylation. 	CYP3A4	29844	29850	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:193	The activity of CYP1A2, CYP2E1 and CYP3A4 were measured with kits according to the manufacturers instructions. 	CYP3A4	30070	30076	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:1	 Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. 	CYP3A4	26	32	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:4	So far, there are few reports about the functional characterization of CYP3A4 variants in terms of specific substrates. 	CYP3A4	341	347	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:5	The aim of this study was to systematically investigate the genetic polymorphisms of 23 CYP3A4 alleles and evaluate their catalytic activities on the metabolism of lidocaine in vitro. 	CYP3A4	478	484	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:6	The wild-type and 22 CYP3A4 variants were expressed in Spodoptera frugiperda 21 insect cells. 	CYP3A4	595	601	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:7	Then the insect microsomes were incubated with the CYP3A4-specific substrate lidocaine. 	CYP3A4	719	725	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	970	976	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1014	1020	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1028	1034	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1090	1096	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1100	1106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1110	1116	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1120	1126	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1134	1140	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:10	Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1. 	CYP3A4	1227	1233	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:11	As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. 	CYP3A4	1269	1275	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:11	As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. 	CYP3A4	1429	1435	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	CYP3A4	2511	2517	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	CYP3A4	2642	2648	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A4	2802	2808	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A4	3122	3128	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:19	It is well known that CYP3A4 enzyme plays a major role in the oxidative metabolism of ~30%-40% of clinically used drugs, such as certain antibiotics (erythromycin), antiarrhythmics (quinidine), antidepressants (sertraline), Cardiovascular drugs (verapamil) as well as some endogenous steroids (testosterone and estradiol)., The expression of CYP3A4 varies 40-fold in individual human livers, which indicates that CYP3A4 is one of the highly polymorphic enzymes. 	CYP3A4	3193	3199	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:20	Recently, increasing evidence has shown that genetic polymorphisms of CYP3A4 significantly contribute to the wide inter-individual variability of enzyme activity. 	CYP3A4	3312	3318	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:21	The enormous variation observed in drug metabolism may result in undesirable adverse side effects or therapeutic failure, thus more attention should be paid to genetic polymorphism of CYP3A4. 	CYP3A4	3589	3595	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:22	To date, 46 different types of CYP3A4 allelic variants have been identified in the Human CYP Allele Nomenclature Committee website (http://www.cypalleles.ki.se/cyp3a4.htm). 	CYP3A4	3628	3634	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:23	In our previous study, Hu et al sequenced the promoter regions and 13 exon junctions of CYP3A4 in DNA from 1,114 healthy subjects from the southern region of China. 	CYP3A4	3858	3864	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:24	Five previously reported alleles (CYP3A4*1G, *4, *5, *18B and *23) were detected. 	CYP3A4	3969	3975	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:25	In addition, a total of 7 novel exonic variants were also detected and further named as new alleles CYP3A4*28-*34 by the Human CYP Allele Nomenclature Committee. 	CYP3A4	4117	4123	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A4	4210	4216	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A4	4294	4300	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:26	In this study, lidocaine, as a CYP3A4-specific substrate, was used to assess the catalytic activities of wild-type CYP3A4*1 and 22 CYP3A4 alleles found in the Chinese Han population (15 alleles were previously reported, and 7 novel alleles with coding regions were newly found). 	CYP3A4	4310	4316	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:37	The open reading frame (ORF) fragments for each CYP3A4 variants were constructed by the overlap extension polymerase chain reaction (PCR) amplification method using the primers that are listed in, and then isolated ORF fragments by PCR amplification using the forward primer 3A4-SALF (5-ACCAGTCGACATGG CTCTCATCCCAGAC-3, introducing 1 Sal site) and the reverse primer 3A4-SR (5-CCAAACTAGTTCAGGCT CCACTTACGGT-3, introducing 1 Spe site). 	CYP3A4	5937	5943	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:38	These full-length PCR products for each of the CYP3A4 variants were digested and ligated to the pFastBac-OR receptor vector to produce the ultimate dual-expression vector pFastBac-OR-CYP3A4. 	CYP3A4	6371	6377	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:38	These full-length PCR products for each of the CYP3A4 variants were digested and ligated to the pFastBac-OR receptor vector to produce the ultimate dual-expression vector pFastBac-OR-CYP3A4. 	CYP3A4	6507	6513	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:49	CYP3A4 expression levels were determined by measured difference spectra. 	CYP3A4	8280	8286	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	CYP3A4	8402	8408	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	CYP3A4	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:51	The addition of b5 was to deliver electrons and support CYP3A4 enzymatic activities. 	CYP3A4	8585	8591	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A4	11874	11880	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A4	11927	11933	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:75	To obtain comprehensive data on the enzymatic properties for catalysis of MEGX by all reported CYP3A4 variants in Chinese population, the wild-type CYP3A4*1 and 22 allelic variants of CYP3A4 were assessed in our study. 	CYP3A4	11963	11969	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:76	The ratio of V_max/K_m represents the intrinsic clearance (C_Lint), which can evaluate the enzymatic activity of each CYP3A4 allelic variant as an evaluation criteria. 	CYP3A4	12116	12122	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:77	Michaelis-Menten plots of lidocaine for the tested 23 CYP3A4 enzymes are shown in, and the corresponding kinetic parameters are summarized in. 	CYP3A4	12220	12226	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A4	12378	12384	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A4	12392	12398	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A4	12489	12495	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:78	For the Michaelis-Menten kinetic analysis, the kinetic parameters of CYP3A4*17 and CYP3A4*30 could not be determined as no concentration of MEGX was detected, which indicated that CYP3A4*17 and CYP3A4*30 showed extremely low activity or no activity. 	CYP3A4	12503	12509	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12570	12576	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12584	12590	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12701	12707	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12727	12733	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12737	12743	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12747	12753	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12762	12768	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12821	12827	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12831	12837	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12841	12847	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12852	12858	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12863	12869	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:79	Except for CYP3A4*17 and CYP3A4*30, almost all allelic variants in  showed significant alteration in V_max values compared with the wild-type CYP3A4*1: Only 4 variants CYP3A4*4, CYP3A4*9, CYP3A4*29, and CYP3A4*31 exhibited no statistical difference; 6 variants (CYP3A4*2, CYP3A4*5, CYP3A4*16, CYP3A4*24, CYP3A4*28, and CYP3A4*33) showed mild decrease; and the remaining 10 variants displayed significantly increased V_max values. 	CYP3A4	12878	12884	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13064	13070	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13074	13080	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13084	13090	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13094	13100	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13104	13110	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13119	13125	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13196	13202	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13221	13227	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13232	13238	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13243	13249	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13254	13260	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13265	13271	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13276	13282	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:80	Meanwhile, most variants showed obvious changes on K_m values: 6 variants (CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*9, CYP3A4*16, and CYP3A4*34) exhibited increased K_m values with ~1.13-2.34-fold compared with CYP3A4*1 and 7 variants (CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, and CYP3A4*33) decreased to 15.01%-69.57%. 	CYP3A4	13291	13297	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A4	13432	13438	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A4	13500	13506	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A4	13671	13677	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:81	As a result, according to intrinsic clearance (V_max/K_m) values of MEGX compared with the wild type, CYP3A4 alleles could be classified into 3 categories: ten variants (CYP3A4*11, *14, *15, *18, *19, *23, *29, *31, *32, and *34) exhibited significantly increased intrinsic clearance values (123.27%-213.61% relative clearance); 5 variants (CYP3A4*2, *5, *9, *16, and *24) showed lower intrinsic clearance values than CYP3A4*1 (27.93%-67.93% relative clearance). 	CYP3A4	13748	13754	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:82	Another 5 variants (CYP3A4*3, *4, *10, *28, and *33) were without statistical significance. 	CYP3A4	13813	13819	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:83	In addition, to investigate the enzymatic abilities of 23 CYP3A4 variants between different substrate, lidocaine and 1 typical probing substrate for the CYP3A4 enzyme were used in the in vitro functional analysis. 	CYP3A4	13943	13949	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:83	In addition, to investigate the enzymatic abilities of 23 CYP3A4 variants between different substrate, lidocaine and 1 typical probing substrate for the CYP3A4 enzyme were used in the in vitro functional analysis. 	CYP3A4	14038	14044	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:84	As shown in,  variants, CYP3A4*17 and CYP3A4*30, exhibited extremely low enzymatic activity or null function for both substrates. 	CYP3A4	14123	14129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:84	As shown in,  variants, CYP3A4*17 and CYP3A4*30, exhibited extremely low enzymatic activity or null function for both substrates. 	CYP3A4	14137	14143	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14245	14251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14255	14261	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14265	14271	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14276	14282	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14287	14293	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14298	14304	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14309	14315	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14320	14326	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14335	14341	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:85	And 9 variants (CYP3A4*4, CYP3A4*5, CYP3A4*11, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*24, CYP3A4*30, and CYP3A4*31) showed similar changed trend of enzymatic activities compared with CYP3A4*1 toward lidocaine and testosterone. 	CYP3A4	14413	14419	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14480	14486	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14508	14514	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14518	14524	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14529	14535	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14540	14546	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14551	14557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:86	Whereas, the remaining CYP3A4 variants, especially CYP3A4*2, CYP3A4*14, CYP3A4*23, CYP3A4*29, CYP3A4*32, and CYP3A4*34, displayed obvious different relative clearance between 2 substrates. 	CYP3A4	14566	14572	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:87	CYP3A4 exhibits remarkable individual variation in expression levels, which may be caused by genetic, environmental, pathological, hormonal, and dietary factors. 	CYP3A4	14646	14652	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:88	Increasing evidence suggests that genetic polymorphism is a primary source of inter-individual difference in drug metabolism., Genetic polymorphism of CYP3A4 can greatly influence the rate of elimination of lidocaine, thereby may result in adverse effects or therapeutic failures. 	CYP3A4	14959	14965	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:90	Therefore, it is of great significance to functionally characterize the enzymatic activity of CYP3A4 variants in the metabolism of lidocaine in vitro. 	CYP3A4	15330	15336	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A4	15423	15429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A4	15506	15512	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A4	15522	15528	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A4	15593	15599	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:91	To better understand the effects of CYP3A4 variants on the metabolism of lidocaine in vitro, we analyzed the wild-type CYP3A4*1 and 22 CYP3A4 variants found in Chinese Han population in detail, of which 7 (CYP3A4*28-*34) were new alleles and another 15 alleles (CYP3A4*2, *3, *4, *5, *9, *10, *11, *14, *15, *16, *17, *18, *19, *23, and *24) had previously been reported. 	CYP3A4	15649	15655	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:92	The enzymatic activity of CYP3A4*1 was used as a control group. 	CYP3A4	15785	15791	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:93	As a novel allelic variant, the CYP3A4*30 (R130STOP), which contains the premature stop codon, produces a nonfunctional protein with a shorter peptide. 	CYP3A4	15855	15861	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:94	As a consequence, the kinetic parameters of CYP3A4*30 could not be detected and it showed no catalytic activity on lidocaine metabolism. 	CYP3A4	16019	16025	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:95	Similar to CYP3A4*30, CYP3A4*17 exhibited extremely low enzymatic activity toward lidocaine. 	CYP3A4	16123	16129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:95	Similar to CYP3A4*30, CYP3A4*17 exhibited extremely low enzymatic activity toward lidocaine. 	CYP3A4	16134	16140	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16236	16242	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16426	16432	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16440	16446	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16473	16479	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16565	16571	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:96	According to previous reports, CYP3A4*17 produced an amino acid substitution: F189S in exon 7, and it exhibited decreased catalytic activity compared with the wild type for both testosterone and chlorpyrifos., Aside from CYP3A4*17 and CYP3A4*30, we found that most of CYP3A4 variants exhibited higher enzymatic activity than wild type, whereas only 5 alleles (CYP3A4*2, *5, *9, *16, and *24) showed a significantly decreased relative clearance compared with CYP3A4*1 (27.93%-67.93%). 	CYP3A4	16663	16669	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:98	Therefore, patients carrying the CYP3A4*2, *5, *9, *16, *17, *24, or *30 should pay more attention to the dose of lidocaine, in order to avoid lidocaine-induced toxicity or delayed emergence from anesthesia. 	CYP3A4	16825	16831	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:99	Four (CYP3A4*29, *31, *32, and *34) of novel alleles exhibited significantly increased intrinsic clearance value for lidocaine from 141.84% to 197.87% of wild-type CYP3A4*1. 	CYP3A4	17006	17012	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:99	Four (CYP3A4*29, *31, *32, and *34) of novel alleles exhibited significantly increased intrinsic clearance value for lidocaine from 141.84% to 197.87% of wild-type CYP3A4*1. 	CYP3A4	17164	17170	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:100	CYP3A4*28 showed both lower V_max and K_m values so that the intrinsic clearance showed no significant difference to that of the CYP3A4*1. 	CYP3A4	17174	17180	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:100	CYP3A4*28 showed both lower V_max and K_m values so that the intrinsic clearance showed no significant difference to that of the CYP3A4*1. 	CYP3A4	17303	17309	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A4	17333	17339	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A4	17351	17357	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:101	Hu et al found that CYP3A4*28 (L22V), CYP3A4*31 (H324Q) and CYP3A4*32 (I335T) can damage protein function. 	CYP3A4	17373	17379	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:102	However, as for our result that these alleles exhibited higher catalytic activity than wild type in our study, it may be interpreted that His324 and Ile335 are not involved in the active site for drug-substrate binding according to previously reported crystal structures of the CYP3A4 enzyme. 	CYP3A4	17698	17704	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:103	CYP3A4*18, contains a nucleotide substitution of T>C at position 878 of the cDNA of CYP3A4 and results in an amino acid change of Leu to Pro at codon 293, is commonly detected in Asians. 	CYP3A4	17713	17719	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:103	CYP3A4*18, contains a nucleotide substitution of T>C at position 878 of the cDNA of CYP3A4 and results in an amino acid change of Leu to Pro at codon 293, is commonly detected in Asians. 	CYP3A4	17797	17803	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:104	According to previous study, CYP3A4*18 exhibited increased turnover numbers for testosterone and chlorpyrifos in vitro. 	CYP3A4	17929	17935	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:105	Similarly, in our study, CYP3A4*18, with a distinctly increased V_max, showed significantly increased relative clearance compared with CYP3A4*1. 	CYP3A4	18045	18051	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:105	Similarly, in our study, CYP3A4*18, with a distinctly increased V_max, showed significantly increased relative clearance compared with CYP3A4*1. 	CYP3A4	18155	18161	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:106	These results are consistent with the previous study of testosterone and chlorpyrifos, 2 typical probing substrates for CYP3A4, thus indicating that our CYP expression and in vitro metabolism system were suitable for analyzing the catalytic activities of the CYP3A4 allelic variants. 	CYP3A4	18285	18291	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:106	These results are consistent with the previous study of testosterone and chlorpyrifos, 2 typical probing substrates for CYP3A4, thus indicating that our CYP expression and in vitro metabolism system were suitable for analyzing the catalytic activities of the CYP3A4 allelic variants. 	CYP3A4	18424	18430	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:107	In addition, CYP3A4*23 was reported by Hu et al for the first time in the Chinese population. 	CYP3A4	18462	18468	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:108	In our work, CYP3A4*23 exhibited significantly increased intrinsic clearance value (206.96% of CYP3A4*1) owing to marked increase in V_max and huge decrease in K_m. 	CYP3A4	18556	18562	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:108	In our work, CYP3A4*23 exhibited significantly increased intrinsic clearance value (206.96% of CYP3A4*1) owing to marked increase in V_max and huge decrease in K_m. 	CYP3A4	18638	18644	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A4	19055	19061	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A4	19100	19106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:109	According to our previous studies, CYP2D6, CYP2C9 and CYP2C19 not only exhibit significant genetic polymorphisms between individuals, but also had substrate-specificity, which show marked differences on the metabolism of various clinical drugs.- Similarly, it has been reported that there is approximately a 10-fold variation in the metabolism of CYP3A4 substrates in vivo, which reveal that CYP3A4 may also exhibit a broad substrate specificity., However, thus far, few studies have been performed on CYP3A4 genetic polymorphisms in the Chinese Han population and this is the first report of all these alleles for lidocaine metabolism. 	CYP3A4	19210	19216	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A4	19405	19411	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A4	19468	19474	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:110	To better understand the enzymatic characteristics of these CYP3A4 allelic isoforms, testosterone, as a probe substrate of CYP3A4, was also used to detect the catalytic activities of these 23 CYP3A4 variants. 	CYP3A4	19537	19543	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19614	19620	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19742	19748	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19752	19758	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19763	19769	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19774	19780	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:111	Then we compared lidocaine with testosterone, although some CYP3A4 variants exhibited similar pattern for the metabolic activity toward testosterone, most of the variants, especially like CYP3A4*2, CYP3A4*29, CYP3A4*32, CYP3A4*33, and CYP3A4*34 showed different relative activities for the probe drug. 	CYP3A4	19789	19795	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:112	These results suggested that CYP3A4 also had substrate-specific alterations in metabolic activity and we infer that amino acid substitution in these sites might have different impacts for different substrate of CYP3A4. 	CYP3A4	19885	19891	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:112	These results suggested that CYP3A4 also had substrate-specific alterations in metabolic activity and we infer that amino acid substitution in these sites might have different impacts for different substrate of CYP3A4. 	CYP3A4	20067	20073	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:113	Moreover, genetic polymorphism and substrate-specificity of CYP3A4 need further study on daily used drugs in order to help in personalized medicine for patients in a safe and reduced toxicity reaction. 	CYP3A4	20135	20141	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:114	In summary, this study provides functional assessment of 23 CYP3A4 variants on lidocaine metabolism in vitro for the first time. 	CYP3A4	20337	20343	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:116	As the first study of all these alleles on lidocaine metabolism, the research may help to improve our understanding of the polymorphism of CYP3A4; on the other hand, this study could help clinical assessment of the lidocaine metabolism and aid the application of this knowledge in clinical practice. 	CYP3A4	20766	20772	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:117	However, further studies are required to examine a wider range of CYP3A4 substrates, including clinically used drugs.	CYP3A4	20993	20999	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:227	Among all human CYPs, CYP3A4 is reported to be involved in the metabolism of 50% of all pharmaceuticals; it is therefore an enzyme of general interest for herb-drug interactions. 	CYP3A4	40767	40773	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:228	Several herbs and natural remedies have been reported to induce or inhibit CYP3A4. 	CYP3A4	40999	41005	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:232	The propensity to inhibit CYP1A2, CYP2C19, CYP2D6, and CYP3A4 of the A. Lancea extract was investigated using human liver microsomes. 	CYP3A4	41315	41321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:235	The potency of inhibitory effects on CYP3A4, CYP2D6, and CYP2C19 was low (mean IC_50 313.51, 54.36, and 16.48 g/ml, respecies.). 	CYP3A4	41871	41877	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP3A4	7872	7878	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP3A4	8907	8913	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP3A4	20573	20579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:10	This observation was further supported by consistent CYP3A4 expression across all treatment groups. 	CYP3A4	1902	1908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:26	Indeed, Berberine has been shown to affect the metabolism of drugs through changes in CYP3A4 expression. 	CYP3A4	4646	4652	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:27	The effects of Berberine on CYP3A4-mediated drug metabolism is of particular interest as this enzyme degrades several widely used statin drugs (eg simvastatin and lovastatin) that may be concomitantly used with Berberine to treat dyslipidemia or hypercholesterolemia. 	CYP3A4	4693	4699	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:118	Two livers per treatment group were evaluated for CYP3A4 and HMG-CoA reductase using a combination of enzyme-linked immunosorbent assays and western blot techniques. 	CYP3A4	19191	19197	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:122	For Enzyme-Linked Immunosorbent Assays quantification of CYP3A4 and HMG-CoA reductase were performed according to manufacturers instructions (LifeSpan BioSciences LS-F22383 and LifeSpan BioSciences LS-F15758). 	CYP3A4	19759	19765	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:207	This decrease in Demethylene Berberine Glucuronide may reflect an alteration in hepatic function such as changes in enzymes responsible for berberine metabolism, of which CYP3A4 is a significant player. 	CYP3A4	33531	33537	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:208	To address this possibility, liver samples from chronically treated animals (14 days) were dissected and CYP3A4 was quantified by Enzyme-Linked Immunosorbent Assays and western blot. 	CYP3A4	33668	33674	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:209	No differences in CYP3A4 expression were observed between treatment groups. 	CYP3A4	33764	33770	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:217	Simvastatin and berberine both undergo metabolism in the liver primarily through CYP3A4. 	CYP3A4	34804	34810	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5868852_OgerInput.txtOger_out.csv:229	While transdermal dihydroberberine unequivocally increased berberine levels in circulation this increase had no effect on liver or kidney function nor altered the expression of hepatic enzymes CYP3A4 and HMG-CoA reductase. 	CYP3A4	37108	37114	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP3A4	8847	8853	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:215	The CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and together, they control the clearance of approximately 50% of all drugs eliminated primarily through P450-mediated biotransformation. 	CYP3A4	32839	32845	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:216	CYP3A4 protein is present in almost all adults, whereas CYP3A5 protein expression varies across different ethnic groups; polymorphisms in the genes encoding these proteins are shown in  and. 	CYP3A4	33041	33047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:218	The CYP3A4*22 variant is also associated with reduced CYP3A4 protein levels and enzyme function, as are rare deleterious coding variants. 	CYP3A4	33501	33507	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:218	The CYP3A4*22 variant is also associated with reduced CYP3A4 protein levels and enzyme function, as are rare deleterious coding variants. 	CYP3A4	33551	33557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A4	33639	33645	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A4	33653	33659	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:220	In the CSKT population, resequencing followed by subsequent genotyping identified four novel CYP3A4 SNVs-three intronic and one in the 5 UTR region. 	CYP3A4	33939	33945	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:221	The known CYP3A4 variants, *1B, *22 and *1G were found at frequencies of 2.2%, 2.4% and 26.8%, respectively. 	CYP3A4	34005	34011	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:226	determined the MAFs of CYP3A4 variants in the Tepehuano and Mestizo populations and found that the frequencies were not significantly different between these two group. 	CYP3A4	34549	34555	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:227	The MAFs of CYP3A4*1B was 8.0% in Tepehuanos, compared to 8.8% in Mestizos and CYP3A4*2 was not detected in the Tepehuanos but was found at a low frequency of 0.5% in Mestizos. 	CYP3A4	34707	34713	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:227	The MAFs of CYP3A4*1B was 8.0% in Tepehuanos, compared to 8.8% in Mestizos and CYP3A4*2 was not detected in the Tepehuanos but was found at a low frequency of 0.5% in Mestizos. 	CYP3A4	34774	34780	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:228	CYP3A4*4, *5 and *18 were not found in either population. 	CYP3A4	34872	34878	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:229	Although the variant allele frequencies were similar between Tepehuanos and Mestizos for CYP3A4, it is important to consider that these populations may share similar allele frequencies in other P450 genes. 	CYP3A4	35019	35025	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:231	found that the CYP3A4*1B MAF was 4.8% in an Amerindian population including the Tarahumara, Tepehuano, Mexicanera, Huichol, Cora, Seri, Mayo and Guarijo groups. 	CYP3A4	35167	35173	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:232	The CYP3A4*1B allele did not significantly affect the parent to metabolite ratio of dextromethorphan to 3-methoxymorphinan, a CYP3A4 mediated pathway. 	CYP3A4	35317	35323	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:232	The CYP3A4*1B allele did not significantly affect the parent to metabolite ratio of dextromethorphan to 3-methoxymorphinan, a CYP3A4 mediated pathway. 	CYP3A4	35439	35445	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5877702_OgerInput.txtOger_out.csv:209	In the same way, PAH such BaP, and their dihydrodiol metabolites, were able to activate PXR and enhance CYP3A4 expression in human cell lines (HepG2 and HEK-293 cells). 	CYP3A4	31703	31709	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:112	Human CYP3A4 is the homologue of mouse CYP3A44/CYP3A41, a protein mainly expressed in the liver and small intestine and responsible for the metabolism of many drugs. 	CYP3A4	19656	19662	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:113	Women have higher CYP3A4 activity than men^,; thus, many drugs metabolized by CYP3A4 clear faster in women than men^,. 	CYP3A4	19834	19840	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:113	Women have higher CYP3A4 activity than men^,; thus, many drugs metabolized by CYP3A4 clear faster in women than men^,. 	CYP3A4	19894	19900	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:127	CYP1A1, 1A2 and CYP2C9 are not expressed in human kidney, whereas the CYP3A4 expression in kidney is highly variable and remains to be elucidated^. 	CYP3A4	22123	22129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:64	Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2. 	CYP3A4	10998	11004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:65	CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism. 	CYP3A4	11041	11047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:108	Podophyllotoxin and-yatein are reported as potent inhibitors of CYP3A4 and-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6. 	CYP3A4	18829	18835	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:109	Our results, reporting no inhibition by podophyllotoxin and moderate/weak inhibition by-yatein against the activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent inhibition of CYP3A4 by these two phytochemicals. 	CYP3A4	19142	19148	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:130	Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. 	CYP3A4	23057	23063	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:180	Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest and Murray et al.. 7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6. 	CYP3A4	29369	29375	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:182	Positive control experiments were conducted with known inhibitors with varying concentrations of ALPHA-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for CYP2D6, and ketoconazole for CYP3A4. 	CYP3A4	29815	29821	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:88	Alternatively, some crystal P450 structures present a protein that exhibits several molecules of tightly bound ligands, as, for instance, the case of human CYP3A4 with a metyrapone molecule bound within the catalytic cavity and a progesterone molecule bound at its surface.  	CYP3A4	15125	15131	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:90	It appears that the inhibitor metyrapone binds the heme iron ion by one of its pyridine nitrogen, and that the progesterone is bound on the CYP3A4 surface to a pocket made by the F/G region, and which colocalized with the mouth of either CAVER channel 3 or 4 in P450 enzymes. 	CYP3A4	15465	15471	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:93	have demonstrated that the drug-drug interaction existing between atorvatstatin, which is a cholesterol-lowering drug, and dronedarone, an antiarrythmic drug, on CYP3A4 was indeed taking place by a crosstalk between a site on the surface of the enzyme, at which progesterone is seen bound in the crystal structure, and the buried active site. 	CYP3A4	15925	15931	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:130	In the same regard, Otyepka and his collaborators used a synergy of MOLE, the standard structure-based approach for identifying access channel, and a bias-exchange molecular metadynamics (BE-META) to study in silico the mechanism(s) of ligand passage through the flexible channels of CYP3A4 embedded in a 1,2-dioleoyl-sn-glycero-3-phosphocholine membrane environment. 	CYP3A4	22843	22849	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:133	A CYP3A4 channel, namely 2af, seems to not permit exiting through it due to a very high free energy at its mouth for the passage of the product. 	CYP3A4	23318	23324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:135	These results provide new insights into the mechanism of ligand release from CYP3A4. 	CYP3A4	23744	23750	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:150	Moreover, the shift of the F-helix and of the F/F loop in CYP2C9 in high-temperature molecular dynamics simulations are shown to close the solvent channel and to open the channel 2b.. A large conformational shift of the F/F loop is also seen in CYP3A4 crystal structures complexed with ketoconazole (a P450 inhibitor) or erythromycin (a CYP3A4 substrate). 	CYP3A4	26024	26030	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:150	Moreover, the shift of the F-helix and of the F/F loop in CYP2C9 in high-temperature molecular dynamics simulations are shown to close the solvent channel and to open the channel 2b.. A large conformational shift of the F/F loop is also seen in CYP3A4 crystal structures complexed with ketoconazole (a P450 inhibitor) or erythromycin (a CYP3A4 substrate). 	CYP3A4	26116	26122	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:157	However, the movements of the different elements forming the F/G region are not always easy to identify or to simulate in molecular dynamics, since, for instance, four of the 24 crystal structures of CYP3A4 available in the Protein Data Bank have missing residues in the F and F helices. 	CYP3A4	27463	27469	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:159	It has been shown that one of them, channel 4, couldbe predominantly a metabolite egress channel in CYP3A4. 	CYP3A4	27949	27955	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:165	In a recent study, Petitjean and his collaborators have analyzed 24 crystal structures of human CYP3A4 with their newly developed algorithm Computing Cavities, Channels, Pores And Pockets (Computing Cavities, Channels, Pores and Pockets) that finds out the different ways used by a cylinder to escape the catalytic cavity. 	CYP3A4	28854	28860	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:166	They choose CYP3A4 because its numerous crystal structures are showing an impressive flexibility of some parts of the protein, suggesting that the ligand access and the exit routes might differ from a P450 structure to the next, and that these differences might be correlated to ligand physicochemical properties. 	CYP3A4	29093	29099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:167	By doing so, they have classified the 24 crystal structures in three groups of different conformations, on closed, named C, in which a substrate-free CYP3A4 structure is found, and two open conformations, named O1 and O2. 	CYP3A4	29545	29551	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:168	They have also identified a series of crucial physicochemical properties for a molecule to be a CYP3A4 ligand, namely its hydrophobicity (LogP), the flatness of the cylinder that describes it, its ability to - interactions, as measured by the Hckel -energy, and the number of ligand molecules that can bind simultaneously to CYP3A4. 	CYP3A4	29713	29719	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:168	They have also identified a series of crucial physicochemical properties for a molecule to be a CYP3A4 ligand, namely its hydrophobicity (LogP), the flatness of the cylinder that describes it, its ability to - interactions, as measured by the Hckel -energy, and the number of ligand molecules that can bind simultaneously to CYP3A4. 	CYP3A4	29942	29948	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:169	In this interesting in silico study, they have highlighted the key role of two amino acid residues, Leu212 and Phe213, in triggering and controlling the shift between the three different conformations of CYP3A4. 	CYP3A4	30154	30160	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:170	Phe213 has been also identified independently as a critical residue in allosteric regulations that were observed with CYP3A4 when two substrates, carbamazepine and progesterone, were mixed. 	CYP3A4	30280	30286	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:173	By molecular dynamic simulations of human CYP3A4, it was predicted that the monooxygenation products of temazepam, which is a benzodiazepine hypnotic, and testosterone are each using a different channel for exiting the catalytic cavity once produced. 	CYP3A4	30985	30991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:176	Two phenylalanine residues were prominent in that control in CYP3A4, Phe215, and Phe220. 	CYP3A4	31562	31568	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:177	In a recent study of the binding of metconazole, an enantiomeric P450 inhibitor, to CYP3A4, it was shown that two aromatic residues were involved in the differential binding of the RS and SR enantiomers within the catalytic cavity. 	CYP3A4	31674	31680	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:181	This again suggests that the different positioning of each enantiomer within CYP3A4 active site could result from each eniantomer using different access channels. 	CYP3A4	32471	32477	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:196	The atomic models of six human P450 enzymes including CYP3A4 anchored to a lipid bilayer were constructed and investigated by molecular dynamics simulations for the position and orientation of the P450 protein on the model membrane. 	CYP3A4	35573	35579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:209	A molecular dynamics study of CYP3A4 embedded in bilayer environments presenting increased levels of cholesterol (from 0% up to 50%) shows that, as cholesterol amounts increase, the immersion an inclination of the CYP3A4 catalytic domain change relatively to the membrane. 	CYP3A4	38207	38213	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:209	A molecular dynamics study of CYP3A4 embedded in bilayer environments presenting increased levels of cholesterol (from 0% up to 50%) shows that, as cholesterol amounts increase, the immersion an inclination of the CYP3A4 catalytic domain change relatively to the membrane. 	CYP3A4	38391	38397	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:210	moreover, the pattern of CYP3A4 accessible channels is altered. 	CYP3A4	38475	38481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP3A4	58776	58782	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A4	64198	64204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A4	64272	64278	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:514	)], 6BETA-hydroxytestosterone [produced by CYP1A1/2, CYP3A4/5/7 and CYP3A43 (Soucek et al. 	CYP3A4	79574	79580	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:668	CYP3A4 and CYP3A5 Baron et al. 	CYP3A4	102313	102319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A4	102372	102378	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A4	102489	102495	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:671	Cyp3A4 mRNA was very variably expressed in various skin systems, whereby it was not clear whether CYP3A4 was distinguished from CYP3A5. 	CYP3A4	102680	102686	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:672	The authors report that CYP3A4 was expressed in native human skin, both in the epidermis (moderate expression in the epidermis of all three donors investigated) and in the dermis (weak expression in the dermis from one out of the three donors). 	CYP3A4	102742	102748	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	CYP3A4	103667	103673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	CYP3A4	103790	103796	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:1	 Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. 	CYP3A4	88	94	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:4	Here we have determined the effect of eight CYP3A4 and seven CYP2C9 Single Nucleotide Polymorphisms on the thermostability of proteins in solution to test these predictions. 	CYP3A4	642	648	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:5	Thermostability assays revealed distinct Cytochrome P450 sub-populations with only 65-70% of wild-type CYP3A4 and CYP2C9 susceptible to rapid heat-induced P450 to P420 conversion. 	CYP3A4	875	881	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:6	CYP3A4 mutations G56D, P218R, S222P, I223R, L373F and M445T and CYP2C9 mutations V76M, I359L and I359T were destabilising, increasing the proportion of protein sensitive to the rapid heat-induced P450 to P420 conversion and/or reducing the half-life of this conversion. 	CYP3A4	952	958	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:14	Over 100 non-synonymous single amino acid substitutions have been reported for isoforms CYP3A4 and CYP2C9 alone^,; these two isoforms are jointly responsible for nearly half of Cytochrome P450 mediated drug metabolism^. 	CYP3A4	2506	2512	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:38	The aim of this study was to test our previous in silico stability prediction in vitro, using a selection of recombinantly expressed CYP3A4 and CYP2C9 mutants. 	CYP3A4	8280	8286	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:39	The 8 CYP3A4 and 7 CYP2C9 variants tested included mutations previously predicted to be neutral, stabilising and destabilising, falling within both functional and undefined regions of the protein structure^. 	CYP3A4	8313	8319	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:40	The positions of the CYP3A4 and CYP2C9 variants selected for in vitro testing are shown in Fig. 	CYP3A4	8536	8542	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:41	Recombinant wild-type and variant His-tagged CYP3A4 and CYP2C9 proteins were expressed in E. coli and purified using immobilized metal affinity chromatography. 	CYP3A4	8656	8662	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:42	The specific holoprotein content of each CYP3A4 and CYP2C9 variant protein sample was determined using carbon monoxide P450 spectral assays^,. 	CYP3A4	8812	8818	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:45	To test the thermostability of the CYP3A4 and CYP2C9, Wild-Type and variant proteins, Carbon Monoxide P450 difference spectra were used to measure the decrease in P450 content at an elevated temperature as a function of time. 	CYP3A4	9358	9364	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:47	Different temperatures were tested to ensure the decrease in P450 could be monitored at a constant temperature over a 30-minute period: 34 C was chosen for CYP3A4 proteins and 48 C for the more stable CYP2C9 proteins. 	CYP3A4	9900	9906	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:48	CYP3A4 and CYP2C9 Wild-Type protein samples both showed an exponential decrease in P450 content, although the graphs did not tend to zero, suggesting either the presence of a stable P450 sub-population or background signal. 	CYP3A4	9962	9968	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:51	Figure  shows the thermostability results for the CYP3A4 Wild-Type and variant proteins. 	CYP3A4	10542	10548	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:56	To determine the effect of polymorphic variation on CYP3A4 stability, the effect of mutations on the half-life of the unstable sub-population and the effect of mutations on the plateau - the proportion of P450 making up the stable sub-population - were considered. 	CYP3A4	11371	11377	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:67	Size exclusion chromatography was carried out on CYP3A4 and CYP2C9 Wild-Type protein samples to determine whether protein oligomerisation could provide an explanation for the presence of P450 sub-populations with different stabilities in solution. 	CYP3A4	13036	13042	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:69	Figure  shows the elution profiles for CYP3A4 and CYP2C9 Wild-Type proteins monitored at 410 nm, the maximum absorbance wavelength of the haem-bound protein. 	CYP3A4	13374	13380	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:71	The data provides evidence that both isoforms do indeed oligomerise in solution; the major peak for both CYP3A4 (66 kDa in monomeric form) and CYP2C9 (63 kDa in monomeric form) correspond roughly to oligomeric structures made up of 9 and 8 subunits respectively. 	CYP3A4	13716	13722	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:72	The major CYP3A4 peak has a shoulder corresponding roughly to a trimeric or tetrameric protein. 	CYP3A4	13884	13890	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:74	In order to test previous in silico predictions on the effects of Single Nucleotide Polymorphisms on Cytochrome P450 stability, recombinant soluble CYP2C9 and CYP3A4 Wild-Type and variant proteins, lacking their N-terminal membrane binding region, were expressed in E. coli and purified from the cell lysate. 	CYP3A4	14385	14391	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP3A4	14635	14641	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:76	CYP2C9 was much more stable than CYP3A4, to the extent that CYP3A4 had a shorter half-life at 34 C than CYP2C9 had at 48 C. The observed differences in stability were consistent with the differences in expression levels and P450:P420 ratios. 	CYP3A4	14662	14668	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:77	Notably, the P420 form of the protein was not detected in any of the CYP2C9 samples, while the P420 form was present in all CYP3A4 samples. 	CYP3A4	14968	14974	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:78	Exponential decay curves for both CYP3A4 and CYP2C9 indicated energetically distinct P450 sub-populations that did not interconvert between each other during the course of the assay. 	CYP3A4	15018	15024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:79	In support of this idea, previous published studies examining the binding kinetics of Carbon Monoxide to CYP3A4 using flash photolysis have argued that there are two kinetically distinct pools of P450, both in the membrane and in solution^,. 	CYP3A4	15272	15278	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:80	Other studies have also observed conformational heterogeneity for CYP2B4^, and CYP3A4 proteins^ using hydrostatic pressure spectroscopy. 	CYP3A4	15488	15494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:85	In another study it was shown that 70% of CYP3A4 in solution and 50% in microsomes was susceptible to substrate-induced spin shifts and rapid, reversible pressure-induced P450 to P420 conversions^. 	CYP3A4	16261	16267	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:87	In solution, this remaining fraction was subject to slow, irreversible inactivation at high pressures indicating that the pressure induced P450 to P420 conversion of CYP3A4 was biphasic consisting of a fast-reversible phase and a slow-irreversible phase. 	CYP3A4	16663	16669	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:91	Similarly to CYP2B4, the addition of detergents known to break up oligomers has been reported to reduce the heterogeneity of CYP3A4 observed in solution. 	CYP3A4	17262	17268	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:95	probed the geometry of CYP3A4 oligomers in microsomes using luminescence energy transfer and intermolecular cross-linking experiments^. 	CYP3A4	17626	17632	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:96	Their results suggest that the most likely size of the CYP3A4 oligomer in solution and in the membrane is a trimer (or multiples of this), involving two different types of interaction interfaces between subunits, one of which is similar to the subunit interface observed in the progesterone-bound CYP3A4 crystal structure (PDB code 1W0F)^. 	CYP3A4	17794	17800	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:96	Their results suggest that the most likely size of the CYP3A4 oligomer in solution and in the membrane is a trimer (or multiples of this), involving two different types of interaction interfaces between subunits, one of which is similar to the subunit interface observed in the progesterone-bound CYP3A4 crystal structure (PDB code 1W0F)^. 	CYP3A4	18036	18042	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:98	In this study we observed similar conformational heterogeneity for both CYP3A4 and CYP2C9 in solution; only 65-70% of the P450 was susceptible to rapid heat-induced P450 to P420 conversion at a constant elevated temperature while the remaining fraction was much more stable, consistent with the literature. 	CYP3A4	18451	18457	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:99	Size exclusion chromatography experiments confirmed that both CYP3A4 and CYP2C9 were predominantly in the oligomeric form in solution. 	CYP3A4	18748	18754	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:100	The estimated molecular weight of the major CYP3A4 oligomer species were 583 and 239 kDa corresponded most closely to a nonamer and a tetramer, respectively. 	CYP3A4	18865	18871	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:102	work which suggests that CYP3A4 oligomers are made up of trimers and would explain the 1:2 conformer distribution observed for CYP3A4, where 3 of the monomeric subunits are more stable than the other 6. 	CYP3A4	19105	19111	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:102	work which suggests that CYP3A4 oligomers are made up of trimers and would explain the 1:2 conformer distribution observed for CYP3A4, where 3 of the monomeric subunits are more stable than the other 6. 	CYP3A4	19207	19213	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:103	A previous study observed at least three major CYP3A4 oligomers in solution with molecular masses of 215, 290, and 450 kDa using continuous molecular weight distribution analysis^. 	CYP3A4	19330	19336	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:110	Mutations in close proximity to the haem-binding region, such as L373F (haem contact) and M445T (predicted to be destabilising by SDM) in CYP3A4, destabilise the haem significantly in both conformers, increasing the proportion of protein sensitive to rapid heat-induced conversion to P420 and decreasing the half-life of this conversion. 	CYP3A4	20751	20757	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:116	While this residue does not fall within a substrate recognition site, it is solvent accessible and is predicted to form part of the CYP3A4:CPR interface so any destabilising effects in this region may also alter interactions with Cytochrome P450 Reductase. 	CYP3A4	21837	21843	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:119	CYP3A4 mutation G56D had a similar effect to the L373F mutation; while Gly 56 is not in close proximity to the haem-binding region, it was predicted to be a destabilising mutation by Site Directed Mutator and falls within SRS1a. 	CYP3A4	22423	22429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:121	For reasons less immediately apparent, P218R and S222P had a significant effect on the thermostability of CYP3A4; P218R and S222P were both predicted to be neutral by Site Directed Mutator and fall within the flexible F-G loop, which is far away from the haem-binding site but forms part of substrate recognition site (2,3) at the proposed interface of the interacting Cytochrome P450 subunits, close to the peripheral effector site acts as a lid over the active site cavity and is comprised of the F and G helix connected by the F-G loop. 	CYP3A4	22988	22994	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:135	Unlike Pro 218 and Ser 222, which are both solvent exposed residues with side chains orientated towards the bulk solvent, Ile 223 is buried indicating that it is unlikely to interact with other CYP3A4 molecules directly without a substantial change in protein conformation. 	CYP3A4	26110	26116	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:143	A recently reported crystal structure of the CYP3A4 I359L variant suggests that this mutation has long range effects - transduced along the I-helix - on the orientation of active site residues, altering the binding mode of losartan within the active site compared to the wild-type structure^. 	CYP3A4	28085	28091	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A4	31614	31620	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A4	31715	31721	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:161	Buried Single Nucleotide Polymorphisms in close proximity to the haem (eg CYP3A4 L373F) as well as Single Nucleotide Polymorphisms further away from the haem-binding site (eg CYP3A4 G56D) - including residues in solvent accessible, variable flexible regions predicted to be neutral (eg CYP3A4, S222P and P218R) - had significant effects on thermostability of the P450 form. 	CYP3A4	31826	31832	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	CYP3A4	32859	32865	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:168	pBJW102.2 vectors containing the N-terminal truncated CYP3A4 and CYP2C9 cDNA sequences were a gift from Procognia Ltd, Maidenhead, UK. 	CYP3A4	33538	33544	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:170	The translated CYP3A4 and CYP2C9 proteins had a 24 amino acid and 28 amino acid deletion at the N-terminus respectively. 	CYP3A4	33903	33909	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP3A4	34035	34041	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:171	Expression plasmids for 8 CYP3A4 and 7 CYP2C9 polymorphic variants were generated from the pBJW102.2 + CYP3A4 and the pBJW102.2 + CYP2C9 wild-type expression plasmids by inverse PCR using the 5phosphorylated primers listed in Supplementary Table. 	CYP3A4	34112	34118	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:185	CYP3A4 and CYP2C9 holo P450 protein content in the enriched protein samples was determined using carbon monoxide spectral assays^. 	CYP3A4	36551	36557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:195	The cuvettes were then placed back into the spectrophotometer maintained at a constant temperature of 34 C (for CYP3A4 samples) or 48 C (for CYP2C9 samples) by circulating water from a heated water bath through the cell holder. 	CYP3A4	38149	38155	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:206	CYP3A4 and CYP2C9 Wild-Type protein samples were separated using the BioSep-SEC-S3000 column with exclusion range of 5 kDa to 700 kDa. 	CYP3A4	39622	39628	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:186	The substrate behavior prediction in the CYP3A4 indicated that only 1 and 2 could be substrates, because these molecules meet the characteristics of the pharmacophore model for this cytochrome. 	CYP3A4	31436	31442	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:192	On the other hand, the compounds 1-4 did not show inhibitory effect on CYP2D6 and CYP3A4. 	CYP3A4	32542	32548	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:112	used NMR-based metabolomics to identify a metabolic signature associated with a variation in induced CYP3A4 activity. 	CYP3A4	17302	17308	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:115	Ultraperformance liquid chromatography combined with mass spectrometry was performed to obtain a marker for CYP3A4 induction: the ratio of 3-hydroxyquinine to quinine (3OH-Q/Q). 	CYP3A4	17565	17571	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:117	showed that the plasma concentrations of 4b-hydroxycholesterol increased after complete induction of CYP3A4/5 by carbamazepine or rifampicin. 	CYP3A4	17770	17776	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:134	Cytochromes CYP2C19, CYP3A4, and CYP1A2 (especially CYP2C9) play a major role in the metabolism of warfarin in the human body. 	CYP3A4	20371	20377	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:146	One example of the modifying influence of external factors is the effect of grapefruit juice components on the expression of cytochrome P-450 (CYP3A4) and, accordingly, on the pharmacokinetics of CYP3A-mediated drugs. 	CYP3A4	22336	22342	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:1	 The Inhibitory Effect of Flavonoid Aglycones on the Metabolic Activity of CYP3A4 Enzyme. 	CYP3A4	75	81	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:5	The aim of this study was to focus on possible interactions between the 30 most commonly encountered flavonoid aglycones on the metabolic activity of CYP3A4 enzyme. 	CYP3A4	569	575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:6	6BETA-hydroxylation of testosterone was used as marker reaction of CYP3A4 activity. 	CYP3A4	651	657	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:9	Out of the 30 flavonoids tested, 7 significantly inhibited CYP3A4, most prominent being acacetin that inhibited 95% of enzyme activity at 1 M concentration. 	CYP3A4	940	946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:11	These results alert on possible flavonoid-drug interactions on the level of CYP3A4. 	CYP3A4	1338	1344	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:25	The greatest contributor to the biotransformation of drugs is CYP3A4/5 (30.2%), followed by CYP2D6 (20.0%), CYP2C9 (12.8%), CYP1A2 (8.9%), and others. 	CYP3A4	3366	3372	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:27	The aim of the present study was to evaluate the inhibitory effect of thirty flavonoid aglycones, most commonly found in herbal drugs and propolis, on the most important drug metabolizing enzyme CYP3A4. 	CYP3A4	3801	3807	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:31	For enzyme activity assessment testosterone 6BETA-hydroxylation was used as it represents a marker reaction of CYP3A4 activity. 	CYP3A4	4314	4320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:34	To test the CYP3A4 enzyme inhibition, residual activity was assessed based on the product of the marker reaction generated by monitoring incubations with addition of flavonoid, as a potential inhibitor, versus incubations without inhibitor.  	CYP3A4	4631	4637	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:37	Negative control (incubation with substrate and without the NADPH generating system) shows no product generation, confirming that 6BETA-hydroxytestosterone is product of generated by CYP3A4 enzyme. 	CYP3A4	5271	5277	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A4	5486	5492	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A4	5573	5579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:39	Troleandomycin, an irreversible inhibitor of CYP3A4, used as a positive control in 25 M concentration caused complete inhibition of CYP3A4, while 0.15 M ketoconazole, a direct reversible inhibitor of CYP3A4, reduced enzyme activity by 80  4% (p < 0.001). 	CYP3A4	5641	5647	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:41	Seven flavonoids have been shown to inhibit CYP3A4 with statistical significance p < 0.05. 	CYP3A4	6028	6034	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:46	However, there are no reports on CYP3A4 inhibition. 	CYP3A4	6491	6497	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:49	Although pharmacokinetic of pinocembrin was studied, no CYP3A4 inhibition was reported. 	CYP3A4	6839	6845	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:51	Residual activity of CYP3A4 after incubations with flavones apigenin, chrysin, chrysin dimethyl ether, and tangerine was 24%, 17%, 61%, and 42%. 	CYP3A4	6953	6959	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:54	Reversible inhibition of CYP3A4 by apigenin was reported by Li et al. 	CYP3A4	7348	7354	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:58	However, based on our study metabolism dependent inhibition of CYP3A4 by apigenin, here reported for the first time, is of greater importance. 	CYP3A4	7609	7615	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:60	Neither chrysin, nor chrysin dimethylether were reported as inhibitors of CYP3A4 previously. 	CYP3A4	8053	8059	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:61	Although the effect of chrysin on 1-hydroxilation of midazolam (another marker reaction of CYP3A4 enzyme) was studied, inhibition of CYP3A4 activity was not observed. 	CYP3A4	8163	8169	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:61	Although the effect of chrysin on 1-hydroxilation of midazolam (another marker reaction of CYP3A4 enzyme) was studied, inhibition of CYP3A4 activity was not observed. 	CYP3A4	8205	8211	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:65	However, in our study in which residual activity of CYP3A4 was studied on testosterone as marker substrate, an inhibitory effect was observed. 	CYP3A4	8672	8678	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:67	who reported that tangeretin inhibited CYP3A4 mediated nifedipine oxidation in human liver microsomes in an uncompetitive manner with inhibition constant of 72 M. Lastly, Takanaga et al. 	CYP3A4	8854	8860	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:68	reported no influence of tangeretin, neither activation, nor inhibition, on CYP3A4 activity when using testosterone as marker substrate on human liver microsomes and recombinant CYP3A4 systems. 	CYP3A4	9078	9084	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:68	reported no influence of tangeretin, neither activation, nor inhibition, on CYP3A4 activity when using testosterone as marker substrate on human liver microsomes and recombinant CYP3A4 systems. 	CYP3A4	9180	9186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:69	Observed difference justifies recommendations of medicinal products regulatory agencies to use at least two marker substrates when studding CYP3A4 activity. 	CYP3A4	9336	9342	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:74	did not observe change in activity of CYP3A4 treated with isorhamnetin on hepatocyte carcinoma cell line HepG2. 	CYP3A4	9853	9859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:80	Interestingly, stimulation of enzyme activity of CYP3A4 was observed with tamarixetin; observed residual activity was 195%. 	CYP3A4	10452	10458	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:84	have shown that tamarixetin has no influence on CYP3A4 induction through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor. 	CYP3A4	10783	10789	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:85	Our observation of stimulation of CYP3A4 activity by tamarixetin is in contrast to von Moltke et al. 	CYP3A4	10928	10934	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:87	Although stimulation in vitro (not mediated by increased induction of enzyme in vivo) is rarely observed, it has been reported that anticancer drug gefitinib is a potent stimulator of CYP3A4. 	CYP3A4	11234	11240	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:88	Looking at the structural features responsible for the inhibitory effect, it can be observed that flavanones and flavones hydroxylated at the positions 5 and 7 of the A ring, and monosubstituted at the position 4 of the B ring, decrease CYP3A4 enzyme activity regardless of group present (methoxy or hydroxyl) eg, acacetin and apigenin. 	CYP3A4	11479	11485	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:89	As the hydroxyl group at the B ring is nonionizable under the physiological pH, hydrophobic interactions of the flavonoid with the CYP3A4 are probably of importance. 	CYP3A4	11710	11716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:91	However, in that instance hydroxyl group should not be methylated, and susceptible to ionization under physiological conditions, indicating importance of ion-ion interactions between flavanones and CYP3A4 enzyme. 	CYP3A4	12126	12132	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:94	To distinguish if the observed metabolism dependent inhibition (of the seven confirmed inhibitors of CYP3A4 in this study) was a result of time dependent inhibition, in which additional time is needed for the inhibitor to interact with enzyme to cause the inhibition, preincubations were conducted without presence of NADPH coenzyme. 	CYP3A4	12838	12844	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:95	In this way, no reduction of CYP3A4 heme iron to Fe^2+ form occurred, giving sufficient time for the potential inhibitor to interact with the enzyme. 	CYP3A4	13100	13106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:97	Residual CYP3A4 activity was 57  10% (p = 0.047), 34  10% (p = 0.005), and 45  3% (p = 0.019), respectively. 	CYP3A4	13328	13334	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:98	However, no statistical difference was observed in residual activity of CYP3A4 enzyme for apigenin between metabolism and time dependent inhibition assays, indicating that apigenin is pure reversible inhibitor of CYP3A4. 	CYP3A4	13500	13506	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:98	However, no statistical difference was observed in residual activity of CYP3A4 enzyme for apigenin between metabolism and time dependent inhibition assays, indicating that apigenin is pure reversible inhibitor of CYP3A4. 	CYP3A4	13641	13647	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:99	No time dependent inhibition was observed with chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin, and this was confirmed in direct inhibition assay, indicating these four flavonoids are irreversible inhibitors of CYP3A4. 	CYP3A4	13877	13883	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:101	Direct inhibition assay showed inhibitory effect of acacetin, apigenin, and chrysin on CYP3A4 by decreasing residual enzyme activity to 46  6% (p = 0.005), 35  18% (p = 0.049), and 54  23% (p = 0.044), respectively. 	CYP3A4	14181	14187	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:102	These results show that no real time dependent inhibition is present, and observed inhibition of CYP3A4 in time dependent inhibition assay is consequence of the direct inhibition. 	CYP3A4	14407	14413	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:103	Time dependent inhibition is extremely rare for human cytochromes P450 and has been previously reported only for cilengitide, an experimental anticancer drug used for treatment of glioblastoma, and CYP3A4 enzyme in which inhibitor was in extremely high millimolar concentration. 	CYP3A4	14688	14694	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:111	Moreover, data published is not always confirmed by subsequent studies, eg, tamarixetin is activator of CYP3A4 in our study, while previously it has been reported that it either has no effect or it inhibits CYP3A4. 	CYP3A4	16240	16246	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:111	Moreover, data published is not always confirmed by subsequent studies, eg, tamarixetin is activator of CYP3A4 in our study, while previously it has been reported that it either has no effect or it inhibits CYP3A4. 	CYP3A4	16343	16349	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:112	For the first time we have reported inhibition of CYP3A4 by acacetin, pinocembrin, chrysin, and chrysin dimethylether, and we have also shown that pinocembrin and isorhamnetin act as irreversible inhibitors of CYP3A4. 	CYP3A4	16401	16407	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:112	For the first time we have reported inhibition of CYP3A4 by acacetin, pinocembrin, chrysin, and chrysin dimethylether, and we have also shown that pinocembrin and isorhamnetin act as irreversible inhibitors of CYP3A4. 	CYP3A4	16561	16567	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:116	Sometimes inhibitors can have both reversible and irreversible effect on the enzyme as it has been shown with cilengitide and CYP3A4. 	CYP3A4	17143	17149	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	CYP3A4	17249	17255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:120	For the evaluation of activity of CYP3A4 testosterone was used as marker substrate (Sigma-Aldrich). 	CYP3A4	18042	18048	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	CYP3A4	18399	18405	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:128	6BETA-Hydroxylation of testosterone was used as marker reaction to monitor activity of the CYP3A4 enzyme. 	CYP3A4	18986	18992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:130	Incubation mixture contained 5 pmol of the CYP3A4 enzyme. 	CYP3A4	19193	19199	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:147	Out of 30 flavonoids screened for potential CYP3A4 enzyme inhibition, 7 showed statistically significant inhibition. 	CYP3A4	21658	21664	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:149	These results bring attention to possible flavonoid-drug interactions on the level of CYP3A4. 	CYP3A4	22041	22047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:150	As CYP3A4 is the most significant enzyme for the metabolism of xenobiotics including drugs, further in vivo studies are needed to assess clinical significance of the observed inhibitions, and possible drug-flavonoid interactions.	CYP3A4	22052	22058	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	CYP3A4	102	108	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:2	Incubation systems were established to investigate the effects of quercetin, kaempferol, isoquercitrin and astragalin in Lysimachia clethroides Duby on the activities of CYP2E1 and CYP3A4 in rat liver microsomes in vitro. 	CYP3A4	315	321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:5	The results suggested that kaempferol exhibited a weak inhibition of CYP2E1 activity with an IC50 of 60.26  2.54 M, while quercetin and kaempferol caused a moderate inhibition of CYP3A4 activity with IC50 values of 18.77  1.69 M and 32.65  1.32 M, respectively. 	CYP3A4	821	827	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:6	Isoquercitrin and astragalin had no effects on the activities of either CYP2E1 or CYP3A4. 	CYP3A4	986	992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:7	It could be speculated from these results that the inhibitory effects of quercetin and kaempferol on the activities of CYP2E1 and CYP3A4 could be the mechanisms underlying the hepatoprotective effects of L. clethroides. 	CYP3A4	1124	1130	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:18	CYP3A4, a major enzyme that is expressed in adult liver, has been considered to be an important factor affecting drug absorption. 	CYP3A4	3132	3138	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:19	CYP2E1 and CYP3A4 are not only the metabolic enzymes directly involved in hepatic oxidative damage, but they also are two important targets of the oxidation mechanism of acute liver injury. 	CYP3A4	3273	3279	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:21	On the basis of previous studies, the impacts of quercetin, kaempferol, isoquercitrin and astragalin on the activities of enzymes CYP2E1 and CYP3A4 in rat liver microsomes were examined, aiming to investigate the correlation between the hepatoprotective effects of L. clethroides and the antioxidant activities of these four compounds. 	CYP3A4	3949	3955	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:36	The regressive equations obtained by the Lineweaver-Burk method for CYP2E1 and CYP3A4 were Y = 835.9883X + 9.1943 (r = 0.9864) and Y = 2388.0110X + 14.1598 (r = 0.9961) respetively. 	CYP3A4	6018	6024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:42	The effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides and ketoconazole (positive control) on CYP3A4 activity are shown in  and. 	CYP3A4	7139	7145	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:43	Ketoconazole strongly inhibited the production of 6BETA-hydroxytestosterone (IC_50 = 0.25  0.01 M), but the effects of the four flavonoids in L. clethroides on CYP3A4 were very weak and their IC_50 values could not be calculated. 	CYP3A4	7334	7340	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:45	CYP2E1 and CYP3A4 are two important metabolic enzymes involved in liver injury. 	CYP3A4	7648	7654	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:48	Radix Glycyrrhizae could protect the liver injury caused by Rhizoma dioscorea bulbifera, possibly due to its induction of activity of CYP2E1 and CYP3A4 and inhibition of the mRNA expression. 	CYP3A4	8245	8251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:49	Clomethiazole and ketoconazole act as the positive inhibitors for CYP2E1 and CYP3A4 can significantly inhibit the formation of metabolites. 	CYP3A4	8368	8374	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:50	The IC_50 values of clomethiazole and ketoconazole were 1.07  0.01 M and 0.25  0.01 M, respectively, which are consistent with literature values, suggesting that the incubation systems in vitro can meet the activities of measurement of CYP2E1 and CYP3A4. 	CYP3A4	8678	8684	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:52	Thus, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol have moderate inhibitory effects on CYP3A4. 	CYP3A4	9016	9022	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:53	The results of this study showed that the two flavone glycosides (isoquercitrin and astragalin) had no effect on the activities of CYP2E1 and CYP3A4. 	CYP3A4	9166	9172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:59	Cytochromes P450, especially CYP2E1 and CYP3A4, are responsible for metabolism of ethanol, CCl_4 and other solvents in the body. 	CYP3A4	9940	9946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:60	In the model of alcohol-induced liver injury, the expression levels of CYP2E1 and CYP3A4 were enhanced. 	CYP3A4	10111	10117	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:66	The occurrence of liver injury can be reduced or even suppressed by minimizing the activities of CYP2E1 and CYP3A4, making the discovery of more compounds with anti-oxidative stress from natural products of important significance. 	CYP3A4	11155	11161	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:112	The incubation conditions of CYP3A4 were basically the same as those described in  but the volume of incubation mixture was 500 L and the reactions were terminated by adding 700 L of ice-cold acetonitrile containing 25 M phenacetin. 	CYP3A4	16109	16115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:133	The effects of flavonoids in L. clethroides on CYP3A4 activity were basically the same as CYP2E1. 	CYP3A4	19367	19373	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:134	The positive control was ketoconazole, and Groups 2 and 3 experiments were performed at concentrations of 0.02, 0.1, 0.2, 1 and 5 M. In vitro rat liver microsomes incubation assay methods were adopted for determining the effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides on the activities of CYP2E1 and CYP3A4. 	CYP3A4	19752	19758	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:135	In conclusion, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol had moderate inhibitory effects on CYP3A4 activity. 	CYP3A4	19894	19900	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:136	Based on these results, it can be speculated that the active hepatoprotective ingredients of L. clethroides include quercetin and kaempferol, which confer the inhibitory effects on the activities of CYP2E1 and CYP3A4. 	CYP3A4	20121	20127	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:137	The reduction of CYP2E1 and CYP3A4 activities can mitigate the biotransformation of CC1_4 and prevent the production of liver damaging substances to exert a liver protective role. 	CYP3A4	20157	20163	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP3A4	505	511	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:6	Unfermented (GRT) and fermented (FRE) rooibos extracts inhibited the activity of CYP2C8 (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) and CYP3A4 (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) based on their respective IC50 concentrations. 	CYP3A4	1100	1106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:8	CYP3A4 showed concentration-dependent inhibition by ASP, GRT, and FRE at 25, 50, and 100 g/mL concentrations. 	CYP3A4	1320	1326	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:9	ASP, GRT, and FRE time-dependently inhibited CYP3A4 activity with GRT and FRE showing a more potent time-dependent inhibition, comparable to erythromycin. 	CYP3A4	1475	1481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP3A4	4645	4651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP3A4	4887	4893	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:32	Atorvastatin used to treat hypercholesterolemia is metabolized by CYP3A4. 	CYP3A4	4973	4979	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:35	Most drugs and xenobiotics including dietary polyphenols have the ability to bind to CYP3A4 as substrates. 	CYP3A4	5540	5546	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP3A4	5801	5807	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP3A4	6319	6325	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP3A4	7235	7241	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP3A4	7466	7472	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP3A4	7551	7557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:54	ASP showed 24% inhibition of CYP2C9 at 100 g/mL and 23% inhibition of CYP3A4 at 200 g/mL activity, while PPAG had no effect on any of these enzymes. 	CYP3A4	7659	7665	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A4	7886	7892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A4	8000	8006	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:60	ASP, GRT, and FRE reduced CYP3A4 activity at 25 g/mL (62.9%, 36.9% and 61.4%, respectively; p < 0.001), 50 g/mL (44.5%, 13.5% and 29.7%, respectively; p < 0.001), and 100 g/mL (28.1%, 1.7% and 9.2%, respectively; p < 0.001) (c). 	CYP3A4	8574	8580	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:64	PPAG demonstrated time-dependent inhibition (p < 0.05) of only CYP3A4 (c). 	CYP3A4	9248	9254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:66	An interesting finding, however, is the time-dependent inhibition of CYP3A4 activity by GRT (p < 0.01) and FRE (p < 0.01), displaying a similar effect to that of erythromycin (c). 	CYP3A4	9382	9388	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:70	These constituents include various bioactive compounds that can either activate or inhibit CYP3A4. 	CYP3A4	10094	10100	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A4	10275	10281	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A4	10356	10362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP3A4	10840	10846	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP3A4	11179	11185	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:76	Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications. 	CYP3A4	11197	11203	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:81	GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC_50 values of 31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively. 	CYP3A4	11865	11871	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:82	ASP, as the major compound, moderately inhibited CYP3A4 activity with an IC_50 value of 69.57  4.03 g/mL. 	CYP3A4	12013	12019	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:83	Luteolin, the aglycone of rooibos flavone glucosides, orientin and isoorientin, and quercetin, the aglycone of rooibos flavonol glycosides, quercetin-3-O-robinobioside, rutin, hyperoside, and isoquercitrin, have previously been shown to inhibit CYP3A4. 	CYP3A4	12315	12321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:84	Quercetin is a more effective inhibitor of CYP3A4 than its 3-O-rutinoside, rutin. 	CYP3A4	12366	12372	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:85	The inhibition of CYP3A4 was also demonstrated to be both dose- and time-dependent. 	CYP3A4	12423	12429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:86	Therefore, they could potentially interfere with the metabolism and alter the pharmacodynamics of drugs, such as atorvastatin, cyclosporine, felodopine, simvastatin, midazolam, erythromycin, and doxorubicin, known to be metabolized by CYP3A4. 	CYP3A4	12724	12730	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP3A4	15300	15306	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:105	ASP could only be implicated in CYP3A4 inhibition. 	CYP3A4	15453	15459	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP3A4	17181	17187	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP3A4	17557	17563	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP3A4	17948	17954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP3A4	18718	18724	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP3A4	18989	18995	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP3A4	19249	19255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP3A4	19460	19466	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP3A4	19895	19901	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP3A4	20045	20051	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A4	20159	20165	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A4	20496	20502	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP3A4	20878	20884	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP3A4	20986	20992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP3A4	21599	21605	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP3A4	22151	22157	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP3A4	22957	22963	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:33	CYP3A4 is a well-known oxidative enzyme that is mostly involved in the metabolism of xenobiotics, and is the most expressed isoform in human liver. 	CYP3A4	4290	4296	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:64	CYP3A4 was not analyzed because it was included in the study during the Western Blot analysis and we did not find any change of expression with the treatments. 	CYP3A4	9081	9087	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP3A4	9960	9966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP3A4	10328	10334	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:92	We also observed that the fluorescent images of CYP3A4 did not report a preferential localization between mitochondria and Endoplasmic Reticulum. 	CYP3A4	13555	13561	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP3A4	30930	30936	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP3A4	83	89	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP3A4	708	714	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A4	4098	4104	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:31	The problem with disturbances of CYP reactions caused by nanomaterials is a new topic, studied most recently on metallic nanoparticles (gold or silver) and using the CYP3A4 isoform. 	CYP3A4	4934	4940	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:37	Single-walled carbon nanotubes (SWCNT) inhibited the activity of the CYP3A4 enzyme by direct interaction between SWCNT and the enzyme. 	CYP3A4	5631	5637	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:7	We genotyped 119 SNPs in ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 genes. 	CYP3A5	971	977	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:21	In addition, because PHT and CBZ are subjected to hepatic metabolism, cytochrome P450 (CYP450) isoenzymes could have an important role, affecting drug exposure in brain tissue, these include CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP1B1 and CYP2E1 proteins. 	CYP3A5	3580	3586	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:28	In this context, the objective of this study was to evaluate whether SNPs in the following genes-ABCB1, ABCC2, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-could improve the accuracy of predicting poor response to AED therapy in patients with MTLE. 	CYP3A5	4808	4814	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5215688_OgerInput.txtOger_out.csv:114	In addition, the most important variables in the prediction model include SNPs in ABCC2, CYP1A2, CYP1B1, CYP2E1, CYP3A4, and CYP3A5, as well as CYP2C9 and CYP2C19, both of which have been previously proposed as pharmacogenetic biomarkers. 	CYP3A5	19882	19888	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:6	The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. 	CYP3A5	1093	1099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:9	Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy. 	CYP3A5	1679	1685	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:12	The relative importance of these enzymes in clozapine clearance seemed to be lower, whereas the patients CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients expressed CYP1A2 at a relatively low level. 	CYP3A5	2526	2532	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:13	For the optimal plasma concentrations (200-600 ng/mL), CYP3A-status guided clozapine dosing was proposed (4.98 mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 2.18 mg/kg for low CYP3A4 expressers). 	CYP3A5	2870	2876	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:46	Patients CYP status was determined by CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and CYP3A4 expression in leukocytes. 	CYP3A5	8354	8360	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:48	Hydrolysis single-nucleotide polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was performed using TaqMan probes (BioSearch Technologies, Novato, CA). 	CYP3A5	8714	8720	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:62	The statistical significance of demographic data, CYP1A2 and CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as covariates of clozapine, norclozapine and clozapine N-oxide concentrations was analyzed by ANOVA using linear model of covariate effects with constant terms. 	CYP3A5	11198	11204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:80	The role of CYP3A4 in the metabolism of clozapine at therapeutic or higher concentrations has been demonstrated; however, the contribution of the highly polymorphic CYP3A5 must be clarified. 	CYP3A5	14562	14568	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A5	14645	14651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A5	14696	14702	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A5	14718	14724	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:81	In the present study, 10 subjects carried the functional CYP3A5*1 allele, whereas most of the patients were CYP3A5 nonexpressers (CYP3A5*3/*3) and were therefore expected to lack the functional CYP3A5 enzyme. 	CYP3A5	14782	14788	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:85	One of the high CYP3A4 expressers carried CYP3A5*1, anticipating rapid metabolism of CYP3A substrates. 	CYP3A5	15423	15429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:87	In CYP3A5 nonexpressers, the normalized concentrations were significantly higher in those displaying low CYP3A4 mRNA levels than in normal or high CYP3A4 expressers (185.5356.53 vs 78.0529.57 or 66.520.25 (ng/mL)/(mg/kg), P<.0001). 	CYP3A5	15594	15600	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:88	The patients CYP3A5 genotype was significantly associated with clozapine concentrations in those patients who expressed CYP3A4 at low levels (P<.0001). 	CYP3A5	15836	15842	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:89	Further confirmation of the role of CYP3A5 is needed because of the relatively small number of CYP3A5 expressers. 	CYP3A5	16011	16017	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:89	Further confirmation of the role of CYP3A5 is needed because of the relatively small number of CYP3A5 expressers. 	CYP3A5	16070	16076	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A5	16386	16392	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:91	The patients were divided into 4 groups according to the CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and CYP3A4 expression (low, normal, and high). 	CYP3A5	16403	16409	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:92	Significantly higher (about 2-fold) clozapine concentration was observed in CYP3A5 nonexpresser patients displaying low CYP3A4 expression than in all the others. 	CYP3A5	16560	16566	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A5	16798	16804	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A5	16925	16931	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:94	The first group consisted of the CYP3A5 nonexpressers with low CYP3A4 mRNA levels, whereas the remaining 3 combinations (normal and high CYP3A4 expressers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 genotype) were grouped, since the separate models for these combinations did not result in significantly different parameters. 	CYP3A5	16965	16971	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:96	The models were able to predict the normalized clozapine concentrations with the standard deviations of 15.68 and 6.65 ng/mL for the low CYP3A4 expressers with CYP3A5*3/*3 genotype and the rest of the patients, respectively. 	CYP3A5	17375	17381	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A5	18400	18406	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:101	The models proposed significantly lower daily dose for the patients expressing CYP3A4 at a low level than for those with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 genotype (the dose range of 51.04-258.33 vs 227.39-586.38 mg/d; P<.0001), whereas the actual dosage applied for low and normal/high CYP3A4 expresser patients or CYP3A5 expressers was identical (245.37158.88 vs 208.98120.69 mg/d; P=.4166). 	CYP3A5	18573	18579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:103	Underdosing occurred more frequently, primarily in the patients expressing CYP3A4 at a normal/high level or in CYP3A5 expressers. 	CYP3A5	18961	18967	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:106	The mathematical model displayed clozapine dosing to be optimal for 40 patients in the normal/high CYP3A4 expresser and CYP3A5 expresser groups (n=68), whereas 41% were underdosed. 	CYP3A5	19441	19447	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:112	The patients who expressed CYP3A4 at a low level displayed significantly lower norclozapine/clozapine ratios than the CYP3A4 normal/high expressers or those who carry CYP3A5*1 (0.55210.1535 vs 0.76550.2088; P<.0001). 	CYP3A5	20615	20621	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:137	In >70% of the patients, CYP1A2 mRNA was expressed at low concentration, whereas a high proportion of the patients (>70%) were CYP3A4 normal/high expressers, and additionally 3 low CYP3A4 expressers displayed normal clozapine-metabolizing capacity because of the functional CYP3A5*1 allele. 	CYP3A5	26240	26246	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:155	For achieving the therapeutic concentration, twice as high a dose was necessary for the normal/high CYP3A4 expressers and CYP3A5*1 carriers than for low CYP3A4 expressers. 	CYP3A5	29650	29656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5492788_OgerInput.txtOger_out.csv:156	Tailored medication controlled by patients CYP3A4 expression and CYP3A5 genotype may facilitate the improvement of the individual clozapine therapy, leading to the dosage optimization for a more effective therapy. 	CYP3A5	29765	29771	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	CYP3A5	24891	24897	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP3A5	7880	7886	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP3A5	8948	8954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP3A5	20581	20587	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP3A5	8855	8861	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:215	The CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity and together, they control the clearance of approximately 50% of all drugs eliminated primarily through P450-mediated biotransformation. 	CYP3A5	32850	32856	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:216	CYP3A4 protein is present in almost all adults, whereas CYP3A5 protein expression varies across different ethnic groups; polymorphisms in the genes encoding these proteins are shown in  and. 	CYP3A5	33097	33103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A5	33236	33242	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A5	33298	33304	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:217	The CYP3A5 enzyme is expressed in individuals having at least one CYP3A5*1 allele, while those with two inactive alleles, CYP3A5*3, *6, or *7, encode a nonfunctional protein; the PM phenotype is most common in Europeans and less so in Asians and African Americans. 	CYP3A5	33354	33360	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:219	The CYP3A4*1B and CYP3A4*1G alleles reportedly affect gene transcription but functional effects are unclear, as the data are mixed and interpretation is complicated by high linkage disequilibrium with CYP3A5*1. 	CYP3A5	33836	33842	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A5	34247	34253	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A5	34278	34284	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A5	34324	34330	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:223	With regard to CYP3A5 in the CSKT population, CYP3A5*1 was detected at a frequency of 7.5%, CYP3A5*3 at 92.5%, while CYP3A5*6 and *7 were not detected. 	CYP3A5	34349	34355	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:224	These data suggest that 14.9% of CSKT individuals express CYP3A5, contributing to their total CYP3A metabolic activity. 	CYP3A5	34442	34448	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:253	About 15% of the CSKT population would be expected to express CYP3A5, based on the CYP3A5*1 allele frequency. 	CYP3A5	38865	38871	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:253	About 15% of the CSKT population would be expected to express CYP3A5, based on the CYP3A5*1 allele frequency. 	CYP3A5	38886	38892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP3A5	58845	58851	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:365	reported that in adult human full-thickness skin biopsies the following CYPs mRNA were increased by treatment with coal tar: CYP1A1, CYP1A2, CYP1B1, CYP2C18; by treatment with all-trans-retinoic acid: CYP26 and NADPH P450 reductase (CYP1A1 and CYP1A2 RNAs decreased); by treatment with clobetasol 17-propionate: CYP3A5. 	CYP3A5	59405	59411	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:377	found in cultured keratinocytes CYP1A1, 1B1, CYP2C, 2E1, 3A5 and 4B1 mRNAs, in cultured Langerhans cells CYP1A1, 1B1, 1E1, 3A4 and 3A7 mRNAs, in fibroblasts CYP1A1, 1B1, 2A6, 2C, 2D6, 2E1, CYP3A5 and 3A7 mRNAs, in cultured melanocytes CYP1A1, 1B1, 2A6 and 2E1 mRNAs. 	CYP3A5	60788	60794	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP3A5	64417	64423	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:508	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin in SkinEthik^ RHE: 2.8, in Episkin^: 9.1, in Episkin^ FTM: 2.6, compared with human skin: 3.0;7-benzoxy 4-trifluoromethylcoumarin O-deethylase activities (CYP3A5/3A7-selective) in SkinEthik^ RHE: 13.3, in Episkin^: 3.6, in Episkin^ FTM: 3.3, compared with human skin: 3.8;7-methoxy-4-trifluoromethylcoumarin O-dealkylase activity was close to the Limit Of Quantitation of 0.5 in all three skin models and in human skin. 	CYP3A5	78751	78757	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:668	CYP3A4 and CYP3A5 Baron et al. 	CYP3A5	102324	102330	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A5	102356	102362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:671	Cyp3A4 mRNA was very variably expressed in various skin systems, whereby it was not clear whether CYP3A4 was distinguished from CYP3A5. 	CYP3A5	102710	102716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:53	456207), CYP3A5 (Lot No. 	CYP3A5	8522	8528	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP3A5	19961	19967	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP3A5	24558	24564	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP3A5	24668	24674	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP3A5	3431	3437	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:22	CYP4A is one of the -hyroxylases involved in metabolizing Arachidonic Acid to -terminal Hydroxyeicosatetraenoic Acids, including the potent vasoconstrictor 20-HETE (hydroxyeicosatetraenoic acid). 	CYP4A	4008	4013	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:23	In addition to regulating EET levels, Soluble Epoxide Hydrolase expression also impacts CYP -hydroxylase pathway; as reported by Yadav et al., CYP4A level was increased in the mesenteric arteries of mice with endothelial expression of Soluble Epoxide Hydrolase (Tie2-sEH Tr mice). 	CYP4A	4347	4352	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:65	The final concentrations, after standardization of dose (0.01, 0.1, 1, & 10 M) response for the various drugs used in this study were 10 M for rosiglitazone (PPARGAMMA-agonist), t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (a selective sEH-inhibitor, University of California, Davis), and 1 M DDMS (dibromo-dodecenyl-methylsulfimide, CYP4A-blocker). 	CYP4A	11557	11562	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:204	This unexpected finding could be reconciled with our functional finding of decreased Coronary Reactive Hyperemia in Tie2-sEH Tr mice if we consider another important finding: the level of CYP4A. 	CYP4A	34418	34423	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:205	CYP4A is an -hyroxylase involved in metabolizing Arachidonic Acid to the potent vasoconstrictor 20-HETE. 	CYP4A	34425	34430	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:207	has recently reported that CYP4A level was increased in the mesenteric arteries of Tie2-sEH Tr mice. 	CYP4A	34570	34575	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:208	These data suggest that while the decrease in mid-chain Hydroxyeicosatetraenoic Acids observed in the heart perfusates of Tie2-sEH Tr mice should have enhanced Coronary Reactive Hyperemia, the reported increased expression of CYP4A in the same mice may have overridden the effect of decreased mid-chain Hydroxyeicosatetraenoic Acids and caused a net effect of decreased Coronary Reactive Hyperemia. 	CYP4A	34870	34875	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:225	As mentioned earlier, -terminal Hydroxyeicosatetraenoic Acids are generated from Arachidonic Acid by CYP -hydroxylases, primarily CYP4A and CYP4F subfamilies, with 20-HETE being the primary product. 	CYP4A	37512	37517	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:230	The changes in the renal production of 20-HETE was consistent with the expression level of CYP4A protein. 	CYP4A	38088	38093	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:235	Upregulation of CYP4A, may contribute to reduced Coronary Reactive Hyperemia in Tie2-sEH Tr compared to Wild Type mice. 	CYP4A	38766	38771	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5215949_OgerInput.txtOger_out.csv:238	One such mechanism is the upregulation of CYP4A reported in Tie2-sEH Tr mice and the possible increase in 20-HETE. 	CYP4A	39249	39254	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:134	It has been reported that elevated concentration of S-Adenosylmethionine reduces CYP2E1^ and CYP39A^, but markedly induces CYP4A^ in Glycine N-Methyltransferase Knockout mice. 	CYP4A	23201	23206	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:136	Interestingly, in our microarray data, CYP4A were significantly induced up to 4- to 6-fold by AAI. 	CYP4A	23380	23385	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:6	Nevertheless, the sex-dependent effect of Doxorubicin on the expression of Cytochrome P450 enzymes is still not known. 	Cytochrome P450	608	623	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:6	Nevertheless, the sex-dependent effect of Doxorubicin on the expression of Cytochrome P450 enzymes is still not known. 	Cytochrome P450	608	623	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:7	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the expression of Cytochrome P450 genes in the hearts of both male and female C57Bl/6 mice. 	Cytochrome P450	761	776	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:7	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the expression of Cytochrome P450 genes in the hearts of both male and female C57Bl/6 mice. 	Cytochrome P450	761	776	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:13	Total RNA was extracted and expression of natriuretic peptides, inflammatory and apoptotic markers, and Cytochrome P450 genes was measured by real-time Time-Polymerase Chain Reaction. 	Cytochrome P450	1368	1383	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:13	Total RNA was extracted and expression of natriuretic peptides, inflammatory and apoptotic markers, and Cytochrome P450 genes was measured by real-time Time-Polymerase Chain Reaction. 	Cytochrome P450	1368	1383	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:15	Acute Doxorubicin exposure altered the gene expression of multiple Cytochrome P450 genes in a sex-dependent manner. 	Cytochrome P450	1764	1779	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:15	Acute Doxorubicin exposure altered the gene expression of multiple Cytochrome P450 genes in a sex-dependent manner. 	Cytochrome P450	1764	1779	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:17	Acute Doxorubicin exposure causes sex-dependent alteration of cardiac Cytochrome P450 gene expression. 	Cytochrome P450	2007	2022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:17	Acute Doxorubicin exposure causes sex-dependent alteration of cardiac Cytochrome P450 gene expression. 	Cytochrome P450	2007	2022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	Cytochrome P450	2054	2069	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	Cytochrome P450	2054	2069	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	Cytochrome P450	2182	2197	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	Cytochrome P450	2182	2197	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450	5052	5067	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450	5052	5067	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450	5142	5157	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450	5142	5157	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:34	Sex-divergent expression of Cytochrome P450 genes has been well studied in the liver; however, a few studies have also reported sex-divergent expression of Cytochrome P450 genes in other organs. 	Cytochrome P450	5309	5324	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:34	Sex-divergent expression of Cytochrome P450 genes has been well studied in the liver; however, a few studies have also reported sex-divergent expression of Cytochrome P450 genes in other organs. 	Cytochrome P450	5309	5324	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:34	Sex-divergent expression of Cytochrome P450 genes has been well studied in the liver; however, a few studies have also reported sex-divergent expression of Cytochrome P450 genes in other organs. 	Cytochrome P450	5437	5452	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:34	Sex-divergent expression of Cytochrome P450 genes has been well studied in the liver; however, a few studies have also reported sex-divergent expression of Cytochrome P450 genes in other organs. 	Cytochrome P450	5437	5452	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:35	Of interest, a recent study has demonstrated sex-dependent expression of some Cytochrome P450 genes in the rodent heart. 	Cytochrome P450	5554	5569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:35	Of interest, a recent study has demonstrated sex-dependent expression of some Cytochrome P450 genes in the rodent heart. 	Cytochrome P450	5554	5569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:36	Nevertheless, the sex-dependent effect of Doxorubicin on Cytochrome P450 gene expression is still not known. 	Cytochrome P450	5654	5669	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:36	Nevertheless, the sex-dependent effect of Doxorubicin on Cytochrome P450 gene expression is still not known. 	Cytochrome P450	5654	5669	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	Cytochrome P450	5820	5835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	Cytochrome P450	5820	5835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	Cytochrome P450	5975	5990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	Cytochrome P450	5975	5990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:38	We demonstrate for the first time that DOX-induced alteration of Cytochrome P450 gene expression is sex-dependent which may explain, at least in part, the sex-related differences of DOX-induced cardiotoxicity. 	Cytochrome P450	6073	6088	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:38	We demonstrate for the first time that DOX-induced alteration of Cytochrome P450 gene expression is sex-dependent which may explain, at least in part, the sex-related differences of DOX-induced cardiotoxicity. 	Cytochrome P450	6073	6088	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:73	Since we previously reported changes of certain Cytochrome P450 genes by acute Doxorubicin exposure in male rats, the mouse orthologs of those rat Cytochrome P450 genes were selected for the current study. 	Cytochrome P450	12746	12761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:73	Since we previously reported changes of certain Cytochrome P450 genes by acute Doxorubicin exposure in male rats, the mouse orthologs of those rat Cytochrome P450 genes were selected for the current study. 	Cytochrome P450	12746	12761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:73	Since we previously reported changes of certain Cytochrome P450 genes by acute Doxorubicin exposure in male rats, the mouse orthologs of those rat Cytochrome P450 genes were selected for the current study. 	Cytochrome P450	12845	12860	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:73	Since we previously reported changes of certain Cytochrome P450 genes by acute Doxorubicin exposure in male rats, the mouse orthologs of those rat Cytochrome P450 genes were selected for the current study. 	Cytochrome P450	12845	12860	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:83	To correct for multiple comparisons, a false discovery rate of 5% was applied for p values of Doxorubicin effect, sex effect, and interaction effect on Cytochrome P450 gene expressions by the Two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. 	Cytochrome P450	14643	14658	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:83	To correct for multiple comparisons, a false discovery rate of 5% was applied for p values of Doxorubicin effect, sex effect, and interaction effect on Cytochrome P450 gene expressions by the Two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. 	Cytochrome P450	14643	14658	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:138	A growing body of evidence suggests an important role of Cytochrome P450 enzymes in the pathogenesis of DOX-induced cardiotoxicity [,. 	Cytochrome P450	25130	25145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:138	A growing body of evidence suggests an important role of Cytochrome P450 enzymes in the pathogenesis of DOX-induced cardiotoxicity [,. 	Cytochrome P450	25130	25145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:139	Cytochrome P450 enzymes play important roles in metabolizing sex steroids and other endogenous compounds, such as arachidonic acid that have significant biological effects on the cardiovascular system. 	Cytochrome P450	25208	25223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:139	Cytochrome P450 enzymes play important roles in metabolizing sex steroids and other endogenous compounds, such as arachidonic acid that have significant biological effects on the cardiovascular system. 	Cytochrome P450	25208	25223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:140	Interestingly, there is a significant sex-divergent expression of several Cytochrome P450 enzymes in both humans and experimental animals. 	Cytochrome P450	25484	25499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:140	Interestingly, there is a significant sex-divergent expression of several Cytochrome P450 enzymes in both humans and experimental animals. 	Cytochrome P450	25484	25499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:141	Therefore, we hypothesized that Doxorubicin alters Cytochrome P450 enzymes in a sex-dependent manner to mediate sexual dimorphism of DOX-induced cardiotoxicity. 	Cytochrome P450	25600	25615	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:141	Therefore, we hypothesized that Doxorubicin alters Cytochrome P450 enzymes in a sex-dependent manner to mediate sexual dimorphism of DOX-induced cardiotoxicity. 	Cytochrome P450	25600	25615	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:189	In addition, we have demonstrated for the first time that acute Doxorubicin exposure alters Cytochrome P450 gene expression in a sex-dependent manner. 	Cytochrome P450	33675	33690	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:189	In addition, we have demonstrated for the first time that acute Doxorubicin exposure alters Cytochrome P450 gene expression in a sex-dependent manner. 	Cytochrome P450	33675	33690	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:1	 Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1. 	Cytochrome P450	129	144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:1	 Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1. 	Cytochrome P450	129	144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:1	 Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. 	Cytochrome P450	23	38	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:1	 Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. 	Cytochrome P450	23	38	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:118	Glutathione-S-transferases and Cytochrome P450 families are the most common detoxification genes among hymenoptera and we examined these two families in detail. 	Cytochrome P450	16449	16464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:118	Glutathione-S-transferases and Cytochrome P450 families are the most common detoxification genes among hymenoptera and we examined these two families in detail. 	Cytochrome P450	16449	16464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:233	Cytochrome P450 superfamily evolution in Formicidae was extensively studied. 	Cytochrome P450	31193	31208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:233	Cytochrome P450 superfamily evolution in Formicidae was extensively studied. 	Cytochrome P450	31193	31208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:240	Cytochrome P450 genes have wide range of substrates and single amino acid substitution can drastically change substrate specificity. 	Cytochrome P450	31931	31946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:240	Cytochrome P450 genes have wide range of substrates and single amino acid substitution can drastically change substrate specificity. 	Cytochrome P450	31931	31946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:242	Cytochrome P450 genes may also be important in resistance to urban pollutants of different chemical composition (polycyclic hydrocarbons, plastics, and petrochemicals). 	Cytochrome P450	32364	32379	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:242	Cytochrome P450 genes may also be important in resistance to urban pollutants of different chemical composition (polycyclic hydrocarbons, plastics, and petrochemicals). 	Cytochrome P450	32364	32379	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	Cytochrome P450	32681	32696	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	Cytochrome P450	32681	32696	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	Cytochrome P450	32953	32968	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	Cytochrome P450	32953	32968	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:166	In recent times, studies have also suggested possible interactions between dietary polyphenols and Cytochrome P450 3A4, which could lead to some adverse effects. 	Cytochrome P450	33303	33318	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:166	In recent times, studies have also suggested possible interactions between dietary polyphenols and Cytochrome P450 3A4, which could lead to some adverse effects. 	Cytochrome P450	33303	33318	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:172	One thing most of these studies reporting on the interaction of polyphenols with Cytochrome P450 enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes. 	Cytochrome P450	34447	34462	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:172	One thing most of these studies reporting on the interaction of polyphenols with Cytochrome P450 enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes. 	Cytochrome P450	34447	34462	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:1	 Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes. 	Cytochrome P450	96	111	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:1	 Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes. 	Cytochrome P450	96	111	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	Cytochrome P450	1580	1595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	Cytochrome P450	1580	1595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:12	For the prediction of herb-drug interaction, it is necessary to investigate the in vitro inhibitory effects of herb drugs and the constituents on major human Cytochrome P450 enzyme activities. 	Cytochrome P450	3461	3476	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:12	For the prediction of herb-drug interaction, it is necessary to investigate the in vitro inhibitory effects of herb drugs and the constituents on major human Cytochrome P450 enzyme activities. 	Cytochrome P450	3461	3476	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:13	In vitro inhibitory effects of the pharmacologically active lignans such as aschantin, honokiol, machilin A, phyllantin, hypophyllantin, and podophyllotoxin on Cytochrome P450 enzymes have been reported. 	Cytochrome P450	3656	3671	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:13	In vitro inhibitory effects of the pharmacologically active lignans such as aschantin, honokiol, machilin A, phyllantin, hypophyllantin, and podophyllotoxin on Cytochrome P450 enzymes have been reported. 	Cytochrome P450	3656	3671	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:14	However, there are no reports on the in vitro and in vivo inhibitory effects of the bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on human Cytochrome P450 enzymes. 	Cytochrome P450	3912	3927	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:14	However, there are no reports on the in vitro and in vivo inhibitory effects of the bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on human Cytochrome P450 enzymes. 	Cytochrome P450	3912	3927	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:15	In the present study, the in vitro inhibition potency and inhibition mechanisms of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) activities in pooled human liver microsomes were evaluated to decide the performance of in vivo drug interaction studies of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin. 	Cytochrome P450	4107	4122	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:15	In the present study, the in vitro inhibition potency and inhibition mechanisms of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) activities in pooled human liver microsomes were evaluated to decide the performance of in vivo drug interaction studies of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin. 	Cytochrome P450	4107	4122	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:16	The reversible and time-dependent inhibitory potencials (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 enzymes were investigated in human liver microsomes. 	Cytochrome P450	4530	4545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:16	The reversible and time-dependent inhibitory potencials (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 enzymes were investigated in human liver microsomes. 	Cytochrome P450	4530	4545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	Cytochrome P450	5339	5354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	Cytochrome P450	5339	5354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:24	In this study, the in vitro inhibitory effects of bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major Cytochrome P450 enzymes were, for the first time, evaluated in pooled human liver microsomes. 	Cytochrome P450	7154	7169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:24	In this study, the in vitro inhibitory effects of bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major Cytochrome P450 enzymes were, for the first time, evaluated in pooled human liver microsomes. 	Cytochrome P450	7154	7169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:28	These results indicate that Cytochrome P450 inhibitory capacity of tetrahydrofurofuranoid lignans depends on the presence of a methylenedioxyphenyl moiety. 	Cytochrome P450	8047	8062	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:28	These results indicate that Cytochrome P450 inhibitory capacity of tetrahydrofurofuranoid lignans depends on the presence of a methylenedioxyphenyl moiety. 	Cytochrome P450	8047	8062	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	Cytochrome P450	11893	11908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:46	The degree of inhibition (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin toward CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities in pooled human liver microsomes were evaluated following our previous method using Cytochrome P450 cocktail substrates and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 	Cytochrome P450	11893	11908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:47	The incubation mixtures were prepared in total volumes of 100 L as follows: 50 mM potassium phosphate buffer (pH 7.4), 1.0 mM NADPH, 10 mM MgCl_2, pooled human liver microsomes (0.2 mg/mL), various concentrations of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, or magnolin in acetonitrile (final concentrations of 0.1-100 M, acetonitrile 0.5% (v/v)), and a cocktail of seven Cytochrome P450 probe substrates (2.0 M amodiaquine, 5 M bufuralol, 2.5 M coumarin, 10 M diclofenac, 100 M [S]-mephenytoin, 2.5 M midazolam, and 50 M phenacetin, acetonitrile 0.5% (v/v)). 	Cytochrome P450	12379	12394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:47	The incubation mixtures were prepared in total volumes of 100 L as follows: 50 mM potassium phosphate buffer (pH 7.4), 1.0 mM NADPH, 10 mM MgCl_2, pooled human liver microsomes (0.2 mg/mL), various concentrations of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, or magnolin in acetonitrile (final concentrations of 0.1-100 M, acetonitrile 0.5% (v/v)), and a cocktail of seven Cytochrome P450 probe substrates (2.0 M amodiaquine, 5 M bufuralol, 2.5 M coumarin, 10 M diclofenac, 100 M [S]-mephenytoin, 2.5 M midazolam, and 50 M phenacetin, acetonitrile 0.5% (v/v)). 	Cytochrome P450	12379	12394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	Cytochrome P450	17429	17444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:66	Aliquots (10 L) of the pre-incubation mixtures were collected at 5, 10, 15, and 20 min after the pre-incubation and transferred to new tubes containing Cytochrome P450 substrates (2 M amodiaquine for CYP2C8, 100 M [S]-mephenytoin for CYP2C19, or 2 M midazolam for CYP3A4), 10 mM MgCl_2, 1 mM NADPH, and 50 mM potassium phosphate buffer (pH 7.4) in 90 L reaction mixtures. 	Cytochrome P450	17429	17444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:76	Epimagnolin A, eudesmin, and magnolin showed no reversible or time-dependent inhibition of 8 major Cytochrome P450 activities at 100 M in human liver microsomes. 	Cytochrome P450	18951	18966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:76	Epimagnolin A, eudesmin, and magnolin showed no reversible or time-dependent inhibition of 8 major Cytochrome P450 activities at 100 M in human liver microsomes. 	Cytochrome P450	18951	18966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:1	 Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. 	Cytochrome P450	1	16	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:1	 Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. 	Cytochrome P450	1	16	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:2	Cytochrome P450 1B1 is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. 	Cytochrome P450	103	118	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:2	Cytochrome P450 1B1 is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. 	Cytochrome P450	103	118	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:3	Despite its up-regulation in prostate cancer, biological significance and clinicopathological features of Cytochrome P450 1b1 are still elusive. 	Cytochrome P450	362	377	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:3	Despite its up-regulation in prostate cancer, biological significance and clinicopathological features of Cytochrome P450 1b1 are still elusive. 	Cytochrome P450	362	377	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:4	Here, we show that overexpression or hyperactivation of Cytochrome P450 1b1 stimulated proliferative, migratory and invasive potential of non-tumorigenic Prostate Cancer cells. 	Cytochrome P450	457	472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:4	Here, we show that overexpression or hyperactivation of Cytochrome P450 1b1 stimulated proliferative, migratory and invasive potential of non-tumorigenic Prostate Cancer cells. 	Cytochrome P450	457	472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:5	Attenuation of Cytochrome P450 1b1 with its specific small hairpin RNAs greatly reduced proliferation through apoptotic cell death and impaired migration and invasion in Prostate Cancer cells. 	Cytochrome P450	593	608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:5	Attenuation of Cytochrome P450 1b1 with its specific small hairpin RNAs greatly reduced proliferation through apoptotic cell death and impaired migration and invasion in Prostate Cancer cells. 	Cytochrome P450	593	608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:6	Intratumoral injection of Cytochrome P450 1b1 shRNA attenuated growth of pre-existing tumors. 	Cytochrome P450	797	812	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:6	Intratumoral injection of Cytochrome P450 1b1 shRNA attenuated growth of pre-existing tumors. 	Cytochrome P450	797	812	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:7	The antitumor effect of Cytochrome P450 1b1 shRNA was also observed in prostate tumor xenograft mouse models. 	Cytochrome P450	889	904	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:7	The antitumor effect of Cytochrome P450 1b1 shRNA was also observed in prostate tumor xenograft mouse models. 	Cytochrome P450	889	904	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:8	Among the genes altered by Cytochrome P450 1b1 knockdown, reduction of caspase-1 activity attenuated the antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	1002	1017	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:8	Among the genes altered by Cytochrome P450 1b1 knockdown, reduction of caspase-1 activity attenuated the antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	1002	1017	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:8	Among the genes altered by Cytochrome P450 1b1 knockdown, reduction of caspase-1 activity attenuated the antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	1100	1115	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:8	Among the genes altered by Cytochrome P450 1b1 knockdown, reduction of caspase-1 activity attenuated the antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	1100	1115	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:9	Indeed, Cytochrome P450 1b1 regulates Caspase-1 expression or activity. 	Cytochrome P450	1140	1155	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:9	Indeed, Cytochrome P450 1b1 regulates Caspase-1 expression or activity. 	Cytochrome P450	1140	1155	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:10	Finally, Cytochrome P450 1b1 expression was increased in higher grades of Prostate Cancer and overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein. 	Cytochrome P450	1213	1228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:10	Finally, Cytochrome P450 1b1 expression was increased in higher grades of Prostate Cancer and overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein. 	Cytochrome P450	1213	1228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:10	Finally, Cytochrome P450 1b1 expression was increased in higher grades of Prostate Cancer and overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein. 	Cytochrome P450	1373	1388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:10	Finally, Cytochrome P450 1b1 expression was increased in higher grades of Prostate Cancer and overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein. 	Cytochrome P450	1373	1388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:11	Cytochrome P450 1b1 expression was reversely associated with Caspase-1 expression in clinical tissue samples. 	Cytochrome P450	1402	1417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:11	Cytochrome P450 1b1 expression was reversely associated with Caspase-1 expression in clinical tissue samples. 	Cytochrome P450	1402	1417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:12	Together, our results demonstrate that Cytochrome P450 1b1 regulates Prostate Cancer tumorigenesis by inhibiting Caspase-1 activation. 	Cytochrome P450	1551	1566	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:12	Together, our results demonstrate that Cytochrome P450 1b1 regulates Prostate Cancer tumorigenesis by inhibiting Caspase-1 activation. 	Cytochrome P450	1551	1566	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:15	Among CYP1 family members, Cytochrome P450 1b1 is the only member of the CYP1B subfamily and mainly implicated in the hydroxylation of estrogen and activation of environmental carcinogens. 	Cytochrome P450	1909	1924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:15	Among CYP1 family members, Cytochrome P450 1b1 is the only member of the CYP1B subfamily and mainly implicated in the hydroxylation of estrogen and activation of environmental carcinogens. 	Cytochrome P450	1909	1924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:16	Cytochrome P450 1b1 protein is found in the cancer cells of various cancerous tissues but is undetectable or minimally expressed in the adjacent normal cells of cancer tissues and normal tissues. 	Cytochrome P450	2071	2086	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:16	Cytochrome P450 1b1 protein is found in the cancer cells of various cancerous tissues but is undetectable or minimally expressed in the adjacent normal cells of cancer tissues and normal tissues. 	Cytochrome P450	2071	2086	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:17	Therefore, Cytochrome P450 1b1 has been recognized as a potential tumor biomarker and a promising target for anticancer therapy. 	Cytochrome P450	2278	2293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:17	Therefore, Cytochrome P450 1b1 has been recognized as a potential tumor biomarker and a promising target for anticancer therapy. 	Cytochrome P450	2278	2293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:18	Tumor-specific overexpression of Cytochrome P450 1b1 indicates its role as a regulator of tumor progression. 	Cytochrome P450	2429	2444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:18	Tumor-specific overexpression of Cytochrome P450 1b1 indicates its role as a regulator of tumor progression. 	Cytochrome P450	2429	2444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:20	showed that Cytochrome P450 1b1 knockdown inhibits endometrial carcinogenesis by affecting cellular proliferation, cell cycle and invasive potential through the regulation of cyclin E1, Skp2, and TRAIL. 	Cytochrome P450	2530	2545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:20	showed that Cytochrome P450 1b1 knockdown inhibits endometrial carcinogenesis by affecting cellular proliferation, cell cycle and invasive potential through the regulation of cyclin E1, Skp2, and TRAIL. 	Cytochrome P450	2530	2545	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:21	In squamous cell carcinoma of the head and neck, Cytochrome P450 1b1 knockdown reduced the migration and proliferation of premalignant cells and CYP1B1-mediated estrogen metabolism is essential for cancer development. 	Cytochrome P450	2770	2785	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:21	In squamous cell carcinoma of the head and neck, Cytochrome P450 1b1 knockdown reduced the migration and proliferation of premalignant cells and CYP1B1-mediated estrogen metabolism is essential for cancer development. 	Cytochrome P450	2770	2785	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:22	We reported that Cytochrome P450 1b1 expression is regulated by miR-200c and high Cytochrome P450 1b1 levels contribute to resistance of renal cell carcinoma to docetaxel. 	Cytochrome P450	2956	2971	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:22	We reported that Cytochrome P450 1b1 expression is regulated by miR-200c and high Cytochrome P450 1b1 levels contribute to resistance of renal cell carcinoma to docetaxel. 	Cytochrome P450	2956	2971	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:22	We reported that Cytochrome P450 1b1 expression is regulated by miR-200c and high Cytochrome P450 1b1 levels contribute to resistance of renal cell carcinoma to docetaxel. 	Cytochrome P450	3021	3036	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:22	We reported that Cytochrome P450 1b1 expression is regulated by miR-200c and high Cytochrome P450 1b1 levels contribute to resistance of renal cell carcinoma to docetaxel. 	Cytochrome P450	3021	3036	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:23	In addition, Cytochrome P450 1b1 reduction altered expression of CDC20 and DAPK1 and resulted in the disturbance of cell cycle and apoptosis in Renal Cell Carcinoma. 	Cytochrome P450	3124	3139	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:23	In addition, Cytochrome P450 1b1 reduction altered expression of CDC20 and DAPK1 and resulted in the disturbance of cell cycle and apoptosis in Renal Cell Carcinoma. 	Cytochrome P450	3124	3139	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:37	Cytochrome P450 1b1 expression has been found in both normal prostate tissues and prostate tumors including normal-adjacent tissues, with markedly higher levels in Prostate Cancer compared with benign tissues [,. 	Cytochrome P450	4858	4873	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:37	Cytochrome P450 1b1 expression has been found in both normal prostate tissues and prostate tumors including normal-adjacent tissues, with markedly higher levels in Prostate Cancer compared with benign tissues [,. 	Cytochrome P450	4858	4873	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:38	CpG methylation of the promoter/enhancer has been suggested as a mechanism controlling cancer-specific expression of Cytochrome P450 1b1. 	Cytochrome P450	5188	5203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:38	CpG methylation of the promoter/enhancer has been suggested as a mechanism controlling cancer-specific expression of Cytochrome P450 1b1. 	Cytochrome P450	5188	5203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:39	Cytochrome P450 1b1 metabolites such as 4-hydroxyestradiol and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine were reported to induce Prostate Cancer in experimental animal models [,. 	Cytochrome P450	5209	5224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:39	Cytochrome P450 1b1 metabolites such as 4-hydroxyestradiol and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine were reported to induce Prostate Cancer in experimental animal models [,. 	Cytochrome P450	5209	5224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:41	Polymorphic variants of Cytochrome P450 1b1 altering the catabolism of estrogen may modify prostate cancer risk and may also predict response to chemotherapy. 	Cytochrome P450	5583	5598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:41	Polymorphic variants of Cytochrome P450 1b1 altering the catabolism of estrogen may modify prostate cancer risk and may also predict response to chemotherapy. 	Cytochrome P450	5583	5598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:42	These evidences strongly suggest that Cytochrome P450 1b1 plays a potentially crucial role in prostate tumor development and progression. 	Cytochrome P450	5756	5771	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:42	These evidences strongly suggest that Cytochrome P450 1b1 plays a potentially crucial role in prostate tumor development and progression. 	Cytochrome P450	5756	5771	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:43	However, the functional impact and clinicopathological significance of Cytochrome P450 1b1 up-regulation in Prostate Cancer are still largely unknown. 	Cytochrome P450	5927	5942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:43	However, the functional impact and clinicopathological significance of Cytochrome P450 1b1 up-regulation in Prostate Cancer are still largely unknown. 	Cytochrome P450	5927	5942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:44	In this study, we explored the functional role of Cytochrome P450 1b1 in the transformation and tumorigenesis of Prostate Cancer. 	Cytochrome P450	6057	6072	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:44	In this study, we explored the functional role of Cytochrome P450 1b1 in the transformation and tumorigenesis of Prostate Cancer. 	Cytochrome P450	6057	6072	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:45	We also assessed the feasibility of Cytochrome P450 1b1 targeting for the treatment of Prostate Cancer in an experimental animal model. 	Cytochrome P450	6173	6188	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:45	We also assessed the feasibility of Cytochrome P450 1b1 targeting for the treatment of Prostate Cancer in an experimental animal model. 	Cytochrome P450	6173	6188	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:46	The molecular target of Cytochrome P450 1b1 action and clinical relevance of its overexpression were also elucidated. 	Cytochrome P450	6297	6312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:46	The molecular target of Cytochrome P450 1b1 action and clinical relevance of its overexpression were also elucidated. 	Cytochrome P450	6297	6312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:48	Relative expression of Cytochrome P450 1b1 protein and mRNA was amplified in all the examined cancer cell lines compared with the RWPE-1 cells. 	Cytochrome P450	6606	6621	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:48	Relative expression of Cytochrome P450 1b1 protein and mRNA was amplified in all the examined cancer cell lines compared with the RWPE-1 cells. 	Cytochrome P450	6606	6621	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:49	To explore the functional role of Cytochrome P450 1b1 in Prostate Cancer, we first investigated the effect of its up-regulation in prostate epithelial cells using RWPE-1 cell lines. 	Cytochrome P450	6761	6776	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:49	To explore the functional role of Cytochrome P450 1b1 in Prostate Cancer, we first investigated the effect of its up-regulation in prostate epithelial cells using RWPE-1 cell lines. 	Cytochrome P450	6761	6776	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:50	Exogenous expression of Cytochrome P450 1b1 significantly enhanced proliferation and colony formation and also stimulated cell motility and invasiveness of RWPE-1 cells and promoted growth, motility and invasiveness of RWPE-1 cells (Figure  to. 	Cytochrome P450	6933	6948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:50	Exogenous expression of Cytochrome P450 1b1 significantly enhanced proliferation and colony formation and also stimulated cell motility and invasiveness of RWPE-1 cells and promoted growth, motility and invasiveness of RWPE-1 cells (Figure  to. 	Cytochrome P450	6933	6948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:51	These results indicate that overexpression and activation of Cytochrome P450 1b1 regulates oncogenic activity in prostate cells. 	Cytochrome P450	7215	7230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:51	These results indicate that overexpression and activation of Cytochrome P450 1b1 regulates oncogenic activity in prostate cells. 	Cytochrome P450	7215	7230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7289	7304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7289	7304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7361	7376	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7361	7376	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7441	7456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:52	Since Cytochrome P450 1b1 is up-regulated in Prostate Cancer cells, we used a Cytochrome P450 1b1 knockdown approach with lentivirus-mediated shRNA targeting Cytochrome P450 1b1 to explore its biological significance. 	Cytochrome P450	7441	7456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:53	To this end, we generated Cytochrome P450 1b1 deficient PC-3 and DU145 cells. 	Cytochrome P450	7527	7542	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:53	To this end, we generated Cytochrome P450 1b1 deficient PC-3 and DU145 cells. 	Cytochrome P450	7527	7542	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:54	Among the 4 shRNA candidates, the Cytochrome P450 1b1 shRNA #4 construct in PC-3 cells and #2 construct in DU145 cells exhibited the best efficiency by transient transfection and were used for establishing stable cell lines. 	Cytochrome P450	7613	7628	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:54	Among the 4 shRNA candidates, the Cytochrome P450 1b1 shRNA #4 construct in PC-3 cells and #2 construct in DU145 cells exhibited the best efficiency by transient transfection and were used for establishing stable cell lines. 	Cytochrome P450	7613	7628	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:55	Subclones were produced from stably transfected Cytochrome P450 1b1 shRNAs and the resultant knockdown cell lines, PC-3/CYP1B1 shRNA #4-2 and #4-3, and DU145/CYP1B1 shRNA #2-12 and #2-23, were selected for the further functional studies (Figure  and ;. 	Cytochrome P450	7852	7867	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:55	Subclones were produced from stably transfected Cytochrome P450 1b1 shRNAs and the resultant knockdown cell lines, PC-3/CYP1B1 shRNA #4-2 and #4-3, and DU145/CYP1B1 shRNA #2-12 and #2-23, were selected for the further functional studies (Figure  and ;. 	Cytochrome P450	7852	7867	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:56	No difference in cell growth and morphology was observed during first and the 2 days of cell growth but cell proliferation was significantly decreased starting 3 days after seeding of both Cytochrome P450 1b1 knockdown cell lines (Figure  and. 	Cytochrome P450	8246	8261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:56	No difference in cell growth and morphology was observed during first and the 2 days of cell growth but cell proliferation was significantly decreased starting 3 days after seeding of both Cytochrome P450 1b1 knockdown cell lines (Figure  and. 	Cytochrome P450	8246	8261	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:57	Clonogenic assays also confirmed the impact of Cytochrome P450 1b1 inhibition on delayed growth of cells (Figure  and. 	Cytochrome P450	8348	8363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:57	Clonogenic assays also confirmed the impact of Cytochrome P450 1b1 inhibition on delayed growth of cells (Figure  and. 	Cytochrome P450	8348	8363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:58	To further understand the growth-inhibitory effect of Cytochrome P450 1b1 reduction, we assessed apoptosis and cell cycle distribution by flow cytometric analysis. 	Cytochrome P450	8474	8489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:58	To further understand the growth-inhibitory effect of Cytochrome P450 1b1 reduction, we assessed apoptosis and cell cycle distribution by flow cytometric analysis. 	Cytochrome P450	8474	8489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:59	The apoptotic cell fractions were significantly increased in Cytochrome P450 1b1 knockdown cells (Figure  and. 	Cytochrome P450	8645	8660	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:59	The apoptotic cell fractions were significantly increased in Cytochrome P450 1b1 knockdown cells (Figure  and. 	Cytochrome P450	8645	8660	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:61	We did observe that Cytochrome P450 1b1 inhibition results in lower motility and invasiveness of Prostate Cancer cells (Figure  and ;. 	Cytochrome P450	8799	8814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:61	We did observe that Cytochrome P450 1b1 inhibition results in lower motility and invasiveness of Prostate Cancer cells (Figure  and ;. 	Cytochrome P450	8799	8814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:62	These results suggest that Cytochrome P450 1b1 plays a role as an oncogene in Prostate Cancer and its targeted inhibition could suppress tumorigenesis. 	Cytochrome P450	8941	8956	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:62	These results suggest that Cytochrome P450 1b1 plays a role as an oncogene in Prostate Cancer and its targeted inhibition could suppress tumorigenesis. 	Cytochrome P450	8941	8956	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:63	To validate the antitumor effect of Cytochrome P450 1b1 inhibition and further examine its use as therapeutic target for prostate cancer, in vivo models were utilized. 	Cytochrome P450	9102	9117	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:63	To validate the antitumor effect of Cytochrome P450 1b1 inhibition and further examine its use as therapeutic target for prostate cancer, in vivo models were utilized. 	Cytochrome P450	9102	9117	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:64	In one model, Cytochrome P450 1b1 or control shRNA were administered intratumourally after allowing inoculated PC-3 cells to establish into tumors. 	Cytochrome P450	9248	9263	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:64	In one model, Cytochrome P450 1b1 or control shRNA were administered intratumourally after allowing inoculated PC-3 cells to establish into tumors. 	Cytochrome P450	9248	9263	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:65	As shown in Figure  and, decreased growth was observed in tumors receiving Cytochrome P450 1b1 shRNA compared to those treated with control shRNA. 	Cytochrome P450	9457	9472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:65	As shown in Figure  and, decreased growth was observed in tumors receiving Cytochrome P450 1b1 shRNA compared to those treated with control shRNA. 	Cytochrome P450	9457	9472	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:66	The average tumor size after 5 weeks of control shRNA injection was 595.7102.6 mm^3 compared to 249.346.6 mm^3 in tumors treated with Cytochrome P450 1b1 shRNA. 	Cytochrome P450	9663	9678	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:66	The average tumor size after 5 weeks of control shRNA injection was 595.7102.6 mm^3 compared to 249.346.6 mm^3 in tumors treated with Cytochrome P450 1b1 shRNA. 	Cytochrome P450	9663	9678	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:67	Administration of Cytochrome P450 1b1 shRNA induced low cell proliferation in tumors compared to those treated with control shRNA (Figure. 	Cytochrome P450	9708	9723	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:67	Administration of Cytochrome P450 1b1 shRNA induced low cell proliferation in tumors compared to those treated with control shRNA (Figure. 	Cytochrome P450	9708	9723	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:68	Reduction of Cytochrome P450 1b1 protein level was confirmed in tumors injected with Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	9842	9857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:68	Reduction of Cytochrome P450 1b1 protein level was confirmed in tumors injected with Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	9842	9857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:68	Reduction of Cytochrome P450 1b1 protein level was confirmed in tumors injected with Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	9914	9929	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:68	Reduction of Cytochrome P450 1b1 protein level was confirmed in tumors injected with Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	9914	9929	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:69	In addition, PC-3 cells stably expressing Cytochrome P450 1b1 shRNA #4-2 or control shRNA were subcutaneously injected into the flank of nude mice. 	Cytochrome P450	9991	10006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:69	In addition, PC-3 cells stably expressing Cytochrome P450 1b1 shRNA #4-2 or control shRNA were subcutaneously injected into the flank of nude mice. 	Cytochrome P450	9991	10006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:70	Decreased prostate tumor growth was observed in tumors expressing Cytochrome P450 1b1 shRNA #4-2 compared to those expressing control shRNA (Figure. 	Cytochrome P450	10163	10178	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:70	Decreased prostate tumor growth was observed in tumors expressing Cytochrome P450 1b1 shRNA #4-2 compared to those expressing control shRNA (Figure. 	Cytochrome P450	10163	10178	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:71	The average tumor size after 5 weeks was 792.5116.2 mm^3 in PC-3/control shRNA cells and 240.081.9 mm^3 in tumors stably expressing Cytochrome P450 1b1 shRNA #4-2 (Figure. 	Cytochrome P450	10378	10393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:71	The average tumor size after 5 weeks was 792.5116.2 mm^3 in PC-3/control shRNA cells and 240.081.9 mm^3 in tumors stably expressing Cytochrome P450 1b1 shRNA #4-2 (Figure. 	Cytochrome P450	10378	10393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:72	Tumor cells containing Cytochrome P450 1b1 shRNA displayed a significant difference in the number of Ki67-positive cells compared to cells harboring control shRNA (Figure. 	Cytochrome P450	10441	10456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:72	Tumor cells containing Cytochrome P450 1b1 shRNA displayed a significant difference in the number of Ki67-positive cells compared to cells harboring control shRNA (Figure. 	Cytochrome P450	10441	10456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:73	The level of Cytochrome P450 1b1 protein was reduced in tumors expressing Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	10603	10618	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:73	The level of Cytochrome P450 1b1 protein was reduced in tumors expressing Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	10603	10618	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:73	The level of Cytochrome P450 1b1 protein was reduced in tumors expressing Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	10664	10679	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:73	The level of Cytochrome P450 1b1 protein was reduced in tumors expressing Cytochrome P450 1b1 shRNA (Figure. 	Cytochrome P450	10664	10679	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:74	These results suggest that Cytochrome P450 1b1 inhibition effectively inhibits growth of tumor cells in vivo and could be a therapeutic target for Prostate Cancer. 	Cytochrome P450	10726	10741	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:74	These results suggest that Cytochrome P450 1b1 inhibition effectively inhibits growth of tumor cells in vivo and could be a therapeutic target for Prostate Cancer. 	Cytochrome P450	10726	10741	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:75	To delineate the mechanism of the Cytochrome P450 1b1 inhibition-induced antitumor effect, we looked for changes in gene expression in PC-3/CYP1B1 shRNA #4-2 cells using the Human Apoptosis RT^2 Profiler PCR Array and Human CancerPathFinder RT^2 Profiler PCR Array. 	Cytochrome P450	10897	10912	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:75	To delineate the mechanism of the Cytochrome P450 1b1 inhibition-induced antitumor effect, we looked for changes in gene expression in PC-3/CYP1B1 shRNA #4-2 cells using the Human Apoptosis RT^2 Profiler PCR Array and Human CancerPathFinder RT^2 Profiler PCR Array. 	Cytochrome P450	10897	10912	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:80	Thus, we hypothesize Caspase-1 to be a potential target of CYP1B1-mediated tumorigenic activity and antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	12161	12176	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:80	Thus, we hypothesize Caspase-1 to be a potential target of CYP1B1-mediated tumorigenic activity and antitumor effect of Cytochrome P450 1b1 inhibition. 	Cytochrome P450	12161	12176	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:81	In addition to PC-3 cells, Cytochrome P450 1b1 knockdown induces Caspase-1 mRNA and protein expression in DU145 cells (Figure  and. 	Cytochrome P450	12220	12235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:81	In addition to PC-3 cells, Cytochrome P450 1b1 knockdown induces Caspase-1 mRNA and protein expression in DU145 cells (Figure  and. 	Cytochrome P450	12220	12235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:82	Consistent with upregulation at the gene level, Caspase-1 enzyme activity was also significantly enhanced in both Cytochrome P450 1b1 knockdown cells (Figure. 	Cytochrome P450	12439	12454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:82	Consistent with upregulation at the gene level, Caspase-1 enzyme activity was also significantly enhanced in both Cytochrome P450 1b1 knockdown cells (Figure. 	Cytochrome P450	12439	12454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:83	To determine the impact of Caspase-1 on the Cytochrome P450 1b1 inhibition-mediated anti-tumor effect, we examined the rate of cell proliferation and apoptosis. 	Cytochrome P450	12528	12543	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:83	To determine the impact of Caspase-1 on the Cytochrome P450 1b1 inhibition-mediated anti-tumor effect, we examined the rate of cell proliferation and apoptosis. 	Cytochrome P450	12528	12543	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:84	Treatment with Z-YVAD-fmk, a specific inhibitor of Caspase-1, accelerated the rates of proliferation in Cytochrome P450 1b1 knockdown cells (Figure. 	Cytochrome P450	12749	12764	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:84	Treatment with Z-YVAD-fmk, a specific inhibitor of Caspase-1, accelerated the rates of proliferation in Cytochrome P450 1b1 knockdown cells (Figure. 	Cytochrome P450	12749	12764	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:86	Next, we evaluated the effect of Caspase-1 in the low migration and invasiveness caused by Cytochrome P450 1b1 inhibition. 	Cytochrome P450	12964	12979	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:86	Next, we evaluated the effect of Caspase-1 in the low migration and invasiveness caused by Cytochrome P450 1b1 inhibition. 	Cytochrome P450	12964	12979	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:88	In addition to the genetic approach, Caspase-1 activity was increased by 2,3,4,5-Tetramethoxystilbene, a chemical inhibitor of Cytochrome P450 1b1 (Figure. 	Cytochrome P450	13267	13282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:88	In addition to the genetic approach, Caspase-1 activity was increased by 2,3,4,5-Tetramethoxystilbene, a chemical inhibitor of Cytochrome P450 1b1 (Figure. 	Cytochrome P450	13267	13282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:90	On the other hand, Cytochrome P450 1b1 overexpression or activation by 7,12-Dimethylbenz[A]Anthracene reduced expression and activity of Caspase-1 in RWPE-1 cells (Figure  and. 	Cytochrome P450	13405	13420	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:90	On the other hand, Cytochrome P450 1b1 overexpression or activation by 7,12-Dimethylbenz[A]Anthracene reduced expression and activity of Caspase-1 in RWPE-1 cells (Figure  and. 	Cytochrome P450	13405	13420	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:92	As shown in Figure, most Cytochrome P450 1b1 protein was expressed in the glandular epithelium of Prostate Cancer tissues. 	Cytochrome P450	13702	13717	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:92	As shown in Figure, most Cytochrome P450 1b1 protein was expressed in the glandular epithelium of Prostate Cancer tissues. 	Cytochrome P450	13702	13717	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:94	In contrast, weak or no epithelial Cytochrome P450 1b1 expression was found in benign prostatic hypertrophy tissues with average staining scores of 0.670.20 (versus 2.170.22 in cancer tissues) was observed in 54.5% of patients with low Gleason score (4-6), 84.0% of patients with Gleason score 7, and 86.7% of patients with higher Gleason score (8-10) with biochemical recurrence in the patient samples (Figure. 	Cytochrome P450	13909	13924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:94	In contrast, weak or no epithelial Cytochrome P450 1b1 expression was found in benign prostatic hypertrophy tissues with average staining scores of 0.670.20 (versus 2.170.22 in cancer tissues) was observed in 54.5% of patients with low Gleason score (4-6), 84.0% of patients with Gleason score 7, and 86.7% of patients with higher Gleason score (8-10) with biochemical recurrence in the patient samples (Figure. 	Cytochrome P450	13909	13924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:95	Furthermore, overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein (Figure. 	Cytochrome P450	14374	14389	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:95	Furthermore, overall survival was significantly reduced in patients with high levels of Cytochrome P450 1b1 protein (Figure. 	Cytochrome P450	14374	14389	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:96	To determine whether Cytochrome P450 1b1 expression is correlated with Caspase-1 level, we first examined the level of Caspase-1 in prostate cancer tissue samples. 	Cytochrome P450	14432	14447	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:96	To determine whether Cytochrome P450 1b1 expression is correlated with Caspase-1 level, we first examined the level of Caspase-1 in prostate cancer tissue samples. 	Cytochrome P450	14432	14447	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:99	Next, we categorized tissue specimens as either high or low Cytochrome P450 1b1 expression groups as previously determined and measured Caspase-1 expression. 	Cytochrome P450	14887	14902	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:99	Next, we categorized tissue specimens as either high or low Cytochrome P450 1b1 expression groups as previously determined and measured Caspase-1 expression. 	Cytochrome P450	14887	14902	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:100	As shown in Figure  and, prostate tumors with strong Cytochrome P450 1b1 expression showed low Caspase-1 levels. 	Cytochrome P450	15038	15053	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:100	As shown in Figure  and, prostate tumors with strong Cytochrome P450 1b1 expression showed low Caspase-1 levels. 	Cytochrome P450	15038	15053	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:101	On the contrary, Prostate Cancer samples with relatively low Cytochrome P450 1b1 expression had a significantly higher level of Caspase-1 expression as compared to those with high Cytochrome P450 1b1 expression. 	Cytochrome P450	15159	15174	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:101	On the contrary, Prostate Cancer samples with relatively low Cytochrome P450 1b1 expression had a significantly higher level of Caspase-1 expression as compared to those with high Cytochrome P450 1b1 expression. 	Cytochrome P450	15159	15174	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:101	On the contrary, Prostate Cancer samples with relatively low Cytochrome P450 1b1 expression had a significantly higher level of Caspase-1 expression as compared to those with high Cytochrome P450 1b1 expression. 	Cytochrome P450	15278	15293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:101	On the contrary, Prostate Cancer samples with relatively low Cytochrome P450 1b1 expression had a significantly higher level of Caspase-1 expression as compared to those with high Cytochrome P450 1b1 expression. 	Cytochrome P450	15278	15293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:102	In addition, increased Caspase-1 expression was found in the tumors injected with or stably expressing Cytochrome P450 1b1 shRNA (Figure  and. 	Cytochrome P450	15413	15428	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:102	In addition, increased Caspase-1 expression was found in the tumors injected with or stably expressing Cytochrome P450 1b1 shRNA (Figure  and. 	Cytochrome P450	15413	15428	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:103	Since Cytochrome P450 1b1 is implicated as an important factor in the development of various cancers, understanding the precise mechanisms of CYP1B1-mediated cancer progression is required in the development of new strategies for cancer treatment. 	Cytochrome P450	15459	15474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:103	Since Cytochrome P450 1b1 is implicated as an important factor in the development of various cancers, understanding the precise mechanisms of CYP1B1-mediated cancer progression is required in the development of new strategies for cancer treatment. 	Cytochrome P450	15459	15474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:104	Cytochrome P450 1b1 provokes an oncogenic phenotype by damaging DNA through the formation of 8-hydroxy-2-deoxyguanosine. 	Cytochrome P450	15701	15716	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:104	Cytochrome P450 1b1 provokes an oncogenic phenotype by damaging DNA through the formation of 8-hydroxy-2-deoxyguanosine. 	Cytochrome P450	15701	15716	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:105	Recently, several molecular targets of Cytochrome P450 1b1 have been found and indicate the participation of Cytochrome P450 1b1 in multiple pathways during the progression of various types of cancer [,. 	Cytochrome P450	15861	15876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:105	Recently, several molecular targets of Cytochrome P450 1b1 have been found and indicate the participation of Cytochrome P450 1b1 in multiple pathways during the progression of various types of cancer [,. 	Cytochrome P450	15861	15876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:105	Recently, several molecular targets of Cytochrome P450 1b1 have been found and indicate the participation of Cytochrome P450 1b1 in multiple pathways during the progression of various types of cancer [,. 	Cytochrome P450	15931	15946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:105	Recently, several molecular targets of Cytochrome P450 1b1 have been found and indicate the participation of Cytochrome P450 1b1 in multiple pathways during the progression of various types of cancer [,. 	Cytochrome P450	15931	15946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:111	2,3,7,8-Tetrachlorodibenzo-p-dioxin, a strong Cytochrome P450 1b1 activator, suppressed activities of Caspase-1 and CASP3 in the apoptotic cell death of hepatocytes. 	Cytochrome P450	16822	16837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:111	2,3,7,8-Tetrachlorodibenzo-p-dioxin, a strong Cytochrome P450 1b1 activator, suppressed activities of Caspase-1 and CASP3 in the apoptotic cell death of hepatocytes. 	Cytochrome P450	16822	16837	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:112	In this study, we found that Caspase-1 is significantly up-regulated by Cytochrome P450 1b1 inhibition and is a newly identified target molecule of CYP1B1-mediated tumorigenesis. 	Cytochrome P450	17014	17029	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:112	In this study, we found that Caspase-1 is significantly up-regulated by Cytochrome P450 1b1 inhibition and is a newly identified target molecule of CYP1B1-mediated tumorigenesis. 	Cytochrome P450	17014	17029	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:114	Given that Cytochrome P450 1b1 knockdown increases Caspase-1, we suggest an alternative mechanism for Caspase-1 suppression and its critical role in CYP1B1-mediated regulation of Prostate Cancer progression. 	Cytochrome P450	17190	17205	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:114	Given that Cytochrome P450 1b1 knockdown increases Caspase-1, we suggest an alternative mechanism for Caspase-1 suppression and its critical role in CYP1B1-mediated regulation of Prostate Cancer progression. 	Cytochrome P450	17190	17205	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:115	According to Gregoraszczuk et al., 17BETA-estradiol (E_2) increases Cytochrome P450 1b1 protein expression, changing the local metabolic activation pathway to increased 4-OHE_2 production. 	Cytochrome P450	17455	17470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:115	According to Gregoraszczuk et al., 17BETA-estradiol (E_2) increases Cytochrome P450 1b1 protein expression, changing the local metabolic activation pathway to increased 4-OHE_2 production. 	Cytochrome P450	17455	17470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:117	Therefore, it is possible that reduction of 4-OHE_2 levels by Cytochrome P450 1b1 suppression may lead to Caspase-1 activation. 	Cytochrome P450	17684	17699	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:117	Therefore, it is possible that reduction of 4-OHE_2 levels by Cytochrome P450 1b1 suppression may lead to Caspase-1 activation. 	Cytochrome P450	17684	17699	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:118	Cytochrome P450 enzyme promotes reactive oxygen species generation which occurs during the metabolic conversion of procarcinogens to their ultimate reactive electrophilic intermediates. 	Cytochrome P450	17750	17765	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:118	Cytochrome P450 enzyme promotes reactive oxygen species generation which occurs during the metabolic conversion of procarcinogens to their ultimate reactive electrophilic intermediates. 	Cytochrome P450	17750	17765	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:119	However, interestingly, a lack of Cytochrome P450 1b1 expression and/or activity leads to accumulation of Reactive Oxygen Species and increased intracellular oxidative stress in retinal endothelial cells, perivascular supporting cells, and trabecular meshwork cells. 	Cytochrome P450	17970	17985	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:119	However, interestingly, a lack of Cytochrome P450 1b1 expression and/or activity leads to accumulation of Reactive Oxygen Species and increased intracellular oxidative stress in retinal endothelial cells, perivascular supporting cells, and trabecular meshwork cells. 	Cytochrome P450	17970	17985	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:121	Therefore, it is plausible that Reactive Oxygen Species produced by Cytochrome P450 1b1 inhibition activates Caspase-1 which induces antitumor effects in Prostate Cancer cells. 	Cytochrome P450	18339	18354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:121	Therefore, it is plausible that Reactive Oxygen Species produced by Cytochrome P450 1b1 inhibition activates Caspase-1 which induces antitumor effects in Prostate Cancer cells. 	Cytochrome P450	18339	18354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:122	Due to a contradictory report suggesting that Cytochrome P450 1b1 shRNA reduces Reactive Oxygen Species production in vascular smooth muscle cell, this hypothesis needs further clarification. 	Cytochrome P450	18494	18509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:122	Due to a contradictory report suggesting that Cytochrome P450 1b1 shRNA reduces Reactive Oxygen Species production in vascular smooth muscle cell, this hypothesis needs further clarification. 	Cytochrome P450	18494	18509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:124	Thus, it would be of interest to examine the expression and function of Cytochrome P450 1b1 in pancreatic cancer and determine its relationship with Caspase-1. 	Cytochrome P450	18810	18825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:124	Thus, it would be of interest to examine the expression and function of Cytochrome P450 1b1 in pancreatic cancer and determine its relationship with Caspase-1. 	Cytochrome P450	18810	18825	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:125	To analyze the therapeutic potential of lentivirus-delivered Cytochrome P450 1b1 shRNA, we performed a pre-clinical study. 	Cytochrome P450	18959	18974	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:125	To analyze the therapeutic potential of lentivirus-delivered Cytochrome P450 1b1 shRNA, we performed a pre-clinical study. 	Cytochrome P450	18959	18974	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:126	The recombinant lentivirus expressing Cytochrome P450 1b1 shRNA was intratumorally injected into established tumors or tumor cells expressing Cytochrome P450 1b1 shRNA were injected into nude mice. 	Cytochrome P450	19059	19074	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:126	The recombinant lentivirus expressing Cytochrome P450 1b1 shRNA was intratumorally injected into established tumors or tumor cells expressing Cytochrome P450 1b1 shRNA were injected into nude mice. 	Cytochrome P450	19059	19074	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:126	The recombinant lentivirus expressing Cytochrome P450 1b1 shRNA was intratumorally injected into established tumors or tumor cells expressing Cytochrome P450 1b1 shRNA were injected into nude mice. 	Cytochrome P450	19163	19178	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:126	The recombinant lentivirus expressing Cytochrome P450 1b1 shRNA was intratumorally injected into established tumors or tumor cells expressing Cytochrome P450 1b1 shRNA were injected into nude mice. 	Cytochrome P450	19163	19178	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:128	These results demonstrate that Cytochrome P450 1b1 inhibition by lentivirus-mediated shRNA resulted in a beneficial effect in vivo. 	Cytochrome P450	19323	19338	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:128	These results demonstrate that Cytochrome P450 1b1 inhibition by lentivirus-mediated shRNA resulted in a beneficial effect in vivo. 	Cytochrome P450	19323	19338	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:129	To our knowledge, our study is the first report determining the therapeutic effect of lentivirus expressing Cytochrome P450 1b1 shRNA. 	Cytochrome P450	19532	19547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:129	To our knowledge, our study is the first report determining the therapeutic effect of lentivirus expressing Cytochrome P450 1b1 shRNA. 	Cytochrome P450	19532	19547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:134	Further development of a lentiviral vector expressing Cytochrome P450 1b1 shRNA may result in a protective effect in vivo against Prostate Cancer. 	Cytochrome P450	19972	19987	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:134	Further development of a lentiviral vector expressing Cytochrome P450 1b1 shRNA may result in a protective effect in vivo against Prostate Cancer. 	Cytochrome P450	19972	19987	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:135	Cytochrome P450 1b1 is overexpressed in a variety of human tumor cells including prostate cancer [,. 	Cytochrome P450	20065	20080	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:135	Cytochrome P450 1b1 is overexpressed in a variety of human tumor cells including prostate cancer [,. 	Cytochrome P450	20065	20080	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:137	Here, we demonstrate that high levels of Cytochrome P450 1b1 are associated with parameters such as Gleason score and survival rate of Prostate Cancer patients. 	Cytochrome P450	20291	20306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:137	Here, we demonstrate that high levels of Cytochrome P450 1b1 are associated with parameters such as Gleason score and survival rate of Prostate Cancer patients. 	Cytochrome P450	20291	20306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:138	Thus, Cytochrome P450 1b1 could be a potential prognostic and diagnostic marker for Prostate Cancer. 	Cytochrome P450	20417	20432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:138	Thus, Cytochrome P450 1b1 could be a potential prognostic and diagnostic marker for Prostate Cancer. 	Cytochrome P450	20417	20432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:139	We also found that Cytochrome P450 1b1 expression is inversely associated with Caspase-1 levels in human Prostate Cancer tissues (Figure. 	Cytochrome P450	20531	20546	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:139	We also found that Cytochrome P450 1b1 expression is inversely associated with Caspase-1 levels in human Prostate Cancer tissues (Figure. 	Cytochrome P450	20531	20546	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:142	In addition, it will be of interest to perform studies on the association of Cytochrome P450 1b1 expression and its polymorphic variants with Caspase-1 expression in Prostate Cancer patients. 	Cytochrome P450	21212	21227	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:142	In addition, it will be of interest to perform studies on the association of Cytochrome P450 1b1 expression and its polymorphic variants with Caspase-1 expression in Prostate Cancer patients. 	Cytochrome P450	21212	21227	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:143	In summary, the present study demonstrates that Cytochrome P450 1b1 induces tumorigenecity of Prostate Cancer cells by modulating Caspase-1 expression. 	Cytochrome P450	21375	21390	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:143	In summary, the present study demonstrates that Cytochrome P450 1b1 induces tumorigenecity of Prostate Cancer cells by modulating Caspase-1 expression. 	Cytochrome P450	21375	21390	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:144	We also presented data indicating the feasibility of using in vivo lentivirus-delivered Cytochrome P450 1b1 shRNA to reduce the tumor burden in animals. 	Cytochrome P450	21567	21582	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:144	We also presented data indicating the feasibility of using in vivo lentivirus-delivered Cytochrome P450 1b1 shRNA to reduce the tumor burden in animals. 	Cytochrome P450	21567	21582	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:145	This result supports the idea that attenuation of Cytochrome P450 1b1 may be useful in the treatment of Prostate Cancer. 	Cytochrome P450	21682	21697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:145	This result supports the idea that attenuation of Cytochrome P450 1b1 may be useful in the treatment of Prostate Cancer. 	Cytochrome P450	21682	21697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:146	Finally, we show the clinical relevance and inverse correlation between Cytochrome P450 1b1 and Caspase-1 in human tissue specimens. 	Cytochrome P450	21825	21840	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:146	Finally, we show the clinical relevance and inverse correlation between Cytochrome P450 1b1 and Caspase-1 in human tissue specimens. 	Cytochrome P450	21825	21840	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:160	Immunoblotting was carried out according to standard protocols with antibodies against TNFRSF9 (Sigma), Lymphotoxin Alpha (GeneTex, San Antonio, TX), Cytochrome P450 1b1, CD27, Interleukin 8, Thrombospondin 1 (Abcam, Cambridge, MA), Spleen Tyrosine Kinase, Fbj Murine Osteosarcoma Viral Oncogene Homolog, Myelocytomatosis Viral Oncogene Homolog, NFKBIA, CASPASE-1 (Cell Signaling Technology, Danvers, MA). 	Cytochrome P450	23553	23568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:160	Immunoblotting was carried out according to standard protocols with antibodies against TNFRSF9 (Sigma), Lymphotoxin Alpha (GeneTex, San Antonio, TX), Cytochrome P450 1b1, CD27, Interleukin 8, Thrombospondin 1 (Abcam, Cambridge, MA), Spleen Tyrosine Kinase, Fbj Murine Osteosarcoma Viral Oncogene Homolog, Myelocytomatosis Viral Oncogene Homolog, NFKBIA, CASPASE-1 (Cell Signaling Technology, Danvers, MA). 	Cytochrome P450	23553	23568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:162	Ectopic expression of Cytochrome P450 1b1 plasmid (OriGene Techologies, Rockville, MD) in RWPE-1 cells and Cytochrome P450 1b1 shRNA (Origene) in PC-3 and DU145 cells along with their controls were achieved using lentivirus as per the manufacturer's instructions. 	Cytochrome P450	23955	23970	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:162	Ectopic expression of Cytochrome P450 1b1 plasmid (OriGene Techologies, Rockville, MD) in RWPE-1 cells and Cytochrome P450 1b1 shRNA (Origene) in PC-3 and DU145 cells along with their controls were achieved using lentivirus as per the manufacturer's instructions. 	Cytochrome P450	23955	23970	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:162	Ectopic expression of Cytochrome P450 1b1 plasmid (OriGene Techologies, Rockville, MD) in RWPE-1 cells and Cytochrome P450 1b1 shRNA (Origene) in PC-3 and DU145 cells along with their controls were achieved using lentivirus as per the manufacturer's instructions. 	Cytochrome P450	24040	24055	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:162	Ectopic expression of Cytochrome P450 1b1 plasmid (OriGene Techologies, Rockville, MD) in RWPE-1 cells and Cytochrome P450 1b1 shRNA (Origene) in PC-3 and DU145 cells along with their controls were achieved using lentivirus as per the manufacturer's instructions. 	Cytochrome P450	24040	24055	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:177	For intratumoral injection of lentivirus-mediated Cytochrome P450 1b1 shRNA, five week old male mice (Charles River, Burlington, MA) were injected subcutaneously into the dorsal flank area with 200 l of RPMI 1640 medium containing PC-3 cells (510^6 cells). 	Cytochrome P450	26209	26224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:177	For intratumoral injection of lentivirus-mediated Cytochrome P450 1b1 shRNA, five week old male mice (Charles River, Burlington, MA) were injected subcutaneously into the dorsal flank area with 200 l of RPMI 1640 medium containing PC-3 cells (510^6 cells). 	Cytochrome P450	26209	26224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:178	Once tumors reached a volume of 30-40 mm^3, the tumors were injected every 3 days with 50 l (410^7 cells) of viral particles containing Cytochrome P450 1b1 or control shRNA. 	Cytochrome P450	26552	26567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:178	Once tumors reached a volume of 30-40 mm^3, the tumors were injected every 3 days with 50 l (410^7 cells) of viral particles containing Cytochrome P450 1b1 or control shRNA. 	Cytochrome P450	26552	26567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:179	For the subcutaneous xenograft mouse model, PC-3 cells (510^6 cells) stably transfected with either Cytochrome P450 1b1 shRNA #4-2 or control shRNA suspended in 100 l RPMI 1640 medium were subcutaneously injected into the right backside flank of five week old male nude mice. 	Cytochrome P450	26690	26705	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:179	For the subcutaneous xenograft mouse model, PC-3 cells (510^6 cells) stably transfected with either Cytochrome P450 1b1 shRNA #4-2 or control shRNA suspended in 100 l RPMI 1640 medium were subcutaneously injected into the right backside flank of five week old male nude mice. 	Cytochrome P450	26690	26705	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:189	To investigate the expression of genes regulated by Cytochrome P450 1b1 inhibition, the RT^2 Profiler PCR Array Human Apoptosis and Human Cancer PathwayFinder (SABiosciences, Frederick, MD) were used as per manufacturer's instructions. 	Cytochrome P450	28759	28774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:189	To investigate the expression of genes regulated by Cytochrome P450 1b1 inhibition, the RT^2 Profiler PCR Array Human Apoptosis and Human Cancer PathwayFinder (SABiosciences, Frederick, MD) were used as per manufacturer's instructions. 	Cytochrome P450	28759	28774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:197	Chi-square test was used for analyzing the correlation between clinicopathologic parameters and Cytochrome P450 1b1 protein expression. 	Cytochrome P450	29849	29864	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:197	Chi-square test was used for analyzing the correlation between clinicopathologic parameters and Cytochrome P450 1b1 protein expression. 	Cytochrome P450	29849	29864	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	Cytochrome P450	409	424	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	Cytochrome P450	409	424	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:7	Nanocarriers were evaluated in vitro for their Cytochrome P450 3a4 inhibition capacity and in vivo for their biodistribution, and finally injected 24 hours prior to the drug docetaxel, for their ability to improve the efficiency of the drug docetaxel. 	Cytochrome P450	754	769	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:7	Nanocarriers were evaluated in vitro for their Cytochrome P450 3a4 inhibition capacity and in vivo for their biodistribution, and finally injected 24 hours prior to the drug docetaxel, for their ability to improve the efficiency of the drug docetaxel. 	Cytochrome P450	754	769	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:8	Nanoparticles of poly(lactic-co-glycolic) acid (PLGA) with a hydrodynamic diameter of 63 nm, functionalized with galactosamine, showed efficient in vitro Cytochrome P450 3a4 inhibition and the highest accumulation in hepatocytes. 	Cytochrome P450	1113	1128	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:8	Nanoparticles of poly(lactic-co-glycolic) acid (PLGA) with a hydrodynamic diameter of 63 nm, functionalized with galactosamine, showed efficient in vitro Cytochrome P450 3a4 inhibition and the highest accumulation in hepatocytes. 	Cytochrome P450	1113	1128	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450	1918	1933	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450	1918	1933	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450	2167	2182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450	2167	2182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	Cytochrome P450	4314	4329	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	Cytochrome P450	4314	4329	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:87	HepaRG cells were cultivated to induce Cytochrome P450 3a4. 	Cytochrome P450	13557	13572	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:87	HepaRG cells were cultivated to induce Cytochrome P450 3a4. 	Cytochrome P450	13557	13572	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	Cytochrome P450	14412	14427	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	Cytochrome P450	14412	14427	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:162	In vitro IC_50 values of Cytochrome P450 3a4 by Bergamottin in different nanocarriers were measured on the HepaRG cell line,, using a fluorogenic substrate: DBOMF. 	Cytochrome P450	24187	24202	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:162	In vitro IC_50 values of Cytochrome P450 3a4 by Bergamottin in different nanocarriers were measured on the HepaRG cell line,, using a fluorogenic substrate: DBOMF. 	Cytochrome P450	24187	24202	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:198	Different nanocarriers were designed to encapsulate the hydrophobic Bergamottin, inhibitor of Cytochrome P450 3a4, to make it injectable and to deliver it to hepatocytes. 	Cytochrome P450	30104	30119	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:198	Different nanocarriers were designed to encapsulate the hydrophobic Bergamottin, inhibitor of Cytochrome P450 3a4, to make it injectable and to deliver it to hepatocytes. 	Cytochrome P450	30104	30119	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450	32167	32182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450	32167	32182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450	32327	32342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450	32327	32342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	Cytochrome P450	35680	35695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	Cytochrome P450	35680	35695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:235	The 24-hour time lapse is more ethical regarding volumes injected to mice and allows Bergamottin to exit from PLGA nanoparticles and to bind to Cytochrome P450 3a4. 	Cytochrome P450	35880	35895	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:235	The 24-hour time lapse is more ethical regarding volumes injected to mice and allows Bergamottin to exit from PLGA nanoparticles and to bind to Cytochrome P450 3a4. 	Cytochrome P450	35880	35895	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:236	Our strategy is to inhibit Cytochrome P450 3a4 activity in hepatocytes, decrease docetaxels metabolism in the liver and increase its concentration in the tumor. 	Cytochrome P450	35928	35943	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:236	Our strategy is to inhibit Cytochrome P450 3a4 activity in hepatocytes, decrease docetaxels metabolism in the liver and increase its concentration in the tumor. 	Cytochrome P450	35928	35943	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:246	Inhibiting Cytochrome P450 3a4 in particular, by which docetaxel is metabolized, would allow increasing the concentration of docetaxel in HCCs and avoid resistance mechanisms. 	Cytochrome P450	37560	37575	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:246	Inhibiting Cytochrome P450 3a4 in particular, by which docetaxel is metabolized, would allow increasing the concentration of docetaxel in HCCs and avoid resistance mechanisms. 	Cytochrome P450	37560	37575	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	Cytochrome P450	38471	38486	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	Cytochrome P450	38471	38486	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450	38899	38914	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450	38899	38914	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:14	Cytochrome P450 (CYP) enzymes are a superfamily of important biocatalysts that perform an extraordinary breadth of biochemical reactions, and have been widely applied to oxidation of complex organic substrates and biosynthesis of chemical building block molecules. 	Cytochrome P450	2392	2407	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:14	Cytochrome P450 (CYP) enzymes are a superfamily of important biocatalysts that perform an extraordinary breadth of biochemical reactions, and have been widely applied to oxidation of complex organic substrates and biosynthesis of chemical building block molecules. 	Cytochrome P450	2392	2407	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:66	Preliminary in vitro screening for potential off-target activity of S2218 included tests for Cytochrome P450 inhibition, a receptor lead profiling panel (consisting of 68 receptor binding assays for GPCRs, ion channels, nuclear receptors, transporters), and a hERG inhibition assay. 	Cytochrome P450	12936	12951	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:66	Preliminary in vitro screening for potential off-target activity of S2218 included tests for Cytochrome P450 inhibition, a receptor lead profiling panel (consisting of 68 receptor binding assays for GPCRs, ion channels, nuclear receptors, transporters), and a hERG inhibition assay. 	Cytochrome P450	12936	12951	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:67	The tests for Cytochrome P450 inhibition were performed using recombinant human enzymes expressed in insect Sf9 cells using spectrofluorimetric substrates. 	Cytochrome P450	13140	13155	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:67	The tests for Cytochrome P450 inhibition were performed using recombinant human enzymes expressed in insect Sf9 cells using spectrofluorimetric substrates. 	Cytochrome P450	13140	13155	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:71	None of the five Cytochrome P450 isoforms tested (CYPs 1A2, 2C19, 2C9, 2D6 and 3A4) were inhibited by >7% in the presence of 10 M S2218 in the spectrofluorimetric assay. 	Cytochrome P450	13611	13626	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:71	None of the five Cytochrome P450 isoforms tested (CYPs 1A2, 2C19, 2C9, 2D6 and 3A4) were inhibited by >7% in the presence of 10 M S2218 in the spectrofluorimetric assay. 	Cytochrome P450	13611	13626	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:395	In addition, none of the aforementioned benzothiadiazine analogs significantly inhibit the major Cytochrome P450 enzymes indicating that these compounds should not affect the metabolism of drug substances. 	Cytochrome P450	66958	66973	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:395	In addition, none of the aforementioned benzothiadiazine analogs significantly inhibit the major Cytochrome P450 enzymes indicating that these compounds should not affect the metabolism of drug substances. 	Cytochrome P450	66958	66973	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:396	In vitro studies using both rat and human liver microsomes have shown that these benzothiadiazine derivatives themselves are resistant to oxidative metabolism by Cytochrome P450 enzymes with >97% of the parent compounds remaining after a 60 min incubation with microsomes of either species. 	Cytochrome P450	67229	67244	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:396	In vitro studies using both rat and human liver microsomes have shown that these benzothiadiazine derivatives themselves are resistant to oxidative metabolism by Cytochrome P450 enzymes with >97% of the parent compounds remaining after a 60 min incubation with microsomes of either species. 	Cytochrome P450	67229	67244	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:458	(2016) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. 	Cytochrome P450	53660	53675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:458	(2016) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. 	Cytochrome P450	53660	53675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:460	(2017) Cytochrome P450 eicosanoids in cerebrovascular function and disease. 	Cytochrome P450	53781	53796	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:460	(2017) Cytochrome P450 eicosanoids in cerebrovascular function and disease. 	Cytochrome P450	53781	53796	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:464	(2015) Cytochrome P450 1 family and cancers. 	Cytochrome P450	54077	54092	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:464	(2015) Cytochrome P450 1 family and cancers. 	Cytochrome P450	54077	54092	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:466	(2016) Recent Structural Insights into Cytochrome P450 Function. 	Cytochrome P450	54228	54243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:466	(2016) Recent Structural Insights into Cytochrome P450 Function. 	Cytochrome P450	54228	54243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:470	(2017) Cytochrome P450derived eicosanoids and heart function. 	Cytochrome P450	54500	54515	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:470	(2017) Cytochrome P450derived eicosanoids and heart function. 	Cytochrome P450	54500	54515	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:515	Subsequent to the formation of PGH_2, the cytochrome P450 activities thromboxane synthase (CYP5A1, TBXAS1, P24557, EC 5.3.99.5) and prostacyclin synthase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A_2 and prostacyclin (PGI_2), respectively (see Cytochrome P450s). 	Cytochrome P450	59228	59243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:515	Subsequent to the formation of PGH_2, the cytochrome P450 activities thromboxane synthase (CYP5A1, TBXAS1, P24557, EC 5.3.99.5) and prostacyclin synthase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A_2 and prostacyclin (PGI_2), respectively (see Cytochrome P450s). 	Cytochrome P450	59228	59243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	Cytochrome P450	406	421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	Cytochrome P450	406	421	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	Cytochrome P450	500	515	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	Cytochrome P450	500	515	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:5	Gene expression levels of all four CYPs and POR, as well as the Cytochrome P450 activities, were higher in TC-HepG2 clones than in parental HepG2 cells. 	Cytochrome P450	910	925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:5	Gene expression levels of all four CYPs and POR, as well as the Cytochrome P450 activities, were higher in TC-HepG2 clones than in parental HepG2 cells. 	Cytochrome P450	910	925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:6	Additionally, the activity levels of all CYPs were reduced in a concentration-dependent manner by specific Cytochrome P450 inhibitors. 	Cytochrome P450	1106	1121	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:6	Additionally, the activity levels of all CYPs were reduced in a concentration-dependent manner by specific Cytochrome P450 inhibitors. 	Cytochrome P450	1106	1121	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:7	Furthermore, preincubation of TC-HepG2 cells with Cytochrome P450 inhibitors known as time-dependent inhibitors prior to the addition of CYP-specific substrates determined that Cytochrome P450 inhibition was enhanced in the Time-Dependent Inhibitors group than in the non-TDI group. 	Cytochrome P450	1184	1199	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:7	Furthermore, preincubation of TC-HepG2 cells with Cytochrome P450 inhibitors known as time-dependent inhibitors prior to the addition of CYP-specific substrates determined that Cytochrome P450 inhibition was enhanced in the Time-Dependent Inhibitors group than in the non-TDI group. 	Cytochrome P450	1184	1199	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:7	Furthermore, preincubation of TC-HepG2 cells with Cytochrome P450 inhibitors known as time-dependent inhibitors prior to the addition of CYP-specific substrates determined that Cytochrome P450 inhibition was enhanced in the Time-Dependent Inhibitors group than in the non-TDI group. 	Cytochrome P450	1311	1326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:7	Furthermore, preincubation of TC-HepG2 cells with Cytochrome P450 inhibitors known as time-dependent inhibitors prior to the addition of CYP-specific substrates determined that Cytochrome P450 inhibition was enhanced in the Time-Dependent Inhibitors group than in the non-TDI group. 	Cytochrome P450	1311	1326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	Cytochrome P450	5861	5876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:37	cDNA of four CYPs expressed in human hepatocytes (CYP2C9, CYP2C19, CYP2D6, CYP3A4) and Cytochrome P450 oxidoreductase (POR) were obtained as artificial synthetic genes (Invitrogen). 	Cytochrome P450	5861	5876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:109	Finally, the assessment of the metabolic activity of four CYPs indicated that all three clones were more active than the original HepG2 cells and that the Cytochrome P450 activity was either comparable or higher than those in primary human hepatocytes. 	Cytochrome P450	15395	15410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:109	Finally, the assessment of the metabolic activity of four CYPs indicated that all three clones were more active than the original HepG2 cells and that the Cytochrome P450 activity was either comparable or higher than those in primary human hepatocytes. 	Cytochrome P450	15395	15410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:111	Consequently, although the gene expression increased, Cytochrome P450 activity was barely detectable. 	Cytochrome P450	15659	15674	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:111	Consequently, although the gene expression increased, Cytochrome P450 activity was barely detectable. 	Cytochrome P450	15659	15674	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:130	Briefly, Cytochrome P450 inhibitors were added to the culture media at the same time as the metabolic substrate to test direct inhibition or 1 hour prior to the addition of the metabolic substrate to test time-dependent inhibition. 	Cytochrome P450	18413	18428	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:130	Briefly, Cytochrome P450 inhibitors were added to the culture media at the same time as the metabolic substrate to test direct inhibition or 1 hour prior to the addition of the metabolic substrate to test time-dependent inhibition. 	Cytochrome P450	18413	18428	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:144	In addition, for all compounds, K_i,app, indicating Cytochrome P450 reactivation, was lower in TC-HepG2 cells than in human hepatocytes. 	Cytochrome P450	20681	20696	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:144	In addition, for all compounds, K_i,app, indicating Cytochrome P450 reactivation, was lower in TC-HepG2 cells than in human hepatocytes. 	Cytochrome P450	20681	20696	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:157	Moreover, transgene expression was maintained over the long-term culture conditions, and Cytochrome P450 activities derived from the transgenes were either comparable or higher than those detected in human hepatocytes. 	Cytochrome P450	22658	22673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:157	Moreover, transgene expression was maintained over the long-term culture conditions, and Cytochrome P450 activities derived from the transgenes were either comparable or higher than those detected in human hepatocytes. 	Cytochrome P450	22658	22673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:160	When no genes were introduced, HepG2 cells exhibited low expression of POR and Cytochrome P450. 	Cytochrome P450	23109	23124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:160	When no genes were introduced, HepG2 cells exhibited low expression of POR and Cytochrome P450. 	Cytochrome P450	23109	23124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:163	Consequently, although the gene expression increased, Cytochrome P450 activity was barely detectable. 	Cytochrome P450	23360	23375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:163	Consequently, although the gene expression increased, Cytochrome P450 activity was barely detectable. 	Cytochrome P450	23360	23375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:164	These results suggest that the introduction of other factors, in addition to POR as a coenzyme, is required to create substitutable hepatic cells from human non-hepatic cells for testing Cytochrome P450 metabolism. 	Cytochrome P450	23595	23610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:164	These results suggest that the introduction of other factors, in addition to POR as a coenzyme, is required to create substitutable hepatic cells from human non-hepatic cells for testing Cytochrome P450 metabolism. 	Cytochrome P450	23595	23610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:165	One major reason for the dropout of candidate compounds during development the removal of novel drugs from the market after launch is drug-drug interactions caused by Cytochrome P450 inhibition. 	Cytochrome P450	23790	23805	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:165	One major reason for the dropout of candidate compounds during development the removal of novel drugs from the market after launch is drug-drug interactions caused by Cytochrome P450 inhibition. 	Cytochrome P450	23790	23805	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:166	To avoid Drug-Drug Interactions, pharmaceutical companies implement Cytochrome P450 inhibition studies starting with the initial drug discovery stage. 	Cytochrome P450	23886	23901	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:166	To avoid Drug-Drug Interactions, pharmaceutical companies implement Cytochrome P450 inhibition studies starting with the initial drug discovery stage. 	Cytochrome P450	23886	23901	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:167	Cytochrome P450 inhibition patterns are categorized as either Direct Inhibition or Time-Dependent Inhibitors. 	Cytochrome P450	23969	23984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:167	Cytochrome P450 inhibition patterns are categorized as either Direct Inhibition or Time-Dependent Inhibitors. 	Cytochrome P450	23969	23984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:174	All four Cytochrome P450 molecular species could replicate the Time-Dependent Inhibitors reported by previous studies using human hepatocytes. 	Cytochrome P450	25216	25231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:174	All four Cytochrome P450 molecular species could replicate the Time-Dependent Inhibitors reported by previous studies using human hepatocytes. 	Cytochrome P450	25216	25231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	Cytochrome P450	24787	24802	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5677914_OgerInput.txtOger_out.csv:144	^ We used the Human Cytochrome P450 Allele Nomenclature Database^ to define variant alleles in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 genes and their effect on their respective CYP protein. 	Cytochrome P450	24787	24802	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	Cytochrome P450	5492	5507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:38	; Mudge et al.. However, the constituent(s) responsible for the in vitro and in vivo Cytochrome P450 inhibition by R. rosea remains to be identified and the concentration of these constituents could not be linked to in vitro enzyme inhibition of CYP1A2, CYP2D6, or CYP3A4 in a previous experiment (Thu et al.. Consequently, it is of interest to study fullextract solutions of R. rosea, as a full extract provides a more accurate depiction of what the consumers are exposed to when they ingest these products. 	Cytochrome P450	5492	5507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:39	The inhibition of Cytochrome P450 enzymes can broadly be divided into two types; reversible and irreversible. 	Cytochrome P450	5934	5949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:39	The inhibition of Cytochrome P450 enzymes can broadly be divided into two types; reversible and irreversible. 	Cytochrome P450	5934	5949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:40	By observing the enzyme kinetics of Cytochrome P450 metabolite production, reversible inhibitors can be further classified into subgroups: competitive, noncompetitive, or uncompetitive inhibitors (Zhang and Wong. 	Cytochrome P450	6062	6077	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:40	By observing the enzyme kinetics of Cytochrome P450 metabolite production, reversible inhibitors can be further classified into subgroups: competitive, noncompetitive, or uncompetitive inhibitors (Zhang and Wong. 	Cytochrome P450	6062	6077	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	Cytochrome P450	16836	16851	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	Cytochrome P450	16836	16851	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:148	In the interpretation of both the in vitro and in vivo inhibitory potential and characteristics of R. rosea on Cytochrome P450 enzyme activity, the potential differences in biochemical activity of multiple unknown constituents must also be taken into consideration. 	Cytochrome P450	20953	20968	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:148	In the interpretation of both the in vitro and in vivo inhibitory potential and characteristics of R. rosea on Cytochrome P450 enzyme activity, the potential differences in biochemical activity of multiple unknown constituents must also be taken into consideration. 	Cytochrome P450	20953	20968	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:155	In conclusion, this study found a noncompetitive inhibition of CYP2C9 by the commercial R. rosea product Arctic Root and adds to the increasing evidence of both in vitro and in vivo Cytochrome P450 inhibitory potential of R. rosea. 	Cytochrome P450	22358	22373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:155	In conclusion, this study found a noncompetitive inhibition of CYP2C9 by the commercial R. rosea product Arctic Root and adds to the increasing evidence of both in vitro and in vivo Cytochrome P450 inhibitory potential of R. rosea. 	Cytochrome P450	22358	22373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:156	Further studies should evaluate possible Cytochrome P450 enzyme effects of other commercially available R. rosea products and in more detail attempt to identify which of the R. rosea constituents that are responsible for these effects. 	Cytochrome P450	22449	22464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:156	Further studies should evaluate possible Cytochrome P450 enzyme effects of other commercially available R. rosea products and in more detail attempt to identify which of the R. rosea constituents that are responsible for these effects. 	Cytochrome P450	22449	22464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450	607	622	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450	607	622	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450	763	778	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450	763	778	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450	975	990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450	975	990	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450	1089	1104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450	1089	1104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:11	As the principal class of hepatic drug metabolizing enzymes, Cytochrome P450 Enzymes play a critically important role in the biosynthesis and degradation of endogenous compounds and the metabolism of drugs and environmental procarcinogens. 	Cytochrome P450	1871	1886	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:11	As the principal class of hepatic drug metabolizing enzymes, Cytochrome P450 Enzymes play a critically important role in the biosynthesis and degradation of endogenous compounds and the metabolism of drugs and environmental procarcinogens. 	Cytochrome P450	1871	1886	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:12	Interindividual variation in drug metabolism, which encompasses genetic polymorphisms of Cytochrome P450 Enzymes, smoking, drinking, age, and gender, has a substantial impact on individual drug safety and efficacy, raising a challenge to guide individualized medicine. 	Cytochrome P450	2139	2154	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:12	Interindividual variation in drug metabolism, which encompasses genetic polymorphisms of Cytochrome P450 Enzymes, smoking, drinking, age, and gender, has a substantial impact on individual drug safety and efficacy, raising a challenge to guide individualized medicine. 	Cytochrome P450	2139	2154	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:17	A multitude of different Cytochrome P450 Enzymes share similar physical and molecular characteristics, are colocalized on the cytoplasmic side of the endoplasmic reticulum, and coordinately carry out the biosynthesis and degradation of endogenous steroids, lipids, and vitamins as well as many exogenous substances. 	Cytochrome P450	3037	3052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:17	A multitude of different Cytochrome P450 Enzymes share similar physical and molecular characteristics, are colocalized on the cytoplasmic side of the endoplasmic reticulum, and coordinately carry out the biosynthesis and degradation of endogenous steroids, lipids, and vitamins as well as many exogenous substances. 	Cytochrome P450	3037	3052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:20	Our previous studies also have shown that a high degree of correlation existed at the mRNA and protein expression levels of Cytochrome P450 Enzymes. 	Cytochrome P450	3722	3737	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:20	Our previous studies also have shown that a high degree of correlation existed at the mRNA and protein expression levels of Cytochrome P450 Enzymes. 	Cytochrome P450	3722	3737	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450	3772	3787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450	3772	3787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450	3959	3974	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450	3959	3974	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:24	Recently, to predict the in vivo clearance for Cytochrome P450 Enzymes more accurately, we introduced correction coefficients into the Vitro-In Vivo Extrapolation method based on the study of Halifax and Houston, who developed the conventional bias corrected in vitro-in vivo extrapolation (CBC-IVIVE) method. 	Cytochrome P450	4485	4500	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:24	Recently, to predict the in vivo clearance for Cytochrome P450 Enzymes more accurately, we introduced correction coefficients into the Vitro-In Vivo Extrapolation method based on the study of Halifax and Houston, who developed the conventional bias corrected in vitro-in vivo extrapolation (CBC-IVIVE) method. 	Cytochrome P450	4485	4500	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:25	Combining descriptive models and CBC-IVIVE might allow us to accurately predict total CYP-mediated drug clearance in vivo based on the measured activities of a few Cytochrome P450 Enzymes using a small quantity of liver tissue. 	Cytochrome P450	4912	4927	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:25	Combining descriptive models and CBC-IVIVE might allow us to accurately predict total CYP-mediated drug clearance in vivo based on the measured activities of a few Cytochrome P450 Enzymes using a small quantity of liver tissue. 	Cytochrome P450	4912	4927	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450	5158	5173	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450	5158	5173	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450	5320	5335	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450	5320	5335	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:27	To strengthen the clinical values, the CL_H of probe drugs for six Cytochrome P450 Enzymes were extrapolated using CBC-IVIVE method, and the extrapolation accuracy was evaluated. 	Cytochrome P450	5454	5469	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:27	To strengthen the clinical values, the CL_H of probe drugs for six Cytochrome P450 Enzymes were extrapolated using CBC-IVIVE method, and the extrapolation accuracy was evaluated. 	Cytochrome P450	5454	5469	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:51	), as follows: First, each kinetic parameter (V_max, K_m, and CL_int) of the ten Cytochrome P450 Enzymes was treated as a dataset, which then generated three datasets. 	Cytochrome P450	10365	10380	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:51	), as follows: First, each kinetic parameter (V_max, K_m, and CL_int) of the ten Cytochrome P450 Enzymes was treated as a dataset, which then generated three datasets. 	Cytochrome P450	10365	10380	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:52	For each training set, the data of one CYP were set as the dependent variable and the datasets of the other Cytochrome P450 Enzymes were set as independent variables, from which a multiple linear regression model was developed by a stepwise method (criteria: probability of F to enter was 0.05, probability of F to remove was 0.10). 	Cytochrome P450	10560	10575	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:52	For each training set, the data of one CYP were set as the dependent variable and the datasets of the other Cytochrome P450 Enzymes were set as independent variables, from which a multiple linear regression model was developed by a stepwise method (criteria: probability of F to enter was 0.05, probability of F to remove was 0.10). 	Cytochrome P450	10560	10575	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	11175	11190	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	11175	11190	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	11293	11308	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	11293	11308	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:63	The correction coefficient, the plasma unbound fraction (f_u,p), and blood-to-plasma concentration ratio (R_B) of each probe drug for six Cytochrome P450 Enzymes were obtained from literature. 	Cytochrome P450	12693	12708	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:63	The correction coefficient, the plasma unbound fraction (f_u,p), and blood-to-plasma concentration ratio (R_B) of each probe drug for six Cytochrome P450 Enzymes were obtained from literature. 	Cytochrome P450	12693	12708	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	Cytochrome P450	14505	14520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	Cytochrome P450	14505	14520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	14960	14975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	14960	14975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	14999	15014	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	14999	15014	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	15176	15191	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450	15176	15191	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450	15260	15275	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450	15260	15275	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450	15349	15364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450	15349	15364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450	15514	15529	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450	15514	15529	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450	15657	15672	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450	15657	15672	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:84	Of note, prediction of some CYP-mediated metabolic activities in vitro did not require knowledge of all four Cytochrome P450 Enzymes activities; some activities could be predicted on just one or two known CYP activities. 	Cytochrome P450	15930	15945	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:84	Of note, prediction of some CYP-mediated metabolic activities in vitro did not require knowledge of all four Cytochrome P450 Enzymes activities; some activities could be predicted on just one or two known CYP activities. 	Cytochrome P450	15930	15945	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450	16738	16753	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450	16738	16753	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450	16809	16824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450	16809	16824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:89	In short, the prediction for six Cytochrome P450 Enzymes needed 1-3 measured CYP values. 	Cytochrome P450	17208	17223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:89	In short, the prediction for six Cytochrome P450 Enzymes needed 1-3 measured CYP values. 	Cytochrome P450	17208	17223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:95	The ranges of predicted CL_int for all Cytochrome P450 Enzymes were smaller than the measured data. 	Cytochrome P450	18090	18105	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:95	The ranges of predicted CL_int for all Cytochrome P450 Enzymes were smaller than the measured data. 	Cytochrome P450	18090	18105	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450	23944	23959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450	23944	23959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450	24025	24040	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450	24025	24040	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24128	24143	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24128	24143	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24225	24240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24225	24240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24348	24363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	24348	24363	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450	25387	25402	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450	25387	25402	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450	25474	25489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450	25474	25489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:134	As a consequence of this, predictive models for K_m of some Cytochrome P450 Enzymes could not be developed. 	Cytochrome P450	25582	25597	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:134	As a consequence of this, predictive models for K_m of some Cytochrome P450 Enzymes could not be developed. 	Cytochrome P450	25582	25597	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:140	Although these descriptive models could use data on some Cytochrome P450 Enzymes to predict activities of others, there are limitations. 	Cytochrome P450	26684	26699	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:140	Although these descriptive models could use data on some Cytochrome P450 Enzymes to predict activities of others, there are limitations. 	Cytochrome P450	26684	26699	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:145	Although the models were established using the data on ten Cytochrome P450 Enzymes from 105 normal liver tissue samples from a Chinese Han population, the models should be further improved and validated in larger samples and in different ethnic groups. 	Cytochrome P450	27267	27282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:145	Although the models were established using the data on ten Cytochrome P450 Enzymes from 105 normal liver tissue samples from a Chinese Han population, the models should be further improved and validated in larger samples and in different ethnic groups. 	Cytochrome P450	27267	27282	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	27538	27553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	27538	27553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	27668	27683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450	27668	27683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	Cytochrome P450	27866	27881	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	Cytochrome P450	27866	27881	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:17	Liver Cytochrome P450 enzymes is the most important drug metabolizing enzymes and responsible for more than 80% of drug metabolism^,. 	Cytochrome P450	2464	2479	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:17	Liver Cytochrome P450 enzymes is the most important drug metabolizing enzymes and responsible for more than 80% of drug metabolism^,. 	Cytochrome P450	2464	2479	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	Cytochrome P450	4573	4588	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	Cytochrome P450	4573	4588	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450	16595	16610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450	16595	16610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450	16768	16783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450	16768	16783	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:90	Previous studies showed that some chemical agents were reported to exacerbate APAP-induced liver injury by enhancing its liver metabolism via inducing the expression of Cytochrome P450 enzymes^-. 	Cytochrome P450	17012	17027	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:90	Previous studies showed that some chemical agents were reported to exacerbate APAP-induced liver injury by enhancing its liver metabolism via inducing the expression of Cytochrome P450 enzymes^-. 	Cytochrome P450	17012	17027	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:161	first reported 3,4,5,4-TMS as a novel selective and strong inhibitor of human Cytochrome P450 1 (CYP1B1). 	Cytochrome P450	25470	25485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:161	first reported 3,4,5,4-TMS as a novel selective and strong inhibitor of human Cytochrome P450 1 (CYP1B1). 	Cytochrome P450	25470	25485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:194	This property of Pentamethoxystilbene could have diversified its role in various cancers, because Cytochrome P450 (P450) 1B1 was expressed in various human tissues, including prostate, ovary, uterus and mammary gland. 	Cytochrome P450	30225	30240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:194	This property of Pentamethoxystilbene could have diversified its role in various cancers, because Cytochrome P450 (P450) 1B1 was expressed in various human tissues, including prostate, ovary, uterus and mammary gland. 	Cytochrome P450	30225	30240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:129	Cytochrome P450 enzymes constitute a superfamily of proteins that play an important role in the metabolism and detoxification of xenobiotics (Brown et al.,. 	Cytochrome P450	20460	20475	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:129	Cytochrome P450 enzymes constitute a superfamily of proteins that play an important role in the metabolism and detoxification of xenobiotics (Brown et al.,. 	Cytochrome P450	20460	20475	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	Cytochrome P450	20661	20676	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	Cytochrome P450	20661	20676	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	Cytochrome P450	20787	20802	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	Cytochrome P450	20787	20802	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	Cytochrome P450	21091	21106	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	Cytochrome P450	21091	21106	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	Cytochrome P450	21202	21217	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	Cytochrome P450	21202	21217	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	Cytochrome P450	21699	21714	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	Cytochrome P450	21699	21714	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:226	This interaction could lead to the reduced metabolism of coadministered drugs which are Cytochrome P450 substrates, leading to potential risks of toxicity. 	Cytochrome P450	40677	40692	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:226	This interaction could lead to the reduced metabolism of coadministered drugs which are Cytochrome P450 substrates, leading to potential risks of toxicity. 	Cytochrome P450	40677	40692	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:229	Previous studies have demonstrated potential Cytochrome P450 inhibitory effects of herbal medicines including grape fruit juice, garlic, ginseng (Ginseng species.	Cytochrome P450	41052	41067	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:229	Previous studies have demonstrated potential Cytochrome P450 inhibitory effects of herbal medicines including grape fruit juice, garlic, ginseng (Ginseng species.	Cytochrome P450	41052	41067	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:236	Based on these data, clinical use of A. Lancea as crude extract should be safe with respect to its low propensity to interfere with major hepatic Cytochrome P450 metabolism when given together with other drugs particularly as an adjunctive therapy with conventional chemotherapeutic drugs. 	Cytochrome P450	42109	42124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5733893_OgerInput.txtOger_out.csv:236	Based on these data, clinical use of A. Lancea as crude extract should be safe with respect to its low propensity to interfere with major hepatic Cytochrome P450 metabolism when given together with other drugs particularly as an adjunctive therapy with conventional chemotherapeutic drugs. 	Cytochrome P450	42109	42124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5758256_OgerInput.txtOger_out.csv:32	Cytochrome P450, a family of heme-containing monooxygenases, plays an important role in the hydroxylation of vitamin D. 	Cytochrome P450	4045	4060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5758256_OgerInput.txtOger_out.csv:32	Cytochrome P450, a family of heme-containing monooxygenases, plays an important role in the hydroxylation of vitamin D. 	Cytochrome P450	4045	4060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:46	net/2142/ 90774), which undoubtedly may be functionally significant, since Cytochrome P450 Reductase is a known protein partner of the microsomal cytochromes P450. 	Cytochrome P450	6527	6542	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:46	net/2142/ 90774), which undoubtedly may be functionally significant, since Cytochrome P450 Reductase is a known protein partner of the microsomal cytochromes P450. 	Cytochrome P450	6527	6542	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	Cytochrome P450	20723	20738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:144	Other well known cytochrome P450 protein partners (CYB5A, Cytochrome P450 Reductase, Nadph-Adrenodoxin Reductase, ADX) and several proteins unrelated to the cytochrome P450 monooxygenase system (FECH, SMAD4, RAB27B, RBP4) were also used for the specificity test. 	Cytochrome P450	20723	20738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:5	Mice were infected with three different doses of Methicillin-Resistant Staphylococcus Aureus and the changes in Cytochrome P450 expression, cytokines, and oxidative stress markers were evaluated. 	Cytochrome P450	771	786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:5	Mice were infected with three different doses of Methicillin-Resistant Staphylococcus Aureus and the changes in Cytochrome P450 expression, cytokines, and oxidative stress markers were evaluated. 	Cytochrome P450	771	786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:9	The increased inflammation and oxidative stress further induced a significant decrease in the mRNA levels and activities of Cytochrome P450 1A2, 2D22, 2E1, and 3A1 in MRSA-infected mice within the first day of infection. 	Cytochrome P450	1649	1664	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:9	The increased inflammation and oxidative stress further induced a significant decrease in the mRNA levels and activities of Cytochrome P450 1A2, 2D22, 2E1, and 3A1 in MRSA-infected mice within the first day of infection. 	Cytochrome P450	1649	1664	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:22	In this study, to assist in unnecessary treatment failure or poisoning, we examined the changes in Cytochrome P450 expression in mice infected with Methicillin-Resistant Staphylococcus Aureus and assessed whether the underlying mechanism was related to the associated changes in cytokines and oxidative stress. 	Cytochrome P450	5384	5399	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:22	In this study, to assist in unnecessary treatment failure or poisoning, we examined the changes in Cytochrome P450 expression in mice infected with Methicillin-Resistant Staphylococcus Aureus and assessed whether the underlying mechanism was related to the associated changes in cytokines and oxidative stress. 	Cytochrome P450	5384	5399	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:43	Cytochrome P450 enzymes were isolated and prepared by differential centrifugation and analyzed for their activity by the use of liver microsomes.. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), weighed, and homogenized in 0.05 mM Tris/KCl buffer (pH 7.4). 	Cytochrome P450	8041	8056	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:43	Cytochrome P450 enzymes were isolated and prepared by differential centrifugation and analyzed for their activity by the use of liver microsomes.. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), weighed, and homogenized in 0.05 mM Tris/KCl buffer (pH 7.4). 	Cytochrome P450	8041	8056	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:53	The expression levels of the following target genes were analyzed: Cytochrome P450 1A2, 2D22, 2E1, and 3A11. 	Cytochrome P450	9910	9925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:53	The expression levels of the following target genes were analyzed: Cytochrome P450 1A2, 2D22, 2E1, and 3A11. 	Cytochrome P450	9910	9925	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:57	The activities of the Cytochrome P450 1A2, 2D22, 2E1, and 3A11 enzymes were assessed as previously described, with slight modifications., All microsomal incubations were conducted for 60 min at 37C in a final volume of 500 L containing pooled microsomes (1 mg/mL protein) and an NADPH-regenerating system. 	Cytochrome P450	10223	10238	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:57	The activities of the Cytochrome P450 1A2, 2D22, 2E1, and 3A11 enzymes were assessed as previously described, with slight modifications., All microsomal incubations were conducted for 60 min at 37C in a final volume of 500 L containing pooled microsomes (1 mg/mL protein) and an NADPH-regenerating system. 	Cytochrome P450	10223	10238	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:63	The relevant enzyme activities were evaluated based on the reduction in concentrations of the four probe substrates: phenacetin, dextromethorphan, chlorzoxazole, and testosterone for Cytochrome P450 1A2, 2D22, 2E1, and 3A11, respectively. 	Cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:63	The relevant enzyme activities were evaluated based on the reduction in concentrations of the four probe substrates: phenacetin, dextromethorphan, chlorzoxazole, and testosterone for Cytochrome P450 1A2, 2D22, 2E1, and 3A11, respectively. 	Cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:84	For Cytochrome P450 1A2 and 3A11 mRNA, a significant decrease was observed in all groups on day 1. 	Cytochrome P450	14396	14411	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:84	For Cytochrome P450 1A2 and 3A11 mRNA, a significant decrease was observed in all groups on day 1. 	Cytochrome P450	14396	14411	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:85	The mRNA level of CYP 1A2 in the L and H groups was significantly decreased on days 3 and 7, but increased on day 7 in group M. The mRNA level of Cytochrome P450 3A11 was decreased significantly on day 3 and remained low in group L on day 7, but was significantly induced in groups M and H. The mRNA level of Cytochrome P450 2D22 was significantly suppressed by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, but was increased in the M group on day 7. 	Cytochrome P450	14637	14652	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:85	The mRNA level of CYP 1A2 in the L and H groups was significantly decreased on days 3 and 7, but increased on day 7 in group M. The mRNA level of Cytochrome P450 3A11 was decreased significantly on day 3 and remained low in group L on day 7, but was significantly induced in groups M and H. The mRNA level of Cytochrome P450 2D22 was significantly suppressed by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, but was increased in the M group on day 7. 	Cytochrome P450	14637	14652	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:85	The mRNA level of CYP 1A2 in the L and H groups was significantly decreased on days 3 and 7, but increased on day 7 in group M. The mRNA level of Cytochrome P450 3A11 was decreased significantly on day 3 and remained low in group L on day 7, but was significantly induced in groups M and H. The mRNA level of Cytochrome P450 2D22 was significantly suppressed by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, but was increased in the M group on day 7. 	Cytochrome P450	14800	14815	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:85	The mRNA level of CYP 1A2 in the L and H groups was significantly decreased on days 3 and 7, but increased on day 7 in group M. The mRNA level of Cytochrome P450 3A11 was decreased significantly on day 3 and remained low in group L on day 7, but was significantly induced in groups M and H. The mRNA level of Cytochrome P450 2D22 was significantly suppressed by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, but was increased in the M group on day 7. 	Cytochrome P450	14800	14815	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:86	The mRNA level of Cytochrome P450 2E1 was significantly reduced by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, increased in the L and M groups, but reduced in the H group on day 3, and then significantly increased in the M and H groups on day 7. 	Cytochrome P450	14990	15005	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:86	The mRNA level of Cytochrome P450 2E1 was significantly reduced by Methicillin-Resistant Staphylococcus Aureus in the M and H groups on day 1, increased in the L and M groups, but reduced in the H group on day 3, and then significantly increased in the M and H groups on day 7. 	Cytochrome P450	14990	15005	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:88	The activities of Cytochrome P450 1A2 and Cytochrome P450 3A11 decreased significantly in the infection groups on day 1. 	Cytochrome P450	15368	15383	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:88	The activities of Cytochrome P450 1A2 and Cytochrome P450 3A11 decreased significantly in the infection groups on day 1. 	Cytochrome P450	15368	15383	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:88	The activities of Cytochrome P450 1A2 and Cytochrome P450 3A11 decreased significantly in the infection groups on day 1. 	Cytochrome P450	15392	15407	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:88	The activities of Cytochrome P450 1A2 and Cytochrome P450 3A11 decreased significantly in the infection groups on day 1. 	Cytochrome P450	15392	15407	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:89	The activity of Cytochrome P450 1A2 was consistently suppressed on days 3 and 7, but recovered to normal levels in the M and L groups on day 3. 	Cytochrome P450	15487	15502	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:89	The activity of Cytochrome P450 1A2 was consistently suppressed on days 3 and 7, but recovered to normal levels in the M and L groups on day 3. 	Cytochrome P450	15487	15502	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:90	The activity of Cytochrome P450 3A11 was continuously suppressed from day 3. 	Cytochrome P450	15631	15646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:90	The activity of Cytochrome P450 3A11 was continuously suppressed from day 3. 	Cytochrome P450	15631	15646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:91	Cytochrome P450 2D22 activity was decreased in the M and H groups on day 3. 	Cytochrome P450	15692	15707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:91	Cytochrome P450 2D22 activity was decreased in the M and H groups on day 3. 	Cytochrome P450	15692	15707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:92	The activity of Cytochrome P450 2E1 was decreased significantly in the M and H groups for 7 days. 	Cytochrome P450	15784	15799	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:92	The activity of Cytochrome P450 2E1 was decreased significantly in the M and H groups for 7 days. 	Cytochrome P450	15784	15799	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:106	CYP450s are the main enzymes responsible for drug metabolism in the liver; their expression is regulated by various factors, including infection, disease, age, food, and stress.- Inflammation and oxidative stress are the main causes for the changes of Cytochrome P450 caused by infection and other diseases. 	Cytochrome P450	19306	19321	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:106	CYP450s are the main enzymes responsible for drug metabolism in the liver; their expression is regulated by various factors, including infection, disease, age, food, and stress.- Inflammation and oxidative stress are the main causes for the changes of Cytochrome P450 caused by infection and other diseases. 	Cytochrome P450	19306	19321	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:108	In addition to the inflammation caused by Escherichia coli, lipopolysaccharide is also a major cause of Cytochrome P450 enzyme inhibition. 	Cytochrome P450	19635	19650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:108	In addition to the inflammation caused by Escherichia coli, lipopolysaccharide is also a major cause of Cytochrome P450 enzyme inhibition. 	Cytochrome P450	19635	19650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:113	NF-B has been implicated in the regulation of P450s through interaction with their induction mechanisms.- Our results demonstrated that Methicillin-Resistant Staphylococcus Aureus has a strong inhibitory effect on the mRNA levels and enzyme activities of Cytochrome P450 enzymes. 	Cytochrome P450	20894	20909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:113	NF-B has been implicated in the regulation of P450s through interaction with their induction mechanisms.- Our results demonstrated that Methicillin-Resistant Staphylococcus Aureus has a strong inhibitory effect on the mRNA levels and enzyme activities of Cytochrome P450 enzymes. 	Cytochrome P450	20894	20909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:114	The inhibitory effect of Cytochrome P450 1A2 and 3A11 was detected from 3 days after infection and resumed on the seventh day, whereas the inhibi tion effect of Cytochrome P450 2D22 and 2E1 lasted until 7 days after infection. 	Cytochrome P450	20944	20959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:114	The inhibitory effect of Cytochrome P450 1A2 and 3A11 was detected from 3 days after infection and resumed on the seventh day, whereas the inhibi tion effect of Cytochrome P450 2D22 and 2E1 lasted until 7 days after infection. 	Cytochrome P450	20944	20959	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:114	The inhibitory effect of Cytochrome P450 1A2 and 3A11 was detected from 3 days after infection and resumed on the seventh day, whereas the inhibi tion effect of Cytochrome P450 2D22 and 2E1 lasted until 7 days after infection. 	Cytochrome P450	21080	21095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:114	The inhibitory effect of Cytochrome P450 1A2 and 3A11 was detected from 3 days after infection and resumed on the seventh day, whereas the inhibi tion effect of Cytochrome P450 2D22 and 2E1 lasted until 7 days after infection. 	Cytochrome P450	21080	21095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:116	This inhibition of Cytochrome P450 enzymes was also accompanied by an increase in oxidative stress in the livers of mice infected with Methicillin-Resistant Staphylococcus Aureus. 	Cytochrome P450	21441	21456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:116	This inhibition of Cytochrome P450 enzymes was also accompanied by an increase in oxidative stress in the livers of mice infected with Methicillin-Resistant Staphylococcus Aureus. 	Cytochrome P450	21441	21456	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:120	The Cytochrome P450 enzyme, a key determinant of drug-drug interactions, forms the basis of clinically personalized drug monitoring. 	Cytochrome P450	22218	22233	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:120	The Cytochrome P450 enzyme, a key determinant of drug-drug interactions, forms the basis of clinically personalized drug monitoring. 	Cytochrome P450	22218	22233	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:124	This is mainly manifested by increased inflammatory factors, decreased antioxidant enzymes, and increased oxidative metabolites, which are accompanied by liver Cytochrome P450 enzyme expression and a rapid decrease in activity. 	Cytochrome P450	23170	23185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:124	This is mainly manifested by increased inflammatory factors, decreased antioxidant enzymes, and increased oxidative metabolites, which are accompanied by liver Cytochrome P450 enzyme expression and a rapid decrease in activity. 	Cytochrome P450	23170	23185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:1	 Gene Duplication Leads to Altered Membrane Topology of a Cytochrome P450 Enzyme in Seed Plants. 	Cytochrome P450	58	73	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:1	 Gene Duplication Leads to Altered Membrane Topology of a Cytochrome P450 Enzyme in Seed Plants. 	Cytochrome P450	58	73	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:1	 Fungal Cytochrome P450s and the P450 Complement of Fusarium graminearum. 	Cytochrome P450	8	23	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:1	 Fungal Cytochrome P450s and the P450 Complement of Fusarium graminearum. 	Cytochrome P450	8	23	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:2	Cytochrome P450s, heme-containing monooxygenases, play important roles in a wide variety of metabolic processes important for development as well as biotic/trophic interactions in most living organisms. 	Cytochrome P450	74	89	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:2	Cytochrome P450s, heme-containing monooxygenases, play important roles in a wide variety of metabolic processes important for development as well as biotic/trophic interactions in most living organisms. 	Cytochrome P450	74	89	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:5	Various fungal Cytochrome P450s are involved in not only ergosterol synthesis and virulence but also in the production of a wide array of secondary metabolites, which exert toxic effects on humans and other animals. 	Cytochrome P450	602	617	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:5	Various fungal Cytochrome P450s are involved in not only ergosterol synthesis and virulence but also in the production of a wide array of secondary metabolites, which exert toxic effects on humans and other animals. 	Cytochrome P450	602	617	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:6	Although few studies have investigated the functions of fungal Cytochrome P450s, a recent systematic functional analysis of CYP genes in the plant pathogen Fusarium graminearum identified several novel Cytochrome P450s specifically involved in virulence, asexual and sexual development, and degradation of xenobiotics. 	Cytochrome P450	866	881	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:6	Although few studies have investigated the functions of fungal Cytochrome P450s, a recent systematic functional analysis of CYP genes in the plant pathogen Fusarium graminearum identified several novel Cytochrome P450s specifically involved in virulence, asexual and sexual development, and degradation of xenobiotics. 	Cytochrome P450	866	881	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:6	Although few studies have investigated the functions of fungal Cytochrome P450s, a recent systematic functional analysis of CYP genes in the plant pathogen Fusarium graminearum identified several novel Cytochrome P450s specifically involved in virulence, asexual and sexual development, and degradation of xenobiotics. 	Cytochrome P450	1005	1020	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:6	Although few studies have investigated the functions of fungal Cytochrome P450s, a recent systematic functional analysis of CYP genes in the plant pathogen Fusarium graminearum identified several novel Cytochrome P450s specifically involved in virulence, asexual and sexual development, and degradation of xenobiotics. 	Cytochrome P450	1005	1020	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:7	This review provides fundamental information on fungal Cytochrome P450s and a new platform for further metabolomic and biochemical studies of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	1177	1192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:7	This review provides fundamental information on fungal Cytochrome P450s and a new platform for further metabolomic and biochemical studies of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	1177	1192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:7	This review provides fundamental information on fungal Cytochrome P450s and a new platform for further metabolomic and biochemical studies of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	1264	1279	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:7	This review provides fundamental information on fungal Cytochrome P450s and a new platform for further metabolomic and biochemical studies of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	1264	1279	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:8	Cytochrome P450s, which are heme-containing proteins, represent one of the largest protein families; they are present in all biological kingdoms. 	Cytochrome P450	1301	1316	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:8	Cytochrome P450s, which are heme-containing proteins, represent one of the largest protein families; they are present in all biological kingdoms. 	Cytochrome P450	1301	1316	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:9	Cytochrome P450s commonly act as terminal monooxygenases in a range of biochemical reactions including hydroxylation, dealkylation, epoxidation, deamination, desulfuration, dehalogenation, sulfoxidation, and N-oxide reduction, by catalyzing the transfer of molecular oxygen to various cellular substrates. 	Cytochrome P450	1447	1462	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:9	Cytochrome P450s commonly act as terminal monooxygenases in a range of biochemical reactions including hydroxylation, dealkylation, epoxidation, deamination, desulfuration, dehalogenation, sulfoxidation, and N-oxide reduction, by catalyzing the transfer of molecular oxygen to various cellular substrates. 	Cytochrome P450	1447	1462	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:10	This diversity of catalytic capabilities and the ability to manipulate them means that Cytochrome P450s have been under the spotlight for biotechnological applications, such as biosynthesis of useful chemical compounds. 	Cytochrome P450	1840	1855	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:10	This diversity of catalytic capabilities and the ability to manipulate them means that Cytochrome P450s have been under the spotlight for biotechnological applications, such as biosynthesis of useful chemical compounds. 	Cytochrome P450	1840	1855	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:13	The function of human Cytochrome P450s has been extensively studied since 1960, particularly with respect to xenobiotic and drug metabolism. 	Cytochrome P450	2160	2175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:13	The function of human Cytochrome P450s has been extensively studied since 1960, particularly with respect to xenobiotic and drug metabolism. 	Cytochrome P450	2160	2175	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:14	Insect genomes contain various numbers of Cytochrome P450s, for example, 76-91 in Drosophila species (fruit flies), 87 in Bombyx mori (silkworm), and 46 in Apis mellifera (honey bee). 	Cytochrome P450	2321	2336	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:14	Insect genomes contain various numbers of Cytochrome P450s, for example, 76-91 in Drosophila species (fruit flies), 87 in Bombyx mori (silkworm), and 46 in Apis mellifera (honey bee). 	Cytochrome P450	2321	2336	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:15	In insects, Cytochrome P450s are involved in the production of defence toxins and pheromones. 	Cytochrome P450	2475	2490	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:15	In insects, Cytochrome P450s are involved in the production of defence toxins and pheromones. 	Cytochrome P450	2475	2490	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:18	Plant Cytochrome P450s are mainly involved in biosynthesis of protective toxins and repellent molecules, as well as various signalling molecules. 	Cytochrome P450	2907	2922	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:18	Plant Cytochrome P450s are mainly involved in biosynthesis of protective toxins and repellent molecules, as well as various signalling molecules. 	Cytochrome P450	2907	2922	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:20	Whereas yeast-like fungi possess relatively few Cytochrome P450s (three in Saccharomyces cerevisiae, six in Cryptococcus neoformans, and 10 in Candida albicans), filamentous fungi tend to possess more CYP genes. 	Cytochrome P450	3174	3189	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:20	Whereas yeast-like fungi possess relatively few Cytochrome P450s (three in Saccharomyces cerevisiae, six in Cryptococcus neoformans, and 10 in Candida albicans), filamentous fungi tend to possess more CYP genes. 	Cytochrome P450	3174	3189	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:21	Plant pathogenic fungi tend to possess larger numbers of CYP genes; for example, Magnaporthe oryzae and Cryphonectria parasitica harbor 107 and 121 Cytochrome P450s, respectively. 	Cytochrome P450	3486	3501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:21	Plant pathogenic fungi tend to possess larger numbers of CYP genes; for example, Magnaporthe oryzae and Cryphonectria parasitica harbor 107 and 121 Cytochrome P450s, respectively. 	Cytochrome P450	3486	3501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:22	Fungal Cytochrome P450s are involved in diverse biological processes, including production of primary and secondary metabolites and denitrification. 	Cytochrome P450	3525	3540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:22	Fungal Cytochrome P450s are involved in diverse biological processes, including production of primary and secondary metabolites and denitrification. 	Cytochrome P450	3525	3540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:23	However, compared to plants and animals, few fungal Cytochrome P450s have been functionally characterized. 	Cytochrome P450	3719	3734	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:23	However, compared to plants and animals, few fungal Cytochrome P450s have been functionally characterized. 	Cytochrome P450	3719	3734	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:24	Investigation of fungal Cytochrome P450s will improve our understanding of fungal biology and metabolism, and may offer opportunities to exploit their catalytic functions. 	Cytochrome P450	3798	3813	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:24	Investigation of fungal Cytochrome P450s will improve our understanding of fungal biology and metabolism, and may offer opportunities to exploit their catalytic functions. 	Cytochrome P450	3798	3813	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:25	In this review, we provide an overview of the fungal metabolic systems in which Cytochrome P450s play roles, such as primary and secondary metabolism, degradation of xenobiotics, and other fungal traits. 	Cytochrome P450	4026	4041	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:25	In this review, we provide an overview of the fungal metabolic systems in which Cytochrome P450s play roles, such as primary and secondary metabolism, degradation of xenobiotics, and other fungal traits. 	Cytochrome P450	4026	4041	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:26	We also present a phenome-based functional analysis of whole CYP genes in the plant pathogenic fungus Fusarium graminearum, which illuminates the functional diversity and potential applications of fungal Cytochrome P450s. 	Cytochrome P450	4354	4369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:26	We also present a phenome-based functional analysis of whole CYP genes in the plant pathogenic fungus Fusarium graminearum, which illuminates the functional diversity and potential applications of fungal Cytochrome P450s. 	Cytochrome P450	4354	4369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:29	In particular, filamentous fungi have an outstanding ability to degrade a variety of toxic substances (eg, environmental pollutants, xenobiotics, and plant-derived toxins), and some filamentous fungi are well known for production of characteristic toxins via Cytochrome P450s. 	Cytochrome P450	5010	5025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:29	In particular, filamentous fungi have an outstanding ability to degrade a variety of toxic substances (eg, environmental pollutants, xenobiotics, and plant-derived toxins), and some filamentous fungi are well known for production of characteristic toxins via Cytochrome P450s. 	Cytochrome P450	5010	5025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:31	CYP nomenclature is mainly based on amino acid sequence identity; 40% identity or greater places Cytochrome P450s in the same family and greater than 55% identity places Cytochrome P450s in the same subfamily. 	Cytochrome P450	5257	5272	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:31	CYP nomenclature is mainly based on amino acid sequence identity; 40% identity or greater places Cytochrome P450s in the same family and greater than 55% identity places Cytochrome P450s in the same subfamily. 	Cytochrome P450	5257	5272	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:31	CYP nomenclature is mainly based on amino acid sequence identity; 40% identity or greater places Cytochrome P450s in the same family and greater than 55% identity places Cytochrome P450s in the same subfamily. 	Cytochrome P450	5330	5345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:31	CYP nomenclature is mainly based on amino acid sequence identity; 40% identity or greater places Cytochrome P450s in the same family and greater than 55% identity places Cytochrome P450s in the same subfamily. 	Cytochrome P450	5330	5345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:32	As mentioned above, Cytochrome P450s are key enzymes in many fungal processes, and classifiable into multigene families, CYP51-CYP69, CYP501-CYP699, and CYP5001-CYP6999. 	Cytochrome P450	5390	5405	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:32	As mentioned above, Cytochrome P450s are key enzymes in many fungal processes, and classifiable into multigene families, CYP51-CYP69, CYP501-CYP699, and CYP5001-CYP6999. 	Cytochrome P450	5390	5405	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:33	CYP51, CYP56, CYP61, and many other known fungal Cytochrome P450s are involved in biosynthesis of primary and secondary metabolites, as well as detoxification/degradation of xenobiotics. 	Cytochrome P450	5589	5604	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:33	CYP51, CYP56, CYP61, and many other known fungal Cytochrome P450s are involved in biosynthesis of primary and secondary metabolites, as well as detoxification/degradation of xenobiotics. 	Cytochrome P450	5589	5604	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:34	Many studies have predicted the functions of Cytochrome P450s of individual fungi using bioinformatics tools. 	Cytochrome P450	5772	5787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:34	Many studies have predicted the functions of Cytochrome P450s of individual fungi using bioinformatics tools. 	Cytochrome P450	5772	5787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:35	Fungal Cytochrome P450s are grouped in 15 clades based on their phylogenetic relationships. 	Cytochrome P450	5844	5859	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:35	Fungal Cytochrome P450s are grouped in 15 clades based on their phylogenetic relationships. 	Cytochrome P450	5844	5859	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:37	Recently, 14,896 Cytochrome P450s were identified from 157 fungal and oomycete species. 	Cytochrome P450	6028	6043	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:37	Recently, 14,896 Cytochrome P450s were identified from 157 fungal and oomycete species. 	Cytochrome P450	6028	6043	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:38	However, the precise biological functions of most fungal Cytochrome P450s remain undefined. 	Cytochrome P450	6156	6171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:38	However, the precise biological functions of most fungal Cytochrome P450s remain undefined. 	Cytochrome P450	6156	6171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:39	For example, the Cytochrome P450s And The P450 Complement of the white rot fungus Phanerochaete chrysosporium comprises ~150 Cytochrome P450s, mostly arranged in gene clusters. 	Cytochrome P450	6208	6223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:39	For example, the Cytochrome P450s And The P450 Complement of the white rot fungus Phanerochaete chrysosporium comprises ~150 Cytochrome P450s, mostly arranged in gene clusters. 	Cytochrome P450	6208	6223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:39	For example, the Cytochrome P450s And The P450 Complement of the white rot fungus Phanerochaete chrysosporium comprises ~150 Cytochrome P450s, mostly arranged in gene clusters. 	Cytochrome P450	6316	6331	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:39	For example, the Cytochrome P450s And The P450 Complement of the white rot fungus Phanerochaete chrysosporium comprises ~150 Cytochrome P450s, mostly arranged in gene clusters. 	Cytochrome P450	6316	6331	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:40	In this fungus, except for the structurally and functionally conserved fungal CYP families, CYP51, CYP61, and CYP53, the roles of the other Cytochrome P450s are still largely unknown and await functional characterization. 	Cytochrome P450	6508	6523	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:40	In this fungus, except for the structurally and functionally conserved fungal CYP families, CYP51, CYP61, and CYP53, the roles of the other Cytochrome P450s are still largely unknown and await functional characterization. 	Cytochrome P450	6508	6523	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:47	Many fungal Cytochrome P450s are known to be involved in mycotoxin biosynthesis. 	Cytochrome P450	7394	7409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:47	Many fungal Cytochrome P450s are known to be involved in mycotoxin biosynthesis. 	Cytochrome P450	7394	7409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:51	Among the 26 genes located in the aflatoxin biosynthetic gene cluster, aflG, aflQ, aflU, and aflV encode Cytochrome P450s. 	Cytochrome P450	8035	8050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:51	Among the 26 genes located in the aflatoxin biosynthetic gene cluster, aflG, aflQ, aflU, and aflV encode Cytochrome P450s. 	Cytochrome P450	8035	8050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:81	In addition to polyketide synthases and non-ribosomal peptide synthases, several key genes required for biosynthesis of Ochratoxin A including putative Cytochrome P450s were identified in a few Aspergillus species. 	Cytochrome P450	12286	12301	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:81	In addition to polyketide synthases and non-ribosomal peptide synthases, several key genes required for biosynthesis of Ochratoxin A including putative Cytochrome P450s were identified in a few Aspergillus species. 	Cytochrome P450	12286	12301	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:87	Among xenobiotic-metabolizing enzymes, Cytochrome P450s are the most abundant and versatile. 	Cytochrome P450	13211	13226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:87	Among xenobiotic-metabolizing enzymes, Cytochrome P450s are the most abundant and versatile. 	Cytochrome P450	13211	13226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:88	Studies of mammalian xenobiotic-metabolizing Cytochrome P450s have led to the discovery and characterization of the xenobiotic metabolism pathways. 	Cytochrome P450	13310	13325	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:88	Studies of mammalian xenobiotic-metabolizing Cytochrome P450s have led to the discovery and characterization of the xenobiotic metabolism pathways. 	Cytochrome P450	13310	13325	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:89	In humans, drug-metabolizing Cytochrome P450s mostly presenting in the liver are responsible for oxidative metabolism of xenobiotics. 	Cytochrome P450	13442	13457	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:89	In humans, drug-metabolizing Cytochrome P450s mostly presenting in the liver are responsible for oxidative metabolism of xenobiotics. 	Cytochrome P450	13442	13457	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:90	Many insect Cytochrome P450s also play roles in detoxification of xenobiotics. 	Cytochrome P450	13559	13574	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:90	Many insect Cytochrome P450s also play roles in detoxification of xenobiotics. 	Cytochrome P450	13559	13574	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:91	Insect Cytochrome P450s are inducible in response to botanical insecticides and/or plant secondary metabolites. 	Cytochrome P450	13633	13648	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:91	Insect Cytochrome P450s are inducible in response to botanical insecticides and/or plant secondary metabolites. 	Cytochrome P450	13633	13648	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:92	Also, some plant Cytochrome P450s involved in the detoxification of xenobiotics such as herbicides. 	Cytochrome P450	13755	13770	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:92	Also, some plant Cytochrome P450s involved in the detoxification of xenobiotics such as herbicides. 	Cytochrome P450	13755	13770	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:95	One of the best-characterized fungal Cytochrome P450s is a pisatin demethylase (PDA, CYP57A1), which was first identified in N. haematococca. 	Cytochrome P450	14339	14354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:95	One of the best-characterized fungal Cytochrome P450s is a pisatin demethylase (PDA, CYP57A1), which was first identified in N. haematococca. 	Cytochrome P450	14339	14354	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:101	One particularly well-studied fungal Cytochrome P450s is CYP51, which mediates primary metabolism of ergosterol biosynthesis. 	Cytochrome P450	14931	14946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:101	One particularly well-studied fungal Cytochrome P450s is CYP51, which mediates primary metabolism of ergosterol biosynthesis. 	Cytochrome P450	14931	14946	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:117	Significant regulation of Cytochrome P450s has been observed during host-pathogen interactions via gene/transcriptome profiling analyses of several fungi, eg, F. graminearum, Curvularia lunata, and Heterobasidion annosum, although the mechanisms are not yet known. 	Cytochrome P450	17156	17171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:117	Significant regulation of Cytochrome P450s has been observed during host-pathogen interactions via gene/transcriptome profiling analyses of several fungi, eg, F. graminearum, Curvularia lunata, and Heterobasidion annosum, although the mechanisms are not yet known. 	Cytochrome P450	17156	17171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:119	Several fungal Cytochrome P450s have been known to play critical roles in primary and secondary metabolism and degradation of xenobiotics. 	Cytochrome P450	17554	17569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:119	Several fungal Cytochrome P450s have been known to play critical roles in primary and secondary metabolism and degradation of xenobiotics. 	Cytochrome P450	17554	17569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:120	Besides, some Cytochrome P450s in pathogenic fungi has emerged as important enzymes in virulence. 	Cytochrome P450	17692	17707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:120	Besides, some Cytochrome P450s in pathogenic fungi has emerged as important enzymes in virulence. 	Cytochrome P450	17692	17707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:121	However, the involvement of Cytochrome P450s in fungal development and other functions, such as virulence or xenobiotic detoxification, has rarely been elucidated, and there has been no systematic approach to the investigation of Cytochrome P450s in filamentous fungi, including plant pathogens. 	Cytochrome P450	17804	17819	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:121	However, the involvement of Cytochrome P450s in fungal development and other functions, such as virulence or xenobiotic detoxification, has rarely been elucidated, and there has been no systematic approach to the investigation of Cytochrome P450s in filamentous fungi, including plant pathogens. 	Cytochrome P450	17804	17819	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:121	However, the involvement of Cytochrome P450s in fungal development and other functions, such as virulence or xenobiotic detoxification, has rarely been elucidated, and there has been no systematic approach to the investigation of Cytochrome P450s in filamentous fungi, including plant pathogens. 	Cytochrome P450	18006	18021	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:121	However, the involvement of Cytochrome P450s in fungal development and other functions, such as virulence or xenobiotic detoxification, has rarely been elucidated, and there has been no systematic approach to the investigation of Cytochrome P450s in filamentous fungi, including plant pathogens. 	Cytochrome P450	18006	18021	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:126	To date, only nine F. graminearum Cytochrome P450s have been functionally characterized. 	Cytochrome P450	18785	18800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:126	To date, only nine F. graminearum Cytochrome P450s have been functionally characterized. 	Cytochrome P450	18785	18800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:128	Four Cytochrome P450s (TRI1, TRI4, TRI13, and TRI11) are involved in trichothecene biosynthesis, and Fg08079 and CLM2 are required for the biosynthesis of butenolide and culmorin, respectively. 	Cytochrome P450	18933	18948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:128	Four Cytochrome P450s (TRI1, TRI4, TRI13, and TRI11) are involved in trichothecene biosynthesis, and Fg08079 and CLM2 are required for the biosynthesis of butenolide and culmorin, respectively. 	Cytochrome P450	18933	18948	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:129	To systematically characterize the Cytochrome P450s And The P450 Complement of F. graminearum, CYP gene knockout mutants were generated, and a comprehensive phenome of 102 CYP mutant library of F. graminearum was tested in 38 traits. 	Cytochrome P450	19157	19172	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:129	To systematically characterize the Cytochrome P450s And The P450 Complement of F. graminearum, CYP gene knockout mutants were generated, and a comprehensive phenome of 102 CYP mutant library of F. graminearum was tested in 38 traits. 	Cytochrome P450	19157	19172	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:137	Four Cytochrome P450s, Tri1, Tri4, Tri11, and Tri13, are involved in biosynthesis of trichothecenes. 	Cytochrome P450	20251	20266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:137	Four Cytochrome P450s, Tri1, Tri4, Tri11, and Tri13, are involved in biosynthesis of trichothecenes. 	Cytochrome P450	20251	20266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:138	Among the four Cytochrome P450s in the trichothecene biosynthetic gene cluster, Tri13, 3-acetyltrichothecene C-4 hydroxylase, is responsible for hydroxylation of trichothecenes at C-4; the gene is therefore a determinant of the DON- and NIV-producing chemotypes in F. graminearum. 	Cytochrome P450	20362	20377	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:138	Among the four Cytochrome P450s in the trichothecene biosynthetic gene cluster, Tri13, 3-acetyltrichothecene C-4 hydroxylase, is responsible for hydroxylation of trichothecenes at C-4; the gene is therefore a determinant of the DON- and NIV-producing chemotypes in F. graminearum. 	Cytochrome P450	20362	20377	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:143	Likewise, some putative xenobiotic-metabolizing Cytochrome P450s in F. graminearum have been characterized based on genetic evidence. 	Cytochrome P450	21089	21104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:143	Likewise, some putative xenobiotic-metabolizing Cytochrome P450s in F. graminearum have been characterized based on genetic evidence. 	Cytochrome P450	21089	21104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:154	Our previous study on the systematic functional characterization of CYP genes in F. graminearum revealed that many novel Cytochrome P450s are closely involved in fungal developmental processes including virulence. 	Cytochrome P450	23013	23028	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:154	Our previous study on the systematic functional characterization of CYP genes in F. graminearum revealed that many novel Cytochrome P450s are closely involved in fungal developmental processes including virulence. 	Cytochrome P450	23013	23028	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:155	Using this phenotypic dataset, we could gain insight into the cryptic functions of Cytochrome P450s in fungi. 	Cytochrome P450	23189	23204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:155	Using this phenotypic dataset, we could gain insight into the cryptic functions of Cytochrome P450s in fungi. 	Cytochrome P450	23189	23204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:162	In infection assays with flowering wheat heads, deletion mutants of five Cytochrome P450s, Fg03700 (CYP620B1), Fg02111 (CYP636A1), Fg00012 (CYP630A1), Fg10451 (CYP53A8), and Fg12737 (CYP537A2), showed reduced virulence compared to the wild type (d). 	Cytochrome P450	24397	24412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:162	In infection assays with flowering wheat heads, deletion mutants of five Cytochrome P450s, Fg03700 (CYP620B1), Fg02111 (CYP636A1), Fg00012 (CYP630A1), Fg10451 (CYP53A8), and Fg12737 (CYP537A2), showed reduced virulence compared to the wild type (d). 	Cytochrome P450	24397	24412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:166	We suspect that these Cytochrome P450s, which displayed reduced virulence when deleted, are involved in degradation of plant-derived metabolites or plant tissues for successful infection. 	Cytochrome P450	24960	24975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:166	We suspect that these Cytochrome P450s, which displayed reduced virulence when deleted, are involved in degradation of plant-derived metabolites or plant tissues for successful infection. 	Cytochrome P450	24960	24975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:167	Recently, comparative in planta transcriptome analyses revealed that more than 40 Cytochrome P450s may be involved in host-pathogen interactions of F. graminearum. 	Cytochrome P450	25208	25223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:167	Recently, comparative in planta transcriptome analyses revealed that more than 40 Cytochrome P450s may be involved in host-pathogen interactions of F. graminearum. 	Cytochrome P450	25208	25223	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:168	Fungal Cytochrome P450s play essential roles for survival, and several azole fungicides that are mainly targeted at the Cytochrome P450s have been commercially used for control of animal and plant pathogenic fungi. 	Cytochrome P450	25297	25312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:168	Fungal Cytochrome P450s play essential roles for survival, and several azole fungicides that are mainly targeted at the Cytochrome P450s have been commercially used for control of animal and plant pathogenic fungi. 	Cytochrome P450	25297	25312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:168	Fungal Cytochrome P450s play essential roles for survival, and several azole fungicides that are mainly targeted at the Cytochrome P450s have been commercially used for control of animal and plant pathogenic fungi. 	Cytochrome P450	25410	25425	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:168	Fungal Cytochrome P450s play essential roles for survival, and several azole fungicides that are mainly targeted at the Cytochrome P450s have been commercially used for control of animal and plant pathogenic fungi. 	Cytochrome P450	25410	25425	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:169	Decades of studies on fungal genetics and biochemistry have established the involvement of Cytochrome P450s in many bioconversion processes related to degradation of foreign compounds and biosynthesis of secondary metabolites in fungi. 	Cytochrome P450	25596	25611	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:169	Decades of studies on fungal genetics and biochemistry have established the involvement of Cytochrome P450s in many bioconversion processes related to degradation of foreign compounds and biosynthesis of secondary metabolites in fungi. 	Cytochrome P450	25596	25611	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:170	However, scant information is available on Cytochrome P450s and their involvement in fungal developmental processes, including virulence, due to the lack of CYP mutants defective in those phenotypes and available up-to-date molecular techniques. 	Cytochrome P450	25784	25799	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:170	However, scant information is available on Cytochrome P450s and their involvement in fungal developmental processes, including virulence, due to the lack of CYP mutants defective in those phenotypes and available up-to-date molecular techniques. 	Cytochrome P450	25784	25799	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:171	Using data from a systematic functional genomic study of F. graminearum, we identified some clues to the novel functions of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	26111	26126	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:171	Using data from a systematic functional genomic study of F. graminearum, we identified some clues to the novel functions of Cytochrome P450s in toxigenic fungi. 	Cytochrome P450	26111	26126	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:172	Further studies should focus on the identification of the substrate specificity of Cytochrome P450s using metabolomic and/or biochemical approaches. 	Cytochrome P450	26231	26246	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:172	Further studies should focus on the identification of the substrate specificity of Cytochrome P450s using metabolomic and/or biochemical approaches. 	Cytochrome P450	26231	26246	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:174	These multidisciplinary studies on Cytochrome P450s will provide fundamental information on fungal-specific Cytochrome P450s compared to those of other organisms and new insights into fungal biology and virulence.	Cytochrome P450	26510	26525	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:174	These multidisciplinary studies on Cytochrome P450s will provide fundamental information on fungal-specific Cytochrome P450s compared to those of other organisms and new insights into fungal biology and virulence.	Cytochrome P450	26510	26525	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:174	These multidisciplinary studies on Cytochrome P450s will provide fundamental information on fungal-specific Cytochrome P450s compared to those of other organisms and new insights into fungal biology and virulence.	Cytochrome P450	26583	26598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5869400_OgerInput.txtOger_out.csv:174	These multidisciplinary studies on Cytochrome P450s will provide fundamental information on fungal-specific Cytochrome P450s compared to those of other organisms and new insights into fungal biology and virulence.	Cytochrome P450	26583	26598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:1	 Inhibition of Cytochrome P450 Activities by Extracts of Hyptis verticillata Jacq.	Cytochrome P450	15	30	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6017200_OgerInput.txtOger_out.csv:1	 Inhibition of Cytochrome P450 Activities by Extracts of Hyptis verticillata Jacq.	Cytochrome P450	15	30	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:9	Cytochrome P450 (P450) have been found in most of organisms where they were looked for, with some noticeable exceptions, such as E. coli. 	Cytochrome P450	1051	1066	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:9	Cytochrome P450 (P450) have been found in most of organisms where they were looked for, with some noticeable exceptions, such as E. coli. 	Cytochrome P450	1051	1066	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:2	The effect of non-synonymous single nucleotide polymorphisms on cytochrome P450 drug metabolism is currently poorly understood due to the large number of polymorphisms, the diversity of potential substrates and the complexity of Cytochrome P450 function. 	Cytochrome P450	356	371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:2	The effect of non-synonymous single nucleotide polymorphisms on cytochrome P450 drug metabolism is currently poorly understood due to the large number of polymorphisms, the diversity of potential substrates and the complexity of Cytochrome P450 function. 	Cytochrome P450	356	371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:3	Previously we carried out in silico studies to explore the effect of Single Nucleotide Polymorphisms on Cytochrome P450 function, using in silico calculations to predict the effect of mutations on protein stability. 	Cytochrome P450	486	501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:3	Previously we carried out in silico studies to explore the effect of Single Nucleotide Polymorphisms on Cytochrome P450 function, using in silico calculations to predict the effect of mutations on protein stability. 	Cytochrome P450	486	501	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:5	Thermostability assays revealed distinct Cytochrome P450 sub-populations with only 65-70% of wild-type CYP3A4 and CYP2C9 susceptible to rapid heat-induced P450 to P420 conversion. 	Cytochrome P450	813	828	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:5	Thermostability assays revealed distinct Cytochrome P450 sub-populations with only 65-70% of wild-type CYP3A4 and CYP2C9 susceptible to rapid heat-induced P450 to P420 conversion. 	Cytochrome P450	813	828	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:9	Cytochrome P450 enzymes, arguably natures most versatile catalysts, are a superfamily of haem-thiolate proteins found across all lineages of life^. 	Cytochrome P450	1602	1617	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:9	Cytochrome P450 enzymes, arguably natures most versatile catalysts, are a superfamily of haem-thiolate proteins found across all lineages of life^. 	Cytochrome P450	1602	1617	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:11	While there are more than 57 different Cytochrome P450 enzymes in humans, only a small number of highly polymorphic isoforms are responsible for the majority of drug metabolism^. 	Cytochrome P450	1909	1924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:11	While there are more than 57 different Cytochrome P450 enzymes in humans, only a small number of highly polymorphic isoforms are responsible for the majority of drug metabolism^. 	Cytochrome P450	1909	1924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:13	Variant alleles include deletions, insertions, copy number variants and single nucleotide polymorphisms, both in the coding and non-coding regions of the genes, which can alter Cytochrome P450 expression levels as well as protein function^. 	Cytochrome P450	2354	2369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:13	Variant alleles include deletions, insertions, copy number variants and single nucleotide polymorphisms, both in the coding and non-coding regions of the genes, which can alter Cytochrome P450 expression levels as well as protein function^. 	Cytochrome P450	2354	2369	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:14	Over 100 non-synonymous single amino acid substitutions have been reported for isoforms CYP3A4 and CYP2C9 alone^,; these two isoforms are jointly responsible for nearly half of Cytochrome P450 mediated drug metabolism^. 	Cytochrome P450	2595	2610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:14	Over 100 non-synonymous single amino acid substitutions have been reported for isoforms CYP3A4 and CYP2C9 alone^,; these two isoforms are jointly responsible for nearly half of Cytochrome P450 mediated drug metabolism^. 	Cytochrome P450	2595	2610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:16	There are now around 800 published Cytochrome P450 X-ray crystal structures, including well over 100 human Cytochrome P450 structures crystallised in the presence and absence of a range of ligands. 	Cytochrome P450	2925	2940	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:16	There are now around 800 published Cytochrome P450 X-ray crystal structures, including well over 100 human Cytochrome P450 structures crystallised in the presence and absence of a range of ligands. 	Cytochrome P450	2925	2940	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:16	There are now around 800 published Cytochrome P450 X-ray crystal structures, including well over 100 human Cytochrome P450 structures crystallised in the presence and absence of a range of ligands. 	Cytochrome P450	2997	3012	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:16	There are now around 800 published Cytochrome P450 X-ray crystal structures, including well over 100 human Cytochrome P450 structures crystallised in the presence and absence of a range of ligands. 	Cytochrome P450	2997	3012	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:22	While CYP450s have traditionally been regarded as monomers, there is increasing evidence that cross-talk occurs between multiple Cytochrome P450 isoforms within the membrane via homo- and hetero-oligomerisation^,. 	Cytochrome P450	4494	4509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:22	While CYP450s have traditionally been regarded as monomers, there is increasing evidence that cross-talk occurs between multiple Cytochrome P450 isoforms within the membrane via homo- and hetero-oligomerisation^,. 	Cytochrome P450	4494	4509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:23	Atypical kinetic profiles are commonly observed for drug metabolising Cytochrome P450 isoforms^, and crystal structures have confirmed that multiple ligands can bind within the large flexible active sites of these enzymes. 	Cytochrome P450	4649	4664	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:23	Atypical kinetic profiles are commonly observed for drug metabolising Cytochrome P450 isoforms^, and crystal structures have confirmed that multiple ligands can bind within the large flexible active sites of these enzymes. 	Cytochrome P450	4649	4664	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:29	In a previous study, we combined in silico protein stability calculation with structure-function relationships to predict the phenotypic effect of Single Nucleotide Polymorphisms in the major drug metabolising Cytochrome P450 isoforms^. 	Cytochrome P450	6030	6045	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:29	In a previous study, we combined in silico protein stability calculation with structure-function relationships to predict the phenotypic effect of Single Nucleotide Polymorphisms in the major drug metabolising Cytochrome P450 isoforms^. 	Cytochrome P450	6030	6045	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:35	Cytochrome P450 function is affected in vivo by a range of factors, including interaction with the membrane, redox partners and other Cytochrome P450 molecules, as well as the diverse range of substrates that could be affected by Single Nucleotide Polymorphisms in a substrate specific manner. 	Cytochrome P450	7177	7192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:35	Cytochrome P450 function is affected in vivo by a range of factors, including interaction with the membrane, redox partners and other Cytochrome P450 molecules, as well as the diverse range of substrates that could be affected by Single Nucleotide Polymorphisms in a substrate specific manner. 	Cytochrome P450	7177	7192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:35	Cytochrome P450 function is affected in vivo by a range of factors, including interaction with the membrane, redox partners and other Cytochrome P450 molecules, as well as the diverse range of substrates that could be affected by Single Nucleotide Polymorphisms in a substrate specific manner. 	Cytochrome P450	7311	7326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:35	Cytochrome P450 function is affected in vivo by a range of factors, including interaction with the membrane, redox partners and other Cytochrome P450 molecules, as well as the diverse range of substrates that could be affected by Single Nucleotide Polymorphisms in a substrate specific manner. 	Cytochrome P450	7311	7326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:37	Despite this, in our previous study we found that Single Nucleotide Polymorphisms predicted to alter protein stability or located in regions important for catalytic function are more likely to have effects on Cytochrome P450 function, based on available in vitro activity data^. 	Cytochrome P450	8077	8092	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:37	Despite this, in our previous study we found that Single Nucleotide Polymorphisms predicted to alter protein stability or located in regions important for catalytic function are more likely to have effects on Cytochrome P450 function, based on available in vitro activity data^. 	Cytochrome P450	8077	8092	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:44	The reduced ferrous form of the haem ion binds Carbon Monoxide, yielding an absorption peak at 450 nm, provided the haem group is correctly incorporated into the Cytochrome P450, providing a measure of the active protein in the sample (although technically the enzyme is rendered inactive on coordination to CO). 	Cytochrome P450	9172	9187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:44	The reduced ferrous form of the haem ion binds Carbon Monoxide, yielding an absorption peak at 450 nm, provided the haem group is correctly incorporated into the Cytochrome P450, providing a measure of the active protein in the sample (although technically the enzyme is rendered inactive on coordination to CO). 	Cytochrome P450	9172	9187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:46	When the Cytochrome P450 protein samples were incubated at an elevated temperature, the peak at 450 nm shifted to 420 nm indicating the thermal conversion of active P450 into inactive P420 (Fig. 	Cytochrome P450	9558	9573	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:46	When the Cytochrome P450 protein samples were incubated at an elevated temperature, the peak at 450 nm shifted to 420 nm indicating the thermal conversion of active P450 into inactive P420 (Fig. 	Cytochrome P450	9558	9573	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:74	In order to test previous in silico predictions on the effects of Single Nucleotide Polymorphisms on Cytochrome P450 stability, recombinant soluble CYP2C9 and CYP3A4 Wild-Type and variant proteins, lacking their N-terminal membrane binding region, were expressed in E. coli and purified from the cell lysate. 	Cytochrome P450	14327	14342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:74	In order to test previous in silico predictions on the effects of Single Nucleotide Polymorphisms on Cytochrome P450 stability, recombinant soluble CYP2C9 and CYP3A4 Wild-Type and variant proteins, lacking their N-terminal membrane binding region, were expressed in E. coli and purified from the cell lysate. 	Cytochrome P450	14327	14342	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:116	While this residue does not fall within a substrate recognition site, it is solvent accessible and is predicted to form part of the CYP3A4:CPR interface so any destabilising effects in this region may also alter interactions with Cytochrome P450 Reductase. 	Cytochrome P450	21935	21950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:116	While this residue does not fall within a substrate recognition site, it is solvent accessible and is predicted to form part of the CYP3A4:CPR interface so any destabilising effects in this region may also alter interactions with Cytochrome P450 Reductase. 	Cytochrome P450	21935	21950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:117	However, studies where the M445T variant was expressed in E.coli, quantified using Carbon Monoxide spectral binding assays and reconstituted with Cytochrome P450 Reductase and lipids, reported no significant difference in turnover numbers for testosterone^, or chlorpyrifos at the single substrate concentrations tested^. 	Cytochrome P450	22108	22123	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:117	However, studies where the M445T variant was expressed in E.coli, quantified using Carbon Monoxide spectral binding assays and reconstituted with Cytochrome P450 Reductase and lipids, reported no significant difference in turnover numbers for testosterone^, or chlorpyrifos at the single substrate concentrations tested^. 	Cytochrome P450	22108	22123	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:118	The presence of lipids and Cytochrome P450 Reductase in their reconstituted reaction mixture may have a stabilising effect on the protein. 	Cytochrome P450	22311	22326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:118	The presence of lipids and Cytochrome P450 Reductase in their reconstituted reaction mixture may have a stabilising effect on the protein. 	Cytochrome P450	22311	22326	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:121	For reasons less immediately apparent, P218R and S222P had a significant effect on the thermostability of CYP3A4; P218R and S222P were both predicted to be neutral by Site Directed Mutator and fall within the flexible F-G loop, which is far away from the haem-binding site but forms part of substrate recognition site (2,3) at the proposed interface of the interacting Cytochrome P450 subunits, close to the peripheral effector site acts as a lid over the active site cavity and is comprised of the F and G helix connected by the F-G loop. 	Cytochrome P450	23251	23266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:121	For reasons less immediately apparent, P218R and S222P had a significant effect on the thermostability of CYP3A4; P218R and S222P were both predicted to be neutral by Site Directed Mutator and fall within the flexible F-G loop, which is far away from the haem-binding site but forms part of substrate recognition site (2,3) at the proposed interface of the interacting Cytochrome P450 subunits, close to the peripheral effector site acts as a lid over the active site cavity and is comprised of the F and G helix connected by the F-G loop. 	Cytochrome P450	23251	23266	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:123	In some Cytochrome P450 structures this region is comprised of two short F and G helixes (eg CYP2C9 PDB 1OG2^) while in other structures it is a disordered loop region (eg CYP2C9 PDB 1R9O^). 	Cytochrome P450	23654	23669	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:123	In some Cytochrome P450 structures this region is comprised of two short F and G helixes (eg CYP2C9 PDB 1OG2^) while in other structures it is a disordered loop region (eg CYP2C9 PDB 1R9O^). 	Cytochrome P450	23654	23669	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:128	The F-G loop has also been implemented in the dimerization of several mammalian Cytochrome P450 isoforms, both in solution and membranes^,,,. 	Cytochrome P450	24794	24809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:128	The F-G loop has also been implemented in the dimerization of several mammalian Cytochrome P450 isoforms, both in solution and membranes^,,,. 	Cytochrome P450	24794	24809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:151	While CYP2C9 R132Q and R150H showed no significant effect on the Cytochrome P450 stability in agreement with the in silico predictions, these Single Nucleotide Polymorphisms have both been reported to affect catalytic activity. 	Cytochrome P450	29927	29942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:151	While CYP2C9 R132Q and R150H showed no significant effect on the Cytochrome P450 stability in agreement with the in silico predictions, these Single Nucleotide Polymorphisms have both been reported to affect catalytic activity. 	Cytochrome P450	29927	29942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:159	This mutation is situated on the surface of the protein, outside the cluster of charged residues responsible for Cytochrome P450 Reductase binding, but it has been proposed that it could affect interactions with CPR^. 	Cytochrome P450	31287	31302	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:159	This mutation is situated on the surface of the protein, outside the cluster of charged residues responsible for Cytochrome P450 Reductase binding, but it has been proposed that it could affect interactions with CPR^. 	Cytochrome P450	31287	31302	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:164	SDMs low sensitivity is expected since effects on haem binding and quaternary structure are not accounted for by SDM: of the 5 false negatives, as predicted by Site Directed Mutator, one (L373F) is a haem contact and two may alter oligomer formation (P218R, S222P); the other two variants were either incorrectly predicted by Site Directed Mutator or have long range effects on oligomer formation, Cytochrome P450 conformation or haem binding, without significantly disrupting the stability of the protein fold. 	Cytochrome P450	32673	32688	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:164	SDMs low sensitivity is expected since effects on haem binding and quaternary structure are not accounted for by SDM: of the 5 false negatives, as predicted by Site Directed Mutator, one (L373F) is a haem contact and two may alter oligomer formation (P218R, S222P); the other two variants were either incorrectly predicted by Site Directed Mutator or have long range effects on oligomer formation, Cytochrome P450 conformation or haem binding, without significantly disrupting the stability of the protein fold. 	Cytochrome P450	32673	32688	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	Cytochrome P450	32978	32993	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	Cytochrome P450	32978	32993	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	Cytochrome P450	33053	33068	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:165	This work provides new insight into structure-function relationships in CYP3A4 and CYP2C9 and demonstrates the utility of in silico approaches such as Site Directed Mutator combined with the Cytochrome P450 functional map^ for predicting the effects of mutations on Cytochrome P450 stability and prioritising Single Nucleotide Polymorphisms for experimental testing. 	Cytochrome P450	33053	33068	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:166	There is a growing body of evidence indicating that homo- and hetero-oligomer formation plays a key role in Cytochrome P450 regulation in membranes^,,,. 	Cytochrome P450	33262	33277	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:166	There is a growing body of evidence indicating that homo- and hetero-oligomer formation plays a key role in Cytochrome P450 regulation in membranes^,,,. 	Cytochrome P450	33262	33277	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:186	Cytochrome P450 protein samples were diluted in storage buffer to a concentration of 1 mg/ml and divided into two cuvettes (one reference and one sample cuvette). 	Cytochrome P450	36682	36697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:186	Cytochrome P450 protein samples were diluted in storage buffer to a concentration of 1 mg/ml and divided into two cuvettes (one reference and one sample cuvette). 	Cytochrome P450	36682	36697	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:210	20 l of Cytochrome P450 protein sample in storage buffer (~2 mg/ml total protein concentration) was injected onto the column. 	Cytochrome P450	40122	40137	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:210	20 l of Cytochrome P450 protein sample in storage buffer (~2 mg/ml total protein concentration) was injected onto the column. 	Cytochrome P450	40122	40137	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6099105_OgerInput.txtOger_out.csv:69	Functional annotations were carried out as described in  and using the same parameters as in : putative Carbohydrate-Active enZYmes (CAZYmes), peroxidases, cytochromes P450 (P450s), cellular transporters, and genes associated with secondary metabolism, were identified using dbCAN, fPoxDB, The Cytochrome P450 Homepage, Transporter Classification Database, and antiSMASH v.4.0.0, respectively. 	Cytochrome P450	9614	9629	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6099105_OgerInput.txtOger_out.csv:69	Functional annotations were carried out as described in  and using the same parameters as in : putative Carbohydrate-Active enZYmes (CAZYmes), peroxidases, cytochromes P450 (P450s), cellular transporters, and genes associated with secondary metabolism, were identified using dbCAN, fPoxDB, The Cytochrome P450 Homepage, Transporter Classification Database, and antiSMASH v.4.0.0, respectively. 	Cytochrome P450	9614	9629	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:2	Spring against Cytochrome P450 and Uridine 5-Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes. 	Cytochrome P450	89	104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:2	Spring against Cytochrome P450 and Uridine 5-Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes. 	Cytochrome P450	89	104	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:181	Evaluation of the target molecules as substrates of Cytochrome P450 shows that 1-4 act as non-substrates of the 2C9 and 2D6 isoforms of cytochrome P450. 	Cytochrome P450	30463	30478	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:181	Evaluation of the target molecules as substrates of Cytochrome P450 shows that 1-4 act as non-substrates of the 2C9 and 2D6 isoforms of cytochrome P450. 	Cytochrome P450	30463	30478	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:184	Regarding Cytochrome P450 2D6, the primary characteristic of their substrates is the presence of basic nitrogen atom placed 5  or 7  from the site of oxidation. 	Cytochrome P450	30934	30949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:184	Regarding Cytochrome P450 2D6, the primary characteristic of their substrates is the presence of basic nitrogen atom placed 5  or 7  from the site of oxidation. 	Cytochrome P450	30934	30949	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:188	Additionally, an important metabolic property to consider is the capability of these compounds to inhibit the Cytochrome P450 isoforms, which is an adverse effect. 	Cytochrome P450	31924	31939	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:188	Additionally, an important metabolic property to consider is the capability of these compounds to inhibit the Cytochrome P450 isoforms, which is an adverse effect. 	Cytochrome P450	31924	31939	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:190	Another Cytochrome P450 isoform inhibited by the studied molecules is the -CYP2C9, in agreement with result obtained in the substrate behavior studies. 	Cytochrome P450	32255	32270	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:190	Another Cytochrome P450 isoform inhibited by the studied molecules is the -CYP2C9, in agreement with result obtained in the substrate behavior studies. 	Cytochrome P450	32255	32270	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:43	Detoxification of insecticides in mosquitoes include three major gene families: Cytochrome P450s, esterases, and glutathion S-transferases. 	Cytochrome P450	4343	4358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:43	Detoxification of insecticides in mosquitoes include three major gene families: Cytochrome P450s, esterases, and glutathion S-transferases. 	Cytochrome P450	4343	4358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:211	They encoded an alcohol dehydrogenase (AAEL012457), an amine oxidase (AAEL009044), Carboxy/choline esterase (AAEL002385), 19 Cytochrome P450, and a glucosyl/glucuronosyl transferase (AAEL003099). 	Cytochrome P450	28541	28556	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:211	They encoded an alcohol dehydrogenase (AAEL012457), an amine oxidase (AAEL009044), Carboxy/choline esterase (AAEL002385), 19 Cytochrome P450, and a glucosyl/glucuronosyl transferase (AAEL003099). 	Cytochrome P450	28541	28556	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:213	Nineteen Cytochrome P450 included, CYP6CB1 (AAEL009018), CYP9M10 (AAEL009125), and P450s of the CYP9J subfamily such as CYP9J10 (AAEL006798) and CYP9J28 (AAEL014617), from which several members were shown to contribute to deltamethrin metabolism. 	Cytochrome P450	28835	28850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165428_OgerInput.txtOger_out.csv:213	Nineteen Cytochrome P450 included, CYP6CB1 (AAEL009018), CYP9M10 (AAEL009125), and P450s of the CYP9J subfamily such as CYP9J10 (AAEL006798) and CYP9J28 (AAEL014617), from which several members were shown to contribute to deltamethrin metabolism. 	Cytochrome P450	28835	28850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:49	Starting at 24 hours, treatment with B[a]P significantly increases the fold change of all three Cytochrome P450 genes, and their expression appears to be the greatest following 48 hours of B[a]P treatment. 	Cytochrome P450	6667	6682	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:49	Starting at 24 hours, treatment with B[a]P significantly increases the fold change of all three Cytochrome P450 genes, and their expression appears to be the greatest following 48 hours of B[a]P treatment. 	Cytochrome P450	6667	6682	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	Cytochrome P450	8056	8071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:61	Exposure to 2 MED Simulated Sunlight slightly increased expression of Cytochrome P450 genes (fold change 2.9, 1.4 and 1.8 for CYP1A1, CYP1A2, and CYP1B1, respectively), but without reaching statistical significance, contrary to skin results. 	Cytochrome P450	8056	8071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:67	The 24-hour delay after B[a]P exposure was chosen because it corresponds to the beginning of the induction of Cytochrome P450 genes. 	Cytochrome P450	9293	9308	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:67	The 24-hour delay after B[a]P exposure was chosen because it corresponds to the beginning of the induction of Cytochrome P450 genes. 	Cytochrome P450	9293	9308	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:81	Treatment of Normal Human Keratinocytes following either the SSL/B[a]P or B[a]P/SSL protocols led to a reduced induction of Cytochrome P450 genes than exposure to pure B[a]P. SSL was also found to lead to a decrease in the yield of adducts produced in DNA upon exposure to B[a]P. At 72 hours, the difference lost statistical significance. 	Cytochrome P450	11353	11368	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:81	Treatment of Normal Human Keratinocytes following either the SSL/B[a]P or B[a]P/SSL protocols led to a reduced induction of Cytochrome P450 genes than exposure to pure B[a]P. SSL was also found to lead to a decrease in the yield of adducts produced in DNA upon exposure to B[a]P. At 72 hours, the difference lost statistical significance. 	Cytochrome P450	11353	11368	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:122	It should be stressed that this stimulation of the expression of Cytochrome P450 genes remains modest compared to the almost two orders of magnitude larger expression following B[a]P treatment. 	Cytochrome P450	17554	17569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:122	It should be stressed that this stimulation of the expression of Cytochrome P450 genes remains modest compared to the almost two orders of magnitude larger expression following B[a]P treatment. 	Cytochrome P450	17554	17569	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:123	We did not observe the same modest stimulation of Cytochrome P450 expression by Simulated Sunlight in the combination with exposure to B[a]P either before or after irradiation. 	Cytochrome P450	17733	17748	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:123	We did not observe the same modest stimulation of Cytochrome P450 expression by Simulated Sunlight in the combination with exposure to B[a]P either before or after irradiation. 	Cytochrome P450	17733	17748	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:132	We made the same observations of a decreased expression of Cytochrome P450 genes and formation of BPDE-N^2-dGuo in this model as in skin. 	Cytochrome P450	19234	19249	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:132	We made the same observations of a decreased expression of Cytochrome P450 genes and formation of BPDE-N^2-dGuo in this model as in skin. 	Cytochrome P450	19234	19249	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:152	Yet, as observed by others^,,,,,, Simulated Sunlight alone lead to a small over expression of Cytochrome P450 genes. 	Cytochrome P450	22330	22345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:152	Yet, as observed by others^,,,,,, Simulated Sunlight alone lead to a small over expression of Cytochrome P450 genes. 	Cytochrome P450	22330	22345	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:163	However, the latter process does not explain the massive reduction in expression of Cytochrome P450 genes. 	Cytochrome P450	24064	24079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:163	However, the latter process does not explain the massive reduction in expression of Cytochrome P450 genes. 	Cytochrome P450	24064	24079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:165	First, the reduced expression of Cytochrome P450 genes could be explained by the well-documented temporary arrest in RNA synthesis in transcribed genes that takes place following Ultraviolet irradiation^-. 	Cytochrome P450	24234	24249	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:165	First, the reduced expression of Cytochrome P450 genes could be explained by the well-documented temporary arrest in RNA synthesis in transcribed genes that takes place following Ultraviolet irradiation^-. 	Cytochrome P450	24234	24249	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:171	In conclusion, our study provides for the first time an extensive picture of the impact of Simulated Sunlight, namely a combination of both UVB and UVA components, on the metabolism and genotoxicity of B[a]P. In contrast to previous data obtained in vitro with pure UVB, solar Ultraviolet radiation appears to have a strong repressive effect on B[a]P-induced gene induction of Cytochrome P450 enzymes and delays formation of BPDE-DNA adducts in skin. 	Cytochrome P450	25567	25582	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:171	In conclusion, our study provides for the first time an extensive picture of the impact of Simulated Sunlight, namely a combination of both UVB and UVA components, on the metabolism and genotoxicity of B[a]P. In contrast to previous data obtained in vitro with pure UVB, solar Ultraviolet radiation appears to have a strong repressive effect on B[a]P-induced gene induction of Cytochrome P450 enzymes and delays formation of BPDE-DNA adducts in skin. 	Cytochrome P450	25567	25582	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	Cytochrome P450	31636	31651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:220	Gene expression analysis was performed on phase I (CYP1A1, CYP1A2, Cytochrome P450 1B1, and EPHX1) and phase II (GSTA1 and GSTP1) metabolism genes. 	Cytochrome P450	31636	31651	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:67	Cytochrome P450 (CYP) can catalyze reactions of oxidation, reduction, or the oxidative breakdown of xenobiotics (Lamb et al. 	Cytochrome P450	9534	9549	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6208721_OgerInput.txtOger_out.csv:67	Cytochrome P450 (CYP) can catalyze reactions of oxidation, reduction, or the oxidative breakdown of xenobiotics (Lamb et al. 	Cytochrome P450	9534	9549	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:21	Cytochrome P450 enzymes are the major heme-containing enzyme family and the most important drug-metabolizing enzymes. 	Cytochrome P450	2885	2900	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:21	Cytochrome P450 enzymes are the major heme-containing enzyme family and the most important drug-metabolizing enzymes. 	Cytochrome P450	2885	2900	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:12	Cytochrome P450 is a particularly well-investigated example^,. 	Cytochrome P450	1639	1654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6232099_OgerInput.txtOger_out.csv:12	Cytochrome P450 is a particularly well-investigated example^,. 	Cytochrome P450	1639	1654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	Cytochrome P450	75	90	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	Cytochrome P450	75	90	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	Cytochrome P450	460	475	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	Cytochrome P450	460	475	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:29	Cytochrome P450 (CYP) enzymes are mainly responsible for the metabolism of drugs and other compounds including phytochemicals in the liver, kidney and intestines. 	Cytochrome P450	4360	4375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:29	Cytochrome P450 (CYP) enzymes are mainly responsible for the metabolism of drugs and other compounds including phytochemicals in the liver, kidney and intestines. 	Cytochrome P450	4360	4375	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:1	 BETA-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP+ Toxicity in Human Neuroblastoma SH-SY5Y Cells. 	Cytochrome P450	39	54	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:1	 BETA-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP+ Toxicity in Human Neuroblastoma SH-SY5Y Cells. 	Cytochrome P450	39	54	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:2	Cytochrome P450 isozymes vary their expression depending on the brain area, the cell type, and the presence of drugs. 	Cytochrome P450	127	142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:2	Cytochrome P450 isozymes vary their expression depending on the brain area, the cell type, and the presence of drugs. 	Cytochrome P450	127	142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:5	We have studied the inducibility of Cytochrome P450 isozymes in human neuroblastoma SH-SY5Y cells, treated with BETA-naphtoflavone (BETA-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot, and metabolic activity assays. 	Cytochrome P450	484	499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:5	We have studied the inducibility of Cytochrome P450 isozymes in human neuroblastoma SH-SY5Y cells, treated with BETA-naphtoflavone (BETA-NF) or ethanol (EtOH) as inducers, by qRT-PCR, Western blot, and metabolic activity assays. 	Cytochrome P450	484	499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:13	These data indicate that Cytochrome P450 is inducible in SH-SY5Y cells and underline this in vitro system for studying the role of CYPs in neurodegeneration. 	Cytochrome P450	1402	1417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:13	These data indicate that Cytochrome P450 is inducible in SH-SY5Y cells and underline this in vitro system for studying the role of CYPs in neurodegeneration. 	Cytochrome P450	1402	1417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:14	Cytochrome P450 is a superfamily of isozymes involved in the metabolism of xenobiotics in liver and other extra-hepatic tissues. 	Cytochrome P450	1535	1550	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:14	Cytochrome P450 is a superfamily of isozymes involved in the metabolism of xenobiotics in liver and other extra-hepatic tissues. 	Cytochrome P450	1535	1550	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:15	In the brain, Cytochrome P450 concentration is approximately 0.5-2% of that in liver microsomes. 	Cytochrome P450	1678	1693	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:15	In the brain, Cytochrome P450 concentration is approximately 0.5-2% of that in liver microsomes. 	Cytochrome P450	1678	1693	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:51	Therefore, other groups have used this cell line for the study of many features linked to this neurodegenerative disease including the induction and protective role of Cytochrome P450 against toxic compounds related to Parkinsons Disease. 	Cytochrome P450	7376	7391	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:51	Therefore, other groups have used this cell line for the study of many features linked to this neurodegenerative disease including the induction and protective role of Cytochrome P450 against toxic compounds related to Parkinsons Disease. 	Cytochrome P450	7376	7391	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:53	BETA-NF is the agonist of the well-known Aryl Hydrocarbon Receptors, which is involved in the regulation of some Cytochrome P450 isoforms. 	Cytochrome P450	7708	7723	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:53	BETA-NF is the agonist of the well-known Aryl Hydrocarbon Receptors, which is involved in the regulation of some Cytochrome P450 isoforms. 	Cytochrome P450	7708	7723	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:56	Here, we introduce a new study where BETA-NF and EtOH have been used to investigate the induction of Cytochrome P450 isozymes in neuroblastoma SH-SY5Y cells and their intracellular localization. 	Cytochrome P450	8080	8095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:56	Here, we introduce a new study where BETA-NF and EtOH have been used to investigate the induction of Cytochrome P450 isozymes in neuroblastoma SH-SY5Y cells and their intracellular localization. 	Cytochrome P450	8080	8095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:69	Differentiated cells presented a significant increase of Cytochrome P450 2D6 protein levels after treatment with either BETA-NF or EtOH of 1.5- and 1.4-fold increase, respectively. 	Cytochrome P450	10031	10046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:69	Differentiated cells presented a significant increase of Cytochrome P450 2D6 protein levels after treatment with either BETA-NF or EtOH of 1.5- and 1.4-fold increase, respectively. 	Cytochrome P450	10031	10046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:70	On the contrary, the treatment with BETA-NF did not promote the increase in the expression of Cytochrome P450 2E1, while EtOH significantly increased it. 	Cytochrome P450	10249	10264	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:70	On the contrary, the treatment with BETA-NF did not promote the increase in the expression of Cytochrome P450 2E1, while EtOH significantly increased it. 	Cytochrome P450	10249	10264	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:72	7-Ethoxycoumarin is metabolized by many Cytochrome P450 isoforms involved in xenobiotic metabolism. 	Cytochrome P450	10433	10448	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:72	7-Ethoxycoumarin is metabolized by many Cytochrome P450 isoforms involved in xenobiotic metabolism. 	Cytochrome P450	10433	10448	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:85	It must be underlined that due to low fluorescent intensity in control conditions, the colocalization plugin was not able to correlate the Cytochrome P450 channel with either mitochondria or Endoplasmic Reticulum. 	Cytochrome P450	12394	12409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:85	It must be underlined that due to low fluorescent intensity in control conditions, the colocalization plugin was not able to correlate the Cytochrome P450 channel with either mitochondria or Endoplasmic Reticulum. 	Cytochrome P450	12394	12409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:106	BETA-NF is known to induce Cytochrome P450 isoforms belonging to the family 1A and 1B, while EtOH induces the expression of CYP2E1 isoform. 	Cytochrome P450	15492	15507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:106	BETA-NF is known to induce Cytochrome P450 isoforms belonging to the family 1A and 1B, while EtOH induces the expression of CYP2E1 isoform. 	Cytochrome P450	15492	15507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:114	Our results are in agreement with Imran et al., who showed that 2,3,7,8-tetrachlordibenzo-p-dioxin, one of the most potent inducers of CYP1 family via Aryl Hydrocarbon Receptors, is able to increase the mRNA levels of these Cytochrome P450 isoforms only at 10 nM in SH-SY5Y cells, while 2.5 and 5 nM did not have this effect. 	Cytochrome P450	16815	16830	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:114	Our results are in agreement with Imran et al., who showed that 2,3,7,8-tetrachlordibenzo-p-dioxin, one of the most potent inducers of CYP1 family via Aryl Hydrocarbon Receptors, is able to increase the mRNA levels of these Cytochrome P450 isoforms only at 10 nM in SH-SY5Y cells, while 2.5 and 5 nM did not have this effect. 	Cytochrome P450	16815	16830	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:130	Furthermore, the Western Blot experiments performed in differentiated cells provide a more realistic view of the Central Nervous System, taken into account the different expression patterns of Cytochrome P450 isoforms in brain cells/areas. 	Cytochrome P450	19210	19225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:130	Furthermore, the Western Blot experiments performed in differentiated cells provide a more realistic view of the Central Nervous System, taken into account the different expression patterns of Cytochrome P450 isoforms in brain cells/areas. 	Cytochrome P450	19210	19225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:138	In order to study the metabolic capability of SH-SY5Y cells after the induction of Cytochrome P450 isoforms, we used 7-ethoxycoumarin as substrate for a broad number of Cytochrome P450 isozymes. 	Cytochrome P450	20583	20598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:138	In order to study the metabolic capability of SH-SY5Y cells after the induction of Cytochrome P450 isoforms, we used 7-ethoxycoumarin as substrate for a broad number of Cytochrome P450 isozymes. 	Cytochrome P450	20583	20598	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:138	In order to study the metabolic capability of SH-SY5Y cells after the induction of Cytochrome P450 isoforms, we used 7-ethoxycoumarin as substrate for a broad number of Cytochrome P450 isozymes. 	Cytochrome P450	20669	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:138	In order to study the metabolic capability of SH-SY5Y cells after the induction of Cytochrome P450 isoforms, we used 7-ethoxycoumarin as substrate for a broad number of Cytochrome P450 isozymes. 	Cytochrome P450	20669	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:147	The localization of Cytochrome P450 in mitochondria can contribute to the bioactivation/detoxification processes of neurotoxins. 	Cytochrome P450	22126	22141	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:147	The localization of Cytochrome P450 in mitochondria can contribute to the bioactivation/detoxification processes of neurotoxins. 	Cytochrome P450	22126	22141	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:163	Therefore, other Cytochrome P450 isoforms can have an important role in xenobiotic metabolism in other brain regions, and at the same time, they do not have to necessarily be associate with positive effects. 	Cytochrome P450	24830	24845	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:163	Therefore, other Cytochrome P450 isoforms can have an important role in xenobiotic metabolism in other brain regions, and at the same time, they do not have to necessarily be associate with positive effects. 	Cytochrome P450	24830	24845	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:165	This toxin can be metabolized by the Cytochrome P450 system as already reported. 	Cytochrome P450	25211	25226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:165	This toxin can be metabolized by the Cytochrome P450 system as already reported. 	Cytochrome P450	25211	25226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26035	26050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26035	26050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26201	26216	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26201	26216	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	Cytochrome P450	28680	28695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	Cytochrome P450	28680	28695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	Cytochrome P450	31730	31745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	Cytochrome P450	31730	31745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:212	The enzyme activities were expressed as pmol metabolite per mg of protein in 24 h. A staining approach to evaluate the Cytochrome P450 location in SH-SY5Y was carried out by confocal imaging. 	Cytochrome P450	33037	33052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:212	The enzyme activities were expressed as pmol metabolite per mg of protein in 24 h. A staining approach to evaluate the Cytochrome P450 location in SH-SY5Y was carried out by confocal imaging. 	Cytochrome P450	33037	33052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:228	Cytochrome P450, a superfamily of monooxygenase, plays critical roles in biosynthesis of plant secondary metabolites such as triterpenes, alkaloids, and sterols. 	Cytochrome P450	34773	34788	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:228	Cytochrome P450, a superfamily of monooxygenase, plays critical roles in biosynthesis of plant secondary metabolites such as triterpenes, alkaloids, and sterols. 	Cytochrome P450	34773	34788	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	Cytochrome P450	794	809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	Cytochrome P450	794	809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	Cytochrome P450	1146	1161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	Cytochrome P450	1146	1161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	Cytochrome P450	2129	2144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	Cytochrome P450	2129	2144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	Cytochrome P450	6154	6169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	Cytochrome P450	6154	6169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	Cytochrome P450	15835	15850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	Cytochrome P450	15835	15850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	21875	21890	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	21875	21890	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	22027	22042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	22027	22042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	Cytochrome P450	22341	22356	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	Cytochrome P450	22341	22356	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	Cytochrome P450	23497	23512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	Cytochrome P450	23497	23512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	Cytochrome P450	23884	23899	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	Cytochrome P450	23884	23899	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	Cytochrome P450	24189	24204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	Cytochrome P450	24189	24204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38170	38185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38170	38185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38205	38220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38205	38220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	Cytochrome P450	41220	41235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	Cytochrome P450	41220	41235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:93	Cytochrome P450s, which comprise one of the largest and oldest gene superfamilies, are known to be involved in the biosynthesis of secondary metabolites such as flavonoids. 	Cytochrome P450	16042	16057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:93	Cytochrome P450s, which comprise one of the largest and oldest gene superfamilies, are known to be involved in the biosynthesis of secondary metabolites such as flavonoids. 	Cytochrome P450	16042	16057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:94	In this study, 78 unigene Differentially Expressed Genes were annotated as Cytochrome P450s. 	Cytochrome P450	16290	16305	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:94	In this study, 78 unigene Differentially Expressed Genes were annotated as Cytochrome P450s. 	Cytochrome P450	16290	16305	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:144	Cytochrome P450s are known to play central roles in the evolution of metabolic complexity and in the production of secondary metabolites, including flavonoid metabolites. 	Cytochrome P450	23127	23142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:144	Cytochrome P450s are known to play central roles in the evolution of metabolic complexity and in the production of secondary metabolites, including flavonoid metabolites. 	Cytochrome P450	23127	23142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:146	Two Cytochrome P450s (CfCYP93B and CfCYP706C) isolated from Coleus forskohlii are involved in the biosynthesis of flavonoids and CYP93B isolated from hybrid Gerbera encodes flavone synthase II, which catalyzes flavanones into flavones. 	Cytochrome P450	23446	23461	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:146	Two Cytochrome P450s (CfCYP93B and CfCYP706C) isolated from Coleus forskohlii are involved in the biosynthesis of flavonoids and CYP93B isolated from hybrid Gerbera encodes flavone synthase II, which catalyzes flavanones into flavones. 	Cytochrome P450	23446	23461	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:147	The expression of Cytochrome P450s also has a significant effect on the content of flavonoids in plants. 	Cytochrome P450	23696	23711	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:147	The expression of Cytochrome P450s also has a significant effect on the content of flavonoids in plants. 	Cytochrome P450	23696	23711	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:64	Several enzymes including those belonging to the Cytochrome P450 family play crucial roles in the generation of either a stable plaque or progression to an unstable plaque with poor prognosis for atherosclerosis outcome (Silvestre-Roig et al., ; Song et al., ; Stefanadis et al.,. 	Cytochrome P450	12470	12485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:64	Several enzymes including those belonging to the Cytochrome P450 family play crucial roles in the generation of either a stable plaque or progression to an unstable plaque with poor prognosis for atherosclerosis outcome (Silvestre-Roig et al., ; Song et al., ; Stefanadis et al.,. 	Cytochrome P450	12470	12485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:75	Cholesterol also acts as a substrate for various enzyme activities including those belonging to the Cytochrome P450 family (Pikuleva, ; Rogers et al.,. 	Cytochrome P450	15379	15394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:75	Cholesterol also acts as a substrate for various enzyme activities including those belonging to the Cytochrome P450 family (Pikuleva, ; Rogers et al.,. 	Cytochrome P450	15379	15394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	Cytochrome P450	22639	22654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	Cytochrome P450	22639	22654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:160	The Cytochrome P450 system has been implicated in the pathogenesis of various CVDs including atherosclerosis and aneurysms (Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	34601	34616	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:160	The Cytochrome P450 system has been implicated in the pathogenesis of various CVDs including atherosclerosis and aneurysms (Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	34601	34616	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	Cytochrome P450	34766	34781	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	Cytochrome P450	34766	34781	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	Cytochrome P450	34961	34976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	Cytochrome P450	34961	34976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:163	The cholesterol metabolizing ability of Cytochrome P450 family members varies depending on the physiological requirements of different organs and in vivo cholesterol levels. 	Cytochrome P450	35213	35228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:163	The cholesterol metabolizing ability of Cytochrome P450 family members varies depending on the physiological requirements of different organs and in vivo cholesterol levels. 	Cytochrome P450	35213	35228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	Cytochrome P450	35373	35388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	Cytochrome P450	35373	35388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:165	The importance of Cytochrome P450 in mycobacteria is known. 	Cytochrome P450	35518	35533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:165	The importance of Cytochrome P450 in mycobacteria is known. 	Cytochrome P450	35518	35533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35623	35638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35623	35638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35660	35675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35660	35675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	Cytochrome P450	35853	35868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	Cytochrome P450	35853	35868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:169	Iron is necessary for mycobacterial Cytochrome P450 (Ouellet et al., ) activity and iron has been recognized as a crucial element for the survival of intracellular mycobacteria (Ratledge, ; Janagama et al., ; Lamont et al.,. 	Cytochrome P450	36083	36098	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:169	Iron is necessary for mycobacterial Cytochrome P450 (Ouellet et al., ) activity and iron has been recognized as a crucial element for the survival of intracellular mycobacteria (Ratledge, ; Janagama et al., ; Lamont et al.,. 	Cytochrome P450	36083	36098	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:170	Thus, the importance of Cytochrome P450 from the pathogen perspective has been explored albeit not in depth. 	Cytochrome P450	36296	36311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:170	Thus, the importance of Cytochrome P450 from the pathogen perspective has been explored albeit not in depth. 	Cytochrome P450	36296	36311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:171	From the host perspective, a transcriptomic analysis of Tuberculosis granulomas has revealed a characteristic downregulation of several Cytochrome P450 genes in cells within these granulomas (Eisenreich et al.,. 	Cytochrome P450	36517	36532	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:171	From the host perspective, a transcriptomic analysis of Tuberculosis granulomas has revealed a characteristic downregulation of several Cytochrome P450 genes in cells within these granulomas (Eisenreich et al.,. 	Cytochrome P450	36517	36532	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36593	36608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36593	36608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36728	36743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36728	36743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:175	Apart from their direct role in modulating host cholesterol metabolism, members of the Cytochrome P450 family such as Cyp4501b1(Cyp1b1) are involved in the metabolism of sex steroidal hormones with the resultant metabolites produced being implicated to play a role in the gender differences noticed to the susceptibility to cardiac and renal diseases (Jennings et al., ; Pingili et al., ; Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	37224	37239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:175	Apart from their direct role in modulating host cholesterol metabolism, members of the Cytochrome P450 family such as Cyp4501b1(Cyp1b1) are involved in the metabolism of sex steroidal hormones with the resultant metabolites produced being implicated to play a role in the gender differences noticed to the susceptibility to cardiac and renal diseases (Jennings et al., ; Pingili et al., ; Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	37224	37239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:183	Therefore, extrapolating from the evidence for Cyp1b1 in gender specific pathogeneis of CVDs, it would be worthwhile to explore further the role of Cytochrome P450 family members in mycobacterial infections due to a necessity for a sex-tailored therapeutic approach in view of the gender related susceptibility to disease. 	Cytochrome P450	39476	39491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:183	Therefore, extrapolating from the evidence for Cyp1b1 in gender specific pathogeneis of CVDs, it would be worthwhile to explore further the role of Cytochrome P450 family members in mycobacterial infections due to a necessity for a sex-tailored therapeutic approach in view of the gender related susceptibility to disease. 	Cytochrome P450	39476	39491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	Cytochrome P450	545	560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	Cytochrome P450	545	560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:4	Kistamicin contains three crosslinks, including an unusual 15-membered A-O-B ring, despite the presence of only two Cytochrome P450 Oxy enzymes thought to catalyse formation of such crosslinks within the biosynthetic gene cluster. 	Cytochrome P450	642	657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:4	Kistamicin contains three crosslinks, including an unusual 15-membered A-O-B ring, despite the presence of only two Cytochrome P450 Oxy enzymes thought to catalyse formation of such crosslinks within the biosynthetic gene cluster. 	Cytochrome P450	642	657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	Cytochrome P450	2803	2818	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	Cytochrome P450	2803	2818	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450	18034	18049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450	18034	18049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450	18347	18362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450	18347	18362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450	39064	39079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450	39064	39079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450	39811	39826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450	39811	39826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450	41236	41251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450	41236	41251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450	50224	50239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450	50224	50239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450	52236	52251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450	52236	52251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:1	 Overexpression of a Novel Cytochrome P450 Promotes Flavonoid Biosynthesis and Osmotic Stress Tolerance in Transgenic Arabidopsis. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:1	 Overexpression of a Novel Cytochrome P450 Promotes Flavonoid Biosynthesis and Osmotic Stress Tolerance in Transgenic Arabidopsis. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:4	However, the explicit regulation mechanism of Cytochrome P450s related to flavonoid biosynthesis largely remains elusive. 	Cytochrome P450	479	494	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:4	However, the explicit regulation mechanism of Cytochrome P450s related to flavonoid biosynthesis largely remains elusive. 	Cytochrome P450	479	494	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:206	The result of the qRT-PCR assays indicated that the expression level of most of the flavonoid pathway genes, including PAL (Phenylalanine ammonia lyase), Chalcone Isomerase (Chalcone isomerase), CYP82G1 (Cytochrome P450 monooxygenase), F3H (flavonoid 3-hydroxylase), and FLS (Flavonol synthase) were more abundantly up-regulated in the ARB3-CtCYP82G24 overexpression line than that of wild-type plant. 	Cytochrome P450	33395	33410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:206	The result of the qRT-PCR assays indicated that the expression level of most of the flavonoid pathway genes, including PAL (Phenylalanine ammonia lyase), Chalcone Isomerase (Chalcone isomerase), CYP82G1 (Cytochrome P450 monooxygenase), F3H (flavonoid 3-hydroxylase), and FLS (Flavonol synthase) were more abundantly up-regulated in the ARB3-CtCYP82G24 overexpression line than that of wild-type plant. 	Cytochrome P450	33395	33410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	Cytochrome P450	5147	5162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	Cytochrome P450	5147	5162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450	5516	5531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450	5516	5531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:35	Cytochrome P450 type I enzymes are located within the inner mitochondrial membrane and are dependent on ferredoxin and ferredoxin reductase for the delivery of their electrons from NADPH. 	Cytochrome P450	5668	5683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:35	Cytochrome P450 type I enzymes are located within the inner mitochondrial membrane and are dependent on ferredoxin and ferredoxin reductase for the delivery of their electrons from NADPH. 	Cytochrome P450	5668	5683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:36	Ferredoxin reductase is a flavoprotein that oxidizes NADPH and transfers electrons to ferredoxin, a small iron-sulfur protein, which acts as a mobile electron carrier, delivering the electrons to the Cytochrome P450. 	Cytochrome P450	6056	6071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:36	Ferredoxin reductase is a flavoprotein that oxidizes NADPH and transfers electrons to ferredoxin, a small iron-sulfur protein, which acts as a mobile electron carrier, delivering the electrons to the Cytochrome P450. 	Cytochrome P450	6056	6071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	Cytochrome P450	6214	6229	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	Cytochrome P450	6214	6229	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:6	Nevertheless, the sex-dependent effect of Doxorubicin on the expression of Cytochrome P450 enzymes is still not known. 	Cytochrome P450 enzymes	608	631	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:18	Since cardiac Cytochrome P450 enzymes metabolize several endogenous compounds to biologically active metabolites, sex-dependent alteration of Cytochrome P450 genes may play a role in the sexual dimorphism of acute DOX-induced cardiotoxicity. 	Cytochrome P450 enzymes	2054	2077	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450 enzymes	5052	5075	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:33	DOX-induced alteration of Cytochrome P450 enzymes may have important toxicological implications, due to the role of Cytochrome P450 enzymes in the metabolism of several biologically active endogenous compounds including arachidonic acid and sex steroids. 	Cytochrome P450 enzymes	5142	5165	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:37	Therefore, in the present study, we determined the effect of acute Doxorubicin exposure on the gene expression of Cytochrome P450 enzymes in the hearts of both male and female C57Bl/6 mice to determine the interaction between sex and Doxorubicin exposure in regulating Cytochrome P450 gene expression. 	Cytochrome P450 enzymes	5820	5843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:138	A growing body of evidence suggests an important role of Cytochrome P450 enzymes in the pathogenesis of DOX-induced cardiotoxicity [,. 	Cytochrome P450 enzymes	25130	25153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:139	Cytochrome P450 enzymes play important roles in metabolizing sex steroids and other endogenous compounds, such as arachidonic acid that have significant biological effects on the cardiovascular system. 	Cytochrome P450 enzymes	25208	25231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:140	Interestingly, there is a significant sex-divergent expression of several Cytochrome P450 enzymes in both humans and experimental animals. 	Cytochrome P450 enzymes	25484	25507	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:141	Therefore, we hypothesized that Doxorubicin alters Cytochrome P450 enzymes in a sex-dependent manner to mediate sexual dimorphism of DOX-induced cardiotoxicity. 	Cytochrome P450 enzymes	25600	25623	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:164	Amongst the Cytochrome P450 enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, Cytochrome P450 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut. 	Cytochrome P450 enzymes	32681	32704	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5408066_OgerInput.txtOger_out.csv:172	One thing most of these studies reporting on the interaction of polyphenols with Cytochrome P450 enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes. 	Cytochrome P450 enzymes	34447	34470	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:13	In vitro inhibitory effects of the pharmacologically active lignans such as aschantin, honokiol, machilin A, phyllantin, hypophyllantin, and podophyllotoxin on Cytochrome P450 enzymes have been reported. 	Cytochrome P450 enzymes	3656	3679	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:14	However, there are no reports on the in vitro and in vivo inhibitory effects of the bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on human Cytochrome P450 enzymes. 	Cytochrome P450 enzymes	3912	3935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:16	The reversible and time-dependent inhibitory potencials (IC_50 values) of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major human Cytochrome P450 enzymes were investigated in human liver microsomes. 	Cytochrome P450 enzymes	4530	4553	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	Cytochrome P450 enzymes	5339	5362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:24	In this study, the in vitro inhibitory effects of bioactive tetrahydrofurofuranoid lignans such as dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on 8 major Cytochrome P450 enzymes were, for the first time, evaluated in pooled human liver microsomes. 	Cytochrome P450 enzymes	7154	7177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:395	In addition, none of the aforementioned benzothiadiazine analogs significantly inhibit the major Cytochrome P450 enzymes indicating that these compounds should not affect the metabolism of drug substances. 	Cytochrome P450 enzymes	66958	66981	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5615155_OgerInput.txtOger_out.csv:396	In vitro studies using both rat and human liver microsomes have shown that these benzothiadiazine derivatives themselves are resistant to oxidative metabolism by Cytochrome P450 enzymes with >97% of the parent compounds remaining after a 60 min incubation with microsomes of either species. 	Cytochrome P450 enzymes	67229	67252	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5655360_OgerInput.txtOger_out.csv:3	To overcome this limitation, we established HepG2 cell lines expressing major Cytochrome P450 enzymes involved in drug metabolism (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and Cytochrome P450 oxidoreductase (POR) using the mammalian-derived artificial chromosome vector. 	Cytochrome P450 enzymes	406	429	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:39	The inhibition of Cytochrome P450 enzymes can broadly be divided into two types; reversible and irreversible. 	Cytochrome P450 enzymes	5934	5957	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	Cytochrome P450 enzymes	16836	16859	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:17	Liver Cytochrome P450 enzymes is the most important drug metabolizing enzymes and responsible for more than 80% of drug metabolism^,. 	Cytochrome P450 enzymes	2464	2487	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:35	N-acetyl p-benzoquinoneimine, a hepatotoxic metabolite of APAP, is metabolized by Cytochrome P450 enzymes in livers, specifically isoforms such as CYP2E1, CYP3A4 and CYP1A2^,. 	Cytochrome P450 enzymes	4573	4596	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450 enzymes	16595	16618	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:89	Cytochrome P450 enzymes are responsible for metabolizing APAP into its reactive metabolite N-Acetyl P-Benzoquinoneimine, and of which CYP1A2, CYP2E1 and CYP3A4 are the main Cytochrome P450 enzymes for the metabolic activation of APAP in liver^,,,. 	Cytochrome P450 enzymes	16768	16791	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:90	Previous studies showed that some chemical agents were reported to exacerbate APAP-induced liver injury by enhancing its liver metabolism via inducing the expression of Cytochrome P450 enzymes^-. 	Cytochrome P450 enzymes	17012	17035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:129	Cytochrome P450 enzymes constitute a superfamily of proteins that play an important role in the metabolism and detoxification of xenobiotics (Brown et al.,. 	Cytochrome P450 enzymes	20460	20483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:43	Cytochrome P450 enzymes were isolated and prepared by differential centrifugation and analyzed for their activity by the use of liver microsomes.. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), weighed, and homogenized in 0.05 mM Tris/KCl buffer (pH 7.4). 	Cytochrome P450 enzymes	8041	8064	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:113	NF-B has been implicated in the regulation of P450s through interaction with their induction mechanisms.- Our results demonstrated that Methicillin-Resistant Staphylococcus Aureus has a strong inhibitory effect on the mRNA levels and enzyme activities of Cytochrome P450 enzymes. 	Cytochrome P450 enzymes	20894	20917	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:116	This inhibition of Cytochrome P450 enzymes was also accompanied by an increase in oxidative stress in the livers of mice infected with Methicillin-Resistant Staphylococcus Aureus. 	Cytochrome P450 enzymes	21441	21464	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:9	Cytochrome P450 enzymes, arguably natures most versatile catalysts, are a superfamily of haem-thiolate proteins found across all lineages of life^. 	Cytochrome P450 enzymes	1602	1625	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6082832_OgerInput.txtOger_out.csv:11	While there are more than 57 different Cytochrome P450 enzymes in humans, only a small number of highly polymorphic isoforms are responsible for the majority of drug metabolism^. 	Cytochrome P450 enzymes	1909	1932	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6168490_OgerInput.txtOger_out.csv:171	In conclusion, our study provides for the first time an extensive picture of the impact of Simulated Sunlight, namely a combination of both UVB and UVA components, on the metabolism and genotoxicity of B[a]P. In contrast to previous data obtained in vitro with pure UVB, solar Ultraviolet radiation appears to have a strong repressive effect on B[a]P-induced gene induction of Cytochrome P450 enzymes and delays formation of BPDE-DNA adducts in skin. 	Cytochrome P450 enzymes	25567	25590	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:21	Cytochrome P450 enzymes are the major heme-containing enzyme family and the most important drug-metabolizing enzymes. 	Cytochrome P450 enzymes	2885	2908	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	Cytochrome P450 enzymes	460	483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	Cytochrome P450 enzymes	22639	22662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	Cytochrome P450 enzymes	34766	34789	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	Cytochrome P450 enzymes	34961	34984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	Cytochrome P450 enzymes	35373	35396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450 enzymes	35623	35646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	Cytochrome P450 enzymes	35853	35876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	Cytochrome P450 enzymes	545	568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	Cytochrome P450 enzymes	2803	2826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	Cytochrome P450 enzymes	5147	5170	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450 enzymes	5516	5539	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450 enzymes	31612	31635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	Cytochrome P450 enzymes	23658	23681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	Cytochrome P450 enzymes	23772	23795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	Cytochrome P450 enzymes	24528	24551	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	Cytochrome P450 enzymes	24717	24740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	Cytochrome P450 enzymes	24842	24865	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:16	In 24 h, Doxorubicin exposure caused male-specific induction of Cyp1b1 and female-specific induction of Cyp2c29 and Cyp2e1. 	Cyp2e1	1929	1935	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:16	In 24 h, Doxorubicin exposure caused male-specific induction of Cyp1b1 and female-specific induction of Cyp2c29 and Cyp2e1. 	Cyp2e1	1929	1935	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:163	Similar to Cyp2c29, acute DOX-induced cardiotoxicity induced the gene expression of Cyp2e1 only in the hearts of female mice 24 h following Doxorubicin administration. 	Cyp2e1	29237	29243	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:163	Similar to Cyp2c29, acute DOX-induced cardiotoxicity induced the gene expression of Cyp2e1 only in the hearts of female mice 24 h following Doxorubicin administration. 	Cyp2e1	29237	29243	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:166	Despite the well-documented role of hepatic Cyp2e1 in mediating alcohol-induced hepatotoxicity, the role of cardiac Cyp2e1 is not well studied. 	Cyp2e1	29670	29676	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:166	Despite the well-documented role of hepatic Cyp2e1 in mediating alcohol-induced hepatotoxicity, the role of cardiac Cyp2e1 is not well studied. 	Cyp2e1	29670	29676	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:166	Despite the well-documented role of hepatic Cyp2e1 in mediating alcohol-induced hepatotoxicity, the role of cardiac Cyp2e1 is not well studied. 	Cyp2e1	29742	29748	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:166	Despite the well-documented role of hepatic Cyp2e1 in mediating alcohol-induced hepatotoxicity, the role of cardiac Cyp2e1 is not well studied. 	Cyp2e1	29742	29748	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:167	Pharmacological inhibition and genetic knock down of Cyp2e1 have been shown to confer cardioprotection in a DOX-induced dilated cardiomyopathy mouse model by inhibiting oxidative stress and apoptosis. 	Cyp2e1	29823	29829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:167	Pharmacological inhibition and genetic knock down of Cyp2e1 have been shown to confer cardioprotection in a DOX-induced dilated cardiomyopathy mouse model by inhibiting oxidative stress and apoptosis. 	Cyp2e1	29823	29829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:168	Nevertheless, Cyp2e1 metabolizes arachidonic acid to 19-hydroxyeicosatetraenoic acid which has cardioprotective properties. 	Cyp2e1	29985	29991	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:168	Nevertheless, Cyp2e1 metabolizes arachidonic acid to 19-hydroxyeicosatetraenoic acid which has cardioprotective properties. 	Cyp2e1	29985	29991	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:169	Therefore, further research is needed to confirm whether cardiac Cyp2e1 is protective or detrimental to the heart. 	Cyp2e1	30160	30166	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:169	Therefore, further research is needed to confirm whether cardiac Cyp2e1 is protective or detrimental to the heart. 	Cyp2e1	30160	30166	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:190	As illustrated in Fig, significant male-specific induction of Cyp1b1 and female-specific induction of Cyp2c29 and Cyp2e1 may play important roles in mediating sex-related differences of DOX-induced cardiotoxicity. 	Cyp2e1	33848	33854	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:190	As illustrated in Fig, significant male-specific induction of Cyp1b1 and female-specific induction of Cyp2c29 and Cyp2e1 may play important roles in mediating sex-related differences of DOX-induced cardiotoxicity. 	Cyp2e1	33848	33854	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8412	8418	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8412	8418	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8613	8619	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:97	One day following Doxorubicin injection, a greater than 80% reduction in the expression of Cyp1a1 in the heart was observed in both male and female mice (p value = 0.05 in males). 	Cyp1a1	17459	17465	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:97	One day following Doxorubicin injection, a greater than 80% reduction in the expression of Cyp1a1 in the heart was observed in both male and female mice (p value = 0.05 in males). 	Cyp1a1	17459	17465	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:98	Cyp1a1 gene expression returned to a control value in females, but not in males, 6 days post-DOX, demonstrating a significant sex effect was observed 6 days after Doxorubicin injection. 	Cyp1a1	17548	17554	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:98	Cyp1a1 gene expression returned to a control value in females, but not in males, 6 days post-DOX, demonstrating a significant sex effect was observed 6 days after Doxorubicin injection. 	Cyp1a1	17548	17554	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:142	In the current study, acute Doxorubicin exposure caused a marked inhibition of Cyp1a1 gene expression in the hearts of male and female mice 1 day after Doxorubicin injection. 	Cyp1a1	25789	25795	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:142	In the current study, acute Doxorubicin exposure caused a marked inhibition of Cyp1a1 gene expression in the hearts of male and female mice 1 day after Doxorubicin injection. 	Cyp1a1	25789	25795	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:144	Similarly, a single 10 mg/kg Doxorubicin injection caused significant induction of Cyp1a1 in the hearts of 8-week-old male C57Bl/6 mice. 	Cyp1a1	26145	26151	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:144	Similarly, a single 10 mg/kg Doxorubicin injection caused significant induction of Cyp1a1 in the hearts of 8-week-old male C57Bl/6 mice. 	Cyp1a1	26145	26151	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:145	In order to confirm our current finding, we used three different sets of Cyp1a1 primers selected from three different studies (Additional file. 	Cyp1a1	26272	26278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:145	In order to confirm our current finding, we used three different sets of Cyp1a1 primers selected from three different studies (Additional file. 	Cyp1a1	26272	26278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:146	The three different experiments resulted in the same finding, confirming the inhibition of Cyp1a1 gene expression in this study. 	Cyp1a1	26434	26440	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:146	The three different experiments resulted in the same finding, confirming the inhibition of Cyp1a1 gene expression in this study. 	Cyp1a1	26434	26440	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:148	DOX-mediated inhibition of Cyp1a1 may be attributed to DOX-induced inflammation, since inflammation has been shown to downregulate Cyp1a1 in the hearts of male C57Bl/6 mice. 	Cyp1a1	26606	26612	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:148	DOX-mediated inhibition of Cyp1a1 may be attributed to DOX-induced inflammation, since inflammation has been shown to downregulate Cyp1a1 in the hearts of male C57Bl/6 mice. 	Cyp1a1	26606	26612	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:148	DOX-mediated inhibition of Cyp1a1 may be attributed to DOX-induced inflammation, since inflammation has been shown to downregulate Cyp1a1 in the hearts of male C57Bl/6 mice. 	Cyp1a1	26710	26716	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:148	DOX-mediated inhibition of Cyp1a1 may be attributed to DOX-induced inflammation, since inflammation has been shown to downregulate Cyp1a1 in the hearts of male C57Bl/6 mice. 	Cyp1a1	26710	26716	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:149	However, this notion cannot explain the inhibition of Cyp1a1 in the hearts of female mice, since they had minimal inflammation. 	Cyp1a1	26807	26813	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:149	However, this notion cannot explain the inhibition of Cyp1a1 in the hearts of female mice, since they had minimal inflammation. 	Cyp1a1	26807	26813	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:150	Of interest, the gene expression of Cyp1a1 returned to a control value 6 days after Doxorubicin administration in female, but not in male mice, indicating the recovery of the female hearts from the early DOX-induced injury. 	Cyp1a1	26917	26923	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:150	Of interest, the gene expression of Cyp1a1 returned to a control value 6 days after Doxorubicin administration in female, but not in male mice, indicating the recovery of the female hearts from the early DOX-induced injury. 	Cyp1a1	26917	26923	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:181	The expression of additional CYPs (Cyp1a1, Cyp1b1, Cyp2e1) was observed in the skin of C57BL/6J mice by Flowers et al.. In the mouse skin the expression of several Cyp genes was demonstrated on the RNA level. 	Cyp1a1	29804	29810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:181	The expression of additional CYPs (Cyp1a1, Cyp1b1, Cyp2e1) was observed in the skin of C57BL/6J mice by Flowers et al.. In the mouse skin the expression of several Cyp genes was demonstrated on the RNA level. 	Cyp1a1	29804	29810	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp1a1	30329	30335	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp1a1	30329	30335	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:187	Cyp1a1, Cyp1b1 and Cyp3a11, but not Ahr expression in the skin also were enhanced by 7,12-Dimethylbenz[A]Anthracene. 	Cyp1a1	31335	31341	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:104	Acute exposure to Doxorubicin significantly increased Cyp4a10 mRNA levels in hearts of both male and female mice (twofold and sixfold induction, respectively) 1 day after Doxorubicin administration. 	Cyp4a	18986	18991	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:105	This was reversed in both sexes 6 days after treatment with a significant effect of sex on Cyp4a10 expression. 	Cyp4a	19222	19227	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:173	Several studies have investigated the sexual divergence of Cyp4a10 expression in the kidney and liver of different strains of mice. 	Cyp4a	30738	30743	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:174	In one study, there was no sex-dependent difference in the expression of Cyp4a10 in the kidney of C57Bl/6 mice. 	Cyp4a	30884	30889	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:175	In another study, Cyp4a10 was expressed at a higher level in the liver and kidney of female than in male C57Bl/6 mice. 	Cyp4a	30941	30946	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:176	To the best of our knowledge, there is no information about sex-related differences in Cyp4a10 expression in the mouse heart. 	Cyp4a	31129	31134	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:177	In the current study, we found that the expression of Cyp4a10 was significantly lower in the hearts of control female than in control male mice in the 24-h cohort, suggesting organ-specific sexual divergence in Cyp4a10 expression. 	Cyp4a	31222	31227	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:177	In the current study, we found that the expression of Cyp4a10 was significantly lower in the hearts of control female than in control male mice in the 24-h cohort, suggesting organ-specific sexual divergence in Cyp4a10 expression. 	Cyp4a	31379	31384	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:178	Although the expression of Cyp4a10 in the hearts of female mice was 60% of its expression in male mice in the 6-day cohort, this difference was not statistically significant. 	Cyp4a	31426	31431	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:183	Lower expression of cardiac Cyp4a10 may contribute to the overall protection of females against heart disease as Cyp4a10 has been shown to metabolize arachidonic acid to the cardiotoxic metabolite 20-hydroxyeicosatetraenoic acid. 	Cyp4a	32319	32324	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:183	Lower expression of cardiac Cyp4a10 may contribute to the overall protection of females against heart disease as Cyp4a10 has been shown to metabolize arachidonic acid to the cardiotoxic metabolite 20-hydroxyeicosatetraenoic acid. 	Cyp4a	32404	32409	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:184	Despite a lower constitutive expression of Cyp4a10 in the female hearts, acute DOX-induced cardiotoxicity caused a marked induction of Cyp4a10 in the hearts of both male and female mice, suggesting that this enzyme may not play an important role in the sexual dimorphism of DOX-induced cardiotoxicity. 	Cyp4a	32564	32569	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:47	These data provide important insights into the structural properties and the molecular selectivity of this M. tuberculosis P450 enzyme, highlighting its capacity to bind large compounds, and the ability of molecules with nitroaromatic groups to moonlight as substrates through inducing formation of high spin heme iron in CYP126A1. 	P450 enzyme	8173	8184	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:47	These data provide important insights into the structural properties and the molecular selectivity of this M. tuberculosis P450 enzyme, highlighting its capacity to bind large compounds, and the ability of molecules with nitroaromatic groups to moonlight as substrates through inducing formation of high spin heme iron in CYP126A1. 	P450 enzyme	8173	8184	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:48	This is the first report of structural data for the widely conserved M. tuberculosis CYP126A1 P450 enzyme and provides important insights into CYP126A1 molecular selectivity and structural adaptation to the binding of large compounds. 	P450 enzyme	8476	8487	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:48	This is the first report of structural data for the widely conserved M. tuberculosis CYP126A1 P450 enzyme and provides important insights into CYP126A1 molecular selectivity and structural adaptation to the binding of large compounds. 	P450 enzyme	8476	8487	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:251	Future work will be directed at the identification of the natural substrate(s) for this widely conserved P450 enzyme. 	P450 enzyme	46790	46801	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:251	Future work will be directed at the identification of the natural substrate(s) for this widely conserved P450 enzyme. 	P450 enzyme	46790	46801	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:3	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency. 	P450 enzyme	443	454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:3	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency. 	P450 enzyme	443	454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:12	For the prediction of herb-drug interaction, it is necessary to investigate the in vitro inhibitory effects of herb drugs and the constituents on major human Cytochrome P450 enzyme activities. 	P450 enzyme	3472	3483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:12	For the prediction of herb-drug interaction, it is necessary to investigate the in vitro inhibitory effects of herb drugs and the constituents on major human Cytochrome P450 enzyme activities. 	P450 enzyme	3472	3483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:118	Cytochrome P450 enzyme promotes reactive oxygen species generation which occurs during the metabolic conversion of procarcinogens to their ultimate reactive electrophilic intermediates. 	P450 enzyme	17761	17772	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:118	Cytochrome P450 enzyme promotes reactive oxygen species generation which occurs during the metabolic conversion of procarcinogens to their ultimate reactive electrophilic intermediates. 	P450 enzyme	17761	17772	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:113	This may suggest that the substrate binding pocket of the two P450 enzymes could accommodate more than one C_12 molecules and that the binding of one C_12 molecule could facilitate the binding of the other to the same P450 enzyme, particularly at low to medium substrate concentrations (10-80 M). 	P450 enzyme	22402	22413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5588734_OgerInput.txtOger_out.csv:113	This may suggest that the substrate binding pocket of the two P450 enzymes could accommodate more than one C_12 molecules and that the binding of one C_12 molecule could facilitate the binding of the other to the same P450 enzyme, particularly at low to medium substrate concentrations (10-80 M). 	P450 enzyme	22402	22413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:449	Obes Rev 17: 42941 [PMID:26997580] The cytochrome P450 enzyme family (CYP450), E.C. 	P450 enzyme	52773	52784	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:449	Obes Rev 17: 42941 [PMID:26997580] The cytochrome P450 enzyme family (CYP450), E.C. 	P450 enzyme	52773	52784	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:482	In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [11, 154, 488]. 	P450 enzyme	55955	55966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:482	In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [11, 154, 488]. 	P450 enzyme	55955	55966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:148	In the interpretation of both the in vitro and in vivo inhibitory potential and characteristics of R. rosea on Cytochrome P450 enzyme activity, the potential differences in biochemical activity of multiple unknown constituents must also be taken into consideration. 	P450 enzyme	20964	20975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:148	In the interpretation of both the in vitro and in vivo inhibitory potential and characteristics of R. rosea on Cytochrome P450 enzyme activity, the potential differences in biochemical activity of multiple unknown constituents must also be taken into consideration. 	P450 enzyme	20964	20975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:156	Further studies should evaluate possible Cytochrome P450 enzyme effects of other commercially available R. rosea products and in more detail attempt to identify which of the R. rosea constituents that are responsible for these effects. 	P450 enzyme	22460	22471	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:156	Further studies should evaluate possible Cytochrome P450 enzyme effects of other commercially available R. rosea products and in more detail attempt to identify which of the R. rosea constituents that are responsible for these effects. 	P450 enzyme	22460	22471	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	P450 enzyme	142	153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	P450 enzyme	142	153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	P450 enzyme	2665	2676	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	P450 enzyme	2665	2676	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5774601_OgerInput.txtOger_out.csv:62	The action of vitamin D and its active metabolite (calcitriol) in the modulation of immune function was documented more than 3 decades ago.- Vitamin D and CYP27B1 (a mitochondrial P450 enzyme that converts 25[OH]D to 1,25[OH]D) play crucial roles in both adaptive and innate immunity. 	P450 enzyme	13720	13731	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5774601_OgerInput.txtOger_out.csv:62	The action of vitamin D and its active metabolite (calcitriol) in the modulation of immune function was documented more than 3 decades ago.- Vitamin D and CYP27B1 (a mitochondrial P450 enzyme that converts 25[OH]D to 1,25[OH]D) play crucial roles in both adaptive and innate immunity. 	P450 enzyme	13720	13731	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:20	We speculated that this effect was a result of changes in the expression of the cytochrome P450 enzyme caused by Methicillin-Resistant Staphylococcus Aureus infection. 	P450 enzyme	4962	4973	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:20	We speculated that this effect was a result of changes in the expression of the cytochrome P450 enzyme caused by Methicillin-Resistant Staphylococcus Aureus infection. 	P450 enzyme	4962	4973	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:108	In addition to the inflammation caused by Escherichia coli, lipopolysaccharide is also a major cause of Cytochrome P450 enzyme inhibition. 	P450 enzyme	19646	19657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:108	In addition to the inflammation caused by Escherichia coli, lipopolysaccharide is also a major cause of Cytochrome P450 enzyme inhibition. 	P450 enzyme	19646	19657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:120	The Cytochrome P450 enzyme, a key determinant of drug-drug interactions, forms the basis of clinically personalized drug monitoring. 	P450 enzyme	22229	22240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:120	The Cytochrome P450 enzyme, a key determinant of drug-drug interactions, forms the basis of clinically personalized drug monitoring. 	P450 enzyme	22229	22240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:124	This is mainly manifested by increased inflammatory factors, decreased antioxidant enzymes, and increased oxidative metabolites, which are accompanied by liver Cytochrome P450 enzyme expression and a rapid decrease in activity. 	P450 enzyme	23181	23192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:124	This is mainly manifested by increased inflammatory factors, decreased antioxidant enzymes, and increased oxidative metabolites, which are accompanied by liver Cytochrome P450 enzyme expression and a rapid decrease in activity. 	P450 enzyme	23181	23192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:36	This investigation suggests a modification of the membrane topology of this protein, unprecedented for a plant P450 enzyme. 	P450 enzyme	4931	4942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:36	This investigation suggests a modification of the membrane topology of this protein, unprecedented for a plant P450 enzyme. 	P450 enzyme	4931	4942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:191	Cross-membrane electron transfer has been suggested to occur with a mammalian P450 enzyme. 	P450 enzyme	31446	31457	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:191	Cross-membrane electron transfer has been suggested to occur with a mammalian P450 enzyme. 	P450 enzyme	31446	31457	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:291	As a control, experimental N-terminal helical segments of ScErg11p (CYP51), the first crystal structure for any full-length cytochrome P450 enzyme showing resolution of the membrane spanning helix available in PDB, were also submitted to PPM server. 	P450 enzyme	46996	47007	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:291	As a control, experimental N-terminal helical segments of ScErg11p (CYP51), the first crystal structure for any full-length cytochrome P450 enzyme showing resolution of the membrane spanning helix available in PDB, were also submitted to PPM server. 	P450 enzyme	46996	47007	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:26	Gene sequence changes (single nucleotide variation and structural variation referred to collectively as alleles) that lead to altered P450 enzyme activity can be classified into four phenotypic groups: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizer (UM). 	P450 enzyme	5308	5319	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:26	Gene sequence changes (single nucleotide variation and structural variation referred to collectively as alleles) that lead to altered P450 enzyme activity can be classified into four phenotypic groups: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizer (UM). 	P450 enzyme	5308	5319	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:23	For instance, Arabidopsis thaliana CYP74A, which is an untypical P450 enzyme that does require molecular dioxygen, is specific of a single substrate yielding an allene oxide. 	P450 enzyme	3155	3166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:23	For instance, Arabidopsis thaliana CYP74A, which is an untypical P450 enzyme that does require molecular dioxygen, is specific of a single substrate yielding an allene oxide. 	P450 enzyme	3155	3166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:53	The most used algorithms, the CAVER-MOLE series that was developed by Michal Otyepka and his collaborators, use a fixed-size sphere of specified diameter placed close to the heme iron ion in the distal cavity of the P450 enzyme to identify all of the direct paths connecting the buried active site to the protein surface by rolling it out of the active site. 	P450 enzyme	9217	9228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:53	The most used algorithms, the CAVER-MOLE series that was developed by Michal Otyepka and his collaborators, use a fixed-size sphere of specified diameter placed close to the heme iron ion in the distal cavity of the P450 enzyme to identify all of the direct paths connecting the buried active site to the protein surface by rolling it out of the active site. 	P450 enzyme	9217	9228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:86	In numerous experiments, multiple molecules of ligands have been observed to bind simultaneously to P450 enzyme. 	P450 enzyme	14773	14784	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:86	In numerous experiments, multiple molecules of ligands have been observed to bind simultaneously to P450 enzyme. 	P450 enzyme	14773	14784	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:102	In the crystal structure of CYP102, also known as P450 BM3, a fatty acid hydroxylase P450 enzyme that is isolated from Bacillus megaterium, the active site cavity is accessible through a clearly visible long channel that links the heme iron distal environment to the bulk solvent. 	P450 enzyme	17486	17497	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:102	In the crystal structure of CYP102, also known as P450 BM3, a fatty acid hydroxylase P450 enzyme that is isolated from Bacillus megaterium, the active site cavity is accessible through a clearly visible long channel that links the heme iron distal environment to the bulk solvent. 	P450 enzyme	17486	17497	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:113	In this historical study, a P450 enzyme was shown for the first time to exhibit some flexibility, coincidental with the opening at the protein surface of an access channel to its buried active site. 	P450 enzyme	19633	19644	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:113	In this historical study, a P450 enzyme was shown for the first time to exhibit some flexibility, coincidental with the opening at the protein surface of an access channel to its buried active site. 	P450 enzyme	19633	19644	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:115	To our knowledge, no plant P450 enzyme has been analyzed for CAVER channels. 	P450 enzyme	20011	20022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:115	To our knowledge, no plant P450 enzyme has been analyzed for CAVER channels. 	P450 enzyme	20011	20022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:192	The composition of the membrane may also affect the P450 functioning; and the orientation of the catalytic domain of the P450 enzyme relative to the membrane was shown to change depending on the charge of the bilayer phospholipids in molecular dynamics simulations. 	P450 enzyme	34727	34738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:192	The composition of the membrane may also affect the P450 functioning; and the orientation of the catalytic domain of the P450 enzyme relative to the membrane was shown to change depending on the charge of the bilayer phospholipids in molecular dynamics simulations. 	P450 enzyme	34727	34738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:251	The molecular dynamics simulation performed on the wild-type and F240A mutant of rat CYP1A1, showed that the preferred channels (those that are open most of the time and are wider at bottleneck during the duration of the simulations) are not the same between the mutant and the wild-type P450 enzyme. 	P450 enzyme	45290	45301	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:251	The molecular dynamics simulation performed on the wild-type and F240A mutant of rat CYP1A1, showed that the preferred channels (those that are open most of the time and are wider at bottleneck during the duration of the simulations) are not the same between the mutant and the wild-type P450 enzyme. 	P450 enzyme	45290	45301	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:300	Such a study would lead to a better knowledge of what combination of amino acid residues in a P450 enzyme distinguishes a ligand (a bound molecule that not reaches easily the productive step of the catalytic cycle) from a substrate (a bound molecule that reaches the productive step). 	P450 enzyme	52771	52782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:300	Such a study would lead to a better knowledge of what combination of amino acid residues in a P450 enzyme distinguishes a ligand (a bound molecule that not reaches easily the productive step of the catalytic cycle) from a substrate (a bound molecule that reaches the productive step). 	P450 enzyme	52771	52782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	P450 enzyme	3621	3632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	P450 enzyme	3621	3632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	P450 enzyme	6536	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	P450 enzyme	6536	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	P450 enzyme	1199	1210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	P450 enzyme	1199	1210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:62	The levels and ratio of the novel constituents varied depending on the P450 enzyme, with CYP712K1 favoring formation of 6 and CYP712K2 favoring formation of 5. 	P450 enzyme	11024	11035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:62	The levels and ratio of the novel constituents varied depending on the P450 enzyme, with CYP712K1 favoring formation of 6 and CYP712K2 favoring formation of 5. 	P450 enzyme	11024	11035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC5270475_OgerInput.txtOger_out.csv:116	In many bacterial P450s, the substrate-induced High Spin shift is associated with a substantial increase in the P450 heme iron Fe^III/Fe^II reduction potential (eg from 368 to 239 mV (versus normal hydrogen electrode) for the Bacillus megaterium CYP102A1 (P450 BM3) heme domain on binding arachidonic acid and from approximately 300 to 170 mV for the Pseudomonas putida P450cam on binding d-camphor) (,. 	P450cam	21428	21435	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:44	Historically, the first attempt to identify access channels in cytochrome P450 was made twenty years ago by Rebecca Wade and her coworkers on cytochrome P450cam (CYP101A1). 	P450cam	7254	7261	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:50	This computational method, as well as the steered molecular dynamics approach, identified several main access/exit channels in the crystal structure of P450cam. 	P450cam	8568	8575	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:76	P450cam (CYP101), which is one of the best characterized of all P450 enzymes, is considered as a model for P450s with narrow substrate specificity. 	P450cam	13127	13134	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:78	P450cam was considered for a long time to not show structural flexibility, since the first crystal structures of the substrate-free and substrate-bound forms of P450cam were similarly exhibiting a compact conformation. 	P450cam	13436	13443	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:78	P450cam was considered for a long time to not show structural flexibility, since the first crystal structures of the substrate-free and substrate-bound forms of P450cam were similarly exhibiting a compact conformation. 	P450cam	13597	13604	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:79	But, some fifteen years later, Goodin and his collaborators showed that P450cam can visit an open conformation in the absence of substrate when the concentration in potassium ion in the crystallization medium is considerably lowered. 	P450cam	13727	13734	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:80	The opening of the P450cam structure is due to a concerted backward movement of the F- and G-helices and an uprising of the F/G loop, together with a higher degree of flexibility of the B/C loop. 	P450cam	13908	13915	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:81	This opening of P450cam structure unveils an access channel linking the protein surface, in the vicinity of the F/G loop, to the catalytic cavity. 	P450cam	14101	14108	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:82	Finally, P450cam was shown to adopt up to three different conformations, named C, I, and O, each being adapted to the substrate size. 	P450cam	14241	14248	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:83	The C-conformation is the one of the camphor complex and with substrate-free P450cam at high potassium ion concentration. 	P450cam	14443	14450	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:85	The O-conformation is the one observed with substrate-free P450cam at low potassium ion concentration. 	P450cam	14629	14636	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:1	 Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. 	Cytochrome P450 Enzymes	23	46	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	607	630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	763	786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450 Enzymes	975	998	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	Cytochrome P450 Enzymes	1089	1112	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:11	As the principal class of hepatic drug metabolizing enzymes, Cytochrome P450 Enzymes play a critically important role in the biosynthesis and degradation of endogenous compounds and the metabolism of drugs and environmental procarcinogens. 	Cytochrome P450 Enzymes	1871	1894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:12	Interindividual variation in drug metabolism, which encompasses genetic polymorphisms of Cytochrome P450 Enzymes, smoking, drinking, age, and gender, has a substantial impact on individual drug safety and efficacy, raising a challenge to guide individualized medicine. 	Cytochrome P450 Enzymes	2139	2162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:17	A multitude of different Cytochrome P450 Enzymes share similar physical and molecular characteristics, are colocalized on the cytoplasmic side of the endoplasmic reticulum, and coordinately carry out the biosynthesis and degradation of endogenous steroids, lipids, and vitamins as well as many exogenous substances. 	Cytochrome P450 Enzymes	3037	3060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:20	Our previous studies also have shown that a high degree of correlation existed at the mRNA and protein expression levels of Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	3722	3745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450 Enzymes	3772	3795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	Cytochrome P450 Enzymes	3959	3982	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:24	Recently, to predict the in vivo clearance for Cytochrome P450 Enzymes more accurately, we introduced correction coefficients into the Vitro-In Vivo Extrapolation method based on the study of Halifax and Houston, who developed the conventional bias corrected in vitro-in vivo extrapolation (CBC-IVIVE) method. 	Cytochrome P450 Enzymes	4485	4508	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:25	Combining descriptive models and CBC-IVIVE might allow us to accurately predict total CYP-mediated drug clearance in vivo based on the measured activities of a few Cytochrome P450 Enzymes using a small quantity of liver tissue. 	Cytochrome P450 Enzymes	4912	4935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450 Enzymes	5158	5181	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	Cytochrome P450 Enzymes	5320	5343	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:27	To strengthen the clinical values, the CL_H of probe drugs for six Cytochrome P450 Enzymes were extrapolated using CBC-IVIVE method, and the extrapolation accuracy was evaluated. 	Cytochrome P450 Enzymes	5454	5477	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:51	), as follows: First, each kinetic parameter (V_max, K_m, and CL_int) of the ten Cytochrome P450 Enzymes was treated as a dataset, which then generated three datasets. 	Cytochrome P450 Enzymes	10365	10388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:52	For each training set, the data of one CYP were set as the dependent variable and the datasets of the other Cytochrome P450 Enzymes were set as independent variables, from which a multiple linear regression model was developed by a stepwise method (criteria: probability of F to enter was 0.05, probability of F to remove was 0.10). 	Cytochrome P450 Enzymes	10560	10583	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	11175	11198	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	11293	11316	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:63	The correction coefficient, the plasma unbound fraction (f_u,p), and blood-to-plasma concentration ratio (R_B) of each probe drug for six Cytochrome P450 Enzymes were obtained from literature. 	Cytochrome P450 Enzymes	12693	12716	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	Cytochrome P450 Enzymes	14505	14528	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450 Enzymes	14960	14983	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450 Enzymes	14999	15022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	Cytochrome P450 Enzymes	15176	15199	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450 Enzymes	15260	15283	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	Cytochrome P450 Enzymes	15349	15372	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450 Enzymes	15514	15537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	Cytochrome P450 Enzymes	15657	15680	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:84	Of note, prediction of some CYP-mediated metabolic activities in vitro did not require knowledge of all four Cytochrome P450 Enzymes activities; some activities could be predicted on just one or two known CYP activities. 	Cytochrome P450 Enzymes	15930	15953	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450 Enzymes	16738	16761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	Cytochrome P450 Enzymes	16809	16832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:89	In short, the prediction for six Cytochrome P450 Enzymes needed 1-3 measured CYP values. 	Cytochrome P450 Enzymes	17208	17231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:95	The ranges of predicted CL_int for all Cytochrome P450 Enzymes were smaller than the measured data. 	Cytochrome P450 Enzymes	18090	18113	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450 Enzymes	23944	23967	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	Cytochrome P450 Enzymes	24025	24048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	24128	24151	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	24225	24248	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	24348	24371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450 Enzymes	25387	25410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	Cytochrome P450 Enzymes	25474	25497	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:134	As a consequence of this, predictive models for K_m of some Cytochrome P450 Enzymes could not be developed. 	Cytochrome P450 Enzymes	25582	25605	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:140	Although these descriptive models could use data on some Cytochrome P450 Enzymes to predict activities of others, there are limitations. 	Cytochrome P450 Enzymes	26684	26707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:145	Although the models were established using the data on ten Cytochrome P450 Enzymes from 105 normal liver tissue samples from a Chinese Han population, the models should be further improved and validated in larger samples and in different ethnic groups. 	Cytochrome P450 Enzymes	27267	27290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	27538	27561	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	Cytochrome P450 Enzymes	27668	27691	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	27866	27889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	Cytochrome P450 Enzymes	20661	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	Cytochrome P450 Enzymes	20787	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	21091	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	Cytochrome P450 Enzymes	21202	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	Cytochrome P450 Enzymes	21699	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	Cytochrome P450 Enzymes	27	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:1	 Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. 	P450 Enzymes	34	46	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5281577_OgerInput.txtOger_out.csv:1	 Suicide Inhibition of Cytochrome P450 Enzymes by Cyclopropylamines via a Ring-Opening Mechanism: Proton-Coupled Electron Transfer Makes a Difference. 	P450 Enzymes	34	46	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	P450 Enzymes	618	630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	P450 Enzymes	618	630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	P450 Enzymes	774	786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:5	The descriptive models for predicting the activities of these Cytochrome P450 Enzymes in Human Liver Microsomes were developed solely on the basis of the measured activities of a smaller number of more readily assayed Cytochrome P450 Enzymes. 	P450 Enzymes	774	786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	P450 Enzymes	986	998	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	P450 Enzymes	986	998	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	P450 Enzymes	1100	1112	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:7	The Vmax, Km, and CLint of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) in Human Liver Microsomes. 	P450 Enzymes	1100	1112	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:11	As the principal class of hepatic drug metabolizing enzymes, Cytochrome P450 Enzymes play a critically important role in the biosynthesis and degradation of endogenous compounds and the metabolism of drugs and environmental procarcinogens. 	P450 Enzymes	1882	1894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:11	As the principal class of hepatic drug metabolizing enzymes, Cytochrome P450 Enzymes play a critically important role in the biosynthesis and degradation of endogenous compounds and the metabolism of drugs and environmental procarcinogens. 	P450 Enzymes	1882	1894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:12	Interindividual variation in drug metabolism, which encompasses genetic polymorphisms of Cytochrome P450 Enzymes, smoking, drinking, age, and gender, has a substantial impact on individual drug safety and efficacy, raising a challenge to guide individualized medicine. 	P450 Enzymes	2150	2162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:12	Interindividual variation in drug metabolism, which encompasses genetic polymorphisms of Cytochrome P450 Enzymes, smoking, drinking, age, and gender, has a substantial impact on individual drug safety and efficacy, raising a challenge to guide individualized medicine. 	P450 Enzymes	2150	2162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:17	A multitude of different Cytochrome P450 Enzymes share similar physical and molecular characteristics, are colocalized on the cytoplasmic side of the endoplasmic reticulum, and coordinately carry out the biosynthesis and degradation of endogenous steroids, lipids, and vitamins as well as many exogenous substances. 	P450 Enzymes	3048	3060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:17	A multitude of different Cytochrome P450 Enzymes share similar physical and molecular characteristics, are colocalized on the cytoplasmic side of the endoplasmic reticulum, and coordinately carry out the biosynthesis and degradation of endogenous steroids, lipids, and vitamins as well as many exogenous substances. 	P450 Enzymes	3048	3060	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:20	Our previous studies also have shown that a high degree of correlation existed at the mRNA and protein expression levels of Cytochrome P450 Enzymes. 	P450 Enzymes	3733	3745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:20	Our previous studies also have shown that a high degree of correlation existed at the mRNA and protein expression levels of Cytochrome P450 Enzymes. 	P450 Enzymes	3733	3745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	P450 Enzymes	3783	3795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	P450 Enzymes	3783	3795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	P450 Enzymes	3970	3982	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:21	These correlations among Cytochrome P450 Enzymes at the protein, mRNA, and activity levels suggest that descriptive models based on multiple linear regression might be developed to predict the activities of some Cytochrome P450 Enzymes solely on the basis of measured activities of a smaller number of more readily assayed CYP enzymes. 	P450 Enzymes	3970	3982	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:24	Recently, to predict the in vivo clearance for Cytochrome P450 Enzymes more accurately, we introduced correction coefficients into the Vitro-In Vivo Extrapolation method based on the study of Halifax and Houston, who developed the conventional bias corrected in vitro-in vivo extrapolation (CBC-IVIVE) method. 	P450 Enzymes	4496	4508	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:24	Recently, to predict the in vivo clearance for Cytochrome P450 Enzymes more accurately, we introduced correction coefficients into the Vitro-In Vivo Extrapolation method based on the study of Halifax and Houston, who developed the conventional bias corrected in vitro-in vivo extrapolation (CBC-IVIVE) method. 	P450 Enzymes	4496	4508	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:25	Combining descriptive models and CBC-IVIVE might allow us to accurately predict total CYP-mediated drug clearance in vivo based on the measured activities of a few Cytochrome P450 Enzymes using a small quantity of liver tissue. 	P450 Enzymes	4923	4935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:25	Combining descriptive models and CBC-IVIVE might allow us to accurately predict total CYP-mediated drug clearance in vivo based on the measured activities of a few Cytochrome P450 Enzymes using a small quantity of liver tissue. 	P450 Enzymes	4923	4935	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	P450 Enzymes	5169	5181	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	P450 Enzymes	5169	5181	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	P450 Enzymes	5331	5343	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:26	Herein, we obtained 105 liver tissue samples derived from 123 liver samples taken from normal tissue adjacent to surgical biopsies, which allowed us to measure the activities of ten Cytochrome P450 Enzymes in each sample and provided the foundation for the development of descriptive models that could be used to estimate the activities of six Cytochrome P450 Enzymes by actually measuring four CYP activities. 	P450 Enzymes	5331	5343	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:27	To strengthen the clinical values, the CL_H of probe drugs for six Cytochrome P450 Enzymes were extrapolated using CBC-IVIVE method, and the extrapolation accuracy was evaluated. 	P450 Enzymes	5465	5477	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:27	To strengthen the clinical values, the CL_H of probe drugs for six Cytochrome P450 Enzymes were extrapolated using CBC-IVIVE method, and the extrapolation accuracy was evaluated. 	P450 Enzymes	5465	5477	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:51	), as follows: First, each kinetic parameter (V_max, K_m, and CL_int) of the ten Cytochrome P450 Enzymes was treated as a dataset, which then generated three datasets. 	P450 Enzymes	10376	10388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:51	), as follows: First, each kinetic parameter (V_max, K_m, and CL_int) of the ten Cytochrome P450 Enzymes was treated as a dataset, which then generated three datasets. 	P450 Enzymes	10376	10388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:52	For each training set, the data of one CYP were set as the dependent variable and the datasets of the other Cytochrome P450 Enzymes were set as independent variables, from which a multiple linear regression model was developed by a stepwise method (criteria: probability of F to enter was 0.05, probability of F to remove was 0.10). 	P450 Enzymes	10571	10583	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:52	For each training set, the data of one CYP were set as the dependent variable and the datasets of the other Cytochrome P450 Enzymes were set as independent variables, from which a multiple linear regression model was developed by a stepwise method (criteria: probability of F to enter was 0.05, probability of F to remove was 0.10). 	P450 Enzymes	10571	10583	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	11186	11198	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	11186	11198	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	11304	11316	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:55	Using the equations generated and refined above, it was found that the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E, and 3A4/5) could be predicted based on the measured activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	11304	11316	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:63	The correction coefficient, the plasma unbound fraction (f_u,p), and blood-to-plasma concentration ratio (R_B) of each probe drug for six Cytochrome P450 Enzymes were obtained from literature. 	P450 Enzymes	12704	12716	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:63	The correction coefficient, the plasma unbound fraction (f_u,p), and blood-to-plasma concentration ratio (R_B) of each probe drug for six Cytochrome P450 Enzymes were obtained from literature. 	P450 Enzymes	12704	12716	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	P450 Enzymes	14516	14528	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:77	The above normal Chinese liver samples were used to measure the ten Cytochrome P450 Enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro using probe substrate metabolism assays. 	P450 Enzymes	14516	14528	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	14971	14983	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	14971	14983	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	15010	15022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	15010	15022	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	15187	15199	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:80	The results show that the descriptive models of V_max and CL_int of all ten Cytochrome P450 Enzymes and K_m of six Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, 2C19, and 3A4/5) could be developed, and the essential structures of these models consisted of the measured V_max, CL_int, and K_m of Cytochrome P450 Enzymes (data not shown). 	P450 Enzymes	15187	15199	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	P450 Enzymes	15271	15283	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	P450 Enzymes	15271	15283	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	P450 Enzymes	15360	15372	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:81	In order to predict activities of several Cytochrome P450 Enzymes based on known CYP activities, the principle that the numbers of Cytochrome P450 Enzymes were known as little as possible was upheld to analyze all multiple linear regression equations carefully. 	P450 Enzymes	15360	15372	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	P450 Enzymes	15525	15537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	P450 Enzymes	15525	15537	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	P450 Enzymes	15668	15680	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:82	The results indicate that the six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5)-mediated metabolic activities in vitro could be predicted if the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19) measured in vitro were known.  	P450 Enzymes	15668	15680	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:84	Of note, prediction of some CYP-mediated metabolic activities in vitro did not require knowledge of all four Cytochrome P450 Enzymes activities; some activities could be predicted on just one or two known CYP activities. 	P450 Enzymes	15941	15953	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:84	Of note, prediction of some CYP-mediated metabolic activities in vitro did not require knowledge of all four Cytochrome P450 Enzymes activities; some activities could be predicted on just one or two known CYP activities. 	P450 Enzymes	15941	15953	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	P450 Enzymes	16749	16761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	P450 Enzymes	16749	16761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	P450 Enzymes	16820	16832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:87	For K_m, although some descriptive models of Cytochrome P450 Enzymes could not be developed, the K_m values of most Cytochrome P450 Enzymes could be calculated as their respective V_max divided by corresponding CL_int. 	P450 Enzymes	16820	16832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:89	In short, the prediction for six Cytochrome P450 Enzymes needed 1-3 measured CYP values. 	P450 Enzymes	17219	17231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:89	In short, the prediction for six Cytochrome P450 Enzymes needed 1-3 measured CYP values. 	P450 Enzymes	17219	17231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:95	The ranges of predicted CL_int for all Cytochrome P450 Enzymes were smaller than the measured data. 	P450 Enzymes	18101	18113	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:95	The ranges of predicted CL_int for all Cytochrome P450 Enzymes were smaller than the measured data. 	P450 Enzymes	18101	18113	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	P450 Enzymes	23955	23967	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	P450 Enzymes	23955	23967	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	P450 Enzymes	24036	24048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:127	The purpose of the present study was to determine the drug clearance values for six Cytochrome P450 Enzymes in vivo and in vivo based on measured activities of four Cytochrome P450 Enzymes in Human Liver Microsomes. 	P450 Enzymes	24036	24048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24139	24151	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24139	24151	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24236	24248	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24236	24248	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24359	24371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:128	Descriptive models for predicting the activities of Cytochrome P450 Enzymes in Human Liver Microsomes were developed first and the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) could be predicted by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	24359	24371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	P450 Enzymes	25398	25410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	P450 Enzymes	25398	25410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	P450 Enzymes	25485	25497	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:133	There is no published correlation between structures of Cytochrome P450 Enzymes from different chromosomes, although haplotypes exist for some Cytochrome P450 Enzymes on the same chromosome. 	P450 Enzymes	25485	25497	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:134	As a consequence of this, predictive models for K_m of some Cytochrome P450 Enzymes could not be developed. 	P450 Enzymes	25593	25605	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:134	As a consequence of this, predictive models for K_m of some Cytochrome P450 Enzymes could not be developed. 	P450 Enzymes	25593	25605	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:140	Although these descriptive models could use data on some Cytochrome P450 Enzymes to predict activities of others, there are limitations. 	P450 Enzymes	26695	26707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:140	Although these descriptive models could use data on some Cytochrome P450 Enzymes to predict activities of others, there are limitations. 	P450 Enzymes	26695	26707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:145	Although the models were established using the data on ten Cytochrome P450 Enzymes from 105 normal liver tissue samples from a Chinese Han population, the models should be further improved and validated in larger samples and in different ethnic groups. 	P450 Enzymes	27278	27290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:145	Although the models were established using the data on ten Cytochrome P450 Enzymes from 105 normal liver tissue samples from a Chinese Han population, the models should be further improved and validated in larger samples and in different ethnic groups. 	P450 Enzymes	27278	27290	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	27549	27561	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	27549	27561	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	27679	27691	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:146	In summary, we developed descriptive models to predict the activities of six Cytochrome P450 Enzymes (CYP2A6, 2C8, 2D6, 2E1, and 3A4/5) in Human Liver Microsomes by actually measuring the activities of four Cytochrome P450 Enzymes (CYP1A2, 2B6, 2C9, and 2C19). 	P450 Enzymes	27679	27691	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	P450 Enzymes	27877	27889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	P450 Enzymes	27877	27889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	P450 Enzymes	20672	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	P450 Enzymes	20672	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	P450 Enzymes	20798	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	P450 Enzymes	20798	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	P450 Enzymes	21102	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	P450 Enzymes	21102	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	P450 Enzymes	21213	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	P450 Enzymes	21213	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	P450 Enzymes	21710	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	P450 Enzymes	21710	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	P450 Enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	P450 Enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	P450 Enzymes	805	817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:6	When added after Oxygen-Glucose Deprivation, CSP-1103 prevented the apoptosis cascade by reducing cytochrome c release and caspase-3 activation and the secondary necrosis. 	cytochrome c	950	962	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:6	When added after Oxygen-Glucose Deprivation, CSP-1103 prevented the apoptosis cascade by reducing cytochrome c release and caspase-3 activation and the secondary necrosis. 	cytochrome c	950	962	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:14	In fact, signs of apoptosis exist, including cytochrome c release, activation of caspases-3 and -9, and terminal deoxynucleotidyl transferase dUTP nick end labeling positivity, thus making this cascade a potential target for neuroprotection. 	cytochrome c	2101	2113	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:14	In fact, signs of apoptosis exist, including cytochrome c release, activation of caspases-3 and -9, and terminal deoxynucleotidyl transferase dUTP nick end labeling positivity, thus making this cascade a potential target for neuroprotection. 	cytochrome c	2101	2113	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:31	Neuronal cells display TUNEL-positivity and release of cytochrome c in the cytosol within 6 h after the Oxygen-Glucose Deprivation, in the absence of lactate dehydrogenase release. 	cytochrome c	6214	6226	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:31	Neuronal cells display TUNEL-positivity and release of cytochrome c in the cytosol within 6 h after the Oxygen-Glucose Deprivation, in the absence of lactate dehydrogenase release. 	cytochrome c	6214	6226	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:46	As a further marker of apoptosis, we investigated the levels of cytochrome c released from mitochondria after Oxygen-Glucose Deprivation exposure. 	cytochrome c	8476	8488	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:46	As a further marker of apoptosis, we investigated the levels of cytochrome c released from mitochondria after Oxygen-Glucose Deprivation exposure. 	cytochrome c	8476	8488	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:73	The neuroprotection elicited by CSP-1103, added in the post Oxygen-Glucose Deprivation period, comprised the inhibition of the cytochrome c- and caspase-3 dependent apoptotic cascade, as well as inhibition of necrosis and the p38 and NF-B signaling pathways. 	cytochrome c	13013	13025	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:73	The neuroprotection elicited by CSP-1103, added in the post Oxygen-Glucose Deprivation period, comprised the inhibition of the cytochrome c- and caspase-3 dependent apoptotic cascade, as well as inhibition of necrosis and the p38 and NF-B signaling pathways. 	cytochrome c	13013	13025	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:74	CSP-1103 reduced the activation of caspase-3 as well as the cytoplasmic release of cytochrome c from mitochondria, which are early markers of apoptotic pathway activation. 	cytochrome c	13228	13240	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:74	CSP-1103 reduced the activation of caspase-3 as well as the cytoplasmic release of cytochrome c from mitochondria, which are early markers of apoptotic pathway activation. 	cytochrome c	13228	13240	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:109	The neuronal apoptosis was evaluated by measuring the level of cytochrome c and cleaved-caspase-3 (immunocytochemistry and WB) at the indicated times. 	cytochrome c	19653	19665	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:109	The neuronal apoptosis was evaluated by measuring the level of cytochrome c and cleaved-caspase-3 (immunocytochemistry and WB) at the indicated times. 	cytochrome c	19653	19665	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:122	The protein lysates (20 g/sample) were processed for Western Blot analysis using the following primary antibodies; polyclonal anti-caspase-3 antibody (1:500, #9662 Cell Signaling, Danvers, MA, USA), monoclonal anti-cytochrome c antibody (1:300, sc13156 Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal anti-p38 Mitogen-Activated Protein Kinase (1:500, #9212 Cell Signaling, Danvers, MA, USA), monoclonal anti-phospho-p38 Mitogen-Activated Protein Kinase (Thr180/Tyr182) antibody (1:500, #4511 Cell Signaling, Danvers, MA, USA), and polyclonal anti-actin antibody (1:1000, #A5060 Sigma Aldrich, St. 	cytochrome c	21904	21916	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:122	The protein lysates (20 g/sample) were processed for Western Blot analysis using the following primary antibodies; polyclonal anti-caspase-3 antibody (1:500, #9662 Cell Signaling, Danvers, MA, USA), monoclonal anti-cytochrome c antibody (1:300, sc13156 Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal anti-p38 Mitogen-Activated Protein Kinase (1:500, #9212 Cell Signaling, Danvers, MA, USA), monoclonal anti-phospho-p38 Mitogen-Activated Protein Kinase (Thr180/Tyr182) antibody (1:500, #4511 Cell Signaling, Danvers, MA, USA), and polyclonal anti-actin antibody (1:1000, #A5060 Sigma Aldrich, St. 	cytochrome c	21904	21916	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5307378_OgerInput.txtOger_out.csv:30	All terminal oxidases, either directly or via soluble cytochrome c, accept electrons from quinones (UQs), which are the most important compounds in the membrane of most prokaryotes, working as lipophilic electron and proton shuttles. 	cytochrome c	5256	5268	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5307378_OgerInput.txtOger_out.csv:30	All terminal oxidases, either directly or via soluble cytochrome c, accept electrons from quinones (UQs), which are the most important compounds in the membrane of most prokaryotes, working as lipophilic electron and proton shuttles. 	cytochrome c	5256	5268	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5307378_OgerInput.txtOger_out.csv:160	The quantity of the enzyme was also assessed by measuring cytochrome c oxidase activity in solubilized membranes, which is independent of the cellular electron transport chain. 	cytochrome c	24559	24571	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5307378_OgerInput.txtOger_out.csv:160	The quantity of the enzyme was also assessed by measuring cytochrome c oxidase activity in solubilized membranes, which is independent of the cellular electron transport chain. 	cytochrome c	24559	24571	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:140	^ With similar background concentrations in control samples, the concentrations of superoxide anion were 1.3 and 0.4 nmol cytochrome c reduced/mg in the animals treated with the tertiary mixture or TCDD alone, respectively. 	cytochrome c	24845	24857	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5363288_OgerInput.txtOger_out.csv:140	^ With similar background concentrations in control samples, the concentrations of superoxide anion were 1.3 and 0.4 nmol cytochrome c reduced/mg in the animals treated with the tertiary mixture or TCDD alone, respectively. 	cytochrome c	24845	24857	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5371394_OgerInput.txtOger_out.csv:100	A diheme cytochrome c_4, Cyc1, has been proposed to be a periplasmic electron shuttle in the iron-oxidizing bacterium M. ferrooxydans. 	cytochrome c	15615	15627	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5371394_OgerInput.txtOger_out.csv:100	A diheme cytochrome c_4, Cyc1, has been proposed to be a periplasmic electron shuttle in the iron-oxidizing bacterium M. ferrooxydans. 	cytochrome c	15615	15627	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:5	The effects of pHK-PAS were correlated with dissociation of endogenous full-length Hexokinase Ii from mitochondria and release of cytochrome c. Of significance, pHK-PAS treatment of noncancerous HEK293 cells resulted in substantially lower cytotoxicity. 	cytochrome c	921	933	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:5	The effects of pHK-PAS were correlated with dissociation of endogenous full-length Hexokinase Ii from mitochondria and release of cytochrome c. Of significance, pHK-PAS treatment of noncancerous HEK293 cells resulted in substantially lower cytotoxicity. 	cytochrome c	921	933	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:21	Moreover, high levels of mitochondria-bound Hexokinase Ii protect cancer cells against death by maintaining the integrity of the Outer Mitochondrial Membrane and inhibiting release of key apoptogenic molecules, such as cytochrome c, from the intermembrane space (,. 	cytochrome c	4388	4400	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:21	Moreover, high levels of mitochondria-bound Hexokinase Ii protect cancer cells against death by maintaining the integrity of the Outer Mitochondrial Membrane and inhibiting release of key apoptogenic molecules, such as cytochrome c, from the intermembrane space (,. 	cytochrome c	4388	4400	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:33	Mouse monoclonal human Hexokinase Ii, VDAC1, cytochrome c, and BETA-actin Abs, as well as horseradish peroxidase-conjugated mouse IgG Ab, were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). 	cytochrome c	6569	6581	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:33	Mouse monoclonal human Hexokinase Ii, VDAC1, cytochrome c, and BETA-actin Abs, as well as horseradish peroxidase-conjugated mouse IgG Ab, were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). 	cytochrome c	6569	6581	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:88	Oxygen Consumption Rate was measured for 20 min to establish a baseline rate, followed by sequential addition of 1.0 M FCCP, an uncoupling agent that induces maximal oxygen consumption by cytochrome c oxidase (complex IV), and a mixture of 1.0 M rotenone and 1.0 M antimycin A, which inhibit complexes I and III, respectively, and effectively shut down mitochondrial respiration. 	cytochrome c	17553	17565	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:88	Oxygen Consumption Rate was measured for 20 min to establish a baseline rate, followed by sequential addition of 1.0 M FCCP, an uncoupling agent that induces maximal oxygen consumption by cytochrome c oxidase (complex IV), and a mixture of 1.0 M rotenone and 1.0 M antimycin A, which inhibit complexes I and III, respectively, and effectively shut down mitochondrial respiration. 	cytochrome c	17553	17565	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:102	Samples (2 g/lane) were electrophoresed on a 10-12% SDS polyacrylamide gel, transferred to a nitrocellulose membrane, and incubated overnight with mouse anti-human Hexokinase Ii, VDAC1, or cytochrome c (1:1000) Abs or anti-BETA-actin Ab (1:2000), followed by incubation for 3 h with horseradish peroxidase-conjugated mouse IgG Ab (1:10,000). 	cytochrome c	19964	19976	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:102	Samples (2 g/lane) were electrophoresed on a 10-12% SDS polyacrylamide gel, transferred to a nitrocellulose membrane, and incubated overnight with mouse anti-human Hexokinase Ii, VDAC1, or cytochrome c (1:1000) Abs or anti-BETA-actin Ab (1:2000), followed by incubation for 3 h with horseradish peroxidase-conjugated mouse IgG Ab (1:10,000). 	cytochrome c	19964	19976	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:198	Depletion of _m by FCCP results in uninhibited electron flow through the mitochondrial respiratory chain, which leads to maximal oxygen consumption by cytochrome c oxidase (complex IV). 	cytochrome c	37192	37204	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:198	Depletion of _m by FCCP results in uninhibited electron flow through the mitochondrial respiratory chain, which leads to maximal oxygen consumption by cytochrome c oxidase (complex IV). 	cytochrome c	37192	37204	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:214	HeLa cells were treated with 50 M pHK-PAS for 24-72 h, and immunoblotting was used to determine the amount of endogenous Hexokinase Ii, Voltage-Dependent Anion Channel, and cytochrome c in mitochondria-enriched and cytosolic fractions at different time points. 	cytochrome c	39799	39811	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:214	HeLa cells were treated with 50 M pHK-PAS for 24-72 h, and immunoblotting was used to determine the amount of endogenous Hexokinase Ii, Voltage-Dependent Anion Channel, and cytochrome c in mitochondria-enriched and cytosolic fractions at different time points. 	cytochrome c	39799	39811	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:216	Similarly, cytochrome c levels in the cytosolic fraction increased with pHK-PAS incubation time. 	cytochrome c	40107	40119	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:216	Similarly, cytochrome c levels in the cytosolic fraction increased with pHK-PAS incubation time. 	cytochrome c	40107	40119	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:218	Taken together, our results demonstrate that pHK-PAS specifically displaces Hexokinase Ii from mitochondria in cancer cells without affecting localization of Voltage-Dependent Anion Channel to the Outer Mitochondrial Membrane, and this disruption of the HKII-VDAC complex triggers release of cytochrome c to the cytosol and apoptosis. 	cytochrome c	40680	40692	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:218	Taken together, our results demonstrate that pHK-PAS specifically displaces Hexokinase Ii from mitochondria in cancer cells without affecting localization of Voltage-Dependent Anion Channel to the Outer Mitochondrial Membrane, and this disruption of the HKII-VDAC complex triggers release of cytochrome c to the cytosol and apoptosis. 	cytochrome c	40680	40692	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:221	However, unlike in HeLa cells, the competitive dissociation of Hexokinase Ii from mitochondria in HEK293 cells was not accompanied by a significant release of cytochrome c to the cytosol. 	cytochrome c	41303	41315	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:221	However, unlike in HeLa cells, the competitive dissociation of Hexokinase Ii from mitochondria in HEK293 cells was not accompanied by a significant release of cytochrome c to the cytosol. 	cytochrome c	41303	41315	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:242	Disruption of the VDAC-HKII interaction leads to _m depolarization, inhibition of mitochondrial respiration and glycolysis, depletion of intracellular ATP levels, release of cytochrome c and, finally, apoptosis. 	cytochrome c	45508	45520	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:242	Disruption of the VDAC-HKII interaction leads to _m depolarization, inhibition of mitochondrial respiration and glycolysis, depletion of intracellular ATP levels, release of cytochrome c and, finally, apoptosis. 	cytochrome c	45508	45520	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:246	Moreover, unlike either the Voltage-Dependent Anion Channel or Bax channels, the VDAC-Bax pore is large enough to allow passage of cytochrome c to the cytosol. 	cytochrome c	46662	46674	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:246	Moreover, unlike either the Voltage-Dependent Anion Channel or Bax channels, the VDAC-Bax pore is large enough to allow passage of cytochrome c to the cytosol. 	cytochrome c	46662	46674	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:259	Dissociation of Hexokinase Ii from mitochondria in noncancerous cells, therefore, does not lead to apoptosis, as illustrated by the lack of cytochrome c release in HEK293 cells. 	cytochrome c	49511	49523	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:259	Dissociation of Hexokinase Ii from mitochondria in noncancerous cells, therefore, does not lead to apoptosis, as illustrated by the lack of cytochrome c release in HEK293 cells. 	cytochrome c	49511	49523	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5388548_OgerInput.txtOger_out.csv:264	Disruption of the HKII-VDAC interaction in cancer cells results in _m depolarization, inhibition of mitochondrial respiration and glycolysis, depletion of intracellular ATP levels, release of cytochrome c, and, finally, apoptosis. 	cytochrome c	50438	50450	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5388548_OgerInput.txtOger_out.csv:264	Disruption of the HKII-VDAC interaction in cancer cells results in _m depolarization, inhibition of mitochondrial respiration and glycolysis, depletion of intracellular ATP levels, release of cytochrome c, and, finally, apoptosis. 	cytochrome c	50438	50450	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:7	ROCK activation phosphorylated Rac1b at Ser71 and increased ROS levels by facilitating the interaction between Rac1b and cytochrome c. Conversely, ROCK inactivation with Y27632 abolished their interaction, concomitant with ROS reduction. 	cytochrome c	986	998	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:7	ROCK activation phosphorylated Rac1b at Ser71 and increased ROS levels by facilitating the interaction between Rac1b and cytochrome c. Conversely, ROCK inactivation with Y27632 abolished their interaction, concomitant with ROS reduction. 	cytochrome c	986	998	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:30	Here, we demonstrated that ROCK could regulate ROS generation by modulating the interaction between Rac1b and cytochrome c. The present screening strategy consisted of two different methods to evaluate the capacity of restoration in senescent HGPS fibroblasts: (i) reducing ROS levels and (ii) increasing cell numbers. 	cytochrome c	4478	4490	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:30	Here, we demonstrated that ROCK could regulate ROS generation by modulating the interaction between Rac1b and cytochrome c. The present screening strategy consisted of two different methods to evaluate the capacity of restoration in senescent HGPS fibroblasts: (i) reducing ROS levels and (ii) increasing cell numbers. 	cytochrome c	4478	4490	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:99	A recent study shows that Rac1 regulates mitochondrial ROS generation via its interaction with cytochrome c (OsbornHeaford et al.,. 	cytochrome c	13557	13569	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:99	A recent study shows that Rac1 regulates mitochondrial ROS generation via its interaction with cytochrome c (OsbornHeaford et al.,. 	cytochrome c	13557	13569	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13730	13742	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13730	13742	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13832	13844	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13832	13844	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13882	13894	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:100	As we had observed that mitochondrial ROS levels were reduced upon Y27632 treatment, we hypothesized that (i) Rac1b would interact with cytochrome c, and (ii) ROCK would regulate ROS levels by modulating the interaction between Rac1b and cytochrome c. We found that Rac1b interacted with cytochrome c and that its interaction was increased by RhoA/ROCK activation but was decreased by cotreatment with Y27632. 	cytochrome c	13882	13894	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:101	The increased association of Rac1b with cytochrome c was expected to increase ROS levels. 	cytochrome c	14044	14056	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:101	The increased association of Rac1b with cytochrome c was expected to increase ROS levels. 	cytochrome c	14044	14056	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:106	These results imply that ROCK regulates mitochondrial function through modulating the interaction between Rac1b and cytochrome c. To further verify whether the ROCK-Rac1b-cytochrome c axis plays an important role in regulating ROS levels, we examined whether Y27632 treatment could decrease ROS generation in Rac1bdeficient cells. 	cytochrome c	14482	14494	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:106	These results imply that ROCK regulates mitochondrial function through modulating the interaction between Rac1b and cytochrome c. To further verify whether the ROCK-Rac1b-cytochrome c axis plays an important role in regulating ROS levels, we examined whether Y27632 treatment could decrease ROS generation in Rac1bdeficient cells. 	cytochrome c	14482	14494	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:106	These results imply that ROCK regulates mitochondrial function through modulating the interaction between Rac1b and cytochrome c. To further verify whether the ROCK-Rac1b-cytochrome c axis plays an important role in regulating ROS levels, we examined whether Y27632 treatment could decrease ROS generation in Rac1bdeficient cells. 	cytochrome c	14537	14549	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:106	These results imply that ROCK regulates mitochondrial function through modulating the interaction between Rac1b and cytochrome c. To further verify whether the ROCK-Rac1b-cytochrome c axis plays an important role in regulating ROS levels, we examined whether Y27632 treatment could decrease ROS generation in Rac1bdeficient cells. 	cytochrome c	14537	14549	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:110	This result implies that the ROSreducing effect of Y27632 is achieved by regulating the ROCK-Rac1b-cytochrome c axis. 	cytochrome c	15037	15049	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:110	This result implies that the ROSreducing effect of Y27632 is achieved by regulating the ROCK-Rac1b-cytochrome c axis. 	cytochrome c	15037	15049	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:113	The heme group of cytochrome c accepts electrons from complex III and transfers them to complex IV (cytochrome c oxidase; COX; Zorov et al.,. 	cytochrome c	15150	15162	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:113	The heme group of cytochrome c accepts electrons from complex III and transfers them to complex IV (cytochrome c oxidase; COX; Zorov et al.,. 	cytochrome c	15150	15162	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:113	The heme group of cytochrome c accepts electrons from complex III and transfers them to complex IV (cytochrome c oxidase; COX; Zorov et al.,. 	cytochrome c	15232	15244	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:113	The heme group of cytochrome c accepts electrons from complex III and transfers them to complex IV (cytochrome c oxidase; COX; Zorov et al.,. 	cytochrome c	15232	15244	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:116	Thus, we examined whether COX activity is regulated by the ROCK-Rac1b-cytochrome c axis. 	cytochrome c	15632	15644	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:116	Thus, we examined whether COX activity is regulated by the ROCK-Rac1b-cytochrome c axis. 	cytochrome c	15632	15644	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:146	Taken together, these data suggest that the amelioration of misshapen nuclei by Y27632 may be achieved by regulating ROCK-Rac1b-cytochrome c axis. 	cytochrome c	19725	19737	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:146	Taken together, these data suggest that the amelioration of misshapen nuclei by Y27632 may be achieved by regulating ROCK-Rac1b-cytochrome c axis. 	cytochrome c	19725	19737	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:151	A previous study has shown that p66Shc triggers mitochondrial ROS generation by oxidizing cytochrome c (Giorgio et al.,. 	cytochrome c	20392	20404	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:151	A previous study has shown that p66Shc triggers mitochondrial ROS generation by oxidizing cytochrome c (Giorgio et al.,. 	cytochrome c	20392	20404	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:152	Similarly, Rac1 produces mitochondrial ROS through directly intercepting electrons from cytochrome c as does p66Shc (OsbornHeaford et al.,. 	cytochrome c	20511	20523	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:152	Similarly, Rac1 produces mitochondrial ROS through directly intercepting electrons from cytochrome c as does p66Shc (OsbornHeaford et al.,. 	cytochrome c	20511	20523	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20717	20729	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20717	20729	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20849	20861	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20849	20861	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20956	20968	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:153	In the current study, we uncovered a novel mechanism in which ROCK regulates mitochondrial ROS generation by modulating the interaction between Rac1b and cytochrome c. RhoA/ROCK activation induced the phosphorylation of Rac1b at Ser 71 and facilitated the interaction between Rac1b and cytochrome c. This interaction could induce the partial reduction in oxygen by intercepting electrons from cytochrome c in a similar manner as p66Shc and Rac1. 	cytochrome c	20956	20968	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:154	On the contrary, ROCK inactivation with Y27632 hampered the interaction between Rac1b and cytochrome c. Taken together, the results from our study reveal the novel roles of ROCK as a binding partner for Rac1b and a regulator of mitochondrial ROS generation. 	cytochrome c	21099	21111	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:154	On the contrary, ROCK inactivation with Y27632 hampered the interaction between Rac1b and cytochrome c. Taken together, the results from our study reveal the novel roles of ROCK as a binding partner for Rac1b and a regulator of mitochondrial ROS generation. 	cytochrome c	21099	21111	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:1	 Specific expression and function of the A-type cytochrome c oxidase under starvation conditions in Pseudomonas aeruginosa. 	cytochrome c	48	60	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:1	 Specific expression and function of the A-type cytochrome c oxidase under starvation conditions in Pseudomonas aeruginosa. 	cytochrome c	48	60	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:2	Pseudomonas aeruginosa has one A-type (caa3) and multiple C-type (cbb3) cytochrome c oxidases as well as two quinol oxidases for aerobic respiration. 	cytochrome c	196	208	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:2	Pseudomonas aeruginosa has one A-type (caa3) and multiple C-type (cbb3) cytochrome c oxidases as well as two quinol oxidases for aerobic respiration. 	cytochrome c	196	208	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:12	The bacterial A-type (aa_3-type) cytochrome c oxidase is a member of the heme-copper oxidase superfamily and is closely related to the mitochondrial terminal oxidase. 	cytochrome c	1948	1960	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:12	The bacterial A-type (aa_3-type) cytochrome c oxidase is a member of the heme-copper oxidase superfamily and is closely related to the mitochondrial terminal oxidase. 	cytochrome c	1948	1960	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:15	Electrons are transferred from cytochrome c to the catalytic center via Cu_A and a low spin heme a, which are located in subunits II and I, respectively. 	cytochrome c	2375	2387	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:15	Electrons are transferred from cytochrome c to the catalytic center via Cu_A and a low spin heme a, which are located in subunits II and I, respectively. 	cytochrome c	2375	2387	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:20	The opportunistic human pathogen Pseudomonas aeruginosa was reported to have at least five terminal oxidases for aerobic respiration, including one A-type and two C-type (cbb_3-1 and cbb_3-2) cytochrome c oxidases, as well as A-type quinol oxidase (bo_3) and cyanide insensitive oxidase (CIO), which is a non-heme-copper quinol oxidase. 	cytochrome c	3201	3213	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:20	The opportunistic human pathogen Pseudomonas aeruginosa was reported to have at least five terminal oxidases for aerobic respiration, including one A-type and two C-type (cbb_3-1 and cbb_3-2) cytochrome c oxidases, as well as A-type quinol oxidase (bo_3) and cyanide insensitive oxidase (CIO), which is a non-heme-copper quinol oxidase. 	cytochrome c	3201	3213	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:23	In the cox gene cluster (PA0105-0108), coxB (PA0105), coxA (PA0106), and coxC (coIII) (PA0108) encode subunits II, I, and III of the A-type cytochrome c oxidase, respectively. 	cytochrome c	3823	3835	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:23	In the cox gene cluster (PA0105-0108), coxB (PA0105), coxA (PA0106), and coxC (coIII) (PA0108) encode subunits II, I, and III of the A-type cytochrome c oxidase, respectively. 	cytochrome c	3823	3835	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:24	The product of the cox genes was reported to be the aa_3 cytochrome c oxidase in previous reports. 	cytochrome c	3916	3928	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:24	The product of the cox genes was reported to be the aa_3 cytochrome c oxidase in previous reports. 	cytochrome c	3916	3928	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:35	In our previous study, we found that a quadruple mutant strain designated as QXAa, which was deficient in the four terminal oxidase gene clusters encoding two C-type cytochrome c oxidases and two quinol oxidases, was unable to grow under aerobic conditions, thereby suggesting that the cox genes were tightly repressed or the gene product was not functional in the mutant. 	cytochrome c	5923	5935	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:35	In our previous study, we found that a quadruple mutant strain designated as QXAa, which was deficient in the four terminal oxidase gene clusters encoding two C-type cytochrome c oxidases and two quinol oxidases, was unable to grow under aerobic conditions, thereby suggesting that the cox genes were tightly repressed or the gene product was not functional in the mutant. 	cytochrome c	5923	5935	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:203	The cytochrome c oxidase activity was not detected by the Nadi assay by the overexpression of the cox genes in the anaerobically grown cells of strain PTO5. 	cytochrome c	30575	30587	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:203	The cytochrome c oxidase activity was not detected by the Nadi assay by the overexpression of the cox genes in the anaerobically grown cells of strain PTO5. 	cytochrome c	30575	30587	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:204	No activity was also observed when the cox genes were overexpressed in the aerobically grown cells of QXCi, which is deficient in the cytochrome c oxidase genes but can grow aerobically by using the CIO quinol oxidase. 	cytochrome c	30862	30874	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:204	No activity was also observed when the cox genes were overexpressed in the aerobically grown cells of QXCi, which is deficient in the cytochrome c oxidase genes but can grow aerobically by using the CIO quinol oxidase. 	cytochrome c	30862	30874	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:218	These results indicate that the poor growth of QXAaS2 was not due to the low cytochrome c oxidase activity. 	cytochrome c	33134	33146	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:218	These results indicate that the poor growth of QXAaS2 was not due to the low cytochrome c oxidase activity. 	cytochrome c	33134	33146	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:236	Thus, the utilization of A-type cytochrome c oxidases only under starvation conditions might be a common feature of several proteobacteria. 	cytochrome c	35581	35593	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:236	Thus, the utilization of A-type cytochrome c oxidases only under starvation conditions might be a common feature of several proteobacteria. 	cytochrome c	35581	35593	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5461723_OgerInput.txtOger_out.csv:60	To complete the oxidation pathway of the SOR reaction products, we searched in the A. copahuensis genome for putative sulfite:acceptor oxidoreductase (SAOR) enzymes using the reported sequence of the molybdopterin binding subunit A of the sulfite:cytochrome c oxidoreductase from Starkeya novella DSM 506 (acc number AAF64400, encoded by sorA gene). 	cytochrome c	12138	12150	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5461723_OgerInput.txtOger_out.csv:60	To complete the oxidation pathway of the SOR reaction products, we searched in the A. copahuensis genome for putative sulfite:acceptor oxidoreductase (SAOR) enzymes using the reported sequence of the molybdopterin binding subunit A of the sulfite:cytochrome c oxidoreductase from Starkeya novella DSM 506 (acc number AAF64400, encoded by sorA gene). 	cytochrome c	12138	12150	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:1	 Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Mutations in CHCHD2 have been identified in some Parkinson's disease cases. 	cytochrome c	111	123	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:1	 Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Mutations in CHCHD2 have been identified in some Parkinson's disease cases. 	cytochrome c	111	123	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:6	CHCHD2 binds to cytochrome c along with a member of the Bax inhibitor-1 superfamily, MICS1, and modulated cell death signalling, suggesting that CHCHD2 dynamically regulates the functions of cytochrome c in both oxidative phosphorylation and cell death in response to mitochondrial stress. 	cytochrome c	891	903	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:6	CHCHD2 binds to cytochrome c along with a member of the Bax inhibitor-1 superfamily, MICS1, and modulated cell death signalling, suggesting that CHCHD2 dynamically regulates the functions of cytochrome c in both oxidative phosphorylation and cell death in response to mitochondrial stress. 	cytochrome c	891	903	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:6	CHCHD2 binds to cytochrome c along with a member of the Bax inhibitor-1 superfamily, MICS1, and modulated cell death signalling, suggesting that CHCHD2 dynamically regulates the functions of cytochrome c in both oxidative phosphorylation and cell death in response to mitochondrial stress. 	cytochrome c	1066	1078	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:6	CHCHD2 binds to cytochrome c along with a member of the Bax inhibitor-1 superfamily, MICS1, and modulated cell death signalling, suggesting that CHCHD2 dynamically regulates the functions of cytochrome c in both oxidative phosphorylation and cell death in response to mitochondrial stress. 	cytochrome c	1066	1078	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:8	Here the authors investigate the physiological and pathological roles of CHCHD2 in Drosophila and mammalian cells, and find that it regulates mitochondrial respiration through stabilizing cytochrome c. Mutations in the CHCHD2 gene cause an autosomal dominant form of late-onset Parkinson's Disease. 	cytochrome c	1414	1426	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:8	Here the authors investigate the physiological and pathological roles of CHCHD2 in Drosophila and mammalian cells, and find that it regulates mitochondrial respiration through stabilizing cytochrome c. Mutations in the CHCHD2 gene cause an autosomal dominant form of late-onset Parkinson's Disease. 	cytochrome c	1414	1426	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:12	A study of yeast CHCHD2 ortholog Mic17 indicated that the loss of Mic17 decreased oxygen consumption and altered activities in respiratory complexes III (ubiquinol-cytochrome c [Cyt c] reductase) and IV (Cyt c oxidase) in Saccharomyces cerevisiae, whereas an oxidative phosphorylation computational expression screen using mouse and human microarray data revealed that CHCHD2 is required for the Oxidative Phosphorylation function in mammalian cells. 	cytochrome c	2419	2431	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:12	A study of yeast CHCHD2 ortholog Mic17 indicated that the loss of Mic17 decreased oxygen consumption and altered activities in respiratory complexes III (ubiquinol-cytochrome c [Cyt c] reductase) and IV (Cyt c oxidase) in Saccharomyces cerevisiae, whereas an oxidative phosphorylation computational expression screen using mouse and human microarray data revealed that CHCHD2 is required for the Oxidative Phosphorylation function in mammalian cells. 	cytochrome c	2419	2431	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:228	For the measurement of the complex III activity, cytochrome c reductase assay buffer (50 mM potassium phosphate buffer pH 7.5, 1 mM n-dodecyl BETA-D-maltoside [DDM], 1 mM KCN, 2 M rotenone, 250 M EDTA, and 1 mg ml^1 BSA, 50 M oxidized cytochrome c) with or without 25 M antimycin A was divided into 100 l aliquots in a microplate and left at RT for 5 min. 	cytochrome c	40996	41008	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:228	For the measurement of the complex III activity, cytochrome c reductase assay buffer (50 mM potassium phosphate buffer pH 7.5, 1 mM n-dodecyl BETA-D-maltoside [DDM], 1 mM KCN, 2 M rotenone, 250 M EDTA, and 1 mg ml^1 BSA, 50 M oxidized cytochrome c) with or without 25 M antimycin A was divided into 100 l aliquots in a microplate and left at RT for 5 min. 	cytochrome c	40996	41008	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:228	For the measurement of the complex III activity, cytochrome c reductase assay buffer (50 mM potassium phosphate buffer pH 7.5, 1 mM n-dodecyl BETA-D-maltoside [DDM], 1 mM KCN, 2 M rotenone, 250 M EDTA, and 1 mg ml^1 BSA, 50 M oxidized cytochrome c) with or without 25 M antimycin A was divided into 100 l aliquots in a microplate and left at RT for 5 min. 	cytochrome c	41182	41194	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:228	For the measurement of the complex III activity, cytochrome c reductase assay buffer (50 mM potassium phosphate buffer pH 7.5, 1 mM n-dodecyl BETA-D-maltoside [DDM], 1 mM KCN, 2 M rotenone, 250 M EDTA, and 1 mg ml^1 BSA, 50 M oxidized cytochrome c) with or without 25 M antimycin A was divided into 100 l aliquots in a microplate and left at RT for 5 min. 	cytochrome c	41182	41194	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:229	The cytochrome c reductase activity was monitored by adding 200 M decylubiquinol, and 0.075 g of mitochondrial samples to the reaction mix and following an increase in absorbance at 550 nm. 	cytochrome c	41307	41319	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:229	The cytochrome c reductase activity was monitored by adding 200 M decylubiquinol, and 0.075 g of mitochondrial samples to the reaction mix and following an increase in absorbance at 550 nm. 	cytochrome c	41307	41319	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:230	For the measurement of the complex IV activity, cytochrome c oxidase buffer (25 mM potassium phosphate pH7.0, 0.45 mM DDM and 100 M reduced cytochrome c) with or without 2 mM KCN was divided into 100 l aliquots in a microplate. 	cytochrome c	41541	41553	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:230	For the measurement of the complex IV activity, cytochrome c oxidase buffer (25 mM potassium phosphate pH7.0, 0.45 mM DDM and 100 M reduced cytochrome c) with or without 2 mM KCN was divided into 100 l aliquots in a microplate. 	cytochrome c	41541	41553	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:230	For the measurement of the complex IV activity, cytochrome c oxidase buffer (25 mM potassium phosphate pH7.0, 0.45 mM DDM and 100 M reduced cytochrome c) with or without 2 mM KCN was divided into 100 l aliquots in a microplate. 	cytochrome c	41633	41645	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:230	For the measurement of the complex IV activity, cytochrome c oxidase buffer (25 mM potassium phosphate pH7.0, 0.45 mM DDM and 100 M reduced cytochrome c) with or without 2 mM KCN was divided into 100 l aliquots in a microplate. 	cytochrome c	41633	41645	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:231	The cytochrome c oxidase activity was monitored by adding 0.1 g of mitochondrial samples to the reaction mix and following a decrease in absorbance at 550 nm. 	cytochrome c	41725	41737	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:231	The cytochrome c oxidase activity was monitored by adding 0.1 g of mitochondrial samples to the reaction mix and following a decrease in absorbance at 550 nm. 	cytochrome c	41725	41737	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5467237_OgerInput.txtOger_out.csv:261	Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat. 	cytochrome c	47024	47036	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5467237_OgerInput.txtOger_out.csv:261	Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat. 	cytochrome c	47024	47036	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:4	We hypothesized that these extracellular non-cytochrome c proteins (ENCP) could contribute to EET, especially with the facilitation of electron mediators. 	cytochrome c	462	474	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:4	We hypothesized that these extracellular non-cytochrome c proteins (ENCP) could contribute to EET, especially with the facilitation of electron mediators. 	cytochrome c	462	474	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:18	The extracellular non-cytochrome c proteins (ENCP) may be generated by secretion or lysis of biofilm cells and play important roles in redox processes, cell protection and other functions. 	cytochrome c	2904	2916	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:18	The extracellular non-cytochrome c proteins (ENCP) may be generated by secretion or lysis of biofilm cells and play important roles in redox processes, cell protection and other functions. 	cytochrome c	2904	2916	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:66	Physiological and molecular tests in this and our previous study demonstrated that the ccmA-mutant of S. decolorationis S12 was deficient in cytochrome c generation and anaerobic growth (Supplementary Figure ). 	cytochrome c	10172	10184	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:66	Physiological and molecular tests in this and our previous study demonstrated that the ccmA-mutant of S. decolorationis S12 was deficient in cytochrome c generation and anaerobic growth (Supplementary Figure ). 	cytochrome c	10172	10184	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:67	To allow planktonic and biofilm cell growth of MT-S12 and WT-S12 strains, MFCs were operated aerobically for the first 24 h after inoculation which showed similar growth of the two strains generating capacity of planktonic MT-S12 and WT-S12 were comparable, indicating that cytochrome c had no significant effects on the aerobic growth and flavin secretion of S. decolorationis S12. 	cytochrome c	10516	10528	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:67	To allow planktonic and biofilm cell growth of MT-S12 and WT-S12 strains, MFCs were operated aerobically for the first 24 h after inoculation which showed similar growth of the two strains generating capacity of planktonic MT-S12 and WT-S12 were comparable, indicating that cytochrome c had no significant effects on the aerobic growth and flavin secretion of S. decolorationis S12. 	cytochrome c	10516	10528	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:70	It is likely that the anaerobic microenvironment within the biofilm prevented the growth of MT-S12 biofilm cells as cytochrome c are needed in Shewanella anaerobic growth. 	cytochrome c	11076	11088	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:70	It is likely that the anaerobic microenvironment within the biofilm prevented the growth of MT-S12 biofilm cells as cytochrome c are needed in Shewanella anaerobic growth. 	cytochrome c	11076	11088	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:77	Electricity generation by WT-S12 started within 3 h upon switch and increased to the maximal value of 56.4 A within 33 h and abiotic controls (Supplementary Figure ) showed no obvious electricity generation, indicating that cytochrome c-deficient MT-S12 lost the electrode respiration capacity. 	cytochrome c	12411	12423	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:77	Electricity generation by WT-S12 started within 3 h upon switch and increased to the maximal value of 56.4 A within 33 h and abiotic controls (Supplementary Figure ) showed no obvious electricity generation, indicating that cytochrome c-deficient MT-S12 lost the electrode respiration capacity. 	cytochrome c	12411	12423	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:78	This is predictable as cytochrome c has been demonstrated to be essential in EET capacity of Shewanella and other reported microbes capable of electrode respiration (;. 	cytochrome c	12505	12517	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:78	This is predictable as cytochrome c has been demonstrated to be essential in EET capacity of Shewanella and other reported microbes capable of electrode respiration (;. 	cytochrome c	12505	12517	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5492636_OgerInput.txtOger_out.csv:123	During previous preliminary genome analysis of M. roseus, three putative terminal oxidoreductases were revealed: two heme-copper cytochrome c oxidases and a quinol oxidase of the bd-type. 	cytochrome c	22578	22590	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5492636_OgerInput.txtOger_out.csv:123	During previous preliminary genome analysis of M. roseus, three putative terminal oxidoreductases were revealed: two heme-copper cytochrome c oxidases and a quinol oxidase of the bd-type. 	cytochrome c	22578	22590	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5492636_OgerInput.txtOger_out.csv:139	Included among those proteins were (i) the catalytic subunit CoxI and the subunit CoxII of the cc(o/b)o_3 cytochrome oxidase, (ii) its redox partner class I soluble cytochrome c_551/c_552 (MROS_0033), two subunits of the alternative complex III, ActC and fused ActDE, encoded in the same cluster with the cc(o/b)o_3 oxidase by MROS_0043 and MROS_0042, respectively, and (iv) the metal ion-binding subunit of copper-transporting ATPase, MROS_1511, proposed to participate in the biogenesis of heme-copper oxidases in M. roseus. 	cytochrome c	26190	26202	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5492636_OgerInput.txtOger_out.csv:139	Included among those proteins were (i) the catalytic subunit CoxI and the subunit CoxII of the cc(o/b)o_3 cytochrome oxidase, (ii) its redox partner class I soluble cytochrome c_551/c_552 (MROS_0033), two subunits of the alternative complex III, ActC and fused ActDE, encoded in the same cluster with the cc(o/b)o_3 oxidase by MROS_0043 and MROS_0042, respectively, and (iv) the metal ion-binding subunit of copper-transporting ATPase, MROS_1511, proposed to participate in the biogenesis of heme-copper oxidases in M. roseus. 	cytochrome c	26190	26202	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5492636_OgerInput.txtOger_out.csv:140	Upregulation at aerobic versus fermentative growth was statistically significant for the following proteins: (i) the catalytic subunit of the Alternative Complex Iii complex, ActB (encoded by MROS_0044), (ii) the NADH-dehydrogenase subunit, NuoG (encoded by MROS_2032), essential to provide the catalytic site for NADH oxidation in respiratory complex I, the SCO1/SenC domain protein encoded by MROS_0039, which is located in the same cluster (MROS_0034-0039) as the cc(o/b)o_3 oxidase genes and could determine the post-translational step in the accumulation of heme-copper oxidase subunits, CoxI and CoxII, (iv) the cytochrome c biogenesis protein F, encoded by MROS_0623 (CcmF). 	cytochrome c	27170	27182	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5492636_OgerInput.txtOger_out.csv:140	Upregulation at aerobic versus fermentative growth was statistically significant for the following proteins: (i) the catalytic subunit of the Alternative Complex Iii complex, ActB (encoded by MROS_0044), (ii) the NADH-dehydrogenase subunit, NuoG (encoded by MROS_2032), essential to provide the catalytic site for NADH oxidation in respiratory complex I, the SCO1/SenC domain protein encoded by MROS_0039, which is located in the same cluster (MROS_0034-0039) as the cc(o/b)o_3 oxidase genes and could determine the post-translational step in the accumulation of heme-copper oxidase subunits, CoxI and CoxII, (iv) the cytochrome c biogenesis protein F, encoded by MROS_0623 (CcmF). 	cytochrome c	27170	27182	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5497933_OgerInput.txtOger_out.csv:19	Approximately 90% of cellular ATP is generated in mitochondria through the OXPHOS pathway, and CYC1 (also referred to cytochrome c1) is a hemecontaining subunit of complex III. 	cytochrome c	3056	3068	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5497933_OgerInput.txtOger_out.csv:19	Approximately 90% of cellular ATP is generated in mitochondria through the OXPHOS pathway, and CYC1 (also referred to cytochrome c1) is a hemecontaining subunit of complex III. 	cytochrome c	3056	3068	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5497933_OgerInput.txtOger_out.csv:159	AbbreviationsCYC1cytochrome c1DCISductal carcinoma in situ ERestrogen receptorGOgene ontologyHER2human epidermal growth factor receptor 2LIlabeling indexOXPHOSoxidative phosphorylationPRprogesterone receptorRPL13Aribosomal protein L13AsiCTRLnegative control siRNA.	cytochrome c	24976	24988	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5497933_OgerInput.txtOger_out.csv:159	AbbreviationsCYC1cytochrome c1DCISductal carcinoma in situ ERestrogen receptorGOgene ontologyHER2human epidermal growth factor receptor 2LIlabeling indexOXPHOSoxidative phosphorylationPRprogesterone receptorRPL13Aribosomal protein L13AsiCTRLnegative control siRNA.	cytochrome c	24976	24988	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5518855_OgerInput.txtOger_out.csv:11	SR48692 induced massive apoptosis, which was related to mitochondrial cytochrome c release and Membrane Potential loss. 	cytochrome c	1152	1164	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5518855_OgerInput.txtOger_out.csv:11	SR48692 induced massive apoptosis, which was related to mitochondrial cytochrome c release and Membrane Potential loss. 	cytochrome c	1152	1164	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5518855_OgerInput.txtOger_out.csv:69	Cells were stained with anti-cytochrome c antibodies. 	cytochrome c	8945	8957	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5518855_OgerInput.txtOger_out.csv:69	Cells were stained with anti-cytochrome c antibodies. 	cytochrome c	8945	8957	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5518855_OgerInput.txtOger_out.csv:198	Increased Mitochondrial Outer Membrane Permeabilisation results in the release of proteins, including cytochrome c, thus initiating a caspase cascade and subsequent cell death (;. 	cytochrome c	27487	27499	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5518855_OgerInput.txtOger_out.csv:198	Increased Mitochondrial Outer Membrane Permeabilisation results in the release of proteins, including cytochrome c, thus initiating a caspase cascade and subsequent cell death (;. 	cytochrome c	27487	27499	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5518855_OgerInput.txtOger_out.csv:200	Our data showed that SR48692 treatment induced cytochrome c release and decline of m. Meanwhile, NTSR1 knockdown also induced significant decline of m. These data indicated that NTSR1 inhibition-induced apoptosis was tightly related to mitochondrial activities. 	cytochrome c	27710	27722	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5518855_OgerInput.txtOger_out.csv:200	Our data showed that SR48692 treatment induced cytochrome c release and decline of m. Meanwhile, NTSR1 knockdown also induced significant decline of m. These data indicated that NTSR1 inhibition-induced apoptosis was tightly related to mitochondrial activities. 	cytochrome c	27710	27722	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:29	The key process of mitochondria-mediated apoptosis is the collapse of mitochondrial membrane potential, which is followed by the translocation of cytochrome c from the mitochondria into the cytosol. 	cytochrome c	4599	4611	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:29	The key process of mitochondria-mediated apoptosis is the collapse of mitochondrial membrane potential, which is followed by the translocation of cytochrome c from the mitochondria into the cytosol. 	cytochrome c	4599	4611	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:128	The release of cytochrome c from the mitochondria to the cytosol is one of the early events that subsequently lead to apoptosis by activation of caspases, including caspase-3. 	cytochrome c	18425	18437	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:128	The release of cytochrome c from the mitochondria to the cytosol is one of the early events that subsequently lead to apoptosis by activation of caspases, including caspase-3. 	cytochrome c	18425	18437	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:129	The release of cytochrome c into cytosol leads to activation of procaspase-9 in the apoptosome and then causes the cleavage of caspase-3. 	cytochrome c	18601	18613	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:129	The release of cytochrome c into cytosol leads to activation of procaspase-9 in the apoptosome and then causes the cleavage of caspase-3. 	cytochrome c	18601	18613	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:137	The mitochondrial pathway of cell death is mediated by Bcl-2 family proteins which disrupt the mitochondria membrane potential and result in release of apoptogenic factors such as cytochrome c, Smac/Diablo, and AIF, into the cytosol. 	cytochrome c	19968	19980	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:137	The mitochondrial pathway of cell death is mediated by Bcl-2 family proteins which disrupt the mitochondria membrane potential and result in release of apoptogenic factors such as cytochrome c, Smac/Diablo, and AIF, into the cytosol. 	cytochrome c	19968	19980	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:139	In this content, we examined the cytochrome c levels in cytosol fractions of cells treated with Se-PPC at doses of 4, 8, and 16 g/mL. 	cytochrome c	20204	20216	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:139	In this content, we examined the cytochrome c levels in cytosol fractions of cells treated with Se-PPC at doses of 4, 8, and 16 g/mL. 	cytochrome c	20204	20216	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:140	The result of western blot showed that the cytosolic cytochrome c protein expression increased markedly in a dose-dependent manner in Se-PPC-treated cells (B). 	cytochrome c	20358	20370	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:140	The result of western blot showed that the cytosolic cytochrome c protein expression increased markedly in a dose-dependent manner in Se-PPC-treated cells (B). 	cytochrome c	20358	20370	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:141	Since release of cytochrome c into the cytosol is usually preceded or accompanied by a loss or disruption of mitochondrial membrane potential and this collapse is an essential step occurring in cells undergoing apoptosis. 	cytochrome c	20482	20494	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:141	Since release of cytochrome c into the cytosol is usually preceded or accompanied by a loss or disruption of mitochondrial membrane potential and this collapse is an essential step occurring in cells undergoing apoptosis. 	cytochrome c	20482	20494	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:28	All of these stimuli result in opening of the mitochondrial permeability transition pore, loss of mitochondrial membrane potential, and release of cytochrome c to activate apoptosome containing Apaf-1, caspase-9, and caspase-3. 	cytochrome c	4958	4970	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:28	All of these stimuli result in opening of the mitochondrial permeability transition pore, loss of mitochondrial membrane potential, and release of cytochrome c to activate apoptosome containing Apaf-1, caspase-9, and caspase-3. 	cytochrome c	4958	4970	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:29	These apoptotic mitochondrial events are regulated by members of B cell lymphoma 2 (Bcl-2) family proteins, in which Bax and Bak trigger cytochrome c release and apoptosis, whereas Bcl2, Bcl-xL and Bcl-w, inhibit apoptosis. 	cytochrome c	5176	5188	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:29	These apoptotic mitochondrial events are regulated by members of B cell lymphoma 2 (Bcl-2) family proteins, in which Bax and Bak trigger cytochrome c release and apoptosis, whereas Bcl2, Bcl-xL and Bcl-w, inhibit apoptosis. 	cytochrome c	5176	5188	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:85	Alpha-mangostin-induced Reactive Oxygen Species generation has also been observed to trigger mitochondria-mediated apoptotic cell death, including increased cytochrome c release and activation of caspase-9/caspase-3 cascade in MDA-MB-231 breast cancer cells. 	cytochrome c	17134	17146	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:85	Alpha-mangostin-induced Reactive Oxygen Species generation has also been observed to trigger mitochondria-mediated apoptotic cell death, including increased cytochrome c release and activation of caspase-9/caspase-3 cascade in MDA-MB-231 breast cancer cells. 	cytochrome c	17134	17146	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5575299_OgerInput.txtOger_out.csv:110	They reported two potential enzymes, cytochrome c reductase (Cgr1) and FAD-binding fumarate reductase (Cgr2), based on the structural and sequence homology analysis for the reduction of digoxin. 	cytochrome c	20747	20759	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5575299_OgerInput.txtOger_out.csv:110	They reported two potential enzymes, cytochrome c reductase (Cgr1) and FAD-binding fumarate reductase (Cgr2), based on the structural and sequence homology analysis for the reduction of digoxin. 	cytochrome c	20747	20759	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5584575_OgerInput.txtOger_out.csv:19	^,  In the model of TNF/galactosamine (TNF/GalN)-induced hepatocyte apoptosis, the sustained C-Jun N-Terminal Kinase activation is critical in modulating the Bcl family members, which are the gatekeepers of mitochondrial outer membrane permeabilization leading to the release of cytochrome c and other apoptogenic proteins. 	cytochrome c	2991	3003	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5584575_OgerInput.txtOger_out.csv:19	^,  In the model of TNF/galactosamine (TNF/GalN)-induced hepatocyte apoptosis, the sustained C-Jun N-Terminal Kinase activation is critical in modulating the Bcl family members, which are the gatekeepers of mitochondrial outer membrane permeabilization leading to the release of cytochrome c and other apoptogenic proteins. 	cytochrome c	2991	3003	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5599026_OgerInput.txtOger_out.csv:63	Complex IV activity was determined by following the oxidation of reduced cytochrome c to decreased absorbance at 550 nm. 	cytochrome c	11220	11232	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5599026_OgerInput.txtOger_out.csv:63	Complex IV activity was determined by following the oxidation of reduced cytochrome c to decreased absorbance at 550 nm. 	cytochrome c	11220	11232	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:288	^ Because Pteridine Reductase-1 enzymes use H_2B as a substrate and also require NADPH for the reaction, the reduction of H_2B to H_4B by Pteridine Reductase-1 is nonenzymatically linked with the reduction of cytochrome c in this assay, which is detected at 550 nm. 	cytochrome c	47766	47778	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5623949_OgerInput.txtOger_out.csv:288	^ Because Pteridine Reductase-1 enzymes use H_2B as a substrate and also require NADPH for the reaction, the reduction of H_2B to H_4B by Pteridine Reductase-1 is nonenzymatically linked with the reduction of cytochrome c in this assay, which is detected at 550 nm. 	cytochrome c	47766	47778	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:291	The final reaction mixture contained the test compound in a range of concentrations and TbPTR1/LmPTR1 (6.0 nM/12.0 nM), H_2B (0.3 M/3.0 M), cytochrome c (100 M/100 M), and NADPH (500 M/500 M). 	cytochrome c	48160	48172	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5623949_OgerInput.txtOger_out.csv:291	The final reaction mixture contained the test compound in a range of concentrations and TbPTR1/LmPTR1 (6.0 nM/12.0 nM), H_2B (0.3 M/3.0 M), cytochrome c (100 M/100 M), and NADPH (500 M/500 M). 	cytochrome c	48160	48172	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5623949_OgerInput.txtOger_out.csv:293	Compound screening was performed by addition of the compound to assay plates (in 100% DMSO), followed by addition of 45 L reaction mix (enzyme, H_2B, and cytochrome c in 20 mM sodium citrate buffer). 	cytochrome c	48451	48463	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5623949_OgerInput.txtOger_out.csv:293	Compound screening was performed by addition of the compound to assay plates (in 100% DMSO), followed by addition of 45 L reaction mix (enzyme, H_2B, and cytochrome c in 20 mM sodium citrate buffer). 	cytochrome c	48451	48463	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:2	Ubiquinol cytochrome c oxidoreductase (bc1 complex) serves as an important electron junction in many respiratory systems. 	cytochrome c	90	102	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:2	Ubiquinol cytochrome c oxidoreductase (bc1 complex) serves as an important electron junction in many respiratory systems. 	cytochrome c	90	102	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:3	It funnels electrons coming from NADH and ubiquinol to cytochrome c, but it is also capable of producing significant amounts of the free radical superoxide. 	cytochrome c	257	269	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:3	It funnels electrons coming from NADH and ubiquinol to cytochrome c, but it is also capable of producing significant amounts of the free radical superoxide. 	cytochrome c	257	269	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:13	Ubiquinol cytochrome c oxidoreductase (bc_1 complex) is an essential enzyme for all mammalian cells. 	cytochrome c	1431	1443	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:13	Ubiquinol cytochrome c oxidoreductase (bc_1 complex) is an essential enzyme for all mammalian cells. 	cytochrome c	1431	1443	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:17	Quinones are lipophilic, mobile electron carrier analogs to the hydrophilic NADH molecule and cytochrome c hemeprotein. 	cytochrome c	2115	2127	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:17	Quinones are lipophilic, mobile electron carrier analogs to the hydrophilic NADH molecule and cytochrome c hemeprotein. 	cytochrome c	2115	2127	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:18	The complex catalyzes the exergonic two-electron oxidation of quinol to the one-electron reduction of cytochrome c while transferring two charge-equivalents across biological membranes. 	cytochrome c	2243	2255	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:18	The complex catalyzes the exergonic two-electron oxidation of quinol to the one-electron reduction of cytochrome c while transferring two charge-equivalents across biological membranes. 	cytochrome c	2243	2255	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:19	The net biochemical reaction is the oxidation of a quinol molecule, reduction of two cytochrome c hemeproteins, release of four chemical protons on the opposite side of charge transfer, and consumption of two matrix protons. 	cytochrome c	2412	2424	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:19	The net biochemical reaction is the oxidation of a quinol molecule, reduction of two cytochrome c hemeproteins, release of four chemical protons on the opposite side of charge transfer, and consumption of two matrix protons. 	cytochrome c	2412	2424	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:22	The first electron is passed down the high potential chain to reduce cytochrome c at this outer surface. 	cytochrome c	2856	2868	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:22	The first electron is passed down the high potential chain to reduce cytochrome c at this outer surface. 	cytochrome c	2856	2868	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:24	Another turnover (ie, a second quinol oxidation at the Q_p site) generates a second reduced cytochrome c molecule and a fully reduced quinol at the Q_n site (matrix side). 	cytochrome c	3188	3200	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:24	Another turnover (ie, a second quinol oxidation at the Q_p site) generates a second reduced cytochrome c molecule and a fully reduced quinol at the Q_n site (matrix side). 	cytochrome c	3188	3200	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:25	In total, two quinol molecules are oxidized to form two reduced cytochrome c molecules and regenerate a quinol molecule at the Q_n site. 	cytochrome c	3332	3344	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:25	In total, two quinol molecules are oxidized to form two reduced cytochrome c molecules and regenerate a quinol molecule at the Q_n site. 	cytochrome c	3332	3344	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:61	Briefly, electrons are added to the complex via ubiquinol (QH_2) oxidation in a two-electron step at the Q_p site and removed via Q reduction at the Q_n site and cytochrome c reduction at the cytochrome c_1 site. 	cytochrome c	8302	8314	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:61	Briefly, electrons are added to the complex via ubiquinol (QH_2) oxidation in a two-electron step at the Q_p site and removed via Q reduction at the Q_n site and cytochrome c reduction at the cytochrome c_1 site. 	cytochrome c	8302	8314	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:61	Briefly, electrons are added to the complex via ubiquinol (QH_2) oxidation in a two-electron step at the Q_p site and removed via Q reduction at the Q_n site and cytochrome c reduction at the cytochrome c_1 site. 	cytochrome c	8332	8344	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:61	Briefly, electrons are added to the complex via ubiquinol (QH_2) oxidation in a two-electron step at the Q_p site and removed via Q reduction at the Q_n site and cytochrome c reduction at the cytochrome c_1 site. 	cytochrome c	8332	8344	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:62	For simplicity, we lump QH_2 oxidation at the Q_p site with cytochrome c reduction at the c_1 site, so electrons enter the bc_1 complex one at a time at the Q_p site. 	cytochrome c	8413	8425	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:62	For simplicity, we lump QH_2 oxidation at the Q_p site with cytochrome c reduction at the c_1 site, so electrons enter the bc_1 complex one at a time at the Q_p site. 	cytochrome c	8413	8425	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:66	We assume the Rieske Iron Sulfur Protein and cytochrome c_1 redox kinetics are not rate limiting under normal turnover conditions. 	cytochrome c	8974	8986	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:66	We assume the Rieske Iron Sulfur Protein and cytochrome c_1 redox kinetics are not rate limiting under normal turnover conditions. 	cytochrome c	8974	8986	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:98	With a steady-state solution for the electronic states known, the steady-state turnover rates for cytochrome c reduction, superoxide production, QH_2 oxidation, and Q reduction can be computed using Eqs. 	cytochrome c	12974	12986	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:98	With a steady-state solution for the electronic states known, the steady-state turnover rates for cytochrome c reduction, superoxide production, QH_2 oxidation, and Q reduction can be computed using Eqs. 	cytochrome c	12974	12986	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:103	The superoxide data consist of rich data sets that report the rate of superoxide production as a function of membrane potential and the effect of antimycin A on both cytochrome c reduction and superoxide production. 	cytochrome c	13492	13504	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:103	The superoxide data consist of rich data sets that report the rate of superoxide production as a function of membrane potential and the effect of antimycin A on both cytochrome c reduction and superoxide production. 	cytochrome c	13492	13504	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:107	In many experiments used to parameterize the model, the Q analogs exhibited a nonenzymatic reaction with cytochrome c that is strongly pH dependent (,. 	cytochrome c	14059	14071	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:107	In many experiments used to parameterize the model, the Q analogs exhibited a nonenzymatic reaction with cytochrome c that is strongly pH dependent (,. 	cytochrome c	14059	14071	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:108	In most articles, the authors indicated that this oxidation rate was subtracted from the measured rate of cytochrome c reduction. 	cytochrome c	14212	14224	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:108	In most articles, the authors indicated that this oxidation rate was subtracted from the measured rate of cytochrome c reduction. 	cytochrome c	14212	14224	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:131	These results show that the model is capable of recapitulating the observed cytochrome c reduction kinetics under a wide variety of experimental conditions. 	cytochrome c	17548	17560	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:131	These results show that the model is capable of recapitulating the observed cytochrome c reduction kinetics under a wide variety of experimental conditions. 	cytochrome c	17548	17560	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:136	Sensitivity analysis identifies the top-10 ranked parameters that are associated with the internal energy states of the enzyme, the rate-limiting step in the catalytic cycle, the antimycin A-inhibition factors, four quinone and cytochrome c binding constants, and parameters related to the experimental design for two data sets. 	cytochrome c	18416	18428	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:136	Sensitivity analysis identifies the top-10 ranked parameters that are associated with the internal energy states of the enzyme, the rate-limiting step in the catalytic cycle, the antimycin A-inhibition factors, four quinone and cytochrome c binding constants, and parameters related to the experimental design for two data sets. 	cytochrome c	18416	18428	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:138	In addition, the values given in  are averages of the nonzero local sensitivity coefficients computed from model outputs (cytochrome c reduction and superoxide production rates) coinciding with the data using Eqs. 	cytochrome c	18830	18842	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:138	In addition, the values given in  are averages of the nonzero local sensitivity coefficients computed from model outputs (cytochrome c reduction and superoxide production rates) coinciding with the data using Eqs. 	cytochrome c	18830	18842	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:147	The model reproduces the cytochrome c reduction and corresponding superoxide production rates for various pharmacological manipulations. 	cytochrome c	19993	20005	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:147	The model reproduces the cytochrome c reduction and corresponding superoxide production rates for various pharmacological manipulations. 	cytochrome c	19993	20005	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:148	Under the control conditions, the phospholipid vesicles reconstituted with bc_1 complex exhibited moderate cytochrome c reduction rates with elevated superoxide production rates. 	cytochrome c	20212	20224	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:148	Under the control conditions, the phospholipid vesicles reconstituted with bc_1 complex exhibited moderate cytochrome c reduction rates with elevated superoxide production rates. 	cytochrome c	20212	20224	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:150	With the addition of FCCP, both the membrane potential and pH gradient are abolished, and the rate of cytochrome c reduction significantly increases whereas the rate of superoxide production dramatically falls to the minimum level. 	cytochrome c	20475	20487	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:150	With the addition of FCCP, both the membrane potential and pH gradient are abolished, and the rate of cytochrome c reduction significantly increases whereas the rate of superoxide production dramatically falls to the minimum level. 	cytochrome c	20475	20487	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:151	When nigericin is present, the pH gradient is converted to a membrane potential that leads to more superoxide production with a negligible effect on cytochrome c reduction relative to the control. 	cytochrome c	20754	20766	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:151	When nigericin is present, the pH gradient is converted to a membrane potential that leads to more superoxide production with a negligible effect on cytochrome c reduction relative to the control. 	cytochrome c	20754	20766	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:153	This leads to a significant stimulation of cytochrome c reduction, and the superoxide production rate collapses to values similar to the FCCP condition. 	cytochrome c	20915	20927	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:153	This leads to a significant stimulation of cytochrome c reduction, and the superoxide production rate collapses to values similar to the FCCP condition. 	cytochrome c	20915	20927	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:155	The cytochrome c reduction rate falls to levels about twice that of the superoxide production. 	cytochrome c	21153	21165	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:155	The cytochrome c reduction rate falls to levels about twice that of the superoxide production. 	cytochrome c	21153	21165	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:156	This is due to the bypass reaction whereby the first electron from QH_2 reduces cytochrome c, the second electron reduces oxygen to produce superoxide (as shown in ), and then the superoxide reduces cytochrome c. In addition, the model recapitulates the exponential dependency on membrane potential for superoxide production rather well. 	cytochrome c	21324	21336	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:156	This is due to the bypass reaction whereby the first electron from QH_2 reduces cytochrome c, the second electron reduces oxygen to produce superoxide (as shown in ), and then the superoxide reduces cytochrome c. In addition, the model recapitulates the exponential dependency on membrane potential for superoxide production rather well. 	cytochrome c	21324	21336	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:156	This is due to the bypass reaction whereby the first electron from QH_2 reduces cytochrome c, the second electron reduces oxygen to produce superoxide (as shown in ), and then the superoxide reduces cytochrome c. In addition, the model recapitulates the exponential dependency on membrane potential for superoxide production rather well. 	cytochrome c	21443	21455	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:156	This is due to the bypass reaction whereby the first electron from QH_2 reduces cytochrome c, the second electron reduces oxygen to produce superoxide (as shown in ), and then the superoxide reduces cytochrome c. In addition, the model recapitulates the exponential dependency on membrane potential for superoxide production rather well. 	cytochrome c	21443	21455	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:197	These net rates are determined by several conditions: 1) increased levels of reduced cytochrome c; 2) the Q and QH_2 dissociation constants at the Q_p site; 3) superoxide scavenging by Q; and 4) antimycin A-dependent effects of the rate constants at the Q_p site, as discussed in the paragraph above. 	cytochrome c	26619	26631	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:197	These net rates are determined by several conditions: 1) increased levels of reduced cytochrome c; 2) the Q and QH_2 dissociation constants at the Q_p site; 3) superoxide scavenging by Q; and 4) antimycin A-dependent effects of the rate constants at the Q_p site, as discussed in the paragraph above. 	cytochrome c	26619	26631	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:200	For condition 1, we found peak superoxide production rates near a 30% oxidized Q pool when cytochrome c was only 5% or 20% reduced. 	cytochrome c	27185	27197	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:200	For condition 1, we found peak superoxide production rates near a 30% oxidized Q pool when cytochrome c was only 5% or 20% reduced. 	cytochrome c	27185	27197	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:201	But it is unlikely that these levels of reduced cytochrome c are produced in either study. 	cytochrome c	27274	27286	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:201	But it is unlikely that these levels of reduced cytochrome c are produced in either study. 	cytochrome c	27274	27286	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:202	In the presence of antimycin A, cytochrome c oxidase keeps cytochrome c completely oxidized. 	cytochrome c	27349	27361	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:202	In the presence of antimycin A, cytochrome c oxidase keeps cytochrome c completely oxidized. 	cytochrome c	27349	27361	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:202	In the presence of antimycin A, cytochrome c oxidase keeps cytochrome c completely oxidized. 	cytochrome c	27376	27388	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:202	In the presence of antimycin A, cytochrome c oxidase keeps cytochrome c completely oxidized. 	cytochrome c	27376	27388	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:207	The ability of antimycin A to stimulate cytochrome c reduction by the bc_1 complex is compelling evidence for cross-monomer electron equilibration. 	cytochrome c	28028	28040	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:207	The ability of antimycin A to stimulate cytochrome c reduction by the bc_1 complex is compelling evidence for cross-monomer electron equilibration. 	cytochrome c	28028	28040	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:211	However, when only a single antimycin A molecule is bound to the dimer, cytochrome c reduction is stimulated. 	cytochrome c	28631	28643	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:211	However, when only a single antimycin A molecule is bound to the dimer, cytochrome c reduction is stimulated. 	cytochrome c	28631	28643	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:216	But when a single antimycin A molecule is bound to the dimer at one of the Q_n sites, both Q_p sites become operational and the rate of cytochrome c reduction is increased by a factor of 2. 	cytochrome c	29131	29143	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:216	But when a single antimycin A molecule is bound to the dimer at one of the Q_n sites, both Q_p sites become operational and the rate of cytochrome c reduction is increased by a factor of 2. 	cytochrome c	29131	29143	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:218	This leads to an overall increase in the maximal rate of cytochrome c reduction by a factor of 1.15 in the heterogeneously inhibited population of bc_1 complexes. 	cytochrome c	29408	29420	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:218	This leads to an overall increase in the maximal rate of cytochrome c reduction by a factor of 1.15 in the heterogeneously inhibited population of bc_1 complexes. 	cytochrome c	29408	29420	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:240	For the Q_n site, Wikstrm derives values for the both QH_2 and Q binding constants with QH_2 binding 100-fold tighter than Q. Using these results, we can derive a See, Right Column Panels of values that leads to tenable cytochrome c reduction and superoxide production rates shown in. 	cytochrome c	32961	32973	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:240	For the Q_n site, Wikstrm derives values for the both QH_2 and Q binding constants with QH_2 binding 100-fold tighter than Q. Using these results, we can derive a See, Right Column Panels of values that leads to tenable cytochrome c reduction and superoxide production rates shown in. 	cytochrome c	32961	32973	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:241	The bell-shaped relationship between the cytochrome c reduction rate and Q-pool redox state and the exponential dependency of superoxide production rate on membrane potential is similar to our prior simulations. 	cytochrome c	33067	33079	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:241	The bell-shaped relationship between the cytochrome c reduction rate and Q-pool redox state and the exponential dependency of superoxide production rate on membrane potential is similar to our prior simulations. 	cytochrome c	33067	33079	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:243	This phenomenon is characterized by the possibility of two free radical production rates at a given rate of cytochrome c reduction. 	cytochrome c	33468	33480	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:243	This phenomenon is characterized by the possibility of two free radical production rates at a given rate of cytochrome c reduction. 	cytochrome c	33468	33480	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:246	Some other notable differences between our previous simulations and the current ones are the overall shapes of the cytochrome c reduction and superoxide production rates as a function of membrane potential and Q-pool redox state, maximum rates of superoxide production, and the enzyme distribution surfaces. 	cytochrome c	33899	33911	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:246	Some other notable differences between our previous simulations and the current ones are the overall shapes of the cytochrome c reduction and superoxide production rates as a function of membrane potential and Q-pool redox state, maximum rates of superoxide production, and the enzyme distribution surfaces. 	cytochrome c	33899	33911	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:247	For cytochrome c reduction, the maximum rate occurs when the Q pool is 90% reduced and the membrane potential is low. 	cytochrome c	34096	34108	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:247	For cytochrome c reduction, the maximum rate occurs when the Q pool is 90% reduced and the membrane potential is low. 	cytochrome c	34096	34108	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:248	But as the membrane potential increases, the maximum rate of cytochrome c reduction occurs when the Q-pool redox state is closer to 65% reduced. 	cytochrome c	34271	34283	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:248	But as the membrane potential increases, the maximum rate of cytochrome c reduction occurs when the Q-pool redox state is closer to 65% reduced. 	cytochrome c	34271	34283	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:256	During cytochrome c reduction, the one-, two-, and three-electron reduced states are the most significant states (see  and. 	cytochrome c	35282	35294	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:256	During cytochrome c reduction, the one-, two-, and three-electron reduced states are the most significant states (see  and. 	cytochrome c	35282	35294	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:263	The bell-shaped relationship between cytochrome c reduction and the Q-pool redox state makes either possibility feasible (see. 	cytochrome c	36314	36326	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:263	The bell-shaped relationship between cytochrome c reduction and the Q-pool redox state makes either possibility feasible (see. 	cytochrome c	36314	36326	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:270	They both report the rate of oxygen consumption (stoichiometrically linked to cytochrome c reduction), membrane potential, pH, and redox state of the cytochrome c pool. 	cytochrome c	37256	37268	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:270	They both report the rate of oxygen consumption (stoichiometrically linked to cytochrome c reduction), membrane potential, pH, and redox state of the cytochrome c pool. 	cytochrome c	37256	37268	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:270	They both report the rate of oxygen consumption (stoichiometrically linked to cytochrome c reduction), membrane potential, pH, and redox state of the cytochrome c pool. 	cytochrome c	37328	37340	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:270	They both report the rate of oxygen consumption (stoichiometrically linked to cytochrome c reduction), membrane potential, pH, and redox state of the cytochrome c pool. 	cytochrome c	37328	37340	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:274	shows model simulations using these data sets as fixed inputs for the model (cytochrome c redox state, membrane potential, and pH) while solving for the Q-pool redox state as a variable for each value of the bc_1 content to match the reported oxygen consumption rates (proportional to the turnover of the bc_1 complex). 	cytochrome c	37742	37754	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:274	shows model simulations using these data sets as fixed inputs for the model (cytochrome c redox state, membrane potential, and pH) while solving for the Q-pool redox state as a variable for each value of the bc_1 content to match the reported oxygen consumption rates (proportional to the turnover of the bc_1 complex). 	cytochrome c	37742	37754	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:242	The reductase domain of NOS catalyses the reduction of cytochrome c and other redoxactive dyes [345]. 	cytochrome c	31821	31833	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5650666_OgerInput.txtOger_out.csv:242	The reductase domain of NOS catalyses the reduction of cytochrome c and other redoxactive dyes [345]. 	cytochrome c	31821	31833	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:26	The cytochrome c oxidase (CcoNOQP) is of the cbb_3 type, often found in microaerophiles, and has a very high oxygen affinity (K _d  40 nM) that may allow growth at lower oxygen levels than the alternative bdlike (CioAB or CydAB) quinol oxidase (K _d  8 M; Jackson et al.,. 	cytochrome c	4302	4314	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:26	The cytochrome c oxidase (CcoNOQP) is of the cbb_3 type, often found in microaerophiles, and has a very high oxygen affinity (K _d  40 nM) that may allow growth at lower oxygen levels than the alternative bdlike (CioAB or CydAB) quinol oxidase (K _d  8 M; Jackson et al.,. 	cytochrome c	4302	4314	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:32	What is clear is that C. jejuni is not deficient in oxidative stress defence enzymes (reviewed by Flint et al., ) with most strains possessing catalase, superoxide dismutase, three cytoplasmic peroxiredoxins (AhpC, Tpx and Bcp), two cytoplasmic methionine sulphoxide reductases, two periplasmic cytochrome c peroxidases, a desulforuberythrin and several hemerythrins (Parkhill et al., ; Flint et al.,. 	cytochrome c	6035	6047	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:32	What is clear is that C. jejuni is not deficient in oxidative stress defence enzymes (reviewed by Flint et al., ) with most strains possessing catalase, superoxide dismutase, three cytoplasmic peroxiredoxins (AhpC, Tpx and Bcp), two cytoplasmic methionine sulphoxide reductases, two periplasmic cytochrome c peroxidases, a desulforuberythrin and several hemerythrins (Parkhill et al., ; Flint et al.,. 	cytochrome c	6035	6047	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:124	At least three soluble periplasmic cytochromes c have been shown to have a role in the transfer of electrons between the cytochrome bc_1 complex and the cbb_3type cytochrome c oxidase (Liu and Kelly, ); these are CccA (Cj1153), CccB (Cj1020) and CccC (Cj0037). 	cytochrome c	24604	24616	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:124	At least three soluble periplasmic cytochromes c have been shown to have a role in the transfer of electrons between the cytochrome bc_1 complex and the cbb_3type cytochrome c oxidase (Liu and Kelly, ); these are CccA (Cj1153), CccB (Cj1020) and CccC (Cj0037). 	cytochrome c	24604	24616	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:128	In contrast, cj0037c (cccC) was strongly downregulated (greater than fivefold) and the CccC protein was correspondingly 23.5fold more abundant at 150% versus 40% aerobiosis (Supporting Information Table S2), suggesting a specific oxygenlinked role, perhaps as the preferred electron donor to the cytochrome c oxidase (Liu and Kelly,. 	cytochrome c	25500	25512	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:128	In contrast, cj0037c (cccC) was strongly downregulated (greater than fivefold) and the CccC protein was correspondingly 23.5fold more abundant at 150% versus 40% aerobiosis (Supporting Information Table S2), suggesting a specific oxygenlinked role, perhaps as the preferred electron donor to the cytochrome c oxidase (Liu and Kelly,. 	cytochrome c	25500	25512	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:130	The ccoP gene of the cbb_3type cytochrome c oxidase (CcoNOQP) was the only gene of this complex that showed an expression change during the transition to low oxygen (Supporting Information Table S1), but CcoP and CcoO were only slightly (1.6 and 1.9fold respectively) more abundant at 40% aerobiosis (Supporting Information Table S2). 	cytochrome c	25944	25956	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:130	The ccoP gene of the cbb_3type cytochrome c oxidase (CcoNOQP) was the only gene of this complex that showed an expression change during the transition to low oxygen (Supporting Information Table S1), but CcoP and CcoO were only slightly (1.6 and 1.9fold respectively) more abundant at 40% aerobiosis (Supporting Information Table S2). 	cytochrome c	25944	25956	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:131	Measurements of cytochrome c oxidase activity confirmed there was no significant difference in cells grown at the high and low aerobiosis conditions (Supporting Information Fig S3F). 	cytochrome c	26264	26276	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:131	Measurements of cytochrome c oxidase activity confirmed there was no significant difference in cells grown at the high and low aerobiosis conditions (Supporting Information Fig S3F). 	cytochrome c	26264	26276	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:134	Apart from FrdABC, these enzymes all have integral cytochrome c electron transferring or catalytic subunits. 	cytochrome c	27438	27450	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:134	Apart from FrdABC, these enzymes all have integral cytochrome c electron transferring or catalytic subunits. 	cytochrome c	27438	27450	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:136	Interestingly, three enzymes of haem biosynthesis, HemA, HemL and HemN, and the cytochrome c synthase CcsBA (Cj1013; Liu and Kelly, ) were 2.1fold, 1.8fold, fourfold and 1.8fold higher at 40% aerobiosis respectively (Supporting Information Table S2), in keeping with an extra demand for cytochrome c biogenesis under these conditions. 	cytochrome c	27777	27789	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:136	Interestingly, three enzymes of haem biosynthesis, HemA, HemL and HemN, and the cytochrome c synthase CcsBA (Cj1013; Liu and Kelly, ) were 2.1fold, 1.8fold, fourfold and 1.8fold higher at 40% aerobiosis respectively (Supporting Information Table S2), in keeping with an extra demand for cytochrome c biogenesis under these conditions. 	cytochrome c	27777	27789	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:136	Interestingly, three enzymes of haem biosynthesis, HemA, HemL and HemN, and the cytochrome c synthase CcsBA (Cj1013; Liu and Kelly, ) were 2.1fold, 1.8fold, fourfold and 1.8fold higher at 40% aerobiosis respectively (Supporting Information Table S2), in keeping with an extra demand for cytochrome c biogenesis under these conditions. 	cytochrome c	27984	27996	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:136	Interestingly, three enzymes of haem biosynthesis, HemA, HemL and HemN, and the cytochrome c synthase CcsBA (Cj1013; Liu and Kelly, ) were 2.1fold, 1.8fold, fourfold and 1.8fold higher at 40% aerobiosis respectively (Supporting Information Table S2), in keeping with an extra demand for cytochrome c biogenesis under these conditions. 	cytochrome c	27984	27996	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:198	Campylobacter jejuni encodes two periplasmic dihaem cytochrome c peroxidases (Cj0358 and Cj0020 in NCTC11168). 	cytochrome c	42864	42876	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:198	Campylobacter jejuni encodes two periplasmic dihaem cytochrome c peroxidases (Cj0358 and Cj0020 in NCTC11168). 	cytochrome c	42864	42876	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5656828_OgerInput.txtOger_out.csv:266	Finally, unlike the cytoplasmic peroxidatic enzymes discussed above, the regulatory behaviour of the two periplasmic cytochrome c peroxidases (CCPs) in C. jejuni is clearly distinct, with cj0358 gene expression and Cj0358 protein abundance being increased at low aerobiosis but cj0020c unchanged. 	cytochrome c	55853	55865	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5656828_OgerInput.txtOger_out.csv:266	Finally, unlike the cytoplasmic peroxidatic enzymes discussed above, the regulatory behaviour of the two periplasmic cytochrome c peroxidases (CCPs) in C. jejuni is clearly distinct, with cj0358 gene expression and Cj0358 protein abundance being increased at low aerobiosis but cj0020c unchanged. 	cytochrome c	55853	55865	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5753153_OgerInput.txtOger_out.csv:176	manifest activation of antioxidant enzymes: catalases, cytochrome c peroxidase, thioredoxin, and superoxide dismutases, and a metabolic shift to the pentose phosphate pathway, characterized by increased NADPH production in the cytoplasm, as an electron source for the glutathione peroxidase system, which points to restoration of the cellular redox homeostasis. 	cytochrome c	33069	33081	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5753153_OgerInput.txtOger_out.csv:176	manifest activation of antioxidant enzymes: catalases, cytochrome c peroxidase, thioredoxin, and superoxide dismutases, and a metabolic shift to the pentose phosphate pathway, characterized by increased NADPH production in the cytoplasm, as an electron source for the glutathione peroxidase system, which points to restoration of the cellular redox homeostasis. 	cytochrome c	33069	33081	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5779948_OgerInput.txtOger_out.csv:63	After blocking with 5% non-fat dry milk in TBS with Tween-20 buffer, blots were incubated with primary monoclonal antibodies at 4C overnight: Rabbit anti-ALPHA-SYN (ab138501; 1:500; Abcam, Cambridge, MA, USA), rabbit anti-P-Ser129 ALPHA-SYN (ab51253; 1:500; Abcam), rabbit anti-Bcl-2 (ab32124; 1:1,000; Abcam), rabbit anti-Bax (ab32503; 1:1,000; Abcam), rabbit anti-Cyt-c (ab133504; 1:1,000; Abcam), anti-GAPDH (A01622-40; 1:3,000; GenScript, Nanjing, China) and anti-cytochrome c oxidase (COX IV; 1:1,000, sc-376731; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), then incubated with goat horseradish peroxidase-conjugated corresponding secondary antibodies (ab6721 and ab6789; 1:3,000; Abcam) at room temperature for 1 h. Proteins were detected using an enhanced chemiluminescence plus kit (Pierce; Thermo Fisher Scientific, Inc.) 	cytochrome c	10188	10200	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5779948_OgerInput.txtOger_out.csv:63	After blocking with 5% non-fat dry milk in TBS with Tween-20 buffer, blots were incubated with primary monoclonal antibodies at 4C overnight: Rabbit anti-ALPHA-SYN (ab138501; 1:500; Abcam, Cambridge, MA, USA), rabbit anti-P-Ser129 ALPHA-SYN (ab51253; 1:500; Abcam), rabbit anti-Bcl-2 (ab32124; 1:1,000; Abcam), rabbit anti-Bax (ab32503; 1:1,000; Abcam), rabbit anti-Cyt-c (ab133504; 1:1,000; Abcam), anti-GAPDH (A01622-40; 1:3,000; GenScript, Nanjing, China) and anti-cytochrome c oxidase (COX IV; 1:1,000, sc-376731; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), then incubated with goat horseradish peroxidase-conjugated corresponding secondary antibodies (ab6721 and ab6789; 1:3,000; Abcam) at room temperature for 1 h. Proteins were detected using an enhanced chemiluminescence plus kit (Pierce; Thermo Fisher Scientific, Inc.) 	cytochrome c	10188	10200	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5823870_OgerInput.txtOger_out.csv:14	Despite its beneficial role in preventing oxidative stress, H_2S can become toxic to both mitochondria and bacterial cells, primarily because it blocks aerobic respiration through inhibition of the cytochrome c oxidase^-. 	cytochrome c	2349	2361	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5823870_OgerInput.txtOger_out.csv:14	Despite its beneficial role in preventing oxidative stress, H_2S can become toxic to both mitochondria and bacterial cells, primarily because it blocks aerobic respiration through inhibition of the cytochrome c oxidase^-. 	cytochrome c	2349	2361	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5823870_OgerInput.txtOger_out.csv:49	Given that H_2S competes with O_2 for cytochrome c oxidase binding, we decided to investigate the role of Blh as a sulfide oxidation enzyme, particularly when O_2 becomes limited to the cells. 	cytochrome c	8553	8565	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5823870_OgerInput.txtOger_out.csv:49	Given that H_2S competes with O_2 for cytochrome c oxidase binding, we decided to investigate the role of Blh as a sulfide oxidation enzyme, particularly when O_2 becomes limited to the cells. 	cytochrome c	8553	8565	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5833777_OgerInput.txtOger_out.csv:9	It also induced mitochondrial apoptosis by increasing the expression of Bax, caspase-9, and poly(ADP-ribose) polymerase and mitochondrial membrane potential loss and leaks of cytochrome c (Cyt C) from mitochondria in MCF-7 cells and decreasing the expression of mitochondrial Bcl-2. 	cytochrome c	1168	1180	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5833777_OgerInput.txtOger_out.csv:9	It also induced mitochondrial apoptosis by increasing the expression of Bax, caspase-9, and poly(ADP-ribose) polymerase and mitochondrial membrane potential loss and leaks of cytochrome c (Cyt C) from mitochondria in MCF-7 cells and decreasing the expression of mitochondrial Bcl-2. 	cytochrome c	1168	1180	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5880829_OgerInput.txtOger_out.csv:8	The cytoplasm around the vacuoles was immunopositive for cytochrome c, tom 20, and SOD-1, suggesting that these vacuoles might occur within mitochondria. 	cytochrome c	738	750	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5880829_OgerInput.txtOger_out.csv:8	The cytoplasm around the vacuoles was immunopositive for cytochrome c, tom 20, and SOD-1, suggesting that these vacuoles might occur within mitochondria. 	cytochrome c	738	750	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5880829_OgerInput.txtOger_out.csv:33	Immunohistochemistry was performed using the following primary antibodies: anti-slow myosin (clone NOQ7.5.4D; 1:4,000; Sigma-Aldrich, Tokyo, Japan), anti-canine fast myosin (rabbit polyclonal; 1:100; Sigma-Aldrich), anti-nestin (rabbit polyclonal; 1:20; Immuno-Biological Laboratories, Fujioka, Japan), anti-myogenin (clone F5D; 1:50; Dako, Tokyo, Japan), anti-cytochrome c (clone A-8; 1:200; Santa Cruz, Dallas, TX, U.S.A.	cytochrome c	3986	3998	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5880829_OgerInput.txtOger_out.csv:33	Immunohistochemistry was performed using the following primary antibodies: anti-slow myosin (clone NOQ7.5.4D; 1:4,000; Sigma-Aldrich, Tokyo, Japan), anti-canine fast myosin (rabbit polyclonal; 1:100; Sigma-Aldrich), anti-nestin (rabbit polyclonal; 1:20; Immuno-Biological Laboratories, Fujioka, Japan), anti-myogenin (clone F5D; 1:50; Dako, Tokyo, Japan), anti-cytochrome c (clone A-8; 1:200; Santa Cruz, Dallas, TX, U.S.A.	cytochrome c	3986	3998	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5880829_OgerInput.txtOger_out.csv:58	The cytoplasm around the vacuoles was immunopositive for cytochrome c, tom 20 (b) and SOD-1 (c). 	cytochrome c	6186	6198	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5880829_OgerInput.txtOger_out.csv:58	The cytoplasm around the vacuoles was immunopositive for cytochrome c, tom 20 (b) and SOD-1 (c). 	cytochrome c	6186	6198	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5880829_OgerInput.txtOger_out.csv:59	Immunohistochemistry for cytochrome c (a), tom 20 (b) and SOD-1 (c). 	cytochrome c	6251	6263	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5880829_OgerInput.txtOger_out.csv:59	Immunohistochemistry for cytochrome c (a), tom 20 (b) and SOD-1 (c). 	cytochrome c	6251	6263	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5880829_OgerInput.txtOger_out.csv:96	In the present Shiba case, the cytoplasm around the vacuoles was immunopositive for mitochondrial markers such as cytochrome c, tom 20, and SOD-1. 	cytochrome c	11364	11376	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5880829_OgerInput.txtOger_out.csv:96	In the present Shiba case, the cytoplasm around the vacuoles was immunopositive for mitochondrial markers such as cytochrome c, tom 20, and SOD-1. 	cytochrome c	11364	11376	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5896948_OgerInput.txtOger_out.csv:1	 Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate. 	cytochrome c	70	82	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5896948_OgerInput.txtOger_out.csv:1	 Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate. 	cytochrome c	70	82	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5896948_OgerInput.txtOger_out.csv:4	To actively target lung cancer cells, we have developed a conjugate of the apoptosis inducing protein cytochrome c with transferrin because the transferrin receptor is overexpressed by many rapidly dividing cancer cells. 	cytochrome c	390	402	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5896948_OgerInput.txtOger_out.csv:4	To actively target lung cancer cells, we have developed a conjugate of the apoptosis inducing protein cytochrome c with transferrin because the transferrin receptor is overexpressed by many rapidly dividing cancer cells. 	cytochrome c	390	402	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5896948_OgerInput.txtOger_out.csv:6	Confocal results demonstrated the cellular uptake of the cytochrome c-transferrin conjugate by transferrin receptor overexpressing A549 lung cancer cells. 	cytochrome c	743	755	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5896948_OgerInput.txtOger_out.csv:6	Confocal results demonstrated the cellular uptake of the cytochrome c-transferrin conjugate by transferrin receptor overexpressing A549 lung cancer cells. 	cytochrome c	743	755	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:4	This is the case for the alternative complex III, a quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	437	449	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:4	This is the case for the alternative complex III, a quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	437	449	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:16	The oxidation of quinol with subsequent reduction of cytochrome c seemed until 1999 to evade the paradigm of diversified respiratory chains in prokaryotes. 	cytochrome c	2407	2419	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:16	The oxidation of quinol with subsequent reduction of cytochrome c seemed until 1999 to evade the paradigm of diversified respiratory chains in prokaryotes. 	cytochrome c	2407	2419	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:18	This notion changed with the identification of alternative complex III, a quinol:cytochrome c/high potential iron-sulfur protein oxidoreductase that was identified in Rhodothermus marinus^. 	cytochrome c	2698	2710	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:18	This notion changed with the identification of alternative complex III, a quinol:cytochrome c/high potential iron-sulfur protein oxidoreductase that was identified in Rhodothermus marinus^. 	cytochrome c	2698	2710	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:22	In addition to reducing periplasmatic proteins, such as HiPIP^ and soluble cytochrome c^, Alternative Complex Iii can directly transfer electrons from quinol to the caa_3 terminal oxidase without the intervention of any soluble electron carrier^. 	cytochrome c	3308	3320	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:22	In addition to reducing periplasmatic proteins, such as HiPIP^ and soluble cytochrome c^, Alternative Complex Iii can directly transfer electrons from quinol to the caa_3 terminal oxidase without the intervention of any soluble electron carrier^. 	cytochrome c	3308	3320	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:54	ActA is a pentaheme cytochrome c, anchored to the membrane by an N-terminal Transmembrane Helices (Supplementary Fig. 	cytochrome c	8426	8438	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:54	ActA is a pentaheme cytochrome c, anchored to the membrane by an N-terminal Transmembrane Helices (Supplementary Fig. 	cytochrome c	8426	8438	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:68	ActE is a monoheme cytochrome c, located on the top of ActA. 	cytochrome c	10287	10299	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:68	ActE is a monoheme cytochrome c, located on the top of ActA. 	cytochrome c	10287	10299	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:111	ACIII is a quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	17071	17083	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:111	ACIII is a quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	17071	17083	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5928083_OgerInput.txtOger_out.csv:129	Our study provides insights into the catalytic mechanism of a type of quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	20320	20332	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5928083_OgerInput.txtOger_out.csv:129	Our study provides insights into the catalytic mechanism of a type of quinol:cytochrome c/HiPIP oxidoreductase. 	cytochrome c	20320	20332	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5939895_OgerInput.txtOger_out.csv:8	Cyanide is a powerful toxic chemical that shows high affinity for iron and other metals, blocking the function of different metalloproteins like the cytochrome c oxidase involved in the cellular respiratory process (Solomonson ; Jnemann ; Gupta, Balomajumder and Agarwal ; Luque-Almagro, Moreno-Vivin and Roldn. 	cytochrome c	1435	1447	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5939895_OgerInput.txtOger_out.csv:8	Cyanide is a powerful toxic chemical that shows high affinity for iron and other metals, blocking the function of different metalloproteins like the cytochrome c oxidase involved in the cellular respiratory process (Solomonson ; Jnemann ; Gupta, Balomajumder and Agarwal ; Luque-Almagro, Moreno-Vivin and Roldn. 	cytochrome c	1435	1447	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5955497_OgerInput.txtOger_out.csv:112	At the beginning of growth, the upregulation of genes involved in oxidative phosphorylation (ctaG, SO3058, coxA) indicates an increase in electron-transporting activity and the hydrolysis of ATP (SO3885), along with the downregulation of subunits for the synthesis of a cytochrome c-oxidase (ccoQ), an ATPase (atpC), a periplasmic monoheme cytochrome C (scyA), and a succinate dehydrogenase (sdhB) responsible for the reduction of ubiquinone to ubiquinol. 	cytochrome c	25802	25814	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5955497_OgerInput.txtOger_out.csv:112	At the beginning of growth, the upregulation of genes involved in oxidative phosphorylation (ctaG, SO3058, coxA) indicates an increase in electron-transporting activity and the hydrolysis of ATP (SO3885), along with the downregulation of subunits for the synthesis of a cytochrome c-oxidase (ccoQ), an ATPase (atpC), a periplasmic monoheme cytochrome C (scyA), and a succinate dehydrogenase (sdhB) responsible for the reduction of ubiquinone to ubiquinol. 	cytochrome c	25802	25814	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5955497_OgerInput.txtOger_out.csv:113	Towards the end of exponential growth, the upregulation of coxA is maintained, accompanied by the downregulation of two subunits for the cbb3-type cytochrome c-oxidase (ccoQ, ccoP), one subunit of the cytochrome bd complex (cydA), and three components of the cytochrome c maturation (Ccm) system (ccmC, ccmD, ccmE), responsible for the catalytic activity of cytochromes. 	cytochrome c	26135	26147	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5955497_OgerInput.txtOger_out.csv:113	Towards the end of exponential growth, the upregulation of coxA is maintained, accompanied by the downregulation of two subunits for the cbb3-type cytochrome c-oxidase (ccoQ, ccoP), one subunit of the cytochrome bd complex (cydA), and three components of the cytochrome c maturation (Ccm) system (ccmC, ccmD, ccmE), responsible for the catalytic activity of cytochromes. 	cytochrome c	26135	26147	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5955497_OgerInput.txtOger_out.csv:113	Towards the end of exponential growth, the upregulation of coxA is maintained, accompanied by the downregulation of two subunits for the cbb3-type cytochrome c-oxidase (ccoQ, ccoP), one subunit of the cytochrome bd complex (cydA), and three components of the cytochrome c maturation (Ccm) system (ccmC, ccmD, ccmE), responsible for the catalytic activity of cytochromes. 	cytochrome c	26247	26259	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5955497_OgerInput.txtOger_out.csv:113	Towards the end of exponential growth, the upregulation of coxA is maintained, accompanied by the downregulation of two subunits for the cbb3-type cytochrome c-oxidase (ccoQ, ccoP), one subunit of the cytochrome bd complex (cydA), and three components of the cytochrome c maturation (Ccm) system (ccmC, ccmD, ccmE), responsible for the catalytic activity of cytochromes. 	cytochrome c	26247	26259	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5979317_OgerInput.txtOger_out.csv:3	The cytochrome c (cyt c) subunit, which possesses three hemes (heme 1, heme 2, and heme 3, from the N-terminal sequence), is known to enable DET; however, details of the electron transfer pathway remain unknown. 	cytochrome c	319	331	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5979317_OgerInput.txtOger_out.csv:3	The cytochrome c (cyt c) subunit, which possesses three hemes (heme 1, heme 2, and heme 3, from the N-terminal sequence), is known to enable DET; however, details of the electron transfer pathway remain unknown. 	cytochrome c	319	331	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5979619_OgerInput.txtOger_out.csv:112	We assessed species diversity among the populations by analyzing the nucleotide sequence in a 670bp region of the mitochondrial cytochrome c oxidase I (COI), a region that has proven effective in species identification within North American Hyalella (Major, Soucek, Giordano, Wetzel, & SotoAdames, ; Wellborn & Broughton, ; Witt et al.,. 	cytochrome c	19896	19908	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5979619_OgerInput.txtOger_out.csv:112	We assessed species diversity among the populations by analyzing the nucleotide sequence in a 670bp region of the mitochondrial cytochrome c oxidase I (COI), a region that has proven effective in species identification within North American Hyalella (Major, Soucek, Giordano, Wetzel, & SotoAdames, ; Wellborn & Broughton, ; Witt et al.,. 	cytochrome c	19896	19908	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:7	The SH1-SH3 extracts protected SH-SY5Y cells from 6-hydroxydopamine (6-OHDA)-induced apoptosis as illustrated by cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	1164	1176	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:7	The SH1-SH3 extracts protected SH-SY5Y cells from 6-hydroxydopamine (6-OHDA)-induced apoptosis as illustrated by cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	1164	1176	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:125	In order to further examine the protective effects of SH1-SH3 on 6-OHDA-induced apoptosis in SH-SY5Y cells, the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation were performed by flow cytometry. 	cytochrome c	19507	19519	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:125	In order to further examine the protective effects of SH1-SH3 on 6-OHDA-induced apoptosis in SH-SY5Y cells, the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation were performed by flow cytometry. 	cytochrome c	19507	19519	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:136	Here, an immunodetection of cytochrome c by flow cytometry was applied to quantify release of cytochrome c in cells. 	cytochrome c	21448	21460	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:136	Here, an immunodetection of cytochrome c by flow cytometry was applied to quantify release of cytochrome c in cells. 	cytochrome c	21448	21460	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:136	Here, an immunodetection of cytochrome c by flow cytometry was applied to quantify release of cytochrome c in cells. 	cytochrome c	21514	21526	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:136	Here, an immunodetection of cytochrome c by flow cytometry was applied to quantify release of cytochrome c in cells. 	cytochrome c	21514	21526	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:138	When cells were treated with 75 M 6-OHDA, the population of high fluorescent cells decreased from 96.80%  0.22% (control) to 43.47%  0.53%, indicating cytochrome c underwent release from mitochondria. 	cytochrome c	21827	21839	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:138	When cells were treated with 75 M 6-OHDA, the population of high fluorescent cells decreased from 96.80%  0.22% (control) to 43.47%  0.53%, indicating cytochrome c underwent release from mitochondria. 	cytochrome c	21827	21839	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:141	In addition, SH3 was more effective at preventing 6-OHDA-induced cytochrome c release in cells than SH1 and SH2. 	cytochrome c	22314	22326	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:141	In addition, SH3 was more effective at preventing 6-OHDA-induced cytochrome c release in cells than SH1 and SH2. 	cytochrome c	22314	22326	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:147	The intrinsic pathway occurs following loss of mitochondrial transmembrane potential, resulting in the release of cytochrome c into the cytoplasm. 	cytochrome c	23061	23073	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:147	The intrinsic pathway occurs following loss of mitochondrial transmembrane potential, resulting in the release of cytochrome c into the cytoplasm. 	cytochrome c	23061	23073	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:163	In summary, all of the treated fucoidan extracts SH1-SH3 protected SH-SY5Y cells from 6-OHDA-induced apoptosis as illustrated by the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	25626	25638	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:163	In summary, all of the treated fucoidan extracts SH1-SH3 protected SH-SY5Y cells from 6-OHDA-induced apoptosis as illustrated by the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	25626	25638	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:252	Next the cells were washed with 2 mL 1 permeabilization buffer twice, and the cells were resuspended with 100 L 1 permeabilization buffer, followed by addition of 10 L FITC (fluorescein isothiocyanate)-labelled anti-cytochrome c antibody (Thermo Fisher Scientific, Waltham, MA, USA), and incubation at room temperature for 60 min in the dark. 	cytochrome c	39629	39641	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:252	Next the cells were washed with 2 mL 1 permeabilization buffer twice, and the cells were resuspended with 100 L 1 permeabilization buffer, followed by addition of 10 L FITC (fluorescein isothiocyanate)-labelled anti-cytochrome c antibody (Thermo Fisher Scientific, Waltham, MA, USA), and incubation at room temperature for 60 min in the dark. 	cytochrome c	39629	39641	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:283	Fucoidan extracts SH1-SH3 protected SH-SY5Y cells from 6-OHDA-induced apoptosis as illustrated by the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	45151	45163	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:283	Fucoidan extracts SH1-SH3 protected SH-SY5Y cells from 6-OHDA-induced apoptosis as illustrated by the cell cycle distribution, cytochrome c release, activation of caspase-8, -9, and -3, and DNA fragmentation analyses. 	cytochrome c	45151	45163	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6033852_OgerInput.txtOger_out.csv:146	As standards was used a mixture containing aldolase (Mm 158 kDa), ferritin (Mm 440 kDa), conalbumin (Mm 75 kDa), carbonic anhydrase (Mm 29 kDa) and cytochrome c (Mm 12.4 kDa), and dextran blue (Mm 2000 kDa) as void volume marker. 	cytochrome c	34459	34471	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6033852_OgerInput.txtOger_out.csv:146	As standards was used a mixture containing aldolase (Mm 158 kDa), ferritin (Mm 440 kDa), conalbumin (Mm 75 kDa), carbonic anhydrase (Mm 29 kDa) and cytochrome c (Mm 12.4 kDa), and dextran blue (Mm 2000 kDa) as void volume marker. 	cytochrome c	34459	34471	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6097799_OgerInput.txtOger_out.csv:108	^ These electrons are transferred to cytochromes c and are finally transferred to oxygen by cytochrome c oxidase. 	cytochrome c	16942	16954	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6097799_OgerInput.txtOger_out.csv:108	^ These electrons are transferred to cytochromes c and are finally transferred to oxygen by cytochrome c oxidase. 	cytochrome c	16942	16954	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:144	Finally, the activation of t-Bid causes the interaction with BAX (1FI6) y/o BAK (2IMT) which stimulates the release of cytochrome c. In this point, the target molecules 2-4 interact with BAX in order to strengthen the release. 	cytochrome c	24044	24056	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6152338_OgerInput.txtOger_out.csv:144	Finally, the activation of t-Bid causes the interaction with BAX (1FI6) y/o BAK (2IMT) which stimulates the release of cytochrome c. In this point, the target molecules 2-4 interact with BAX in order to strengthen the release. 	cytochrome c	24044	24056	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6272101_OgerInput.txtOger_out.csv:200	In addition, it has been shown that some of the stress signals mediated and regulated by BCL2 family proteins result in mitochondria releasing cytochrome c. This is, indeed, the first step in the intrinsic pathway of apoptosis. 	cytochrome c	23576	23588	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6272101_OgerInput.txtOger_out.csv:200	In addition, it has been shown that some of the stress signals mediated and regulated by BCL2 family proteins result in mitochondria releasing cytochrome c. This is, indeed, the first step in the intrinsic pathway of apoptosis. 	cytochrome c	23576	23588	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:3	Sodium alginate, bovine serum albumin, and cytochrome c represented extracellular polysaccharides, proteins, and electrochemically active components, respectively. 	cytochrome c	323	335	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:3	Sodium alginate, bovine serum albumin, and cytochrome c represented extracellular polysaccharides, proteins, and electrochemically active components, respectively. 	cytochrome c	323	335	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:5	Relative to the anaerobic inorganic control, Pb release increased by 156, 202, and 198 g/L when sEPS was present on the cathode side at 200 mg/L (100 mg/L alginate + 100 mg/L BSA), 400 mg/L (200 mg/L alginate + 200 mg/L BSA), and 200 mg/L with 123.84 mg/L cytochrome c, respectively, under anaerobic conditions. 	cytochrome c	826	838	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:5	Relative to the anaerobic inorganic control, Pb release increased by 156, 202, and 198 g/L when sEPS was present on the cathode side at 200 mg/L (100 mg/L alginate + 100 mg/L BSA), 400 mg/L (200 mg/L alginate + 200 mg/L BSA), and 200 mg/L with 123.84 mg/L cytochrome c, respectively, under anaerobic conditions. 	cytochrome c	826	838	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:35	In the absence of bacterial cells and cytochrome c (Cyto. 	cytochrome c	6071	6083	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:35	In the absence of bacterial cells and cytochrome c (Cyto. 	cytochrome c	6071	6083	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:97	c on the cathode, three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that (1) the interaction between Dissolved Oxygen and cytochrome c was significant and (2) the interaction between Dissolved Oxygen and cells was also significant. 	cytochrome c	17756	17768	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:97	c on the cathode, three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that (1) the interaction between Dissolved Oxygen and cytochrome c was significant and (2) the interaction between Dissolved Oxygen and cells was also significant. 	cytochrome c	17756	17768	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:97	c on the cathode, three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that (1) the interaction between Dissolved Oxygen and cytochrome c was significant and (2) the interaction between Dissolved Oxygen and cells was also significant. 	cytochrome c	17841	17853	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:97	c on the cathode, three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that (1) the interaction between Dissolved Oxygen and cytochrome c was significant and (2) the interaction between Dissolved Oxygen and cells was also significant. 	cytochrome c	17841	17853	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:98	Except for Dissolved Oxygen, the main effects of the two other factors were not significant, suggesting that in the presence of cytochrome c, availability of oxygen to the cathode is crucial. 	cytochrome c	18079	18091	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:98	Except for Dissolved Oxygen, the main effects of the two other factors were not significant, suggesting that in the presence of cytochrome c, availability of oxygen to the cathode is crucial. 	cytochrome c	18079	18091	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:100	The same Analysis Of Variance with aqueous lead concentrations as the response showed that the interaction between Dissolved Oxygen and cytochrome c was significant (F_1,13 = 4.78, p < 0.05); the main effects of Dissolved Oxygen and cytochrome c were also significant. 	cytochrome c	18485	18497	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:100	The same Analysis Of Variance with aqueous lead concentrations as the response showed that the interaction between Dissolved Oxygen and cytochrome c was significant (F_1,13 = 4.78, p < 0.05); the main effects of Dissolved Oxygen and cytochrome c were also significant. 	cytochrome c	18485	18497	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:100	The same Analysis Of Variance with aqueous lead concentrations as the response showed that the interaction between Dissolved Oxygen and cytochrome c was significant (F_1,13 = 4.78, p < 0.05); the main effects of Dissolved Oxygen and cytochrome c were also significant. 	cytochrome c	18582	18594	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:100	The same Analysis Of Variance with aqueous lead concentrations as the response showed that the interaction between Dissolved Oxygen and cytochrome c was significant (F_1,13 = 4.78, p < 0.05); the main effects of Dissolved Oxygen and cytochrome c were also significant. 	cytochrome c	18582	18594	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:101	In addition, a hematite-hematite galvanic test showed that cytochrome c, without oxygen, cannot ennoble iron oxide. 	cytochrome c	18677	18689	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:101	In addition, a hematite-hematite galvanic test showed that cytochrome c, without oxygen, cannot ennoble iron oxide. 	cytochrome c	18677	18689	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:102	The UV-vis absorption spectra show peaks near 520 and 550 nm emerging after the reaction of cytochrome c on the cathode (B), implying the reduction of cytochrome c. 	cytochrome c	18826	18838	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:102	The UV-vis absorption spectra show peaks near 520 and 550 nm emerging after the reaction of cytochrome c on the cathode (B), implying the reduction of cytochrome c. 	cytochrome c	18826	18838	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:102	The UV-vis absorption spectra show peaks near 520 and 550 nm emerging after the reaction of cytochrome c on the cathode (B), implying the reduction of cytochrome c. 	cytochrome c	18885	18897	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:102	The UV-vis absorption spectra show peaks near 520 and 550 nm emerging after the reaction of cytochrome c on the cathode (B), implying the reduction of cytochrome c. 	cytochrome c	18885	18897	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:103	^ This evidence leads to the conclusions that during these corrosion tests (1) cytochrome c can be oxidized by Dissolved Oxygen and (2) cytochrome c may have mediated electron transfer from a more reduced cathode to Dissolved Oxygen and thus facilitated the oxidation of the cathode by Dissolved Oxygen. 	cytochrome c	18978	18990	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:103	^ This evidence leads to the conclusions that during these corrosion tests (1) cytochrome c can be oxidized by Dissolved Oxygen and (2) cytochrome c may have mediated electron transfer from a more reduced cathode to Dissolved Oxygen and thus facilitated the oxidation of the cathode by Dissolved Oxygen. 	cytochrome c	18978	18990	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:103	^ This evidence leads to the conclusions that during these corrosion tests (1) cytochrome c can be oxidized by Dissolved Oxygen and (2) cytochrome c may have mediated electron transfer from a more reduced cathode to Dissolved Oxygen and thus facilitated the oxidation of the cathode by Dissolved Oxygen. 	cytochrome c	19035	19047	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:103	^ This evidence leads to the conclusions that during these corrosion tests (1) cytochrome c can be oxidized by Dissolved Oxygen and (2) cytochrome c may have mediated electron transfer from a more reduced cathode to Dissolved Oxygen and thus facilitated the oxidation of the cathode by Dissolved Oxygen. 	cytochrome c	19035	19047	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:104	Moreover, the SEC ICP-MS chromatograms (A) indicate that cytochrome c dramatically alters the apparent molecular weight distribution of lead. 	cytochrome c	19260	19272	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:104	Moreover, the SEC ICP-MS chromatograms (A) indicate that cytochrome c dramatically alters the apparent molecular weight distribution of lead. 	cytochrome c	19260	19272	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:105	Although present at a low level, cytochrome c may be better able to complex with lead compared to alginate, perhaps due to its relatively small size (12 000 Daltons). 	cytochrome c	19378	19390	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:105	Although present at a low level, cytochrome c may be better able to complex with lead compared to alginate, perhaps due to its relatively small size (12 000 Daltons). 	cytochrome c	19378	19390	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:106	Thus, it is reasonable to assume that cytochrome c may have also complexed ferrous ions, assisting the cathode to revert to the oxidized condition. 	cytochrome c	19550	19562	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:106	Thus, it is reasonable to assume that cytochrome c may have also complexed ferrous ions, assisting the cathode to revert to the oxidized condition. 	cytochrome c	19550	19562	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:108	c on the anode, a three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that all the interactions were not significant and only the main effect of Dissolved Oxygen was significant. 	cytochrome c	19772	19784	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:108	c on the anode, a three-way Analysis Of Variance of theoretically oxidized lead on Dissolved Oxygen, cytochrome c, and cells showed that all the interactions were not significant and only the main effect of Dissolved Oxygen was significant. 	cytochrome c	19772	19784	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:109	In contrast, Analysis Of Variance with measured lead concentrations as the response showed that the interaction between cytochrome c and cells was significant and the main effects of cytochrome c (F_1,13 = 42.23, p < 0.0001) and cells (F_1,13 = 12.99, p < 0.001) were also significant. 	cytochrome c	20032	20044	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:109	In contrast, Analysis Of Variance with measured lead concentrations as the response showed that the interaction between cytochrome c and cells was significant and the main effects of cytochrome c (F_1,13 = 42.23, p < 0.0001) and cells (F_1,13 = 12.99, p < 0.001) were also significant. 	cytochrome c	20032	20044	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:109	In contrast, Analysis Of Variance with measured lead concentrations as the response showed that the interaction between cytochrome c and cells was significant and the main effects of cytochrome c (F_1,13 = 42.23, p < 0.0001) and cells (F_1,13 = 12.99, p < 0.001) were also significant. 	cytochrome c	20095	20107	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:109	In contrast, Analysis Of Variance with measured lead concentrations as the response showed that the interaction between cytochrome c and cells was significant and the main effects of cytochrome c (F_1,13 = 42.23, p < 0.0001) and cells (F_1,13 = 12.99, p < 0.001) were also significant. 	cytochrome c	20095	20107	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:110	When the cathode was under anaerobic condition, the corrosion current in the presence of cytochrome c generally fell in the low range, below 3 A, as evident from  (sEPS on Pb, C&D). 	cytochrome c	20287	20299	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:110	When the cathode was under anaerobic condition, the corrosion current in the presence of cytochrome c generally fell in the low range, below 3 A, as evident from  (sEPS on Pb, C&D). 	cytochrome c	20287	20299	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:112	These observations indicate that (1) galvanic current cannot reveal the effect of cytochrome c and its interaction with DO/cells on the anode and (2) when cytochrome c is in contact with lead, it encourages non-galvanic corrosion. 	cytochrome c	20601	20613	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:112	These observations indicate that (1) galvanic current cannot reveal the effect of cytochrome c and its interaction with DO/cells on the anode and (2) when cytochrome c is in contact with lead, it encourages non-galvanic corrosion. 	cytochrome c	20601	20613	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:112	These observations indicate that (1) galvanic current cannot reveal the effect of cytochrome c and its interaction with DO/cells on the anode and (2) when cytochrome c is in contact with lead, it encourages non-galvanic corrosion. 	cytochrome c	20674	20686	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:112	These observations indicate that (1) galvanic current cannot reveal the effect of cytochrome c and its interaction with DO/cells on the anode and (2) when cytochrome c is in contact with lead, it encourages non-galvanic corrosion. 	cytochrome c	20674	20686	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:113	The lead-lead galvanic test with cytochrome c supports the idea that cytochrome c can accept electrons from lead. 	cytochrome c	20783	20795	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:113	The lead-lead galvanic test with cytochrome c supports the idea that cytochrome c can accept electrons from lead. 	cytochrome c	20783	20795	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:113	The lead-lead galvanic test with cytochrome c supports the idea that cytochrome c can accept electrons from lead. 	cytochrome c	20819	20831	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:113	The lead-lead galvanic test with cytochrome c supports the idea that cytochrome c can accept electrons from lead. 	cytochrome c	20819	20831	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:114	Although an environmental biofilm actively conducting dissimilatory metal oxide reduction usually contains a fraction of oxidized cytochrome c,^ microorganisms involved in a corrosion reaction may directly oxidize metal surfaces with the assistance of oxidized cytochrome c. 	cytochrome c	20994	21006	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:114	Although an environmental biofilm actively conducting dissimilatory metal oxide reduction usually contains a fraction of oxidized cytochrome c,^ microorganisms involved in a corrosion reaction may directly oxidize metal surfaces with the assistance of oxidized cytochrome c. 	cytochrome c	20994	21006	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:114	Although an environmental biofilm actively conducting dissimilatory metal oxide reduction usually contains a fraction of oxidized cytochrome c,^ microorganisms involved in a corrosion reaction may directly oxidize metal surfaces with the assistance of oxidized cytochrome c. 	cytochrome c	21125	21137	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:114	Although an environmental biofilm actively conducting dissimilatory metal oxide reduction usually contains a fraction of oxidized cytochrome c,^ microorganisms involved in a corrosion reaction may directly oxidize metal surfaces with the assistance of oxidized cytochrome c. 	cytochrome c	21125	21137	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:115	^,,,,, Together with its lead-binding ability (A), the current work suggests that electrochemically active proteins, such as cytochrome c, may result in localized non-galvanic corrosion of lead. 	cytochrome c	21264	21276	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:115	^,,,,, Together with its lead-binding ability (A), the current work suggests that electrochemically active proteins, such as cytochrome c, may result in localized non-galvanic corrosion of lead. 	cytochrome c	21264	21276	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:121	This direct electron transfer might have relied on either cytoplasmic membrane-associated or extracellular cytochrome c. 	cytochrome c	22366	22378	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:121	This direct electron transfer might have relied on either cytoplasmic membrane-associated or extracellular cytochrome c. 	cytochrome c	22366	22378	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:132	Sodium alginate and bovine serum albumin were employed as models for polysaccharides and proteins in Extracellular Polymeric Substances, respectively; cytochrome c was used to represent electrochemically active small-sized proteins in Extracellular Polymeric Substances. 	cytochrome c	24630	24642	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:132	Sodium alginate and bovine serum albumin were employed as models for polysaccharides and proteins in Extracellular Polymeric Substances, respectively; cytochrome c was used to represent electrochemically active small-sized proteins in Extracellular Polymeric Substances. 	cytochrome c	24630	24642	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:135	Within each group, three different sEPS conditions were examined: 100 mg/L alginate + 100 mg/L Bovine Serum Albumin (labeled sEPS1); 200 mg/L alginate + 200 mg/L Bovine Serum Albumin (labeled sEPS2); and 100 mg/L alginate + 100 mg/L Bovine Serum Albumin + 123.84 mg/L cytochrome c (C7752, Sigma-Aldrich) (labeled Cyto. 	cytochrome c	25326	25338	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:135	Within each group, three different sEPS conditions were examined: 100 mg/L alginate + 100 mg/L Bovine Serum Albumin (labeled sEPS1); 200 mg/L alginate + 200 mg/L Bovine Serum Albumin (labeled sEPS2); and 100 mg/L alginate + 100 mg/L Bovine Serum Albumin + 123.84 mg/L cytochrome c (C7752, Sigma-Aldrich) (labeled Cyto. 	cytochrome c	25326	25338	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:139	The concentration of cytochrome c was determined according to a previous study on Geobacter species. 	cytochrome c	25786	25798	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:139	The concentration of cytochrome c was determined according to a previous study on Geobacter species. 	cytochrome c	25786	25798	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:145	In the presence of cytochrome c and cells, three-way Analysis Of Variance was applied to examine the main effects of Dissolved Oxygen (anaerobic and aerobic), cytochrome c (sEPS1 and Cyto. 	cytochrome c	26850	26862	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:145	In the presence of cytochrome c and cells, three-way Analysis Of Variance was applied to examine the main effects of Dissolved Oxygen (anaerobic and aerobic), cytochrome c (sEPS1 and Cyto. 	cytochrome c	26850	26862	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:145	In the presence of cytochrome c and cells, three-way Analysis Of Variance was applied to examine the main effects of Dissolved Oxygen (anaerobic and aerobic), cytochrome c (sEPS1 and Cyto. 	cytochrome c	26990	27002	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:145	In the presence of cytochrome c and cells, three-way Analysis Of Variance was applied to examine the main effects of Dissolved Oxygen (anaerobic and aerobic), cytochrome c (sEPS1 and Cyto. 	cytochrome c	26990	27002	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:163	Flakes of cytochrome c were dissolved in the base electrolyte when needed. 	cytochrome c	29427	29439	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:163	Flakes of cytochrome c were dissolved in the base electrolyte when needed. 	cytochrome c	29427	29439	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:180	The experiment was run following these steps: de-aeration, equilibrium current (ie, zero current) collection for 3 h, disconnection, injection of a specified amount of sEPS/cytochrome c stock solution to the control side (connected to the COM port), de-aeration of the control side, and current collection for another 3 h. A half level of cytochrome c was used (61.92 mg/L). 	cytochrome c	31853	31865	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:180	The experiment was run following these steps: de-aeration, equilibrium current (ie, zero current) collection for 3 h, disconnection, injection of a specified amount of sEPS/cytochrome c stock solution to the control side (connected to the COM port), de-aeration of the control side, and current collection for another 3 h. A half level of cytochrome c was used (61.92 mg/L). 	cytochrome c	31853	31865	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:180	The experiment was run following these steps: de-aeration, equilibrium current (ie, zero current) collection for 3 h, disconnection, injection of a specified amount of sEPS/cytochrome c stock solution to the control side (connected to the COM port), de-aeration of the control side, and current collection for another 3 h. A half level of cytochrome c was used (61.92 mg/L). 	cytochrome c	32019	32031	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:180	The experiment was run following these steps: de-aeration, equilibrium current (ie, zero current) collection for 3 h, disconnection, injection of a specified amount of sEPS/cytochrome c stock solution to the control side (connected to the COM port), de-aeration of the control side, and current collection for another 3 h. A half level of cytochrome c was used (61.92 mg/L). 	cytochrome c	32019	32031	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6292600_OgerInput.txtOger_out.csv:44	Although the cytochrome c oxidase subunit 1 (COI) is a marker of choice for single animal specimen DNA barcoding (see BOLD,), its interest has been disputed for DNA metabarcoding studies. 	cytochrome c	6394	6406	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6292600_OgerInput.txtOger_out.csv:44	Although the cytochrome c oxidase subunit 1 (COI) is a marker of choice for single animal specimen DNA barcoding (see BOLD,), its interest has been disputed for DNA metabarcoding studies. 	cytochrome c	6394	6406	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6305584_OgerInput.txtOger_out.csv:177	For example, the subunits of cytochrome c reductase (QcrCAB; MSMEG_4261-4263) and aa_3 cytochrome c oxidase (CtaC; MSMEG_4268), as well as the subunits of H^+-ATPases (eg, alfa, beta, H, F, and A; MSMEG_4938, MSMEG_4936, MSMEG_4939, MSMEG_4940, MSMEG_4942, respectively) are enriched in the PM-CW proteome. 	cytochrome c	29718	29730	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6305584_OgerInput.txtOger_out.csv:177	For example, the subunits of cytochrome c reductase (QcrCAB; MSMEG_4261-4263) and aa_3 cytochrome c oxidase (CtaC; MSMEG_4268), as well as the subunits of H^+-ATPases (eg, alfa, beta, H, F, and A; MSMEG_4938, MSMEG_4936, MSMEG_4939, MSMEG_4940, MSMEG_4942, respectively) are enriched in the PM-CW proteome. 	cytochrome c	29718	29730	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6305584_OgerInput.txtOger_out.csv:177	For example, the subunits of cytochrome c reductase (QcrCAB; MSMEG_4261-4263) and aa_3 cytochrome c oxidase (CtaC; MSMEG_4268), as well as the subunits of H^+-ATPases (eg, alfa, beta, H, F, and A; MSMEG_4938, MSMEG_4936, MSMEG_4939, MSMEG_4940, MSMEG_4942, respectively) are enriched in the PM-CW proteome. 	cytochrome c	29776	29788	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6305584_OgerInput.txtOger_out.csv:177	For example, the subunits of cytochrome c reductase (QcrCAB; MSMEG_4261-4263) and aa_3 cytochrome c oxidase (CtaC; MSMEG_4268), as well as the subunits of H^+-ATPases (eg, alfa, beta, H, F, and A; MSMEG_4938, MSMEG_4936, MSMEG_4939, MSMEG_4940, MSMEG_4942, respectively) are enriched in the PM-CW proteome. 	cytochrome c	29776	29788	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:5	Moreover, it also induced cytochrome c release from the mitochondria to the cytoplasm and metacaspase activation. 	cytochrome c	669	681	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:5	Moreover, it also induced cytochrome c release from the mitochondria to the cytoplasm and metacaspase activation. 	cytochrome c	669	681	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:24	Moreover, a loss of cytochrome c synthesis (or depletion of its levels within the cells) also results in apoptosis. 	cytochrome c	3845	3857	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:24	Moreover, a loss of cytochrome c synthesis (or depletion of its levels within the cells) also results in apoptosis. 	cytochrome c	3845	3857	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:59	To analyze cytosolic and mitochondrial cytochrome c levels, the obtained supernatant was centrifuged at 50,000 rpm for 45 min. 	cytochrome c	8600	8612	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:59	To analyze cytosolic and mitochondrial cytochrome c levels, the obtained supernatant was centrifuged at 50,000 rpm for 45 min. 	cytochrome c	8600	8612	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:60	The released cytoplasmic cytochrome c was measured in the supernatant. 	cytochrome c	8713	8725	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:60	The released cytoplasmic cytochrome c was measured in the supernatant. 	cytochrome c	8713	8725	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:62	After treatment with 500 mg/mL ascorbic acid for 5 min, the cytochrome c content in the cytoplasmic or mitochondrial samples was determined by spectrophotometric analysis at 550 nm. 	cytochrome c	8915	8927	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:62	After treatment with 500 mg/mL ascorbic acid for 5 min, the cytochrome c content in the cytoplasmic or mitochondrial samples was determined by spectrophotometric analysis at 550 nm. 	cytochrome c	8915	8927	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:110	Here, the translocation of cytochrome c from the mitochondria and metacaspase activity were examined. 	cytochrome c	15393	15405	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:110	Here, the translocation of cytochrome c from the mitochondria and metacaspase activity were examined. 	cytochrome c	15393	15405	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15532	15544	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15532	15544	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15597	15609	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15597	15609	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15748	15760	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:111	Compared to the control cells, the relative levels of cytosolic cytochrome c were observed to have increased while mitochondrial cytochrome c contents were simultaneously observed to have decreased upon coumarin treatment, thereby revealing that coumarin triggered the release of cytochrome c from the mitochondria to the cytosol. 	cytochrome c	15748	15760	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:120	Mitochondria also play an important role in yeast apoptosis since this organelle is the major site for ROS production and contains many proapoptotic factors such as cytochrome c, Aif1p, and Nuc1p (Pereira et al.,. 	cytochrome c	17068	17080	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:120	Mitochondria also play an important role in yeast apoptosis since this organelle is the major site for ROS production and contains many proapoptotic factors such as cytochrome c, Aif1p, and Nuc1p (Pereira et al.,. 	cytochrome c	17068	17080	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:145	To study the pattern of cell death, the features of yeast apoptosis were determined, including PS externalization, DNA fragmentation, cytochrome c release, and metacaspase activation (Carmona-Gutierrez et al.,. 	cytochrome c	21030	21042	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:145	To study the pattern of cell death, the features of yeast apoptosis were determined, including PS externalization, DNA fragmentation, cytochrome c release, and metacaspase activation (Carmona-Gutierrez et al.,. 	cytochrome c	21030	21042	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:146	The results showed that coumarin treatment led to PS exposure on the outer leaflet, DNA fragmentation and nuclear condensation, cytochrome c release from the mitochondria to the cytosol, and metacaspase activation, suggesting that coumarin induced apoptosis in C. albicans. 	cytochrome c	21235	21247	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:146	The results showed that coumarin treatment led to PS exposure on the outer leaflet, DNA fragmentation and nuclear condensation, cytochrome c release from the mitochondria to the cytosol, and metacaspase activation, suggesting that coumarin induced apoptosis in C. albicans. 	cytochrome c	21235	21247	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:150	During apoptosis, oxidative stress induces the mitochondrial permeability transition pore (PTP) to open, which then triggers the mitochondrial outer membrane permeabilization (MOMP) that is involved in the release of cytochrome c and other proapoptotic factors, leading to subsequent metacaspase activation (Simon et al.,. 	cytochrome c	22172	22184	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:150	During apoptosis, oxidative stress induces the mitochondrial permeability transition pore (PTP) to open, which then triggers the mitochondrial outer membrane permeabilization (MOMP) that is involved in the release of cytochrome c and other proapoptotic factors, leading to subsequent metacaspase activation (Simon et al.,. 	cytochrome c	22172	22184	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:157	Under oxidative stress, this Ca^2+ signal can lead to PTP opening and release of cytochrome c and other proapoptotic factors, which ultimately results in the formation of apoptotic bodies and cell death. 	cytochrome c	23178	23190	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:157	Under oxidative stress, this Ca^2+ signal can lead to PTP opening and release of cytochrome c and other proapoptotic factors, which ultimately results in the formation of apoptotic bodies and cell death. 	cytochrome c	23178	23190	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:181	LY, CW, and YY participated in measuring ROS, Ca^2+ levels, cytochrome c contents, and metacasapse activity. 	cytochrome c	26759	26771	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:181	LY, CW, and YY participated in measuring ROS, Ca^2+ levels, cytochrome c contents, and metacasapse activity. 	cytochrome c	26759	26771	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6362234_OgerInput.txtOger_out.csv:2	Comparative genomic studies of the bacterial MFS-type copper importer CcoA, required for cbb3-type cytochrome c oxidase (cbb3-Cox) biogenesis, revealed a widespread CcoA-like transporters family, containing the conserved CcoA Cu-binding MxxxM and HxxxM motifs. 	cytochrome c	181	193	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6362234_OgerInput.txtOger_out.csv:2	Comparative genomic studies of the bacterial MFS-type copper importer CcoA, required for cbb3-type cytochrome c oxidase (cbb3-Cox) biogenesis, revealed a widespread CcoA-like transporters family, containing the conserved CcoA Cu-binding MxxxM and HxxxM motifs. 	cytochrome c	181	193	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6362234_OgerInput.txtOger_out.csv:20	Earlier genetic and biochemical studies unequivocally established that CcoA imports Cu destined to the catalytic site (Cu_B center) of the cbb_3-type cytochrome c oxidases (cbb_3-Cox), where O_2 is reduced to H_2O during aerobic respiration^-. 	cytochrome c	3598	3610	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6362234_OgerInput.txtOger_out.csv:20	Earlier genetic and biochemical studies unequivocally established that CcoA imports Cu destined to the catalytic site (Cu_B center) of the cbb_3-type cytochrome c oxidases (cbb_3-Cox), where O_2 is reduced to H_2O during aerobic respiration^-. 	cytochrome c	3598	3610	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6362234_OgerInput.txtOger_out.csv:51	The third neighborhood N3 (green triangles in Fig ) contained genes encoding a BamE-like outer membrane protein assembly factor (PF04355), a putative ubiquinol-cytochrome c oxidoreductase (cytochrome bc_1 complex) chaperone (PF03981), a putative thiamine-monophosphate kinase (PF00586-PF02769) and/or a putative 6,7-dimethyl-8-ribityllumazine synthase (ribH involved in riboflavin biosynthesis, PF00885). 	cytochrome c	10507	10519	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6362234_OgerInput.txtOger_out.csv:51	The third neighborhood N3 (green triangles in Fig ) contained genes encoding a BamE-like outer membrane protein assembly factor (PF04355), a putative ubiquinol-cytochrome c oxidoreductase (cytochrome bc_1 complex) chaperone (PF03981), a putative thiamine-monophosphate kinase (PF00586-PF02769) and/or a putative 6,7-dimethyl-8-ribityllumazine synthase (ribH involved in riboflavin biosynthesis, PF00885). 	cytochrome c	10507	10519	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6362234_OgerInput.txtOger_out.csv:54	The Riboflavin Biosynthesis Pathway protein RibH, BamE-like outer membrane protein assembly factor, and ubiquinol-cytochrome c oxidoreductase chaperone from N3 were enriched at the family, but not at the order level (SI Table. 	cytochrome c	11163	11175	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6362234_OgerInput.txtOger_out.csv:54	The Riboflavin Biosynthesis Pathway protein RibH, BamE-like outer membrane protein assembly factor, and ubiquinol-cytochrome c oxidoreductase chaperone from N3 were enriched at the family, but not at the order level (SI Table. 	cytochrome c	11163	11175	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6362234_OgerInput.txtOger_out.csv:129	Notably, some Called Rfnt genes located in neighborhood N3 were found to be associated with a gene encoding a putative chaperone of ubiquinol-cytochrome c oxidoreductase. 	cytochrome c	26955	26967	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6362234_OgerInput.txtOger_out.csv:129	Notably, some Called Rfnt genes located in neighborhood N3 were found to be associated with a gene encoding a putative chaperone of ubiquinol-cytochrome c oxidoreductase. 	cytochrome c	26955	26967	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:35	To 200 L of diluted cell lysate in 0.3 mol L^1 potassium phosphate buffer at pH 7.7 containing 40 mol L^1 cytochrome c, 100 mol L^1 NADPH was added to initiate the reduction of cytochrome c and the reaction was followed at 550 nm and 23C. 	cytochrome c	6198	6210	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6411694_OgerInput.txtOger_out.csv:35	To 200 L of diluted cell lysate in 0.3 mol L^1 potassium phosphate buffer at pH 7.7 containing 40 mol L^1 cytochrome c, 100 mol L^1 NADPH was added to initiate the reduction of cytochrome c and the reaction was followed at 550 nm and 23C. 	cytochrome c	6198	6210	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:35	To 200 L of diluted cell lysate in 0.3 mol L^1 potassium phosphate buffer at pH 7.7 containing 40 mol L^1 cytochrome c, 100 mol L^1 NADPH was added to initiate the reduction of cytochrome c and the reaction was followed at 550 nm and 23C. 	cytochrome c	6269	6281	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6411694_OgerInput.txtOger_out.csv:35	To 200 L of diluted cell lysate in 0.3 mol L^1 potassium phosphate buffer at pH 7.7 containing 40 mol L^1 cytochrome c, 100 mol L^1 NADPH was added to initiate the reduction of cytochrome c and the reaction was followed at 550 nm and 23C. 	cytochrome c	6269	6281	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:36	The reaction rate was calculated using an extinction coefficient of e_550 nm of 21 mmol L^1 cm^1 for reduced cytochrome c. POR activity was converted to POR content based on the assumption that 3000 nmol of cytochrome c is reduced/min per nmol POR at 23C., All incubations were carried out in 96well PCR plates in 50 L total volume at 37C, as previously described. 	cytochrome c	6440	6452	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6411694_OgerInput.txtOger_out.csv:36	The reaction rate was calculated using an extinction coefficient of e_550 nm of 21 mmol L^1 cm^1 for reduced cytochrome c. POR activity was converted to POR content based on the assumption that 3000 nmol of cytochrome c is reduced/min per nmol POR at 23C., All incubations were carried out in 96well PCR plates in 50 L total volume at 37C, as previously described. 	cytochrome c	6440	6452	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:36	The reaction rate was calculated using an extinction coefficient of e_550 nm of 21 mmol L^1 cm^1 for reduced cytochrome c. POR activity was converted to POR content based on the assumption that 3000 nmol of cytochrome c is reduced/min per nmol POR at 23C., All incubations were carried out in 96well PCR plates in 50 L total volume at 37C, as previously described. 	cytochrome c	6538	6550	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6411694_OgerInput.txtOger_out.csv:36	The reaction rate was calculated using an extinction coefficient of e_550 nm of 21 mmol L^1 cm^1 for reduced cytochrome c. POR activity was converted to POR content based on the assumption that 3000 nmol of cytochrome c is reduced/min per nmol POR at 23C., All incubations were carried out in 96well PCR plates in 50 L total volume at 37C, as previously described. 	cytochrome c	6538	6550	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:4	This enhancement was ultra-structurally verified via observation of trapped mitochondria within LC3-labeled membranes, upregulation of LC3 protein levels, colocalization of LC3 and cytochrome c, and reduced expression of mitochondrial proteins. 	cytochrome c	918	930	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:4	This enhancement was ultra-structurally verified via observation of trapped mitochondria within LC3-labeled membranes, upregulation of LC3 protein levels, colocalization of LC3 and cytochrome c, and reduced expression of mitochondrial proteins. 	cytochrome c	918	930	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	cytochrome c	5826	5838	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	cytochrome c	5826	5838	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:52	For double labeling of LC3 with either cytochrome c (a mitochondrial marker) or p62, we used a simultaneous application of two primary antibodies followed by Alexa Fluor 594 and 488-conjugated secondary antibodies. 	cytochrome c	9299	9311	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:52	For double labeling of LC3 with either cytochrome c (a mitochondrial marker) or p62, we used a simultaneous application of two primary antibodies followed by Alexa Fluor 594 and 488-conjugated secondary antibodies. 	cytochrome c	9299	9311	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:72	Proteins were detected with the specific primary antibodies for LC3, cytochrome c, Parkin, TFEB, COX IV, and iNOS, and then with specific peroxidase-labeled secondary antibodies as previously reported. 	cytochrome c	12899	12911	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:72	Proteins were detected with the specific primary antibodies for LC3, cytochrome c, Parkin, TFEB, COX IV, and iNOS, and then with specific peroxidase-labeled secondary antibodies as previously reported. 	cytochrome c	12899	12911	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:92	Double-labeling with IF LC3 and cytochrome c revealed enhanced co-localization in ETR SCs (A), indicating the formation of mitophagosomes as reported in past studies. 	cytochrome c	16369	16381	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:92	Double-labeling with IF LC3 and cytochrome c revealed enhanced co-localization in ETR SCs (A), indicating the formation of mitophagosomes as reported in past studies. 	cytochrome c	16369	16381	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:93	Western blot and analysis (B,C) showed a significant reduction of cytochrome c (15 kDa), indicating mitochondrial damage within Mversus Additional Western blot analysis showed that the expression level of COX IV (17 kDa) (inner mitochondrial membrane protein) was also reduced in testes of ETRs (D,E). 	cytochrome c	16570	16582	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:93	Western blot and analysis (B,C) showed a significant reduction of cytochrome c (15 kDa), indicating mitochondrial damage within Mversus Additional Western blot analysis showed that the expression level of COX IV (17 kDa) (inner mitochondrial membrane protein) was also reduced in testes of ETRs (D,E). 	cytochrome c	16570	16582	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:124	Enhanced autophagic clearance of damaged mitochondria within MVs of ETR SCs in the current study is evidenced by engulfment of these mitochondria by LC3-II-decorated autophagosomal membranes, enhanced co-localization of LC3 with cytochrome c and p62, and reduced cytochrome c protein levels. 	cytochrome c	22097	22109	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:124	Enhanced autophagic clearance of damaged mitochondria within MVs of ETR SCs in the current study is evidenced by engulfment of these mitochondria by LC3-II-decorated autophagosomal membranes, enhanced co-localization of LC3 with cytochrome c and p62, and reduced cytochrome c protein levels. 	cytochrome c	22097	22109	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:124	Enhanced autophagic clearance of damaged mitochondria within MVs of ETR SCs in the current study is evidenced by engulfment of these mitochondria by LC3-II-decorated autophagosomal membranes, enhanced co-localization of LC3 with cytochrome c and p62, and reduced cytochrome c protein levels. 	cytochrome c	22131	22143	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:124	Enhanced autophagic clearance of damaged mitochondria within MVs of ETR SCs in the current study is evidenced by engulfment of these mitochondria by LC3-II-decorated autophagosomal membranes, enhanced co-localization of LC3 with cytochrome c and p62, and reduced cytochrome c protein levels. 	cytochrome c	22131	22143	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6479175_OgerInput.txtOger_out.csv:100	By checking available publications, we have found the following enzymes that have been reported as ETC components under anaerobic conditions: FADH_2-NAD oxidoreductase Rnf; membrane-bound hydrogenases Ech and Mbh; methyltransferase Mtr; NADH dehydrogenases Nuo, Ndh, and Hox; cytochrome c reductase Pet and TorC; cytochrome bd oxidase Cyd; sulfate reductase Apr; nitrite reductase NrfA; nitrate reductases Nar and NapA; fumarate reductase Sdh; and cytochrome o oxidase Cyo (;. 	cytochrome c	15976	15988	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6479175_OgerInput.txtOger_out.csv:100	By checking available publications, we have found the following enzymes that have been reported as ETC components under anaerobic conditions: FADH_2-NAD oxidoreductase Rnf; membrane-bound hydrogenases Ech and Mbh; methyltransferase Mtr; NADH dehydrogenases Nuo, Ndh, and Hox; cytochrome c reductase Pet and TorC; cytochrome bd oxidase Cyd; sulfate reductase Apr; nitrite reductase NrfA; nitrate reductases Nar and NapA; fumarate reductase Sdh; and cytochrome o oxidase Cyo (;. 	cytochrome c	15976	15988	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6479175_OgerInput.txtOger_out.csv:147	Second, the abundance of cytochrome c reductase (Pet and torC) and sulfate reductase Apr was less than 1 in all samples, and the species whose genomes encoded it were not detected in this study. 	cytochrome c	27536	27548	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6479175_OgerInput.txtOger_out.csv:147	Second, the abundance of cytochrome c reductase (Pet and torC) and sulfate reductase Apr was less than 1 in all samples, and the species whose genomes encoded it were not detected in this study. 	cytochrome c	27536	27548	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6479175_OgerInput.txtOger_out.csv:148	We therefore speculated that the species whose genomes encoded cytochrome c reductase and Apr could not be present in the ruminal microbiome. 	cytochrome c	27769	27781	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6479175_OgerInput.txtOger_out.csv:148	We therefore speculated that the species whose genomes encoded cytochrome c reductase and Apr could not be present in the ruminal microbiome. 	cytochrome c	27769	27781	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:52	The OxLDL mediated ROS generated triggers the cytochrome c mediated apoptosis cascade leading to cellular death and debris accumulation (Leiva et al.,. 	cytochrome c	9775	9787	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6482252_OgerInput.txtOger_out.csv:52	The OxLDL mediated ROS generated triggers the cytochrome c mediated apoptosis cascade leading to cellular death and debris accumulation (Leiva et al.,. 	cytochrome c	9775	9787	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6627380_OgerInput.txtOger_out.csv:841	The Surface-Enhanced Raman Scattering spectra of hen egg white lysozyme, avidin, cytochrome c, hemoglobin, and Bovine Serum Albumin, recorded using these nanoparticles, are similar to the Raman ones recorded in solution or in solid samples. 	cytochrome c	152665	152677	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6627380_OgerInput.txtOger_out.csv:841	The Surface-Enhanced Raman Scattering spectra of hen egg white lysozyme, avidin, cytochrome c, hemoglobin, and Bovine Serum Albumin, recorded using these nanoparticles, are similar to the Raman ones recorded in solution or in solid samples. 	cytochrome c	152665	152677	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6642182_OgerInput.txtOger_out.csv:4	Here, we report a quantum biological electron tunnelling junction and its application in real-time optical detection of Quantum Biological Electron Tunnelling and the dynamics of Electron Transfer in mitochondrial cytochrome c during cell life and death process. 	cytochrome c	608	620	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6642182_OgerInput.txtOger_out.csv:4	Here, we report a quantum biological electron tunnelling junction and its application in real-time optical detection of Quantum Biological Electron Tunnelling and the dynamics of Electron Transfer in mitochondrial cytochrome c during cell life and death process. 	cytochrome c	608	620	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6642182_OgerInput.txtOger_out.csv:6	Using Quantum Biological Electron Tunnelling spectroscopy, we optically capture real-time Electron Transfer in cytochrome c redox dynamics during cellular apoptosis and necrosis in living cells. 	cytochrome c	926	938	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6642182_OgerInput.txtOger_out.csv:6	Using Quantum Biological Electron Tunnelling spectroscopy, we optically capture real-time Electron Transfer in cytochrome c redox dynamics during cellular apoptosis and necrosis in living cells. 	cytochrome c	926	938	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6642182_OgerInput.txtOger_out.csv:9	Here, the authors demonstrate real-time optical detection of quantum biological electron tunnelling between nanoparticles and cytochrome c inside living cells. 	cytochrome c	1575	1587	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6642182_OgerInput.txtOger_out.csv:9	Here, the authors demonstrate real-time optical detection of quantum biological electron tunnelling between nanoparticles and cytochrome c inside living cells. 	cytochrome c	1575	1587	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6642182_OgerInput.txtOger_out.csv:40	Here, we report the first observation of Quantum Biological Electron Tunnelling in living enzyme cytochrome c (Cyt c), which plays key functions in many metabolic processes as well as life and death decisions, such as respiration^,, apoptosis activation^, the regulation of many diseases, such as diabetes^ and neurodegenerative disorders^. 	cytochrome c	6769	6781	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6642182_OgerInput.txtOger_out.csv:40	Here, we report the first observation of Quantum Biological Electron Tunnelling in living enzyme cytochrome c (Cyt c), which plays key functions in many metabolic processes as well as life and death decisions, such as respiration^,, apoptosis activation^, the regulation of many diseases, such as diabetes^ and neurodegenerative disorders^. 	cytochrome c	6769	6781	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6649120_OgerInput.txtOger_out.csv:50	Consequently, some of these proteins, namely, cytochrome c (Cyt c) and hemoglobin, were also tested for peroxide inactivation and were found to behave in a similar manner as Horseradish Peroxidase (A,B). 	cytochrome c	7393	7405	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6649120_OgerInput.txtOger_out.csv:50	Consequently, some of these proteins, namely, cytochrome c (Cyt c) and hemoglobin, were also tested for peroxide inactivation and were found to behave in a similar manner as Horseradish Peroxidase (A,B). 	cytochrome c	7393	7405	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6724507_OgerInput.txtOger_out.csv:187	Cyanide was also used to inhibit cytochrome c oxidase, preventing the transport of electrons from cytochrome c to oxygen. 	cytochrome c	28816	28828	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6724507_OgerInput.txtOger_out.csv:187	Cyanide was also used to inhibit cytochrome c oxidase, preventing the transport of electrons from cytochrome c to oxygen. 	cytochrome c	28816	28828	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6724507_OgerInput.txtOger_out.csv:187	Cyanide was also used to inhibit cytochrome c oxidase, preventing the transport of electrons from cytochrome c to oxygen. 	cytochrome c	28881	28893	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6724507_OgerInput.txtOger_out.csv:187	Cyanide was also used to inhibit cytochrome c oxidase, preventing the transport of electrons from cytochrome c to oxygen. 	cytochrome c	28881	28893	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:5	This complex has two unique characteristics: (i) it lacks an extracellular cytochrome c, and (ii) the periplasmic decaheme cytochrome c undergoes proteolytic cleavage to produce a functional electron transfer protein. 	cytochrome c	624	636	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:5	This complex has two unique characteristics: (i) it lacks an extracellular cytochrome c, and (ii) the periplasmic decaheme cytochrome c undergoes proteolytic cleavage to produce a functional electron transfer protein. 	cytochrome c	624	636	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:5	This complex has two unique characteristics: (i) it lacks an extracellular cytochrome c, and (ii) the periplasmic decaheme cytochrome c undergoes proteolytic cleavage to produce a functional electron transfer protein. 	cytochrome c	672	684	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:5	This complex has two unique characteristics: (i) it lacks an extracellular cytochrome c, and (ii) the periplasmic decaheme cytochrome c undergoes proteolytic cleavage to produce a functional electron transfer protein. 	cytochrome c	672	684	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:10	Using Rhodopseudomonas palustris TIE-1 as a model, we show that a single periplasmic decaheme cytochrome c, PioA, and an outer membrane porin, PioB, form a complex allowing extracellular electron uptake across the outer membrane from both soluble iron and poised electrodes. 	cytochrome c	1340	1352	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:10	Using Rhodopseudomonas palustris TIE-1 as a model, we show that a single periplasmic decaheme cytochrome c, PioA, and an outer membrane porin, PioB, form a complex allowing extracellular electron uptake across the outer membrane from both soluble iron and poised electrodes. 	cytochrome c	1340	1352	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:27	The Shewanella complex is comprised of a porin (MtrB) and two decaheme cytochrome c proteins (MtrA and MtrC from periplasmic and extracellular sides, respectively) as an electron conduit. 	cytochrome c	4059	4071	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:27	The Shewanella complex is comprised of a porin (MtrB) and two decaheme cytochrome c proteins (MtrA and MtrC from periplasmic and extracellular sides, respectively) as an electron conduit. 	cytochrome c	4059	4071	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:28	Deletion of the extracellular decaheme cytochrome c component of the conduit (MtrC and its paralogues, OmcA and MtrF) abrogates Shewanellas ability to reduce Fe(III) or transfer electrons to electrodes. 	cytochrome c	4215	4227	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:28	Deletion of the extracellular decaheme cytochrome c component of the conduit (MtrC and its paralogues, OmcA and MtrF) abrogates Shewanellas ability to reduce Fe(III) or transfer electrons to electrodes. 	cytochrome c	4215	4227	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:35	The operon encodes PioA, a decaheme cytochrome c (cyt c), PioB, an outer membrane porin, and PioC, a high-potential iron-sulfur protein. 	cytochrome c	5416	5428	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:35	The operon encodes PioA, a decaheme cytochrome c (cyt c), PioB, an outer membrane porin, and PioC, a high-potential iron-sulfur protein. 	cytochrome c	5416	5428	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:43	Therefore, the PioAB complex is distinct from other porin-cytochrome c systems found in nonphototrophic bacteria. 	cytochrome c	6759	6771	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:43	Therefore, the PioAB complex is distinct from other porin-cytochrome c systems found in nonphototrophic bacteria. 	cytochrome c	6759	6771	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6831781_OgerInput.txtOger_out.csv:54	For correct localization of the protein in E. colis periplasm, we replaced the PioA signal peptide with a validated signal peptide of the cytochrome c_4 gene. 	cytochrome c	8639	8651	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6831781_OgerInput.txtOger_out.csv:54	For correct localization of the protein in E. colis periplasm, we replaced the PioA signal peptide with a validated signal peptide of the cytochrome c_4 gene. 	cytochrome c	8639	8651	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6880542_OgerInput.txtOger_out.csv:157	Bacterial respiration takes place via respiratory chain mechanism consisting of (i) NADH-quinone oxidoreductase, (ii) succinate dehydrogenase, (iii) cytochrome c oxidoreductase and (iv) cytochrome c oxidase. 	cytochrome c	19627	19639	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6880542_OgerInput.txtOger_out.csv:157	Bacterial respiration takes place via respiratory chain mechanism consisting of (i) NADH-quinone oxidoreductase, (ii) succinate dehydrogenase, (iii) cytochrome c oxidoreductase and (iv) cytochrome c oxidase. 	cytochrome c	19627	19639	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6880542_OgerInput.txtOger_out.csv:157	Bacterial respiration takes place via respiratory chain mechanism consisting of (i) NADH-quinone oxidoreductase, (ii) succinate dehydrogenase, (iii) cytochrome c oxidoreductase and (iv) cytochrome c oxidase. 	cytochrome c	19664	19676	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6880542_OgerInput.txtOger_out.csv:157	Bacterial respiration takes place via respiratory chain mechanism consisting of (i) NADH-quinone oxidoreductase, (ii) succinate dehydrogenase, (iii) cytochrome c oxidoreductase and (iv) cytochrome c oxidase. 	cytochrome c	19664	19676	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6880542_OgerInput.txtOger_out.csv:213	Various peroxidases use FAD-linked oxidase, cytochrome c oxidase and H_2O_2 generated by them for dynamic participation in LDCs degradation. 	cytochrome c	28400	28412	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6880542_OgerInput.txtOger_out.csv:213	Various peroxidases use FAD-linked oxidase, cytochrome c oxidase and H_2O_2 generated by them for dynamic participation in LDCs degradation. 	cytochrome c	28400	28412	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6962339_OgerInput.txtOger_out.csv:49	A mutant strain of Methanosarcina mazei lacking the gene MM_0633 encoding for the multi-heme cytochrome c family protein (mutant name - M. mazei 633 k.o.) 	cytochrome c	8260	8272	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6962339_OgerInput.txtOger_out.csv:49	A mutant strain of Methanosarcina mazei lacking the gene MM_0633 encoding for the multi-heme cytochrome c family protein (mutant name - M. mazei 633 k.o.) 	cytochrome c	8260	8272	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:24	Part of the RpoS regulon are genes for the cytochrome c oxidase, which is thought to be most likely responsible for cell growth with oxygen, but genes for a cytochrome d ubiquinol oxidase and a rubredoxin-oxygen oxidoreductase have also been found to be regulated by RpoS and encode for enzymes that may play a role in oxygen reduction. 	cytochrome c	3102	3114	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:24	Part of the RpoS regulon are genes for the cytochrome c oxidase, which is thought to be most likely responsible for cell growth with oxygen, but genes for a cytochrome d ubiquinol oxidase and a rubredoxin-oxygen oxidoreductase have also been found to be regulated by RpoS and encode for enzymes that may play a role in oxygen reduction. 	cytochrome c	3102	3114	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:172	Usually in aerobic bacteria, cytochrome bc1 complex and cytochrome c oxidase, which represent complexes III and IV of the oxidative phosphorylation pathway, are responsible for the transportation of electrons from the membrane bound quinon pool to a cytochrome c, which then functions as electron donor for the reduction of oxygen to water. 	cytochrome c	23858	23870	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:172	Usually in aerobic bacteria, cytochrome bc1 complex and cytochrome c oxidase, which represent complexes III and IV of the oxidative phosphorylation pathway, are responsible for the transportation of electrons from the membrane bound quinon pool to a cytochrome c, which then functions as electron donor for the reduction of oxygen to water. 	cytochrome c	23858	23870	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:172	Usually in aerobic bacteria, cytochrome bc1 complex and cytochrome c oxidase, which represent complexes III and IV of the oxidative phosphorylation pathway, are responsible for the transportation of electrons from the membrane bound quinon pool to a cytochrome c, which then functions as electron donor for the reduction of oxygen to water. 	cytochrome c	24052	24064	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:172	Usually in aerobic bacteria, cytochrome bc1 complex and cytochrome c oxidase, which represent complexes III and IV of the oxidative phosphorylation pathway, are responsible for the transportation of electrons from the membrane bound quinon pool to a cytochrome c, which then functions as electron donor for the reduction of oxygen to water. 	cytochrome c	24052	24064	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:173	The cytochrome c oxidase was formerly suspected to be the enzyme responsible for oxygen reduction in G. sulfurreducens. 	cytochrome c	24147	24159	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:173	The cytochrome c oxidase was formerly suspected to be the enzyme responsible for oxygen reduction in G. sulfurreducens. 	cytochrome c	24147	24159	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:176	These authors even reported that cell growth with oxygen was impossible without cytochrome c oxidase (W. Lin, unpublished results according to). 	cytochrome c	24483	24495	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:176	These authors even reported that cell growth with oxygen was impossible without cytochrome c oxidase (W. Lin, unpublished results according to). 	cytochrome c	24483	24495	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6964889_OgerInput.txtOger_out.csv:189	This organism contains two oxygen reductases, a c-type oxidase cc(b/o)c_3 cytochrome oxidase) and a bd-type quinol oxidase, both are similar to the cytochrome c oxidase (98% query coverage and 61.12% identity) and the cytochrome bd menaquinol oxidase (99% query coverage and 57.47% identity) of G. sulfurreducens, respectively (determined by BLASTP). 	cytochrome c	26550	26562	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6964889_OgerInput.txtOger_out.csv:189	This organism contains two oxygen reductases, a c-type oxidase cc(b/o)c_3 cytochrome oxidase) and a bd-type quinol oxidase, both are similar to the cytochrome c oxidase (98% query coverage and 61.12% identity) and the cytochrome bd menaquinol oxidase (99% query coverage and 57.47% identity) of G. sulfurreducens, respectively (determined by BLASTP). 	cytochrome c	26550	26562	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome c	16989	17001	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome c	16989	17001	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome c	17190	17202	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome c	17190	17202	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:5	S. oneidensis MR-1 encodes two cytochrome c synthetases (CcmF and SirE) and two apocytochrome c chaperones (CcmI and SirG). 	cytochrome c	538	550	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:5	S. oneidensis MR-1 encodes two cytochrome c synthetases (CcmF and SirE) and two apocytochrome c chaperones (CcmI and SirG). 	cytochrome c	538	550	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:29	SO_0265 was identified as ccmI, and was initially determined to have a nonessential role in cytochrome c maturation in S. oneidensis^, but subsequently found to have a role in maturation of canonical heme binding motifs and to be required for maturation of the nitrite reductase, NrfA^. 	cytochrome c	3875	3887	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:29	SO_0265 was identified as ccmI, and was initially determined to have a nonessential role in cytochrome c maturation in S. oneidensis^, but subsequently found to have a role in maturation of canonical heme binding motifs and to be required for maturation of the nitrite reductase, NrfA^. 	cytochrome c	3875	3887	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:133	SirEF are similar to the NrfEF cytochrome c synthetase and thiol-oxidoreductase that are required for heme ligation to the CXXCK site in NrfA (31). 	cytochrome c	18402	18414	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:133	SirEF are similar to the NrfEF cytochrome c synthetase and thiol-oxidoreductase that are required for heme ligation to the CXXCK site in NrfA (31). 	cytochrome c	18402	18414	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:157	These results indicated that the sulfite reduction deficiency observed in the cytochrome c maturation mutants was due to decreased protein levels, most likely due to instability and degradation of the unmatured apoprotein. 	cytochrome c	22371	22383	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:157	These results indicated that the sulfite reduction deficiency observed in the cytochrome c maturation mutants was due to decreased protein levels, most likely due to instability and degradation of the unmatured apoprotein. 	cytochrome c	22371	22383	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:168	In bacteria, System I (Ccm) or System II (Ccs) is required for holocytochrome c maturation and involves an apocytochrome c chaperone and a cytochrome c synthetase. 	cytochrome c	24321	24333	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:168	In bacteria, System I (Ccm) or System II (Ccs) is required for holocytochrome c maturation and involves an apocytochrome c chaperone and a cytochrome c synthetase. 	cytochrome c	24321	24333	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:173	Recently, CcmI_So (SO_0265) was identified as a cytochrome c maturation protein required for maturation of the nitrite reductase NrfA^, and that we predicted functions as an apocytochrome c chaperone for maturation of the sulfite reductase SirA. 	cytochrome c	25280	25292	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:173	Recently, CcmI_So (SO_0265) was identified as a cytochrome c maturation protein required for maturation of the nitrite reductase NrfA^, and that we predicted functions as an apocytochrome c chaperone for maturation of the sulfite reductase SirA. 	cytochrome c	25280	25292	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:181	The lack of a dedicated cytochrome c synthetase system for maturation of the nitrite reductase in S. oneidensis, suggests that CcmFHI may form the heme lyase complex responsible for heme attachment to the CXXCK site. 	cytochrome c	26592	26604	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:181	The lack of a dedicated cytochrome c synthetase system for maturation of the nitrite reductase in S. oneidensis, suggests that CcmFHI may form the heme lyase complex responsible for heme attachment to the CXXCK site. 	cytochrome c	26592	26604	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:200	SirEF, which are similar to cytochrome c synthetases (CcmF) and thiol oxidoreductases (CcmH)^, appear to be essential for sulfite reductase activity and stability. 	cytochrome c	29660	29672	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:200	SirEF, which are similar to cytochrome c synthetases (CcmF) and thiol oxidoreductases (CcmH)^, appear to be essential for sulfite reductase activity and stability. 	cytochrome c	29660	29672	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:201	Our results suggest that SirA requires a dedicated cytochrome c synthetase for its maturation, but unlike other c-type cytochromes studied to date, it appears to require two apocytochrome c chaperones for this process. 	cytochrome c	29847	29859	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:201	Our results suggest that SirA requires a dedicated cytochrome c synthetase for its maturation, but unlike other c-type cytochromes studied to date, it appears to require two apocytochrome c chaperones for this process. 	cytochrome c	29847	29859	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:204	Our results described above, in combination with previously published findings, indicate an unusual cytochrome c maturation system in S. oneidensis. 	cytochrome c	30499	30511	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:204	Our results described above, in combination with previously published findings, indicate an unusual cytochrome c maturation system in S. oneidensis. 	cytochrome c	30499	30511	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6976685_OgerInput.txtOger_out.csv:210	These findings add another twist to the already complex mechanism of cytochrome c maturation in bacteria.	cytochrome c	31233	31245	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6976685_OgerInput.txtOger_out.csv:210	These findings add another twist to the already complex mechanism of cytochrome c maturation in bacteria.	cytochrome c	31233	31245	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:252	On the other hand, Ferredoxin did not stimulate the formation of O_2^ measured using O_2^ traps such as epinephrine or cytochrome c. This suggests that the formation of O_2^ by exogenous Ferredoxin is very slow in comparison to the formation of O_2^ by thylakoid-bound photoreductants. 	cytochrome c	35452	35464	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:252	On the other hand, Ferredoxin did not stimulate the formation of O_2^ measured using O_2^ traps such as epinephrine or cytochrome c. This suggests that the formation of O_2^ by exogenous Ferredoxin is very slow in comparison to the formation of O_2^ by thylakoid-bound photoreductants. 	cytochrome c	35452	35464	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:405	Formation of 21 mol O_2^ (mg Chl)^1 h^1, measured as an SOD-dependent cytochrome c reduction, was observed in D1/D2/cytochrome b559 complexes illuminated at 200 W m^2 in the presence of an artificial electron donor. 	cytochrome c	59448	59460	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:405	Formation of 21 mol O_2^ (mg Chl)^1 h^1, measured as an SOD-dependent cytochrome c reduction, was observed in D1/D2/cytochrome b559 complexes illuminated at 200 W m^2 in the presence of an artificial electron donor. 	cytochrome c	59448	59460	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:492	It has been shown that both the photoreduction of cytochrome c and photooxidation of epinephrine, which have been used as traps for O_2^, were inhibited by SOD. 	cytochrome c	73080	73092	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:492	It has been shown that both the photoreduction of cytochrome c and photooxidation of epinephrine, which have been used as traps for O_2^, were inhibited by SOD. 	cytochrome c	73080	73092	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:560	The accumulation of H_2O_2 in a thylakoid suspension in the presence of cytochrome c, that reacts with O_2^ in aqueous phase (Reaction (31)) preventing the dismutation of O_2^, was attributed to the formation of H_2O_2 within the thylakoid membrane via Reaction (114). 	cytochrome c	84516	84528	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:560	The accumulation of H_2O_2 in a thylakoid suspension in the presence of cytochrome c, that reacts with O_2^ in aqueous phase (Reaction (31)) preventing the dismutation of O_2^, was attributed to the formation of H_2O_2 within the thylakoid membrane via Reaction (114). 	cytochrome c	84516	84528	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:585	The amount of detectable O_2^, measured using cytochrome c as a trap of O_2^, was found to be about 25% of the amount of O_2^ estimated from the O_2 consumption rate. 	cytochrome c	88157	88169	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:585	The amount of detectable O_2^, measured using cytochrome c as a trap of O_2^, was found to be about 25% of the amount of O_2^ estimated from the O_2 consumption rate. 	cytochrome c	88157	88169	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:589	Thylakoid membranes have also been shown to accumulate H_2O_2 in the presence of cytochrome c that reacts with O_2^ and prevents the formation of H_2O_2 via superoxide dismutation (Reaction (31)). 	cytochrome c	88907	88919	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:589	Thylakoid membranes have also been shown to accumulate H_2O_2 in the presence of cytochrome c that reacts with O_2^ and prevents the formation of H_2O_2 via superoxide dismutation (Reaction (31)). 	cytochrome c	88907	88919	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:591	These results contradict with the results of Asada et al., where cytochrome c completely inhibited H_2O_2 formation by thylakoids. 	cytochrome c	89270	89282	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:591	These results contradict with the results of Asada et al., where cytochrome c completely inhibited H_2O_2 formation by thylakoids. 	cytochrome c	89270	89282	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:592	However, in a later work of Takahashi and Asada, the formation of H_2O_2 in the presence of cytochrome c was shown. 	cytochrome c	89428	89440	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7020446_OgerInput.txtOger_out.csv:592	However, in a later work of Takahashi and Asada, the formation of H_2O_2 in the presence of cytochrome c was shown. 	cytochrome c	89428	89440	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:47	In fact, cytotoxic effects of exogenous Carbon Monoxide involve cytochrome c oxidase inhibition and defects on mitochondrial metabolism and energy production. 	cytochrome c	7442	7454	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:47	In fact, cytotoxic effects of exogenous Carbon Monoxide involve cytochrome c oxidase inhibition and defects on mitochondrial metabolism and energy production. 	cytochrome c	7442	7454	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:49	Likewise in HEK293 cells, it was also demonstrated that HO-1 overexpression and endogenous Carbon Monoxide production also moderately decreased cellular respiration along with partial inhibition of cytochrome c oxidase. 	cytochrome c	7876	7888	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:49	Likewise in HEK293 cells, it was also demonstrated that HO-1 overexpression and endogenous Carbon Monoxide production also moderately decreased cellular respiration along with partial inhibition of cytochrome c oxidase. 	cytochrome c	7876	7888	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:50	In fact, Carbon Monoxide binds to cytochrome c oxidase and slows down the rate of electron transport, leading to electrons accumulation, in particular at complex III. 	cytochrome c	7932	7944	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:50	In fact, Carbon Monoxide binds to cytochrome c oxidase and slows down the rate of electron transport, leading to electrons accumulation, in particular at complex III. 	cytochrome c	7932	7944	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:52	Likewise, CO-mediated inhibition of cytochrome c oxidase can be partial or transitory, which enables low levels of ROS production without further damaging mitochondria. 	cytochrome c	8371	8383	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:52	Likewise, CO-mediated inhibition of cytochrome c oxidase can be partial or transitory, which enables low levels of ROS production without further damaging mitochondria. 	cytochrome c	8371	8383	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:54	Low concentrations of exogenous Carbon Monoxide partially inhibited cytochrome c activity, generating mitochondrial ROS, which in turn limited LPS-induced inflammation by promoting p38 MAPK phosphorylation and decreasing TNF-ALPHA levels. 	cytochrome c	8721	8733	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:54	Low concentrations of exogenous Carbon Monoxide partially inhibited cytochrome c activity, generating mitochondrial ROS, which in turn limited LPS-induced inflammation by promoting p38 MAPK phosphorylation and decreasing TNF-ALPHA levels. 	cytochrome c	8721	8733	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:63	Subcellular localization of Carbon Monoxide can also regulate ROS production, for instance Taill and colleagues have demonstrated that CORM-2 treatment inhibited the activity of NAD(P)H oxidase cytochrome b_558, which decreases plasmatic membrane ROS production, while there is an increase on mitochondrial ROS generation by targeting cytochrome c oxidase. 	cytochrome c	10569	10581	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:63	Subcellular localization of Carbon Monoxide can also regulate ROS production, for instance Taill and colleagues have demonstrated that CORM-2 treatment inhibited the activity of NAD(P)H oxidase cytochrome b_558, which decreases plasmatic membrane ROS production, while there is an increase on mitochondrial ROS generation by targeting cytochrome c oxidase. 	cytochrome c	10569	10581	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:84	Moreover, the same researchers also shown that under hypoxia, HIF-1 modulates the expression of cytochrome c oxidase subunit 4, by decreasing COX4-1 and increasing COX4-2, which promotes COX activity, oxygen consumption and ATP production. 	cytochrome c	14362	14374	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:84	Moreover, the same researchers also shown that under hypoxia, HIF-1 modulates the expression of cytochrome c oxidase subunit 4, by decreasing COX4-1 and increasing COX4-2, which promotes COX activity, oxygen consumption and ATP production. 	cytochrome c	14362	14374	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:94	Likewise, knockdown expression of Transcription Factor Eb also decrease expression of lysosomal genes (Lamp1, cathepsin B and TPP1), along with a decrease on mitochondrial DNA, mitochondrial biogenesis markers (PGC-1ALPHA, Nrf1 and TFAM) and mitochondrial proteins, such as COX II, COX IV and cytochrome c. In summary, Transcription Factor Eb emerges as a key regulator of CO-dependent cytoprotection in hepatocytes, being associated with modulation of Mitochondria Via Autophagy and mitochondrial biogenesis. 	cytochrome c	15988	16000	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:94	Likewise, knockdown expression of Transcription Factor Eb also decrease expression of lysosomal genes (Lamp1, cathepsin B and TPP1), along with a decrease on mitochondrial DNA, mitochondrial biogenesis markers (PGC-1ALPHA, Nrf1 and TFAM) and mitochondrial proteins, such as COX II, COX IV and cytochrome c. In summary, Transcription Factor Eb emerges as a key regulator of CO-dependent cytoprotection in hepatocytes, being associated with modulation of Mitochondria Via Autophagy and mitochondrial biogenesis. 	cytochrome c	15988	16000	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:109	Overexpression of HO-1 or its up-regulation by treatment with cobalt protoporphyrin leaded to a robust increase in carnitine, citrate, deoxynucleotide, dicarboxylate and ADP/ATP carriers, along with an increase on cytochrome c oxidase activity, suggesting an improvement on mitochondrial metabolism. 	cytochrome c	18962	18974	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:109	Overexpression of HO-1 or its up-regulation by treatment with cobalt protoporphyrin leaded to a robust increase in carnitine, citrate, deoxynucleotide, dicarboxylate and ADP/ATP carriers, along with an increase on cytochrome c oxidase activity, suggesting an improvement on mitochondrial metabolism. 	cytochrome c	18962	18974	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:111	Carbon Monoxide protection against Membrane Permeabilization was assessed by inhibition of mitochondrial swelling, mitochondrial depolarization, inner membrane permeabilization and cytochrome c release, as well as by modulation of cytochrome c oxidase activity. 	cytochrome c	19467	19479	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:111	Carbon Monoxide protection against Membrane Permeabilization was assessed by inhibition of mitochondrial swelling, mitochondrial depolarization, inner membrane permeabilization and cytochrome c release, as well as by modulation of cytochrome c oxidase activity. 	cytochrome c	19467	19479	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:111	Carbon Monoxide protection against Membrane Permeabilization was assessed by inhibition of mitochondrial swelling, mitochondrial depolarization, inner membrane permeabilization and cytochrome c release, as well as by modulation of cytochrome c oxidase activity. 	cytochrome c	19517	19529	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:111	Carbon Monoxide protection against Membrane Permeabilization was assessed by inhibition of mitochondrial swelling, mitochondrial depolarization, inner membrane permeabilization and cytochrome c release, as well as by modulation of cytochrome c oxidase activity. 	cytochrome c	19517	19529	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:113	In addition, Carbon Monoxide transiently decreased specific activity of cytochrome c oxidase during the first 10 min of exposition and at 30 min there was an increase of its activity. 	cytochrome c	19816	19828	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:113	In addition, Carbon Monoxide transiently decreased specific activity of cytochrome c oxidase during the first 10 min of exposition and at 30 min there was an increase of its activity. 	cytochrome c	19816	19828	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:114	This CO-induced two-step response in cytochrome c activity was also observed in non-synaptic mitochondria isolated from rat cortex. 	cytochrome c	19965	19977	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:114	This CO-induced two-step response in cytochrome c activity was also observed in non-synaptic mitochondria isolated from rat cortex. 	cytochrome c	19965	19977	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:116	Carbon Monoxide pushed the glycolysis/oxidative phosphorylation balance towards Glycolysis/Oxidative Phosphorylation and increased specific activity of cytochrome c oxidase, along with an enhancement of mitochondrial population. 	cytochrome c	20388	20400	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:116	Carbon Monoxide pushed the glycolysis/oxidative phosphorylation balance towards Glycolysis/Oxidative Phosphorylation and increased specific activity of cytochrome c oxidase, along with an enhancement of mitochondrial population. 	cytochrome c	20388	20400	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:119	Therefore, one may speculate that Carbon Monoxide generates small amounts of ROS by partially and transitorily inhibiting cytochrome c oxidase. 	cytochrome c	20973	20985	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:119	Therefore, one may speculate that Carbon Monoxide generates small amounts of ROS by partially and transitorily inhibiting cytochrome c oxidase. 	cytochrome c	20973	20985	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:120	These ROS act as signaling molecules that, in turn, improve mitochondrial metabolism and function; including cytochrome c oxidase activity. 	cytochrome c	21104	21116	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:120	These ROS act as signaling molecules that, in turn, improve mitochondrial metabolism and function; including cytochrome c oxidase activity. 	cytochrome c	21104	21116	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:121	Nevertheless, the molecular mechanisms underlying this dual effect of Carbon Monoxide on cytochrome c oxidase activity is not yet clearly disclosed. 	cytochrome c	21224	21236	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:121	Nevertheless, the molecular mechanisms underlying this dual effect of Carbon Monoxide on cytochrome c oxidase activity is not yet clearly disclosed. 	cytochrome c	21224	21236	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:229	The fact that Carbon Monoxide targets mitochondria, in particular cytochrome c oxidase, originates several consequences: (i) generation of ROS for downstream signaling, (ii) alterations in oxygen consumption implying uncoupling effects and/or improvement of mitochondrial respiration and ATP production, (iii) regulation of mitochondrial quality control, including mitochondrial biogenesis, Mitochondria Via Autophagy and fusion/fission. 	cytochrome c	39270	39282	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:229	The fact that Carbon Monoxide targets mitochondria, in particular cytochrome c oxidase, originates several consequences: (i) generation of ROS for downstream signaling, (ii) alterations in oxygen consumption implying uncoupling effects and/or improvement of mitochondrial respiration and ATP production, (iii) regulation of mitochondrial quality control, including mitochondrial biogenesis, Mitochondria Via Autophagy and fusion/fission. 	cytochrome c	39270	39282	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:301	Citrate synthase and complex I-IV activities were determined by monitoring appearance or disappearance of specific substrates at specific wavelengths using spectrophotometry (eg, oxidation of NADH for complex I activity at 340 nm in the presence and absence of rotenone to evaluate complex I-specific activity, reduction of cytochrome c for complex III activity at 550 nm). 	cytochrome c	53382	53394	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7069944_OgerInput.txtOger_out.csv:301	Citrate synthase and complex I-IV activities were determined by monitoring appearance or disappearance of specific substrates at specific wavelengths using spectrophotometry (eg, oxidation of NADH for complex I activity at 340 nm in the presence and absence of rotenone to evaluate complex I-specific activity, reduction of cytochrome c for complex III activity at 550 nm). 	cytochrome c	53382	53394	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:1	 Porcine deltacoronavirus induces caspase-dependent apoptosis through activation of the cytochrome c-mediated intrinsic mitochondrial pathway. 	cytochrome c	88	100	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:1	 Porcine deltacoronavirus induces caspase-dependent apoptosis through activation of the cytochrome c-mediated intrinsic mitochondrial pathway. 	cytochrome c	88	100	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:4	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	498	510	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:4	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	498	510	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:5	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	553	565	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:5	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	553	565	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:9	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	1102	1114	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:9	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	1102	1114	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:10	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	1157	1169	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:10	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	1157	1169	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:16	Experimental data indicated that Porcine Deltacoronavirus infection led to Bax-mediated mitochondrial outer membrane permeabilization, resulting in specific relocation of the mitochondrial cytochrome c (cyt c) into the cytoplasm. 	cytochrome c	2279	2291	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:16	Experimental data indicated that Porcine Deltacoronavirus infection led to Bax-mediated mitochondrial outer membrane permeabilization, resulting in specific relocation of the mitochondrial cytochrome c (cyt c) into the cytoplasm. 	cytochrome c	2279	2291	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:42	Antibodies specific for cytochrome c (cyt c), apoptosis-inducing factor, Bax, Sp1, and BETA-actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 	cytochrome c	6588	6600	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:42	Antibodies specific for cytochrome c (cyt c), apoptosis-inducing factor, Bax, Sp1, and BETA-actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 	cytochrome c	6588	6600	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	623	635	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	623	635	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	660	672	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	660	672	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:8	In addition, cells with predominantly ferrous cytochrome c content were found in deprived Nitrosomonas eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	1285	1297	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:8	In addition, cells with predominantly ferrous cytochrome c content were found in deprived Nitrosomonas eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	1285	1297	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:24	The electron transport along these pathways is predominantly performed by several cytochrome c proteins, some of which hold more than one heme c in their protic matrix. 	cytochrome c	4191	4203	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:24	The electron transport along these pathways is predominantly performed by several cytochrome c proteins, some of which hold more than one heme c in their protic matrix. 	cytochrome c	4191	4203	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:25	For a scheme of the electron transport and the ammonia oxidation pathways for N. europaea, including the associated cytochrome c proteins, see Sedlacek et al.. A comparative quantitative proteomic study of growing and ammonia-starved N. europaea cells by Pellitteri-Hahn et al. 	cytochrome c	4394	4406	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:25	For a scheme of the electron transport and the ammonia oxidation pathways for N. europaea, including the associated cytochrome c proteins, see Sedlacek et al.. A comparative quantitative proteomic study of growing and ammonia-starved N. europaea cells by Pellitteri-Hahn et al. 	cytochrome c	4394	4406	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:26	found that energy-starved cells shifted their cellular activity from biosynthesis toward cellular survival functions, reporting a significantly increased abundance of cytochrome c in the ammonia-starved cells as compared to growing cells, which was interpreted as a cellular strategy for a rapid growth response. 	cytochrome c	4723	4735	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:26	found that energy-starved cells shifted their cellular activity from biosynthesis toward cellular survival functions, reporting a significantly increased abundance of cytochrome c in the ammonia-starved cells as compared to growing cells, which was interpreted as a cellular strategy for a rapid growth response. 	cytochrome c	4723	4735	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:29	The mRNA levels for cytochrome c reported by Wei et al. 	cytochrome c	5150	5162	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:29	The mRNA levels for cytochrome c reported by Wei et al. 	cytochrome c	5150	5162	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7569	7581	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7569	7581	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7768	7780	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7768	7780	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:45	Hu et al., in their annotation of the resonance Raman spectra of extracted cytochrome c, previously reported large changes in both the resonant excitation wavelength and the specifically enhanced molecular vibrations dependent on the redox state of the protein. 	cytochrome c	7909	7921	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:45	Hu et al., in their annotation of the resonance Raman spectra of extracted cytochrome c, previously reported large changes in both the resonant excitation wavelength and the specifically enhanced molecular vibrations dependent on the redox state of the protein. 	cytochrome c	7909	7921	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:48	cm^1, which at 532 nm excitation is one of the strongest Raman lines in ferrous cytochrome c, but is very weak if the protein is in ferric state. 	cytochrome c	8328	8340	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:48	cm^1, which at 532 nm excitation is one of the strongest Raman lines in ferrous cytochrome c, but is very weak if the protein is in ferric state. 	cytochrome c	8328	8340	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome c	8513	8525	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome c	8513	8525	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:53	monitored photothermally induced mitochondrially mediated apoptosis in situ based on the Raman spectrum of cytochrome c, using surface-enhanced resonant Raman microscopy with gold nanoparticles and 785 nm excitation. 	cytochrome c	8792	8804	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:53	monitored photothermally induced mitochondrially mediated apoptosis in situ based on the Raman spectrum of cytochrome c, using surface-enhanced resonant Raman microscopy with gold nanoparticles and 785 nm excitation. 	cytochrome c	8792	8804	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:55	for the quantitative detection of cytochrome c in living cells, and Zhu et al. 	cytochrome c	9003	9015	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:55	for the quantitative detection of cytochrome c in living cells, and Zhu et al. 	cytochrome c	9003	9015	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:56	studied the influence of redox state on cytochrome c release in apoptosis using Raman microscopy with nickel substrates. 	cytochrome c	9088	9100	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:56	studied the influence of redox state on cytochrome c release in apoptosis using Raman microscopy with nickel substrates. 	cytochrome c	9088	9100	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:57	In this work, we present a proof of concept of the use of straightforward confocal Raman microscopy with 532 nm excitation, resonant to the Q-band of the heme c moiety in cytochrome c, to non-invasively and in vivo analyze the response of four species of AOB, Nitrosomonas europaea, Nitrosomonas eutropha, Nitrosospira briensis, and Nitrosospira species. 	cytochrome c	9340	9352	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:57	In this work, we present a proof of concept of the use of straightforward confocal Raman microscopy with 532 nm excitation, resonant to the Q-band of the heme c moiety in cytochrome c, to non-invasively and in vivo analyze the response of four species of AOB, Nitrosomonas europaea, Nitrosomonas eutropha, Nitrosospira briensis, and Nitrosospira species. 	cytochrome c	9340	9352	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:58	to oxygen deprivation in comparison to non-oxygen-deprived cultures based on 1000 individual cells per sampling, confirming elevated cytochrome c content and activity following oxygen deprivation in a purely optical measurement with low impact on culture volumes. 	cytochrome c	9657	9669	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:58	to oxygen deprivation in comparison to non-oxygen-deprived cultures based on 1000 individual cells per sampling, confirming elevated cytochrome c content and activity following oxygen deprivation in a purely optical measurement with low impact on culture volumes. 	cytochrome c	9657	9669	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:79	A frequency-doubled continuous-wave Nd:YAG laser at 531.9 nm, suitable for resonantly enhancing the Q-band of the heme c moiety of cytochrome c in its ferrous (Fe^2+) state, was used for excitation. 	cytochrome c	13036	13048	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:79	A frequency-doubled continuous-wave Nd:YAG laser at 531.9 nm, suitable for resonantly enhancing the Q-band of the heme c moiety of cytochrome c in its ferrous (Fe^2+) state, was used for excitation. 	cytochrome c	13036	13048	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:105	The Raman lines of the four main vibrations of resonantly excited cytochrome c, _15, _22, _21, and _19 at 750, 1130, 1314, and 1587 rel. 	cytochrome c	16061	16073	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:105	The Raman lines of the four main vibrations of resonantly excited cytochrome c, _15, _22, _21, and _19 at 750, 1130, 1314, and 1587 rel. 	cytochrome c	16061	16073	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16670	16682	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16670	16682	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16815	16827	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16815	16827	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	16976	16988	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	16976	16988	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	17028	17040	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	17028	17040	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:118	cm^1 and used it to differentiate between healthy and apoptotic and pre-apoptotic brain cells of Mongolian gerbils, associating the line shift with cytochrome c deformation due to the protein binding to membrane elements. 	cytochrome c	17507	17519	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:118	cm^1 and used it to differentiate between healthy and apoptotic and pre-apoptotic brain cells of Mongolian gerbils, associating the line shift with cytochrome c deformation due to the protein binding to membrane elements. 	cytochrome c	17507	17519	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:119	A similar observation was reported earlier by Murgida and Hildebrandt, who saw a 10 cm^1 upshift in the line of the _19 vibration in ferrous compared to ferric cytochrome c adsorbed to a surface-enhanced Raman active substrate. 	cytochrome c	17741	17753	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:119	A similar observation was reported earlier by Murgida and Hildebrandt, who saw a 10 cm^1 upshift in the line of the _19 vibration in ferrous compared to ferric cytochrome c adsorbed to a surface-enhanced Raman active substrate. 	cytochrome c	17741	17753	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	17961	17973	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	17961	17973	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18070	18082	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18070	18082	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18174	18186	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18174	18186	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:122	Therefore, the relative intensity (I_Raman) of the two Raman lines (relRI) could be used as a functional marker for the summarized redox state (ferrous versus ferric) of all the cytochrome c of the respective bacterial cell, and thus its ongoing electron transport activity at the time of measurement  with I_Raman being the intensity of the Raman line associated with the respective vibration in the spectrum of that individual bacterial cell. 	cytochrome c	18525	18537	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:122	Therefore, the relative intensity (I_Raman) of the two Raman lines (relRI) could be used as a functional marker for the summarized redox state (ferrous versus ferric) of all the cytochrome c of the respective bacterial cell, and thus its ongoing electron transport activity at the time of measurement  with I_Raman being the intensity of the Raman line associated with the respective vibration in the spectrum of that individual bacterial cell. 	cytochrome c	18525	18537	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:136	The elevated cytochrome c activity of oxygen-deprived N. eutropha and Nitrosospira fit well with the results reported by Sedlacek et al. 	cytochrome c	22228	22240	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:136	The elevated cytochrome c activity of oxygen-deprived N. eutropha and Nitrosospira fit well with the results reported by Sedlacek et al. 	cytochrome c	22228	22240	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22432	22444	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22432	22444	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22530	22542	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22530	22542	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:139	used transcriptomics on stressed N. europaea to elucidate the stress response to either ammonia or oxygen limitation, reporting that the transcripts for protein-encoding genes related to energy production and conservation, including for the proteins AMO, HAO, and NOR, were increased during oxygen-deprived growth, while three cytochrome c proteins associated with the ammonia-oxidizing pathway were even among the top 20% of genes transcribed under stress conditions. 	cytochrome c	22962	22974	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:139	used transcriptomics on stressed N. europaea to elucidate the stress response to either ammonia or oxygen limitation, reporting that the transcripts for protein-encoding genes related to energy production and conservation, including for the proteins AMO, HAO, and NOR, were increased during oxygen-deprived growth, while three cytochrome c proteins associated with the ammonia-oxidizing pathway were even among the top 20% of genes transcribed under stress conditions. 	cytochrome c	22962	22974	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23256	23268	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23256	23268	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23381	23393	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23381	23393	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:141	The observed differences in cytochrome c activity of Nitrosospira briensis and Nitrosospira species (Nsp 02) correlated well with their respective oxygenation histories (compare. 	cytochrome c	23432	23444	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:141	The observed differences in cytochrome c activity of Nitrosospira briensis and Nitrosospira species (Nsp 02) correlated well with their respective oxygenation histories (compare. 	cytochrome c	23432	23444	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:142	Nitrosospira briensis has been reported to have decreasing AMO mRNA expression during starvation, but to rapidly recover after starvation periods of up to two weeks, with only small changes in the soluble proteins, including cytochrome c, between growing and ammonium-starved cells. 	cytochrome c	23808	23820	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:142	Nitrosospira briensis has been reported to have decreasing AMO mRNA expression during starvation, but to rapidly recover after starvation periods of up to two weeks, with only small changes in the soluble proteins, including cytochrome c, between growing and ammonium-starved cells. 	cytochrome c	23808	23820	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:147	However, the relRI trends of N. europaea did not show an elevated cytochrome c activity indicative of a noticeable stress response in its cells at all (see b). 	cytochrome c	24385	24397	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:147	However, the relRI trends of N. europaea did not show an elevated cytochrome c activity indicative of a noticeable stress response in its cells at all (see b). 	cytochrome c	24385	24397	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:153	Interestingly, the oxygen-deprived N. eutropha appeared to have a significantly more evenly distributed cytochrome c activity, with its relRI ranging from 1.7 to 1.9, than non-deprived N. eutropha, with a relRI range from 1.2 to 1.75 (see. 	cytochrome c	25536	25548	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:153	Interestingly, the oxygen-deprived N. eutropha appeared to have a significantly more evenly distributed cytochrome c activity, with its relRI ranging from 1.7 to 1.9, than non-deprived N. eutropha, with a relRI range from 1.2 to 1.75 (see. 	cytochrome c	25536	25548	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:48	In line with previous evidence, the level of cytosolic cytochrome-c was already detectable 2 h after Oxygen-Glucose Deprivation and further increased at 6 h. CSP-1103 significantly prevented cytochrome-c release from 2 h on (A-D). 	cytochrome-c	8809	8821	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:48	In line with previous evidence, the level of cytosolic cytochrome-c was already detectable 2 h after Oxygen-Glucose Deprivation and further increased at 6 h. CSP-1103 significantly prevented cytochrome-c release from 2 h on (A-D). 	cytochrome-c	8809	8821	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5297816_OgerInput.txtOger_out.csv:48	In line with previous evidence, the level of cytosolic cytochrome-c was already detectable 2 h after Oxygen-Glucose Deprivation and further increased at 6 h. CSP-1103 significantly prevented cytochrome-c release from 2 h on (A-D). 	cytochrome-c	8945	8957	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5297816_OgerInput.txtOger_out.csv:48	In line with previous evidence, the level of cytosolic cytochrome-c was already detectable 2 h after Oxygen-Glucose Deprivation and further increased at 6 h. CSP-1103 significantly prevented cytochrome-c release from 2 h on (A-D). 	cytochrome-c	8945	8957	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5665621_OgerInput.txtOger_out.csv:56	Selection of a laser excitation wavelength corresponding to the electronic absorption maximum of a particular chemical^ (for example 530.9 nm will excite cytochromes)^ enhances the Raman signal of particular bands by a factor of 10^3-10^5 (ref.. This has been used to extensively study haemoglobin and observe cytochrome-c release from mitochondria during apoptosis. 	cytochrome-c	8415	8427	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5665621_OgerInput.txtOger_out.csv:56	Selection of a laser excitation wavelength corresponding to the electronic absorption maximum of a particular chemical^ (for example 530.9 nm will excite cytochromes)^ enhances the Raman signal of particular bands by a factor of 10^3-10^5 (ref.. This has been used to extensively study haemoglobin and observe cytochrome-c release from mitochondria during apoptosis. 	cytochrome-c	8415	8427	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5779948_OgerInput.txtOger_out.csv:7	The protein expression levels of total ALPHA-SYN, phosphorylated Ser129 ALPHA-SYN, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein and cytochrome-c (Cyt-c) were analyzed by western blotting. 	cytochrome-c	811	823	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5779948_OgerInput.txtOger_out.csv:7	The protein expression levels of total ALPHA-SYN, phosphorylated Ser129 ALPHA-SYN, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein and cytochrome-c (Cyt-c) were analyzed by western blotting. 	cytochrome-c	811	823	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:34	They reported that the heme-copper-containing cytochrome-c oxidases encoded by N. europaea were upregulated during oxygen-limited growth. 	cytochrome-c	5764	5776	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:34	They reported that the heme-copper-containing cytochrome-c oxidases encoded by N. europaea were upregulated during oxygen-limited growth. 	cytochrome-c	5764	5776	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:43	Incidentally, we used confocal Raman microscopy with cytochrome-c-resonant excitation at 532 nm and hierarchical cluster analysis for the in vivo discrimination and identification of several species of purple non-sulfur bacteria and AOB in planktonic cultures, as well as associated in microbial wastewater biofilms. 	cytochrome-c	7137	7149	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:43	Incidentally, we used confocal Raman microscopy with cytochrome-c-resonant excitation at 532 nm and hierarchical cluster analysis for the in vivo discrimination and identification of several species of purple non-sulfur bacteria and AOB in planktonic cultures, as well as associated in microbial wastewater biofilms. 	cytochrome-c	7137	7149	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome-c	8444	8456	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome-c	8444	8456	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:96	Since cytochrome-c-resonant Raman spectra always contain a fluorescent background originating from the cytochrome itself, the Raman spectra were baseline corrected using the IMM algorithm developed by Koch et al., which combines computational efficiency with reliable maintaining of line shapes and relative intensities against the background of strong fluorescence often found in Raman spectra recorded in vivo. 	cytochrome-c	14664	14676	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:96	Since cytochrome-c-resonant Raman spectra always contain a fluorescent background originating from the cytochrome itself, the Raman spectra were baseline corrected using the IMM algorithm developed by Koch et al., which combines computational efficiency with reliable maintaining of line shapes and relative intensities against the background of strong fluorescence often found in Raman spectra recorded in vivo. 	cytochrome-c	14664	14676	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:224	We studied the cytochrome P450 superfamily in detail, as it is known for its crucial role in resistance to xenobiotics [,. 	cytochrome P450 superfamily	30020	30047	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5333191_OgerInput.txtOger_out.csv:224	We studied the cytochrome P450 superfamily in detail, as it is known for its crucial role in resistance to xenobiotics [,. 	cytochrome P450 superfamily	30020	30047	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	cytochrome P450 superfamily	23809	23836	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:134	Similar to other toxic effects of TCDD, DNA oxidation damage and oxidative stress have been assumed to be connected with the AhR and activation of cytochrome P450 superfamily of enzymes, especially CYP1A1. 	cytochrome P450 superfamily	23809	23836	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:160	DNA oxidation damage in rodents exposed to DLCs is probably induced through upregulation of cytochrome P450 superfamily of enzymes, mediated by AhR-dependent pathways. 	cytochrome P450 superfamily	28551	28578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:160	DNA oxidation damage in rodents exposed to DLCs is probably induced through upregulation of cytochrome P450 superfamily of enzymes, mediated by AhR-dependent pathways. 	cytochrome P450 superfamily	28551	28578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:14	The cytochrome P450 superfamily is involved in the metabolism of a diverse range of xenobiotics and endogenous compounds. 	cytochrome P450 superfamily	1764	1791	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:14	The cytochrome P450 superfamily is involved in the metabolism of a diverse range of xenobiotics and endogenous compounds. 	cytochrome P450 superfamily	1764	1791	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:12	Human thromboxane synthase belongs to the cytochrome P450 superfamily (CYP5A1). 	cytochrome P450 superfamily	1915	1942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:12	Human thromboxane synthase belongs to the cytochrome P450 superfamily (CYP5A1). 	cytochrome P450 superfamily	1915	1942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:107	^ While MCF-7 cells used to develop the ER-Luc cells express metabolic enzymes from the cytochrome P450 superfamily (and thus possess the ability for endogenous biotransformation of chemicals), formation of MBP was dependent on the presence of S9 enzymes. 	cytochrome P450 superfamily	23273	23300	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:61	We searched PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese Biomedical Literature Database, and Wanfang Database (between January 1990 and October 2016) using the following search terms: (Ischemic stroke OR IS) AND (cytochrome p450 2E1 OR cytochrome p450 IIJ2 OR CYP2J2) AND (SNP OR polymorphism OR allele OR variation). 	cytochrome p450	9723	9738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:61	We searched PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese Biomedical Literature Database, and Wanfang Database (between January 1990 and October 2016) using the following search terms: (Ischemic stroke OR IS) AND (cytochrome p450 2E1 OR cytochrome p450 IIJ2 OR CYP2J2) AND (SNP OR polymorphism OR allele OR variation). 	cytochrome p450	9723	9738	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:61	We searched PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese Biomedical Literature Database, and Wanfang Database (between January 1990 and October 2016) using the following search terms: (Ischemic stroke OR IS) AND (cytochrome p450 2E1 OR cytochrome p450 IIJ2 OR CYP2J2) AND (SNP OR polymorphism OR allele OR variation). 	cytochrome p450	9746	9761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5348184_OgerInput.txtOger_out.csv:61	We searched PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese Biomedical Literature Database, and Wanfang Database (between January 1990 and October 2016) using the following search terms: (Ischemic stroke OR IS) AND (cytochrome p450 2E1 OR cytochrome p450 IIJ2 OR CYP2J2) AND (SNP OR polymorphism OR allele OR variation). 	cytochrome p450	9746	9761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6637849_OgerInput.txtOger_out.csv:21	Heme b (Fe protoporphyrin IX) is the most versatile heme in organisms and is a constituent of the b type cytochromes, catalases, peroxidases, cytochrome p450, globin and nitrate reductase (;. 	cytochrome p450	3506	3521	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6637849_OgerInput.txtOger_out.csv:21	Heme b (Fe protoporphyrin IX) is the most versatile heme in organisms and is a constituent of the b type cytochromes, catalases, peroxidases, cytochrome p450, globin and nitrate reductase (;. 	cytochrome p450	3506	3521	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:97	Phenobarbital is known to induce the expression of cytochrome p450 enzymes in the liver, and the induction of these enzymes are likely to speed up the metabolism of not only Phenobarbital, but also estrogens and progestins. 	cytochrome p450	17623	17638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:97	Phenobarbital is known to induce the expression of cytochrome p450 enzymes in the liver, and the induction of these enzymes are likely to speed up the metabolism of not only Phenobarbital, but also estrogens and progestins. 	cytochrome p450	17623	17638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:169	In case of cytochrome p450 and cytochrome p450 monooxygenase multiple isomers were reported. 	cytochrome p450	25814	25829	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:169	In case of cytochrome p450 and cytochrome p450 monooxygenase multiple isomers were reported. 	cytochrome p450	25814	25829	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:169	In case of cytochrome p450 and cytochrome p450 monooxygenase multiple isomers were reported. 	cytochrome p450	25834	25849	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:169	In case of cytochrome p450 and cytochrome p450 monooxygenase multiple isomers were reported. 	cytochrome p450	25834	25849	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:173	and Kyoto Encyclopedia Gene And Genome pathway of terpenoid backbone biosynthesis, the tentative biosynthesis pathway of andrographolide in kalmegh was proposed of cytochrome p450 related to specialized terpene metabolism were identified (suppl Table S7). 	cytochrome p450	26167	26182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:173	and Kyoto Encyclopedia Gene And Genome pathway of terpenoid backbone biosynthesis, the tentative biosynthesis pathway of andrographolide in kalmegh was proposed of cytochrome p450 related to specialized terpene metabolism were identified (suppl Table S7). 	cytochrome p450	26167	26182	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:175	The cytochrome p450 enzyme converts Ent-diterpenol into andrographolide and deoxy-didehydroandrographolide secondary metabolites, whereas cytochrome p450 GT (glycosyl transferase) converts Ent-diterpenol into neoandrographolide (Garg et al. 	cytochrome p450	26398	26413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:175	The cytochrome p450 enzyme converts Ent-diterpenol into andrographolide and deoxy-didehydroandrographolide secondary metabolites, whereas cytochrome p450 GT (glycosyl transferase) converts Ent-diterpenol into neoandrographolide (Garg et al. 	cytochrome p450	26398	26413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:175	The cytochrome p450 enzyme converts Ent-diterpenol into andrographolide and deoxy-didehydroandrographolide secondary metabolites, whereas cytochrome p450 GT (glycosyl transferase) converts Ent-diterpenol into neoandrographolide (Garg et al. 	cytochrome p450	26532	26547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:175	The cytochrome p450 enzyme converts Ent-diterpenol into andrographolide and deoxy-didehydroandrographolide secondary metabolites, whereas cytochrome p450 GT (glycosyl transferase) converts Ent-diterpenol into neoandrographolide (Garg et al. 	cytochrome p450	26532	26547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:178	In functional annotation of this leaf transcriptome, the cytochrome p450 GT was not reported may be because of its higher expression was reported in root tissue, not in leaf (Garg et al.. The expression of deoxy-didehydroandrographolide was highest in stem, whereas, very low in leaf tissue (Garg et al. ) 	cytochrome p450	26712	26727	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:178	In functional annotation of this leaf transcriptome, the cytochrome p450 GT was not reported may be because of its higher expression was reported in root tissue, not in leaf (Garg et al.. The expression of deoxy-didehydroandrographolide was highest in stem, whereas, very low in leaf tissue (Garg et al. ) 	cytochrome p450	26712	26727	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27113	27128	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27113	27128	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27130	27145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27130	27145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:152	^ With the same TEQ dose used in this study (100 ng/kg/day), a limited subset of genes, which included CAT, cytochrome b5 (CYPB5), and COX oxidative stress response genes, was activated by PeCDF and PCB 126 alone, but not TCDD. 	cytochrome b	27088	27100	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b	692	704	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b	724	736	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b	4921	4933	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b	4945	4957	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:33	However, the bacterial ARCO is a two-component system that uses ferredoxin fused to the C-termini Mitochondrial Amidoxime Reducing Component enzyme (YcbX) instead of cytochrome and as a second component, uses flavin reductase (CysJ) instead of NADH cytochrome b_5 reductase. 	cytochrome b	5220	5232	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b	5430	5442	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b	5472	5484	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b	6913	6925	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b	6936	6948	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b	29147	29159	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b	29197	29209	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b	5065	5077	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b	5235	5247	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b	5819	5831	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b	5843	5855	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b	6577	6589	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b	6601	6613	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b	8714	8726	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b	8738	8750	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:67	Since it is thought that cytochrome b5 reductase 3 is of particular importance as a globin reductase, experiments were performed in vascular Smooth Muscle Cells with b5R-siRNA treatment to knockdown B5 Reductase 3 expression. 	cytochrome b	10907	10919	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:177	Smooth Muscle Cells were transfected with Cygb siRNA or cytochrome b5 reductase 3 siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's recommendations. 	cytochrome b	30548	30560	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:186	The following antibodies (Santa Cruz Biotechnology) were used: rabbit polyclonal anti-Cygb (sc-66855; diluted 1:200), anti-Mb (sc-25607; diluted 1:200), anti-Hb-ALPHA (sc-21005; diluted 1:200), cytochrome b5 reductase 3 (sc-398043; diluted 1:200) and mouse monoclonal anti-actin (sc-47778; diluted 1:500). 	cytochrome b	32484	32496	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:192	The reduction of globins by a reductant or a reducing system (cytochrome b5 reductase/b5/NADH) was performed in a cuvette under anaerobic conditions. 	cytochrome b	33672	33684	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:210	Two Clark-type Nitric Oxide electrodes (NOCHM-4, WPI, Sarasota, FL) were placed in the chamber through two ports on the side wall of the chamber for measuring the rate of Nitric Oxide metabolism by isolated normal Smooth Muscle Cells, Cygb knockdown (Cygb siRNA) Smooth Muscle Cells or cytochrome b5 reductase 3 knockdown (b5R siRNA) Smooth Muscle Cells. 	cytochrome b	37368	37380	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5437217_OgerInput.txtOger_out.csv:262	Similarly, the non-synonymous polymorphism T14798C, which maps to cytochrome b gene, was strongly associated with differential abundance of Dialister in the vaginal posterior fornix (Evaldson et al.,. 	cytochrome b	57651	57663	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	cytochrome b	12645	12657	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5461723_OgerInput.txtOger_out.csv:114	We found homologous of the sox genes in a cluster that codes for putative SoxA (quinol oxidases subunit II), SoxB (cytochromes aa _3 subunit) and SoxC (quinol oxidase cytochrome b subunit) proteins, all with very high similarity to SoxABC proteins of Acidianus, Metallosphaera, and Sulfolobus species. 	cytochrome b	23135	23147	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5461723_OgerInput.txtOger_out.csv:121	As mentioned above A. copahuensis has homologous proteins to the cbsAB/soxNL cluster encoding a cytochrome b (SoxN), a 2Fe-2S Rieske protein (SoxL) and an analog to the cytochromes c _1 (CbsA). 	cytochrome b	24364	24376	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome b	1296	1308	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:6	Additionally, the DNP sensitivity-enhanced two-dimensional 13C/13C chemical shift correlations via proton driven spin diffusion provided distance constraints to characterize protein-lipid interactions and revealed the transmembrane topology of cytochrome b5. 	cytochrome b	1581	1593	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome b	3748	3760	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:27	In this study, we demonstrate the feasibility of ssNMR spectroscopy^- for probing transmembrane interactions of membrane-bound bitopic proteins, namely the intact mammalian cytochrome P450-cytochrome b_5 complex, in lipid bilayers. 	cytochrome b	6801	6813	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:32	This crucial transmembrane-transmembrane interaction of the full-length liver microsomal cytochrome P450 2B4 with its full-length redox partner, cytochrome b_5, is investigated in this study. 	cytochrome b	7803	7815	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:33	Rabbit cytochrome b_5, a 16.7 kDa protein, is composed of three structurally distinct domains: a 25-amino acid transmembrane ALPHA-helix domain at the carboxyl-terminus and a 95-residue heme-containing electron-carrier soluble domain at the amino-terminus; the two domains are connected via a 14-amino acid flexible linker domain^,. 	cytochrome b	7857	7869	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:34	In addition to the aforementioned drug metabolisms through the complex formations, cytochrome b_5 also catalyzes a wide variety of biosynthesis including testosterones, cholesterols, and unsaturated lipids^. 	cytochrome b	8266	8278	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b	8485	8497	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b	8611	8623	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome b	8839	8851	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b	9059	9071	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b	9162	9174	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b	9399	9411	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b	9788	9800	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:39	These high-resolution full-length structures are significant breakthroughs towards the complete understanding of the functional aspects of membrane-bound mammalian cytochromes, as it is known that the lack of transmembrane anchors reduces to only 40% of all enzymatic activities in the case of cytochrome P450 2B4, and results in a total loss of electron transfer capability to cytochromes P450 in the case of cytochrome b_5 ^, --. 	cytochrome b	10311	10323	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:40	A recent solution NMR study from our group revealed the first full-length dynamic interactions of the membrane-bound complex between rabbit cytochrome P450 2B4 and cytochrome b_5 reconstituted in isotropic bicelles and the electron transfer pathway between catalytic domains of the complex. 	cytochrome b	10497	10509	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:43	The combination of these developments have enabled us to report the DNP solid-state NMR spectroscopy probing transmembrane-transmembrane interactions of the cytochrome P450-cytochrome b_5 complex embedded in lipid bilayers at an atomic-level for the first time. 	cytochrome b	11449	11461	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:54	The overexpression and purification of selectively ^13C-labeled cytochrome b_5 and uniformly ^15N-labeled cytochrome P450 were reported previously^,. 	cytochrome b	12567	12579	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:55	Solution NMR measurements on ^13C-labeled cytochrome b_5 embedded in q = 0.25 DLPC/DHPC isotropic bicelles confirmed that the scrambling of isotope ^13C-labels did not occur. 	cytochrome b	12695	12707	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b	12919	12931	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b	12996	13008	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b	13284	13296	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b	13328	13340	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:68	Rabbit cytochrome b_5 and cytochrome P450 were overexpressed and purified from E. Coli ^, and then reconstituted^,  into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid bilayers hydrated with biradical solutions of [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) containing DNP polarizing agents, AMUPol^ or TOTAPOL (1-(TEMPO-4-oxy)-3-(TEMPO-4-amino)propan-2-ol)^, as described in the previous section. 	cytochrome b	14972	14984	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:71	Furthermore, our previous studies revealed that multidimensional MAS ssNMR experiments performed on uniformly ^13C-labeled cytochrome b_5 reconstituted in DMPC mutilamellar vesicles (MLVs) gave rise to spectra with low signal-to-noise ratio at 310 K^. 	cytochrome b	15846	15858	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:72	This surprisingly poor performance of dipolar-based ssNMR is attributed to the highly dynamic features of cytochrome b_5 ^,. 	cytochrome b	16081	16093	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:75	In order to evaluate the polarizing efficiency of these two different biradicals, one-dimensional ^13C CPMAS NMR spectra^ of selectively ^13C-labeled cytochrome b_5 embedded in DMPC MLVs were recorded with and without microwave irradiation, as shown in Fig. 	cytochrome b	16627	16639	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:83	Sensitivity-enhanced DNP two-dimensional (2D) ^13C-^13C chemical shift correlation experiments under MAS conditions were performed on 10 mM AMUPol-containing membrane-bound selectively ^13C-labeled cytochrome b_5 using the proton driven spin diffusion (PDSD) pulse sequence^,. 	cytochrome b	18417	18429	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:84	As reported in our previous studies, 2D ^13C/^13C PDSD chemical shift correlation experiments on uniformly ^13C^15,N-labeled cytochrome b_5 at cryogenic temperatures exhibited inhomogeneous broadening of resonances mainly due to the presence of multiple conformations, which largely gave rise to unresolved cross peaks in the all ^13C/^13C PDSD spectra at 100 K^,. 	cytochrome b	18621	18633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:86	In order to achieve better spectral resolution, 2D DNP NMR was performed on cytochrome b_5 with site-specific ^13C-labeled chemical groups in selected amino acid residues, as shown in Fig. 	cytochrome b	19074	19086	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:89	This dilution of observed correlations in 2D PDSD experiments allowed us to acquire well-resolved cross peaks of cytochrome b_5 even at 99.5 K. Furthermore, based on these well-resolved 2D ^13C/^13C chemical shift correlations, 80% of ^13C chemical shift resonances of ^13C-labeled sites in transmembrane domain can be assigned, as shown in Fig  and summarized in Table. 	cytochrome b	19619	19631	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:91	In the previous studies, high-resolution structural interactions between the soluble domains of the cytochrome P450-cytochrome b_5 complex have been investigated, and structure of the complex was reported^,. 	cytochrome b	20211	20223	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:98	To address these goals, we strategically chose specific site labeling of selective amino acids, including [1-^13C] valine, [2-^13C] leucine, [3-^13C] alanine, and tryptophan (indole ring-2-^13C), to make use of the unique patterns in the amino acid sequence of cytochrome b_5. 	cytochrome b	22361	22373	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:99	In cytochrome b_5, the unique sets of amino acids, Trp_113Val_114, Ala_120Leu_121, and Val_123Ala_124Leu_125, are only found in the transmembrane region. 	cytochrome b	22380	22392	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:109	In this study, the high sensitivity of DNP spectroscopy allows us to observe protein-lipid intramolecular interactions between cytochrome b_5 and lipids. 	cytochrome b	24726	24738	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:114	In addition to these intramolecular ^13C correlations of cytochrome b_5 significant lipid-protein intermolecular interactions were observed in the 2D ^13C/^13C PDSD chemical shift correlation spectrum, as shown in Fig. 	cytochrome b	25573	25585	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:116	Based on these resonance assignments, interatomic interactions between amino acid residues in cytochrome b_5 (including L99, W109, W110, W113, L121, L125), and DMPC lipid bilayers were unequivocally observed. 	cytochrome b	25999	26011	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:121	On the other hand, interaction between L99 and the lipid bilayer also agrees with our previous results obtained by high-resolution MAS NMR and solution NMR on the rabbit cytochrome b_5 embedded in dodecyl-phosphocholine (DPC) micelles^,. 	cytochrome b	27131	27143	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b	27293	27305	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b	27374	27386	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:123	Particularly, it is known that the soluble domain (particularly, the F-G loop region) of cytochrome P450 is tightly bound to the lipid membrane due to its hydrophobicity; therefore, its redox binding partners, like cytochrome b_5, have to be suitably oriented to form a productive complex^,. 	cytochrome b	27712	27724	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome b	27867	27879	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:126	Our experimental results suggest that the transmembrane topology of cytochrome b_5 can be determined using the aforementioned protein-lipid interactions, as shown in Fig. 	cytochrome b	28394	28406	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:127	The distance between the ^13C labeled positions of W113 and L125 is 22.4  based on the PDB structure of cytochrome b_5 ^. 	cytochrome b	28601	28613	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:130	This topological information of the ALPHA-helix domain of cytochrome b_5 in DMPC lipid bilayers is in excellent agreement with our previous ssNMR studies on magnetically-aligned bicelles (15  3)^,. 	cytochrome b	28945	28957	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:131	This suggests that intermolecular interactions between cytochrome b_5 and DMPC lipid bilayers, including side chain-lipid interactions, can be retained even under frozen conditions, even though the lipid phases vary from liquid-crystalline phase to gel phase under these two distinct experimental conditions. 	cytochrome b	29140	29152	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b	29511	29523	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b	29633	29645	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome b	30057	30069	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome b	30631	30643	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:137	Purified labeled proteins, both rabbit cytochrome b_5 and cytochrome 2B4, were first assembled into a complex, and then reconstituted into DMPC lipid bilayers hydrated with AMUPol solutions containing [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) as described in the materials and methods section. 	cytochrome b	30798	30810	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome b	31167	31179	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:140	At these cryogenic temperatures, cytochrome b_5 maintains its topology and ALPHA-helical structure in the transmembrane region, hence the functional transmembrane complex of cytochromes can be retained under the experimental conditions employed in this study. 	cytochrome b	31553	31565	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome b	32398	32410	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome b	32521	32533	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:145	According to these studies, the molecular interactions in the soluble domains of cytochromes exhibit dynamic encounter complexes mediated by both hydrophobic and electrostatic interactions with multiple complex formations, which were explained through the mutagenesis studies and line-broadening of unformly-^15N labeled cytochrome b_5 using solution NMR spectroscopy^. 	cytochrome b	33001	33013	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome b	33353	33365	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:151	Interestingly, the presence of highly conserved LxxxL motif between L121 and L125 was observed in the amino acid sequences of cytochrome b_5 from various eukaryotes, as shown in Fig. 	cytochrome b	34181	34193	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b	34715	34727	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b	34853	34865	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:155	The experimental results indicate that the topology of cytochrome b_5 in the DMPC lipid bilayers suggest that amino acid residues, L121 and L125 are located near the upper chain/glycerol region, which has an unique environment for membrane-associated proteins. 	cytochrome b	34937	34949	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:160	Herein, possible driving forces for the transmembrane complex formation in cytochrome P450-cytochrome b_5 would be a combination of: (i) van der Waals-London interactions^, (ii) electrostatic attraction, estimated by 1-3 kcal, between oppositely charged electric dipolar moments in the association of C- and N-terminal ALPHA-helices^, and (iii) hydrophobic interactions of ALPHA-helices near the surface of the lipid bilayer based on the leucine zipper-like motifs ^, -,. 	cytochrome b	35884	35896	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome b	36372	36384	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:164	This study represents the first experimental report revealing the topology and structure of the transmembrane domains of membrane-bound cytochrome P450-cytochrome b_5 complex in the functional full-length form. 	cytochrome b	36950	36962	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:171	In particular, the remarkable sensitivity enhancement of NMR signals achieved by DNP at cryogenic temperatures can potentially provide structural information of in-vivo membrane protein complexes at-work, as we have recently demonstrated for cytochrome b_5 in in-cell conditions^,. 	cytochrome b	38669	38681	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5596851_OgerInput.txtOger_out.csv:3	Here, we used the mitochondrial cytochrome b (Cytb) and 12 nuclear DNA loci to investigate phylogeographic structures of the sharpbelly (Hemiculter leucisculus) in rivers in southern China and explored how the geological and climatic factors have shaped the genetic diversity and evolutionary history of this species. 	cytochrome b	327	339	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5596851_OgerInput.txtOger_out.csv:50	The partial mitochondrial cytochrome b gene (Cytb) was amplified for all individuals using the universal primers L14724 and H15915. 	cytochrome b	7688	7700	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b	544	556	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b	576	588	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:5	We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b 5 reductase, to mediate ellipticine oxidation in these enzyme systems. 	cytochrome b	772	784	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:11	In the presence of NADPH or NADH, cytochrome b 5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. 	cytochrome b	1681	1693	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b	1939	1951	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b	2026	2038	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b	2180	2192	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b	2275	2287	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b	3659	3671	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b	3712	3724	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b	4079	4091	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b	4126	4138	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b	4157	4169	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:23	It was demonstrated that a second electron donor, cytochrome b _5, could also modulate (stimulate and/or inhibit) the activity of several CYPs, both in vitro and in vivo. 	cytochrome b	4280	4292	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:25	Interestingly, in the case of ellipticine, cytochrome b _5, when reconstituted with CYP3A4 and POR, alters the ratio of ellipticine metabolites formed by this CYP. 	cytochrome b	4563	4575	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:26	Under these conditions, the amounts of the detoxification metabolites (7-hydroxyellipticine and 9-hydroxyellipticine) were not changed with added cytochrome b _5, whereas oxidation of ellipticine to 12-hydroxyellipticine, 13-hydroxyellipticine, and ellipticine N ^2-oxide, the metabolites responsible for the formation of covalent DNA adducts, increased considerably. 	cytochrome b	4830	4842	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:28	Hence, cytochrome b _5 seems to play a key role in the CYP3A4-mediated DNA-damage caused by these ellipticine metabolites [,. 	cytochrome b	5151	5163	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b	5350	5362	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b	5401	5413	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b	5436	5448	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	cytochrome b	5536	5548	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:31	They also showed that this heme protein with NADH:cytochrome b _5 reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. 	cytochrome b	5721	5733	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b	5886	5898	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b	5912	5924	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b	6284	6296	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b	6310	6322	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b	6500	6512	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b	6903	6915	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b	6929	6941	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b	7312	7324	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b	7342	7354	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b	7430	7442	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b	7477	7489	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:39	NADPH and NADH, cofactors of the two microsomal reductases POR and NADH:cytochrome b _5 reductase, respectively, were utilized as electron donors for CYP-mediated ellipticine oxidation. 	cytochrome b	7573	7585	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b	8724	8736	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b	8782	8794	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b	8864	8876	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:46	In this system, reconstitution with cytochrome b _5 only increased the formation of 12-hydroxy- and 13-hydroxyellipticine but not that of 9-hydroxyellipticine. 	cytochrome b	9149	9161	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	cytochrome b	9417	9429	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b	9656	9668	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b	9784	9796	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b	9875	9887	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b	9968	9980	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b	10045	10057	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b	10367	10379	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b	10572	10584	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b	10769	10781	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b	11139	11151	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:55	This finding demonstrated that cytochrome b _5 influences the CYP3A4 catalytic activity in at least two ways. 	cytochrome b	11192	11204	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b	11501	11513	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b	11627	11639	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b	11643	11655	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:58	Second, cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, resulting in changes in profile of ellipticine metabolite formation. 	cytochrome b	11796	11808	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	cytochrome b	13522	13534	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:66	The present study was aimed to advance our knowledge regarding the role of cytochrome b _5 in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. 	cytochrome b	13785	13797	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:67	Our results demonstrated that the function of cytochrome b _5 in this reaction is complex. 	cytochrome b	13940	13952	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b	14140	14152	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b	14170	14182	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b	14216	14228	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b	14427	14439	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14487	14499	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14631	14643	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14661	14673	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b	14814	14826	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b	14840	14852	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	cytochrome b	15979	15991	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b	16256	16268	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b	16297	16309	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17248	17260	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17278	17290	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17455	17467	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17502	17514	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b	18060	18072	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b	19426	19438	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	cytochrome b	20690	20702	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b	8452	8464	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5754280_OgerInput.txtOger_out.csv:114	However, reduction of CoM-S-S-CoB is catalyzed by a membrane-bound heterodisulfide reductase, which obtains electrons from reduced methanophenazine (MPhH_2, functionally analogous to quinoles) via its cytochrome b subunit, which is coupled to the generation of a proton motive force. 	cytochrome b	17621	17633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5754280_OgerInput.txtOger_out.csv:115	During hydrogenotrophic methanogenesis, a membrane-bound (F_420 non-reducing) hydrogenase (Vho) oxidizes H_2 and transfers electrons via cytochrome b to oxidized methanophenazine, again generating a proton motive force. 	cytochrome b	17841	17853	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	cytochrome b	9006	9018	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	cytochrome b	15689	15701	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:196	(presence of CYP and cytochrome b5). 	cytochrome b	32182	32194	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:152	^ With the same TEQ dose used in this study (100 ng/kg/day), a limited subset of genes, which included CAT, cytochrome b5 (CYPB5), and COX oxidative stress response genes, was activated by PeCDF and PCB 126 alone, but not TCDD. 	cytochrome b5	27088	27101	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:152	^ With the same TEQ dose used in this study (100 ng/kg/day), a limited subset of genes, which included CAT, cytochrome b5 (CYPB5), and COX oxidative stress response genes, was activated by PeCDF and PCB 126 alone, but not TCDD. 	cytochrome b5	27088	27101	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b5	692	705	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b5	692	705	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b5	724	737	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:7	It is known that crARC requires a cytochrome b5 (crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from NADH to the substrates. 	cytochrome b5	724	737	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b5	5065	5078	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b5	5065	5078	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b5	5235	5248	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:32	Endothelial cytochrome b5 reductase 3 was further reported to regulate this process through the reduction of the haem iron of Hb-ALPHA, and genetic and pharmacological inhibition of cytochrome b5 reductase 3 was found to enhance Nitric Oxide bioactivity in small vessels. 	cytochrome b5	5235	5248	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b5	5819	5832	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b5	5819	5832	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b5	5843	5856	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:36	When coupled with suitable cellular reducing systems, such as ascorbate or cytochrome b5 reductase/cytochrome b5/NADH, Cygb has been demonstrated to function as a Nitric Oxide Dioxygenase, efficiently regulating the rate of O_2-dependent Nitric Oxide consumption. 	cytochrome b5	5843	5856	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b5	6577	6590	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b5	6577	6590	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b5	6601	6614	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:40	Both ascorbate and cytochrome b5 reductase/cytochrome b5/NADH serve as effective reducing systems for Cygb, with the latter serving as the major reducing system in Smooth Muscle Cells. 	cytochrome b5	6601	6614	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b5	8714	8727	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b5	8714	8727	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b5	8738	8751	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:53	We observe that the reduction rate of Cygb is 10 times faster than that of other globins such as Myoglobin or Hb-ALPHA when reductase systems (such as cytochrome b5 reductase/cytochrome b5/NADH) are used, and several hundred times greater when ascorbate is the reductant. 	cytochrome b5	8738	8751	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:67	Since it is thought that cytochrome b5 reductase 3 is of particular importance as a globin reductase, experiments were performed in vascular Smooth Muscle Cells with b5R-siRNA treatment to knockdown B5 Reductase 3 expression. 	cytochrome b5	10907	10920	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:67	Since it is thought that cytochrome b5 reductase 3 is of particular importance as a globin reductase, experiments were performed in vascular Smooth Muscle Cells with b5R-siRNA treatment to knockdown B5 Reductase 3 expression. 	cytochrome b5	10907	10920	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:177	Smooth Muscle Cells were transfected with Cygb siRNA or cytochrome b5 reductase 3 siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's recommendations. 	cytochrome b5	30548	30561	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:177	Smooth Muscle Cells were transfected with Cygb siRNA or cytochrome b5 reductase 3 siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's recommendations. 	cytochrome b5	30548	30561	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:186	The following antibodies (Santa Cruz Biotechnology) were used: rabbit polyclonal anti-Cygb (sc-66855; diluted 1:200), anti-Mb (sc-25607; diluted 1:200), anti-Hb-ALPHA (sc-21005; diluted 1:200), cytochrome b5 reductase 3 (sc-398043; diluted 1:200) and mouse monoclonal anti-actin (sc-47778; diluted 1:500). 	cytochrome b5	32484	32497	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:186	The following antibodies (Santa Cruz Biotechnology) were used: rabbit polyclonal anti-Cygb (sc-66855; diluted 1:200), anti-Mb (sc-25607; diluted 1:200), anti-Hb-ALPHA (sc-21005; diluted 1:200), cytochrome b5 reductase 3 (sc-398043; diluted 1:200) and mouse monoclonal anti-actin (sc-47778; diluted 1:500). 	cytochrome b5	32484	32497	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:192	The reduction of globins by a reductant or a reducing system (cytochrome b5 reductase/b5/NADH) was performed in a cuvette under anaerobic conditions. 	cytochrome b5	33672	33685	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:192	The reduction of globins by a reductant or a reducing system (cytochrome b5 reductase/b5/NADH) was performed in a cuvette under anaerobic conditions. 	cytochrome b5	33672	33685	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:210	Two Clark-type Nitric Oxide electrodes (NOCHM-4, WPI, Sarasota, FL) were placed in the chamber through two ports on the side wall of the chamber for measuring the rate of Nitric Oxide metabolism by isolated normal Smooth Muscle Cells, Cygb knockdown (Cygb siRNA) Smooth Muscle Cells or cytochrome b5 reductase 3 knockdown (b5R siRNA) Smooth Muscle Cells. 	cytochrome b5	37368	37381	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5394235_OgerInput.txtOger_out.csv:210	Two Clark-type Nitric Oxide electrodes (NOCHM-4, WPI, Sarasota, FL) were placed in the chamber through two ports on the side wall of the chamber for measuring the rate of Nitric Oxide metabolism by isolated normal Smooth Muscle Cells, Cygb knockdown (Cygb siRNA) Smooth Muscle Cells or cytochrome b5 reductase 3 knockdown (b5R siRNA) Smooth Muscle Cells. 	cytochrome b5	37368	37381	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome b5	1296	1309	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome b5	1296	1309	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:6	Additionally, the DNP sensitivity-enhanced two-dimensional 13C/13C chemical shift correlations via proton driven spin diffusion provided distance constraints to characterize protein-lipid interactions and revealed the transmembrane topology of cytochrome b5. 	cytochrome b5	1581	1594	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:6	Additionally, the DNP sensitivity-enhanced two-dimensional 13C/13C chemical shift correlations via proton driven spin diffusion provided distance constraints to characterize protein-lipid interactions and revealed the transmembrane topology of cytochrome b5. 	cytochrome b5	1581	1594	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b5	8452	8465	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b5	8452	8465	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:166	The maximum activity of 7-ethoxyresorufin-o-deethylase (EROD) is substantially higher (1.2-3.0-fold) for PeCDF than TCDD with the same TEQ dose. 	EROD	29678	29682	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC5363288_OgerInput.txtOger_out.csv:168	observed significant, nonadditive interaction for EROD activity at 31 and 53 weeks in the tertiary mixture exposed samples but not at 14 weeks. 	EROD	29834	29838	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:463	Both activities (EROD and phenacetin deethylase) were not markedly changed after a freezing/thawing cycle, whereas Kao et al. 	EROD	72392	72396	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:10	In the determination of CYP1 function, 7-ethoxyresorufin is generally used as a common substrate of CYP1s, and CYP1A1 has the highest turnover rate in 7-ethoxyresorufin O-deethylation (EROD). 	EROD	1677	1681	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:26	Palmatine (10 M) activated DRE and increased CYP1A1 mRNA and EROD activity in HepG2 cells, whereas EROD activity remained the same in the primary culture of human hepatocytes. 	EROD	4144	4148	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:26	Palmatine (10 M) activated DRE and increased CYP1A1 mRNA and EROD activity in HepG2 cells, whereas EROD activity remained the same in the primary culture of human hepatocytes. 	EROD	4182	4186	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:28	In mice, berberine (300 mg/kg) increased hepatic Cyp1a2 mRNA without affecting EROD activity. 	EROD	4500	4504	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:61	B(a)P (2 M, 24 h) stimulated cellular EROD activity by 2-fold in MCF-7 cells, but not in MB-231 cells. 	EROD	8517	8521	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:62	In MCF-7 and MB-231 cells, the 24-h exposure to 0.2-20 M berberine, palmatine and jatrorrhizine did not significantly affect cellular EROD activity. 	EROD	8716	8720	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:63	Even after prolonging the exposure time to 48 h, 10 M berberine did not increase EROD activity in MCF-7 cells. 	EROD	8812	8816	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:95	However, the CYP1A1 protein level and microsomal EROD activity were induced by B(a)P in the liver, but not the ovaries. 	EROD	13010	13014	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:99	Our findings revealed that neither CYP1A1/1B1 protein levels nor EROD activity in MCF-7 cells were significantly affected by protoberberines at a non-cytotoxic concentration (10 M). 	EROD	13518	13522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b_5	4921	4935	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b_5	4921	4935	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b_5	4945	4959	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:32	In the presence of NADH, each human Molybdenum enzyme exerts reductase activity towards NHCs with cytochrome b_5 and NADH cytochrome b_5 reductase. 	cytochrome b_5	4945	4959	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:33	However, the bacterial ARCO is a two-component system that uses ferredoxin fused to the C-termini Mitochondrial Amidoxime Reducing Component enzyme (YcbX) instead of cytochrome and as a second component, uses flavin reductase (CysJ) instead of NADH cytochrome b_5 reductase. 	cytochrome b_5	5220	5234	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:33	However, the bacterial ARCO is a two-component system that uses ferredoxin fused to the C-termini Mitochondrial Amidoxime Reducing Component enzyme (YcbX) instead of cytochrome and as a second component, uses flavin reductase (CysJ) instead of NADH cytochrome b_5 reductase. 	cytochrome b_5	5220	5234	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b_5	5430	5444	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b_5	5430	5444	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b_5	5472	5486	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:35	We found that Chlamydomonas ARCO is the Molybdenum enzyme crARC, the cytochrome b_5-1 (crCytb5-1) and one NADH cytochrome b_5 reductase (crCytb5-R), similar to its human counterpart and different from the two components in a prokaryotic system. 	cytochrome b_5	5472	5486	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b_5	6913	6927	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b_5	6913	6927	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b_5	6936	6950	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:42	The human ARCO apart from the N-Hydroxylated Compounds and N-Omega-Hydroxy-L-Arginine reductions is also able to catalyze the reduction of nitrite to NO using cytochrome b_5-1-1 and cytochrome b_5 reductase as partners, however, only under anaerobic conditions. 	cytochrome b_5	6936	6950	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b_5	29147	29161	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b_5	29147	29161	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b_5	29197	29211	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5372681_OgerInput.txtOger_out.csv:186	However, N-Hydroxylated Compounds reductase activity in humans is strictly dependent on cytochrome b_5 reductase CYB5R3 and mitochondrial cytochrome b_5 CYTB5. 	cytochrome b_5	29197	29211	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	cytochrome b_5	12645	12659	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5447053_OgerInput.txtOger_out.csv:58	Intriguingly, a large part of the reducing substrates are employed by eukaryotic P450 enzymes to generate Reactive Oxygen Species, while the efficiency and coupling of P450 enzymes are regulated by cofactors, such as cytochrome b_5, or by post-translational modifications, such as phosphorylation. 	cytochrome b_5	12645	12659	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome b_5	3748	3762	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:15	These are particularly notable drawbacks for bitopic proteins that contain bulky soluble domains, such as the membrane-anchored catalytic enzymes like mammalian cytochrome P450, cytochrome b_5, and cytochrome P450 reductases^, --. 	cytochrome b_5	3748	3762	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:27	In this study, we demonstrate the feasibility of ssNMR spectroscopy^- for probing transmembrane interactions of membrane-bound bitopic proteins, namely the intact mammalian cytochrome P450-cytochrome b_5 complex, in lipid bilayers. 	cytochrome b_5	6801	6815	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:27	In this study, we demonstrate the feasibility of ssNMR spectroscopy^- for probing transmembrane interactions of membrane-bound bitopic proteins, namely the intact mammalian cytochrome P450-cytochrome b_5 complex, in lipid bilayers. 	cytochrome b_5	6801	6815	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:32	This crucial transmembrane-transmembrane interaction of the full-length liver microsomal cytochrome P450 2B4 with its full-length redox partner, cytochrome b_5, is investigated in this study. 	cytochrome b_5	7803	7817	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:32	This crucial transmembrane-transmembrane interaction of the full-length liver microsomal cytochrome P450 2B4 with its full-length redox partner, cytochrome b_5, is investigated in this study. 	cytochrome b_5	7803	7817	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:33	Rabbit cytochrome b_5, a 16.7 kDa protein, is composed of three structurally distinct domains: a 25-amino acid transmembrane ALPHA-helix domain at the carboxyl-terminus and a 95-residue heme-containing electron-carrier soluble domain at the amino-terminus; the two domains are connected via a 14-amino acid flexible linker domain^,. 	cytochrome b_5	7857	7871	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:33	Rabbit cytochrome b_5, a 16.7 kDa protein, is composed of three structurally distinct domains: a 25-amino acid transmembrane ALPHA-helix domain at the carboxyl-terminus and a 95-residue heme-containing electron-carrier soluble domain at the amino-terminus; the two domains are connected via a 14-amino acid flexible linker domain^,. 	cytochrome b_5	7857	7871	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:34	In addition to the aforementioned drug metabolisms through the complex formations, cytochrome b_5 also catalyzes a wide variety of biosynthesis including testosterones, cholesterols, and unsaturated lipids^. 	cytochrome b_5	8266	8280	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:34	In addition to the aforementioned drug metabolisms through the complex formations, cytochrome b_5 also catalyzes a wide variety of biosynthesis including testosterones, cholesterols, and unsaturated lipids^. 	cytochrome b_5	8266	8280	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b_5	8485	8499	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b_5	8485	8499	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b_5	8611	8625	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:35	Depending on the substrates, the cytochrome P450 isozymes and/or the experimental conditions, cytochrome b_5 can significantly enhance the enzymatic turnover of cytochrome P450 by up to 100-fold, in some cases, however, cytochrome b_5 does not affect or even inhibits the catalytic activities of cytochromes P450. 	cytochrome b_5	8611	8625	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome b_5	8839	8853	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:36	In the case of rabbit cytochrome P450 2B4, a 55.7 kDa protein, when metabolizing benzphetamine and methoxyflurane stoichiometrically, cytochrome b_5 stimulates the enzymatic activities of cytochrome P450 2B4 predominantly by reducing the amount of the side-product superoxide^,. 	cytochrome b_5	8839	8853	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b_5	9059	9073	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b_5	9059	9073	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b_5	9162	9176	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:37	In order to fully understand the molecular mechanism of these key roles of cytochrome b_5, elucidating the atomic-resolution structure of the full-length form of cytochrome P450-cytochrome b_5 complex is quintessential. 	cytochrome b_5	9162	9176	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b_5	9399	9413	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b_5	9399	9413	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b_5	9788	9802	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:38	Despite the physiological importance of their full-length forms for their complete catalytic functions,the X-ray and solution NMR structures of both membrane-bound eukaryotic cytochrome P450 and cytochrome b_5 have been determined only for the truncated forms of hydrophilic heme-containing cytosolic catalytic domains, in which the hydrophobic transmembrane domains were removed to overcome the difficulties in overexpression, solubilization, purification, and crystallization^, with the exception of recent solution- and solid-state NMR studies from our group on full-length rabbit cytochrome b_5 and cytochrome P450 2B4^, --, as well as an X-ray crystallography study on cytochrome P450 51A1^. 	cytochrome b_5	9788	9802	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:39	These high-resolution full-length structures are significant breakthroughs towards the complete understanding of the functional aspects of membrane-bound mammalian cytochromes, as it is known that the lack of transmembrane anchors reduces to only 40% of all enzymatic activities in the case of cytochrome P450 2B4, and results in a total loss of electron transfer capability to cytochromes P450 in the case of cytochrome b_5 ^, --. 	cytochrome b_5	10311	10325	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:39	These high-resolution full-length structures are significant breakthroughs towards the complete understanding of the functional aspects of membrane-bound mammalian cytochromes, as it is known that the lack of transmembrane anchors reduces to only 40% of all enzymatic activities in the case of cytochrome P450 2B4, and results in a total loss of electron transfer capability to cytochromes P450 in the case of cytochrome b_5 ^, --. 	cytochrome b_5	10311	10325	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:40	A recent solution NMR study from our group revealed the first full-length dynamic interactions of the membrane-bound complex between rabbit cytochrome P450 2B4 and cytochrome b_5 reconstituted in isotropic bicelles and the electron transfer pathway between catalytic domains of the complex. 	cytochrome b_5	10497	10511	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:40	A recent solution NMR study from our group revealed the first full-length dynamic interactions of the membrane-bound complex between rabbit cytochrome P450 2B4 and cytochrome b_5 reconstituted in isotropic bicelles and the electron transfer pathway between catalytic domains of the complex. 	cytochrome b_5	10497	10511	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:43	The combination of these developments have enabled us to report the DNP solid-state NMR spectroscopy probing transmembrane-transmembrane interactions of the cytochrome P450-cytochrome b_5 complex embedded in lipid bilayers at an atomic-level for the first time. 	cytochrome b_5	11449	11463	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:43	The combination of these developments have enabled us to report the DNP solid-state NMR spectroscopy probing transmembrane-transmembrane interactions of the cytochrome P450-cytochrome b_5 complex embedded in lipid bilayers at an atomic-level for the first time. 	cytochrome b_5	11449	11463	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:54	The overexpression and purification of selectively ^13C-labeled cytochrome b_5 and uniformly ^15N-labeled cytochrome P450 were reported previously^,. 	cytochrome b_5	12567	12581	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:54	The overexpression and purification of selectively ^13C-labeled cytochrome b_5 and uniformly ^15N-labeled cytochrome P450 were reported previously^,. 	cytochrome b_5	12567	12581	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:55	Solution NMR measurements on ^13C-labeled cytochrome b_5 embedded in q = 0.25 DLPC/DHPC isotropic bicelles confirmed that the scrambling of isotope ^13C-labels did not occur. 	cytochrome b_5	12695	12709	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:55	Solution NMR measurements on ^13C-labeled cytochrome b_5 embedded in q = 0.25 DLPC/DHPC isotropic bicelles confirmed that the scrambling of isotope ^13C-labels did not occur. 	cytochrome b_5	12695	12709	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b_5	12919	12933	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b_5	12919	12933	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b_5	12996	13010	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:56	Five milligrams of DMPC powder was hydrated using 10 l of 2.98 mM selectively ^13C-labeled cytochrome b_5 in a DNP solution (or 10 l of 1.2 mM selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex in a DNP solution), [D_8]glycerol, and stock biradical solutions. 	cytochrome b_5	12996	13010	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b_5	13284	13298	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b_5	13284	13298	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b_5	13328	13342	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:58	The selectively ^13C-labeled cytochrome b_5 (or selectively ^13C-labeled cytochrome b_5-uniformly ^15N-labeled cytochrome P450 complex) reconstituted in DMPC multilamellar vesicles with a 10 mM DNP polarizing agent and were packed into 3.2 mm sapphire MAS rotors. 	cytochrome b_5	13328	13342	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:68	Rabbit cytochrome b_5 and cytochrome P450 were overexpressed and purified from E. Coli ^, and then reconstituted^,  into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid bilayers hydrated with biradical solutions of [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) containing DNP polarizing agents, AMUPol^ or TOTAPOL (1-(TEMPO-4-oxy)-3-(TEMPO-4-amino)propan-2-ol)^, as described in the previous section. 	cytochrome b_5	14972	14986	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:68	Rabbit cytochrome b_5 and cytochrome P450 were overexpressed and purified from E. Coli ^, and then reconstituted^,  into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid bilayers hydrated with biradical solutions of [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) containing DNP polarizing agents, AMUPol^ or TOTAPOL (1-(TEMPO-4-oxy)-3-(TEMPO-4-amino)propan-2-ol)^, as described in the previous section. 	cytochrome b_5	14972	14986	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:71	Furthermore, our previous studies revealed that multidimensional MAS ssNMR experiments performed on uniformly ^13C-labeled cytochrome b_5 reconstituted in DMPC mutilamellar vesicles (MLVs) gave rise to spectra with low signal-to-noise ratio at 310 K^. 	cytochrome b_5	15846	15860	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:71	Furthermore, our previous studies revealed that multidimensional MAS ssNMR experiments performed on uniformly ^13C-labeled cytochrome b_5 reconstituted in DMPC mutilamellar vesicles (MLVs) gave rise to spectra with low signal-to-noise ratio at 310 K^. 	cytochrome b_5	15846	15860	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:72	This surprisingly poor performance of dipolar-based ssNMR is attributed to the highly dynamic features of cytochrome b_5 ^,. 	cytochrome b_5	16081	16095	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:72	This surprisingly poor performance of dipolar-based ssNMR is attributed to the highly dynamic features of cytochrome b_5 ^,. 	cytochrome b_5	16081	16095	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:75	In order to evaluate the polarizing efficiency of these two different biradicals, one-dimensional ^13C CPMAS NMR spectra^ of selectively ^13C-labeled cytochrome b_5 embedded in DMPC MLVs were recorded with and without microwave irradiation, as shown in Fig. 	cytochrome b_5	16627	16641	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:75	In order to evaluate the polarizing efficiency of these two different biradicals, one-dimensional ^13C CPMAS NMR spectra^ of selectively ^13C-labeled cytochrome b_5 embedded in DMPC MLVs were recorded with and without microwave irradiation, as shown in Fig. 	cytochrome b_5	16627	16641	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:83	Sensitivity-enhanced DNP two-dimensional (2D) ^13C-^13C chemical shift correlation experiments under MAS conditions were performed on 10 mM AMUPol-containing membrane-bound selectively ^13C-labeled cytochrome b_5 using the proton driven spin diffusion (PDSD) pulse sequence^,. 	cytochrome b_5	18417	18431	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:83	Sensitivity-enhanced DNP two-dimensional (2D) ^13C-^13C chemical shift correlation experiments under MAS conditions were performed on 10 mM AMUPol-containing membrane-bound selectively ^13C-labeled cytochrome b_5 using the proton driven spin diffusion (PDSD) pulse sequence^,. 	cytochrome b_5	18417	18431	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:84	As reported in our previous studies, 2D ^13C/^13C PDSD chemical shift correlation experiments on uniformly ^13C^15,N-labeled cytochrome b_5 at cryogenic temperatures exhibited inhomogeneous broadening of resonances mainly due to the presence of multiple conformations, which largely gave rise to unresolved cross peaks in the all ^13C/^13C PDSD spectra at 100 K^,. 	cytochrome b_5	18621	18635	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:84	As reported in our previous studies, 2D ^13C/^13C PDSD chemical shift correlation experiments on uniformly ^13C^15,N-labeled cytochrome b_5 at cryogenic temperatures exhibited inhomogeneous broadening of resonances mainly due to the presence of multiple conformations, which largely gave rise to unresolved cross peaks in the all ^13C/^13C PDSD spectra at 100 K^,. 	cytochrome b_5	18621	18635	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:86	In order to achieve better spectral resolution, 2D DNP NMR was performed on cytochrome b_5 with site-specific ^13C-labeled chemical groups in selected amino acid residues, as shown in Fig. 	cytochrome b_5	19074	19088	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:86	In order to achieve better spectral resolution, 2D DNP NMR was performed on cytochrome b_5 with site-specific ^13C-labeled chemical groups in selected amino acid residues, as shown in Fig. 	cytochrome b_5	19074	19088	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:89	This dilution of observed correlations in 2D PDSD experiments allowed us to acquire well-resolved cross peaks of cytochrome b_5 even at 99.5 K. Furthermore, based on these well-resolved 2D ^13C/^13C chemical shift correlations, 80% of ^13C chemical shift resonances of ^13C-labeled sites in transmembrane domain can be assigned, as shown in Fig  and summarized in Table. 	cytochrome b_5	19619	19633	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:89	This dilution of observed correlations in 2D PDSD experiments allowed us to acquire well-resolved cross peaks of cytochrome b_5 even at 99.5 K. Furthermore, based on these well-resolved 2D ^13C/^13C chemical shift correlations, 80% of ^13C chemical shift resonances of ^13C-labeled sites in transmembrane domain can be assigned, as shown in Fig  and summarized in Table. 	cytochrome b_5	19619	19633	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:91	In the previous studies, high-resolution structural interactions between the soluble domains of the cytochrome P450-cytochrome b_5 complex have been investigated, and structure of the complex was reported^,. 	cytochrome b_5	20211	20225	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:91	In the previous studies, high-resolution structural interactions between the soluble domains of the cytochrome P450-cytochrome b_5 complex have been investigated, and structure of the complex was reported^,. 	cytochrome b_5	20211	20225	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:98	To address these goals, we strategically chose specific site labeling of selective amino acids, including [1-^13C] valine, [2-^13C] leucine, [3-^13C] alanine, and tryptophan (indole ring-2-^13C), to make use of the unique patterns in the amino acid sequence of cytochrome b_5. 	cytochrome b_5	22361	22375	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:98	To address these goals, we strategically chose specific site labeling of selective amino acids, including [1-^13C] valine, [2-^13C] leucine, [3-^13C] alanine, and tryptophan (indole ring-2-^13C), to make use of the unique patterns in the amino acid sequence of cytochrome b_5. 	cytochrome b_5	22361	22375	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:99	In cytochrome b_5, the unique sets of amino acids, Trp_113Val_114, Ala_120Leu_121, and Val_123Ala_124Leu_125, are only found in the transmembrane region. 	cytochrome b_5	22380	22394	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:99	In cytochrome b_5, the unique sets of amino acids, Trp_113Val_114, Ala_120Leu_121, and Val_123Ala_124Leu_125, are only found in the transmembrane region. 	cytochrome b_5	22380	22394	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:109	In this study, the high sensitivity of DNP spectroscopy allows us to observe protein-lipid intramolecular interactions between cytochrome b_5 and lipids. 	cytochrome b_5	24726	24740	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:109	In this study, the high sensitivity of DNP spectroscopy allows us to observe protein-lipid intramolecular interactions between cytochrome b_5 and lipids. 	cytochrome b_5	24726	24740	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:114	In addition to these intramolecular ^13C correlations of cytochrome b_5 significant lipid-protein intermolecular interactions were observed in the 2D ^13C/^13C PDSD chemical shift correlation spectrum, as shown in Fig. 	cytochrome b_5	25573	25587	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:114	In addition to these intramolecular ^13C correlations of cytochrome b_5 significant lipid-protein intermolecular interactions were observed in the 2D ^13C/^13C PDSD chemical shift correlation spectrum, as shown in Fig. 	cytochrome b_5	25573	25587	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:116	Based on these resonance assignments, interatomic interactions between amino acid residues in cytochrome b_5 (including L99, W109, W110, W113, L121, L125), and DMPC lipid bilayers were unequivocally observed. 	cytochrome b_5	25999	26013	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:116	Based on these resonance assignments, interatomic interactions between amino acid residues in cytochrome b_5 (including L99, W109, W110, W113, L121, L125), and DMPC lipid bilayers were unequivocally observed. 	cytochrome b_5	25999	26013	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:121	On the other hand, interaction between L99 and the lipid bilayer also agrees with our previous results obtained by high-resolution MAS NMR and solution NMR on the rabbit cytochrome b_5 embedded in dodecyl-phosphocholine (DPC) micelles^,. 	cytochrome b_5	27131	27145	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:121	On the other hand, interaction between L99 and the lipid bilayer also agrees with our previous results obtained by high-resolution MAS NMR and solution NMR on the rabbit cytochrome b_5 embedded in dodecyl-phosphocholine (DPC) micelles^,. 	cytochrome b_5	27131	27145	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b_5	27293	27307	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b_5	27293	27307	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b_5	27374	27388	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:122	In the lipid bilayer environment, based on the membrane interaction between the linker region cytochrome b_5 and the lipid bilayer, it is predicted that the soluble domain of cytochrome b_5 can adapt certain orientations, which will result in a productive complex formation with cytochrome P450^,. 	cytochrome b_5	27374	27388	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:123	Particularly, it is known that the soluble domain (particularly, the F-G loop region) of cytochrome P450 is tightly bound to the lipid membrane due to its hydrophobicity; therefore, its redox binding partners, like cytochrome b_5, have to be suitably oriented to form a productive complex^,. 	cytochrome b_5	27712	27726	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:123	Particularly, it is known that the soluble domain (particularly, the F-G loop region) of cytochrome P450 is tightly bound to the lipid membrane due to its hydrophobicity; therefore, its redox binding partners, like cytochrome b_5, have to be suitably oriented to form a productive complex^,. 	cytochrome b_5	27712	27726	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome b_5	27867	27881	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:124	Thus, restricting the motions of redox partners of cytochrome P450, including cytochrome b_5 and cytochrome P450-reductase, to produce productive orientations would be one of the biological roles of the relatively flexible linker domain that connects the soluble domain and the transmembrane ALPHA-helix domain in the redox partner^,. 	cytochrome b_5	27867	27881	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:126	Our experimental results suggest that the transmembrane topology of cytochrome b_5 can be determined using the aforementioned protein-lipid interactions, as shown in Fig. 	cytochrome b_5	28394	28408	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:126	Our experimental results suggest that the transmembrane topology of cytochrome b_5 can be determined using the aforementioned protein-lipid interactions, as shown in Fig. 	cytochrome b_5	28394	28408	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:127	The distance between the ^13C labeled positions of W113 and L125 is 22.4  based on the PDB structure of cytochrome b_5 ^. 	cytochrome b_5	28601	28615	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:127	The distance between the ^13C labeled positions of W113 and L125 is 22.4  based on the PDB structure of cytochrome b_5 ^. 	cytochrome b_5	28601	28615	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:130	This topological information of the ALPHA-helix domain of cytochrome b_5 in DMPC lipid bilayers is in excellent agreement with our previous ssNMR studies on magnetically-aligned bicelles (15  3)^,. 	cytochrome b_5	28945	28959	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:130	This topological information of the ALPHA-helix domain of cytochrome b_5 in DMPC lipid bilayers is in excellent agreement with our previous ssNMR studies on magnetically-aligned bicelles (15  3)^,. 	cytochrome b_5	28945	28959	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:131	This suggests that intermolecular interactions between cytochrome b_5 and DMPC lipid bilayers, including side chain-lipid interactions, can be retained even under frozen conditions, even though the lipid phases vary from liquid-crystalline phase to gel phase under these two distinct experimental conditions. 	cytochrome b_5	29140	29154	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:131	This suggests that intermolecular interactions between cytochrome b_5 and DMPC lipid bilayers, including side chain-lipid interactions, can be retained even under frozen conditions, even though the lipid phases vary from liquid-crystalline phase to gel phase under these two distinct experimental conditions. 	cytochrome b_5	29140	29154	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b_5	29511	29525	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b_5	29511	29525	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b_5	29633	29647	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:132	Furthermore, our previous studies of oriented ssNMR experiments concluded that, upon the full-length cytochrome P450-cytochrome b_5 complex formation in membrane, the ALPHA-helical structure and the topology of the transmembrane domain of cytochrome b_5 are not altered^. 	cytochrome b_5	29633	29647	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome b_5	30057	30071	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:134	For decades, it has been widely recognized that the transmembrane domains of cytochrome P450 and cytochrome b_5 are essential for catalytic activities of cytochrome P450^-,. 	cytochrome b_5	30057	30071	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome b_5	30631	30645	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome b_5	30631	30645	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:137	Purified labeled proteins, both rabbit cytochrome b_5 and cytochrome 2B4, were first assembled into a complex, and then reconstituted into DMPC lipid bilayers hydrated with AMUPol solutions containing [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) as described in the materials and methods section. 	cytochrome b_5	30798	30812	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:137	Purified labeled proteins, both rabbit cytochrome b_5 and cytochrome 2B4, were first assembled into a complex, and then reconstituted into DMPC lipid bilayers hydrated with AMUPol solutions containing [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) as described in the materials and methods section. 	cytochrome b_5	30798	30812	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome b_5	31167	31181	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome b_5	31167	31181	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:140	At these cryogenic temperatures, cytochrome b_5 maintains its topology and ALPHA-helical structure in the transmembrane region, hence the functional transmembrane complex of cytochromes can be retained under the experimental conditions employed in this study. 	cytochrome b_5	31553	31567	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:140	At these cryogenic temperatures, cytochrome b_5 maintains its topology and ALPHA-helical structure in the transmembrane region, hence the functional transmembrane complex of cytochromes can be retained under the experimental conditions employed in this study. 	cytochrome b_5	31553	31567	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome b_5	32398	32412	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome b_5	32398	32412	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome b_5	32521	32535	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome b_5	32521	32535	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:145	According to these studies, the molecular interactions in the soluble domains of cytochromes exhibit dynamic encounter complexes mediated by both hydrophobic and electrostatic interactions with multiple complex formations, which were explained through the mutagenesis studies and line-broadening of unformly-^15N labeled cytochrome b_5 using solution NMR spectroscopy^. 	cytochrome b_5	33001	33015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:145	According to these studies, the molecular interactions in the soluble domains of cytochromes exhibit dynamic encounter complexes mediated by both hydrophobic and electrostatic interactions with multiple complex formations, which were explained through the mutagenesis studies and line-broadening of unformly-^15N labeled cytochrome b_5 using solution NMR spectroscopy^. 	cytochrome b_5	33001	33015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome b_5	33353	33367	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome b_5	33353	33367	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:151	Interestingly, the presence of highly conserved LxxxL motif between L121 and L125 was observed in the amino acid sequences of cytochrome b_5 from various eukaryotes, as shown in Fig. 	cytochrome b_5	34181	34195	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:28	P-glycoprotein (Pgp) and cytochrome P450 3A4 have been recognized as determinants of the bioavailability of widely used immunosuppressants such as CsA, tacrolimus, and sirolimus. 	cytochrome P450 3A	5327	5345	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:120	Proliferation signal inhibitors such as sirolimus and EVR are substrates of cytochrome P450 3A4 and Pgp and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with proliferation signal inhibitors are comparable to those with CNIs. 	cytochrome P450 3A	20455	20473	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:1	 Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. 	cytochrome P450 3A	12	30	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:2	Most drugs are metabolized by hepatic cytochrome P450 3A4, resulting in their reduced bioavailability. 	cytochrome P450 3A	123	141	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	cytochrome P450 3A	1772	1790	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:1	 Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. 	cytochrome P450 3A	58	76	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	cytochrome P450 3A	90	108	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450 3A	2490	2508	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:28	P-glycoprotein (Pgp) and cytochrome P450 3A4 have been recognized as determinants of the bioavailability of widely used immunosuppressants such as CsA, tacrolimus, and sirolimus. 	cytochrome P450 3A4	5327	5346	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:120	Proliferation signal inhibitors such as sirolimus and EVR are substrates of cytochrome P450 3A4 and Pgp and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with proliferation signal inhibitors are comparable to those with CNIs. 	cytochrome P450 3A4	20455	20474	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:1	 Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. 	cytochrome P450 3A4	12	31	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:2	Most drugs are metabolized by hepatic cytochrome P450 3A4, resulting in their reduced bioavailability. 	cytochrome P450 3A4	123	142	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	cytochrome P450 3A4	1772	1791	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:1	 Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. 	cytochrome P450 3A4	58	77	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:2	Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. 	cytochrome P450 3A4	90	109	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450 3A4	2490	2509	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:125	The bioavailability and metabolism of CsA are controlled by efflux pumps belonging to the ABC transporter family as Pgp and members of the cytochrome P-450 isoenzyme, and CsA can thus be involved in the activity of efflux pumps. 	cytochrome P-450	21291	21307	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5380267_OgerInput.txtOger_out.csv:125	The bioavailability and metabolism of CsA are controlled by efflux pumps belonging to the ABC transporter family as Pgp and members of the cytochrome P-450 isoenzyme, and CsA can thus be involved in the activity of efflux pumps. 	cytochrome P-450	21291	21307	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5554347_OgerInput.txtOger_out.csv:29	The aqueous extract of A. paniculata significantly increased the pentoxyresorufin O-dealkylase activity, suggesting that A. paniculata constituents might affect hepatic cytochrome P-450 enzyme. 	cytochrome P-450	4119	4135	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5554347_OgerInput.txtOger_out.csv:29	The aqueous extract of A. paniculata significantly increased the pentoxyresorufin O-dealkylase activity, suggesting that A. paniculata constituents might affect hepatic cytochrome P-450 enzyme. 	cytochrome P-450	4119	4135	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:193	PMS was reported to be a potent and selective inhibitor of human cytochrome P-450 (CYP1B1). 	cytochrome P-450	30100	30116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5707660_OgerInput.txtOger_out.csv:193	PMS was reported to be a potent and selective inhibitor of human cytochrome P-450 (CYP1B1). 	cytochrome P-450	30100	30116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:146	One example of the modifying influence of external factors is the effect of grapefruit juice components on the expression of cytochrome P-450 (CYP3A4) and, accordingly, on the pharmacokinetics of CYP3A-mediated drugs. 	cytochrome P-450	22318	22334	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6164342_OgerInput.txtOger_out.csv:146	One example of the modifying influence of external factors is the effect of grapefruit juice components on the expression of cytochrome P-450 (CYP3A4) and, accordingly, on the pharmacokinetics of CYP3A-mediated drugs. 	cytochrome P-450	22318	22334	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:10	Various molecules such as heme, fatty acid 2-hydroxylase, cytochrome P-450 enzymes, insulin receptor, epidermal growth factor receptor, Erbb2, and membrane progestin receptor ALPHA (mPRALPHA, PAQR7) can interact and associate with Pgrmc1. 	cytochrome P-450	1729	1745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:10	Various molecules such as heme, fatty acid 2-hydroxylase, cytochrome P-450 enzymes, insulin receptor, epidermal growth factor receptor, Erbb2, and membrane progestin receptor ALPHA (mPRALPHA, PAQR7) can interact and associate with Pgrmc1. 	cytochrome P-450	1729	1745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6358801_OgerInput.txtOger_out.csv:74	Similarly, the blue light induced the expression of putative LDA enzymes including aryl-alcohol dehydrogenase (XLOC_008717), pyranose 2-oxidase (XLOC_009983), and monooxygenase (XLOC_003435) and the red light influenced the expression of cytochrome P-450 (XLOC_007791, XLOC_00671, XLOC_006683, XLOC_001969, and XLOC_007717). 	cytochrome P-450	15561	15577	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC5418208_OgerInput.txtOger_out.csv:111	Cytochrome c is a component of the ETC. 	Cytochrome c	15056	15068	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5418208_OgerInput.txtOger_out.csv:111	Cytochrome c is a component of the ETC. 	Cytochrome c	15056	15068	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:19	Cytochrome c is fused with subunit II in these enzymes. 	Cytochrome c	2953	2965	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:19	Cytochrome c is fused with subunit II in these enzymes. 	Cytochrome c	2953	2965	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5436846_OgerInput.txtOger_out.csv:85	Cytochrome c oxidase activity was visualized using the Nadi assay according to the method described previously. 	Cytochrome c	13284	13296	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5436846_OgerInput.txtOger_out.csv:85	Cytochrome c oxidase activity was visualized using the Nadi assay according to the method described previously. 	Cytochrome c	13284	13296	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:1	 Electricity Generation by Shewanella decolorationis S12 without Cytochrome c. Bacterial extracellular electron transfer (EET) plays a key role in various natural and engineering processes. 	Cytochrome c	65	77	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:1	 Electricity Generation by Shewanella decolorationis S12 without Cytochrome c. Bacterial extracellular electron transfer (EET) plays a key role in various natural and engineering processes. 	Cytochrome c	65	77	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5476703_OgerInput.txtOger_out.csv:65	Cytochrome c is essential for the anaerobic growth of Shewanella species. 	Cytochrome c	9957	9969	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5476703_OgerInput.txtOger_out.csv:65	Cytochrome c is essential for the anaerobic growth of Shewanella species. 	Cytochrome c	9957	9969	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5497933_OgerInput.txtOger_out.csv:1	 Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. 	Cytochrome c	1	13	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5497933_OgerInput.txtOger_out.csv:1	 Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. 	Cytochrome c	1	13	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5497933_OgerInput.txtOger_out.csv:4	Cytochrome c1 (CYC1) is a subunit of complex III in the mitochondrial oxidative phosphorylation that is involved in energy production. 	Cytochrome c	473	485	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5497933_OgerInput.txtOger_out.csv:4	Cytochrome c1 (CYC1) is a subunit of complex III in the mitochondrial oxidative phosphorylation that is involved in energy production. 	Cytochrome c	473	485	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5518855_OgerInput.txtOger_out.csv:7	Cytochrome c release was detected by using immunofluorescence. 	Cytochrome c	676	688	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5518855_OgerInput.txtOger_out.csv:7	Cytochrome c release was detected by using immunofluorescence. 	Cytochrome c	676	688	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:138	Cytochrome c then forms an apoptosome containing apoptosis activating factor 1 and caspase-9, which then activates the downstream apoptotic signals. 	Cytochrome c	20022	20034	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:138	Cytochrome c then forms an apoptosome containing apoptosis activating factor 1 and caspase-9, which then activates the downstream apoptotic signals. 	Cytochrome c	20022	20034	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5627346_OgerInput.txtOger_out.csv:1	 Analysis of a Functional Dimer Model of Ubiquinol Cytochrome c Oxidoreductase. 	Cytochrome c	51	63	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5627346_OgerInput.txtOger_out.csv:1	 Analysis of a Functional Dimer Model of Ubiquinol Cytochrome c Oxidoreductase. 	Cytochrome c	51	63	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5896948_OgerInput.txtOger_out.csv:5	Cytochrome c and transferrin were cross-linked with a redox sensitive disulfide bond for the intra-cellular release of the protein upon endocytosis by the transferrin receptor. 	Cytochrome c	509	521	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5896948_OgerInput.txtOger_out.csv:5	Cytochrome c and transferrin were cross-linked with a redox sensitive disulfide bond for the intra-cellular release of the protein upon endocytosis by the transferrin receptor. 	Cytochrome c	509	521	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5896948_OgerInput.txtOger_out.csv:21	Cytochrome c (Cyt c) is one such protein that has attracted the attention of research groups due to its potential to be developed into a potent and selective anticancer drug. 	Cytochrome c	2702	2714	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5896948_OgerInput.txtOger_out.csv:21	Cytochrome c (Cyt c) is one such protein that has attracted the attention of research groups due to its potential to be developed into a potent and selective anticancer drug. 	Cytochrome c	2702	2714	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5979317_OgerInput.txtOger_out.csv:1	 Mutagenesis Study of the Cytochrome c Subunit Responsible for the Direct Electron Transfer-Type Catalytic Activity of FAD-Dependent Glucose Dehydrogenase. 	Cytochrome c	26	38	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5979317_OgerInput.txtOger_out.csv:1	 Mutagenesis Study of the Cytochrome c Subunit Responsible for the Direct Electron Transfer-Type Catalytic Activity of FAD-Dependent Glucose Dehydrogenase. 	Cytochrome c	26	38	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:135	Cytochrome c release from mitochondria to cytosol is a hallmark of apoptosis and is often utilized to characterize the mitochondria-dependent apoptotic pathway. 	Cytochrome c	21259	21271	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:135	Cytochrome c release from mitochondria to cytosol is a hallmark of apoptosis and is often utilized to characterize the mitochondria-dependent apoptotic pathway. 	Cytochrome c	21259	21271	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6017888_OgerInput.txtOger_out.csv:148	Cytochrome c forms a complex with the cytoplasmic protein Apaf-1 and pro-caspase-9 that is termed the apoptosome that results in activation of caspase-3, leading to systematic disassembly of the cell. 	Cytochrome c	23094	23106	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6017888_OgerInput.txtOger_out.csv:148	Cytochrome c forms a complex with the cytoplasmic protein Apaf-1 and pro-caspase-9 that is termed the apoptosome that results in activation of caspase-3, leading to systematic disassembly of the cell. 	Cytochrome c	23094	23106	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6289567_OgerInput.txtOger_out.csv:95	Cytochrome c, mobile in Extracellular Polymeric Substances or associated with cytoplasmic membranes, is widely reported as the reducing/oxidizing equivalent during microorganism-metal oxide redox reactions^, and was chosen here as a model molecule. 	Cytochrome c	17395	17407	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6289567_OgerInput.txtOger_out.csv:95	Cytochrome c, mobile in Extracellular Polymeric Substances or associated with cytoplasmic membranes, is widely reported as the reducing/oxidizing equivalent during microorganism-metal oxide redox reactions^, and was chosen here as a model molecule. 	Cytochrome c	17395	17407	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6292386_OgerInput.txtOger_out.csv:158	Cytochrome c oxidases, both aa3- and cbb3-type, were widespread in all three lake environments and frequently co-occurred within MAGs. 	Cytochrome c	26680	26692	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6292386_OgerInput.txtOger_out.csv:158	Cytochrome c oxidases, both aa3- and cbb3-type, were widespread in all three lake environments and frequently co-occurred within MAGs. 	Cytochrome c	26680	26692	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:56	Cytochrome c levels were examined as described previously with minor modification (Choi and Lee, ; Yun and Lee,. 	Cytochrome c	8177	8189	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:56	Cytochrome c levels were examined as described previously with minor modification (Choi and Lee, ; Yun and Lee,. 	Cytochrome c	8177	8189	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:109	Cytochrome c release from the mitochondria to the cytoplasm is a crucial event, which activates metacaspase, thereby inducing apoptosis (Wu et al.,. 	Cytochrome c	15217	15229	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:109	Cytochrome c release from the mitochondria to the cytoplasm is a crucial event, which activates metacaspase, thereby inducing apoptosis (Wu et al.,. 	Cytochrome c	15217	15229	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	Cytochrome c	6149	6161	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	Cytochrome c	6149	6161	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:3	Cytochrome c showed a significant response to Bombyx Mori Nucleopolyhedrovirus infection in our previous transcriptome study. 	Cytochrome c	207	219	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5454865_OgerInput.txtOger_out.csv:3	The inhibitory potentials of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on eight major human cytochrome P450 enzyme activities in human liver microsomes were evaluated using liquid chromatography-tandem mass spectrometry to determine the inhibition mechanisms and inhibition potency. 	cytochrome P450 enzyme	432	454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:449	Obes Rev 17: 42941 [PMID:26997580] The cytochrome P450 enzyme family (CYP450), E.C. 	cytochrome P450 enzyme	52762	52784	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5650666_OgerInput.txtOger_out.csv:482	In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [11, 154, 488]. 	cytochrome P450 enzyme	55944	55966	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:20	We speculated that this effect was a result of changes in the expression of the cytochrome P450 enzyme caused by Methicillin-Resistant Staphylococcus Aureus infection. 	cytochrome P450 enzyme	4951	4973	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5850782_OgerInput.txtOger_out.csv:291	As a control, experimental N-terminal helical segments of ScErg11p (CYP51), the first crystal structure for any full-length cytochrome P450 enzyme showing resolution of the membrane spanning helix available in PDB, were also submitted to PPM server. 	cytochrome P450 enzyme	46985	47007	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	cytochrome P450 enzyme	3610	3632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	cytochrome P450 enzyme	1188	1210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:24	Apart from this QC also reported as an inhibitor of cytochrome P450 enzyme which is the main enzyme of Mycophenolic Acid metabolism (;. 	cytochrome P450 enzyme	3224	3246	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	cytochrome P450 enzyme	31511	31533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2B6	1145	1151	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:5	Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1-hydroxylation at 100 M in human liver microsomes. 	CYP2B6	1145	1151	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2B6	1416	1422	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:6	Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M. Epimagnolin A, eudesmin, and magnolin showed no the reversible and time-dependent inhibition of eight major Cytochrome P450 activities at 100 M in human liver microsomes. 	CYP2B6	1416	1422	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2B6	4896	4902	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:17	Dimethyllirioresinol weakly inhibited CYP2C19-catalyzed [S]-mephenytoin 4-hydroxylation and CYP2C8-catalyzed amodiaquine N-deethylation with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed diclofenac 4-hydroxylation, CYP2D6-catalyzed bufuralol 1-hydroxylation, and CYP3A4-catalyzed midazolam 1-hydroxylation activities at 100 M in human liver microsomes. 	CYP2B6	4896	4902	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2B6	5196	5202	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:18	Magnolin, epimagnolin A, and eudesmin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes did not cause the IC_50 value shift of eight Cytochrome P450 enzymes, indicating that dimethyllirioresinol, magnolin, epimagnolin A, or eudesmin may not be mechanism-based inhibitors. 	CYP2B6	5196	5202	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2B6	7366	7372	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:25	Dimethyllirioresinol exhibited weak inhibition of CYP2C8 and CYP2C19 activities without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes. 	CYP2B6	7366	7372	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2B6	7540	7546	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:26	Magnolin, epimagnolin A, and eudesmin showed no the reversible and time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes and the potent time-dependent inhibition of CYP2C19, CYP2C8, and CYP3A4 activities (IC_50 values of 1.6, 4.0, and 17.9 M, respectively) in human liver microsomes. 	CYP2B6	7540	7546	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:57	For the evaluation of the inhibitory effects of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on CYP2B6-catalyzed bupropion hydroxylation, each incubation mixture in a total volume of 100 L contained 50 mM potassium phosphate buffer (pH 7.4), 10 mM MgCl_2, pooled human liver microsomes (0.2 mg/mL), 50 M bupropion, and various concentrations of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, or magnolin in acetonitrile (0.1-100 M), according to our previous report. 	CYP2B6	14922	14928	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:57	For the evaluation of the inhibitory effects of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, and magnolin on CYP2B6-catalyzed bupropion hydroxylation, each incubation mixture in a total volume of 100 L contained 50 mM potassium phosphate buffer (pH 7.4), 10 mM MgCl_2, pooled human liver microsomes (0.2 mg/mL), 50 M bupropion, and various concentrations of dimethyllirioresinol, epimagnolin A, eudesmin, fargesin, or magnolin in acetonitrile (0.1-100 M), according to our previous report. 	CYP2B6	14922	14928	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2B6	18583	18589	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2B6	18583	18589	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2B6	18770	18776	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:75	Fargesin negligibly inhibited CYP1A2, CYP2A6, CYP2B6, and CYP2D6 activities at 100 M. Dimethyllirioresinol weakly inhibited CYP2C19 and CYP2C8 with IC_50 values of 55.1 and 85.0 M, respectively, without inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 activities at 100 M in human liver microsomes. 	CYP2B6	18770	18776	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP2B6	2151	2157	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5543069_OgerInput.txtOger_out.csv:12	This reaction is catalyzed by cytochrome P450 (CYP) enzymes, including CYP2C19, CYP3A, CYP2B6, CYP1A2, and CYP2C9. 	CYP2B6	2151	2157	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2B6	15799	15805	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5552748_OgerInput.txtOger_out.csv:96	The complex metabolism of tamoxifen, which include catalytic activity of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in this study. 	CYP2B6	15799	15805	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2B6	17048	17054	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:126	When comparing our observed 32% inhibition of CYP2C9 at 1% ethanol with the investigated Cytochrome P450 enzymes at similar ethanol concentration in the study by Busby et al., we found that the CYP2C9 inhibition was more potent than for CYP1A2, CYP2A6, CYP2C8, and CYP3A4, and weaker than for CYP1A1, CYP2B6, CYP2C19, and CYP2D6. 	CYP2B6	17048	17054	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2B6	8304	8310	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:41	According to the recent methods, ten CYP-mediated metabolic activities were measured in individual assays by incubating Human Liver Microsomes (0.3 mg protein/ml for CYP1A2, 2A6, and 2E1; 0.2 mg protein/ml for CYP2D6 and 3A4/5; 0.5 mg protein/ml for CYP2B6, 2C8, 2C9, and 2C19), 100 mM phosphate buffer (pH 7.4), and 1 mM reduced nicotinamide adenine dinucleotide phosphate with seven or eight concentrations of substrate (6.25-800 M for phenacetin, 0.156-20 M for coumarin, 7.8-500 M for bupropion, 2.5-80 M for paclitaxel, 31.25-2000 M for tolbutamide, 3.9-500 M for omeprazole, 0.625-960 M for dextromethorphan, 7.8-1000 M for chlorzoxazone, and 0.39-50 M for midazolam). 	CYP2B6	8304	8310	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2B6	16422	16428	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:85	More specifically, the V_max of CYP2A6 could be predicted based on the V_max of CYP2C19, the V_max of CYP2D6 could be predicted by the V_max of CYP2C9, the V_max of CYP2E1 could be predicted by the V_max of CYP1A2, the V_max of CYP2C8 could be predicted based on the V_max values of CYP2C9 and 2B6, and the V_max values of CYP3A4/5 could be predicted based on the V_max values of CYP2B6 and 2C19. 	CYP2B6	16422	16428	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2B6	16573	16579	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:86	For CL_int, CYP2A6 could be predicted based on CYP2C19, CYP2C8 could be predicted based on CYP2C9, CYP2D6 could be predicted based on CYP2B6, CYP2E1 could be predicted based on CYP1A2 and 2C19, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2B6	16573	16579	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2B6	17047	17053	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:88	Taken together, the activity of CYP2A6 could be predicted based on the activity of CYP2C19, CYP2C8 and 2D6 could be predicted based on CYP2B6 and 2C9, CYP2E1 could be predicted based on CYP2C19 and 1A2, CYP3A4/5 could be predicted based on CYP1A2, 2B6, and 2C19. 	CYP2B6	17047	17053	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5725946_OgerInput.txtOger_out.csv:108	Efavirenz is metabolized through CYP2B6. 	CYP2B6	15449	15455	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5725946_OgerInput.txtOger_out.csv:108	Efavirenz is metabolized through CYP2B6. 	CYP2B6	15449	15455	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5725946_OgerInput.txtOger_out.csv:110	The prevalence of poor phenotypes of CYP2B6 has been reported to be as high as 20.56% in a study performed in similar population. 	CYP2B6	15614	15620	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5725946_OgerInput.txtOger_out.csv:110	The prevalence of poor phenotypes of CYP2B6 has been reported to be as high as 20.56% in a study performed in similar population. 	CYP2B6	15614	15620	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:37	They were created by crossbreeding a previously created transgenic strain containing CYP2A13/CYP2B6/CYP2F1 with the CYP2F2 KO mice. 	CYP2B6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5837194_OgerInput.txtOger_out.csv:37	They were created by crossbreeding a previously created transgenic strain containing CYP2A13/CYP2B6/CYP2F1 with the CYP2F2 KO mice. 	CYP2B6	6593	6599	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2B6	8806	8812	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:43	These studies reported P450 polymorphisms in Indigenous North American populations for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and CYP4F2. 	CYP2B6	8806	8812	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:75	The CYP2B6 enzyme metabolizes bupropion, cyclophosphamide, efavirenz, ketamine, methadone, as well as other drugs. 	CYP2B6	13855	13861	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:75	The CYP2B6 enzyme metabolizes bupropion, cyclophosphamide, efavirenz, ketamine, methadone, as well as other drugs. 	CYP2B6	13855	13861	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:77	CYP2B6*4 (K262R) variation confers increased enzyme activity, while CYP2B6*6 is a haplotype that includes both K262R and Q172H and confers reduced function; it is common among different ethnic groups. 	CYP2B6	14051	14057	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:77	CYP2B6*4 (K262R) variation confers increased enzyme activity, while CYP2B6*6 is a haplotype that includes both K262R and Q172H and confers reduced function; it is common among different ethnic groups. 	CYP2B6	14051	14057	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:77	CYP2B6*4 (K262R) variation confers increased enzyme activity, while CYP2B6*6 is a haplotype that includes both K262R and Q172H and confers reduced function; it is common among different ethnic groups. 	CYP2B6	14119	14125	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:77	CYP2B6*4 (K262R) variation confers increased enzyme activity, while CYP2B6*6 is a haplotype that includes both K262R and Q172H and confers reduced function; it is common among different ethnic groups. 	CYP2B6	14119	14125	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:78	For example, in the Yupik AN population, the reported CYP2B6*6, was 51.7%. 	CYP2B6	14306	14312	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:78	For example, in the Yupik AN population, the reported CYP2B6*6, was 51.7%. 	CYP2B6	14306	14312	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:79	Unlike CYP2A6, CYP2B6 genotype was not found to be associated with nicotine metabolism in this population. 	CYP2B6	14342	14348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:79	Unlike CYP2A6, CYP2B6 genotype was not found to be associated with nicotine metabolism in this population. 	CYP2B6	14342	14348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:80	Previous studies found weak linkage disequilibrium between the CYP2A6 and CYP2B6 genes (localized together on chromosome 19), however, Binnington et al. 	CYP2B6	14508	14514	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:80	Previous studies found weak linkage disequilibrium between the CYP2A6 and CYP2B6 genes (localized together on chromosome 19), however, Binnington et al. 	CYP2B6	14508	14514	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:82	The authors proposed that the unique linkage disequilibrium observed between the reference CYP2A6*1B allele and the low activity CYP2B6*6 allele may be responsible for the higher nicotine metabolism in Yupik individuals with CYP2B6*6 genotype. 	CYP2B6	14804	14810	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:82	The authors proposed that the unique linkage disequilibrium observed between the reference CYP2A6*1B allele and the low activity CYP2B6*6 allele may be responsible for the higher nicotine metabolism in Yupik individuals with CYP2B6*6 genotype. 	CYP2B6	14804	14810	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:82	The authors proposed that the unique linkage disequilibrium observed between the reference CYP2A6*1B allele and the low activity CYP2B6*6 allele may be responsible for the higher nicotine metabolism in Yupik individuals with CYP2B6*6 genotype. 	CYP2B6	14900	14906	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5872083_OgerInput.txtOger_out.csv:82	The authors proposed that the unique linkage disequilibrium observed between the reference CYP2A6*1B allele and the low activity CYP2B6*6 allele may be responsible for the higher nicotine metabolism in Yupik individuals with CYP2B6*6 genotype. 	CYP2B6	14900	14906	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:24	This plant P450 exhibits a crystal structure that is highly similar to any other P450 enzymes, such as that of human CYP2B6, which reduces molecular dioxygen and reacts with hundreds of different substrates. 	CYP2B6	3382	3388	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:24	This plant P450 exhibits a crystal structure that is highly similar to any other P450 enzymes, such as that of human CYP2B6, which reduces molecular dioxygen and reacts with hundreds of different substrates. 	CYP2B6	3382	3388	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:259	One of the structural determinants of substrate specificity for cyclophosphamide, which is an antitumor prodrug, has been recently identified in CYP2B6 and CYP2B11 enzymes. 	CYP2B6	46542	46548	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:259	One of the structural determinants of substrate specificity for cyclophosphamide, which is an antitumor prodrug, has been recently identified in CYP2B6 and CYP2B11 enzymes. 	CYP2B6	46542	46548	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:260	CYP2B11 presents a K_M for cyclophosphamide 50-fold lower than that of CYP2B6. 	CYP2B6	46641	46647	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:260	CYP2B11 presents a K_M for cyclophosphamide 50-fold lower than that of CYP2B6. 	CYP2B6	46641	46647	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:261	The CYP2B6 sequence was sliced into 15 contiguous sequence modules and each of them was used to replace its counterpart into the CYP2B11 backbone, generating 15 individual chimeras. 	CYP2B6	46653	46659	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:261	The CYP2B6 sequence was sliced into 15 contiguous sequence modules and each of them was used to replace its counterpart into the CYP2B11 backbone, generating 15 individual chimeras. 	CYP2B6	46653	46659	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:262	One of the 15 chimeras, namely, chimera G, was found to be exhibit an affinity for cyclophosphamide that was similar to that of CYP2B6 though its sequence is that of CYP2B11 with a minor change of six residues into those of the CYP2B6 sequence. 	CYP2B6	46959	46965	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:262	One of the 15 chimeras, namely, chimera G, was found to be exhibit an affinity for cyclophosphamide that was similar to that of CYP2B6 though its sequence is that of CYP2B11 with a minor change of six residues into those of the CYP2B6 sequence. 	CYP2B6	46959	46965	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:262	One of the 15 chimeras, namely, chimera G, was found to be exhibit an affinity for cyclophosphamide that was similar to that of CYP2B6 though its sequence is that of CYP2B11 with a minor change of six residues into those of the CYP2B6 sequence. 	CYP2B6	47059	47065	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:262	One of the 15 chimeras, namely, chimera G, was found to be exhibit an affinity for cyclophosphamide that was similar to that of CYP2B6 though its sequence is that of CYP2B11 with a minor change of six residues into those of the CYP2B6 sequence. 	CYP2B6	47059	47065	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:263	When positioned on the crystal structure of CYP2B6, these changes are found to be located on the F/G region, inside the F/G region. 	CYP2B6	47120	47126	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:263	When positioned on the crystal structure of CYP2B6, these changes are found to be located on the F/G region, inside the F/G region. 	CYP2B6	47120	47126	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:264	The entrance of channel 2f, one of the several access channels viewed in CYP2B6, is lined by the F/G elements. 	CYP2B6	47281	47287	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:264	The entrance of channel 2f, one of the several access channels viewed in CYP2B6, is lined by the F/G elements. 	CYP2B6	47281	47287	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:265	When these fifteen CYP2B6/2B11 chimeras were assayed with a marker CYP2B substrate, namely 7-ethoxy-4-trifluorometyl-coumarin, they all exhibit a similar affinity for this fluorogenic substrate. 	CYP2B6	47338	47344	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:265	When these fifteen CYP2B6/2B11 chimeras were assayed with a marker CYP2B substrate, namely 7-ethoxy-4-trifluorometyl-coumarin, they all exhibit a similar affinity for this fluorogenic substrate. 	CYP2B6	47338	47344	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2B6	58726	58732	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:362	reported the presence of the following CYPs mRNA in full-thickness human skin biopsies: CYP1B1, CYP2B6 (not present in some individuals), CYP2D6, CYP3A4; low expression: CYP1A1, CYP2C9, CYP2C18, CYP2C19, CYP2E1 and CYP3A5 mRNAs; not detected: CYP1A2, 2A6, and 2C8. 	CYP2B6	58726	58732	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:367	reported that in adult human skin the CYP2B6 RNA, but not CYP2A6 and 3A4 mRNAs decreased with increasing age. 	CYP2B6	59469	59475	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:367	reported that in adult human skin the CYP2B6 RNA, but not CYP2A6 and 3A4 mRNAs decreased with increasing age. 	CYP2B6	59469	59475	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:372	No CYP2A6 and 3A4 mRNA was seen in the human keratinocyte cell line HCaT, while CYP2B6 mRNA levels were about the same as in skin (Janmohamed et al.. Rea et al. 	CYP2B6	59955	59961	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:372	No CYP2A6 and 3A4 mRNA was seen in the human keratinocyte cell line HCaT, while CYP2B6 mRNA levels were about the same as in skin (Janmohamed et al.. Rea et al. 	CYP2B6	59955	59961	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:375	observed similar levels of the mRNAs of CYP2B6/7, CYP 2E1, CYP reductase and the aryl hydrocarbon receptor nuclear translocator, while that of CY1A1, 1B1 and aryl hydrocarbon receptor RNA levels were higher in the SVpgC2a cells. 	CYP2B6	60397	60403	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:375	observed similar levels of the mRNAs of CYP2B6/7, CYP 2E1, CYP reductase and the aryl hydrocarbon receptor nuclear translocator, while that of CY1A1, 1B1 and aryl hydrocarbon receptor RNA levels were higher in the SVpgC2a cells. 	CYP2B6	60397	60403	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:389	mRNAs coding for CYP1A1, 1B1, 2E1, 2J2, 3A5, 4B1, low levels of RNAs coding for CYP2C18 and 3A4, but no RNA coding for CYP2B6 were recognized by Neis et al. 	CYP2B6	62273	62279	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:389	mRNAs coding for CYP1A1, 1B1, 2E1, 2J2, 3A5, 4B1, low levels of RNAs coding for CYP2C18 and 3A4, but no RNA coding for CYP2B6 were recognized by Neis et al. 	CYP2B6	62273	62279	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:394	observed in total human skin, in human epidermis, in EpiSkin^ and in EpiskinTMF^ mRNAs for the following CYPs: Low levels (below 200,000 copies/g total RNA): CYP2B6, 2D6, 2E1, 1A1, 1B1, 2C8, 2C18, 2F1 and 3A5; very low levels (below 10,000 copies/g total RNA): CYP2C9, 1A2 and 3A7. 	CYP2B6	62985	62991	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:394	observed in total human skin, in human epidermis, in EpiSkin^ and in EpiskinTMF^ mRNAs for the following CYPs: Low levels (below 200,000 copies/g total RNA): CYP2B6, 2D6, 2E1, 1A1, 1B1, 2C8, 2C18, 2F1 and 3A5; very low levels (below 10,000 copies/g total RNA): CYP2C9, 1A2 and 3A7. 	CYP2B6	62985	62991	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:398	A considerable number of CYPs mRNAs were found in both, Full-Thickness Human Bottom Skin and EpiDerm^: CYP1A2, 1B1, 2C9, 2C18, 2J2, 2R1, 2S1, 3A5 and 4B1 and a considerable number of CYPs mRNAs were found in neither Full-Thickness Human Bottom Skin nor EpiDerm^: CYP2B6, 2C8, 2C19, 2F1, 3A4 and 3A7 (for further studies on CYPs transcripts expression in reconstructed human skin models see Hayden et al. 	CYP2B6	63823	63829	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:398	A considerable number of CYPs mRNAs were found in both, Full-Thickness Human Bottom Skin and EpiDerm^: CYP1A2, 1B1, 2C9, 2C18, 2J2, 2R1, 2S1, 3A5 and 4B1 and a considerable number of CYPs mRNAs were found in neither Full-Thickness Human Bottom Skin nor EpiDerm^: CYP2B6, 2C8, 2C19, 2F1, 3A4 and 3A7 (for further studies on CYPs transcripts expression in reconstructed human skin models see Hayden et al. 	CYP2B6	63823	63829	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP2B6	64264	64270	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP2B6	64264	64270	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:423	reported that they did not find CYP1, CYP2B6 or CYP3A proteins In the reconstructed human skin models EpiDerm, EpiSkin^ and SkinEthik^ RHE. 	CYP2B6	66579	66585	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:423	reported that they did not find CYP1, CYP2B6 or CYP3A proteins In the reconstructed human skin models EpiDerm, EpiSkin^ and SkinEthik^ RHE. 	CYP2B6	66579	66585	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:597	reported the finding of CYP2B6 mRNA in human skin, Baron et al. 	CYP2B6	91984	91990	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:597	reported the finding of CYP2B6 mRNA in human skin, Baron et al. 	CYP2B6	91984	91990	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:600	did neither detect CYP2B6 mRNA in human skin nor in primary human keratinocytes nor in fibroblasts nor in Langerhans cells. 	CYP2B6	92163	92169	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:600	did neither detect CYP2B6 mRNA in human skin nor in primary human keratinocytes nor in fibroblasts nor in Langerhans cells. 	CYP2B6	92163	92169	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:603	did not detect CYP2B6 mRNA in the three-dimensional reconstructed human skin models EpiDerm^ and StrataTest^. 	CYP2B6	92329	92335	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:603	did not detect CYP2B6 mRNA in the three-dimensional reconstructed human skin models EpiDerm^ and StrataTest^. 	CYP2B6	92329	92335	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:607	that CYP2B6 mRNA levels ranged in skin biopsies from 27 individuals from the highest values measured for 10 CYPs down to undetected. 	CYP2B6	92900	92906	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:607	that CYP2B6 mRNA levels ranged in skin biopsies from 27 individuals from the highest values measured for 10 CYPs down to undetected. 	CYP2B6	92900	92906	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:609	reported that in the human epidermis CYP2B6 protein was detected and was localized in the suprabasal cell layers. 	CYP2B6	93078	93084	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:609	reported that in the human epidermis CYP2B6 protein was detected and was localized in the suprabasal cell layers. 	CYP2B6	93078	93084	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:610	Most but not all studies report failure of finding CYP2B6-dependent enzymatic activities in human skin or human skin-derived preparations. 	CYP2B6	93206	93212	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:610	Most but not all studies report failure of finding CYP2B6-dependent enzymatic activities in human skin or human skin-derived preparations. 	CYP2B6	93206	93212	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:614	Attempts to induce PROD activities in the human reconstructed skin model EpiDerm^ using quite a number of CYP2B6 inducers (phenobarbital, rifampicin, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) as well as cyclophosphamide) also failed (Gtz et al.. In contrast to these negative findings Baron et al. 	CYP2B6	93642	93648	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:614	Attempts to induce PROD activities in the human reconstructed skin model EpiDerm^ using quite a number of CYP2B6 inducers (phenobarbital, rifampicin, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) as well as cyclophosphamide) also failed (Gtz et al.. In contrast to these negative findings Baron et al. 	CYP2B6	93642	93648	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:616	As found in skin-derived preparations or in other systems CYP2B6 is active toward: several physiological substrates (including 17BETA-estradiol, estrone, testosterone, retinoic acid),xenobiotic compounds (including coumarin, nicotine, cyclophosphamide, ochratoxin A) (Ekins and Wrighton ; Oesch-Bartlomowicz and Oesch. 	CYP2B6	94065	94071	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:616	As found in skin-derived preparations or in other systems CYP2B6 is active toward: several physiological substrates (including 17BETA-estradiol, estrone, testosterone, retinoic acid),xenobiotic compounds (including coumarin, nicotine, cyclophosphamide, ochratoxin A) (Ekins and Wrighton ; Oesch-Bartlomowicz and Oesch. 	CYP2B6	94065	94071	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2B6	9333	9339	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6151550_OgerInput.txtOger_out.csv:57	Phenacetin O-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine N-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry. 	CYP2B6	9333	9339	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:24	CYP2B6, 1A1, and 3A4, have not been directly related to Parkinsons Disease, but they also have an important role in the central nervous system as they can be regulated by several xenobiotics in both the liver and the brain. 	CYP2B6	3112	3118	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:24	CYP2B6, 1A1, and 3A4, have not been directly related to Parkinsons Disease, but they also have an important role in the central nervous system as they can be regulated by several xenobiotics in both the liver and the brain. 	CYP2B6	3112	3118	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:25	In the liver, CYP2B6 is involved in the metabolism of therapeutic drugs and other exogenous and endogenous compounds. 	CYP2B6	3350	3356	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:25	In the liver, CYP2B6 is involved in the metabolism of therapeutic drugs and other exogenous and endogenous compounds. 	CYP2B6	3350	3356	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:26	Additionally, CYP2B6 has been found in the frontal cortex of human brain and other brain areas of African Green monkeys. 	CYP2B6	3468	3474	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:26	Additionally, CYP2B6 has been found in the frontal cortex of human brain and other brain areas of African Green monkeys. 	CYP2B6	3468	3474	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:27	CNS-acting drugs, such as bupropion or selegiline, can be therefore be metabolized by CYP2B6. 	CYP2B6	3661	3667	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:27	CNS-acting drugs, such as bupropion or selegiline, can be therefore be metabolized by CYP2B6. 	CYP2B6	3661	3667	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2B6	18442	18448	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2B6	18442	18448	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2B6	31197	31203	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2B6	31197	31203	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:44	456254), CYP2B6 (Lot No. 	CYP2B6	8283	8289	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:44	456254), CYP2B6 (Lot No. 	CYP2B6	8283	8289	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2B6	12843	12849	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2B6	12843	12849	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2B6	14113	14119	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2B6	14113	14119	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:1	 Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. 	CYP2B6	43	49	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:1	 Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. 	CYP2B6	43	49	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:2	Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6 enzyme, is associated with substratespecific altered clearance of multiple drugs. 	CYP2B6	105	111	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:2	Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6 enzyme, is associated with substratespecific altered clearance of multiple drugs. 	CYP2B6	105	111	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:3	CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotinerelated behaviors because of reported CYP2B6  mRNA expression in human brain tissue. 	CYP2B6	233	239	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:3	CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotinerelated behaviors because of reported CYP2B6  mRNA expression in human brain tissue. 	CYP2B6	233	239	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:3	CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotinerelated behaviors because of reported CYP2B6  mRNA expression in human brain tissue. 	CYP2B6	389	395	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:3	CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotinerelated behaviors because of reported CYP2B6  mRNA expression in human brain tissue. 	CYP2B6	389	395	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:4	Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. 	CYP2B6	468	474	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:4	Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. 	CYP2B6	468	474	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:4	Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. 	CYP2B6	569	575	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:4	Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. 	CYP2B6	569	575	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:5	We generated recombinant enzymes in insect cells corresponding to nine common CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine oxidation to nicotine iminium ion and nornicotine for both (S) and (R)nicotine. 	CYP2B6	699	705	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:5	We generated recombinant enzymes in insect cells corresponding to nine common CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine oxidation to nicotine iminium ion and nornicotine for both (S) and (R)nicotine. 	CYP2B6	699	705	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	873	879	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	873	879	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	886	892	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	886	892	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	977	983	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:6	Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. 	CYP2B6	977	983	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:9	Furthermore, metabolism of common CYP2B6 probe substrates, methadone and ketamine, is not detected in the presence of brain microsomes. 	CYP2B6	1309	1315	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:9	Furthermore, metabolism of common CYP2B6 probe substrates, methadone and ketamine, is not detected in the presence of brain microsomes. 	CYP2B6	1309	1315	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1428	1434	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1428	1434	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1485	1491	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1485	1491	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1570	1576	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:10	We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. 	CYP2B6	1570	1576	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:13	CYP2B6 is a minor contributor to hepatic nicotine metabolism with a K _m approximately 10fold higher than that of CYP2A6. 	CYP2B6	1925	1931	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:13	CYP2B6 is a minor contributor to hepatic nicotine metabolism with a K _m approximately 10fold higher than that of CYP2A6. 	CYP2B6	1925	1931	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:14	Genetic variation in the CYP2B6 locus has a small but clinically insignificant influence on in vivo nicotine clearance in most subjects,,  but may be important in CYP2A6 slow metabolizers. 	CYP2B6	2072	2078	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:14	Genetic variation in the CYP2B6 locus has a small but clinically insignificant influence on in vivo nicotine clearance in most subjects,,  but may be important in CYP2A6 slow metabolizers. 	CYP2B6	2072	2078	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:15	CYP2B6 has also been reported to be expressed in human brain tissue, unlike CYP2A6, and it has therefore been proposed that genetic variation affecting the CYP2B6 enzyme might play a significant role in nicotinerelated phenotypes. 	CYP2B6	2236	2242	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:15	CYP2B6 has also been reported to be expressed in human brain tissue, unlike CYP2A6, and it has therefore been proposed that genetic variation affecting the CYP2B6 enzyme might play a significant role in nicotinerelated phenotypes. 	CYP2B6	2236	2242	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:15	CYP2B6 has also been reported to be expressed in human brain tissue, unlike CYP2A6, and it has therefore been proposed that genetic variation affecting the CYP2B6 enzyme might play a significant role in nicotinerelated phenotypes. 	CYP2B6	2392	2398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:15	CYP2B6 has also been reported to be expressed in human brain tissue, unlike CYP2A6, and it has therefore been proposed that genetic variation affecting the CYP2B6 enzyme might play a significant role in nicotinerelated phenotypes. 	CYP2B6	2392	2398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2467	2473	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2467	2473	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2531	2537	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2531	2537	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2844	2850	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2844	2850	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2868	2874	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2868	2874	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2930	2936	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:16	CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://eversusgs.washington.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele.,  Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substratespecific, activities of different CYP2B6 isoforms cannot be assumed for untested substrates, such as nicotine. 	CYP2B6	2930	2936	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:17	Therefore, we have expressed polymorphic CYP2B6 enzymes and measured their nicotine metabolism activity in vitro. 	CYP2B6	3048	3054	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:17	Therefore, we have expressed polymorphic CYP2B6 enzymes and measured their nicotine metabolism activity in vitro. 	CYP2B6	3048	3054	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:18	We further attempted to measure cytochrome P450mediated nicotine metabolism in human brain microsomes, where FMO activity was previously demonstrated,,  using nicotine and other CYP2B6 probe substrates. 	CYP2B6	3299	3305	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:18	We further attempted to measure cytochrome P450mediated nicotine metabolism in human brain microsomes, where FMO activity was previously demonstrated,,  using nicotine and other CYP2B6 probe substrates. 	CYP2B6	3299	3305	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:19	CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b _5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described.,  Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymorphisms on metabolism. 	CYP2B6	3324	3330	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:19	CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b _5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described.,  Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymorphisms on metabolism. 	CYP2B6	3324	3330	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:20	There is growing evidence that the influence of CYP2B6 polymorphisms varies between substrates, and may vary between enantiomers of those substrates. 	CYP2B6	3785	3791	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:20	There is growing evidence that the influence of CYP2B6 polymorphisms varies between substrates, and may vary between enantiomers of those substrates. 	CYP2B6	3785	3791	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:29	Results were expressed as fmol min^1 mg^1 of total brain protein, as CYP2B6 protein was not detectable. 	CYP2B6	5340	5346	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:29	Results were expressed as fmol min^1 mg^1 of total brain protein, as CYP2B6 protein was not detectable. 	CYP2B6	5340	5346	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:37	Incubations with recombinant CYP2B6/POR/b5 proceeded for 10 minutes and incubations with human brain microsomes proceeded for 1 hour, unless otherwise noted, following a 2minute preincubation and initiation with 25, 50, 100, 250, 500, 1000, 1,500, or 2,000 mol L^1 Snicotine or Rnicotine (Toronto Research Chemicals, Toronto, Canada) in the presence of 1 mmol L^1 NADPH (SigmaAldrich, St. 	CYP2B6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:37	Incubations with recombinant CYP2B6/POR/b5 proceeded for 10 minutes and incubations with human brain microsomes proceeded for 1 hour, unless otherwise noted, following a 2minute preincubation and initiation with 25, 50, 100, 250, 500, 1000, 1,500, or 2,000 mol L^1 Snicotine or Rnicotine (Toronto Research Chemicals, Toronto, Canada) in the presence of 1 mmol L^1 NADPH (SigmaAldrich, St. 	CYP2B6	6725	6731	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:64	Under these conditions, the retention times for nicotine iminium and nornicotine (a minor CYP2B6 nicotine metabolite) were 2.5 and 3.7 minutes, respectively; for cis and trans nicotineNoxide, they were 4.7 and 5.2 minutes, respectively. 	CYP2B6	11742	11748	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:64	Under these conditions, the retention times for nicotine iminium and nornicotine (a minor CYP2B6 nicotine metabolite) were 2.5 and 3.7 minutes, respectively; for cis and trans nicotineNoxide, they were 4.7 and 5.2 minutes, respectively. 	CYP2B6	11742	11748	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:68	Nine recombinant versions of the CYP2B6 enzymes, representing common CYP2B6 haplotypes, were expressed to assess their relative nicotine metabolism activities. 	CYP2B6	12484	12490	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:68	Nine recombinant versions of the CYP2B6 enzymes, representing common CYP2B6 haplotypes, were expressed to assess their relative nicotine metabolism activities. 	CYP2B6	12484	12490	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:68	Nine recombinant versions of the CYP2B6 enzymes, representing common CYP2B6 haplotypes, were expressed to assess their relative nicotine metabolism activities. 	CYP2B6	12520	12526	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:68	Nine recombinant versions of the CYP2B6 enzymes, representing common CYP2B6 haplotypes, were expressed to assess their relative nicotine metabolism activities. 	CYP2B6	12520	12526	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	12867	12873	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	12867	12873	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	12955	12961	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	12955	12961	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	13053	13059	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	13053	13059	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	13113	13119	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:70	In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomerspecific, incubations with four CYP2B6 haplotypes were repeated with (R)nicotinenicotine and (S)nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl_int = 0.8 vs 1.8 L^1 min^1 nmol^1) and nornicotine (Cl_int = 0.1 vs 0.2 L^1 min^1 nmol^1). 	CYP2B6	13113	13119	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:71	Interestingly, the regioselectivity of the enzyme, that is, the metabolite ratio of nicotine iminium ion vs nornicotine, was relatively consistent among different CYP2B6 variants, but differed between (S) and (R)nicotine (Tables  and. 	CYP2B6	13450	13456	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:71	Interestingly, the regioselectivity of the enzyme, that is, the metabolite ratio of nicotine iminium ion vs nornicotine, was relatively consistent among different CYP2B6 variants, but differed between (S) and (R)nicotine (Tables  and. 	CYP2B6	13450	13456	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:79	On further characterizing one brain, we found the NADPHindependent nicotineiminium formation did not follow MichaelisMenten kinetics and ketamine (80 mol L^1), the approximate K _m for CYP2B6 for each substrate.,  Neither 2ethylidene1,5dimethyl3,3diphenylpyrrolidine (EDDP) nor norketamine were detected, respectively. 	CYP2B6	14597	14603	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:79	On further characterizing one brain, we found the NADPHindependent nicotineiminium formation did not follow MichaelisMenten kinetics and ketamine (80 mol L^1), the approximate K _m for CYP2B6 for each substrate.,  Neither 2ethylidene1,5dimethyl3,3diphenylpyrrolidine (EDDP) nor norketamine were detected, respectively. 	CYP2B6	14597	14603	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	14964	14970	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	14964	14970	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15342	15348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15342	15348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15355	15361	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15355	15361	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15406	15412	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15406	15412	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16199	16205	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16199	16205	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16212	16218	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16212	16218	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16280	16286	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16280	16286	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16337	16343	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16337	16343	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16392	16398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16392	16398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16488	16494	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16488	16494	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16510	16516	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16510	16516	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16523	16529	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16523	16529	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	16743	16749	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	16743	16749	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	17085	17091	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC5454865_OgerInput.txtOger_out.csv:12	For the prediction of herb-drug interaction, it is necessary to investigate the in vitro inhibitory effects of herb drugs and the constituents on major human Cytochrome P450 enzyme activities. 	Cytochrome P450 enzyme	3461	3483	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5503597_OgerInput.txtOger_out.csv:118	Cytochrome P450 enzyme promotes reactive oxygen species generation which occurs during the metabolic conversion of procarcinogens to their ultimate reactive electrophilic intermediates. 	Cytochrome P450 enzyme	17750	17772	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:148	In the interpretation of both the in vitro and in vivo inhibitory potential and characteristics of R. rosea on Cytochrome P450 enzyme activity, the potential differences in biochemical activity of multiple unknown constituents must also be taken into consideration. 	Cytochrome P450 enzyme	20953	20975	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5684854_OgerInput.txtOger_out.csv:156	Further studies should evaluate possible Cytochrome P450 enzyme effects of other commercially available R. rosea products and in more detail attempt to identify which of the R. rosea constituents that are responsible for these effects. 	Cytochrome P450 enzyme	22449	22471	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:108	In addition to the inflammation caused by Escherichia coli, lipopolysaccharide is also a major cause of Cytochrome P450 enzyme inhibition. 	Cytochrome P450 enzyme	19635	19657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:120	The Cytochrome P450 enzyme, a key determinant of drug-drug interactions, forms the basis of clinically personalized drug monitoring. 	Cytochrome P450 enzyme	22218	22240	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5815478_OgerInput.txtOger_out.csv:124	This is mainly manifested by increased inflammatory factors, decreased antioxidant enzymes, and increased oxidative metabolites, which are accompanied by liver Cytochrome P450 enzyme expression and a rapid decrease in activity. 	Cytochrome P450 enzyme	23170	23192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	Cytochrome P450 enzyme	6525	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:182	Although H19 does not seem to play a role in bile acid synthesis, its direct repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR. 	CYP7	23588	23592	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_714', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:182	Although H19 does not seem to play a role in bile acid synthesis, its direct repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR. 	CYP7	23588	23592	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_712', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:182	Although H19 does not seem to play a role in bile acid synthesis, its direct repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR. 	CYP7	23588	23592	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_655', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:182	Although H19 does not seem to play a role in bile acid synthesis, its direct repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR. 	CYP7	23588	23592	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_653', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP7	64458	64462	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_714', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP7	64458	64462	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_712', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP7	64458	64462	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_655', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP7	64458	64462	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_653', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:134	The genes that are overexpressed in Theca cells (cluster 4) are particularly involved in cholesterol import (SCARB1, STARD5), bile acid metabolism (CH25H), HDL-mediated lipid transport (APOA1, PLTP, SCARB1), lipid degradation (LPL, PLIN5), and steroidogenesis (CYP27A, CYP7B1, TM7SF2). 	CYP7	25478	25482	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_714', 'CUI-less')
PMC5488788_OgerInput.txtOger_out.csv:57	According to the Karu model, red (~630 nm) photons are absorbed in cytochrome C oxidase, a key enzyme in the electron transport chain embedded within the membrane of mitochondria. 	cytochrome C	8377	8389	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5488788_OgerInput.txtOger_out.csv:57	According to the Karu model, red (~630 nm) photons are absorbed in cytochrome C oxidase, a key enzyme in the electron transport chain embedded within the membrane of mitochondria. 	cytochrome C	8377	8389	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:5	Further investigation on intracellular mechanisms indicated that cytochrome C was released from mitochondria into cytosol in A549 cells after Se-PPC treatment. 	cytochrome C	915	927	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:5	Further investigation on intracellular mechanisms indicated that cytochrome C was released from mitochondria into cytosol in A549 cells after Se-PPC treatment. 	cytochrome C	915	927	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:84	This assay was performed according to cytochrome C releasing apoptosis assay kits (Biovision, San Francisco, CA, USA) instructions. 	cytochrome C	12908	12920	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:84	This assay was performed according to cytochrome C releasing apoptosis assay kits (Biovision, San Francisco, CA, USA) instructions. 	cytochrome C	12908	12920	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5532657_OgerInput.txtOger_out.csv:90	Then western blot proceeded with cytochrome C antibody (Biovision, San Francisco, CA, USA). 	cytochrome C	13677	13689	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5532657_OgerInput.txtOger_out.csv:90	Then western blot proceeded with cytochrome C antibody (Biovision, San Francisco, CA, USA). 	cytochrome C	13677	13689	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:4	We found that ALPHA-mangostin effectively inhibited cell viability, resulted in loss of mitochondrial membrane potential, release of cytochrome C, increase of Bax, decrease of Bcl-2, and activation of caspase-9/caspase-3 cascade in cervical cancer cells. 	cytochrome C	487	499	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:4	We found that ALPHA-mangostin effectively inhibited cell viability, resulted in loss of mitochondrial membrane potential, release of cytochrome C, increase of Bax, decrease of Bcl-2, and activation of caspase-9/caspase-3 cascade in cervical cancer cells. 	cytochrome C	487	499	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:43	To further demonstrate ALPHA-mangostin-induced apoptotic cell death in cervical cancer cells, mitochondrial membrane potential, expression of apoptosis activator, Bax, and anti-apoptotic protein, Bcl-2, and release of cytochrome C were tested. 	cytochrome C	7790	7802	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:43	To further demonstrate ALPHA-mangostin-induced apoptotic cell death in cervical cancer cells, mitochondrial membrane potential, expression of apoptosis activator, Bax, and anti-apoptotic protein, Bcl-2, and release of cytochrome C were tested. 	cytochrome C	7790	7802	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:45	A simultaneous increase of pro-apoptotic proteins, including Bax and cytochrome C, and a decrease in anti-apoptotic protein, Bcl-2, were also observed upon treatment of increased concentrations of ALPHA-mangostin in both HeLa and SiHa cells (Figure  and. 	cytochrome C	8061	8073	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:45	A simultaneous increase of pro-apoptotic proteins, including Bax and cytochrome C, and a decrease in anti-apoptotic protein, Bcl-2, were also observed upon treatment of increased concentrations of ALPHA-mangostin in both HeLa and SiHa cells (Figure  and. 	cytochrome C	8061	8073	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:62	In summary, results of these experiments demonstrate that ALPHA-mangostin enhances Reactive Oxygen Species amounts to activate the ASK/p38 signaling pathway and damage the integrity of mitochondria, including loss of Membrane Potential, increase of Bax and cytochrome C release, and decrease of Bcl-2, leading to activation of caspase-9/caspase-3 cascade, and induction of apoptosis in cervical cancer cells (Figure. 	cytochrome C	11661	11673	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:62	In summary, results of these experiments demonstrate that ALPHA-mangostin enhances Reactive Oxygen Species amounts to activate the ASK/p38 signaling pathway and damage the integrity of mitochondria, including loss of Membrane Potential, increase of Bax and cytochrome C release, and decrease of Bcl-2, leading to activation of caspase-9/caspase-3 cascade, and induction of apoptosis in cervical cancer cells (Figure. 	cytochrome C	11661	11673	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:63	Results of the present study have shown that ALPHA-mangostin induces generation of Reactive Oxygen Species to activate the ASK/p38 signaling pathway and rupture mitochondria, followed by loss of Membrane Potential, increase of Bax and cytochrome C release, decrease of Bcl-2, leading to triggering caspase-9/caspase-3 cascade and inducing apoptosis in cervical cancer cells. 	cytochrome C	12056	12068	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:63	Results of the present study have shown that ALPHA-mangostin induces generation of Reactive Oxygen Species to activate the ASK/p38 signaling pathway and rupture mitochondria, followed by loss of Membrane Potential, increase of Bax and cytochrome C release, decrease of Bcl-2, leading to triggering caspase-9/caspase-3 cascade and inducing apoptosis in cervical cancer cells. 	cytochrome C	12056	12068	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:98	The antibodies against phosphory-ERK, phosphory-p38, phosphory-JNK, ERK, p38, JNK, phosphory-MKK3/6, MKK3/6, Bcl-2, Bax, cytochrome C, COX4, ALPHA-tubulin, BETA-actin, siRNA-ERK, siRNA-JNK and siRNA-p38, siRNA-ASK1, siRNA-MKK3/6 were purchased from Santa Cruz Biotechnology (Dallas, Texas). 	cytochrome C	19476	19488	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:98	The antibodies against phosphory-ERK, phosphory-p38, phosphory-JNK, ERK, p38, JNK, phosphory-MKK3/6, MKK3/6, Bcl-2, Bax, cytochrome C, COX4, ALPHA-tubulin, BETA-actin, siRNA-ERK, siRNA-JNK and siRNA-p38, siRNA-ASK1, siRNA-MKK3/6 were purchased from Santa Cruz Biotechnology (Dallas, Texas). 	cytochrome C	19476	19488	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5564576_OgerInput.txtOger_out.csv:117	After blocking, the membrane was hybridized with the antibodies against cleaved-caspase-3 (1:1000), cleaved-caspase-9 (1:1000), cleaved-PARP (1:1000), phosphory-ERK (1:1000), phosphory-p38 (1:1000), phosphory-JNK (1:1000), ERK (1:2000), p38 (1:1000), JNK (1:1000), phosphory-ASK1 (1:1000), Apoptosis Signal-Regulating Kinase 1 (1:1000), phosphory-MKK3/6 (1:1000), MKK3/6 (1:1000), Bcl-2 (1:1000), Bax (1:1000), cytochrome C (1:500), COX4 (1:1000), ALPHA-tubulin (1:2000) and BETA-actin (1:2000). 	cytochrome C	23090	23102	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5564576_OgerInput.txtOger_out.csv:117	After blocking, the membrane was hybridized with the antibodies against cleaved-caspase-3 (1:1000), cleaved-caspase-9 (1:1000), cleaved-PARP (1:1000), phosphory-ERK (1:1000), phosphory-p38 (1:1000), phosphory-JNK (1:1000), ERK (1:2000), p38 (1:1000), JNK (1:1000), phosphory-ASK1 (1:1000), Apoptosis Signal-Regulating Kinase 1 (1:1000), phosphory-MKK3/6 (1:1000), MKK3/6 (1:1000), Bcl-2 (1:1000), Bax (1:1000), cytochrome C (1:500), COX4 (1:1000), ALPHA-tubulin (1:2000) and BETA-actin (1:2000). 	cytochrome C	23090	23102	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:31	Reduced nicotinamide adenine dinucleotide phosphate and horse cytochrome C were obtained from Solarbio Science and Technology co.. Methanol and acetonitrile were HPLC grade and were purchased from Siyou Chemical Reagent Co.. As reported recently, 105 liver samples were selected from 123 liver samples obtained from patients undergoing liver surgery during 2012 and 2014 at the First Affiliated Hospital of Zhengzhou University, the Peoples Hospital of Henan Province, and the Tumors Hospital of Henan Province. 	cytochrome C	6096	6108	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5696450_OgerInput.txtOger_out.csv:31	Reduced nicotinamide adenine dinucleotide phosphate and horse cytochrome C were obtained from Solarbio Science and Technology co.. Methanol and acetonitrile were HPLC grade and were purchased from Siyou Chemical Reagent Co.. As reported recently, 105 liver samples were selected from 123 liver samples obtained from patients undergoing liver surgery during 2012 and 2014 at the First Affiliated Hospital of Zhengzhou University, the Peoples Hospital of Henan Province, and the Tumors Hospital of Henan Province. 	cytochrome C	6096	6108	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5823870_OgerInput.txtOger_out.csv:88	Since H_2S blocks aerobic respiration by competing with O_2 for cytochrome C oxidase binding, Blh helps to maintain a high O_2 flux, especially when O_2 becomes a limiting factor to the cells. 	cytochrome C	15836	15848	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5823870_OgerInput.txtOger_out.csv:88	Since H_2S blocks aerobic respiration by competing with O_2 for cytochrome C oxidase binding, Blh helps to maintain a high O_2 flux, especially when O_2 becomes a limiting factor to the cells. 	cytochrome C	15836	15848	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5955497_OgerInput.txtOger_out.csv:112	At the beginning of growth, the upregulation of genes involved in oxidative phosphorylation (ctaG, SO3058, coxA) indicates an increase in electron-transporting activity and the hydrolysis of ATP (SO3885), along with the downregulation of subunits for the synthesis of a cytochrome c-oxidase (ccoQ), an ATPase (atpC), a periplasmic monoheme cytochrome C (scyA), and a succinate dehydrogenase (sdhB) responsible for the reduction of ubiquinone to ubiquinol. 	cytochrome C	25872	25884	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5955497_OgerInput.txtOger_out.csv:112	At the beginning of growth, the upregulation of genes involved in oxidative phosphorylation (ctaG, SO3058, coxA) indicates an increase in electron-transporting activity and the hydrolysis of ATP (SO3885), along with the downregulation of subunits for the synthesis of a cytochrome c-oxidase (ccoQ), an ATPase (atpC), a periplasmic monoheme cytochrome C (scyA), and a succinate dehydrogenase (sdhB) responsible for the reduction of ubiquinone to ubiquinol. 	cytochrome C	25872	25884	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6152338_OgerInput.txtOger_out.csv:85	The mitochondrial stress causes both the release of cytochrome C, the conversion of the procaspase 9 in caspase 9, and finally the activation of caspases 3 and 7. 	cytochrome C	15252	15264	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6152338_OgerInput.txtOger_out.csv:85	The mitochondrial stress causes both the release of cytochrome C, the conversion of the procaspase 9 in caspase 9, and finally the activation of caspases 3 and 7. 	cytochrome C	15252	15264	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6272101_OgerInput.txtOger_out.csv:9	We found that mitochondrial release of cytochrome C into the cytoplasm also increased, indicating that apoptosis had been activated. 	cytochrome C	1071	1083	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6272101_OgerInput.txtOger_out.csv:9	We found that mitochondrial release of cytochrome C into the cytoplasm also increased, indicating that apoptosis had been activated. 	cytochrome C	1071	1083	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6272101_OgerInput.txtOger_out.csv:261	It then causes mitochondrial outer membrane permeabilization, releasing cytochrome C and inducing apoptosis.,  In this study, after transfection of B16 cells with pcDNA3.1UTB, cytochrome C was released from mitochondria; downregulated BCL2 and upregulated BAX levels were related to melanoma cell apoptosis, presenting further evidence that the p53 pathway is activated when UTB is overexpressed in B16 cells. 	cytochrome C	32184	32196	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6272101_OgerInput.txtOger_out.csv:261	It then causes mitochondrial outer membrane permeabilization, releasing cytochrome C and inducing apoptosis.,  In this study, after transfection of B16 cells with pcDNA3.1UTB, cytochrome C was released from mitochondria; downregulated BCL2 and upregulated BAX levels were related to melanoma cell apoptosis, presenting further evidence that the p53 pathway is activated when UTB is overexpressed in B16 cells. 	cytochrome C	32184	32196	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6272101_OgerInput.txtOger_out.csv:261	It then causes mitochondrial outer membrane permeabilization, releasing cytochrome C and inducing apoptosis.,  In this study, after transfection of B16 cells with pcDNA3.1UTB, cytochrome C was released from mitochondria; downregulated BCL2 and upregulated BAX levels were related to melanoma cell apoptosis, presenting further evidence that the p53 pathway is activated when UTB is overexpressed in B16 cells. 	cytochrome C	32288	32300	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6272101_OgerInput.txtOger_out.csv:261	It then causes mitochondrial outer membrane permeabilization, releasing cytochrome C and inducing apoptosis.,  In this study, after transfection of B16 cells with pcDNA3.1UTB, cytochrome C was released from mitochondria; downregulated BCL2 and upregulated BAX levels were related to melanoma cell apoptosis, presenting further evidence that the p53 pathway is activated when UTB is overexpressed in B16 cells. 	cytochrome C	32288	32300	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6646835_OgerInput.txtOger_out.csv:135	Numerous oxidative metabolic functions were identified in these bins, including oxygen respiration, thiosulfate oxidation through the Sox pathway and metal oxidation via multiheme cytochrome C. A strong metabolic potential for degradation of various organic compounds, including urea, hydrocarbons and aromatic compounds was also identified. 	cytochrome C	23902	23914	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6646835_OgerInput.txtOger_out.csv:135	Numerous oxidative metabolic functions were identified in these bins, including oxygen respiration, thiosulfate oxidation through the Sox pathway and metal oxidation via multiheme cytochrome C. A strong metabolic potential for degradation of various organic compounds, including urea, hydrocarbons and aromatic compounds was also identified. 	cytochrome C	23902	23914	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:7	Apoptosis rate, cytochrome C and cleaved caspase3 increased, and cell viability decreased following bubble contact for 10, 20 or 30 minutes, but not for 1 or 5 minutes. 	cytochrome C	769	781	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:7	Apoptosis rate, cytochrome C and cleaved caspase3 increased, and cell viability decreased following bubble contact for 10, 20 or 30 minutes, but not for 1 or 5 minutes. 	cytochrome C	769	781	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:29	Cell viability, apoptosis rate and expressions of cytochrome C and cleaved caspase3 were determined prior to the experiment for assessing endothelial function at 12 hours following bubble contact. 	cytochrome C	4222	4234	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	Cytochrome P450 3a	409	427	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:7	Nanocarriers were evaluated in vitro for their Cytochrome P450 3a4 inhibition capacity and in vivo for their biodistribution, and finally injected 24 hours prior to the drug docetaxel, for their ability to improve the efficiency of the drug docetaxel. 	Cytochrome P450 3a	754	772	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:8	Nanoparticles of poly(lactic-co-glycolic) acid (PLGA) with a hydrodynamic diameter of 63 nm, functionalized with galactosamine, showed efficient in vitro Cytochrome P450 3a4 inhibition and the highest accumulation in hepatocytes. 	Cytochrome P450 3a	1113	1131	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450 3a	1918	1936	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450 3a	2167	2185	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	Cytochrome P450 3a	4314	4332	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:87	HepaRG cells were cultivated to induce Cytochrome P450 3a4. 	Cytochrome P450 3a	13557	13575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	Cytochrome P450 3a	14412	14430	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:162	In vitro IC_50 values of Cytochrome P450 3a4 by Bergamottin in different nanocarriers were measured on the HepaRG cell line,, using a fluorogenic substrate: DBOMF. 	Cytochrome P450 3a	24187	24205	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:198	Different nanocarriers were designed to encapsulate the hydrophobic Bergamottin, inhibitor of Cytochrome P450 3a4, to make it injectable and to deliver it to hepatocytes. 	Cytochrome P450 3a	30104	30122	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450 3a	32167	32185	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450 3a	32327	32345	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	Cytochrome P450 3a	35680	35698	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:235	The 24-hour time lapse is more ethical regarding volumes injected to mice and allows Bergamottin to exit from PLGA nanoparticles and to bind to Cytochrome P450 3a4. 	Cytochrome P450 3a	35880	35898	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:236	Our strategy is to inhibit Cytochrome P450 3a4 activity in hepatocytes, decrease docetaxels metabolism in the liver and increase its concentration in the tumor. 	Cytochrome P450 3a	35928	35946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:246	Inhibiting Cytochrome P450 3a4 in particular, by which docetaxel is metabolized, would allow increasing the concentration of docetaxel in HCCs and avoid resistance mechanisms. 	Cytochrome P450 3a	37560	37578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	Cytochrome P450 3a	38471	38489	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450 3a	38899	38917	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450 3a	18034	18052	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450 3a	18347	18365	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:4	Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic Cytochrome P450 3a4 and leave drug-metabolizing enzymes in other organs undisturbed. 	Cytochrome P450 3a4	409	428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:7	Nanocarriers were evaluated in vitro for their Cytochrome P450 3a4 inhibition capacity and in vivo for their biodistribution, and finally injected 24 hours prior to the drug docetaxel, for their ability to improve the efficiency of the drug docetaxel. 	Cytochrome P450 3a4	754	773	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:8	Nanoparticles of poly(lactic-co-glycolic) acid (PLGA) with a hydrodynamic diameter of 63 nm, functionalized with galactosamine, showed efficient in vitro Cytochrome P450 3a4 inhibition and the highest accumulation in hepatocytes. 	Cytochrome P450 3a4	1113	1132	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450 3a4	1918	1937	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:10	Taxotere^ (docetaxel) is a chemotherapy agent used in clinic, injected intravenously, for several indications, such as non-small cell lung cancer, breast cancer, gastric cancer and prostate cancer., Docetaxel is extensively metabolized by cytochrome P450 3A4, resulting in low systemic bioavailability.- Recently, docetaxel was administered with oral drugs that are known to be potent Cytochrome P450 3a4 inhibitors to increase its bioavailability and to enable its oral administration, especially by the inhibition of intestinal CYP34A., However, on top of their own pharmacological activity, these orally administered inhibitors of Cytochrome P450 3a4 generally have a wide biodistribution. 	Cytochrome P450 3a4	2167	2186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:21	In parallel, these nanocarriers, loaded with bergamottin, a natural CYP3A4-inhibiting agent,- were tested for their ability to interact with hepatocytes in vitro, modulate Cytochrome P450 3a4 activity and increase the antitumor efficacy of docetaxel. 	Cytochrome P450 3a4	4314	4333	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:87	HepaRG cells were cultivated to induce Cytochrome P450 3a4. 	Cytochrome P450 3a4	13557	13576	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:95	Half-maximal inhibitory concentration (IC_50) was determined on CYP3A4-expressing HepaRG cells, after incubation of the fluorogenic substrate DBOMF, specific for Cytochrome P450 3a4. 	Cytochrome P450 3a4	14412	14431	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:162	In vitro IC_50 values of Cytochrome P450 3a4 by Bergamottin in different nanocarriers were measured on the HepaRG cell line,, using a fluorogenic substrate: DBOMF. 	Cytochrome P450 3a4	24187	24206	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:198	Different nanocarriers were designed to encapsulate the hydrophobic Bergamottin, inhibitor of Cytochrome P450 3a4, to make it injectable and to deliver it to hepatocytes. 	Cytochrome P450 3a4	30104	30123	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450 3a4	32167	32186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:212	Indeed, as a polysaccharide, HA is reported to confer stealth properties to the nanoparticles they functionalize., To test the Cytochrome P450 3a4 inhibition of the Bergamottin in the nanocarriers, their IC_50 was evaluated on the hepatocyte cell line, HepaRG, induced to express active Cytochrome P450 3a4. 	Cytochrome P450 3a4	32327	32346	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:234	Even though PLGA-Ga reach the hepatocytes very rapidly, Bergamottin is a suicide inhibitor of CYP3A4: its inhibition lasts until the neosynthesis of Cytochrome P450 3a4 proteins, so for at least 24 hours. 	Cytochrome P450 3a4	35680	35699	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:235	The 24-hour time lapse is more ethical regarding volumes injected to mice and allows Bergamottin to exit from PLGA nanoparticles and to bind to Cytochrome P450 3a4. 	Cytochrome P450 3a4	35880	35899	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:236	Our strategy is to inhibit Cytochrome P450 3a4 activity in hepatocytes, decrease docetaxels metabolism in the liver and increase its concentration in the tumor. 	Cytochrome P450 3a4	35928	35947	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:246	Inhibiting Cytochrome P450 3a4 in particular, by which docetaxel is metabolized, would allow increasing the concentration of docetaxel in HCCs and avoid resistance mechanisms. 	Cytochrome P450 3a4	37560	37579	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:252	The taxane paclitaxel for instance is metabolized by both Cytochrome P450 3a4 and CYP2C8. 	Cytochrome P450 3a4	38471	38490	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450 3a4	38899	38918	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450 3a4	18034	18053	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450 3a4	18347	18366	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b 5	544	558	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b 5	544	558	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b 5	576	590	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:4	Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b 5 reductase and/or cytochrome b 5 in Supersomes to oxidize this drug. 	cytochrome b 5	576	590	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:5	We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b 5 reductase, to mediate ellipticine oxidation in these enzyme systems. 	cytochrome b 5	772	786	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:5	We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b 5 reductase, to mediate ellipticine oxidation in these enzyme systems. 	cytochrome b 5	772	786	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:11	In the presence of NADPH or NADH, cytochrome b 5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. 	cytochrome b 5	1681	1695	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:11	In the presence of NADPH or NADH, cytochrome b 5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. 	cytochrome b 5	1681	1695	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	1939	1953	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	1939	1953	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2026	2040	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2026	2040	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	3659	3674	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	3659	3674	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	3712	3727	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:20	This enzymatic system also contains other enzymes such as NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b _5 accompanied with its reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	3712	3727	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4079	4094	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4079	4094	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4126	4141	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4126	4141	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4157	4172	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:22	The second electron needed for the reduction of CYP in the monooxygenase reaction cycle may also be provided by cytochrome b _5 in the presence of POR or NADH:cytochrome b _5 reductase, but cytochrome b _5 also plays additional roles in the monooxygenase system. 	cytochrome b _5	4157	4172	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:23	It was demonstrated that a second electron donor, cytochrome b _5, could also modulate (stimulate and/or inhibit) the activity of several CYPs, both in vitro and in vivo. 	cytochrome b _5	4280	4295	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:23	It was demonstrated that a second electron donor, cytochrome b _5, could also modulate (stimulate and/or inhibit) the activity of several CYPs, both in vitro and in vivo. 	cytochrome b _5	4280	4295	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:25	Interestingly, in the case of ellipticine, cytochrome b _5, when reconstituted with CYP3A4 and POR, alters the ratio of ellipticine metabolites formed by this CYP. 	cytochrome b _5	4563	4578	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:25	Interestingly, in the case of ellipticine, cytochrome b _5, when reconstituted with CYP3A4 and POR, alters the ratio of ellipticine metabolites formed by this CYP. 	cytochrome b _5	4563	4578	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:26	Under these conditions, the amounts of the detoxification metabolites (7-hydroxyellipticine and 9-hydroxyellipticine) were not changed with added cytochrome b _5, whereas oxidation of ellipticine to 12-hydroxyellipticine, 13-hydroxyellipticine, and ellipticine N ^2-oxide, the metabolites responsible for the formation of covalent DNA adducts, increased considerably. 	cytochrome b _5	4830	4845	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:26	Under these conditions, the amounts of the detoxification metabolites (7-hydroxyellipticine and 9-hydroxyellipticine) were not changed with added cytochrome b _5, whereas oxidation of ellipticine to 12-hydroxyellipticine, 13-hydroxyellipticine, and ellipticine N ^2-oxide, the metabolites responsible for the formation of covalent DNA adducts, increased considerably. 	cytochrome b _5	4830	4845	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:28	Hence, cytochrome b _5 seems to play a key role in the CYP3A4-mediated DNA-damage caused by these ellipticine metabolites [,. 	cytochrome b _5	5151	5166	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:28	Hence, cytochrome b _5 seems to play a key role in the CYP3A4-mediated DNA-damage caused by these ellipticine metabolites [,. 	cytochrome b _5	5151	5166	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5350	5365	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5350	5365	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5401	5416	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5401	5416	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5436	5451	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:29	CYP3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b _5 containing heme, while neither apo-cytochrome b _5 without heme or Mn-cytochrome b _5 had such an effect. 	cytochrome b _5	5436	5451	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	cytochrome b _5	5536	5551	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:30	Results found by Guengerich and his coworkers demonstrated that cytochrome b _5 added to recombinant CYP3A4 reconstituted with POR enhanced CYP3A4 marker activity, testosterone 6-BETA-hydroxylation. 	cytochrome b _5	5536	5551	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:31	They also showed that this heme protein with NADH:cytochrome b _5 reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. 	cytochrome b _5	5721	5736	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:31	They also showed that this heme protein with NADH:cytochrome b _5 reductase and NADH might even substitute the POR/NADPH system in the CYP3A4 catalysis of this marker reaction. 	cytochrome b _5	5721	5736	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b _5	5886	5901	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b _5	5886	5901	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b _5	5912	5927	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:32	Recently, we have found that the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also substitute the POR/NADPH system and act as an electron donor to another CYP enzyme, CYP1A1, for the oxidation of benzo[a]pyrene (BaP). 	cytochrome b _5	5912	5927	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6284	6299	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6284	6299	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6310	6325	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6310	6325	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6500	6515	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:34	Here, we investigated in detail, whether the NADH:cytochrome b _5 reductase/cytochrome b _5/NADH system can also be the sole electron donor in the CYP3A4-catalyzed oxidation of ellipticine, Another aim of this work was to shed more light on the further functions of cytochrome b _5 in this CYP3A4-mediated reaction. 	cytochrome b _5	6500	6515	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b _5	6903	6918	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b _5	6903	6918	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b _5	6929	6944	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:37	In addition to the classical reductase POR with its cofactor NADPH, cytochrome b _5 plus NADH:cytochrome b _5 reductase has come into focus, and, therefore, its role in ellipticine oxidation was the aim of this study. 	cytochrome b _5	6929	6944	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7312	7327	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7312	7327	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7342	7357	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7342	7357	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7430	7445	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7430	7445	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7477	7492	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:38	Three enzymatic systems were utilized for such a study: (i) human hepatic microsomes, (ii) microsomes of baculovirus-infected insect cells (Supersomes) containing over-expressed amounts of human recombinant CYP3A4 and POR, as well as the basal levels of NADH:cytochrome b _5 reductase and cytochrome b _5, and (iii) the analogous Supersomes, but also containing over-expressed cytochrome b _5, at a molar ratio of CYP3A4 to cytochrome b _5 of 1:5. 	cytochrome b _5	7477	7492	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:39	NADPH and NADH, cofactors of the two microsomal reductases POR and NADH:cytochrome b _5 reductase, respectively, were utilized as electron donors for CYP-mediated ellipticine oxidation. 	cytochrome b _5	7573	7588	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:39	NADPH and NADH, cofactors of the two microsomal reductases POR and NADH:cytochrome b _5 reductase, respectively, were utilized as electron donors for CYP-mediated ellipticine oxidation. 	cytochrome b _5	7573	7588	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8724	8739	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8724	8739	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8782	8797	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8782	8797	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8864	8879	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:44	Our results showed that the Supersomal CYP3A4 systems are capable of catalyzing this marker reaction, both in the presence of NADPH and NADH, and cytochrome b _5 stimulated this reaction enormously where cytochrome b _5 was over-expressed with CYP3A4 and POR at a molar ratio of CYP3A4:cytochrome b _5 of 1:5 already in the cells from which CYP3A4-Supersomes (microsomes) were isolated. 	cytochrome b _5	8864	8879	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:46	In this system, reconstitution with cytochrome b _5 only increased the formation of 12-hydroxy- and 13-hydroxyellipticine but not that of 9-hydroxyellipticine. 	cytochrome b _5	9149	9164	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:46	In this system, reconstitution with cytochrome b _5 only increased the formation of 12-hydroxy- and 13-hydroxyellipticine but not that of 9-hydroxyellipticine. 	cytochrome b _5	9149	9164	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	cytochrome b _5	9417	9432	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:47	This finding indicated that this heme protein does not only influence the transfer of electrons during the second reduction of CYP3A4, but that cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, leading to an altered profile of ellipticine metabolites. 	cytochrome b _5	9417	9432	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b _5	9656	9671	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b _5	9656	9671	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b _5	9784	9799	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:48	Indeed, our previous studies have indicated a high specificity of interaction of CYP3A4 with holo-cytochrome b _5 containing heme, which is necessary not only for electron transfer but also for the natural conformation of the cytochrome b _5 and CYP3A4 proteins. 	cytochrome b _5	9784	9799	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	9875	9890	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	9875	9890	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	9968	9983	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	9968	9983	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	10045	10060	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:49	These results, and those found for the interaction of cytochrome b _5 with CYP1A1, demonstrate that the natural three-dimensional structure of the cytochrome b _5 protein dictates the optimal conformational state of the CYP-cytochrome b _5 complex. 	cytochrome b _5	10045	10060	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b _5	10367	10382	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b _5	10367	10382	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b _5	10572	10587	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:52	One reason might be that the co-expression of the CYP3A4 and cytochrome b _5 proteins from their cDNA into the membrane of endoplasmic reticulum may produce protein molecules in conformation states that are different from those generated after the reconstitution of cytochrome b _5 with CYP3A4 in Supersomes, thus leading to different enzymatic activity of the monooxygenase system. 	cytochrome b _5	10572	10587	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b _5	10769	10784	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b _5	10769	10784	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b _5	11139	11154	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:54	In the presence of NADH, cytochrome b _5 over-expressed in CYP3A4-Supersomes also enhanced ellipticine oxidation to individual metabolites, but to different degrees; 9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-fold, and 13-hydroxyellipticine by 6.5-fold, which led to the formation of an altered pattern of ellipticine metabolites compared to basal levels without over-expressed cytochrome b _5 (Fig. 	cytochrome b _5	11139	11154	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:55	This finding demonstrated that cytochrome b _5 influences the CYP3A4 catalytic activity in at least two ways. 	cytochrome b _5	11192	11207	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:55	This finding demonstrated that cytochrome b _5 influences the CYP3A4 catalytic activity in at least two ways. 	cytochrome b _5	11192	11207	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11501	11516	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11501	11516	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11627	11642	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11627	11642	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11643	11658	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:57	This again indicates that the NADH:cytochrome b _5 reductase as an NADH-dependent reductase can substitute POR in this enzymatic reaction and that the NADH/NADH:cytochrome b _5/cytochrome b _5 system might act as an exclusive donor of electrons for this CYP3A4-mediated ellipticine oxidation independent of NADPH and POR. 	cytochrome b _5	11643	11658	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:58	Second, cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, resulting in changes in profile of ellipticine metabolite formation. 	cytochrome b _5	11796	11811	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:58	Second, cytochrome b _5 can also induce changes in the conformation of the CYP3A4 protein, resulting in changes in profile of ellipticine metabolite formation. 	cytochrome b _5	11796	11811	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	cytochrome b _5	13522	13537	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:65	In accordance with an increase in ellipticine oxidation catalyzed by CYP3A4-Supersomes with over-expressed cytochrome b _5, shown in Fig, the presence of this heme protein in the CYP3A4 system led to higher levels of ellipticine-derived DNA adducts, both in the presence of NADPH and NADH (Fig. 	cytochrome b _5	13522	13537	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:66	The present study was aimed to advance our knowledge regarding the role of cytochrome b _5 in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. 	cytochrome b _5	13785	13800	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:66	The present study was aimed to advance our knowledge regarding the role of cytochrome b _5 in the reaction cycle of CYP3A4 catalyzing the oxidation of the anticancer drug ellipticine. 	cytochrome b _5	13785	13800	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:67	Our results demonstrated that the function of cytochrome b _5 in this reaction is complex. 	cytochrome b _5	13940	13955	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:67	Our results demonstrated that the function of cytochrome b _5 in this reaction is complex. 	cytochrome b _5	13940	13955	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14140	14155	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14140	14155	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14170	14185	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14170	14185	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14216	14231	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14216	14231	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	14427	14442	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	14427	14442	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14487	14502	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14487	14502	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14631	14646	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14631	14646	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp1a2	8377	8383	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp1a2	8377	8383	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp1a2	8605	8611	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp1a2	8605	8611	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:28	In mice, berberine (300 mg/kg) increased hepatic Cyp1a2 mRNA without affecting EROD activity. 	Cyp1a2	4470	4476	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:28	In mice, berberine (300 mg/kg) increased hepatic Cyp1a2 mRNA without affecting EROD activity. 	Cyp1a2	4470	4476	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:196	Although neonatal survival is associated with CYP1A2 in Cyp1a2 knockout mice, the relationship between retinol and reproductive diseases remains unclear. 	Cyp1a2	26018	26024	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:196	Although neonatal survival is associated with CYP1A2 in Cyp1a2 knockout mice, the relationship between retinol and reproductive diseases remains unclear. 	Cyp1a2	26018	26024	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:210	For example, as early as in 1995, Gonzalez and colleagues reported that neonatal deaths were observed in the Cyp1a2 global Knockout mouse model, possibly due to respiratory distress caused by Cyp1a2 deficiency. 	Cyp1a2	27942	27948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:210	For example, as early as in 1995, Gonzalez and colleagues reported that neonatal deaths were observed in the Cyp1a2 global Knockout mouse model, possibly due to respiratory distress caused by Cyp1a2 deficiency. 	Cyp1a2	27942	27948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:210	For example, as early as in 1995, Gonzalez and colleagues reported that neonatal deaths were observed in the Cyp1a2 global Knockout mouse model, possibly due to respiratory distress caused by Cyp1a2 deficiency. 	Cyp1a2	28025	28031	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:210	For example, as early as in 1995, Gonzalez and colleagues reported that neonatal deaths were observed in the Cyp1a2 global Knockout mouse model, possibly due to respiratory distress caused by Cyp1a2 deficiency. 	Cyp1a2	28025	28031	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28044	28050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28044	28050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp3a	8385	8390	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp3a	8624	8629	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:187	Cyp1a1, Cyp1b1 and Cyp3a11, but not Ahr expression in the skin also were enhanced by 7,12-Dimethylbenz[A]Anthracene. 	Cyp3a	31354	31359	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:188	48 h after application of 7,12-Dimethylbenz[A]Anthracene, skin expression of Pxr and Cyp1a1 mRNAs were markedly increased, Cyp1b1 and Cyp3a11 only moderately and Ahr not at all. 	Cyp3a	31586	31591	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:190	Expression of Cyp1b1 and Cyp1a1 mRNAs peaked at 4 h, expression of Cyp3a11 mRNA peaked at 24 h (upregulation of Pregnane X Receptor in the DMBA-treated skin was confirmed at the protein level). 	Cyp3a	31738	31743	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:4	We observed a significant increase in the expression of Cyp3a11 in female SPF mice compared to the male group. 	Cyp3a	681	686	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:5	However, the sex differences were erased in GF mice, and the expression of Cyp3a11 was about the same in both sexes. 	Cyp3a	811	816	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:66	The Cyp3a11 mRNA was significantly increased (21 times) in female SPF mice compared to their male counterparts. 	Cyp3a	9520	9525	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:68	The expression of Cyp3a13 was slightly increased in the females of both the group SPF and GF mice. 	Cyp3a	9796	9801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:87	A higher expression of Cyp3a11 in female mice than males was reported earlier (;. 	Cyp3a	12199	12204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:54	Sort=Bait immobilized on the optical chip and identified another potential protein partner (CYP11B2). 	CYP11B2	7761	7768	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:54	Sort=Bait immobilized on the optical chip and identified another potential protein partner (CYP11B2). 	CYP11B2	7761	7768	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:54	Sort=Bait immobilized on the optical chip and identified another potential protein partner (CYP11B2). 	CYP11B2	7761	7768	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:54	Sort=Bait immobilized on the optical chip and identified another potential protein partner (CYP11B2). 	CYP11B2	7761	7768	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	8179	8186	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	8179	8186	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	8179	8186	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:56	Since CYP2E1 is involved in the metabolism of various indole derivatives, we further investigated the possible influence of the well-known endogenous bioregulator isatin (indole-2,3-dione) on the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	8179	8186	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:60	Sort=Bait  CYP11B2 interaction. 	CYP11B2	8531	8538	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:60	Sort=Bait  CYP11B2 interaction. 	CYP11B2	8531	8538	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:60	Sort=Bait  CYP11B2 interaction. 	CYP11B2	8531	8538	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:60	Sort=Bait  CYP11B2 interaction. 	CYP11B2	8531	8538	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11B2	8852	8859	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11B2	8852	8859	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11B2	8852	8859	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11B2	8852	8859	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B2	20626	20633	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B2	20626	20633	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B2	20626	20633	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B2	20626	20633	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:145	It was shown that all protein analytes, except for CYP11B2, did not bind to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	20979	20986	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:145	It was shown that all protein analytes, except for CYP11B2, did not bind to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	20979	20986	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:145	It was shown that all protein analytes, except for CYP11B2, did not bind to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	20979	20986	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:145	It was shown that all protein analytes, except for CYP11B2, did not bind to Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	20979	20986	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21392	21399	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21392	21399	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21392	21399	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:149	Thus, we can confidently state that the interaction of CYP2E1 and CYP11B2 with Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21392	21399	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:152	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21602	21609	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:152	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21602	21609	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:152	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21602	21609	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:152	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	21602	21609	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:156	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22091	22098	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:156	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22091	22098	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:156	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22091	22098	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:156	Sort=Bait  CYP11B2 and Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22091	22098	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:160	Sort=Bait  CYP11B2. 	CYP11B2	22488	22495	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:160	Sort=Bait  CYP11B2. 	CYP11B2	22488	22495	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:160	Sort=Bait  CYP11B2. 	CYP11B2	22488	22495	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:160	Sort=Bait  CYP11B2. 	CYP11B2	22488	22495	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22747	22754	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22747	22754	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22747	22754	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22747	22754	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22812	22819	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22812	22819	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22812	22819	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22812	22819	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11A1	7854	7861	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11A1	7854	7861	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11A1	7854	7861	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11A1	7854	7861	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11A1	8782	8789	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11A1	8782	8789	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11A1	8782	8789	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	CYP11A1	8782	8789	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11A1	20608	20615	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11A1	20608	20615	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11A1	20608	20615	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11A1	20608	20615	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:63	CYP11A1 converts cholesterol to pregnenolone, followed by the HSD3B2-catalyzed conversion of pregnenolone to the ^4 steroid, progesterone. 	CYP11A1	10680	10687	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:63	CYP11A1 converts cholesterol to pregnenolone, followed by the HSD3B2-catalyzed conversion of pregnenolone to the ^4 steroid, progesterone. 	CYP11A1	10680	10687	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:63	CYP11A1 converts cholesterol to pregnenolone, followed by the HSD3B2-catalyzed conversion of pregnenolone to the ^4 steroid, progesterone. 	CYP11A1	10680	10687	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:63	CYP11A1 converts cholesterol to pregnenolone, followed by the HSD3B2-catalyzed conversion of pregnenolone to the ^4 steroid, progesterone. 	CYP11A1	10680	10687	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP11A1	11770	11777	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP11A1	11770	11777	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP11A1	11770	11777	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP11A1	11770	11777	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP11A1	36437	36444	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP11A1	36437	36444	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP11A1	36437	36444	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP11A1	36437	36444	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP11A1	32428	32435	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP11A1	32428	32435	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP11A1	32428	32435	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP11A1	32428	32435	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:13	This is performed by CYP11A1 in mammals and CYP90B1 in plants. 	CYP11A1	1410	1417	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:13	This is performed by CYP11A1 in mammals and CYP90B1 in plants. 	CYP11A1	1410	1417	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:13	This is performed by CYP11A1 in mammals and CYP90B1 in plants. 	CYP11A1	1410	1417	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:13	This is performed by CYP11A1 in mammals and CYP90B1 in plants. 	CYP11A1	1410	1417	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:28	The first reaction is the conversion of cholesterol to pregnenolone by the cholesterol side-chain cleavage enzyme CYP11A1. 	CYP11A1	3444	3451	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:28	The first reaction is the conversion of cholesterol to pregnenolone by the cholesterol side-chain cleavage enzyme CYP11A1. 	CYP11A1	3444	3451	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:28	The first reaction is the conversion of cholesterol to pregnenolone by the cholesterol side-chain cleavage enzyme CYP11A1. 	CYP11A1	3444	3451	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:28	The first reaction is the conversion of cholesterol to pregnenolone by the cholesterol side-chain cleavage enzyme CYP11A1. 	CYP11A1	3444	3451	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:109	In vertebrates, the conversion of cholesterol to pregnenolone is mediated by CYP11A1 homologues. 	CYP11A1	15817	15824	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:109	In vertebrates, the conversion of cholesterol to pregnenolone is mediated by CYP11A1 homologues. 	CYP11A1	15817	15824	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:109	In vertebrates, the conversion of cholesterol to pregnenolone is mediated by CYP11A1 homologues. 	CYP11A1	15817	15824	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:109	In vertebrates, the conversion of cholesterol to pregnenolone is mediated by CYP11A1 homologues. 	CYP11A1	15817	15824	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:110	CYP11A1 perform a triple reaction, including Adrenodoxin reductase, Adrenodoxine, and side-chain cleavage. 	CYP11A1	15837	15844	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:110	CYP11A1 perform a triple reaction, including Adrenodoxin reductase, Adrenodoxine, and side-chain cleavage. 	CYP11A1	15837	15844	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:110	CYP11A1 perform a triple reaction, including Adrenodoxin reductase, Adrenodoxine, and side-chain cleavage. 	CYP11A1	15837	15844	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:110	CYP11A1 perform a triple reaction, including Adrenodoxin reductase, Adrenodoxine, and side-chain cleavage. 	CYP11A1	15837	15844	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:112	CYP11A1 performs the 22R-C hydroxylation of cholesterol, followed by 20R-C hydroxylation (B). 	CYP11A1	16200	16207	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:112	CYP11A1 performs the 22R-C hydroxylation of cholesterol, followed by 20R-C hydroxylation (B). 	CYP11A1	16200	16207	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:112	CYP11A1 performs the 22R-C hydroxylation of cholesterol, followed by 20R-C hydroxylation (B). 	CYP11A1	16200	16207	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:112	CYP11A1 performs the 22R-C hydroxylation of cholesterol, followed by 20R-C hydroxylation (B). 	CYP11A1	16200	16207	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11B1	7863	7870	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_448', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11B1	7863	7870	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_781', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11B1	7863	7870	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_447', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:55	Surface Plasmon Resonance experiments with five control cytochromes P450 (CYP2C19, CYP11A1, CYP11B1, CYP3A4, CYP3A5) were negative, indicating the high specificity of the detected PPIs. 	CYP11B1	7863	7870	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_780', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B1	20617	20624	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_448', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B1	20617	20624	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_781', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B1	20617	20624	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_447', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:143	Sort=Bait and CYP2E1 interaction was tested by running control Surface Plasmon Resonance experiments using both microsomal (CYP2C19, CYP3A4, CYP3A5) and mitochondrial (CYP11A1, CYP11B1, CYP11B2) cytochromes P450 as analytes. 	CYP11B1	20617	20624	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_780', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:72	Finally, CYP11B1, located in the mitochondria of the zona fasciculata cells, facilitates the final step in glucocorticoid biosynthesis by catalyzing the conversion of 11-deoxycortisol to cortisol. 	CYP11B1	12119	12126	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_448', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:72	Finally, CYP11B1, located in the mitochondria of the zona fasciculata cells, facilitates the final step in glucocorticoid biosynthesis by catalyzing the conversion of 11-deoxycortisol to cortisol. 	CYP11B1	12119	12126	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_781', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:72	Finally, CYP11B1, located in the mitochondria of the zona fasciculata cells, facilitates the final step in glucocorticoid biosynthesis by catalyzing the conversion of 11-deoxycortisol to cortisol. 	CYP11B1	12119	12126	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_447', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:72	Finally, CYP11B1, located in the mitochondria of the zona fasciculata cells, facilitates the final step in glucocorticoid biosynthesis by catalyzing the conversion of 11-deoxycortisol to cortisol. 	CYP11B1	12119	12126	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_780', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:35	Previous studies have suggested that Glycine N-Methyltransferase may participate in and serve as a cofactor for the regulation of detoxification gene expression, such as CYP 1A1 and CYP1A2, thereby decreasing the formations of BaP- and AFB1-DNA adducts^-. 	CYP 1A1	6112	6119	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:35	Previous studies have suggested that Glycine N-Methyltransferase may participate in and serve as a cofactor for the regulation of detoxification gene expression, such as CYP 1A1 and CYP1A2, thereby decreasing the formations of BaP- and AFB1-DNA adducts^-. 	CYP 1A1	6112	6119	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:131	Therefore, we monitored the mRNA and protein expression of CYPs (CYP 1A1 and 2A6) in U1 cells after four days of Cell Culture Supernatant exposure. 	CYP 1A1	22023	22030	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:131	Therefore, we monitored the mRNA and protein expression of CYPs (CYP 1A1 and 2A6) in U1 cells after four days of Cell Culture Supernatant exposure. 	CYP 1A1	22023	22030	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:132	We particularly examined the expressions of CYP 1A1 and 2A6, because these CYPs are significantly expressed in U1 cells, and they are induced by various xenobiotics including tobacco constituents and environmental contaminants via an oxidative stress pathway. 	CYP 1A1	22150	22157	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:132	We particularly examined the expressions of CYP 1A1 and 2A6, because these CYPs are significantly expressed in U1 cells, and they are induced by various xenobiotics including tobacco constituents and environmental contaminants via an oxidative stress pathway. 	CYP 1A1	22150	22157	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:145	Further, the commonly used housekeeping genes of cells, actin, and Glyceraldehyde 3-Phosphate Dehydrogenase, were detected only in Caski cells but not in their Eversus Finally, the Extracellular Vesicles demonstrated acetylcholine esterase activity (C), suggesting the isolation of functional Eversus To determine whether oxidative stress plays a potential role in Caski cell-induced effects on U1 cells, we measured important oxidative stress-inducing CYP enzymes, common antioxidant enzymes (AOE), and Human Papillomavirus proteins in Caski-derived Eversus Our Western blot images showed the expression of CYP enzymes (CYP 1A1, 1B1, and 2A6), AOE (SOD1), and Human Papillomavirus 16 oncoprotein E6 in CCS-derived Extracellular Vesicles (A;. 	CYP 1A1	25094	25101	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:145	Further, the commonly used housekeeping genes of cells, actin, and Glyceraldehyde 3-Phosphate Dehydrogenase, were detected only in Caski cells but not in their Eversus Finally, the Extracellular Vesicles demonstrated acetylcholine esterase activity (C), suggesting the isolation of functional Eversus To determine whether oxidative stress plays a potential role in Caski cell-induced effects on U1 cells, we measured important oxidative stress-inducing CYP enzymes, common antioxidant enzymes (AOE), and Human Papillomavirus proteins in Caski-derived Eversus Our Western blot images showed the expression of CYP enzymes (CYP 1A1, 1B1, and 2A6), AOE (SOD1), and Human Papillomavirus 16 oncoprotein E6 in CCS-derived Extracellular Vesicles (A;. 	CYP 1A1	25094	25101	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:162	Treatment of resveratrol (p-value < 0.0001, n =3), ellipticine (p-value < 0.0001, n =3), or tryptamine (p-value < 0.0001, n =3) significantly reduced the viral load in CCS-EVs exposed U1 cells, suggesting the role of CYP 1A1 and 2A6, and oxidative stress on viral load increase in U1 cells (A,B). 	CYP 1A1	28317	28324	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:1	Chinese woodchucks with different susceptibility to WHV infection differ in their genetic background exemplified by cytochrome B and MHC-DRB molecules. 	cytochrome B	117	129	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:3	In this study, we aimed to determine the susceptibility to WHV infection of M. himalayana from different areas and their association with the animal genetic background exemplified by cytochrome B and MHC-DRB molecules. 	cytochrome B	455	467	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:6	The sequences of cytochrome B gene and MHC-DRB molecules were obtained and sorted with Clustalx software. 	cytochrome B	765	777	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:10	All of the animals belong to the same subspecies M. himalayana robusta identified by cytochrome B gene sequences. 	cytochrome B	1257	1269	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:11	Based on their nucleotide variation pattern, 8 alleles of cytochrome B gene were identified, and 7 MHC-DRB alleles were identified. 	cytochrome B	1344	1356	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:12	Allele A of cytochrome B and Allele Mamo-DRB1*02 of MHC-DRB was found to be frequent in animals from TR and TD areas, while Allele H of cytochrome B and Allele Mamo-DRB1*07 of MHC-DRB was predominant in animals from GD and WL areas. 	cytochrome B	1430	1442	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:12	Allele A of cytochrome B and Allele Mamo-DRB1*02 of MHC-DRB was found to be frequent in animals from TR and TD areas, while Allele H of cytochrome B and Allele Mamo-DRB1*07 of MHC-DRB was predominant in animals from GD and WL areas. 	cytochrome B	1554	1566	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:14	The genetic background exemplified by cytochrome B and MHC-DRB differed in Chinese woodchucks with different susceptibility to WHV infection. 	cytochrome B	1845	1857	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:31	Therefore, partial or complete sequences of the mitochondrial genome, in particular the sequences of the mitochondrial cytochrome B, have been used extensively in studies on population genetics, phylogeny and phylogeography in Rodentia. 	cytochrome B	5084	5096	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:38	We aimed to determine the association between WHV infection and the genetic background of M himalayana exemplified by cytochrome B and MHC-DRB molecules. 	cytochrome B	6013	6025	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:56	The PCR Primers cytB-1/2 were designed according to the cytochrome B sequence of M. Himalayan (AY143928). 	cytochrome B	8360	8372	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:63	The PCR fragments of cytochrome B were purified and subjected to direct sequencing from both orientations using primers cytB-1 and cytB-2. 	cytochrome B	9152	9164	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:81	Whole blood was collected before WHV inoculation, and cytochrome B gene fragments were amplified using total DNA and the primer cytB-1 and cytB-2. 	cytochrome B	11377	11389	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:82	The PCR products were directly sequenced, and cytochrome B sequences from 37 Chinese woodchucks were obtained, 11 from TR area, 8 from TD area, 9 from GD area, and 9 from WL area. 	cytochrome B	11516	11528	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:83	Notably, only partial sequence of cytochrome B gene (nt 64-1080) was included for the analysis, since the direct sequencing only generated reliable data for the middle part of PCR fragments. 	cytochrome B	11684	11696	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:85	Based on the pattern of the substitutions, all of the sequences were assigned to 8 alleles, named A, B, C, D, E, F, G, and H. Chinese woodchucks mainly belong to 5 species, M. himalayana, M. sibirica, M. caudata, M. baibacina, and M. bobak, therefore the cytochrome B sequences of the 5 Chinese woodchuck species were downloaded from GenBank, at least two sequences for each species. 	cytochrome B	12271	12283	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:86	The phylogenetic tree of cytochrome B sequences was conducted using the 14 downloaded sequences and the 8 alleles, and indicated that all of the animals from the 4 areas belonged to the same species M. himalayana from M. himalayana robusta was published by Steppen et al., and the animals were collected from Yushu, Qinghai, China. 	cytochrome B	12425	12437	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:89	Since the mitochondrial DNA haplotype frequencies were considered to be primarily controlled by migration and genetic drift, and that most intraspecies variation is selectively neutral, we compared the frequencies of the 8 cytochrome B alleles in the animals from the four areas have allele A (37.84%, 14/37) or H (35.14%, 13/37), indicating these two alleles were the predominant alleles in the animals from TR, TD, GD, and WL areas of Qinghai province and 11.76% (2/17) (P = 0.1089), respectively, while those of allele H were 5.00% (1/20) and 70.59% (12/17) (P < 0.0001), respectively (Table. 	cytochrome B	13539	13551	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:90	These results indicated allele A and H of mitochondrial cytochrome B gene may be predominant in animals with the high or low replicative pattern of WHV infection, respectively. 	cytochrome B	13968	13980	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:99	All of the animals belong to the same subspecies M. himalayana robusta identified by the analysis of mitochondrial cytochrome B sequences. 	cytochrome B	15621	15633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:100	Based on the profiles of the nucleotide substitutions, eight different alleles of mitochondrial cytochrome B gene were identified in the animals used in this study. 	cytochrome B	15741	15753	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:189	Two full-length microsomal P450s, namely CYP19 aromatase and yeast CYP51, have also been crystallized and their structure shows clearly the position of the N-terminal membrane anchor relative to the rest of the protein. 	CYP19	34077	34082	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:189	Two full-length microsomal P450s, namely CYP19 aromatase and yeast CYP51, have also been crystallized and their structure shows clearly the position of the N-terminal membrane anchor relative to the rest of the protein. 	CYP19	34077	34082	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:189	Two full-length microsomal P450s, namely CYP19 aromatase and yeast CYP51, have also been crystallized and their structure shows clearly the position of the N-terminal membrane anchor relative to the rest of the protein. 	CYP19	34077	34082	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:189	Two full-length microsomal P450s, namely CYP19 aromatase and yeast CYP51, have also been crystallized and their structure shows clearly the position of the N-terminal membrane anchor relative to the rest of the protein. 	CYP19	34077	34082	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:64	The methylated isoflavone, biochanin A inhibits aromatase activity when a significant reduction in CYP19 mRNA abundance was found in estrogen receptor-negative breast cancer cells. 	CYP19	10949	10954	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:64	The methylated isoflavone, biochanin A inhibits aromatase activity when a significant reduction in CYP19 mRNA abundance was found in estrogen receptor-negative breast cancer cells. 	CYP19	10949	10954	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:64	The methylated isoflavone, biochanin A inhibits aromatase activity when a significant reduction in CYP19 mRNA abundance was found in estrogen receptor-negative breast cancer cells. 	CYP19	10949	10954	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:64	The methylated isoflavone, biochanin A inhibits aromatase activity when a significant reduction in CYP19 mRNA abundance was found in estrogen receptor-negative breast cancer cells. 	CYP19	10949	10954	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:122	The resulting A4 (and testosterone) enters the granulosa cells where the expression of CYP19A1 (aromatase) results in estrogen biosynthesis. 	CYP19	21099	21104	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:122	The resulting A4 (and testosterone) enters the granulosa cells where the expression of CYP19A1 (aromatase) results in estrogen biosynthesis. 	CYP19	21099	21104	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:122	The resulting A4 (and testosterone) enters the granulosa cells where the expression of CYP19A1 (aromatase) results in estrogen biosynthesis. 	CYP19	21099	21104	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:122	The resulting A4 (and testosterone) enters the granulosa cells where the expression of CYP19A1 (aromatase) results in estrogen biosynthesis. 	CYP19	21099	21104	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:126	While A4 can be metabolized to testosterone by AKR1C3 in the theca cells, the majority diffuses to the granulosa cells where the high expression levels of CYP19A1 results in the production of estrone. 	CYP19	22046	22051	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:126	While A4 can be metabolized to testosterone by AKR1C3 in the theca cells, the majority diffuses to the granulosa cells where the high expression levels of CYP19A1 results in the production of estrone. 	CYP19	22046	22051	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:126	While A4 can be metabolized to testosterone by AKR1C3 in the theca cells, the majority diffuses to the granulosa cells where the high expression levels of CYP19A1 results in the production of estrone. 	CYP19	22046	22051	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:126	While A4 can be metabolized to testosterone by AKR1C3 in the theca cells, the majority diffuses to the granulosa cells where the high expression levels of CYP19A1 results in the production of estrone. 	CYP19	22046	22051	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:128	Testosterone diffusing from the theca cells also serves as the substrate for CYP19A1, directly contributing to 17BETA-estradiol production. 	CYP19	22276	22281	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:128	Testosterone diffusing from the theca cells also serves as the substrate for CYP19A1, directly contributing to 17BETA-estradiol production. 	CYP19	22276	22281	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:128	Testosterone diffusing from the theca cells also serves as the substrate for CYP19A1, directly contributing to 17BETA-estradiol production. 	CYP19	22276	22281	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:128	Testosterone diffusing from the theca cells also serves as the substrate for CYP19A1, directly contributing to 17BETA-estradiol production. 	CYP19	22276	22281	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:129	Some CYPs metabolize only one (or very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple substrates. 	CYP19	24229	24234	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:129	Some CYPs metabolize only one (or very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple substrates. 	CYP19	24229	24234	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:129	Some CYPs metabolize only one (or very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple substrates. 	CYP19	24229	24234	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:129	Some CYPs metabolize only one (or very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple substrates. 	CYP19	24229	24234	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP19	33788	33793	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP19	33788	33793	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP19	33788	33793	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP19	33788	33793	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:220	Hollenberg and his coworkers have identified several putative access channels in CYP2B1 enzyme using CAVER. 	CYP2B1	40136	40142	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:220	Hollenberg and his coworkers have identified several putative access channels in CYP2B1 enzyme using CAVER. 	CYP2B1	40136	40142	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:220	Hollenberg and his coworkers have identified several putative access channels in CYP2B1 enzyme using CAVER. 	CYP2B1	40136	40142	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:220	Hollenberg and his coworkers have identified several putative access channels in CYP2B1 enzyme using CAVER. 	CYP2B1	40136	40142	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:224	However, this variant was catalyzing the O-deethylation of the coumarin substrate at a rate that was five-fold lower than that of the wild-type CYP2B1. 	CYP2B1	40804	40810	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:224	However, this variant was catalyzing the O-deethylation of the coumarin substrate at a rate that was five-fold lower than that of the wild-type CYP2B1. 	CYP2B1	40804	40810	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:224	However, this variant was catalyzing the O-deethylation of the coumarin substrate at a rate that was five-fold lower than that of the wild-type CYP2B1. 	CYP2B1	40804	40810	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:224	However, this variant was catalyzing the O-deethylation of the coumarin substrate at a rate that was five-fold lower than that of the wild-type CYP2B1. 	CYP2B1	40804	40810	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:225	The differential modification of the dynamics of the multiple access channels in CYP2B1 by blocking one of them had resulted in a differential impact on substrate specificity by filling the empty space in the protein periphery. 	CYP2B1	40893	40899	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:225	The differential modification of the dynamics of the multiple access channels in CYP2B1 by blocking one of them had resulted in a differential impact on substrate specificity by filling the empty space in the protein periphery. 	CYP2B1	40893	40899	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:225	The differential modification of the dynamics of the multiple access channels in CYP2B1 by blocking one of them had resulted in a differential impact on substrate specificity by filling the empty space in the protein periphery. 	CYP2B1	40893	40899	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:225	The differential modification of the dynamics of the multiple access channels in CYP2B1 by blocking one of them had resulted in a differential impact on substrate specificity by filling the empty space in the protein periphery. 	CYP2B1	40893	40899	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP2B1	9649	9655	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP2B1	9649	9655	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP2B1	9649	9655	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP2B1	9649	9655	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP2B1	31998	32004	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP2B1	31998	32004	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP2B1	31998	32004	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:193	(CYP1A1/A2 and CYP2B1/B2 localized predominantly in the epidermis and sebaceous glands), Jugert et al. 	CYP2B1	31998	32004	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP2B1	64800	64806	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP2B1	64800	64806	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP2B1	64800	64806	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:406	reported the presence of CYP1A1/A2 and CYP2B1/B2 proteins in human skin, localized predominantly in the epidermis and sebaceous glands. 	CYP2B1	64800	64806	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:63	observed CYP1A1/A2 and CYP2B1/B2 protein in the rat epidermal preparations, the former noticed in addition CYP1A1 protein after treatment with 3-methylcholanthrene (3-MC), the latter even without pretreatment. 	CYP1A1 protein	9733	9747	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:408	in that CYP1A1 protein was found predominantly in the basal cells of the (buttock) epidermis, but CYP1B1 protein in the epidermal cells other than the basal cells. 	CYP1A1 protein	64991	65005	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:413	showed in human whole skin increases of CYP1A1 protein after pretreatment with benzo[a]pyrene. 	CYP1A1 protein	65465	65479	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:415	demonstrated the presence of CYP1A1, 2B6, 2E1 and 3A proteins, CYP1A1 protein at least in some individual cells. 	CYP1A1 protein	65663	65677	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:416	Treatment with benz[a]anthracene led to a large increase in the number of cells containing CYP1A1 protein and to a large increase of the level of this protein. 	CYP1A1 protein	65804	65818	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:553	CYP1A1 protein Polycyclic aromatic hydrocarbons, such as BP, dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene, and other Polycyclic Aromatic Hydrocarbon are substrates of CYP1A1 generating electrophilically reactive genotoxins including epoxides, but also phenols which are then conjugated yielding glucuronides and sulfates allowing for facilitated excretion. 	CYP1A1 protein	86093	86107	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:6	Berberine significantly increased micro RNA (miR)-21-3p by 36% and the transfection of an inhibitor of miR-21-3p restored the induction of CYP1A1 protein with a 50% increase. 	CYP1A1 protein	921	935	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:8	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression. 	CYP1A1 protein	1188	1202	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:30	However, the increase of CYP1A1 protein by berberine was only ~16% of that by TCDD, suggesting that berberine might cause post-transcriptional down-regulation of CYP1A1 expression. 	CYP1A1 protein	4628	4642	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:67	In MCF-7 cells, exposure to 2 M B(a)P for 24 and 48 h increased CYP1A1 protein level by 2-fold and 36%, respectively (A). 	CYP1A1 protein	9304	9318	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:81	Transfection of a miR-21-3p hairpin inhibitor restored the berberine-mediated induction of CYP1A1 protein with a 50  19% increase (C). 	CYP1A1 protein	10996	11010	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:82	In miR-21-5p hairpin inhibitor-transfected cells, CYP1A1 protein level remained unchanged after berberine exposure. 	CYP1A1 protein	11090	11104	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:84	These results revealed that berberine stimulated miR-21-3p, suppressing the elevation of CYP1A1 protein. 	CYP1A1 protein	11359	11373	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:95	However, the CYP1A1 protein level and microsomal EROD activity were induced by B(a)P in the liver, but not the ovaries. 	CYP1A1 protein	12974	12988	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:97	Elevated levels of miRs, including miR-21, can contribute to the post-transcriptional downregulation of ovary CYP1A1 protein expression. 	CYP1A1 protein	13248	13262	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:98	Although one immunoblot showed a weak to mild elevation in CYP1A1 protein in MCF-7 cells exposed to 10-40 M berberine for 48 h, the statistical significance has not been proven. 	CYP1A1 protein	13334	13348	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	PROD	11568	11572	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	PROD	11568	11572	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	PROD	11969	11973	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:77	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective): 1.01  0.14, PROD (CYP2B-selective): below detection at an limit of quantification of 1.87 pmol, tolbutamide 4-hydroxylation (CYP2C9-selective) 0.47  0.04, bufuralol 1-hydroxylation (CYP2D6-selective) 1.33  0.17, chlorzoxazone 6-hydroxylation (CYP2E1-selective) below detection at an Limit Of Quantitation of 12.8 pmol, midazolam 1-hydroxylation (CYP3A-selective) 0.58  0.09 (Rolsted et al.. Localization Early studies already tried to differentiate whether the rat skin CYP activities were present in different skin layers. 	PROD	11969	11973	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:205	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD, para-nitrophenol hydroxylase, and erythromycin N-demethylase activities, Das et al. 	PROD	33105	33109	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:205	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD, para-nitrophenol hydroxylase, and erythromycin N-demethylase activities, Das et al. 	PROD	33105	33109	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	PROD	33468	33472	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	PROD	33468	33472	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:316	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 4.62  0.54, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation 1.66  0.49, bufuralol 1-hydroxylation 0.26  0.03, chlorzoxazone 6-hydroxylation below detection (LOQ 12.8 pmol), midazolam 1-hydroxylation 2.32  0.21. 	PROD	50707	50711	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:316	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 4.62  0.54, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation 1.66  0.49, bufuralol 1-hydroxylation 0.26  0.03, chlorzoxazone 6-hydroxylation below detection (LOQ 12.8 pmol), midazolam 1-hydroxylation 2.32  0.21. 	PROD	50707	50711	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	PROD	70115	70119	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	PROD	70115	70119	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:447	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-methoxyresorufin-O-demethylase, PROD or O-dealkylase activities for 7-methoxy-4-trifluoromethylcoumarin (broad-spectrum CYP12) substrate were not detected. 	PROD	70774	70778	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:447	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-methoxyresorufin-O-demethylase, PROD or O-dealkylase activities for 7-methoxy-4-trifluoromethylcoumarin (broad-spectrum CYP12) substrate were not detected. 	PROD	70774	70778	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:468	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP 1-selective): 10.7 pmol/min/mg protein, PROD (CYP2B-selective): 1.43 pmol/min/mg protein, para-nitrophenol hydroxylase (CYP2E1-selective): 1.81 nmol/min/mg protein, erythromycin N-demethylase (CYP 3A-selective): 3.26 nmol/min/mg protein. 	PROD	73085	73089	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:468	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP 1-selective): 10.7 pmol/min/mg protein, PROD (CYP2B-selective): 1.43 pmol/min/mg protein, para-nitrophenol hydroxylase (CYP2E1-selective): 1.81 nmol/min/mg protein, erythromycin N-demethylase (CYP 3A-selective): 3.26 nmol/min/mg protein. 	PROD	73085	73089	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:479	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were present and were increased by treatment with the CYP inducers 3-methylcholanthrene, BETA-naphthoflavone and phenobarbital and decreased by the presence of the CYP inhibitors ALPHA-naphthoflavone and metyrapone (Gelardi et al.. A comparative study by Gtz et al. 	PROD	74305	74309	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:479	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were present and were increased by treatment with the CYP inducers 3-methylcholanthrene, BETA-naphthoflavone and phenobarbital and decreased by the presence of the CYP inhibitors ALPHA-naphthoflavone and metyrapone (Gelardi et al.. A comparative study by Gtz et al. 	PROD	74305	74309	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:484	PROD activity (CYP2B-selective) was not increased by rifampicin, CITCO (6-(4-chlorophenyl)imidazo-[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or cyclophosphamide. 	PROD	75109	75113	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:484	PROD activity (CYP2B-selective) was not increased by rifampicin, CITCO (6-(4-chlorophenyl)imidazo-[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or cyclophosphamide. 	PROD	75109	75113	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:487	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and BROD activities were below the Limit Of Detection. 	PROD	75602	75606	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:487	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and BROD activities were below the Limit Of Detection. 	PROD	75602	75606	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:490	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and 7-benzoxyresorufin O-debenzylase activities were observed already early on in a reconstructed epidermis model generated from human hair follicles of the outer root sheath (Pham et al.. 7-Ethoxycoumarin-O-Dealkylase activity was seen in EpiSkin^ and was increased at low concentrations of the CYP inducers and inhibitors econazole and clotrimazole, and was inhibited in presence of their high concentrations (Cotovio et al.. Harris et al. 	PROD	75777	75781	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:490	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and 7-benzoxyresorufin O-debenzylase activities were observed already early on in a reconstructed epidermis model generated from human hair follicles of the outer root sheath (Pham et al.. 7-Ethoxycoumarin-O-Dealkylase activity was seen in EpiSkin^ and was increased at low concentrations of the CYP inducers and inhibitors econazole and clotrimazole, and was inhibited in presence of their high concentrations (Cotovio et al.. Harris et al. 	PROD	75777	75781	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:500	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 0.001 nmol/min/mg protein, for PROD 0.0025 nmol/min/mg protein and for BROD 0.002 nmol/min/mg protein (Jckh et al.. In EpiDerm^ microsomes no Et Al. 	PROD	77113	77117	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:500	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 0.001 nmol/min/mg protein, for PROD 0.0025 nmol/min/mg protein and for BROD 0.002 nmol/min/mg protein (Jckh et al.. In EpiDerm^ microsomes no Et Al. 	PROD	77113	77117	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:501	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-Methoxyresorufin-O-Demethylase, PROD or 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities were detected (LOD for Et Al. 	PROD	77327	77331	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:501	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-Methoxyresorufin-O-Demethylase, PROD or 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities were detected (LOD for Et Al. 	PROD	77327	77331	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:502	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-Methoxyresorufin-O-Demethylase and PROD < 0.2 pmolminmg protein), while very low CYP3A activities were detected (Gtz et al.. These activities and lack of observed activities, respectively, were similar as the results obtained by the same authors in human skin (presented above under Human skin). 	PROD	77524	77528	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:502	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, 7-Methoxyresorufin-O-Demethylase and PROD < 0.2 pmolminmg protein), while very low CYP3A activities were detected (Gtz et al.. These activities and lack of observed activities, respectively, were similar as the results obtained by the same authors in human skin (presented above under Human skin). 	PROD	77524	77528	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77876	77880	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77876	77880	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77953	77957	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77953	77957	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	PROD	78333	78337	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	BROD	11619	11623	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_387', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:74	reported cutaneous dealkylase activity for 7-ethoxyresorufin (CYP1-selective), 7-pentoxyresorufin (PROD) (CYP2B-selective), and 7-benzyloxyresorufin (BROD) (broader spectrum for rat CYPs including CYP1A1, 2B1/2 and 3A1). 	BROD	11619	11623	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:487	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and BROD activities were below the Limit Of Detection. 	BROD	75611	75615	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_387', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:487	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD and BROD activities were below the Limit Of Detection. 	BROD	75611	75615	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:500	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 0.001 nmol/min/mg protein, for PROD 0.0025 nmol/min/mg protein and for BROD 0.002 nmol/min/mg protein (Jckh et al.. In EpiDerm^ microsomes no Et Al. 	BROD	77153	77157	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_387', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:500	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 0.001 nmol/min/mg protein, for PROD 0.0025 nmol/min/mg protein and for BROD 0.002 nmol/min/mg protein (Jckh et al.. In EpiDerm^ microsomes no Et Al. 	BROD	77153	77157	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	BROD	78341	78345	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_387', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	BROD	78341	78345	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP 2D6	33607	33614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP 2D6	33607	33614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP 2D6	33607	33614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:209	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin 95.4  4.2, PROD below detection (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective substrate) below detection, bufuralol 1-hydroxylation (CYP 2D6-selective substrate) 9.23  0.67, chlorzoxazone 6-hydroxylation (CYP2E1-selective substrate) 20.8  0.5, midazolam 1-hydroxylation (CYP3A-selective substrate) 8.70  0.28. 	CYP 2D6	33607	33614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP 2D6	70272	70279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP 2D6	70272	70279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP 2D6	70272	70279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:443	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin (CYP1-selective) not detected (LOQ 1.87 pmol), PROD (CYP2B-selective) not detected (LOQ 1.87 pmol), tolbutamide 4-hydroxylation (CYP2C9-selective) 0.46  0.05 pmol/h/mg protein, bufuralol 1-hydroxylation (CYP 2D6-selective) not detected (LOQ 1.08 pmol), chlorzoxazone 6-hydroxylation (CYP2E1-selective) 2.83  0.34 pmol/h/mg protein, midazolam 1-hydroxylation (CYP3A-selective) 2.35  0.23 pmol/h/mg protein. 	CYP 2D6	70272	70279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:57	Paliperidone is not metabolized by CYP 2D6 cytochrome system. 	CYP 2D6	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:57	Paliperidone is not metabolized by CYP 2D6 cytochrome system. 	CYP 2D6	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:57	Paliperidone is not metabolized by CYP 2D6 cytochrome system. 	CYP 2D6	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:57	Paliperidone is not metabolized by CYP 2D6 cytochrome system. 	CYP 2D6	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:402	): The major hepatic CYPs, namely CYP1A2, CYP2C9/18/19 and CYP3A4 were absent or present only at low levels, notably CYP1A2, CYP2B6, CYP3A4 and the fetal form CYP3A7 were not expressed, while the following were expressed at weak or good levels: CYP1B1, CYP2C18, CYP2R1, CYP2S1, CYP3A5, CYP4B1, CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1. 	CYP26B1	64466	64473	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:8	Replicated associations for variants in CYP4X1, CYP24A1, and CYP26B1 with disease-free survival of all patients or patients stratified to subgroups according to therapy type have not passed a false discovery rate test. 	CYP26B1	1189	1196	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:78	The rs62150087 in CYP26B1 significantly associated with Disease-Free Survival in a group of cytotoxic therapy-treated patients (p = 0.016, HR = 0.54, CI = 0.33-0.89), but not in unselected patients (p = 0.122). 	CYP26B1	11526	11533	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:83	Variant rs62150087 in CYP26B1 was significantly associated with Disease-Free Survival in the HER2-enriched group of the patients regardless of the therapy (all patients or patients who received cytotoxic therapy). 	CYP26B1	12221	12228	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:115	The variant rs62150087 (500 bp downstream of CYP26B1) was associated with Disease-Free Survival in our sets of patients. 	CYP26B1	16504	16511	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:118	A genome-wide association study on the Chinese population identified CYP26B1 as a candidate gene for esophageal squamous cell carcinoma risk. 	CYP26B1	16963	16970	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:119	According to the authors, a variant rs138478634 in CYP26B1 influences the risk through catabolism of an anticancer nutrient all-trans retinoic acid. 	CYP26B1	17087	17094	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:120	Considering the ability of CYP26B1 to metabolize retinoic acid, there is support for the observed effect of rs62150087 on worse patient survival. 	CYP26B1	17212	17219	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:9	Both the Cytochrome B SYBR and probe Polymerase Chain Reaction protocols showed as high sensitivity and specificity as their conventional counterpart, except missing one P. malariae sample. 	Cytochrome B	1268	1280	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:13	For use in clinical diagnosis and epidemiological studies the highly sensitive and user-friendly Cytochrome B SYBR q-PCR method is a relevant tool. 	Cytochrome B	1926	1938	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:29	Subsequently, mitochondrial targets, such as Cytochrome B, emerged since the genome is conserved and exists in about 20-160 copies depending on the development stage [,. 	Cytochrome B	4819	4831	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:31	A genus-specific Cytochrome B conventional Polymerase Chain Reaction has proved to be highly sensitive and specific in field studies [,. 	Cytochrome B	5262	5274	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:35	The clinical patient material, used to assess the sensitivity and specificity of the designed Cytochrome B SYBR/TaqMan real-time assays, was a defined collection of 33 confirmed positive (18 P. falciparum, eight P. vivax, three P. ovale, two P. malariae, and two P. falciparum + P. malariae), and 80 confirmed negative samples, from 113 fever patients with potential malaria collected between 2006 and 2013 at Haukeland University Hospital, Bergen, Norway. 	Cytochrome B	6476	6488	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:36	The consensus on which samples were positive or negative was based on results from previously performed analyses by routine microscopy, the Polymerase Chain Reaction reference method described by Singh et al., a genus-specific Cytochrome B Polymerase Chain Reaction, a species-specific 18S Polymerase Chain Reaction (all conventional), and sequencing. 	Cytochrome B	7066	7078	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:39	The samples were confirmed positive by the same genus-specific Cytochrome B, and species-specific 18S conventional Polymerase Chain Reaction assays (or sequencing) as the Norwegian cohort. 	Cytochrome B	7694	7706	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:44	To serve as a standard curve for q-PCR, a custom designed EcoRI linearized q-PCR template, with a pUCminusMCS vector backbone and this studys Cytochrome B amplification target (220 bp) as insert (OriGene Technologies, Rockville, MD, USA), was applied in a 10-fold dilution series, range 2.7 x 10^8-2.7 copies of target DNA/reaction (rxn), run in duplicates. 	Cytochrome B	8959	8971	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:45	A conventional single-step genus-specific Cytochrome B Polymerase Chain Reaction was converted to one SYBR and one TaqMan real-time Polymerase Chain Reaction protocol using the same primers. 	Cytochrome B	9217	9229	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:49	For the Cytochrome B SYBR/TaqMan real-time Polymerase Chain Reaction protocols designed and optimized in this study the following primers were applied: PgMt19 F3 forward (5-tcg ctt cta acg gtg aac) and PgMt19 B3 reverse (5-aat tga tag tat cag cta tcc ata g), previously published for a loop-mediated isothermal amplification method. 	Cytochrome B	9799	9811	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:53	To investigate the quality of the stored DNA, samples of extremely low parasitaemia were reanalysed with the Cytochrome B conventional Polymerase Chain Reaction (primers PgMt19 F3&B3), run in triplicates, as previously described by Haanshuus et al., but with a primer concentration of 1 M (incorrect concentration given in the publication). 	Cytochrome B	10758	10770	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:54	To ensure that real-time Polymerase Chain Reaction products showed the same high quality sequences for species identification as for the Cytochrome B conventional Polymerase Chain Reaction, all positive products amplified by the Cytochrome B SYBR real-time Polymerase Chain Reaction from the Norwegian material, were sequenced in one direction applying primer PgMt19 F3 as previously described. 	Cytochrome B	11127	11139	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:54	To ensure that real-time Polymerase Chain Reaction products showed the same high quality sequences for species identification as for the Cytochrome B conventional Polymerase Chain Reaction, all positive products amplified by the Cytochrome B SYBR real-time Polymerase Chain Reaction from the Norwegian material, were sequenced in one direction applying primer PgMt19 F3 as previously described. 	Cytochrome B	11219	11231	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:65	The sensitivity and specificity of the designed and optimized genus-specific Cytochrome B SYBR and TaqMan Polymerase Chain Reaction protocols were assessed applying the Norwegian clinical material. 	Cytochrome B	12828	12840	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:68	Among the five included assays the Var Gene Acidic Terminal Sequence TaqMan Polymerase Chain Reaction method showed a high sensitivity, and was therefore chosen for further assessment together with the designed Cytochrome B SYBR/TaqMan Polymerase Chain Reaction protocols, applying P.falciparum positive Tanzanian field material. 	Cytochrome B	13605	13617	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:69	Furthermore, the sensitivity of applying whole blood versus that of using filter paper as field material was compared, and the difference in C_t trends for the Cytochrome B SYBR real-time Polymerase Chain Reaction results are shown in. 	Cytochrome B	13884	13896	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:70	Among the field samples extracted from whole blood, previously obtained research microscopy and Rapid Diagnostic Tests results were correlated with positive C_t values of the Cytochrome B SYBR Polymerase Chain Reaction as presented in. 	Cytochrome B	14135	14147	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:72	Therefore, the quality of the stored DNA was tested by reanalysing, with the Cytochrome B conventional Polymerase Chain Reaction, all samples which were negative or had a C_t value above 30 by the Cytochrome B SYBR real-time method.  	Cytochrome B	14459	14471	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:72	Therefore, the quality of the stored DNA was tested by reanalysing, with the Cytochrome B conventional Polymerase Chain Reaction, all samples which were negative or had a C_t value above 30 by the Cytochrome B SYBR real-time method.  	Cytochrome B	14579	14591	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:74	The designed Cytochrome B SYBR Polymerase Chain Reaction assay showed better results than using TaqMan probe (Tables  and  and  and. 	Cytochrome B	14726	14738	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:78	To present an alternative and relevant application of q-PCR data in epidemiological studies, the association between low-level parasitaemia identified by the Cytochrome B SYBR q-PCR results and clinical and demographic factors (among the 74 field samples extracted from whole blood), were evaluated applying cross tabulation and multiple logistic regression analysis. 	Cytochrome B	15534	15546	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:81	When applying 2 l template, 1000 copies of the Cytochrome B target/rxn, corresponds to 3-25 P. falciparum p/l depending on the parasite stage. 	Cytochrome B	16191	16203	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:91	The genus-specific Cytochrome B conventional Polymerase Chain Reaction, has previously been applied in studies from Tanzania and India, where the Polymerase Chain Reaction detected as much as 72% (55/76, N = 304) and 71% (162/228, N = 1168) submicroscopic malaria respectively [,. 	Cytochrome B	17562	17574	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:97	), the Cytochrome B SYBR (Xu et al.	Cytochrome B	18563	18575	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:98	), and this studys Cytochrome B SYBR Polymerase Chain Reaction. 	Cytochrome B	18610	18622	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:99	The Cytochrome B SYBR assay from Xu et al. 	Cytochrome B	18659	18671	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:102	), and the Cytochrome B SYBR (Xu et al.	Cytochrome B	19000	19012	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:120	Due to potentially reduced quality of the stored DNA, and low reproducibility for samples with extremely low parasitaemia, the field material (N = 111) was also used for sensitivity assessment of the the designed Cytochrome B SYBR/TaqMan and the Var Gene Acidic Terminal Sequence TaqMan Polymerase Chain Reaction methods. 	Cytochrome B	22183	22195	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:122	also showed that the Var Gene Acidic Terminal Sequence assay detected five more positive samples than the Cytochrome B SYBR method. 	Cytochrome B	22711	22723	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:123	With regards to the two different amplification targets Cytochrome B versus Var Gene Acidic Terminal Sequence, Cytochrome B Polymerase Chain Reaction assays should in theory be twice as sensitive as Var Gene Acidic Terminal Sequence Polymerase Chain Reaction in detecting gametocytes, while Var Gene Acidic Terminal Sequence targets should be about three times as sensitive as Cytochrome B in detecting ring stage parasites. 	Cytochrome B	22793	22805	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:123	With regards to the two different amplification targets Cytochrome B versus Var Gene Acidic Terminal Sequence, Cytochrome B Polymerase Chain Reaction assays should in theory be twice as sensitive as Var Gene Acidic Terminal Sequence Polymerase Chain Reaction in detecting gametocytes, while Var Gene Acidic Terminal Sequence targets should be about three times as sensitive as Cytochrome B in detecting ring stage parasites. 	Cytochrome B	22848	22860	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:123	With regards to the two different amplification targets Cytochrome B versus Var Gene Acidic Terminal Sequence, Cytochrome B Polymerase Chain Reaction assays should in theory be twice as sensitive as Var Gene Acidic Terminal Sequence Polymerase Chain Reaction in detecting gametocytes, while Var Gene Acidic Terminal Sequence targets should be about three times as sensitive as Cytochrome B in detecting ring stage parasites. 	Cytochrome B	23114	23126	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:141	The quality of the stored DNA in this study was tested by reanalyzing the samples with the Cytochrome B conventional Polymerase Chain Reaction used in the first analyses of the Tanzanian field material. 	Cytochrome B	26403	26415	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:148	The highly sensitive, specific, and user-friendly Cytochrome B SYBR q-PCR developed in this study can be useful in both epidemiological and clinical malaria studies. 	Cytochrome B	27599	27611	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:421	The possible generation of O_2^ by quinones at Q_A and Q_B pockets is illustrated in A. In untreated chloroplasts, D1/D2/Cytochrome B559 is found in high potential, intermediate potential and low potential forms. 	Cytochrome B	62189	62201	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:423	The E_m values of the three forms of D1/D2/Cytochrome B559 are (see review): High Potential form: 350-450 mV;IP form: 150-260 mV;LP form: 50-110 mV. 	Cytochrome B	62426	62438	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:428	In isolated thylakoid membranes, 85% of D1/D2/Cytochrome B559 was in the High Potential form. 	Cytochrome B	63099	63111	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:431	This idea is supported by the finding that PQH_2 can reduce D1/D2/Cytochrome B559 in both intact chloroplasts and in PSII Reaction Centers preparates. 	Cytochrome B	63498	63510	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:432	The photoreduction of D1/D2/Cytochrome B559 was found in isolated thylakoids and was inhibited by DCMU. 	Cytochrome B	63611	63623	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:433	In Triton X-100-solubilized PSII particles, which mostly have the Low Potential form of D1/D2/Cytochrome B559, short-chain PQs stimulated both photoreduction and dark oxidation of D1/D2/Cytochrome B559. 	Cytochrome B	63781	63793	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:433	In Triton X-100-solubilized PSII particles, which mostly have the Low Potential form of D1/D2/Cytochrome B559, short-chain PQs stimulated both photoreduction and dark oxidation of D1/D2/Cytochrome B559. 	Cytochrome B	63873	63885	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:434	The involvement of D1/D2/Cytochrome B559 in electron transfer reactions of PSII indicates that D1/D2/Cytochrome B559 is a redox active component that can potentially reduce O_2. 	Cytochrome B	63915	63927	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:434	The involvement of D1/D2/Cytochrome B559 in electron transfer reactions of PSII indicates that D1/D2/Cytochrome B559 is a redox active component that can potentially reduce O_2. 	Cytochrome B	63991	64003	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:435	It has been shown that fast, dark reoxidation of the PQ pool in thylakoid membranes is not caused by direct oxidation of PQH_2 by O_2, and it was suggested that the Low Potential form of D1/D2/Cytochrome B559 can transfer an electron to O_2 and thereby act as a PQH_2:O_2 oxidoreductase. 	Cytochrome B	64261	64273	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:436	In isolated PSII membranes, O_2 has been shown to compete with prenylquinones for oxidation of the Low Potential form of D1/D2/Cytochrome B559, suggesting that Low Potential D1/D2/Cytochrome B559 can form O_2^. 	Cytochrome B	64483	64495	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:436	In isolated PSII membranes, O_2 has been shown to compete with prenylquinones for oxidation of the Low Potential form of D1/D2/Cytochrome B559, suggesting that Low Potential D1/D2/Cytochrome B559 can form O_2^. 	Cytochrome B	64536	64548	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:438	This finding was interpreted to indicate that these quinones reduce Low Potential D1/D2/Cytochrome B559, which then undergoes spontaneous autoxidation, resulting in O_2^ formation. 	Cytochrome B	64741	64753	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:439	However, the reduction in O_2 by Low Potential D1/D2/Cytochrome B559 is thermodynamically unfavorable, taking into account that the redox potential of the Low Potential form is usually within 20-110 mV in untreated membranes, although sometimes an Low Potential form with a negative potential is observed. 	Cytochrome B	64887	64899	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:4	However, little is known about the role of Bombyx mori Cytochrome C in resistance to Bombyx Mori Nucleopolyhedrovirus infection. 	Cytochrome C	388	400	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:4	However, little is known about the role of Bombyx mori Cytochrome C in resistance to Bombyx Mori Nucleopolyhedrovirus infection. 	Cytochrome C	388	400	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:20	However, the role of Cytochrome C is not clear in insect cell apoptosis. 	Cytochrome C	2927	2939	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:20	However, the role of Cytochrome C is not clear in insect cell apoptosis. 	Cytochrome C	2927	2939	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:21	It has been reported that Cytochrome C is not involved in apoptosis in Drosophila by the release from mitochondria. 	Cytochrome C	3005	3017	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:21	It has been reported that Cytochrome C is not involved in apoptosis in Drosophila by the release from mitochondria. 	Cytochrome C	3005	3017	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:22	In another study, mitochondria were involved in host defenses against environmental pressure by releasing Cytochrome C into the cytoplasm to activate apoptosis in the Spodoptera litura and Spodoptera frugiperda (Sf9) cell line. 	Cytochrome C	3201	3213	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:22	In another study, mitochondria were involved in host defenses against environmental pressure by releasing Cytochrome C into the cytoplasm to activate apoptosis in the Spodoptera litura and Spodoptera frugiperda (Sf9) cell line. 	Cytochrome C	3201	3213	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:25	It has been reported widely that Cytochrome C showed a significant response to viral infection. 	Cytochrome C	3573	3585	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:25	It has been reported widely that Cytochrome C showed a significant response to viral infection. 	Cytochrome C	3573	3585	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:26	Liu et al., reported that Cytochrome C activates the apoptotic signaling pathway to defend against Anagrapha falcifera Multiple Nuclear Polyhedrosis Virus infection in Lepidopteran Spodoptera litura cells. 	Cytochrome C	3662	3674	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:26	Liu et al., reported that Cytochrome C activates the apoptotic signaling pathway to defend against Anagrapha falcifera Multiple Nuclear Polyhedrosis Virus infection in Lepidopteran Spodoptera litura cells. 	Cytochrome C	3662	3674	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:27	Carthy et al., found that Cytochrome C released from mitochondria may be involved in activating caspase after coxsackievirus B3 infection, and this contributes to the loss of host cell viability and progeny virus release. 	Cytochrome C	3868	3880	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:27	Carthy et al., found that Cytochrome C released from mitochondria may be involved in activating caspase after coxsackievirus B3 infection, and this contributes to the loss of host cell viability and progeny virus release. 	Cytochrome C	3868	3880	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:28	Machida et al., reported that inhibition of Cytochrome C release resulted in suppression of Fas-mediated cell death, which could cause hepatitis C virus persistent infection in transgenic mice. 	Cytochrome C	4108	4120	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:28	Machida et al., reported that inhibition of Cytochrome C release resulted in suppression of Fas-mediated cell death, which could cause hepatitis C virus persistent infection in transgenic mice. 	Cytochrome C	4108	4120	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:29	In our previous transcriptome study, Cytochrome C showed a significant response in resistant strain BC9 following Bombyx Mori Nucleopolyhedrovirus infection, and it might be involved in regulating the mitochondrial apoptosis pathway to defend against Bombyx Mori Nucleopolyhedrovirus infection, but that still needs further study. 	Cytochrome C	4295	4307	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:29	In our previous transcriptome study, Cytochrome C showed a significant response in resistant strain BC9 following Bombyx Mori Nucleopolyhedrovirus infection, and it might be involved in regulating the mitochondrial apoptosis pathway to defend against Bombyx Mori Nucleopolyhedrovirus infection, but that still needs further study. 	Cytochrome C	4295	4307	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:39	Therefore, the high conservation of Cytochrome C amino acids among different species shows that Bombyx Mori Cytc may play a vital role in the apoptosis pathway in the silkworm. 	Cytochrome C	6765	6777	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:39	Therefore, the high conservation of Cytochrome C amino acids among different species shows that Bombyx Mori Cytc may play a vital role in the apoptosis pathway in the silkworm. 	Cytochrome C	6765	6777	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:40	The CDS sequence of Bombyx Mori Cytc and those in other species were derived from NCBI, which were used to analyze the evolutionary relationships of Cytochrome C among different species. 	Cytochrome C	7055	7067	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:40	The CDS sequence of Bombyx Mori Cytc and those in other species were derived from NCBI, which were used to analyze the evolutionary relationships of Cytochrome C among different species. 	Cytochrome C	7055	7067	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:43	The homologous gene sequences of Bombyx Mori Cytc in M. musculus and Arabidopsis shared a low sequence identity with Bombyx Mori Cytc, indicating that Cytochrome C gene in the earlier species might have diverged before the appearance of these orders during evolution. 	Cytochrome C	7523	7535	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:43	The homologous gene sequences of Bombyx Mori Cytc in M. musculus and Arabidopsis shared a low sequence identity with Bombyx Mori Cytc, indicating that Cytochrome C gene in the earlier species might have diverged before the appearance of these orders during evolution. 	Cytochrome C	7523	7535	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:66	The lack of CYP17A1 expression in the zona glomerulosa together with the abundant expression of HSD3B2 ensures that all steroid intermediates are directed towards aldosterone biosynthesis. 	CYP17	11088	11093	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:66	The lack of CYP17A1 expression in the zona glomerulosa together with the abundant expression of HSD3B2 ensures that all steroid intermediates are directed towards aldosterone biosynthesis. 	CYP17	11088	11093	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP17	11939	11944	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:70	Pregnenolone, produced from the CYP11A1 catalyzed side-chain cleavage of cholesterol, is converted to 17ALPHA-hydroxyprogesterone (17OHP), the universal precursor of cortisol production, by HSD3B2 and CYP17A1 17ALPHA-hydroxylase activity. 	CYP17	11939	11944	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	CYP17	12544	12549	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	CYP17	12544	12549	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	CYP17	12708	12713	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	CYP17	12708	12713	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	CYP17	12818	12823	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	CYP17	12818	12823	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:87	Like in the zona reticularis, the Leydig cells of the testes follow the ^5 pathway due to the co-expression of CYP17A1 and CYB5A. 	CYP17	14665	14670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:87	Like in the zona reticularis, the Leydig cells of the testes follow the ^5 pathway due to the co-expression of CYP17A1 and CYB5A. 	CYP17	14665	14670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:107	Allopregnanolone can then be converted to 17ALPHA-hydroxyallopregnanolone, which serves as an excellent substrate for the 17,20-lyase activity of CYP17A1, yielding androsterone. 	CYP17	18236	18241	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:107	Allopregnanolone can then be converted to 17ALPHA-hydroxyallopregnanolone, which serves as an excellent substrate for the 17,20-lyase activity of CYP17A1, yielding androsterone. 	CYP17	18236	18241	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP17	36477	36482	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	CYP17	36477	36482	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:333	The 20alpha/Beta-Reduction Of Tetrahydrocortisol and Tetrahydrocortisone can also be subject to an elusive side-chain cleavage reaction not catalyzed by CYP17A1, producing C_19 metabolites of glucocorticoid origin. 	CYP17	55541	55546	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:333	The 20alpha/Beta-Reduction Of Tetrahydrocortisol and Tetrahydrocortisone can also be subject to an elusive side-chain cleavage reaction not catalyzed by CYP17A1, producing C_19 metabolites of glucocorticoid origin. 	CYP17	55541	55546	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP17	32499	32504	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP17	32499	32504	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:79	The cytochromes P450 17A1/19A1 (CYP17A1/CYP17A1) have a strong correlation with cell apoptosis, because most of them have an Abiraterone-specific active site. 	CYP17	13443	13448	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:79	The cytochromes P450 17A1/19A1 (CYP17A1/CYP17A1) have a strong correlation with cell apoptosis, because most of them have an Abiraterone-specific active site. 	CYP17	13443	13448	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:79	The cytochromes P450 17A1/19A1 (CYP17A1/CYP17A1) have a strong correlation with cell apoptosis, because most of them have an Abiraterone-specific active site. 	CYP17	13451	13456	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:79	The cytochromes P450 17A1/19A1 (CYP17A1/CYP17A1) have a strong correlation with cell apoptosis, because most of them have an Abiraterone-specific active site. 	CYP17	13451	13456	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:80	As can be seen in, the CYP17A1 proteins (except 3S7S) have stronger binding abilities than the reference drug Abiraterone acetate (8.91 kcal/mol). 	CYP17	13593	13598	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:80	As can be seen in, the CYP17A1 proteins (except 3S7S) have stronger binding abilities than the reference drug Abiraterone acetate (8.91 kcal/mol). 	CYP17	13593	13598	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:91	A similar analysis suggests that 12n could interact strongly with CYP17A1 family proteins (6CIZ). 	CYP17	15067	15072	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:91	A similar analysis suggests that 12n could interact strongly with CYP17A1 family proteins (6CIZ). 	CYP17	15067	15072	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:95	The most active compound, 12n, fitted the active sites of CYP17A1 (6CIZ) well. 	CYP17	15833	15838	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:95	The most active compound, 12n, fitted the active sites of CYP17A1 (6CIZ) well. 	CYP17	15833	15838	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP17	33665	33670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP17	33665	33670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	17,20-lyase	12684	12695	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:75	The CYP17A1-catalyzed 17ALPHA-hydroxylation of pregnenolone yields 17ALPHA-hydroxypregnenolone, which serves as the preferred substrate for the 17,20-lyase activity of CYP17A1, producing C_19 steroids from C_21 precursors [,. 	17,20-lyase	12684	12695	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	17,20-lyase	12794	12805	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	17,20-lyase	12794	12805	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:107	Allopregnanolone can then be converted to 17ALPHA-hydroxyallopregnanolone, which serves as an excellent substrate for the 17,20-lyase activity of CYP17A1, yielding androsterone. 	17,20-lyase	18212	18223	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:107	Allopregnanolone can then be converted to 17ALPHA-hydroxyallopregnanolone, which serves as an excellent substrate for the 17,20-lyase activity of CYP17A1, yielding androsterone. 	17,20-lyase	18212	18223	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	17,20-lyase	36453	36464	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:217	Examples for such reactions from steroid biosynthesis are the side-chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-lyase activity of CYP17A1 producing C_19 steroids from C_21 substrates (Section 2.5.3). 	17,20-lyase	36453	36464	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:267	Interestingly, enzymes with 20BETA-HSD and 17,20-lyase activity have been recently identified in a microbial inhabitant of the urinary tract. 	17,20-lyase	43860	43871	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:267	Interestingly, enzymes with 20BETA-HSD and 17,20-lyase activity have been recently identified in a microbial inhabitant of the urinary tract. 	17,20-lyase	43860	43871	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	17,20-lyase	33691	33702	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:2	In mammalian retina, cholesterol excess is mainly metabolized to oxysterols by cytochromes P450 27A1 and 46A1 (CYP46A1) or removed on lipoprotein particles containing apolipoprotein E. In contrast, esterification by sterol-O-acyltransferase 1 plays only a minor role in this process. 	CYP46A1	206	213	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:2	In mammalian retina, cholesterol excess is mainly metabolized to oxysterols by cytochromes P450 27A1 and 46A1 (CYP46A1) or removed on lipoprotein particles containing apolipoprotein E. In contrast, esterification by sterol-O-acyltransferase 1 plays only a minor role in this process. 	CYP46A1	206	213	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	CYP46A1	3547	3554	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	CYP46A1	3547	3554	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:100	The second were the genes related to inflammation (Ccl2, Cox2, Il-6, and TnfALPHA), whose expression is controlled by NF-B, which in turn is negatively regulated by liver X receptors (LXRs, transcription factors) when they are activated by oxysterols produced by Cytochromes P450 27a1 and CYP46A1. 	CYP46A1	16676	16683	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:100	The second were the genes related to inflammation (Ccl2, Cox2, Il-6, and TnfALPHA), whose expression is controlled by NF-B, which in turn is negatively regulated by liver X receptors (LXRs, transcription factors) when they are activated by oxysterols produced by Cytochromes P450 27a1 and CYP46A1. 	CYP46A1	16676	16683	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:109	Nevertheless, collectively, the data obtained suggested that cholesterol transport mediated by the major retinal apolipoproteins did not seem to be significantly affected by simultaneous absence of Cytochromes P450 27a1, CYP46A1, and SOAT1. 	CYP46A1	18311	18318	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:109	Nevertheless, collectively, the data obtained suggested that cholesterol transport mediated by the major retinal apolipoproteins did not seem to be significantly affected by simultaneous absence of Cytochromes P450 27a1, CYP46A1, and SOAT1. 	CYP46A1	18311	18318	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	CYP46A1	21069	21076	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	CYP46A1	21069	21076	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	CYP46A1	21877	21884	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:3	Accordingly, retinal cholesterol levels are unchanged in Soat1/ mice but are increased in Cyp27a1/Cyp46a1/ and Apoe/ mice. 	Cyp46	477	482	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46	535	540	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46	562	567	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:6	Conversely, in Cyp27a1/Cyp46a1/Apoe/ mice, retinal cholesterol levels were increased while anatomical structure and vasculature were unaffected with only male mice showing a decrease in electroretinographic responses. 	Cyp46	759	764	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46	1086	1091	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46	1113	1118	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:9	In addition, there was altered abundance of proteins in Cyp27a1/Cyp46a1/Soat1/ mice that can affect photoreceptor function, survival, and retinal energy homeostasis (glucose and fatty acid metabolism). 	Cyp46	1380	1385	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:26	To ascertain retinal significance of cholesterol removal by metabolism and Lipoprotein Particles, we previously comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/ mice and mice lacking Apolipoprotein E, a major apolipoprotein in the retina. 	Cyp46	4447	4452	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:28	In addition, there were focal accumulations of free (unesterified) cholesterol in the Cyp27a1^/Cyp46a1^/ retina, impairments in the retinal function (as assessed by electroretinographic recordings, ERG), and pathologic changes in retinal blood vessels. 	Cyp46	4830	4835	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:33	We also generated Cyp27a1^/Cyp46a1^/Soat1^/ mice and established that retinal cholesterol esterification is mediated by SOAT1. 	Cyp46	5743	5748	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46	6249	6254	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46	6321	6326	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:37	In addition, we mapped retinal proteins and processes in Cyp27a1^/ Cyp46a1^/ Soat1^/- mice that could be linked to retinal cholesterol-related pathways and be important for retinal structure, function, and metabolism. 	Cyp46	6664	6669	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:45	Cyp27a1^/ Cyp46a1^/ mice were generated previously in this laboratory and were on a mixed strain background (C57BL/6J; 129S6/SvEv). 	Cyp46	7211	7216	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46	7342	7347	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46	7419	7424	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46	7449	7454	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:59	Briefly, three biological replicates per genotype (Cyp27a1^/Cyp46a1^/Soat1^/ or C57BL/6J, 6-8 month old male mice), each containing two retinas from two different mice, were frozen, cryo-pulverized, and lysed with 3% SDS. 	Cyp46	9569	9574	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46	12786	12791	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46	12816	12821	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:85	In Cyp27a1^/ Cyp46a1^/ Soat1^/ mice of both sexes, dark-adapted (scotopic) ERGs were decreased at 6 months, and this decrease was more pronounced at 12 months (A). 	Cyp46	13318	13323	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:86	In addition, male Cyp27a1^/Cyp46a1^/ Soat1^/ mice had a decrease in the b- wave of light-adapted (photopic) ERGs, also with a progression at 1 year. 	Cyp46	13496	13501	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:88	In Cyp27a1^/ Cyp46a1^/Apoe^/ mice, the ERGs of female animals were essentially unaffected, and only male mice had statistically significant reductions in both scotopic and photopic ERGs at 12 months (C). 	Cyp46	13810	13815	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46	14285	14290	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46	14312	14317	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46	14493	14498	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46	14523	14528	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46	14630	14635	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:92	Yet serum cholesterol did not seem to be an important contributor to retinal cholesterol as the sex differences in the levels of this sterol in Apoe^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were not translated into similar sex differences in the levels of total retinal cholesterol. 	Cyp46	14816	14821	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46	15081	15086	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46	15199	15204	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:95	This compensatory decrease is consistent with the known sensitivity of cholesterol biosynthesis to changes in intracellular levels of unesterified cholesterol and can be a reason for why total retinal cholesterol was normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46	15469	15474	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46	15575	15580	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46	15731	15736	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46	16043	16048	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46	16073	16078	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46	16960	16965	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46	16991	16996	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46	17051	17056	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46	17110	17115	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:105	This was conducted on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type male mice to gain insight into whether there are additional mechanisms that contribute to the normalization of retinal cholesterol levels besides a decrease in cholesterol biosynthesis. 	Cyp46	17360	17365	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:107	The label-free analysis was used, which confirmed unaltered retinal expression of APOA4 and Apolipoprotein E suggested by the mRNA measurements but did not show altered abundance of APOA1, APOA2, and APOJ, whose gene expression was affected in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina of male mice. 	Cyp46	17952	17957	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:111	Out of these proteins, the abundance of 41 proteins was increased and that of 3 proteins was decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46	18531	18536	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:112	Protein grouping based on function suggested that at least 6 biological processes could be affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina: (1) cytoskeletal dynamics and vesicle formation (11 proteins, ); (2) energy homeostasis (9 proteins, ); (3) genetic information transfer (DNA/RNA processing, transcription, regulation of transcription and translation, 9 proteins); (4) inflammation (7 proteins); (5) synaptic function (4 proteins); and (6) ubiquitination (3 proteins). 	Cyp46	18689	18694	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46	19439	19444	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46	19470	19475	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46	19592	19597	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46	19644	19649	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46	19837	19842	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46	19868	19873	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:118	This observation is consistent with increased photoreceptor apoptosis documented previously in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46	20045	20050	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46	20084	20089	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46	20159	20164	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:120	Similarly, Cyp27a1^/Cyp46a1^/Soat1^/ mice had more frequent extracellular vesicles in the outer nuclear layer (I-M, R-T), and extensive budding of the caveoli-like structures in the blood vessel pericytes and endothelium of the ganglion cell layer. 	Cyp46	20408	20413	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46	20728	20733	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46	20779	20784	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	Cyp46	21221	21226	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46	21293	21298	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46	21398	21403	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:125	Yet, the retinal cholesterol levels were normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice (B), thus suggesting that there are compensatory responses in the retina, which lowered the sterol levels. 	Cyp46	21517	21522	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46	21680	21685	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46	22009	22014	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22374	22379	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22434	22439	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22500	22505	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46	22656	22661	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46	22686	22691	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46	22949	22954	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:3	Accordingly, retinal cholesterol levels are unchanged in Soat1/ mice but are increased in Cyp27a1/Cyp46a1/ and Apoe/ mice. 	Cyp46a1	477	484	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:3	Accordingly, retinal cholesterol levels are unchanged in Soat1/ mice but are increased in Cyp27a1/Cyp46a1/ and Apoe/ mice. 	Cyp46a1	477	484	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46a1	535	542	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46a1	535	542	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46a1	562	569	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:4	Herein, we characterized Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ mice. 	Cyp46a1	562	569	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:6	Conversely, in Cyp27a1/Cyp46a1/Apoe/ mice, retinal cholesterol levels were increased while anatomical structure and vasculature were unaffected with only male mice showing a decrease in electroretinographic responses. 	Cyp46a1	759	766	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:6	Conversely, in Cyp27a1/Cyp46a1/Apoe/ mice, retinal cholesterol levels were increased while anatomical structure and vasculature were unaffected with only male mice showing a decrease in electroretinographic responses. 	Cyp46a1	759	766	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46a1	1086	1093	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46a1	1086	1093	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46a1	1113	1120	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:7	Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms in the Cyp27a1/Cyp46a1/Soat1/ and Cyp27a1/Cyp46a1/Apoe/ retina. 	Cyp46a1	1113	1120	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:9	In addition, there was altered abundance of proteins in Cyp27a1/Cyp46a1/Soat1/ mice that can affect photoreceptor function, survival, and retinal energy homeostasis (glucose and fatty acid metabolism). 	Cyp46a1	1380	1387	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:9	In addition, there was altered abundance of proteins in Cyp27a1/Cyp46a1/Soat1/ mice that can affect photoreceptor function, survival, and retinal energy homeostasis (glucose and fatty acid metabolism). 	Cyp46a1	1380	1387	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:26	To ascertain retinal significance of cholesterol removal by metabolism and Lipoprotein Particles, we previously comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/ mice and mice lacking Apolipoprotein E, a major apolipoprotein in the retina. 	Cyp46a1	4447	4454	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:26	To ascertain retinal significance of cholesterol removal by metabolism and Lipoprotein Particles, we previously comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/ mice and mice lacking Apolipoprotein E, a major apolipoprotein in the retina. 	Cyp46a1	4447	4454	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:28	In addition, there were focal accumulations of free (unesterified) cholesterol in the Cyp27a1^/Cyp46a1^/ retina, impairments in the retinal function (as assessed by electroretinographic recordings, ERG), and pathologic changes in retinal blood vessels. 	Cyp46a1	4830	4837	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:28	In addition, there were focal accumulations of free (unesterified) cholesterol in the Cyp27a1^/Cyp46a1^/ retina, impairments in the retinal function (as assessed by electroretinographic recordings, ERG), and pathologic changes in retinal blood vessels. 	Cyp46a1	4830	4837	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:33	We also generated Cyp27a1^/Cyp46a1^/Soat1^/ mice and established that retinal cholesterol esterification is mediated by SOAT1. 	Cyp46a1	5743	5750	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:33	We also generated Cyp27a1^/Cyp46a1^/Soat1^/ mice and established that retinal cholesterol esterification is mediated by SOAT1. 	Cyp46a1	5743	5750	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	6249	6256	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	6249	6256	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	6321	6328	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:35	The purpose of the present work was to gain insight into the interplay between retinal pathways of cholesterol output by finishing ophthalmic characterizations of Cyp27a1^/Cyp46a1^/Soat1^/ mice and generating as well as characterizing Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	6321	6328	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:37	In addition, we mapped retinal proteins and processes in Cyp27a1^/ Cyp46a1^/ Soat1^/- mice that could be linked to retinal cholesterol-related pathways and be important for retinal structure, function, and metabolism. 	Cyp46a1	6664	6671	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:37	In addition, we mapped retinal proteins and processes in Cyp27a1^/ Cyp46a1^/ Soat1^/- mice that could be linked to retinal cholesterol-related pathways and be important for retinal structure, function, and metabolism. 	Cyp46a1	6664	6671	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:45	Cyp27a1^/ Cyp46a1^/ mice were generated previously in this laboratory and were on a mixed strain background (C57BL/6J; 129S6/SvEv). 	Cyp46a1	7211	7218	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:45	Cyp27a1^/ Cyp46a1^/ mice were generated previously in this laboratory and were on a mixed strain background (C57BL/6J; 129S6/SvEv). 	Cyp46a1	7211	7218	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7342	7349	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7342	7349	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7419	7426	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7419	7426	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7449	7456	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:46	Cyp27a1^/Cyp46a1^/ mice were crossed with Soat1^/ or Apoe^/ mice to generate Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, respectively. 	Cyp46a1	7449	7456	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:59	Briefly, three biological replicates per genotype (Cyp27a1^/Cyp46a1^/Soat1^/ or C57BL/6J, 6-8 month old male mice), each containing two retinas from two different mice, were frozen, cryo-pulverized, and lysed with 3% SDS. 	Cyp46a1	9569	9576	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:59	Briefly, three biological replicates per genotype (Cyp27a1^/Cyp46a1^/Soat1^/ or C57BL/6J, 6-8 month old male mice), each containing two retinas from two different mice, were frozen, cryo-pulverized, and lysed with 3% SDS. 	Cyp46a1	9569	9576	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46a1	12786	12793	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46a1	12786	12793	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46a1	12816	12823	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:80	We examined 6- and 12- month old Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/ Apoe^/ by using SD-OCT, Fluorescein Angiography, and ERG. 	Cyp46a1	12816	12823	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:85	In Cyp27a1^/ Cyp46a1^/ Soat1^/ mice of both sexes, dark-adapted (scotopic) ERGs were decreased at 6 months, and this decrease was more pronounced at 12 months (A). 	Cyp46a1	13318	13325	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:85	In Cyp27a1^/ Cyp46a1^/ Soat1^/ mice of both sexes, dark-adapted (scotopic) ERGs were decreased at 6 months, and this decrease was more pronounced at 12 months (A). 	Cyp46a1	13318	13325	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:86	In addition, male Cyp27a1^/Cyp46a1^/ Soat1^/ mice had a decrease in the b- wave of light-adapted (photopic) ERGs, also with a progression at 1 year. 	Cyp46a1	13496	13503	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:86	In addition, male Cyp27a1^/Cyp46a1^/ Soat1^/ mice had a decrease in the b- wave of light-adapted (photopic) ERGs, also with a progression at 1 year. 	Cyp46a1	13496	13503	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:88	In Cyp27a1^/ Cyp46a1^/Apoe^/ mice, the ERGs of female animals were essentially unaffected, and only male mice had statistically significant reductions in both scotopic and photopic ERGs at 12 months (C). 	Cyp46a1	13810	13817	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:88	In Cyp27a1^/ Cyp46a1^/Apoe^/ mice, the ERGs of female animals were essentially unaffected, and only male mice had statistically significant reductions in both scotopic and photopic ERGs at 12 months (C). 	Cyp46a1	13810	13817	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46a1	14285	14292	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46a1	14285	14292	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46a1	14312	14319	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:90	Three retinal sterols (cholesterol, lathosterol, and desmosterol) as well as serum cholesterol were quantified in Cyp27a1^/Cyp46a1^/Soat1^/, Cyp27a1^/Cyp46a1^/Apoe^/, and Soat1^/ mice and compared with those in other knockout lines determined by us previously. 	Cyp46a1	14312	14319	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14493	14500	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14493	14500	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14523	14530	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14523	14530	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14630	14637	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:91	In both serum and retina, the levels of total cholesterol in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were more similar to those in Soat1^/ and Apoe^/ mice, respectively, than in Cyp27a1^/Cyp46a1^/ mice (A,B,. 	Cyp46a1	14630	14637	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:92	Yet serum cholesterol did not seem to be an important contributor to retinal cholesterol as the sex differences in the levels of this sterol in Apoe^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were not translated into similar sex differences in the levels of total retinal cholesterol. 	Cyp46a1	14816	14823	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:92	Yet serum cholesterol did not seem to be an important contributor to retinal cholesterol as the sex differences in the levels of this sterol in Apoe^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice were not translated into similar sex differences in the levels of total retinal cholesterol. 	Cyp46a1	14816	14823	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46a1	15081	15088	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46a1	15081	15088	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46a1	15199	15206	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:94	In Cyp27a1^/Cyp46a1^/Soat1^/ mice, retinal lathosterol but not desmosterol content was decreased as compared to those in Cyp27a1^/Cyp46a1^/ and Soat1^/ mice (C,D,. 	Cyp46a1	15199	15206	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:95	This compensatory decrease is consistent with the known sensitivity of cholesterol biosynthesis to changes in intracellular levels of unesterified cholesterol and can be a reason for why total retinal cholesterol was normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	15469	15476	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:95	This compensatory decrease is consistent with the known sensitivity of cholesterol biosynthesis to changes in intracellular levels of unesterified cholesterol and can be a reason for why total retinal cholesterol was normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	15469	15476	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46a1	15575	15582	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46a1	15575	15582	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46a1	15731	15738	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:96	Similarly, a decrease in retinal cholesterol biosynthesis was observed in Cyp27a1^/Cyp46a1^/Apoe^/ mice, whose levels of both retinal lathosterol and desmosterol were approximately the mean between the sterol levels in Apoe^/ and Cyp27a1^/Cyp46a1^/ mice and mirrored the total cholesterol levels in the retina of the three genotypes. 	Cyp46a1	15731	15738	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46a1	16043	16050	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46a1	16043	16050	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46a1	16073	16080	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:98	Two groups of retinal genes were quantified in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and compared with that in wild type C57BL/6J animals. 	Cyp46a1	16073	16080	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46a1	16960	16967	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46a1	16960	16967	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46a1	16991	16998	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:102	However, these changes were mostly sex-specific and therefore likely did not contribute to retinal cholesterol levels that were similar in female and male animals of the Cyp27a1^/Cyp46a1^/ Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ genotypes. 	Cyp46a1	16991	16998	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46a1	17051	17058	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46a1	17051	17058	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46a1	17110	17117	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:103	Only Apoa1 and Apoa2 in Cyp27a1^/Cyp46a1^/Soat1^/ mice as well as Apob and Apoj in Cyp27a1^/Cyp46a1^/Apoe^/ mice showed expression changes that are common for both sexes. 	Cyp46a1	17110	17117	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:105	This was conducted on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type male mice to gain insight into whether there are additional mechanisms that contribute to the normalization of retinal cholesterol levels besides a decrease in cholesterol biosynthesis. 	Cyp46a1	17360	17367	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:105	This was conducted on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type male mice to gain insight into whether there are additional mechanisms that contribute to the normalization of retinal cholesterol levels besides a decrease in cholesterol biosynthesis. 	Cyp46a1	17360	17367	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:107	The label-free analysis was used, which confirmed unaltered retinal expression of APOA4 and Apolipoprotein E suggested by the mRNA measurements but did not show altered abundance of APOA1, APOA2, and APOJ, whose gene expression was affected in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina of male mice. 	Cyp46a1	17952	17959	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:107	The label-free analysis was used, which confirmed unaltered retinal expression of APOA4 and Apolipoprotein E suggested by the mRNA measurements but did not show altered abundance of APOA1, APOA2, and APOJ, whose gene expression was affected in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina of male mice. 	Cyp46a1	17952	17959	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:111	Out of these proteins, the abundance of 41 proteins was increased and that of 3 proteins was decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46a1	18531	18538	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:111	Out of these proteins, the abundance of 41 proteins was increased and that of 3 proteins was decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46a1	18531	18538	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:112	Protein grouping based on function suggested that at least 6 biological processes could be affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina: (1) cytoskeletal dynamics and vesicle formation (11 proteins, ); (2) energy homeostasis (9 proteins, ); (3) genetic information transfer (DNA/RNA processing, transcription, regulation of transcription and translation, 9 proteins); (4) inflammation (7 proteins); (5) synaptic function (4 proteins); and (6) ubiquitination (3 proteins). 	Cyp46a1	18689	18696	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:112	Protein grouping based on function suggested that at least 6 biological processes could be affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina: (1) cytoskeletal dynamics and vesicle formation (11 proteins, ); (2) energy homeostasis (9 proteins, ); (3) genetic information transfer (DNA/RNA processing, transcription, regulation of transcription and translation, 9 proteins); (4) inflammation (7 proteins); (5) synaptic function (4 proteins); and (6) ubiquitination (3 proteins). 	Cyp46a1	18689	18696	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	19439	19446	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	19439	19446	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	19470	19477	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:115	This approach revealed several differences between Wild Type, Cyp27a1^/Cyp46a1^/Soat1^/, and Cyp27a1^/Cyp46a1^/Apoe^/ mice. 	Cyp46a1	19470	19477	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46a1	19592	19599	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46a1	19592	19599	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46a1	19644	19651	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:116	First, undigested material was observed in some of the Retinal Pigment Epithelium cells of Cyp27a1^/Cyp46a1^/Soat1^/ mice but not Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice (A-C), probably a reflection of impaired phagocytosis at the phagolysosomal stage. 	Cyp46a1	19644	19651	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46a1	19837	19844	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46a1	19837	19844	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46a1	19868	19875	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:117	Second, chromatin condensation was more abundant in the photoreceptor nuclei of Cyp27a1^/Cyp46a1^/Soat1^/ than Cyp27a1^/Cyp46a1^/Apoe^/ mice and was essentially absent in Wild Type mice (D-F). 	Cyp46a1	19868	19875	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:118	This observation is consistent with increased photoreceptor apoptosis documented previously in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	20045	20052	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:118	This observation is consistent with increased photoreceptor apoptosis documented previously in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	20045	20052	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46a1	20084	20091	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46a1	20084	20091	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46a1	20159	20166	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:119	Third, Cyp27a1^/Cyp46a1^/Soat1^/ mice had increased, as compared to Wild Type and Cyp27a1^/Cyp46a1^/Apoe^/ mice, with the presence of multivesicular bodies at both apical and basal sides of the Retinal Pigment Epithelium (A-H, O-Q) in agreement with the change in vesicular traffic suggested by the proteomics analysis. 	Cyp46a1	20159	20166	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:120	Similarly, Cyp27a1^/Cyp46a1^/Soat1^/ mice had more frequent extracellular vesicles in the outer nuclear layer (I-M, R-T), and extensive budding of the caveoli-like structures in the blood vessel pericytes and endothelium of the ganglion cell layer. 	Cyp46a1	20408	20415	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:120	Similarly, Cyp27a1^/Cyp46a1^/Soat1^/ mice had more frequent extracellular vesicles in the outer nuclear layer (I-M, R-T), and extensive budding of the caveoli-like structures in the blood vessel pericytes and endothelium of the ganglion cell layer. 	Cyp46a1	20408	20415	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46a1	20728	20735	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46a1	20728	20735	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46a1	20779	20786	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:121	Thus, intracellular and extracellular vesicular traffic seemed to be increased in Cyp27a1^/Cyp46a1^/Soat1^/ relative to Wild Type or Cyp27a1^/Cyp46a1^/Apoe^/ mice and directed toward both choriocapillaries and inner retina blood vessels. 	Cyp46a1	20779	20786	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	Cyp46a1	21221	21228	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	Cyp46a1	21221	21228	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46a1	21293	21300	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46a1	21293	21300	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46a1	21398	21405	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:124	Hence by generating Cyp27a1^/Cyp46a1^/Soat1^/ mice, we expected that their retinal cholesterol will still be increased as in Cyp27a1^/Cyp46a1^/ mice but be unesterified as in Soat1^/ mice (B). 	Cyp46a1	21398	21405	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:125	Yet, the retinal cholesterol levels were normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice (B), thus suggesting that there are compensatory responses in the retina, which lowered the sterol levels. 	Cyp46a1	21517	21524	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:125	Yet, the retinal cholesterol levels were normal in Cyp27a1^/Cyp46a1^/Soat1^/ mice (B), thus suggesting that there are compensatory responses in the retina, which lowered the sterol levels. 	Cyp46a1	21517	21524	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46a1	21680	21687	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46a1	21680	21687	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46a1	22009	22016	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46a1	22009	22016	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22374	22381	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22374	22381	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22434	22441	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22434	22441	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22500	22507	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22500	22507	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22656	22663	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22656	22663	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22686	22693	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22686	22693	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46a1	22949	22956	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46a1	22949	22956	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:133	Rather, retinal proteomics pointed to enhanced vesicle formation in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina as an expression of 7 proteins from the endosomal, secretory, and protrusion formation pathways (CHGA, HDAC6, PAFAH1B, SEPT6, SRP19, TAGLN2, and TAGLN3, ) was increased in the former. 	Cyp46a1	23293	23300	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:3	Here, we describe a novel in vivo system using genetically modified rats deficient in the Cyp27b1 or Vdr genes. 	Cyp27b1	456	463	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:3	Here, we describe a novel in vivo system using genetically modified rats deficient in the Cyp27b1 or Vdr genes. 	Cyp27b1	456	463	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:5	Although Cyp27b1-knockout, Vdr-KO, and Vdr (R270L) rats each showed rickets symptoms, including abnormal bone formation, they were significantly different from each other. 	Cyp27b1	641	648	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:5	Although Cyp27b1-knockout, Vdr-KO, and Vdr (R270L) rats each showed rickets symptoms, including abnormal bone formation, they were significantly different from each other. 	Cyp27b1	641	648	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:6	Administration of 25(OH)D3 reversed rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. 	Cyp27b1	860	867	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:6	Administration of 25(OH)D3 reversed rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. 	Cyp27b1	860	867	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:7	Interestingly, 1,25(OH)2D3 was synthesized in Cyp27b1-KO rats, probably by Cyp27a1. 	Cyp27b1	939	946	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:7	Interestingly, 1,25(OH)2D3 was synthesized in Cyp27b1-KO rats, probably by Cyp27a1. 	Cyp27b1	939	946	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:24	To confirm the direct action of 25(OH)D_3 in vivo, we previously examined its effect on osteogenesis in Cyp27b1 knockout mice. 	Cyp27b1	3627	3634	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:24	To confirm the direct action of 25(OH)D_3 in vivo, we previously examined its effect on osteogenesis in Cyp27b1 knockout mice. 	Cyp27b1	3627	3634	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:26	Surprisingly, 1,25(OH)_2D_3 was detected at normal levels in Cyp27b1-KO mice administered 25(OH)D_3 at 150 gkg^1day^1. 	Cyp27b1	3875	3882	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:26	Surprisingly, 1,25(OH)_2D_3 was detected at normal levels in Cyp27b1-KO mice administered 25(OH)D_3 at 150 gkg^1day^1. 	Cyp27b1	3875	3882	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:27	Plasma calcium levels, bone mineral densities, and sexual reproduction in Cyp27b1-KO mice were all normalized by 25(OH)D_3 administration, while plasma 25(OH)D_3 levels were enhanced several-fold relative to the normal level^. 	Cyp27b1	4007	4014	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:27	Plasma calcium levels, bone mineral densities, and sexual reproduction in Cyp27b1-KO mice were all normalized by 25(OH)D_3 administration, while plasma 25(OH)D_3 levels were enhanced several-fold relative to the normal level^. 	Cyp27b1	4007	4014	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:28	Based on the activity of 1ALPHA-hydroxylation toward 25(OH)D_3 in liver mitochondrial fractions prepared from Cyp27b1-KO mice, we assumed that Cyp27a1 converted 25(OH)D_3 to 1,25(OH)_2D_3^. 	Cyp27b1	4270	4277	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:28	Based on the activity of 1ALPHA-hydroxylation toward 25(OH)D_3 in liver mitochondrial fractions prepared from Cyp27b1-KO mice, we assumed that Cyp27a1 converted 25(OH)D_3 to 1,25(OH)_2D_3^. 	Cyp27b1	4270	4277	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:31	Thus, we generated a Cyp27b1-deficient rat model to clarify the detailed metabolism of 25(OH)D_3. 	Cyp27b1	4579	4586	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:31	Thus, we generated a Cyp27b1-deficient rat model to clarify the detailed metabolism of 25(OH)D_3. 	Cyp27b1	4579	4586	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:32	In the current study, Cyp27b1-KO rats were produced by genome editing using the CRISPR/Cas9 system^-. 	Cyp27b1	4678	4685	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:32	In the current study, Cyp27b1-KO rats were produced by genome editing using the CRISPR/Cas9 system^-. 	Cyp27b1	4678	4685	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:33	As mentioned above, it was difficult to verify the direct effect of 25(OH)D_3 in Cyp27b1-KO mice due to the Cyp27b1-independent production of 1,25(OH)_2D_3, and it was reasonable to assume that a similar phenomenon would occur in rats. 	Cyp27b1	4839	4846	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:33	As mentioned above, it was difficult to verify the direct effect of 25(OH)D_3 in Cyp27b1-KO mice due to the Cyp27b1-independent production of 1,25(OH)_2D_3, and it was reasonable to assume that a similar phenomenon would occur in rats. 	Cyp27b1	4839	4846	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:33	As mentioned above, it was difficult to verify the direct effect of 25(OH)D_3 in Cyp27b1-KO mice due to the Cyp27b1-independent production of 1,25(OH)_2D_3, and it was reasonable to assume that a similar phenomenon would occur in rats. 	Cyp27b1	4866	4873	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:33	As mentioned above, it was difficult to verify the direct effect of 25(OH)D_3 in Cyp27b1-KO mice due to the Cyp27b1-independent production of 1,25(OH)_2D_3, and it was reasonable to assume that a similar phenomenon would occur in rats. 	Cyp27b1	4866	4873	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:41	Five offspring were obtained from 125 embryos microinjected for Cyp27b1-KO, 4 of which had mutations at target sites. 	Cyp27b1	6135	6142	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:41	Five offspring were obtained from 125 embryos microinjected for Cyp27b1-KO, 4 of which had mutations at target sites. 	Cyp27b1	6135	6142	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:42	Among the 4 pups with target mutations, 1 was found to have a 25 amino acid deletion containing the cysteine residue, which is the fifth ligand of heme iron and the active center of Cyp27b1. 	Cyp27b1	6371	6378	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:42	Among the 4 pups with target mutations, 1 was found to have a 25 amino acid deletion containing the cysteine residue, which is the fifth ligand of heme iron and the active center of Cyp27b1. 	Cyp27b1	6371	6378	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:50	We also confirmed that no off-target site events occurred in potential Off Target Sites searched by the CRISPR Direct tool (http://crispr.dbcls.jp/) among all Genetically Modified rat strains except for Cyp27b1-OTS8. 	Cyp27b1	7551	7558	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:50	We also confirmed that no off-target site events occurred in potential Off Target Sites searched by the CRISPR Direct tool (http://crispr.dbcls.jp/) among all Genetically Modified rat strains except for Cyp27b1-OTS8. 	Cyp27b1	7551	7558	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:51	We could not examine the Off-Target Site event in Cyp27b1-OTS8 because it was impossible to amplify this region (see Supplementary Tables  and. 	Cyp27b1	7615	7622	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:51	We could not examine the Off-Target Site event in Cyp27b1-OTS8 because it was impossible to amplify this region (see Supplementary Tables  and. 	Cyp27b1	7615	7622	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:53	The appearance of WT, mutant Vdr (R270L) and Vdr-KO rats fed an F-2 diet and Cyp27b1-KO rats fed a CE-2 diet at 15 weeks after birth are detailed in Fig. 	Cyp27b1	7855	7862	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:53	The appearance of WT, mutant Vdr (R270L) and Vdr-KO rats fed an F-2 diet and Cyp27b1-KO rats fed a CE-2 diet at 15 weeks after birth are detailed in Fig. 	Cyp27b1	7855	7862	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:54	Whereas Cyp27b1-KO rats were much smaller than WT rats, Vdr (R270L) and Vdr-KO rats were somewhat smaller than WT rats. 	Cyp27b1	7940	7947	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:54	Whereas Cyp27b1-KO rats were much smaller than WT rats, Vdr (R270L) and Vdr-KO rats were somewhat smaller than WT rats. 	Cyp27b1	7940	7947	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:58	Heterozygotes of Cyp27b1-KO, Vdr (R270L), and Vdr-KO rats showed phenotypes similar to those of WT rats at 15 weeks. 	Cyp27b1	8450	8457	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:58	Heterozygotes of Cyp27b1-KO, Vdr (R270L), and Vdr-KO rats showed phenotypes similar to those of WT rats at 15 weeks. 	Cyp27b1	8450	8457	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:59	Growth curves of mutant Vdr (R270L) and Vdr-KO rats fed the F-2 diet and Cyp27b1-KO rats fed the CE-2 diet are shown in Fig. 	Cyp27b1	8623	8630	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:59	Growth curves of mutant Vdr (R270L) and Vdr-KO rats fed the F-2 diet and Cyp27b1-KO rats fed the CE-2 diet are shown in Fig. 	Cyp27b1	8623	8630	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:60	Growth was significantly inhibited in Cyp27b1-KO rats but was only slightly inhibited in Vdr (R270L) and Vdr-KO rats compared to that of WT rats, whereas no animals died at 15 weeks of age among the Cyp27b1-KO rats fed the CE-2 diet. 	Cyp27b1	8713	8720	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:60	Growth was significantly inhibited in Cyp27b1-KO rats but was only slightly inhibited in Vdr (R270L) and Vdr-KO rats compared to that of WT rats, whereas no animals died at 15 weeks of age among the Cyp27b1-KO rats fed the CE-2 diet. 	Cyp27b1	8713	8720	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:60	Growth was significantly inhibited in Cyp27b1-KO rats but was only slightly inhibited in Vdr (R270L) and Vdr-KO rats compared to that of WT rats, whereas no animals died at 15 weeks of age among the Cyp27b1-KO rats fed the CE-2 diet. 	Cyp27b1	8874	8881	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:60	Growth was significantly inhibited in Cyp27b1-KO rats but was only slightly inhibited in Vdr (R270L) and Vdr-KO rats compared to that of WT rats, whereas no animals died at 15 weeks of age among the Cyp27b1-KO rats fed the CE-2 diet. 	Cyp27b1	8874	8881	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:61	Thus, subsequent analyses were performed with the F-2 diet for mutant Vdr (R270L) and Vdr-KO rats, while a CE-2 diet containing 1.15% calcium was used for Cyp27b1-KO rats. 	Cyp27b1	9064	9071	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:61	Thus, subsequent analyses were performed with the F-2 diet for mutant Vdr (R270L) and Vdr-KO rats, while a CE-2 diet containing 1.15% calcium was used for Cyp27b1-KO rats. 	Cyp27b1	9064	9071	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:63	The femur lengths of Cyp27b1-KO, mutant Vdr (R270L) and Vdr-KO rats were shorter than those of WT rats. 	Cyp27b1	9298	9305	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:63	The femur lengths of Cyp27b1-KO, mutant Vdr (R270L) and Vdr-KO rats were shorter than those of WT rats. 	Cyp27b1	9298	9305	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:65	Although Vdr (R270L) and Vdr-KO rats did not show clear changes in total bone mineral density, the Bone Mineral Density of cortical bone in Cyp27b1-KO rats was significantly decreased (t = 21.108, df = 3.245, p < 0.001), resulting in decreased total Bone Mineral Density (t = 13.782, df = 6, p < 0.001) rats and Vdr-KO rats at 15 weeks of age, as evidenced by toluidine blue staining, indicating the histological features of rickets rats but not in Vdr-KO rats at 15 weeks of age. 	Cyp27b1	9674	9681	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:65	Although Vdr (R270L) and Vdr-KO rats did not show clear changes in total bone mineral density, the Bone Mineral Density of cortical bone in Cyp27b1-KO rats was significantly decreased (t = 21.108, df = 3.245, p < 0.001), resulting in decreased total Bone Mineral Density (t = 13.782, df = 6, p < 0.001) rats and Vdr-KO rats at 15 weeks of age, as evidenced by toluidine blue staining, indicating the histological features of rickets rats but not in Vdr-KO rats at 15 weeks of age. 	Cyp27b1	9674	9681	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10087	10094	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10087	10094	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10219	10226	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10219	10226	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10470	10477	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:66	Although all Genetically Modified rats showed abnormal bone morphology, Cyp27b1-KO rats showed more severe bone disorders than the other Genetically Modified rats rats (t = 3.881, df = 12, p = 0.002) and Cyp27b1-KO rats (t = 7.584, df = 7.845, p < 0.001), whose secretion is induced by the reduced plasma calcium level via calcium-sensing receptor in the parathyroid, was significantly increased in Vdr (R270L) rats (t = 4.295, df = 5.026, p = 0.008) and Cyp27b1-KO rats (t = 8.448, df = 8, p < 0.001), whereas the plasma calcium level in Vdr-KO mice was much lower than that in wild-type mice^,. 	Cyp27b1	10470	10477	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:74	As shown in Fig, the plasma 1,25(OH)_2D_3 level was significantly increased in Vdr (R270L) (t = 4.024, df = 8, p = 0.004) and Vdr-KO rats (t = 2.723, df = 5, p = 0.042) but was significantly decreased in Cyp27b1-KO rats (8.0  3.2 pg/mL (mean  SEM, n = 7)) compared to that in WT rats (24.8  5.2 pg/mL, (mean  SEM, n = 7)) (t = 2.771, df = 12, p = 0.017). 	Cyp27b1	11841	11848	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:74	As shown in Fig, the plasma 1,25(OH)_2D_3 level was significantly increased in Vdr (R270L) (t = 4.024, df = 8, p = 0.004) and Vdr-KO rats (t = 2.723, df = 5, p = 0.042) but was significantly decreased in Cyp27b1-KO rats (8.0  3.2 pg/mL (mean  SEM, n = 7)) compared to that in WT rats (24.8  5.2 pg/mL, (mean  SEM, n = 7)) (t = 2.771, df = 12, p = 0.017). 	Cyp27b1	11841	11848	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:75	This result was somewhat different from that in Cyp27b1-KO mice^, which showed no detectable 1,25(OH)_2D_3 (<5 pg/mL). 	Cyp27b1	12040	12047	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:75	This result was somewhat different from that in Cyp27b1-KO mice^, which showed no detectable 1,25(OH)_2D_3 (<5 pg/mL). 	Cyp27b1	12040	12047	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:76	In a previous study, we demonstrated that dietary administration of 25(OH)D_3 to Cyp27b1-KO mice reversed type I rickets hallmarks, such as growth failure, skeletal disorders and hypocalcemia^. 	Cyp27b1	12192	12199	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:76	In a previous study, we demonstrated that dietary administration of 25(OH)D_3 to Cyp27b1-KO mice reversed type I rickets hallmarks, such as growth failure, skeletal disorders and hypocalcemia^. 	Cyp27b1	12192	12199	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:77	Dietary administration of 25(OH)D_3 to Cyp27b1-KO rats at 200 gkg^1day^1 also significantly reversed growth failure (see Supplementary Fig. 	Cyp27b1	12344	12351	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:77	Dietary administration of 25(OH)D_3 to Cyp27b1-KO rats at 200 gkg^1day^1 also significantly reversed growth failure (see Supplementary Fig. 	Cyp27b1	12344	12351	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:79	Histological analysis of the femoral sections demonstrated a normalized structure of the cortex and trabecular bone by 25(OH)D_3 administration in Cyp27b1-KO rats. 	Cyp27b1	12748	12755	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:79	Histological analysis of the femoral sections demonstrated a normalized structure of the cortex and trabecular bone by 25(OH)D_3 administration in Cyp27b1-KO rats. 	Cyp27b1	12748	12755	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:81	In addition, 25(OH)D_3 administration dramatically corrected the osteomalacic features of the Cyp27b1-KO rats (see Supplementary Fig. 	Cyp27b1	12979	12986	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:81	In addition, 25(OH)D_3 administration dramatically corrected the osteomalacic features of the Cyp27b1-KO rats (see Supplementary Fig. 	Cyp27b1	12979	12986	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13047	13054	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13047	13054	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13202	13209	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13202	13209	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13341	13348	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:82	The plasma calcium level of Cyp27b1-KO rats was fully restored by 25(OH)D_3 administration (F(1, 21) = 45.6, p < 0.001), and the markedly elevated plasma Parathyroid Hormone level in Cyp27b1-KO rats (F(1, 11) = 90.6, p < 0.001) was normalized after 25(OH)D_3 administration (F(1, 11) = 62.2, p < 0.001)_2D_3 deficiency in Cyp27b1-KO rats was normalized by 25(OH)D_3 administration (F(1, 16) = 15.4, p = 0.001)D_3^. 	Cyp27b1	13341	13348	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:83	Liver mitochondrial fractions prepared from Cyp27b1-KO rats showed 1ALPHA-hydroxylation activity toward 25(OH)D_3. 	Cyp27b1	13478	13485	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:83	Liver mitochondrial fractions prepared from Cyp27b1-KO rats showed 1ALPHA-hydroxylation activity toward 25(OH)D_3. 	Cyp27b1	13478	13485	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:85	These results were also quite similar to those in Cyp27b1-KO mice, suggesting that the most likely candidate for the other 1ALPHA-hydroxylase is Cyp27a1^. 	Cyp27b1	13704	13711	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:85	These results were also quite similar to those in Cyp27b1-KO mice, suggesting that the most likely candidate for the other 1ALPHA-hydroxylase is Cyp27a1^. 	Cyp27b1	13704	13711	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:95	When wild-type and Vdr (R270L) rats were compared, a difference was seen in (1) VDR-dependent 1,25(OH)_2D_3 effects and Cyp27b1-KO rats may reveal (2) VDR-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	16129	16136	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:95	When wild-type and Vdr (R270L) rats were compared, a difference was seen in (1) VDR-dependent 1,25(OH)_2D_3 effects and Cyp27b1-KO rats may reveal (2) VDR-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	16129	16136	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:104	The plasma level of 1,25(OH)_2D_3 was dramatically reduced, probably by the reduction in Cyp27b1 expression resulting from the decrease in plasma Parathyroid Hormone content. 	Cyp27b1	17746	17753	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:104	The plasma level of 1,25(OH)_2D_3 was dramatically reduced, probably by the reduction in Cyp27b1 expression resulting from the decrease in plasma Parathyroid Hormone content. 	Cyp27b1	17746	17753	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:107	Growth failure and rickets were observed in both Vdr (R270L) and Cyp27b1-KO rats. 	Cyp27b1	18332	18339	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:107	Growth failure and rickets were observed in both Vdr (R270L) and Cyp27b1-KO rats. 	Cyp27b1	18332	18339	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:109	The morphological abnormalities observed in Cyp27b1-KO rats appeared to be closely linked with a decrease in cortical bone density and an increase in femoral cancellous bone density. 	Cyp27b1	18511	18518	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:109	The morphological abnormalities observed in Cyp27b1-KO rats appeared to be closely linked with a decrease in cortical bone density and an increase in femoral cancellous bone density. 	Cyp27b1	18511	18518	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:110	Comparisons of growth rates and plasma calcium levels revealed more severe symptoms in Cyp27b1-KO rats than in Vdr (R270L) rats. 	Cyp27b1	18737	18744	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:110	Comparisons of growth rates and plasma calcium levels revealed more severe symptoms in Cyp27b1-KO rats than in Vdr (R270L) rats. 	Cyp27b1	18737	18744	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:112	It is most likely that Cyp27b1-KO rats showed more severe rickets symptoms than mutant Vdr (R270L) rats because of the absence of Vdr-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	18952	18959	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:112	It is most likely that Cyp27b1-KO rats showed more severe rickets symptoms than mutant Vdr (R270L) rats because of the absence of Vdr-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	18952	18959	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:113	Membrane-associated rapid response steroid-binding proteins, such as GRP58, ERp57, ERp60, and Pdia3^, could be involved in calcium absorption in the small intestine, and it is presumed that the remarkable difference in the plasma calcium concentration between Vdr (R270L) rats and Cyp27b1-KO rats was based on the Vdr-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	19382	19389	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:113	Membrane-associated rapid response steroid-binding proteins, such as GRP58, ERp57, ERp60, and Pdia3^, could be involved in calcium absorption in the small intestine, and it is presumed that the remarkable difference in the plasma calcium concentration between Vdr (R270L) rats and Cyp27b1-KO rats was based on the Vdr-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	19382	19389	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:114	As with Vdr (R270L) rats, administration of 25(OH)D_3 exerted pronounced effects on Cyp27b1-KO rats, resulting in normalization of plasma calcium and Parathyroid Hormone levels, osteogenesis, and infertility in females. 	Cyp27b1	19541	19548	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:114	As with Vdr (R270L) rats, administration of 25(OH)D_3 exerted pronounced effects on Cyp27b1-KO rats, resulting in normalization of plasma calcium and Parathyroid Hormone levels, osteogenesis, and infertility in females. 	Cyp27b1	19541	19548	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:115	However, 1,25(OH)_2D_3 was detected in the blood of Cyp27b1-KO rats at the same levels as in wild-type rats. 	Cyp27b1	19729	19736	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:115	However, 1,25(OH)_2D_3 was detected in the blood of Cyp27b1-KO rats at the same levels as in wild-type rats. 	Cyp27b1	19729	19736	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:116	As described in our previous study, the generation of 1,25(OH)_2D_3 following 25(OH)D_3 administration was also observed in Cyp27b1-KO mice^. 	Cyp27b1	19910	19917	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:116	As described in our previous study, the generation of 1,25(OH)_2D_3 following 25(OH)D_3 administration was also observed in Cyp27b1-KO mice^. 	Cyp27b1	19910	19917	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:117	1ALPHA-Hydroxylase activity toward 25(OH)D_3 in a liver mitochondrial fraction prepared from Cyp27b1-KO rats suggested that Cyp27a1, a 1ALPHA-hydroxylase abundant in the liver, is most likely responsible for the generation of 1,25(OH)_2D_3. 	Cyp27b1	20021	20028	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:117	1ALPHA-Hydroxylase activity toward 25(OH)D_3 in a liver mitochondrial fraction prepared from Cyp27b1-KO rats suggested that Cyp27a1, a 1ALPHA-hydroxylase abundant in the liver, is most likely responsible for the generation of 1,25(OH)_2D_3. 	Cyp27b1	20021	20028	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:118	It should be noted that 25(OH)D_3 administration is highly effective in type I rickets models, such as Cyp27b1-KO rats. 	Cyp27b1	20272	20279	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:118	It should be noted that 25(OH)D_3 administration is highly effective in type I rickets models, such as Cyp27b1-KO rats. 	Cyp27b1	20272	20279	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25143	25150	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25143	25150	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
